
<html>
<head>
<style>

    h2 {
        text-align: center;
        font-family: Helvetica, Arial, sans-serif;
    }
    table { 
        margin-left: auto;
        margin-right: auto;
    }
    table, th, td {
        border: 1px solid black;
        border-collapse: collapse;
    }
    th, td {
        padding: 5px;
        text-align: center;
        font-family: Helvetica, Arial, sans-serif;
        font-size: 90%;
    }
    table tbody tr:hover {
        background-color: #dddddd;
    }
    .wide {
        width: 90%; 
    }

</style>
</head>
<body>
<table border="1" class="dataframe wide">
  <thead>
    <tr style="text-align: right;">
      <th></th>
      <th>transcription_factor</th>
      <th>n_unique_pubs</th>
      <th>n_unique_pubs_by_type</th>
      <th>score</th>
      <th>ensembl_id</th>
      <th>abstracts</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <th>0</th>
      <td>VDR</td>
      <td>6</td>
      <td>TH:2, NKT:1, TC2:1, TREG:1, TREG17:1</td>
      <td>1.000000</td>
      <td>ENSG00000111424</td>
      <td><details><summary>Subtypes</summary><details><summary>TH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/25576905">25576905</a><div class="entities" style="line-height: 2.5"><h3><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    VDR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> FokI polymorphism is associated with a reduced T-helper cell population under vitamin D stimulation in type 1 diabetes patients.</h3></br>Type 1 diabetes (T1D) is an autoimmune disease mediated by T-helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. Additionally, the immune system regulator vitamin D, exerts its modulatory effects through the vitamin D receptor (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    VDR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) expressed in Th cells. Furthermore, several genetic variants in the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    VDR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> gene including the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    VDR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> FokI (rs10735810) polymorphism have been implicated in T1D susceptibility in some Caucasian populations. Aim of the present study was to investigate the possible functional role of the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    VDR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> FokI gene polymorphism in Th cells from T1D patients and healthy controls (HC).</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/25201466">25201466</a><div class="entities" style="line-height: 2.5"><h3>A human vitamin D receptor mutation causes rickets and impaired Th1/Th17 responses.</h3></br>We present a brother and sister with severe rickets, alopecia and highly elevated serum levels of 1,25-dihydroxyvitamin D (1,25-(OH)2D3). Genomic sequencing showed a homozygous point mutation (A133G) in the vitamin D receptor gene, leading to an amino acid change in the DNA binding domain (K45E), which was described previously. Hereditary vitamin D resistant rickets (HVDRR) was diagnosed. Functional studies in skin biopsy fibroblasts confirmed this. 1,25-(OH)2D3 reduced T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cell population-specific cytokine expression of interferon γ (Th1), interleukins IL-17A (Th17) and IL-22 (Th17/Th22) in peripheral blood mononuclear cells (PBMCs) from the patient's parents, whereas IL-4 (Th2) levels were higher, reflecting an immunosuppressive condition. None of these factors were regulated by 1,25-(OH)2D3 in PBMCs from the boy. At present, both patients (boy is 23 years of age, girl is 7) have not experienced any major immune-related disorders. Although both children developed alopecia, the girl did so earlier than the boy. The boy showed complete recovery from the rickets at the age of 17 and does not require any vitamin D supplementations to date. In conclusion, we characterized two siblings with HVDRR, due to a mutation in the DNA binding domain of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    VDR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. Despite a defective T cell response to vitamin D, no signs of any inflammatory-related abnormalities were seen, thus questioning an essential role of vitamin D in the immune system. Despite the fact that currently medicine is not required, close monitoring in the future of these patients is warranted for potential recurrence of vitamin D dependence and diagnosis of (chronic) inflammatory-related diseases.</div></details><details><summary>NKT</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/21114675">21114675</a><div class="entities" style="line-height: 2.5"><h3>Why do T cells express the vitamin D receptor?</h3></br>Vitamin D is an important regulator of immune function. T cells express the vitamin D receptor (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    VDR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) and have been shown to be direct and indirect vitamin D targets. Why should T cells be responsive to vitamin D? The data suggest that expression of the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    VDR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is required for the development of two cell types, NKT cells and CD8αα T cells, which inhibit autoimmunity. In addition, effector T cell cytokine production is regulated by vitamin D. Available evidence suggests that <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NKT    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and CD8αα T cells express the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    VDR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> as part of the selection process to protect against the generation of autoimmunity, particularly in the gut.</div></details><details><summary>TC2</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/26750596">26750596</a><div class="entities" style="line-height: 2.5"><h3>1,25D3 prevents CD8(+)Tc2 skewing and asthma development through <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    VDR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> binding changes to the Cyp11a1 promoter.</h3></br>Effector CD8(+) T cells convert from IFN-γ(+) (Tc1) to IL-13(+) (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tc2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells in the presence of IL-4. Underlying regulatory mechanisms are not fully defined. Here, we show that addition of 1,25D3, the active form of vitamin D3, during CD8(+) T cell differentiation prevents IL-4-induced conversion to IL-13-producers. Transfer of 1,25D3-treated CD8(+) T cells into sensitized and challenged CD8(+)-deficient recipients fails to restore development of lung allergic responses. 1,25D3 alters vitamin D receptor (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    VDR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) recruitment to the Cyp11a1 promoter in vitro and in vivo in the presence of IL-4. As a result, protein levels and enzymatic activity of CYP11A1, a steroidogenic enzyme regulating CD8(+) T cell conversion, are decreased. An epistatic effect between CYP11A1 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    VDR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> polymorphisms may contribute to the predisposition to childhood asthma. These data identify a role for 1,25D3 in the molecular programming of CD8(+) T cell conversion to an IL-13-secreting phenotype through regulation of steroidogenesis, potentially governing asthma susceptibility. </div></details><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27614264">27614264</a><div class="entities" style="line-height: 2.5"><h3>Decreased immunosuppressive actions of 1α, 25-dihydroxyvitamin D3  in patients with immune thrombocytopenia.</h3></br>Primary immune thrombocytopenia (ITP) is an acquired autoimmune disea<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    se.    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> 1α, 25-dihydrox<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    yvi    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>tamin D3  [1,25(O<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    H)2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> D3 ] and vitamin D receptor (VDR) play important immune-suppres<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    siv    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>e roles in immune system. It has been reported that serum 1,25(OH)2 D3  were lower in ITP patients. In this study, we evaluated local 1,25(OH)2 D3  level and VDR mRNA expression further, and determined whether 1,25(OH)2 D3 /VDR were correlated with T cell dysfunction in ITP patients. We found that 1,25(OH)2 D3 /VDR levels were decreased in active ITP patients, and 1,25(OH)2 D3  had significant anti-inflammatory effects on ITP pat<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    ien    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>ts, including both anti-proliferation of peripheral blood mononuclear cells (PBMCs) and reversing the abnormal T cells polarization. 1,25(OH)2 D3  inhibited the differentiation of T helper (Th)1 and Tc1 cells but induced the differentiation of Th2, Tc2 and T regulatory (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells in ITP patients. However, the percentage of Th17 cells were not affected obviously with 1,25(OH)2 D3 . In addition, 1,25(OH)2 D3  also suppressed pro-inflammatory cytokines (INF-γ and IL-17A) but promoted anti-inflammatory cytokine (IL-10) secretion in ITP patients. In conclusion, decreased 1,25(OH)2 D3 /VDR might participate in the pathogenesis of ITP, and appropriate supplement of 1,25(OH)2 D3  may be a promising treatment.</div></details></details></td>
    </tr>
    <tr>
      <th>1</th>
      <td>FOXP3</td>
      <td>1779</td>
      <td>TREG:1640, TH17:85, TH1:44, TEFF:41, TH:39, TREG1:24, TFH:19, TFREG:14, NKT:12, TH2:11, TREG17:9, TH3:4, TEM:3, TFH1LIKE:3, TRM:2, γδT:2, TC1:2, TH22:1, TH9:1, THP:1, TEMRA:1, TCM:1, TC9:1, MAIT:1</td>
      <td>1.000000</td>
      <td>ENSG00000049768</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/30560927">30560927</a><div class="entities" style="line-height: 2.5"><h3>Interleukin 2 modulates thymic-derived regulatory T cell epigenetic landscape.</h3></br><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+ CD4+  regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> ) cells are essential for preventing fatal autoimmunity and safeguard immune homeostasis in vivo. While expression of the transcription factor <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and IL-2 signals are both required for the development and function of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>  cells, the commitment to the Treg  cell lineage occurs during thymic selection upon T cell receptor (TCR) triggering, and precedes the expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. Whether signals beside TCR contribute to establish <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>  cell epigenetic and functional identity is still unknown. Here, using a mouse model with reduced IL-2 signaling, we show that IL-2 regulates the positioning of the pioneer factor SATB1 in CD4+  thymocytes and controls genome wide chromatin accessibility of thymic-derived Treg  cells. We also show that <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>  cells receiving only low IL-2 signals can suppress endogenous but not WT autoreactive T cell responses in vitro and in vivo. Our findings have broad implications for potential therapeutic strategies to reprogram Treg  cells in vivo.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/30199269">30199269</a><div class="entities" style="line-height: 2.5"><h3>Correlation of Immune Cells and Cytokines in the Tumor Microenvironment with Elevated Neutrophil-To-Lymphocyte Ratio in Blood: An Analysis of Muscle-Invasive Bladder Cancer.</h3></br>We investigated the relationship between Neutrophil-to-lymphocyte ratio (NLR) and the quantities of neutrophil elastase, CD3, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, and CD204 in tumor-infiltrating cells and circulating cytokines (IL-2, -6, -8, 17a, and TGF-β) in muscle-invasive bladder cancer. IL-6 and IL-8 levels showed a significant correlation with NLR in blood and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+ cells around the tumor. After co-culture of peripheral blood cells with bladder cancer cell lines, the induction of regulatory T cell (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) was higher in T24 whose IL-6 and IL-8 levels were higher. High NLR correlates with increased IL-6 and IL-8 and Treg expression.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/30159338">30159338</a><div class="entities" style="line-height: 2.5"><h3>Anti-IL-22 Antibody Attenuates Acute Graft-versus-Host Disease via Increasing <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+  T Cell through Modulation of CD11b+  Cell Function.</h3></br>Transfer of splenocytes isolated from B6 mice into normal B6D2F1 mice induces acute graft-versus-host disease (aGVHD), resulting in the expansion of donor cytotoxic T lymphocytes that eliminate recipient B cells. The cytokine IL-22, secreted by Th1 cells, Th17 cells, and innate immune cells, is structurally related to IL-10. To investigate the association between IL-22 and aGVHD, an anti-mouse IL-22 antibody (IL-22Ab) was used to ablate IL-22 activity in a mouse aGVHD model. Administration of IL-22Ab significantly reduced the progression of aGVHD in B6D2F1 recipients of B6 grafts. IL-22Ab treatment also decreased the percentage of interferon-<i>γ</i>+  and tumor necrosis factor-<i>α</i>+  T cells but increased the number of forkhead box p3+  regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>). In the presence of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and donor CD11b+  cells, IL-22Ab protected against aGVHD. <i>In vitro</i> Treg induction was more efficient when CD4+ CD25-  T cells differentiated in the presence of CD11b+  cells obtained from IL-22Ab-treated GVHD mice, compared with cocultured untreated control cells. Finally, IL-22Ab modulated the expression of cytokines and costimulatory molecules in CD11b+  cells in aGVHD mice. We therefore conclude that IL-22Ab administration represents a viable approach for treating aGVHD.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/30059947">30059947</a><div class="entities" style="line-height: 2.5"><h3>Impairment of regulatory T cells in patients with neonatal necrotizing enterocolitis.</h3></br>Necrotizing enterocolitis (NEC) is a life-threatening condition that can occur in about 7% of pre-term infants, and approximately 20% to 30% of the cases will end in death. An overactive immune response is thought to be a primary instigator of many symptoms during NEC. Hence, we hypothesized that NEC patients might present impairment in regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells that limited their capacity to contain the excessive inflammation-induced damage. To investigate this, peripheral blood mononuclear cells were collected from NEC and non-NEC infants with matching age and weight. Treg cells, identified as CD3+ CD4+ CD25<sup>+/hi</sup><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+  T cells, were present at significantly lower frequency in NEC infants than in non-NEC infants. We also observed that the frequency of IL‑17+  CD4+  T cells was significantly higher in NEC infants, while the frequencies of IL‑10+  and TGF‑β+  CD4+  T cells were significantly lower in NEC infants. The CD4+ CD25<sup>+/hi</sup> Treg cells from NEC infants were capable of suppressing CD4+ CD25-  T conventional cell proliferation, but with significantly reduced potency than the CD4+ CD25<sup>+/hi</sup> Treg cells from non-NEC infants. In addition, the CD4+ CD25<sup>+/hi</sup> Treg cells from non-NEC infants, but not those from NEC infants, were capable of suppressing IL‑17 expression. Furthermore, the CD4+ CD25<sup>+/hi</sup> Treg cells from NEC infants displayed reduced expression of CTLA‑4, LAG‑3, and Helios, compared to those from non-NEC infants. Overall, these results demonstrated that Treg cells from NEC infants displayed a multitude of functional impairments, and suggested that Treg cells might serve as a treatment target in NEC.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/29990511">29990511</a><div class="entities" style="line-height: 2.5"><h3>Implications of uterine NK cells and regulatory T cells in the endometrium of infertile women.</h3></br>A range of studies have shown that the complex process of implantation and an establishment of a pregnancy also involves immune factors. Disturbances in these underlying immune mechanisms might lead to implantation and pregnancy failure and may be involved in the pathogenesis of unexplained infertility. Several studies have reported that imbalances in uterine NK (uNK) cell abundance are associated with infertility; however, controversies exist. An increased amount of CD56+  uNK cells along with a decrease in CD16+  uNK cells have been associated with normal fertility in some studies. Very few studies of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+  regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) in the pre-implantation endometrium have been performed. Results are sparse and controversial, studies reporting both increased and decreased numbers of Tregs, respectively, in women suffering from infertility. In conclusion, studies imply that uNK cells, <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and HLA-G carry pivotal roles regarding the establishment of a healthy pregnancy, and that abnormal immune mechanisms involving these parameters may be associated with infertility. However, more research in early phases of the reproductive cycle, such as investigating the conditions in the endometrium before implantation, is needed to further clarify the underlying mechanisms.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/29851536">29851536</a><div class="entities" style="line-height: 2.5"><h3>Analysis of Helios gene expression and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> TSDR methylation in the newly diagnosed Rheumatoid Arthritis patients.</h3></br>The control of auto-reactive cells is defective in rheumatoid arthritis (RA). Regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells which play a key role in the modulation of immune responses have an impaired function in RA. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is a master regulator of Treg cells which its expression is under the tight control of epigenetic mechanisms. In the current study, we analyzed the epigenetic modulation of the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> Treg-specific demethylated region (TSDR) and Helios gene expression to determine Treg cells alteration in RA patients.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/29778842">29778842</a><div class="entities" style="line-height: 2.5"><h3>Curcumin attenuates sepsis-induced acute organ dysfunction by preventing inflammation and enhancing the suppressive function of Tregs.</h3></br>Sepsis is characterized by the extensive release of cytokines and other mediators. It results in a dysregulated immune response and can lead to organ damage and death. Curcumin has anti-inflammatory properties and immunoregulation functions in various disorders such as sepsis, cancer, rheumatoid arthritis, cardiovascular diseases, lung fibrosis, gallstone formation, and diabetes. This paper investigates the effects of curcumin on immune status and inflammatory response in mice subjected to cecal ligation and puncture (CLP). Inflammatory tissue injury was evaluated by histological observation. Magnetic microbeads were used to isolate splenic CD4+ CD25+ regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>), and phenotypes were then analyzed by flow cytometry. The levels of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> were detected by Western blot and real-time PCR and cytokine levels were determined by enzyme-linked immunosorbent assay. We found that the administration of curcumin significantly alleviated inflammatory injury of the lung and kidney in septic mice. The suppressive function of Treg cells was enhanced and the plasma levels of IL-10 increased after treatment with curcumin. Furthermore, the secretion of plasma TNF-α and IL-6 was notably inhibited in septic mice treated with curcumin and administration with curcumin could improve survival after CLP. These data suggest that curcumin could be used as a potential therapeutic agent for sepsis.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/29854846">29854846</a><div class="entities" style="line-height: 2.5"><h3>All-Trans Retinoic Acid Induces <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    CD4+CD25+FOXP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+ Regulatory T Cells by Increasing <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FOXP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> Demethylation in Systemic Sclerosis CD4+ T Cells.</h3></br>Retinoic acid (RA) is an active metabolite of vitamin A and has been reported to improve the clinical symptoms of patients with systemic sclerosis (SSc). However, the mechanism of RA in the prevention of SSc remains unclear. Regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) are a subpopulation of T cells with immunosuppressive activity. The quantitative and functional defects of Tregs may mediate the immune dysfunction in SSc. The addition of all-trans retinoic acid (ATRA) to human naïve CD4+ cells could promote the maturation of Tregs and increase the stable expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. In this study, we explored the role of RA on Tregs in SSc CD4+ T cells and its possible epigenetic mechanisms, so as to further understand the mechanisms of RA on SSc.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/29671006">29671006</a><div class="entities" style="line-height: 2.5"><h3>Regulatory T cells control endothelial chemokine production and migration of T cells into intestinal tumors of APC<sup>min/+</sup> mice.</h3></br>Tumor-infiltrating lymphocytes are crucial for anti-tumor immunity. We have previously shown that regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) are able to<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">     redu    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>ce T cell transendothelial migration in vitro and accumulation of effector T cells in intestinal tumors in vivo. Treg depletion also resulted in increased levels of the chemokines CXCL9 and CXCL10 specifically in the tumors. In this study, we investigated the mechanisms for Treg mediated suppression of T cell migration into intestinal tumors in the APC<sup>min/+</sup> mouse model. By breeding APC<sup>min/+</sup> mice with DEREG mice, which harbour a high affinity diphtheria toxin receptor under the control of the FOXP3 promoter, we were able to deplete Treg in tumor-bearing mice. Using adoptive transfer experiments, we could document a markedly increased migration of T cells specifically into Treg depleted tumors, and that Treg depletion results in increased production of the CXCR3 ligand CXCL10 from endothelial cells in the tumors. Furthermore, we were able to demonstrate that T cells use CXCR3 to migrate into intestinal tumors. In addition, human colon adenocarcinomas express high levels of mRNA CXCR3 ligands and tumor endothelial cells produce CXCL9 and CXCL10 ex vivo. In conclusion, this study demonstrates that Treg reduce endothelial CXCL10 production, inhibit T cell migration into tumors and that CXCR3 mediated signalling is crucial for lymphocyte accumulation in intestinal tumors. Thus, immunotherapy aimed at Treg depletion may be effective by increasing not only T effector cell activity, but also their accumulation in tumors.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/29532697">29532697</a><div class="entities" style="line-height: 2.5"><h3><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FOXP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+ Treg as a therapeutic target for promoting anti-tumor immunity.</h3></br>Regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) characterized by expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FOXP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and strong immunosuppressive activity play a key role in regulating homeostasis in health and disease. Areas covered: Human Treg are highly diverse phenotypically and functionally. In the tumor microenvironment (TME), Treg are reprogrammed by the tumor, acquiring an activated phenotype and enhanced suppressor functions. No unique phenotypic markers for Treg accumulating in human tumors exist. Treg are heterogeneous and use numerous mechanisms to mediate suppression, which either silences anti-tumor immune surveillance or prevents tissue damage by activated T cells. Treg plasticity in the TME endows them with dual functionality. Treg frequency in tumors associates either with poor or improved survival. Treg responses to immune checkpoint inhibition (ICI) differ from the restorative effects ICIs induce in other immune cells. Therapies used to silence Treg, including ICIs, are only partly successful. Treg persistence and resistance to depletion are critical for maintaining homeostasis. Expert opinion: Treg emerge as a heterogeneous subset of immunosuppressive T cells, which usually, but not always, favor tumor progression. Treg are also engaged in non-immune activities that benefit the host. Therapeutic silencing of Treg in cancer requires a deeper understanding of Treg activities in human health and disease.</div></details><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/29543869">29543869</a><div class="entities" style="line-height: 2.5"><h3>N-3 polyunsaturated fatty acids restore Th17 and Treg balance in collagen antibody-induced arthritis.</h3></br>N-3 polyunsaturated fatty acids (PUFA) have anti-inflammatory effects and were considered useful for the treatment of rheumatoid arthritis (RA). Recently, several studies suggested that n-3 PUFAs attenuated arthritis in animal model and human, however the mechanism is still unclear. Interleukin 17 (IL-17) is a pro-inflammatory cytokine mainly produced by T helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells which cause tissue inflammation and bone erosion leading to joint destruction. In contrast, regulatory T (Treg) cells down-regulate various immune responses by suppression of naïve T cells. The imbalance between Th17 cells and Tregs cell is important for the pathogenesis of RA. Here, we investigated whether n-3 PUFAs attenuate arthritis in collagen antibody-induced arthritis (CAIA) model. We used fat-1 transgenic mice expressing the Caenorhabditis elegans fat-1 gene encoding an n-3 fatty acid desaturase that converts n-6 to n-3 fatty acids, leading to abundant n-3 fatty acids without the need of a dietary n-3 supply. Clinical arthritis score was significantly attenuated in fat-1 mice compared to wild type (WT) mice on day 7 (1.6±1.8, p = 0.012) and day 9 (1.5±1.6, p = 0.003). Ankle thickness also decreased significantly in fat-1 mice compared to WT mice (1.82±0.11, p = 0.008). The pathologic finding showed that inflammatory cell infiltration and bone destruction were reduced in fat-1 mice compared to WT. The expression levels of IL-17 and related cytokines including IL-6 and IL-23 decreased in the spleen and ankle joint tissue of fat-1 mice compared to WT mice. Furthermore, Treg cells were expanded in the spleen of fat-1 mice and Treg cell differentiation was significantly higher in fat-1 mice than in wild type (p = 0.038). These data suggest that n-3 PUFAs could attenuate arthritis through increasing the expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and the differentiation of Treg, while reducing IL-17 production. Therefore, dietary supplementation of n-3 PUFAs could have a therapeutic potential for the treatment of RA.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/29475096">29475096</a><div class="entities" style="line-height: 2.5"><h3>Phenotypic and functional profile of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Treg cells in allergic fungal sinusitis.</h3></br>Interleukin-17 producing T helper (Th17) and regulatory T cells (Treg) cells have been identified to play a critical role in atopic inflammation. However, conflicting reports on the role of Th17/Treg cells in allergic fungal rhinosinusitis (AFRS) patients of different ethnicities has mystified its pathogenesis. To better understand the pathophysiological mechanisms involved in AFRS, we conducted a prospective, analytical, case-control study involving 40 confirmed immunocompetent AFRS patients and 20 healthy controls. The distribution of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Treg cells in PBMC, intracellular mRNA expression of retinoid orphan nuclear receptor (RORγt) in Th17 and forkhead transcription factor (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) in Treg cells, and serum cytokine levels were investigated. Aspergillus flavus was identified from majority (85%) of patient tissue biopsies. Total serum IgE level along with cytokines IL-17, IL-21, IL-1β and TGF-β were comparatively elevated in AFRS. Nevertheless, IL-2 and IL-10 were reduced. Higher percentages of CD3+ CD4+  T cells in AFRS with increased expression of CD161 and/or IL-23R markers were observed. Though, lower percentages of CD4+ CD25+  Treg cells with elevated expression of GITR were patent. Transcription factor RORγt mRNA was upregulated, whereas <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mRNA was downregulated in AFRS patients. This inclination of Th17/Treg balance towards Th17, and the proposed role of Tregs on Th1 and Th2 cells in AFRS, directed us to conclude that Aspergillus infestation may lead to development of atopy and immunological dysbalance inciting a Th17 driven response, thereby, promoting aggravation of nasal polyposis. The observation may provide new insight into the molecular mechanisms leading to revision of the classical paradigm.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/29353353">29353353</a><div class="entities" style="line-height: 2.5"><h3>Peripheral Th17/Treg imbalance in elderly patients with ischemic stroke.</h3></br>CD4+ CD25+  regulatory T (Treg) cells and Th17 cells play important roles in peripheral immunity. Immune responses are main elements in the pathogenesis of ischemic stroke (IS). The contribution of Th17 cells in IS patients has not been proved, and whether the balance of Treg/Th17 cells is changed in IS patients remains unidentified. In the present study, we studied Th17 and Treg cell frequency, cytokine secretion, expression of transcription factors, and microRNAs related to <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Treg cells differentiation, which is compared between IS patients and control group. Thirty patients with IS and 30 individuals as control group were enrolled in this study. The frequency of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Treg lymphocytes, the expression of transcription factors and microRNAs related to these cells, and the serum levels of associated cytokines were assessed by flow cytometry, real-time PCR, and ELISA, respectively. A significant reduction in proportion of peripheral Treg cell frequency and the levels of TGF-β and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FOXP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression were observed in patients with IS compared with controls, while the proportions of Th17 were increased dramatically, and these effects were along with increases in the levels of IL-17A and RORγt expression in IS patients. The levels of mir-326 and mir-106b-25 expression were increased in patients with IS. These studies suggest that the increase in proportion of Th17 cells and decrease in Treg cells might contribute to the pathogenesis of IS. Manipulating the balance between Tregs and Th17 cells might be helpful for the treatment of IS.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/29099629">29099629</a><div class="entities" style="line-height: 2.5"><h3>Regulatory T cells improve pregnancy rate in RIF patients after additional IVIG treatment.</h3></br>RIF (repeated implantation failure) women with immunologic basis and cellular abnormalities may benefit from intravenous immunoglobulins (IVIG) as an immunomodulator based on different studies. In this study, we evaluated the effect of IVIG on the frequency and function of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Treg cells, as two important subgroups of CD4 +  T cells in implantation and pregnancy rates. Seventy-two RIF patients with preconception Th1⁄Th2 ratio and natural killer (NK) cells frequency and activity elevation were selected and divided into two groups; 40 out of 72 received IVIG, aspirin, and heparin (anoxaparin) and constituted the treatment group and 32 patients received aspirin and heparin (anoxaparin) and no IVIG and were the control group. Th17, Treg frequency, transcription factors, cytokine gene expression, and cytokine secretion were evaluated by flow cytometry, real-time PCR, and ELISA, respectively. Post-treatment evaluation of the IVIG grouprevealed a significant increase in Treg associated parameters such as Treg frequency (p = 0.0186), Foxp3 (p =<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">     0.00    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>04), and cytokine mRNA levels (IL-10, p = 0.0058 and TGF- β, p = 0.0038), however, in the case of Th17, a significant difference was only observed in a reduction in the RORγt mRNA level (p = 0.0218). In conclusion, IVIG therapy may be a good choice in the treatment of implantation failure in RIF women especially with an immunologic basis, and may improve the implantation and pregnancy rate by affecting immunoregulatory mechanisms such as Tregs.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/29050947">29050947</a><div class="entities" style="line-height: 2.5"><h3>Cyclic AMP-Responsive Element-Binding Protein (CREB) is Critical in Autoimmunity by Promoting Th17 but Inhibiting Treg Cell Differentiation.</h3></br>The molecular mechanisms that govern differential T cell development into pro-inflammatory <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> vs. regulatory T (Treg) cells remain unclear. Here, we show that selective deletion of CREB in T cells or Th17 cells impaired Th17 cell differentiation in vitro and in vivo, and led to resistance to autoimmune diseases. Mechanistically, CREB, activated by CD3-PKC-ϴ signaling, plays a key role in regulating Th17 cell differentiation, at least in part through directly binding to the Il17-Il17f gene locus. Unexpectedly, although dispensable for <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FOXP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression and for the homeostasis and suppressive function of thymus-derived Treg cells, CREB negatively regulates the survival of TGF-β-induced Treg cells, and deletion of CREB resulted in increased <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FOXP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+ Treg cells in the intestine and protection in a colitis model. Thus, CREB is critical in autoimmune diseases by promoting Th17 cell and inhibiting de novo Treg cell generation.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28993118">28993118</a><div class="entities" style="line-height: 2.5"><h3>Th17/Treg Ratio in Serum Predicts Onset of Postoperative Atrial Fibrillation After Off-Pump Coronary Artery Bypass Graft Surgery.</h3></br>The aim of this study is to identify whether the balance between T helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells and CD4+ CD25+ <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+  regulatory T (Treg) cells could predict the postoperative atrial fibrillation (POAF) after coronary artery bypass graft surgery (CABG).</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28290453">28290453</a><div class="entities" style="line-height: 2.5"><h3>Suppressive IL-17A+<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">     Foxp    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>3+  and ex-Th17 IL-17Aneg <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+  Treg  cells are a source of tumour-associated Treg  cells.</h3></br><mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and regulatory T (Treg ) cells are integral in maintaining immune homeostasis and Th17-Treg  imbalance is associated with inflammatory immunosuppression in cancer. Here we show that Th17 cells are a source of tumour-induced <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+  cells. In addition to natural (n)Treg  and induced (i)Treg  cells that develop from naive precursors, suppressive IL-17A+ <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+  and ex-Th17 <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+  cells are converted from IL-17A+ Foxp3neg  cells in tumour-bearing mice. Metabolic phenotyping of Foxp3-expressing IL-17A+ , ex-Th17 and iTreg  cells demonstrates the dissociation between the metabolic fitness and the suppressive function of Foxp3-expressing Treg  cell subsets. Although all Foxp3-expressing subsets are immunosuppressive, glycolysis is a prominent metabolic pathway exerted only by IL-17A+ <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+  cells. Transcriptome analysis and flow cytometry of IL-17A+ <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+  cells indicate that Folr4, GARP, Itgb8, Pglyrp1, Il1rl1, Itgae, TIGIT and ICOS are Th17-to-Treg  cell transdifferentiation-associated markers. Tumour-associated Th17-to-Treg  cell conversion identified here provides insights for targeting the dynamism of Th17-Treg  cells in cancer immunotherapy.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28198408">28198408</a><div class="entities" style="line-height: 2.5"><h3>Therapeutic effects of human adipose tissue-derived stem cell (hADSC) transplantation on experimental autoimmune encephalomyelitis (EAE) mice.</h3></br>This study is to investigate the therapeutic effects of human adipose tissue-derived stem cell (hADSC) transplantation on experimental autoimmune encephalomyelitis (EAE) in mice. EAE mouse model was established by MOG35-55 immunization. Body weight and neurological function were assessed. H&E and LFB staining was performed to evaluate histopathological changes. Flow cytometry was used to detect <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Treg cells. ELISA and real-time PCR were performed to determine transcription factor and pro-inflammatory cytokine levels. Transplantation of hADSCs significantly alleviated the body weight loss and neurological function impairment of EAE mice. Inflammatory cell infiltration and demyelination were significantly increased, which were relieved by hADSC transplantation. Moreover, the Th17 cells and the ROR-γt mRNA level were significantly elevated, while the Treg cells and the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mRNA level were significantly declined, resulting in significantly increased Th17/Treg ratio. This was reversed by the transplantation of hADSCs. Furthermore, serum levels of IL-17A, IL-6, IL-23, and TGF-β, were significantly increased, which could be influenced by the hADSC transplantation. Transplantation of hADSCs alleviates the neurological function impairment and histological changes, and reduces the inflammatory cell infiltration and demyelination in EAE mice, which might be associated with the regulation of Th17/Treg balance.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28157396">28157396</a><div class="entities" style="line-height: 2.5"><h3>Notch Signaling Modulates the Balance of Regulatory T Cells and T Helper 17 Cells in Patients with Chronic Hepatitis C.</h3></br>The imbalance of regulatory T cells (Tregs) and T helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells contributes to the persistent hepatitis C virus (HCV) infection. However, modulatory factors associated with Tregs-Th17 balance were not fully elucidated. A recent study demonstrated an immunoregulatory strategy by inactivation of Notch signaling to reverse the disequilibrium of Tregs-Th17 cells in immune thrombocytopenia. Thus, the aim of this study was to assess the effect of Notch signaling in regulating the functions of Tregs and Th17 cells in chronic hepatitis C. A total of 46 patients with chronic hepatitis C and 17 normal controls (NCs) were enrolled. mRNA expressions of Notch1 and Notch2 were semiquantified by real-time reserve polymerase chain reaction. Percentages of Tregs-Th17, levels of key transcriptional factors, and cytokine productions were measured in response to treatment by DAPT, a γ-secretase inhibitor to suppress Notch signaling. We found that Notch1 and Notch2 mRNAs were significantly elevated in peripheral blood mononuclear cells from chronic hepatitis C patients compared with those from NCs. DAPT treatment reduced Th17 response by downregulation of RORγt expression and interleukin (IL)-17/IL-22 secretion. Tregs proportion, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression, and IL-10 production did not change significantly with DAPT treatment in chronic hepatitis C; however, blockage of Notch signaling inhibited the suppressive function of Tregs. Moreover, effective anti-HCV therapy not only reduced Notch1 and Notch2 expression but also decreased Tregs and Th17 proportions. The current data provided a novel mechanism underlying the modulation of Treg-Th17 balance. The link between Notch signaling and Th cells might lead to a new intervention for breaking immunotolerance of chronic HCV infection.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28091550">28091550</a><div class="entities" style="line-height: 2.5"><h3>Imbalance of Th17/Treg cells in pathogenesis of patients with human leukocyte antigen B27 associated acute anterior uveitis.</h3></br>Th17 and regulatory T cells, involved in the pathogenesis of several autoimmune diseases, are new lineages of CD4+ T helper cells. However, the role of their imbalance in human leukocyte antigen B27-associated acute anterior uveitis has not been elucidated. In our study, the percentages of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Treg cells, their molecular markers and related factors in peripheral blood of patients and healthy controls were measured by flow cytometry, real-time RT-PCR and ELISA. We observed a remarkable increase of CD4+ and CD4+IL-17+ T cells in peripheral blood of patients compared to controls. The molecular markers and related factors of Th17 cell were also showed a distinct elevation. Interestingly, we observed an obvious decrease of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    CD4+CD25+Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+ T cells and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mRNA level in patients. The ratio of Th17/Treg in patients was dramatically higher than controls. Moreover, the ratio of Th17/Treg cells had a more significantly positive correlation with the disease activity score than Th17 cells whereas Treg cells had a negative correlation. Our findings demonstrated a distinct increase of Th17 cells and a significant decrease of Treg cells in patients compared to controls. The imbalance of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Treg cells may play a vital role in the pathogenesis of the disease.</div></details><details><summary>TH1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/29475096">29475096</a><div class="entities" style="line-height: 2.5"><h3>Phenotypic and functional profile of Th17 and Treg cells in allergic fungal sinusitis.</h3></br>Interleukin-17 producing T helper (Th17) and regulatory T cells (Treg) cells have been identified to play a critical role in atopic inflammation. However, conflicting reports on the role of Th17/Treg cells in allergic fungal rhinosinusitis (AFRS) patients of different ethnicities has mystified its pathogenesis. To better understand the pathophysiological mechanisms involved in AFRS, we conducted a prospective, analytical, case-control study involving 40 confirmed immunocompetent AFRS patients and 20 healthy controls. The distribution of Th17 and Treg cells in PBMC, intracellular mRNA expression of retinoid orphan nuclear receptor (RORγt) in Th17 and forkhead transcription factor (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) in Treg cells, and serum cytokine levels were investigated. Aspergillus flavus was identified from majority (85%) of patient tissue biopsies. Total serum IgE level along with cytokines IL-17, IL-21, IL-1β and TGF-β were comparatively elevated in AFRS. Nevertheless, IL-2 and IL-10 were reduced. Higher percentages of CD3+ CD4+  T cells in AFRS with increased expression of CD161 and/or IL-23R markers were observed. Though, lower percentages of CD4+ CD25+  Treg cells with elevated expression of GITR were patent. Transcription factor RORγt mRNA was upregulated, whereas <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mRNA was downregulated in AFRS patients. This inclination of Th17/Treg balance towards Th17, and the proposed role of Tregs on <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells in AFRS, directed us to conclude that Aspergillus infestation may lead to development of atopy and immunological dysbalance inciting a Th17 driven response, thereby, promoting aggravation of nasal polyposis. The observation may provide new insight into the molecular mechanisms leading to revision of the classical paradigm.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28913840">28913840</a><div class="entities" style="line-height: 2.5"><h3>Loss of regulatory characteristics in CD4+  CD25<sup>+/hi</sup> T cells induced by impaired transforming growth factor beta secretion in pneumoconiosis.</h3></br>Pneumoconiosis is caused by the accumulation of airborne dust in the lung, which stimulates a progress<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    ive i    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>nflammatory response that ultimately results in lung fibrosis and respiratory failure. It is possible that regulatory cells in the immune system could function to suppress inf<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    lamma    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>tion and possibly slow or reverse disease progression. However, results<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">     in t    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>his study suggest that in pneumoconiosis patients, the regulatory T cells (Tregs) and B cells are functionally impaired. First, we found that pneumoconiosis patients presented an upregulation of CD4+  CD25+  T cells compared to controls, whereas the CD4+  CD25+  and CD4+  CD25hi  T cells were enriched with <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1-    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th17-like cells but not Foxp3-expressing Treg cells and evidenced by significantly higher T-bet, interferon (IFN)-γ, and interleukin (IL)-17 expression but lower Foxp3 and transforming growth factor (TGF)-β expression. Regarding the CD4+  CD25hi  T cell subset, the frequency of this cell type in pneumoconiosis patients was significantly reduced compared to controls, together with a reduction in <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and TGF-β and an enrichment in T-bet, RORγt, IFN-γ, and IL-17. This skewing toward Th1 and Th17 types of inflammation could be driven by monocytes and B cells, since after depleting CD14+  monocytes and CD19+  B cells, the levels of IFN-γ and IL-17 were significantly decreased. Whole peripheral blood mononuclear cells and isolated monocytes and B cells in pneumoconiosis patients also presented reduced capacity of TGF-β secretion. Furthermore, monocytes and B cells from pneumoconiosis patients presented reduced capacity in inducing Foxp3 upregulation, a function that could be rescued by exogenous TGF-β. Together, these data indicated a potential pathway for the progression of pneumoconiosis through a loss of Foxp3+  Treg cells associated with impaired TGF-β secretion.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28850267">28850267</a><div class="entities" style="line-height: 2.5"><h3>KLRG1 expression identifies short-lived <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+  Treg  effector cells with functional plasticity in islets of NOD mice.</h3></br>A progressive waning in <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+  regulatory T (Treg ) cell function provokes autoimmunity in the non-obese diabetic (NOD) mouse model of type 1 diabetes (T1D), a cellular defe<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    ct re    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>scued by prophylactic IL-2 therapy. We showed that most islet-infiltrating Treg  cells express inducible T cell co-stimulator (ICOS) in pre-diabetic NOD mice, and that ICOS+  Treg  cells display enhanced fitness and suppressive function in situ. Moreover, T1D progression is associated with decreased expansion and suppressive activity of ICOS+ <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+  Treg  cells, in islets, an observation consistent with the exacerbated T1D seen in NOD.BDC2.5 mice in which the ICOS pathway is abrogated. Here, we show that a large proportion of islet-resident Treg  cells express the KLRG1 marker of terminally differentiation, in contrast to islet-infiltrating ICOS-  Treg  or Teff  cells. We hypothesized that KLRG1 expression designates a subpopulation of ICOS+  Treg  cells in islets that progressively loses function, and contributes to the immune dysregulation observed at T1D onset. Indeed, KLRG1-expressing ICOS+  Treg  cells are prone to apoptosis, and have an impaired proliferative capacity and suppressive function in vitro and in vivo. T1D protective low-dose IL-2 treatment in vivo could not rescue the loss of KLRG1-expressing Treg  cells in situ. While the global pool of Foxp3+  Treg  cells displays some degree of functional plasticity in vivo, the KLRG1+  ICOS+  Treg  cell subset is particularly susceptible to lose Foxp3 expression and reprogram into <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1-    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> or Th17-like effector T (Teff ) cells in the pancreas microenvironment. Overall, KLRG1 expression delineates a subpopulation of dysfunctional Treg  cells during T1D progression in autoantigen-specific TCR transgenic NOD mice.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28665747">28665747</a><div class="entities" style="line-height: 2.5"><h3>Analysis of immunological mechanisms exerted by HBsAg-HBIG therapeutic vaccine combined with Adefovir in chronic hepatitis B patients.</h3></br>An HBsAg-HBIG therapeutic vaccine (Yeast-derived Immune Complexes, YIC) for chronic hepatitis B (CHB) patients has undergone a series of clinical trials. The HBeAg sero-conversion rate of YIC varied from 21.9% to 14% depending on the immunization protocols from 6 to 12 injections. To analyze the immunological mechanisms exerted by 6 injections of YIC, 44 CHB patients were separately immunized with YIC, alum as adjuvant control or normal saline as blank control, with add on of antiviral drug Adefovir in all groups. Kinetic increase in <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells CD4+  T cell sub-populations with association in decrease in Treg cells and increase of Tc1 and Tc17 cells in CD8+  T cells were observed in YIC immunized group. No such changes were found in the other groups. By multifunctional analysis of cytokine profiles, significant increase of IL-2 levels was observed, both in CD4+  and CD8+  T cells in the YIC immunized group, accompanied by increase in IFN-gamma and decrease of inhibitory factors (IL-10, TGF-β and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) in CD4+  T cells. In the alum immunized group, slight increase of IL-10, TGF-β and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in CD4+  T cells was found after the second injection, but decreased after more injections, suggesting that alum induced early inflammatory responses to a certain extent. Similar patterns of responses of IL-17A and TNF-α in CD8+ T cells were shown between YIC and the saline group. Results indicate that add on of Adefovir, did not affect host specific immune responses.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/26968551">26968551</a><div class="entities" style="line-height: 2.5"><h3>Cyclosporine restores hematopoietic function by compensating for decreased Tregs in patients with pure red cell aplasia and acquired aplastic anemia.</h3></br>Most patients with acquired pure red cell aplasia (PRCA) and some with acquired aplastic anemia (AA) respond well to cyclosporine (CsA), but thereafter often show CsA dependency. The mechanism underlying this dependency remains unknown. We established a reliable method for measuring the regulatory T cell (Treg) count using <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and Helios expression as markers and determined the balance between Tregs and other helper T cell subsets in 16 PRCA and 29 AA patients. The ratios of interferon-γ-producing CD4(+) (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) T cells to Tregs in untreated patients and CsA-dependent patients were significantly higher (PRCA 5.77 ± 1.47 and 7.38 ± 2.58; AA 6.18 ± 2.35 and 8.94 ± 4.06) than in healthy volunteers (HVs; 3.33 ± 0.90) due to the profound decrease in the percentage of Tregs. In contrast, the ratios were comparable to HVs in convalescent CsA-treated AA patients (4.74 ± 2.10) and AA patients in remission after the cessation of CsA treatment (4.24 ± 1.67). Low-dose CsA (100 ng/ml) inhibited the proliferation of conventional T cells (Tconv) to a similar degree to the inhibition by Tregs in a co-culture with a 1:1 Treg/Tconv ratio. The data suggest that CsA may reverse the hematopoietic suppression in PRCA and AA patients by compensating for the inadequate immune regulatory function that occurs due to a profound decrease in the Treg count.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/26684629">26684629</a><div class="entities" style="line-height: 2.5"><h3><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    CD4+CD25+Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+ T regulatory cells, <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> (CCR5, IL-2, IFN-γ) and Th2 (CCR4, IL-4, Il-13) type chemokine receptors and intracellular cytokines in children with common variable immunodeficiency.</h3></br>Common variable immunodeficiency (CVID) is a heterogeneous group of primary antibody deficiencies characterized by decreased serum immunoglobulin G along with a decrease in serum IgA and/or IgM, defective specific antibody production, and recurrent bacterial infections. Abnormal lymphocyte trafficking, dysregulated cellular responses to chemokines, and uncontrolled T cell polarization may be involved in the pathogenesis and may help to understand the clinical complications. We evaluated T helper cell subsets (chemokine receptors CCR4, CCR5, and CCR7), expressions on T lymphocytes, intracellular cytokines - IL-2, IL-4, IL-13, IFN- γ-on CD4(+) T cells, and expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    CD4(+)CD25(+)Foxp3(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> regulatory T cells of 20 CVID patients and 26 healthy controls. Autoimmune clinical findings and other complications were also determined. Percentages and absolute numbers of CD4(+)CD25(+) <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> cells did not show any significant difference between CVID cases and healthy controls nor between severe and moderate disease patients. The only significant difference regarding Th1 and Th2 type intracellular cytokines was the decreased absolute numbers of CD3(+)CD4(+)IL4(+) cells in CVID cases. There were some findings about T helper cell type dominance in CVID patients such as positive correlation between hepatomegaly and high IL-2 and IFN-γ in CD3(+)CD4(+) cells and very high expression of CCR5 (Th1) on CD3(+)CD4(+) cells in patients with granuloma. Th1 (CCR5) and Th2 (CCR4) type chemokine receptors did not show any dominance in CVID cases. However, frequencies of CCR7 expressing CD3(+) T cells, CD3(+)CD4(+) T helper cells and CD3(+)CD8(+) T cytotoxic cells were significantly lower in severe CVID patients. In addition, presence of autoimmune clinical findings was negatively correlated with CCR7(+) cells. As CCR7 is a key mediator balancing immunity and tolerance in the immune system, the abnormality of this mediator may contribute to the profound immune dysregulation seen in CVID. In addition, Th1 cells seem to be more involved in the disease pathogenesis than Th2 cells. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/25730867">25730867</a><div class="entities" style="line-height: 2.5"><h3>Dendritic cell SIRT1-HIF1α axis programs the differentiation of CD4+ T cells through IL-12 and TGF-β1.</h3></br>The differentiation of naive CD4(+) T cells into distinct lineages plays critical roles in mediating adaptive immunity or maintaining immune tolerance. In addition to being a first line of defense, the innate immune system also actively instructs adaptive immunity through antigen presentation and immunoregulatory cytokine production. Here we found that sirtuin 1 (SIRT1), a type III histone deacetylase, plays an essential role in mediating proinflammatory signaling in dendritic cells (DCs), consequentially modulating the balance of proinflammatory T helper type 1 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells and antiinflammatory <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> regulatory T cells (T(reg) cells). Genetic deletion of SIRT1 in DCs restrained the generation of T(reg) cells while driving TH1 development, resulting in an enhanced T cell-mediated inflammation against microbial responses. Beyond this finding, SIRT1 signaled through a hypoxia-inducible factor-1 alpha (HIF1α)-dependent pathway, orchestrating the reciprocal TH1 and T(reg) lineage commitment through DC-derived IL-12 and TGF-β1. Our studies implicates a DC-based SIRT1-HIF1α metabolic checkpoint in controlling T cell lineage specification.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/25485537">25485537</a><div class="entities" style="line-height: 2.5"><h3>Inactivation of Notch signaling reverses the Th17/Treg imbalance in cells from patients with immune thrombocytopenia.</h3></br>T helper 17 (Th17) cells and regulatory T (Treg) cells, along with <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells, may contribute to the development of immune thrombocytopenia (ITP). The imbalance of Th17/Treg toward Th17 cells has been shown to play a pivotal role in the peripheral immune response. Notch signaling has been implicated in peripheral T cell activation and effector cell differentiation. However, the role of Th17/Treg in the pathogenesis of ITP and the effect of Notch signaling on Th17/Treg imbalances remain largely elusive in ITP. In vitro, we treated peripheral blood mononuclear cells (PBMCs) from ITP and healthy controls with γ-secretase inhibitor (DAPT). Th17 cells and Treg cells were measured by flow cytometry and IL-17, IL-21, and IL-10 secretion by enzyme immunoassay technique. The mRNA expression of Ntoch1, Hes1, Hey1, RORγt, and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> was investigated by RT-PCR. Cell proliferation and apoptosis were determined by the Cell Counting Kit-8 and apoptosis detection kit. We demonstrated that DAPT was effective in inhibiting mRNA expression of Notch signaling molecules. In untreated cultured PBMCs from ITP patients, we observed elevated Th17 cell and IL-21 levels and RORγt mRNA expression, decreased Treg cells and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mRNA expression, and an increased ratio of Th17/Treg and RORγt/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. After inactivating Notch signal by DAPT, Th17 cells and Th17/Treg ratio were dose dependently decreased and accompanied by the reduction of IL-17 in culture supernatants and RORγt mRNA expression in ITP patients. However, no significant difference was found for Treg cells and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mRNA expression, RORγt/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> ratio, and IL-21 and IL-10 levels after DAPT treatment in ITP patients. We also present evidence that the effect of DAPT inhibition on the Th17 cell response was associated with downregulation of RORγt and IL-17 transcription using human in vitro polarization. In conclusion, our findings highlight the importance of Notch signaling in Th17/Treg imbalances in ITP. Inactivation of Notch signaling might be a potential immunoregulatory strategy in ITP patients. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/25449852">25449852</a><div class="entities" style="line-height: 2.5"><h3>Aging disturbs the balance between effector and regulatory CD4+ T cells.</h3></br>Healthy aging requires an optimal balance between pro-inflammatory and anti-inflammatory immune responses. Although CD4+ T cells play an essential role in many immune responses, few studies have directly assessed the effect of aging on the balance between effector T (Teff) cells and regulatory T (Treg) cells. Here, we determined if and how aging affects the ratio between Treg and Teff cells. Percentages of both naive Treg (nTreg; <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    CD45RA+CD25(int)FOXP3(low)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) and memory Treg (memTreg; CD45RA-<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    CD25(high)FOXP3(high    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>)) cells were determined by flow cytometry in peripheral blood samples of healthy individuals of various ages (20-84 years). Circulating Th1, Th2 and Th17 effector cells were identified by intracellular staining for IFN-γ, IL-4 and IL-17, respectively, upon in vitro stimulation with PMA and calcium ionophore. Whereas proportions of nTreg cells declined with age, memTreg cells increased. Both <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells were largely maintained in the circulation of aged humans, whereas Th17 cells were decreased. Similar to memTreg cells, the 3 Teff subsets resided primarily in the memory CD4+ T cell compartment. Overall, Treg/Teff ratios were increased in the memory CD4+ T cell compartment of aged individuals when compared to that of young individuals. Finally, the relative increase of memTreg cells in elderly individuals was associated with poor responses to influenza vaccination. Taken together, our findings imply that aging disturbs the balance between Treg cells and Teff cells.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/25352158">25352158</a><div class="entities" style="line-height: 2.5"><h3>Skewed T-helper (Th)1/2- and Th17/T regulatory‑cell balances in patients with renal cell carcinoma.</h3></br>The characterization of CD4+ T cell subsets reflects the immune status and is important in the maintenance of tumorigenesis and homeostasis. To identify changes in the balance of T helper (Th)1, Th2, Th17 and regulatory T cells (Treg) in individuals with renal cell carcinoma (RCC), the present study investigated a total of 131 patients with RCC and 36 healthy volunteers. The number of CD4+ T‑bet+ cells, CD4+ GATA binding protein 3+ cells, CD4+ RAR-related orphan receptor γt+ cells, CD4+ CD25hi CD127lo CD45RA‑ cells and CD4+ CD25hi CD127lo CD45RA+ cells, defined as Th1, Th2, Th17, activated and naïve Treg cells, respectively, were detected in the peripheral blood using flow cytometric analysis. In addition, tumor‑infiltrating forkhead box P3 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3)+    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> cells were examined using immunohistochemistry. Compared with healthy volunteers, a significant decrease in the peripheral percentages of Th1, activated and naïve Treg cells was observed in patients with RCC, while those of the Th2 and Th17 cells were increased. In particular, as the tumor stage and grade progressed, the levels of Th1, activated and naïve Treg cells in the peripheral blood decreased; however, the levels of Th2 and Th17 cells increased. Furthermore, the number of tumor-infiltrating <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+ cells increased with increasing tumor stage. These results demonstrated that the balance of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells was skewed towards the Th2 profile and the balance of Th17 and Treg cells was skewed towards the Th17 profile in the peripheral blood of patients with renal cell carcinoma (RCC) and Treg cells were recruited to the tumor sites. Therefore, dysfunctional host anti‑tumor immunity was observed in patients with RCC, with a skewed Th1/Th2 and Th17/Treg balance.</div></details><details><summary>TEFF</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28850267">28850267</a><div class="entities" style="line-height: 2.5"><h3>KLRG1 expression identifies short-lived <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+  Treg  effector cells with functional plasticity in islets of NOD mice.</h3></br>A progressive waning in <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+  regulatory T (Treg ) cell function provokes autoimmunity in the non-obese diabetic (NOD) mouse model of type 1 diabetes (T1D), a cellular defe<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    ct re    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>scued by prophylactic IL-2 therapy. We showed that most islet-infiltrating Treg  cells express inducible T cell co-stimulator (ICOS) in pre-diabetic NOD mice, and that ICOS+  Treg  cells display enhanced fitness and suppressive function in situ. Moreover, T1D progression is associated with decreased expansion and suppressive activity of ICOS+ <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+  Treg  cells, in islets, an observation consistent with the exacerbated T1D seen in NOD.BDC2.5 mice in which the ICOS pathway is abrogated. Here, we show that a large proportion of islet-resident Treg  cells express the KLRG1 marker of terminally differentiation, in contrast to islet-infiltrating ICOS-  Treg  or Teff  cells. We hypothesized that KLRG1 expression designates a subpopulation of ICOS+  Treg  cells in islets that progressively loses function, and contributes to the immune dysregulation observed at T1D onset. Indeed, KLRG1-expressing ICOS+  Treg  cells are prone to apoptosis, and have an impaired proliferative capacity and suppressive function in vitro and in vivo. T1D protective low-dose IL-2 treatment in vivo could not rescue the loss of KLRG1-expressing Treg  cells in situ. While the global pool of Foxp3+  Treg  cells displays some degree of functional plasticity in vivo, the KLRG1+  ICOS+  Treg  cell subset is particularly susceptible to lose Foxp3 expression and reprogram into Th1- or Th17-like effector T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Teff    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> ) cells in the pancreas microenvironment. Overall, KLRG1 expression delineates a subpopulation of dysfunctional Treg  cells during T1D progression in autoantigen-specific TCR transgenic NOD mice.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28113084">28113084</a><div class="entities" style="line-height: 2.5"><h3>Increase of IRF-1 gene expression and impairment of T regulatory cells suppression activity on patients with myelodysplastic syndrome: A longitudinal one-year study.</h3></br>Studies have demonstrated that abnormalities in interferon regulatory factor-1 (IRF-1) expression might develop myelodysplastic syndromes (MDS). IRF-1 was described as modulator of T regulatory (Treg) cells by suppressing <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> on mice. We aimed to determine the role of Treg and IRF-1 in MDS. Thirty-eight MDS patients fulfilling WHO criteria and classified according to risk scores were evaluated at time 0 (T0) and after 12 months (T12) for: Treg suppression activity in coculture with T effector (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Teff    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells; IRF-1 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> genetic expression by qRT-PCR; IL-2, -4, -6, -10, -17, TNFα and IFNγ production by Cytometric Bead Array. No differences in <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression (T0=0.06±0.06 vs T12=0.06±0.12, p=0.5), Treg number (T0=5.62±2.84×105  vs T12=4.87±2.62×105 ; p=0.3) and Teff percentage (T0=16.8±9.56% vs T12=13.1±6.3%; p=0.06) were observed on T12. Low risk MDS patients showed a higher number of Treg (5.2±2.6×105 ) versus high risk group (2.6±1.2×105 , p=0.03). Treg suppression activity was impaired on T0 and T12.Cytokine production and IRF-1 expression were increased on T12. The correlation between IRF-1 and FoxP3 was negative (r2 =0.317, p=0.045) <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    on T0    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. These results suggest a hyper activity of the immune system, probably secondary to Treg suppression activity impairment. This state may induce the loss of tolerance culminating in the proliferation of MDS clones.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27859048">27859048</a><div class="entities" style="line-height: 2.5"><h3>β-cell-specific IL-35 therapy suppresses ongoing autoimmune diabetes in NOD mice.</h3></br>IL-35 is a recently identified c<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    ytoki    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>ne exhibiting potent immunosuppressive properties. The therapeutic potential and effects of IL-35 on pathogenic T effector cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Teff    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+  Treg, however, are ill defined. We tested the capacity of IL-35 to suppress ongoing autoimmunity in NOD mice. For this purpose, an adeno-associated virus vector in which IL-35 transgene expression is selectively targeted to β cells via an insulin promoter (AAV8mIP-IL35) was used. AAV8mIP-IL35 vaccination of NOD mice at a late preclinical stage of type 1 diabetes (T1D) suppressed β-cell autoimmunity and prevented diabetes onset. Numbers of islet-resident conventional CD4+  and CD8+  T cells, and DCs were reduced within 4 weeks of AAV8mIP-IL35 treatment. The diminished islet T cell pool correlated with suppressed proliferation, and a decreased frequency of IFN-γ-expressing Teff. Ectopic IL-35 also reduced islet Foxp3+  Treg numbers and proliferation, and protection was independent of induction/expansion of adaptive islet immunoregulatory T cells. These findings demonstrate that IL-35-mediated suppression is sufficiently robust to block established β-cell autoimmunity, and support the use of IL-35 to treat T1D and other T cell-mediated autoimmune diseases.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27865385">27865385</a><div class="entities" style="line-height: 2.5"><h3>The characteristic profiles of PD-1 and PD-L1 expressions and dynamic changes during treatment in active tuberculosis.</h3></br>PD-1 is a cell surface receptor of activated T and B lymphocytes and it's role in tuberculosis is controversial because of lack of congruence between clinical study and animal model. To investigate the immunological pathogenesis mechanisms of tuberculosis and to develop the immune therapy target essential for controlling tuberculosis, here we explored the expression characteristics and dynamic changes of PD-1/PD-L1 pathway in different CD4+T cell subsets. We enrolled 24 human subjects including 15 active tuberculosis (ATB) patients and 9 healthy donors (HD). The expressions of PD-1 and PD-L1 on CD4+T cells increased significantly in ATB patients than HD. ATB patients had a higher proportion of regulatory T cells (Treg, CD4+ CD25 + <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+) than HD. The expressions of PD-1 and PD-L1 increased remarkably on CD4+T cell subsets, including Treg cells, Tresp (CD4+ CD25- ) cells and <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Teff    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> (CD4+ CD25 + <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3-    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) cells. Finally, clinical improvement following effective anti-TB therapy is correlated with significantly decreased expression of PD-1 in Tresp and Teff cells, but not in Treg cells. Thus, expression profiles of PD-1 in T cell subpopulations may be used as a candidate to predict the clinical efficacy of anti-tuberculosis therapy. Modulation of PD-1/PD-L1 pathway in CD4 subsets may offer an immunotherapy target for the control of tuberculosis.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27149428">27149428</a><div class="entities" style="line-height: 2.5"><h3>Hepatitis C virus-induced myeloid-derived suppressor cells regulate T cell differentiation and function via the signal transducer and activator of transcription 3 pathway.</h3></br>T cells play a pivotal role in controlling viral infection; however, the precise mechanisms responsible for regulating T cell differentiation and function during infections are incompletely understood. In this study, we demonstrated an expansion of myeloid-derived suppressor cells (MDSCs), in particular the monocytic MDSCs (M-MDSCs; CD14(+) CD33(+) CD11b(+) HLA-DR(-/low) ), in patients with chronic hepatitis C virus (HCV) infection. Notably, HCV-induced M-MDSCs express high levels of phosphorylated signal transducer and activator of transcription 3 (pSTAT3) and interleukin-10 (IL-10) compared with healthy subjects. Blocking STAT3 signalling reduced HCV-mediated M-MDSC expansion and decreased IL-10 expression. Importantly, we observed a significant increase in the numbers of CD4(+) CD25(+) <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> regulatory T (Treg) cells following incubation of healthy peripheral blood mononuclear cells (PBMCs) with MDSCs derived from HCV-infected patients or treated with HCV core protein. In addition, depletion of MDSCs from PBMCs led to a significant reduction of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> Treg cells developed during chronic HCV infection. Moreover, depletion of MDSCs from PBMCs significantly increased interferon-γ production by CD4(+) T effector (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Teff    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells derived from HCV patients. These results suggest that HCV-induced MDSCs promote Treg cell development and inhibit Teff cell function, suggesting a novel mechanism for T cell regulation and a new strategy for immunotherapy against human viral diseases.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27197182">27197182</a><div class="entities" style="line-height: 2.5"><h3>ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor Rejection.</h3></br>ICOS is a T cell coregulatory receptor that provides a costimulatory signal to T cells during antigen-mediated activation. Antitumor immunity can be improved by ICOS-targeting therapies, but their mechanism of action remains unclear. Here, we define the role of ICOS signaling in antitumor immunity using a blocking, nondepleting antibody against ICOS ligand (ICOS-L). ICOS signaling provided critical support for the effector function of CD4(+) <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3(-)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> T cells during anti-OX40-driven tumor immune responses. By itself, ICOS-L blockade reduced accumulation of intratumoral T regulatory cells (Treg), but it was insufficient to substantially inhibit tumor growth. Furthermore, it did not impede antitumor responses mediated by anti-4-1BB-driven CD8(+) T cells. We found that anti-OX40 efficacy, which is based on Treg depletion and to a large degree on CD4(+) effector T cell (Teff) responses, was impaired with ICOS-L blockade. In contrast, the provision of additional ICOS signaling through direct ICOS-L expression by tumor cells enhanced tumor rejection and survival when administered along with anti-OX40 therapy. Taken together, our results showed that ICOS signaling during antitumor responses acts on both <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Teff    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Treg cells, which have opposing roles in promoting immune activation. Thus, effective therapies targeting the ICOS pathway should seek to promote ICOS signaling specifically in effector CD4(+) T cells by combining ICOS agonism and Treg depletion. Cancer Res; 76(13); 3684-9. ©2016 AACR.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/25816350">25816350</a><div class="entities" style="line-height: 2.5"><h3>Decreased HIV-specific T-regulatory responses are associated with effective DC-vaccine induced immunity.</h3></br>The role of regulatory T cells (Tregs) in vaccination has been poorly investigated. We have reported that vaccination with ex vivo-generated dendritic-cells (DC) loaded with HIV-lipopeptides (LIPO-5-DC vaccine) in HIV-infected patients was well tolerated and highly immunogenic. These responses and their relation to viral replication following analytical treatment interruption (ATI) were variable. Here, we investigated whether the presence of HIV-specific Tregs might explain these differences. Co-expression of CD25, CD134, CD39 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> was used to delineate both antigen-specific Tregs and effectors T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Teffs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>). Median LIPO-5 specific-CD25+CD134+ polyfunctional T cells increased from 0.1% (IQR 0-0.3) before vaccination (week -4) to 2.1% (IQR 1.1-3.9) at week 16 following 4 immunizations (p=0.001) and were inversely correlated with maximum viral load following ATI (r=-0.77, p=0.001). Vaccinees who displayed lower levels of HIV-specific <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    CD4+CD134+CD25+CD39+FoxP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+ Tregs responded better to the LIPO-5-DC vaccine. After vaccination, the frequency of HIV-specific Tregs decreased (from 69.3 at week -4 to 31.7% at week 16) and inversely correlated with HIV-specific IFN-γ-producing cells (r=-0.64, p=0.002). We show that therapeutic immunization skewed the HIV-specific response from regulatory to effector phenotype which impacts on the magnitude of viral replication following ATI.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/25634360">25634360</a><div class="entities" style="line-height: 2.5"><h3>Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.</h3></br>Most autoimmune diseases (AID) are linked to an imbalance between autoreactive effector T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Teffs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) and regulatory T cells (Tregs). While blocking Teffs with immunosuppression has long been the only therapeutic option, activating/expanding Tregs may achieve the same objective without the toxicity of immunosuppression. We showed that low-dose interleukin-2 (ld-IL-2) safely expands/activates Tregs in patients with AID, such HCV-induced vasculitis and Type 1 Diabetes (T1D). Here we analyzed the kinetics and dose-relationship of IL-2 effects on immune responses in T1D patients. Ld-IL-2 therapy induced a dose-dependent increase in <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    CD4(+)Foxp3(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    CD8(+)Foxp3(+    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) Treg numbers and proportions, the duration of which was markedly dose-dependent. Tregs expressed enhanced levels of activation markers, including CD25, GITR, CTLA-4 and basal pSTAT5, and retained a 20-fold higher sensitivity to IL-2 than Teff and NK cells. Plasma levels of regulatory cytokines were increased in a dose-dependent manner, while cytokines linked to Teff and Th17 inflammatory cells were mostly unchanged. Global transcriptome analyses showed a dose-dependent decrease in immune response signatures. At the highest dose, Teff responses against beta-cell antigens were suppressed in all 4 patients tested. These results inform of broader changes induced by ld-IL-2 beyond direct effects on Tregs, and relevant for further development of ld-IL-2 for therapy and prevention of T1D, and other autoimmune and inflammatory diseases. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/25449852">25449852</a><div class="entities" style="line-height: 2.5"><h3>Aging disturbs the balance between effector and regulatory CD4+ T cells.</h3></br>Healthy aging requires an optimal balance between pro-inflammatory and anti-inflammatory immune responses. Although CD4+ T cells play an essential role in many immune responses, few studies have directly assessed the effect of aging on the balance between effector T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Teff    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells and regulatory T (Treg) cells. Here, we determined if and how aging affects the ratio between Treg and Teff cells. Percentages of both naive Treg (nTreg; <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    CD45RA+CD25(int)FOXP3(low)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) and memory Treg (memTreg; CD45RA-<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    CD25(high)FOXP3(high    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>)) cells were determined by flow cytometry in peripheral blood samples of healthy individuals of various ages (20-84 years). Circulating Th1, Th2 and Th17 effector cells were identified by intracellular staining for IFN-γ, IL-4 and IL-17, respectively, upon in vitro stimulation with PMA and calcium ionophore. Whereas proportions of nTreg cells declined with age, memTreg cells increased. Both Th1 and Th2 cells were largely maintained in the circulation of aged humans, whereas Th17 cells were decreased. Similar to memTreg cells, the 3 Teff subsets resided primarily in the memory CD4+ T cell compartment. Overall, Treg/Teff ratios were increased in the memory CD4+ T cell compartment of aged individuals when compared to that of young individuals. Finally, the relative increase of memTreg cells in elderly individuals was associated with poor responses to influenza vaccination. Taken together, our findings imply that aging disturbs the balance between Treg cells and Teff cells.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/25453751">25453751</a><div class="entities" style="line-height: 2.5"><h3>Helios-positive functional regulatory T cells are decreased in decidua of miscarriage cases with normal fetal chromosomal content.</h3></br>Regulatory (Treg) T cells play essential roles in the maintenance of allogeneic pregnancy in mice and humans. Recent data show that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression occurs in both immuno-suppressive Treg and -nonsuppressive effector T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Teff    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells upon activation in humans. Samstein et al. (2012) reported that inducible Treg (iTreg) cells enforce maternal-fetal tolerance in placental mammals. Therefore, we should reanalyze which types of Treg cell play an important role in the maintenance of allogeneic pregnancy. In this study, we studied the frequencies of naïve Treg cells, effector Treg cells, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> Teff cells, Helios(+) naturally occurring Treg (nTreg) cells, and Helios(-) iTreg cells using flow cytometry. The frequencies of effector Treg cells and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> Teff cells among <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    CD4(+)Foxp3(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> cells in the decidua of miscarriage cases with a normal embryo karyotype (n=8) were significantly lower (P=0.0105) and significantly higher (P=0.0258) than those in normally progressing pregnancies (n=11), respectively. However, these frequencies in miscarriages with an abnormal embryo karyotype (n=15) were similar to those in normally progressing pregnancies. The frequencies of these cell populations in the three groups were unchanged in peripheral blood; on the other hand, most of the effector Treg cells in the decidua were Helios(+) nTreg cells and these frequencies were significantly higher than those in peripheral blood, while those among effector Treg and naïve Treg cells in the decidua and peripheral blood were similar among the three groups. These data suggest that decreased Helios(+) effector nTreg might play an important role in the maintenance of pregnancy in humans. </div></details><details><summary>TH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28504697">28504697</a><div class="entities" style="line-height: 2.5"><h3>The transcriptional coactivator TAZ regulates reciprocal differentiation of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> 17 cells and Treg  cells.</h3></br>An imbalance in the lineages of immunosuppressive regulatory T cells (Treg  cells) and the inflammatory TH 17 subset of helper T cells leads to the development of autoimmune and/or inflammatory disease. Here we found that TAZ, a coactivator of TEAD transcription factors of Hippo signaling, was expressed under TH 17 cell-inducing conditions and was required for TH 17 differentiation and TH 17 cell-mediated inflammatory diseases. TAZ was a critical co-activator of the TH 17-defining transcription factor RORγt. In addition, TAZ attenuated Treg  cell development by decreasing acetylation of the Treg  cell master regulator <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mediated by the histone acetyltransferase Tip60, which targeted <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> for proteasomal degradation. In contrast, under Treg  cell-skewing conditions, TEAD1 expression and sequestration of TAZ from the transcription factors RORγt and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> promoted Treg  cell differentiation. Furthermore, deficiency in TAZ or overexpression of TEAD1 induced Treg  cell differentiation, whereas expression of a transgene encoding TAZ or activation of TAZ directed TH 17 cell differentiation. Our results demonstrate a pivotal role for TAZ in regulating the differentiation of Treg  cells and <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> 17 cells.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27902985">27902985</a><div class="entities" style="line-height: 2.5"><h3>Disease Manifestation and Inflammatory Activity as Modulators of Th17/Treg Balance and RORC/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> Methylation in Systemic Sclerosis.</h3></br>There is much evidence that T cells are strongly involved in the pathogenesis of localized and systemic forms of scleroderma (SSc). A dysbalance between <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+ regulatory CD4+ T cells (Tregs) and inflammatory T-helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) 17 cells has been suggested.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27893700">27893700</a><div class="entities" style="line-height: 2.5"><h3>Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> 17 cells.</h3></br>The cellular sources of interleukin 6 (IL-6) that are relevant for differentiation of the TH 17 subset of helper T cells remain unclear. Here we used a novel strategy for the conditional deletion of distinct IL-6-producing cell types to show that dendritic cells (DCs) positive for the signaling regulator Sirpα were essential for the generation of pathogenic <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> 17 cells. Using their IL-6 receptor α-chain (IL-6Rα), Sirpα+  DCs trans-presented IL-6 to T cells during the process of cognate interaction. While ambient IL-6 was sufficient to suppress the induction of expression of the transcription factor <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in T cells, trans-presentation of IL-6 by DC-bound IL-6Rα (called 'IL-6 cluster signaling' here) was needed to prevent premature induction of interferon-γ (IFN-γ) expression in T cells and to generate pathogenic <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> 17 cells in vivo. Our findings should guide therapeutic approaches for the treatment of TH 17-cell-mediated autoimmune diseases.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27754729">27754729</a><div class="entities" style="line-height: 2.5"><h3>Is TGFβ as an anti-inflammatory cytokine required for differentiation of inflammatory <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> 17 cells?</h3></br>T-Helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> 17) cells are a CD4+  TH  subset that plays a critical role in the pathophysiology of inflammatory disorders, especially chronic forms. It seems that the derivation of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> 17 cells from their precursors take place in inflammatory microenvironment. The role of transforming growth factor (TGF)-β as an anti-inflammatory cytokine in TH 17 cell differentiation is controversial. To address some of the discrepancies that exist among different studies, this study was undertaken to more clarify the TGFβ role in human TH 17 cell differentiation. Here, CD4+  T cells were isolated from peripheral blood samples and cultured in X-VIVO 15 serum-free medium. Purified cells were then treated with different combinations of polarizing cytokines (interleukin [IL]1-β, -6, and -23, with or without TGFβ), neutralizing anti-interferon (IFN)-γ and anti-IL-4 antibodies and polyclonal stimulators anti-CD3 and -CD28 antibodies, and then analyzed for IL-17, IFNγ, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, and CD25 expression by flow cytometry and for release of IL-17, -21, -22, and -10 into culture media by ELISA. The effects of selective inhibition of TGFβ signaling pathway on TH 17 cell polarization were also determined by using small molecules SB-431542 and A83-01. The current study found that a combination of pro-inflammatory cytokines, including IL-1β, -6, and -23, but not TGFβ, could be used as a cytokine combination to induce development of human <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> 17 cells. It was also shown that TGFβ acted as a negative regulator in this regard and also led to reduced IL-17 and IL-22 production while inducing <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression. Indeed, blocking of TGFβ signaling pathways by selective inhibitors up-regulated TH 17 cell differentiation. From the data here, we concluded that TGFβ down-regulates human TH 17 cell differentiation and that a presence of pro-inflammatory cytokines (along with IFNγ and IL-4 neutralizing antibodies) is sufficient for optimal differentiation of human <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> 17 cells.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27602995">27602995</a><div class="entities" style="line-height: 2.5"><h3>Medium-dose estrogen ameliorates experimental autoimmune encephalomyelitis in ovariectomized mice.</h3></br>Estrogen is a neuro-protective hormone in various central nervous system (CNS) disorders. The present study evaluated the role of estrogen during experimental autoimmune encephalomyelitis (EAE) at doses selected to mimic any suppressive potential from the hormone during pregnancy. Here, mice were ovariectomized and then 2 weeks later treated with MOG antigen to induce EAE. Concurrently, mice then received (subcutaneously) an implanted pellet to deliver varying estrogen amounts over a 21-day period. Clinical scores and other parameters were monitored daily for the 21 days. At the end of the period, brain/spinal cord histology was performed to measure lymphocyte infiltration; T cell profiles were determined through ELISA, flow cytometry, and real-time PCR. Transcription factor expression levels in the CNS were assessed using real-time PCR; T cell differentiation was evaluated via flow cytometry. The results demonstrated that estrogen inhibited development of EAE. Histological studies revealed limited leukocyte infiltration into the CNS. High and medium dose of estrogen increased TH 2 and Treg  cell production of interleukin (IL)-4, IL-10, and transforming growth factor (TGF)-β, but concurrently resulted in a significant reduction in production of interferon (IFN)-γ, IL-17, and IL-6. Flow cytometry revealed there were also significant decreases in the percentages of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> 1 and TH 17 cells, as well as significant increase in percentages of Treg  and TH 2 cells in the spleen and lymph nodes. Real-time PCR results indicated that high- and medium-dose estrogen treatments reduced T-bet and ROR-γt factor expression, but enhanced <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and GATA3 expression. Collectively, these results demonstrated that a medium dose of estrogen - similar to a pregnancy level of estrogen - could potentially reduce the incidence and severity of autoimmune EAE and possibly other autoimmune pathologies.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/26475497">26475497</a><div class="entities" style="line-height: 2.5"><h3>T regulatory (Treg) and T helper 17 (Th17) lymphocytes in thyroid autoimmunity.</h3></br>Different immune cell subsets have a relevant role in the pathogenesis of and tissue damage seen in autoimmune thyroid diseases (AITD), including T regulatory (Treg) lymphocytes and T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) 17 cells. There are several types of CD4+ Treg cells (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+, CD69+, Tr1), which are able to prevent the appearance of autoimmune diseases, down regulating the immune response and the inflammatory phenomenon. However, despite their presence in peripheral blood and thyroid tissue from patients with AITD, these cells are apparently unable to put down the autoimmune process. Moreover, many reports indicate the involvement of Th17 cells in chronic inflammatory diseases, including AITD. Nevertheless, it is now evident that these lymphocytes show a remarkable plasticity, giving rise to anti-inflammatory (including Treg lymphocytes) and pro-inflammatory cell subtypes. Nowadays, both Treg and Th17 cells must be considered as key elements in the pathogenesis of AITD as well as plausible potential targets for the next generation of therapeutic options of this condition. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/26525134">26525134</a><div class="entities" style="line-height: 2.5"><h3>Age-Related Differences in Percentages of Regulatory and Effector T Lymphocytes and Their Subsets in Healthy Individuals and Characteristic STAT1/STAT5 Signalling Response in Helper T Lymphocytes.</h3></br>The dynamic process of the development of the immune system can in itself result in age-related immune malfunctions. In this study, we analysed lymphocyte subsets in the peripheral blood of 60 healthy donors, divided into groups of children, adolescents, and adults, focusing on effector (Teff) and regulatory (Treg) T lymphocytes and STAT1/STAT5 signalling response in helper T lymphocytes (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) in adults, using flow cytometry. Our results demonstrate a decrease in the percentage of total Tregs and an increase in the percentage of total Teffs with age and a consequential immense increase in the Teff/Treg ratio. The increase of Teffs was most apparent in Th1, Th1Th17, and Th17CD161- subsets. Significant Th lymphocyte STAT1 expression differences were observed between children and adolescents, which were associated with the decrease in activated Tregs. Higher expression of STAT1 was found in FoxP3hi than in FoxP3low Th lymphocytes, while significant IL-2 induced STAT5 phosphorylation differences were found among the subsets of Th lymphocytes in adults. Our study demonstrates age-related changes in circulating Teff and Treg, as well as significant differences in STAT5/STAT1 signalling among <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+ Th lymphocytes, providing new advances in the understanding of immunosenescence. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/25640656">25640656</a><div class="entities" style="line-height: 2.5"><h3>The role of all-trans retinoic acid in the biology of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+ regulatory T cells.</h3></br>Regulatory T (Treg) cells are necessary for immune system homeostasis and the prevention of autoimmune diseases. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is specifically expressed in Treg cells and plays a key role in their differentiation and function. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> Treg cells are consisted of naturally occurring, thymus-derived Treg (nTreg) and peripheral-induced Treg (iTreg) cells that may have different functional characteristics or synergistic roles. All-trans retinoic acid (atRA), a vitamin A metabolite, regulates a wide range of biological processes, including cell differentiation and proliferation. Recent studies demonstrated that atRA also regulates the differentiation of T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells and Treg cells. Moreover, atRA also sustains nTreg stability under inflammatory conditions. In this review, we summarize the significant progress of our understanding of the role(s) and mechanisms of atRA in Treg biology. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/24292092">24292092</a><div class="entities" style="line-height: 2.5"><h3>Expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and interleukin-17 in lichen planus lesions with emphasis on difference in oral and cutaneous variants.</h3></br><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is a specific marker for regulatory T cells (Tregs), and interleukin (IL)-17 is the signature cytokine of T-helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) 17 cells. Recent studies suggested that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+ Tregs and IL-17+ Th17 cells may be involved in pathogenesis of lichen planus (LP). The objectives of this study were to examine the immunoexpression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and IL-17 in archival paraffin-embedded biopsy specimens from 80 cases of LP (oral LP, n = 42; cutaneous LP, n = 38) and compare against normal control tissues (oral mucosa, n = 10; skin, n = 10). The results showed that the mean number of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and IL-17 expression in LP was significantly higher compared to controls, respectively (both P < 0.001). A positive correlation between <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and IL-17 expression (r = 0.273; P = 0.014) was observed. Moreover, the mean number of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression in oral LP was significantly higher than cutaneous LP (P < 0.001). Collectively, our findings demonstrated the increased expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and IL-17 in LP lesions including oral and cutaneous variants. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expressing in oral LP was higher than cutaneous LP, which may be associated with the difference in clinical behaviour of the two variants of the disease. Further studies are required to investigate the immunopathologic mechanisms and therapeutic target of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+ Tregs and IL-17+ Th17 cells in LP. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/24194584">24194584</a><div class="entities" style="line-height: 2.5"><h3>The duration of T cell stimulation is a critical determinant of cell fate and plasticity.</h3></br>Variations in T cell receptor (TCR) signal strength, as indicated by differential activation of downstream signaling pathways, determine the fate of naïve T cells after encounter with antigen. Low-strength signals favor differentiation into regulatory T (T(reg)) cells containing the transcription factor <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, whereas high-strength signals favor generation of interleukin-2-producing T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(H)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. We constructed a logic circuit model of TCR signaling pathways, a major feature of which is an incoherent feed-forward loop involving both TCR-dependent activation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and its inhibition by mammalian target of rapamycin (mTOR), leading to the transient appearance of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> cells under T(H) cell-generating conditions. Experiments confirmed this behavior and the prediction that the immunosuppressive cytokine TGF-β (transforming growth factor-β) could generate T(reg) cells even during continued Akt-mTOR signaling. We predicted that sustained mTOR activity could suppress <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FOXP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression upon TGF-β removal, suggesting a possible mechanism for the experimentally observed instability of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> cells. Our model predicted, and experiments confirmed, that transient stimulation of cells with high-dose antigen generated T(H), T(reg), and nonactivated cells in proportions depending on the duration of TCR stimulation. Experimental analysis of cells after antigen removal identified three populations that correlated with these T cell fates. Further analysis of simulations implicated a negative feedback loop involving <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, the phosphatase PTEN, and Akt-mTOR in determining fate. These results suggest that there is a critical time after TCR stimulation during which heterogeneity in the differentiating population of cells leads to increased plasticity of cell fate.</div></details><details><summary>TFH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/29870918">29870918</a><div class="entities" style="line-height: 2.5"><h3>The prevalence and function of CD4+ CXCR5+ <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+  follicular regulatory T cells in diffuse large B cell lymphoma.</h3></br>CD4+ CXCR5+ <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+  follicular regulatory T (Tfr) cells possess critical roles in suppressing the germinal center reaction, B cell activation, and follicular helper T cell (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cytokine secretion. Since diffuse large B cell lymphoma (DLBCL) can arise from B cells undergoing germinal center reaction and/or differentiation, we hypothesized that Tfr cells might be involved in DLBCL. In the present study, we recruited thirty-five DLBCL patients and twenty-five healthy controls. Data showed that DLBCL patients presented an enrichment of circulating CD4+ CXCR5+ <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+  Tfr cells compared to controls. In the primary tumor isolated from enlarged lymph nodes, Tfr cells made up of roughly 3% to 16% of infiltrating T cells. Higher levels of tumor-infiltrating Tfr cells were observed in patients with less advanced DLBCL stages, and in patients that stayed in remission 24 months after the initial R-CHOP treatment. High BCL6 and high <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FOXP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression was observed in Tfr cells ex vivo. After anti-CD3/CD28 and IL-2 stimulation, the Tfr cells more closely resembled Treg cells and presented high IL10 and TGFB1 expression. CD4+ CD25+ CXCR5+  Tfr cells and CD4+ CD25+ CXCR5-  non-Tfr Treg cells could suppress CD4+ CD25-  Tconv cell and CD8+  T cell proliferation with similar capacity. However, Tfr cells were less capable of suppressing IFNG expression than Treg cells, and although both cell types supported CD19+  tumor cell proliferation, Tfr cells were less supportive than the non-Tfr Treg cells. Overall, this study suggested that Tfr cells were involved in intratumoral immunity, were likely beneficial to DLBCL patients, and were functionally distinctive from non-Tfr Treg cells. The distribution pattern and the prognostic value of Tfr cells in DLBCL should be examined in further studies.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/29545616">29545616</a><div class="entities" style="line-height: 2.5"><h3>Apolipoprotein AI prevents regulatory to follicular helper T cell switching during atherosclerosis.</h3></br>Regulatory T (Treg) cells contribute to the anti-inflammatory response during atherogenesis. Here we show that during atherogenesis Treg cells lose <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression and their immunosuppressive function, leading to the conversion of a fraction of these cells into T follicular helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. We show that Tfh cells are pro-atherogenic and that their depletion reduces atherosclerosis. Mechanistically, the conversion of Treg cells to Tfh cells correlates with reduced expression of IL-2Rα and pSTAT5 levels and increased expression of IL-6Rα. In vitro, incubation of naive T cells with oxLDL prevents their differentiation into Treg cells. Furthermore, injection of lipid-free Apolipoprotein AI (ApoAI) into ApoE<sup>-/-</sup> mice reduces intracellular cholesterol levels in Treg cells and prevents their conversion into Tfh cells. Together our results suggest that ApoAI, the main protein in high-density lipoprotein particles, modulates the cellular fate of Treg cells and thus influences the immune response during atherosclerosis.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/29414660">29414660</a><div class="entities" style="line-height: 2.5"><h3>Increased circulating CD4+ CXCR5+ <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+  follicular regulatory T cells correlated with severity of systemic lupus erythematosus patients.</h3></br>As one specialized subset of regulatory T cells (Tregs), follicular regulatory T cells (TFR) could suppress follicular helper T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TFH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) and B cells in germinal centers to maintain immune homeostasis. The unbalance of TFR and TFH cells could result in abnormal germinal center responses and contribute to pathogenesis of autoimmune diseases. However, the role of TFR cells in systemic lupus erythematosus (SLE) remains unclear. This study revealed a significant increase of CD4+ CXCR5+ <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FOXP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+  TFR cells in peripheral blood of SLE patients compared with healthy controls. Meanwhile, the suppression ability of circulating TFR cells was not altered. The ratios of TFR/TFH were increased in SLE patients and the frequency of TFR was positively correlated with auto-antibodies and SLEDAI scores of SLE patients. Our results demonstrated that circulating TFR cells were increased during SLE, which suggested that elevated TFR might be a response to the pathogenesis of SLE to suppress TFH function and may provide novel insight for the pathogenesis of SLE.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/29109300">29109300</a><div class="entities" style="line-height: 2.5"><h3>The shifted balance between circulating follicular regulatory T cells and follicular helper T cells in patients with ulcerative colitis.</h3></br>B-cell immunity participates in the pathogenesis of ulcerative colitis (UC). The immune balance between follicular regulatory T (TFR) cells and follicular helper T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TFH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells is important in regulating B-cell responses. However, the alteration of TFR/TFH balance in UC remains unclear. Peripheral blood from 25 UC patients and 15 healthy controls was examined for the frequencies of circulating TFR, TFH, and regulatory T (Treg) cells by flow cytometry. Levels of serum cytokines were measured using cytometric bead array (CBA). Disease activity was evaluated by the Mayo Clinic Score. Compared with controls, UC patients exhibited significant reductions in circulating <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+ CXCR5+  TFR cells, the subset interleukin (IL)-10+ <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+ CXCR5+  cells, and Treg cells, but significant expansions in <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3-    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> CXCR5+  TFH cells and IL-21+ <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3-    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> CXCR5+  cells. UC patients also had reduced levels of serum IL-10 and elevated levels of serum IL-21. The values of Mayo Clinic Score, C-reactive protein (CRP), or erythrocyte sedimentation rate (ESR) in UC patients were negatively correlated with circulating TFR cells, serum IL-10 level, and TFR/TFH ratio, while positively correlated with circulating TFH cells and serum IL-21 level. Alterations in circulating TFR and TFH cells shift the balance from immune tolerance to immune responsive state, contributing to dysregulated B-cell immunity and the pathogenesis of UC.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28698369">28698369</a><div class="entities" style="line-height: 2.5"><h3>A distinct subpopulation of CD25-  T-follicular regulatory cells localizes in the germinal centers.</h3></br>T-follicular helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells differentiate through a multistep process, culminating in germinal center (GC) localized GC-Tfh cells that provide support to GC-B cells. T-follicular regulatory (Tfr) cells have critical roles in the control of Tfh cells and GC formation. Although Tfh-cell differentiation is inhibited by IL-2, regulatory T (Treg) cell differentiation and survival depend on it. Here, we describe a CD25-  subpopulation within both murine and human PD1+ CXCR5+ <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+  Tfr cells. It is preferentially located in the GC and can be clearly differentiated from CD25+  non-GC-Tfr, Tfh, and effector Treg (eTreg) cells by the expression of a wide range of molecules. In comparison to CD25+  Tfr and eTreg cells, CD25-  Tfr cells partially down-regulate IL-2-dependent canonical Treg features, but retain suppressive function, while simultaneously up-regulating genes associated with <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and GC-Tfh cells. We suggest that, similar to Tfh cells, Tfr cells follow a differentiation pathway generating a mature GC-localized subpopulation, CD25-  Tfr cells.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27999289">27999289</a><div class="entities" style="line-height: 2.5"><h3>Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma.</h3></br>Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is characterized by a low percentage of neoplastic lymphocyte predominant (LP) cells in a background of lymphocytes. The goal of this study is to characterize the microenvironment in NLPHL. Ten NLPHL cases and seven reactive lymph nodes (RLN) were analyzed by flow cytometry for the main immune cells and multiple specific subpopulations. To discriminate between cells in or outside the tumor cell area, we used CD26. We observed significantly lower levels of CD20+ B-cells and CD56+ NK cells and higher levels of CD4+ T cells in NLPHL in comparison to RLN. In the subpopulations, we observed increased numbers of PD-1+CD4+ T follicular helper cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TFH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>), CD69+CD4+ and CD69+CD8+ T cells and CCR7-CD45RA-CD4+ effector memory T cells, while <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxP3+CD4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+ T regulatory cells (Tregs) and CCR7-CD45RA+ terminally differentiated CD4+ T cells were decreased in NLPHL compared to RLN. CD69+ cells were increased in the tumor cell area in CD4+ and CD8+ T cells, while <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxP3+CD25+CD4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+ Tregs and CD25+CD8+ T cells were significantly increased outside the tumor area. Thus, we show a markedly altered microenvironment in NLPHL, with lower numbers of NK cells and Tregs. PD-1+CD4+ and CD69+ T cells were located inside, and Tregs and CD25+CD8+ cells outside the tumor cell area.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27473945">27473945</a><div class="entities" style="line-height: 2.5"><h3>Imbalance of circulating <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    CD4(+)CXCR5(+)FOXP3(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> Tfr-like cells and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    CD4(+)CXCR5(+)FOXP3(-)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> Tfh-like cells in myasthenia gravis.</h3></br>Follicular regulatory T (Tfr) cells are defined as a specialized subset of regulatory T cells (Tregs) that act to control the overactivation of follicular helper T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells and B cells in germinal centers. Accumulating evidence has demonstrated that the dysregulation of either Tfr cells or Tfh cells results in abnormal germinal center responses that contribute to the pathogenesis of autoimmune diseases. However, the role that Tfr cells and Tfh cells play in myasthenia gravis (MG) remains unclear. This study revealed a significantly decreased frequency of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    CD4(+)CXCR5(+)FOXP3(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> Tfr-like cells and an increased frequency of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    CD4(+)CXCR5(+)FOXP3(-)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> Tfh-like cells in the peripheral blood of MG patients compared with healthy controls. Moreover, the Tfr-like/Tfh-like ratio was inversely correlated with the clinical severity of the MG patients. Interestingly, glucocorticoid (GC) treatment can restore the imbalance of circulating Tfr-like/Tfh-like cells, and this restoration is accompanied by reduced clinical symptoms. These results suggested, for the first time, that an imbalance of circulating Tfr-like and Tfh-like cells may be involved in the immunopathogenesis of MG and may provide novel insight for the development of MG therapies. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27296664">27296664</a><div class="entities" style="line-height: 2.5"><h3>The Lupus Susceptibility Gene Pbx1 Regulates the Balance between Follicular Helper T Cell and Regulatory T Cell Differentiation.</h3></br>Pbx1 controls chromatin accessibility to a large number of genes and is entirely conserved between mice and humans. The Pbx1-d dominant-negative isoform is more frequent in CD4(+) T cells from lupus patients than from healthy controls. Pbx1-d is associated with the production of autoreactive T cells in mice carrying the Sle1a1 lupus-susceptibility locus. Transgenic (Tg) expression of Pbx1-d in CD4(+) T cells reproduced the phenotypes of Sle1a1 mice, with increased inflammatory functions of CD4(+) T cells and impaired <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> regulatory T cell (Treg) homeostasis. Pbx1-d-Tg expression also expanded the number of follicular helper T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TFHs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) in a cell-intrinsic and Ag-specific manner, which was enhanced in recall responses and resulted in Th1-biased Abs. Moreover, Pbx1-d-Tg CD4(+) T cells upregulated the expression of miR-10a, miR-21, and miR-155, which were implicated in Treg and follicular helper T cell homeostasis. Our results suggest that Pbx1-d impacts lupus development by regulating effector T cell differentiation and promoting TFHs at the expense of Tregs. In addition, our results identify Pbx1 as a novel regulator of CD4(+) T cell effector function.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/26541894">26541894</a><div class="entities" style="line-height: 2.5"><h3>TGF-β induces the differentiation of human CXCL13-producing CD4(+) T cells.</h3></br>In the ectopic lymphoid-like structures present in chronic inflammatory conditions such as rheumatoid arthritis, a subset of human effector memory CD4(+) T cells that lacks features of follicular helper T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells produces CXCL13. Here, we report that TGF-β induces the differentiation of human CXCL13-producing CD4(+) T cells from naïve CD4(+) T cells. The TGF-β-induced CXCL13-producing CD4(+) T cells do not express CXCR5, B-cell lymphoma 6 (BCL6), and other Tfh-cell markers. Furthermore, expression levels of CD25 (IL-2Rα) in CXCL13-producing CD4(+) T cells are significantly lower than those in <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxP3(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in vitro induced Treg cells. Consistent with this, neutralization of IL-2 and knockdown of STAT5 clearly upregulate CXCL13 production by CD4(+) T cells, while downregulating the expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. Furthermore, overexpression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in naïve CD4(+) T cells downregulates CXCL13 production, and knockdown of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> fails to inhibit the differentiation of CXCL13-producing CD4(+) T cells. As reported in rheumatoid arthritis, proinflammatory cytokines enhance secondary CXCL13 production from reactivated CXCL13-producing CD4(+) T cells. Our findings demonstrate that CXCL13-producing CD4(+) T cells lacking Tfh-cell features differentiate via TGF-β signaling but not via <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, and exert their function in IL-2-limited but TGF-β-rich and proinflammatory cytokine-rich inflammatory conditions. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/26062018">26062018</a><div class="entities" style="line-height: 2.5"><h3>Pathogenic Transdifferentiation of Th17 Cells Contribute to Perpetuation of Rheumatoid Arthritis during Anti-TNF Treatment.</h3></br>T-helper cells producing interleukin (IL)-17A and IL-17F cytokines (Th17 cells) are considered the source of autoimmunity in rheumatoid arthritis (RA). In this study, we characterized specific pathogenic features of Th17 cells in RA. By using nano-string technology, we analyzed transcription of 419 genes in the peripheral blood CCR6(+)CXCR3(-) CD4(+) cells of 14 RA patients and 6 healthy controls and identified 109 genes discriminating Th17 cells of RA patients from the controls. Th17 cells of RA patients had an aggressive pathogenic profile and in addition to signature cytokines IL-17, IL-23 and IL-21, and transcriptional regulators RAR-related orphan receptor gamma of T cells (RORγt) and Janus kinase 2 (JAK2), they produced high levels of IL-23R, C-C chemokine ligand type 20 (CCL20), granulocyte-monocyte colony-stimulating factor (GM-CSF ) and transcription factor Tbet required for synovial homing. We showed that Th17 cells are enriched with Helios-producing <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3-    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and IL2RA-deficient cells, indicating altered regulatory profile. The follicular T-helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells presented a functional profile of adaptor molecules, transcriptional regulator Bcl-6 and B-cell activating cytokines IL-21, IL-31 and leukemia inhibitory factor (LIF ). We observed that anti-tumor necrosis factor (TNF) treatment had a limited effect on the transcription signature of Th17 cells. Patients in remission retained the machinery of receptors (IL-23R and IL-1R1), proinflammatory cytokines (IL-17F, IL-23, IL-21 and TNF ) and adaptor molecules (C-X-C chemokine receptor 5 [CXCR5] and cytotoxic T lymphocyte-associated protein 4 [CTLA-4]), essential for efficient transdifferentiation and accumulation of Th17 cells. This study convincingly shows that the peripheral blood CCR6(+)CXCR3(-) CD4(+) cells of RA patients harbor pathogenic subsets of Th17 and Tfh cells, which may transdifferentiate from Tregs and contribute to perpetuation of the disease. </div></details><details><summary>TFREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/24324208">24324208</a><div class="entities" style="line-height: 2.5"><h3><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3⁺    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> T(reg) cells in humoral immunity.</h3></br>T(reg) cells are essential for the maintenance of immune homeostasis and prevention of autoimmunity. In humoral immune responses, loss of T(reg) cell function causes increased levels of serum autoantibodies, hyper-IgE, spontaneous generation of germinal centres, and enhanced numbers of specialised T follicular helper cells (T(fh) cells) controlled by the lineage-defining transcription factor BCL-6 (B-cell lymphoma 6). Recent studies have demonstrated that a subset of T(reg) cells [T follicular regulatory (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(freg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells] are able to co-opt the follicular T cell program by gaining expression of BCL-6 and travelling to the follicle where they have an important role in the control of expansion of T(fh) cells and the germinal centre reaction. However, the mechanisms by which they exert this control are still under investigation. In this review, we discuss the effects of T(reg) cells on humoral immunity and the mechanisms by which they exert their regulatory function.</div></details><details><summary>NKT</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/25190363">25190363</a><div class="entities" style="line-height: 2.5"><h3>The panoply of αβT cells in the skin.</h3></br>Skin protects body from continual attack by microbial pathogens and environmental factors. Such barrier function of skin is achieved by multiple components including immune system, which is mainly regulated by lymphocytes. T lymphocytes (T cells) that express T cell receptor (TCR) α and β chains (αβT cells) control the strength and the type of immune response. CD4T cell population consists of helper T (Th) cell-subsets and immunosuppressive regulatory T (Treg) cells. Th1 cells produce IFN-γ and protect against intracellular pathogens. Th2 cells produce IL-4 family cytokines and participate in allergic skin diseases, including atopic dermatitis (AD). Th17 cells secrete IL-17, recruit granulocytes to fight against extracellular microorganisms, and play a role in psoriasis and AD. Th22 cells produce IL-22 that activates epithelial cells and mediates acanthosis in psoriasis and AD. On the other hand, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+ Treg cells attenuate immune responses partly via TGF-β or IL-10. Tissue resident memory T (Trm) cells in the skin-most of which are epidermal CD8T cells-constitute the first line of the defense against repeated infections. CD8 T cells are also engaged in psoriasis, lichen planus, and drug eruptions. Skin harbors innate-like αβT cells such as natural killer T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NKT    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells as well, whose function is not fully revealed. Understanding these αβT cells helps to comprehend skin diseases. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/22156591">22156591</a><div class="entities" style="line-height: 2.5"><h3>Rapamycin combined with TGF-β converts human invariant NKT cells into suppressive <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+ regulatory cells.</h3></br>Invariant <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NKT    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> (iNKT) cells constitute a versatile T cell subset with important regulatory functions, which are thought to result essentially from their capacity to promptly produce cytokines that influence the Th1/Th2 balance. In this study, we report that these cells can also express <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, an important transcriptional regulator associated with suppressive activity, once they have been exposed to TGF-β. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> was expressed by iNKT cells from both peripheral and cord blood. CD4(+) iNKT cells acquired <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression preferentially, although a lower proportion of their CD4(-) counterpart also became positive. All <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> iNKT cells displayed CD25 but not necessarily CTLA4 or GITR, regardless of the upregulation of these markers in the presence of TGF-β. Exposure to TGF-β decreased IL-4 and IFN-γ production while increasing IL-10, independently from <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression. IL-17 was not detected. TGF-β induced high levels of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, but no suppressor activity, which emerged only in the presence of rapamycin. Peripheral and cord blood <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> iNKT cells suppressed the proliferation of conventional autologous and heterologous CD4(+) T cells equally, in a cell contact-dependent and Ag-independent manner. Our findings demonstrate that human iNKT cells become suppressive in the presence of TGF-β plus rapamycin, thus adding a new facet to their complex functional properties.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21314851">21314851</a><div class="entities" style="line-height: 2.5"><h3>Low circulating CD4(+) CD25(+) <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> T regulatory cell levels predict miscarriage risk in newly pregnant women with a history of failure.</h3></br>PROBLEM  The purpose of this study was to determine whether quant<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    ificatio    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>n of peripheral blood Treg cell levels could be used as an indicator of miscarriage risk in newly pregnant women with a hist<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    ory of i    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>mmunologic reprodu<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    ctive fa    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>ilure. METHOD OF ST<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    UDY      <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>Fifty-four preg<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    nant wom    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>en with <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    a history of immunologic in    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>fer<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    tility a    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>nd/or pregnancy loss were retrospectively evaluated (mean a<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    ge: 36.7    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> ± 4.9 years, 2.8 ± 2.5 previous miscarriages; 1.5 ± 1.9 previous IVF failures). Twenty-three of these women experienced another first trimester miscarriage, and 31 of these women continued their current pregnancies past 12 weeks ('pregnancy success'). The following immunologic parameters were assessed in the first trimester: NK cell 50:1 cytotoxicity, CD56(+)  16(+)  CD3(-) (NK), CD56(+)  CD3(+) (NKT), TNFα/IL-10, IFNγ/IL-10, CD4(+)  CD25(-) Foxp3(+) , total CD4(+)  Foxp3(+) (CD4(+ ) CD25(+)  Foxp3 plus CD25(- ) Foxp3(+) ), and CD4(+)  CD25(+)  Foxp3(+) levels. RESULTS  Patients with successful ongoing pregnancies experienced a mean (CD4(+)  CD25(+)  Foxp3(+) ) 'Treg' level of 0.72 ± 0.52%, while those that miscarried in the first trimester experienced a mean Treg level of 0.37 ± 0.29% (P = 0.005). Markers not significantly different between the loss and success groups were NK 50:1 cytotoxicity (P = 0.63), CD56(+)  16(+)  3(+) NK cells (P = 0.63), CD56(+)  3(+)   <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NKT    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> (P = 0.30), TNFα(+) IL-10(+) (P = 0.13), IFNg(+) IL-10(+) (P = 0.63), and CD4(+)  25(-)  Foxp3(+) cells (P = 0.10), although total CD4(+)  Foxp3(+) levels remained significant (P = 0.02) and CD4(+)  25(+) Foxp3(+) showed the most significant difference (P = 0.005). Mean day of blood draw was 49.2 ± 36.1 days pregnant (median 39.0 days). In addition, patients with a low Treg level (<0.7%) in the first trimester experienced a significantly lower ongoing pregnancy rate than those with a higher Treg level (>0.7%) in the first trimester [44% (15/34) versus 80% (16/20); P = 0.01]. Of the 18 successful pregnancies with sequential Treg results, 85% (11/13) showed a T-regulatory-cell-level increase (mean Treg change 0.33 ± 0.32), while only 40% (2/5) of the failed pregnancies showed a Treg increase (mean Treg change -0.08 ± 0.28; P = 0.02). CONCLUSIONS  From these data, we propose that CD4(+)  CD25(+)  Foxp3(+) T regulatory cells may serve as a superior pregnancy marker for assessing miscarriage risk in newly pregnant women. Larger follow-up studies are needed for confirmation.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/19277040">19277040</a><div class="entities" style="line-height: 2.5"><h3>The effects of trastuzumab on the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    CD4+CD25+FoxP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+ and CD4+IL17A+ T cell axis in patients with breast cancer.</h3></br>In addition to the direct targeting effects on HER2-positive cells, trastuzumab may have a therapeutic role modulating the activity of the cellular immune system in patients with breast cancer. To investigate this further, the balance of T-regulatory (T(reg)), Th17, natural killer (NK) and NK T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NKT    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells before, during and after trastuzumab therapy was investigated. Sequential frequencies of circulating T(reg) cells, Th17 cells, NK and NKT cells were measured in peripheral blood of breast cancer patients and normal controls throughout therapy. Individuals with breast cancer had significantly higher T(reg) frequencies of peripheral blood compared with healthy controls (9.2 or 8.6 vs 6%; P<0.05), and no significant differences in T(reg) frequencies were observed between HER2-positive and HER2-negative individuals. The number of Th17 cells was lowest in HER2-positive patients compared with both healthy controls and HER2-negative patients (0.31 vs 0.75% or 0.84%; P=0.01). There appeared to be an inverse relationship between T(reg) and Th17 frequencies in metastatic breast cancer (MBC) with T(reg) levels significantly reduced during treatment with trastuzumab (P=0.04), whereas Th17 frequencies were concomitantly increased (P=0.04). This study supports earlier data that T(reg) cells are present at higher frequencies in breast cancer patients compared with healthy individuals. For the first time, we show that HER2-positive individuals with breast carcinomas have reduced numbers of circulating Th17 cells, which appear, in turn to have an inverse relationship with T(reg) frequency in MBC. The change in balance of the T(reg) : Th17 ratio appears to characterise the cancer state, and furthermore, is disrupted by trastuzumab therapy.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28481005">28481005</a><div class="entities" style="line-height: 2.5"><h3>Mesenchymal stem cells attenuate acute liver injury by altering ratio between interleukin 17 producing and regulatory natural killer T cells.</h3></br>Mesenchymal stem cells (MSCs) are, due to immunomodulatory characteristics, considered as novel agents in the treatment of immune-mediated acute liver failure. Although it is known that MSCs can regulate activation of T lymphocytes, their capacity to modulate function of neutrophils and natural killer T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NKT    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, major interleukin (IL) 17-producing cells in acute liver injury, is still unknown. By using 2 well-established murine models of neutrophil and NKT cell-mediated acute liver failure (induced by carbon tetrachloride and α-galactoceramide), we investigated molecular and cellular mechanisms involved in MSC-mediated modulation of IL17 signaling during acute liver injury. Single intravenous injection of MSCs attenuate acute hepatitis and hepatotoxicity of NKT cells in a paracrine, indoleamine 2,3-dioxygenase (IDO)-dependent manner. Decreased levels of inflammatory IL17 and increased levels of immunosuppressive IL10 in serum, reduced number of interleukin 17-producing natural killer T (NKT17) cells, and increased presence of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    forkhead box P3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> + IL10-producing natural killer T regulatory cells (NKTregs) were noticed in the injured livers of MSC-treated mice. MSCs did not significantly alter the total number of IL17-producing neutrophils, CD4+, and CD8 + T lymphocytes in the injured livers. Injection of mesenchymal stem cell-conditioned medium (MSC-CM) resulted with an increased NKTreg/NKT17 ratio in the liver and attenuated hepatitis in vivo and significantly reduced hepatotoxicity of NKT cells in vitro. This phenomenon was completely abrogated in the presence of IDO inhibitor, 1-methyltryptophan. In conclusion, the capacity of MSCs to alter NKT17/NKTreg ratio and suppress hepatotoxicity of NKT cells in an IDO-dependent manner may be used as a new therapeutic approach in IL17-driven liver inflammation. Liver Transplantation 23 1040-1050 2017 AASLD.</div></details><details><summary>TH2</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27576175">27576175</a><div class="entities" style="line-height: 2.5"><h3>The paracrine immunomodulatory interactions between the human dental pulp derived mesenchymal stem cells and CD4 T cell subsets.</h3></br>Mesenchymal stem cells (MSCs) have strong immunomodulatory properties, however these properties may show some differences according to the tissue<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">     type     <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>of their isolate. In this study we investigated the paracrine interactions between human DP derived MSCs (hDP-MSCs) and the CD4+  T helper cell subsets to establish their immunomodulatory mechanisms. We found that the CD4+ -Tbet+  (Th1) and CD4+ -Gata3+  (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells were suppressed by the hDP-MSCs, but the CD4+ -Stat3+  (Th17) and CD4+ -CD25+ -FoxP3+  (Treg) cells were stimulated. The expressions of T cell specific cytokines interferon gamma (IFN-g), interleukin (IL)-4 and IL-17a decreased, but IL-10 and transforming growth factor beta-1 (TGF-b1) increased with the hDP-MSCs. The expressions of indoleamine-pyrrole 2,3-dioxygenase (IDO), prostaglandin E2 (PGE2), soluble human leukocyte antigen G (sHLA-G) derived from hDP-MSCs slightly increased, but hepatocyte growth factor (HGF) significantly increased in the co-culture groups. According to our findings, the hDP-MSCs can suppress the Th1 and Th2 subsets but stimulate the Th17 and Treg subsets. The Stat3 expression of Th17 cells may have been stimulated by the HGF, and thus the pro-inflammatory Th17 cells may have altered into the immunosuppressive regulatory Th17 cells. Further prospective studies are needed to confirm our findings.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/26507707">26507707</a><div class="entities" style="line-height: 2.5"><h3>Multicolor flow-cytometric analysis of milk allergen-specific T-helper type 2 cells revealed coexpression of interleukin-4 with <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>.</h3></br>Allergen-specific T-helper type 2 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells play an important role in the development of allergic inflammation; however, investigations of the properties of allergen-specific T cells have been challenging in humans. Despite clear evidence that forkhead box p3 (Foxp3) is expressed in conventional effector T cells, its function has remained unknown.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/25599562">25599562</a><div class="entities" style="line-height: 2.5"><h3>Protein kinase CK2 enables regulatory T cells to suppress excessive TH2 responses in vivo.</h3></br>The quality of the adaptive immune response depends on the differentiation of distinct CD4(+) helper T cell subsets, and the magnitude of an immune response is controlled by <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    CD4(+)Foxp3(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> regulatory T cells (Treg cells). However, how a tissue- and cell type-specific suppressor program of Treg cells is mechanistically orchestrated has remained largely unexplored. Through the use of Treg cell-specific gene targeting, we found that the suppression of allergic immune responses in the lungs mediated by T helper type 2 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells was dependent on the activity of the protein kinase CK2. Genetic ablation of the β-subunit of CK2 specifically in Treg cells resulted in the proliferation of a hitherto-unexplored ILT3(+) Treg cell subpopulation that was unable to control the maturation of IRF4(+)PD-L2(+) dendritic cells required for the development of TH2 responses in vivo. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/20227920">20227920</a><div class="entities" style="line-height: 2.5"><h3>Combined T regulatory cell and <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> expression profile identifies children with cow's milk allergy.</h3></br>The role of T regulatory cells in spontaneous recovery from cow's milk allergy (CMA) is unclear. We investigated the mRNA expression of 12 T cell markers and the protein expression of CD4, CD25, CD127, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> after in vitro beta-lactoglobulin stimulation of peripheral blood mononuclear cells from children with persisting CMA (n=16), early recovery (n=20) or no atopy (n=21). Artificial neural networks with exhaustive search for all marker combinations revealed that markers <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, Nfat-C2, IL-16 and GATA-3 distinguished patients with persisting CMA most accurately from other study groups. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mRNA expression following beta-lactoglobulin stimulation was highest in children with persisting CMA. Also the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> intensity in CD4(+) CD25(high)CD127(low) cells was higher in children with CMA compared with non-atopic children. The expression profile of both Th2- and T regulatory cell-related genes thus reflects the clinical activity of CMA. Tolerance, in contrast, is not characterized by activation of circulating T regulatory cells.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27172902">27172902</a><div class="entities" style="line-height: 2.5"><h3>Cisplatin induces tolerogenic dendritic cells in response to TLR agonists via the abundant production of IL-10, thereby promoting Th2- and Tr1-biased T cell immunity.</h3></br>Although many advantageous roles of cisplatin (cis-diamminedichloroplatinum (II), CDDP) have been reported in cancer therapy, the immunomodulatory roles of cisplatin in the phenotypic and functional alterations of dendritic cells (DCs) are poorly understood. Here, we investigated the effect of cisplatin on the functionality of DCs and the changes in signaling pathways activated upon toll-like receptor (TLR) stimulation. Cisplatin-treated DCs down-regulated the expression of cell surface molecules (CD80, CD86, MHC class I and II) and up-regulated endocytic capacity in a dose-dependent manner. Upon stimulation with various TLR agonists, cisplatin-treated DCs showed markedly increased IL-10 production through activation of the p38 MAPK and NF-κB signaling pathways without altering the levels of TNF-α and IL-12p70, indicating the cisplatin-mediated induction of tolerogenic DCs. This effect was dependent on the production of IL-10 from DCs, as neither DCs isolated from IL-10-/- mice nor IL-10-neutralized DCs generated tolerogenic DCs. Interestingly, DCs that were co-treated with cisplatin and lipopolysaccharide (LPS) exhibited a decreased immunostimulatory capacity for inducing the proliferation of Th1- and Th17-type T cells; instead, these DCs contributed to Th2-type T cell immunity. Furthermore, in vitro and in vivo investigations revealed a unique T cell population, IL-10-producing <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    CD3+CD4+LAG-3+CD49b+CD25-Foxp3-    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> Tr1 cells, that was significantly increased without altering the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+ regulatory T cell population. Taken together, our results suggest that cisplatin induces immune-suppressive tolerogenic DCs in TLR agonist-induced inflammatory conditions via abundant IL-10 production, thereby skewing Th cell differentiation towards <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Tr1 cells. This relationship may provide cancer cells with an opportunity to evade the immune system. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/22532281">22532281</a><div class="entities" style="line-height: 2.5"><h3>[Mechanism of action of nasal glucocorticosteroids in the treatment of allergic rhinitis. Part 1: Pathophysiology, molecular basis].</h3></br>Allergic rhinitis (AR) is a common airway disease characterized by mucosal swelling leading to congestion, mucosal hyperreactivity and increased secretions. Inflammatory processes in the mucosa are responsible for most symptoms and are characterized by mucosal remodeling after longer time periods. The early phase response, which is characterized by sneezing, rhinorrhea and nasal congestion, is the response of the sensory nerve terminals and blood vessels in the nasal mucosa to chemical mediators such as histamine, prostaglandins and leukotrienes. Nasal exposure to allergens leads to infiltration of inflammatory cells, such as activated eosinophils and T helper type 2 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, into the nasal mucosa by chemoattractant factors such as cytokines including interleukin 5 (IL-5), chemical mediators including cysLTs and chemokines including eotaxin. Edema of the nasal mucosa develops as a secondary reaction with inflammatory cells. This inflammation, referred to as the late-phase response, develops 6-10 h after allergen challenge and causes prolonged nasal congestion. In addition, a neurogenic mechanism is activated after liberation of substance P and others. Therefore, allergic rhinitis is a complex immunogenic disease that also activates mechanisms of the immune system in general. Antiallergic and antiinflammatory medications such as nasal glucocorticosteroids (nGCS) are thought to be the most effective treatment for controlling the symptoms and inflammatory mechanisms of AR. The antiinflammatory action of nGCS depends on at least two different mechanisms: transactivation and transrepression. Moreover, they regulate immune functions by inducing regulatory cytokines and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    forkhead box P3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>). <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is of upmost importance as a transcription factor of regulatory T cells, allowing the inhibition of effector function and proliferation of other CD4+ cells.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/18800988">18800988</a><div class="entities" style="line-height: 2.5"><h3>Desmoglein 3-specific T regulatory 1 cells consist of two subpopulations with differential expression of the transcription factor <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>.</h3></br>Pemphigus vulgaris (PV) is an autoimmune bullous skin disorder associated with autoantibodies against desmoglein (Dsg) 3. An imbalance of type 1 regulatory T (Tr1) cells and T helper type 2 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells specific for Dsg3 may be critical for the loss of tolerance against Dsg3 in PV. Within the population of Dsg3-responsive, interleukin (IL)-10-secreting Tr1 cell clones, two major subpopulations were identified and sorted by fluorescence-activated cell sorting (FACS) based on their size and granularity. Upon in vitro culture, the larger subpopulation differentiated back into the two former subpopulations of the Tr1 cell clones, while the smaller subpopulation died within 2 weeks. The smaller subpopulation of the Tr1 cell clones was characterized by the expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, the secretion of IL-10, transforming growth factor (TGF)-beta and IL-5 upon stimulation with Dsg3, a proliferative response to IL-2 but not to Dsg3 or mitogenic stimuli, and an inhibitory effect on the proliferative response of Dsg3-responsive Th clones in a Dsg3-specific manner. In contrast, the larger subpopulation showed a Th-like phenotype, lacking <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, cytotoxic T lymphocyte antigen 4 (CTLA4) and glucocorticoid-induced tumour necrosis factor receptor (GITR) expression and IL-2 secretion, and did not mount a proliferative response to Dsg3 and mitogenic stimuli. The two Tr1 subpopulations showed expression of identical T cell receptor (TCR) V beta chains which varied among the PV patients studied. Upon inhibition of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, the smaller Tr1 subpopulation developed a proliferate response to Dsg3 and mitogenic stimuli, no longer suppressed Dsg3-specific Th cells, lost expression of GITR and CTLA4 and secreted IL-2. Thus, our observations suggest a distinct relationship between Dsg3-specific Tr1 and Th-like cells which may be critical for the continuous generation and survival of Dsg3-specific Tr1 cells.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/17686103">17686103</a><div class="entities" style="line-height: 2.5"><h3>Effects of pollen and nasal glucocorticoid on <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FOXP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+, GATA-3+ and T-bet+ cells in allergic rhinitis.</h3></br>T-regulatory cells (Treg) affect the balance of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(H)2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and T(H)1 cells. Treg, T(H)2 and T(H)1 cells are regulated by the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FOXP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, GATA-3 and T-bet transcription factors respectively. Our aim was to determine the number of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FOXP3(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, GATA-3(+) and T-bet(+) cells in nasal mucosa in symptom-free allergic rhinitis (AR) patients vs healthy controls, as well as the effects of natural pollen exposure and concomitant nasal glucocorticoid treatment on these cells.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/16623931">16623931</a><div class="entities" style="line-height: 2.5"><h3>High-altitude climate therapy reduces local airway inflammation and modulates lymphocyte activation.</h3></br>High-altitude climate therapy is a well-established therapeutic option, which improves clinical symptoms in asthma. However, little is known about the underlying immunological mechanisms. The study investigates the influence of high-altitude climate therapy on airway inflammation and cellular components of specific and unspecific immune response. Exhaled NO significantly decreased within 3 weeks of therapy in patients with allergic and intrinsic, moderate and severe asthma. Interleukin-10 (IL-10)-secreting peripheral blood mononuclear cells (PBMC) increased within 3 weeks of therapy in six of 11 patients, whereas transforming growth factor-beta(1)-secreting PBMC remained stable. Furthermore, monocyte activation, assessed by CD80 expression significantly decreased during therapy. The frequency of CRTH2-expressing T cells decreased, while regulatory T cells (T(reg)) remained stable. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FOXP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and GATA-3 mRNA expression in CD4(+) T cells did not change, while interferon-gamma and IL-13 mRNA expression decreased in eight of 10 patients. The current data demonstrate that high-altitude climate therapy reduces local airway inflammation. Furthermore, monocytes switch towards a tolerogenic phenotype under high-altitude climate therapy. The T(reg)/Th2 ratio increases; however, because of the absence of antigens/allergens, no de novo differentiation of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> nor T(reg) cells is observed. The high-altitude climate therapy therefore may form the immunological basis for the endogenous control of allergen-driven diseases.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/17172648">17172648</a><div class="entities" style="line-height: 2.5"><h3>TH2 cells in the pathogenesis of airway remodeling: regulatory T cells a plausible panacea for asthma.</h3></br>T-helper type 2 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are one of the hallmarks of airway remodeling. The daunting task of regaining tolerance will be to regulate airway hyperresponsiveness (AHR) and remodeling in chronic asthma by balancing the ballet of TH1 and TH2 cells. The mechanism of tolerance appears to be modulated by a specialized subset of T cells called regulatory T cells (Tregs). Currently there are six subtypes of Tregs including CD4+CD25+ naturally occurring (N-Tregs), inducible naïve CD4+CD25- T cells (TR1), TR1 memory phenotype, T-helper type 3 (TH3), CD4-CD25+DX5+ natural killer T cells (TRNKT), and CD4-CD25+CD8+ cytotoxic T cells (TRCTC). The development of Tregs is controversial as to whether they occur in the thymus or peripheral lymphoid tissue. Studies have shown that NTregs are generated in the thymus and TR1 cells occur in the periphery. Nevertheless, Tregs express an arsenal of molecular membrane markers: CD3, CD25, CD62L, CD69, BTLA, GITR, ICOS, Neuroplin- 1 (Nrp-1), and PD-1. However, the most definitive marker is Forkhead Winged-Helix Transcriptional Factor Box p3 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>). The suppression of N-Tregs occurs by cell-to-cell contact, and low levels of IL-10 and moderate levels of TGF-beta, but the primary mechanism involves the sequestration and activation of neighboring naïve CD4+CD25- T cells to become TR1 cells. In contrast, TR1 cells exert their suppressive properties by copious secretion of IL-10 and TGF- beta. These suppressive mechanisms occur by the inhibition of IL-2 production and the promotion of cell cycle arrest. The development of this specialized subset of T cells is an enigma, but their understanding will provide a plausible panacea for asthma.</div></details><details><summary>TREG17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/24511136">24511136</a><div class="entities" style="line-height: 2.5"><h3>Stat3 programs Th17-specific regulatory T cells to control GN.</h3></br>A pathogenic role for Th17 cells in inflammatory renal disease is well established. The mechanisms underlying their counter-regulation are, however, largely unknown. Recently, Th17 lineage-specific regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) that depend on activation of the transcription factor Stat3 were identified. We studied the function of Treg17 in the nephrotoxic nephritis (NTN) model of crescentic GN. The absence of Treg17 cells in <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3(Cre)×Stat3(fl/fl)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mice resulted in the aggravation of NTN and skewing of renal and systemic immune responses toward Th17. Detailed analysis of Stat3-deficient Tregs revealed that the survival, activation, proliferation, and suppressive function of these cells remained intact. However, Tregs from <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3(Cre)×Stat3(fl/fl)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mice lacked surface expression of the chemokine receptor CCR6, which resulted in impaired renal trafficking. Furthermore, aggravation of NTN was reversible in the absence of Th17 responses, as shown in CD4(Cre)×Stat3(fl/fl) mice lacking both Treg17 and Th17 cells, suggesting that Th17 cells are indeed the major target of Treg17 cells. Notably, immunohistochemistry revealed CCR6-bearing Treg17 cells in kidney biopsy specimens of patients with GN. CCR6 expression on human Treg17 cells also appears dependent on STAT3, as shown by analysis of Tregs from patients with dominant-negative STAT3 mutations. Our data indicate the presence and involvement of Stat3/STAT3-dependent Treg17 cells that specifically target Th17 cells in murine and human crescentic GN, and suggest the kidney-specific action of these Treg17 cells is regulated by CCR6-directed migration into areas of Th17 inflammation.</div></details><details><summary>TH3</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/25018055">25018055</a><div class="entities" style="line-height: 2.5"><h3>Serum Th17 cytokines in leprosy: correlation with circulating CD4(+) CD25 (high)FoxP3 (+) T-regs cells, as well as down regulatory cytokines.</h3></br>Leprosy is not only a bacte<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    riological disease b    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>ut also an immunological disease, in which T helper17 and CD4(+) <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    CD25(high)FoxP3(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> regulatory T cells (T-regs), among others, may play a role. We aimed to evaluate serum levels of interleukin (IL)-17, IL-22 (Th17 cytokines), IL-10 and transforming growth factor (TGF)-β (down regulatory cytokines) in 43 untreated leprosy patients and 40 controls by enzyme-linked immunosorbent assay, and to assess circulating CD4(+) <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    CD25(high)FoxP3(+)T-    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>regs in patients using flow cytometry. Patients were grouped into tuberculoid, pure neural, borderline, lepromatous, type 1 reactional leprosy, and erythema nodosum leprosum. IL-10 and TGF-β were significantly higher in patients as compared to controls (p < 0.001), while IL-17, but not IL-22, was significantly lower (p < 0.001), with no significant difference comparing patients' subgroups. Significantly higher CD4(+) CD25(high)FoxP3(+)T-regs levels was detected in tuberculoid, type 1 reaction and pure neural leprosy, while the lowest levels in erythema nodosum leprosum (p < 0.001). TregsFoxP3 expression% was significantly lower in pure neural leprosy than other patients' subgroups (p < 0.05). T-regs/T-effs was lowest in erythema nodosum leprosum (p < 0.05). TGF-β correlated negatively with TregsFoxP3 expression% and T-effs% (p = 0.009 and 0.018 respectively). Leprosy is associated with defective IL-17 and overproduction of IL-10 and TGF-β. Tuberculoid, type 1 reaction and pure neural leprosy express significantly higher circulating T-regs, consistent with effector immune mechanisms activation, but with lower TregsFoxP3 expression (in pure neural leprosy). Erythema nodosum leprosum is characterized by deficient T-regs and increased TregsFoxP3 expression%. The present study pinpointed a potential role of Th17, CD4(+) <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    CD25(high)FoxP3(+)T    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>-regs, and probably CD4(+) CD25(+)IL-10(+) T regulatory cells 1 (Tr1), and <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> in leprosy. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/22754651">22754651</a><div class="entities" style="line-height: 2.5"><h3>Regulatory T cells in arterivirus and coronavirus infections: do they protect against disease or enhance it?</h3></br>Regulatory T cells (T(regs)) are a subset of T cells that are responsible for maintaining peripheral immune tolerance and homeostasis. The hallmark of T(regs) is the expression of the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    forkhead box P3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) transcription factor. Natural regulatory T cells (nT(regs)) are a distinct population of T cells that express CD4 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. nTregs develop in the thymus and function in maintaining peripheral immune tolerance. Other CD4(+), CD4(-)CD8(-), and CD8(+)CD28(-) T cells can be induced to acquire regulatory function by antigenic stimulation, depending on the cytokine milieu. Inducible (or adaptive) T(regs) frequently express high levels of the interleukin 2 receptor (CD25). Atypical T(regs) express <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and CD4 but have no surface expression of CD25. Type 1 regulatory T cells (Tr1 cells) produce IL-10, while T helper 3 cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) produce TGF-β. The function of inducible T(regs) is presumably to maintain immune homeostasis, especially in the context of chronic inflammation or infection. Induction of T(regs) in coronaviral infections protects against the more severe forms of the disease attributable to the host response. However, arteriviruses have exploited these T cell subsets as a means to dampen the immune response allowing for viral persistence. T(reg) induction or activation in the pathogenesis of disease has been described in both porcine reproductive and respiratory syndrome virus, lactate dehydrogenase elevating virus, and mouse hepatitis virus. This review discusses the development and biology of regulatory T cells in the context of arteriviral and coronaviral infection.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/19210347">19210347</a><div class="entities" style="line-height: 2.5"><h3>T cell-mediated immunoregulation in the gastrointestinal tract.</h3></br>In the intestinal tract, only a single layer of epithelial cells separates innate and adaptive immune effector cells from a vast amount of antigens. Here, the immune system faces a considerable challenge in tolerating commensal flora and dietary antigens while preventing the dissemination of potential pathogens. Failure to tightly control immune reactions may result in detrimental inflammation. In this respect, 'conventional' regulatory CD4(+) T cells, including naturally occurring and adaptive CD4(+) CD25(+) <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> T cells, <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Tr1 cells, have recently been the focus of considerable attention. However, regulatory mechanisms in the intestinal mucosa are highly complex, including adaptations of nonhaematopoietic cells and innate immune cells as well as the presence of unconventional T cells with regulatory properties such as resident TCRgammadelta or TCRalphabeta CD8(+) intraepithelial lymphocytes. This review aims to summarize the currently available knowledge on conventional and unconventional regulatory T cell subsets (Tregs), with special emphasis on clinical data and the potential role or malfunctioning of Tregs in four major human gastrointestinal diseases, i.e. inflammatory bowel diseases, coeliac disease, food allergy and colorectal cancer. We conclude that the clinical data confirms some but not all of the findings derived from experimental animal models.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/16214099">16214099</a><div class="entities" style="line-height: 2.5"><h3>Thymic regulatory T cells.</h3></br>Several types of T regulatory (Treg) cells have been described in both mice and humans, including natural or professional (CD4+CD25+ T cells) and adaptive (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Tr1 cells) Treg cells. The former develops in the thymus and results in an endogeneous long-lived population of self-antigen-specific T cells in the periphery poised to prevent potentially autoimmune reactions. The second subset develops as a consequence of activation of mature T cells under particular conditions of sub-optimal antigen exposure and/or costimulation. Natural Treg cells are positively selected in the cortex through their TCR interactions with self-peptides presented by thymic stromal cells. It is likely that this high-affinity recognition results in signals rendering them anergic and able to produce anti-apoptoptic molecules which protect them from negative selection. Recently, small subsets of CD4+CD25+ and of CD8+CD25+ cells sharing similar characteristics have been detected in human fetal and post-natal thymuses. Both CD4+CD25+ and CD8+CD25+ human thymocytes express <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and GITR mRNA, as well as surface CCR8 and TNFR2 and cytoplasmic CTLA-4 proteins, which are common features of mature Treg cells. Following activation they do not proliferate or produce cytokines, but express surface CTLA-4 and TGF-beta1. They suppress the proliferation of autologous CD4+CD25- thymocytes to allogeneic stimulation by a contact-dependent mechanism related to the combined action of surface CTLA-4 and TGF-beta leading to the inhibition of the IL-2R alpha chain on target T cells. Lastly, both CD4+CD25+ and CD8+CD25+ Treg thymocytes exert strong suppressive activity on Th1, but much lower on Th2 cells, since these latter may escape from suppression via their ability to respond to growth factors other than IL-2. Treg cells that develop in, and emerge from, the thymus are certainly responsible for the maintenance of self-tolerance and prevention of autoimmune disorders. The result that Th1 cells are highly susceptible to the suppressive activity of Treg thymocytes is consistent with the important role of these cells in protecting against the Th1-mediated immune response to autoantigens.</div></details><details><summary>TEM</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28881482">28881482</a><div class="entities" style="line-height: 2.5"><h3>Altered expression of antigen-specific memory and regulatory T cell subsets differentiate latent and active tuberculosis.</h3></br>Although one-third of the world population is infected with Mycobacterium tuberculosis, only 5-10% of the infected individuals will develop active tuberculosis (TB) disease and the rest will remain infected with no symptoms, known as latent TB infection (LTBI). Identifying biomarkers that differentiate latent and active TB disease enables effective TB control, as early detection, treatment of active TB and preventive treatment of individuals with LTBI are crucial steps involved in TB control. Here, we have evaluated the frequency of antigen-specific memory and regulatory T (Treg) cells in 15 healthy household contacts (HHC) and 15 pulmonary TB patients (PTB) to identify biomarkers for differential diagnosis of LTBI and active TB. Among all the antigens tested in the present study, early secretory antigenic target-6 (ESAT-6) -specific CD4+  and CD8+  central memory (Tcm) cells showed 93% positivity in HHC and 20% positivity in PTB. The novel test antigens Rv0753c and Rv0009 both displayed 80% and 20% positivity in HHC and PTB, respectively. In contrast to Tcm cells, effector memory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tem    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells showed a higher response in PTB than HHC; both ESAT-6 and Rv0009 showed similar positivity of 80% in PTB and 33% in HHC. PTB patients have a higher proportion of circulating antigen-reactive Treg cells (CD4+   CD25+   <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+  ) than LTBI. Rv2204c-specific Treg cells showed maximum positivity of 73% in PTB and 20% in HHC. Collectively, our data conclude that ESAT-6-specific Tcm cells and Rv2204c-specific Treg cells might be useful biomarkers to discriminate LTBI from active TB.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/23747721">23747721</a><div class="entities" style="line-height: 2.5"><h3>CD45RA-Foxp3(high) activated/effector regulatory T cells in the CCR7 + CD45RA-CD27 + CD28+central memory subset are decreased in peripheral blood from patients with rheumatoid arthritis.</h3></br>Human CD4+ T cells can be classified as either naïve, central memory (TCM), or effector memory (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TEM    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. To identify the CD4+ T cell<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">     subs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>ets most important in the pathogenesis of rheumatoid arthritis (RA), we phenotypically defined human CD4+ T cells as functionally distinct subsets, and analyzed the distribution and characteristics of each subset in the peripheral blood. We classified CD4+ T cells into six novel subsets based on the expression of CD45RA, CCR7, CD27, and CD28. The CCR7 + CD45RA-CD27 + CD28+ TCM subset comprised a significantly smaller proportion of CD4+ T cells in RA patients compared to healthy controls. The frequency of TNF-α-producing cells in the CCR7-CD45RA-CD27 + CD28+ TEM subset was significantly increased in RA. Furthermore, within the CCR7 + CD45RA-CD27 + CD28+ TCM subset, which was decreased in periperal blood from RA, the proportions of total Foxp3+ Treg cells and CD45RA-Foxp3(high) activated/effector Treg cells were significantly lower in RA patients. Our findings suggest that the increased proportion of TNF-α-producing cells and the decreased proportion of CD45RA-Foxp3(high) activated/effector Treg cells in particular subsets may have critical roles in the pathogenesis of RA.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/20970557">20970557</a><div class="entities" style="line-height: 2.5"><h3>Kidney transplant recipients show an increase in the ratio of T cell effector memory/central memory as compared to nontransplant recipients on the waiting list.</h3></br>Studies of allotolerance in animal models do not usually consider the presence of preexisting memory T cells and activated immune status. However, humans are exposed throughout life to a multitude of external agents that enhance the immune memory. In this article, we consider the effect that a previous kidney transplant has on the number of regulatory T cells (Tregs), effector memory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TEM    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>), and central memory T cells (TCM). Sixty-three patients with end-stage renal disease were studied just before being transplanted (51 first transplants and 12 retransplants). The numbers of Tregs (CD4+ <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    CD25highCD127lowCD27+CD62L+CD45RO+FOXP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+), TEM (CD3+CD45RO+CD62L+), and TCM (CD3+CD45RO+CD62L-) cell subsets were quantified in peripheral blood by flow cytometry. The absolute number of Tregs was slightly lower in patients with previous allografts (median, 95% confidence interval [CI]: 16.7 cells/mm3, 12-20.5) than in those who received their first transplants (median, 95% CI: 19.6 cells/mm3, 19.3-29.6; P-NS). Clearer differences were found with the number of CD3+ TCM, since the transplanted patients had lower numbers (238 cells/mm3, 153-323) than those who had not yet received transplants (378 cells/mm3, 317-439; P=.029). As a result, the TEM/TCM ratios of both CD4+ and CD8+ T cells in patients with previous allografts were higher than in those who received first transplants. In conclusion, the assessment of just the number of Tregs in renal transplant patients is not enough and must be read together with the number of TEM and TCM. The TEM:TCM ratio increases in patients with previous allografts, probably due to activation of the immune response in renal transplantation.</div></details><details><summary>TRM</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28674001">28674001</a><div class="entities" style="line-height: 2.5"><h3>Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses.</h3></br>The recent development of immunotherapy as a cancer treatment has proved effective over recent years, but the precise dynamics between the tumor microenvironment (TME), nontumor microenvironment (NTME), and the systemic immune system remain elusive. Here, we interrogated these compartments in hepatocellular carcinoma (HCC) using high-dimensional proteomic and transcriptomic analyses. By time-of-flight mass cytometry, we found that the TME was enriched in regulatory T cells (Tregs), tissue resident memory CD8+  T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TRM    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> s), resident natural killer cells (NKR s), and tumor-associated macrophages (TAMs). This finding was also validated with immunofluorescence staining on <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+ CD4+  and PD-1+ CD8+  T cells. Interestingly, Tregs and TRM s isolated from the TME expressed multiple markers for T cell exhaustion, including PD-1, Lag-3, and Tim-3 compared with Tregs and TRM s isolated from the NTME. We found PD-1+  TRM s were the predominant T cell subset responsive to anti-PD-1 treatment and significantly reduced in number with increasing HCC tumor progression. Furthermore, T-bet was identified as a key transcription factor, negatively correlated with PD-1 expression on memory CD8+  T cells, and the PD-1:T-bet ratio increased upon exposure to tumor antigens. Finally, transcriptomic analysis of tumor and adjacent nontumor tissues identified a chemotactic gradient for recruitment of TAMs and NKR s via CXCR3/CXCL10 and CCR6/CCL20 pathways, respectively. Taken together, these data confirm the existence of an immunosuppressive gradient across the TME, NTME, and peripheral blood in primary HCC that manipulates the activation status of tumor-infiltrating leukocytes and renders them immunocompromised against tumor cells. By understanding the immunologic composition of this gradient, more effective immunotherapeutics for HCC may be designed.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/25190363">25190363</a><div class="entities" style="line-height: 2.5"><h3>The panoply of αβT cells in the skin.</h3></br>Skin protects body from continual attack by microbial pathogens and environmental factors. Such barrier function of skin is achieved by multiple components including immune system, which is mainly regulated by lymphocytes. T lymphocytes (T cells) that express T cell receptor (TCR) α and β chains (αβT cells) control the strength and the type of immune response. CD4T cell population consists of helper T (Th) cell-subsets and immunosuppressive regulatory T (Treg) cells. Th1 cells produce IFN-γ and protect against intracellular pathogens. Th2 cells produce IL-4 family cytokines and participate in allergic skin diseases, including atopic dermatitis (AD). Th17 cells secrete IL-17, recruit granulocytes to fight against extracellular microorganisms, and play a role in psoriasis and AD. Th22 cells produce IL-22 that activates epithelial cells and mediates acanthosis in psoriasis and AD. On the other hand, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+ Treg cells attenuate immune responses partly via TGF-β or IL-10. Tissue resident memory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Trm    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells in the skin-most of which are epidermal CD8T cells-constitute the first line of the defense against repeated infections. CD8 T cells are also engaged in psoriasis, lichen planus, and drug eruptions. Skin harbors innate-like αβT cells such as natural killer T (NKT) cells as well, whose function is not fully revealed. Understanding these αβT cells helps to comprehend skin diseases. </div></details><details><summary>TC1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/25055034">25055034</a><div class="entities" style="line-height: 2.5"><h3>[Tc1-mediated contact sensitivity reaction, its mechanism and regulation].</h3></br>The contact hypersensitivity reaction (CHS) to haptens is a classic example of cell-mediated immune response. In the effector phase, two stages can be distinguished: an early component, that appears only 2 hours after subsequent contact with the hapten, and the late component that develops approximately 24 hours later which is mediated by TCRαβ+ cells. The effector lymphocytes may be CD4+ T helper 1 (Th1) cells or CD8+ T cytotoxic 1 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tc1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, which depends on the employed hapten and/or mice strain. NKT lymphocytes play the crucial role in the CHS initiation, by supporting B1 cells in the antigen-specific IgM antibodies production. The development of an early component is essential for the recruitment of T effector (Teff) cells to the side of hapten deposition and for the complete expansion of inflammatory reaction. The CHS reaction is under T regulatory (Treg) cells control, both in the induction phase as well as in the effector phase. A new view of a negative regulation of the Tc1 mediated CHS response is based on the suppression induced by epicutaneous (EC) application of protein antigen. The DNP-BSA skin application, on a gauze patch, leads to a state of immunosuppression. This maneuver results in rising the population of Treg cells with <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TCRαβ+CD4+CD25+Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+ phenotype. The mechanism of suppression requires direct contact between Treg cells and Teff cells and the participation of CTLA-4 molecule is also necessary. The described method of evoking immune tolerance via EC immunization may contribute to elaborate a new method of allergic contact dermatitis therapy. This is because of its effectiveness, ease of induction and non-invasive protein antigen application. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/20966498">20966498</a><div class="entities" style="line-height: 2.5"><h3>[The role of stromal mast cells in the modification of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    CD4+CD25+Foxp³    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> regulatory T cells, Th17 lymphocytes and cytotoxic lymphocytes <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tc1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> in the development and progression of tumor].</h3></br>Despite the lack of direct evidence that immune surveillance cells protect against tumor development, indirect clinical observations and experimental studies indicate activity in the immune response against cancer cells of various origin. Little is known about the effects of the stromal tumor mast cell (MC) in the activity of immune cells, i.e. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    CD4+CD25+Foxp³+    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> regulatory T cells, Th17 lymphocytes, cytotoxic lymphocytes Tc1 and their mutual modulatory function and regulation of the antitumor immune response. Factors synthesized by stromal tumor mast cells including histamine, COX-2, CXCL8 (IL-8), VEGF, IL-6, TNF, iNOS, MMP-8, and MMP-9 may, on the one hand, directly affect the activity of T lymphocyte subpopulations, i.e. iTreg, Tc1, and Th17, and thus regulate immunological processes occurring in the vicinity of the tumor. On the other hand, through effects on angiogenesis, apoptosis, the cell cycle, secretion of cytokines and the expression of adhesion molecules, they may indirectly determine the progression of the neoplasm. Understanding the regulatory mechanisms occurring in the system: tumor stroma mast cell → immune cells infiltrating the tumor (iTreg, Tc1, Th17 lymphocytes) → expression of factors involved in angiogenesis, apoptosis, the cell cycle, and secretion of cytokines and adhesion molecules creates the future possibility of influencing the activation and regulation of selected proneoplastic and antineoplastic factors appearing in the neoplasm environment. Research on these mechanisms may be the beginning of a new approach to the fight against cancer growth and provide an opportunity to introduce new methods of treatment. The aim of this study was to present the current knowledge on the role of stromal tumor CD117+ mast cells and factors secreted by these cells in the activation of T lymphocyte subpopulations, i.e. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    CD4+CD25+Foxp³+    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> regulatory T cells, Th17 lymphocytes, and cytotoxic lymphocytes Tc1, as well as to present their impact on the degree of tumor invasiveness by regulating the synthesis of factors secreted by the lymphocyte subpopulations studied, e.g. IL-10 and TGF-β (iTreg), IL-17A and IL-6 (Th17), IFN-γ and IL-2 (Tc1).</div></details><details><summary>TH22</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/25190363">25190363</a><div class="entities" style="line-height: 2.5"><h3>The panoply of αβT cells in the skin.</h3></br>Skin protects body from continual attack by microbial pathogens and environmental factors. Such barrier function of skin is achieved by multiple components including immune system, which is mainly regulated by lymphocytes. T lymphocytes (T cells) that express T cell receptor (TCR) α and β chains (αβT cells) control the strength and the type of immune response. CD4T cell population consists of helper T (Th) cell-subsets and immunosuppressive regulatory T (Treg) cells. Th1 cells produce IFN-γ and protect against intracellular pathogens. Th2 cells produce IL-4 family cytokines and participate in allergic skin diseases, including atopic dermatitis (AD). Th17 cells secrete IL-17, recruit granulocytes to fight against extracellular microorganisms, and play a role in psoriasis and AD. <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th22    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells produce IL-22 that activates epithelial cells and mediates acanthosis in psoriasis and AD. On the other hand, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+ Treg cells attenuate immune responses partly via TGF-β or IL-10. Tissue resident memory T (Trm) cells in the skin-most of which are epidermal CD8T cells-constitute the first line of the defense against repeated infections. CD8 T cells are also engaged in psoriasis, lichen planus, and drug eruptions. Skin harbors innate-like αβT cells such as natural killer T (NKT) cells as well, whose function is not fully revealed. Understanding these αβT cells helps to comprehend skin diseases. </div></details><details><summary>TH9</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/22842344">22842344</a><div class="entities" style="line-height: 2.5"><h3>OX40 signaling favors the induction of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(H)9    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells and airway inflammation.</h3></br>The mechanisms that regulate the T(H)9 subset of helper T cells and diseases mediated by <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(H)9    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells remain poorly defined. Here we found that the costimulatory receptor OX40 was a powerful inducer of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(H)9    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells in vitro and T(H)9 cell-dependent airway inflammation in vivo. In polarizing conditions based on transforming growth factor-β (TGF-β), ligation of OX40 inhibited the production of induced regulatory T cells and the T(H)17 subset of helper T cells and diverted <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    CD4(+)Foxp3(-)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> T cells to a T(H)9 phenotype. Mechanistically, OX40 activated the ubiquitin ligase TRAF6, which triggered induction of the kinase NIK in CD4(+) T cells and the noncanonical transcription factor NF-κB pathway; this subsequently led to the generation of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(H)9    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells. Thus, our study identifies a previously unknown mechanism for the induction of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(H)9    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells and may have important clinical implications in allergic inflammation.</div></details><details><summary>THP</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/19912251">19912251</a><div class="entities" style="line-height: 2.5"><h3>Translational mini-review series on Th17 cells: induction of interleukin-17 production by regulatory T cells.</h3></br>Uncommitted (naive) CD4(+) T helper cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Thp    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) can be induced to differentiate to specific lineages according to the local cytokine milieu, towards T helper type 1 (Th1), Th2, Th17 and regulatory T cell (T(reg)) phenotypes in a mutually exclusive manner. Each phenotype is characterized by unique signalling pathways and expression of specific transcription factors, notably T-bet for Th1, GATA-3 for Th2, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    forkhead box P3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) for T(regs) and receptor-related orphan receptor (ROR)alpha and RORgammat for Th17 cells. T(regs) and Th17 cells have been demonstrated to arise from common precursors in a reciprocal manner based on exposure to transforming growth factor (TGF)-beta or TGF-beta plus interleukin (IL)-6 and carry out diametrically opposing functions, namely suppression or propagation of inflammation, respectively. However, while epigenetic modifications in Th1 and Th2 differentiated cells prevents their conversion to other phenotypes, Th17 cells generated in vitro using TGF-beta and IL-6 are unstable and can convert to other phenotypes, especially Th1, both in vitro and in vivo. T(regs) are generated from naive precursors both in the thymus (natural, nT(regs)) and in the periphery (induced, iT(regs)). The highly suppressive function of T(regs) enables them to control many inflammatory diseases in animals and makes them particularly attractive candidates for immunotherapy in humans. The stability of the T(reg) phenotype is therefore of paramount importance in this context. Recent descriptions of T(reg) biology have suggested that components of pathogens or inflammatory mediators may subvert the suppressive function of T(regs) in order to allow propagation of adequate immune responses. Unexpectedly, however, a number of groups have now described conversion of T(regs) to the Th17 phenotype induced by appropriate inflammatory stimuli. These observations are particularly relevant in the context of cell therapy but may also explain some of the dysregulation seen in autoimmune diseases. In this paper, we review T(reg) to Th17 conversion and propose some potential mechanisms for this phenomenon.</div></details><details><summary>TEMRA</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/25421756">25421756</a><div class="entities" style="line-height: 2.5"><h3>Low expression of CD39(+) /CD45RA(+) on regulatory T cells (Treg ) cells in type 1 diabetic children in contrast to high expression of CD101(+) /CD129(+) on Treg cells in children with coeliac disease.</h3></br>Type 1 diabetes (T1D) and coeliac disease are both characterized by an autoimmune feature. As T1D and coeliac disease share the same risk genes, patients risk subsequently developing the other disease. This study aimed to investigate the expression of T helper (Th), T cytotoxic (Tc) and regulatory T cells (Treg ) in T1D and/or coeliac disease children in comparison to healthy children. Subgroups of T cells (Th : CD4(+) or Tc : CD8(+) ); naive (CD27(+) CD28(+) CD45RA(+) CCR7(+) ), central memory (CD27(+) CD28(+) CD45RA(-) CCR7(+) ), effector memory (early differentiated; CD27(+) CD28(+) CD45RA(-) CCR7(-) and late differentiated; CD27(-) CD28(-) CD45RA(-) CCR7(-) ), terminally differentiated effector cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TEMRA    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>; CD27(-) CD28(-) CD45RA(+) CCR7(-) ) and Treg (CD4(+) CD25(+) <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FOXP3(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> CD127(-) ) cells, and their expression of CD39, CD45RA, CD101 and CD129, were studied by flow cytometry in T1D and/or coeliac disease children or without any of these diseases (reference group). Children diagnosed with both T1D and coeliac disease showed a higher percentage of TEMRA CD4(+) cells (P < 0·05), but lower percentages of both early and late effector memory CD8(+) cells (P < 0·05) compared to references. Children with exclusively T1D had lower median fluorescence intensity (MFI) of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    forkhead box protein 3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) (P < 0·05) and also a lower percentage of CD39(+) and CD45RA(+) within the Treg population (CD4(+) CD25(+) <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FOXP3(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> CD127(-) ) (P < 0·05). Children with exclusively coeliac disease had a higher MFI of CD101 (P < 0·01), as well as a higher percentage of CD129(+) (P < 0·05), in the CD4(+) CD25(hi) lymphocyte population, compared to references. In conclusion, children with combined T1D and coeliac disease have a higher percentage of differentiated CD4(+) cells compared to CD8(+) cells. T1D children show signs of low CD39(+) /CD45RA(+) Treg cells that may indicate loss of suppressive function. Conversely, children with coeliac disease show signs of CD101(+) /CD129(+) Treg cells that may indicate suppressor activity. </div></details><details><summary>TCM</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/20970557">20970557</a><div class="entities" style="line-height: 2.5"><h3>Kidney transplant recipients show an increase in the ratio of T cell effector memory/central memory as compared to nontransplant recipients on the waiting list.</h3></br>Studies of allotolerance in animal models do not usually consider the presence of preexisting memory T cells and activated immune status. However, humans are exposed throughout life to a multitude of external agents that enhance the immune memory. In this article, we consider the effect that a previous kidney transplant has on the number of regulatory T cells (Tregs), effector memory T cells (TEM), and central memory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TCM    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>). Sixty-three patients with end-stage renal disease were studied just before being transplanted (51 first transplants and 12 retransplants). The numbers of Tregs (CD4+ <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    CD25highCD127lowCD27+CD62L+CD45RO+FOXP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+), TEM (CD3+CD45RO+CD62L+), and TCM (CD3+CD45RO+CD62L-) cell subsets were quantified in peripheral blood by flow cytometry. The absolute number of Tregs was slightly lower in patients with previous allografts (median, 95% confidence interval [CI]: 16.7 cells/mm3, 12-20.5) than in those who received their first transplants (median, 95% CI: 19.6 cells/mm3, 19.3-29.6; P-NS). Clearer differences were found with the number of CD3+ TCM, since the transplanted patients had lower numbers (238 cells/mm3, 153-323) than those who had not yet received transplants (378 cells/mm3, 317-439; P=.029). As a result, the TEM/TCM ratios of both CD4+ and CD8+ T cells in patients with previous allografts were higher than in those who received first transplants. In conclusion, the assessment of just the number of Tregs in renal transplant patients is not enough and must be read together with the number of TEM and TCM. The TEM:TCM ratio increases in patients with previous allografts, probably due to activation of the immune response in renal transplantation.</div></details><details><summary>TC9</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/23254356">23254356</a><div class="entities" style="line-height: 2.5"><h3>Tc9 cells, a new subset of CD8(+) T cells, support Th2-mediated airway inflammation.</h3></br>Similar to T-helper (Th) cells, CD8(+) T cells also differentiate into distinct subpopulations. However, the existence of IL-9-producing CD8(+) T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tc9    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells has not been elucidated so far. We show that murine CD8(+) T cells activated in the presence of IL-4 plus TGF-β develop into transient IL-9 producers characterized by specific IFN-γ and IL-10 expression patterns as well as by low cytotoxic function along with diminished expression of the CTL-associated transcription factors T-bet and Eomesodermin. Similarly to the CD4(+) counterpart, Tc9 cells required for their differentiation STAT6 and IRF4. Tc9 cells deficient for these master regulators displayed increased levels of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> that in turn suppressed IL-9 production. In an allergic airway disease model, Tc9 cells promoted the onset of airway inflammation, mediated by subpathogenic numbers of Th2 cells. This support was specific for Tc9 cells because CTLs failed to exert this function. We detected increased Tc9 frequency in the periphery in mice and humans with atopic dermatitis, a Th2-associated skin disease that often precedes asthma. Thus, our data point to the existence of Tc9 cells and to their supportive function in Th2-dependent airway inflammation, suggesting that these cells might be a therapeutic target in allergic disorders.</div></details><details><summary>MAIT</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/25862133">25862133</a><div class="entities" style="line-height: 2.5"><h3>An emerging role for immune regulatory subsets in chronic lymphocytic leukaemia.</h3></br>The last few years has seen the burgeoning of a new category of therapeutics for cancer targeting immune regulatory pathways. Antibodies that block the PD-1/PD-L1 interaction are perhaps the most prominent of these new anti-cancer therapies, but several other inhibitory receptor ligand interactions have also shown promise as targets in clinical trials, including CTLA-4/CD80 and Lag-3/MHC class II. Related to this is a rapidly improving knowledge of 'regulatory' lymphocyte lineages, including NKT cells, <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    MAIT    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells, B regulatory cells and others. These cells have potent cytokine responses that can influence the functioning of other immune cells and many researchers believe that they could be effective targets for therapies designed to enhance immune responses to cancer. This review will outline our current understanding of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FOXP3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+ 'Tregs', NKT cells, <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    MAIT    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells and B regulatory cells immune regulatory cell populations in cancer, with a particular focus on chronic lymphocytic leukaemia (CLL). We will discuss evidence linking CLL with immune regulatory dysfunction and the potential for new therapies targeting regulatory cells. </div></details></details></td>
    </tr>
    <tr>
      <th>2</th>
      <td>RUNX3</td>
      <td>3</td>
      <td>TH17:1, TH2:1, TRM:1</td>
      <td>0.939717</td>
      <td>ENSG00000020633</td>
      <td><details><summary>Subtypes</summary><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27082311">27082311</a><div class="entities" style="line-height: 2.5"><h3>Downregulation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RUNX3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> moderates the frequency of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th22 cells in patients with psoriasis.</h3></br>Psoriasis is a common chronic inflammatory and T cell-meditated skin disease. Runt-related transcription factor 3 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RUNX3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>), one of the runt‑domain family of transcription factors, has been reported to be a susceptibility gene for psoriasis. The present study was designed to delineate the role and underlying mechanism of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RUNX3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> involved in the differentiation of T helper (Th) 17 and Th22 cells in psoriasis. The results of the present study demonstrated that the expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RUNX3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> increased significantly in CD4‑positive (CD4+) T cells from patients with psoriasis, compared with healthy controls. In addition, increased levels of interleukin (IL)‑6, IL‑20 and IL‑22, and increased frequencies of Th17 and Th22 cells were found in the patients with psoriasis patients, compared with the healthy controls. It was also found that the overexpression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RUNX3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> increased the levels of Th17‑ and Th22‑associated cytokines in the CD4+ T cells from the healthy controls. However, the inhibition of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RUNX3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> reduced the levels of the associated cytokines and decreased the frequency of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th22 cells in the CD4+ T cells from the patients with psoriasis. Taken together, the present study suggested that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RUNX3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> regulated the differentiation of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th22 cells in psoriasis, providing a promising therapeutic strategy for the treatment of psoriasis. </div></details><details><summary>TH2</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/29700302">29700302</a><div class="entities" style="line-height: 2.5"><h3>Bcl11b is essential for licensing Th2 differentiation during helminth infection and allergic asthma.</h3></br>During helminth infection and allergic asthma, naive CD4+  T cells differentiate into cytokine-producing Type-2 helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells that resolve the infection or induce asthma-associated pathology. Mechanisms regulating the Th2 differentiation in vivo remain poorly understood. Here we report that mice lacking Bcl11b in mature T cells have a diminished capacity to mount Th2 responses during helminth infection and allergic asthma, showing reduced Th2 cytokines and Gata3, and elevated <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Runx3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. We provide evidence that Bcl11b is required to maintain chromatin accessibility at Th2-cytokine promoters and locus-control regions, and binds the Il4 HS IV silencer, reducing its accessibility. Bcl11b also binds Gata3-intronic and downstream-noncoding sites, sustaining the Gata3 expression. In addition, Bcl11b binds and deactivates upstream enhancers at <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Runx3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> locus, restricting the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Runx3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression and its availability to act at the Il4 HS IV silencer. Thus, our results establish novel roles for Bcl11b in the regulatory loop that licenses Th2 program in vivo.</div></details><details><summary>TRM</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/29211713">29211713</a><div class="entities" style="line-height: 2.5"><h3><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Runx3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> programs CD8+  T cell residency in non-lymphoid tissues and tumours.</h3></br>Tissue-resident memory CD8+  T (TRM ) cells are found at common sites of pathogen exposure, where they elicit rapid and robust protective immune responses. However, the molecular signals that control TRM  cell differentiation and homeostasis are not fully understood. Here we show that mouse <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TRM    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>  precursor cells represent a unique CD8+  T cell subset that is distinct from the precursors of circulating memory cell populations at the levels of gene expression and chromatin accessibility. Using computational and pooled in vivo RNA interference screens, we identify the transcription factor <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Runx3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> as a key regulator of TRM  cell differentiation and homeostasis. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Runx3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> was required to establish TRM  cell populations in diverse tissue environments, and supported the expression of crucial tissue-residency genes while suppressing genes associated with tissue egress and recirculation. Furthermore, we show that human and mouse tumour-infiltrating lymphocytes share a core tissue-residency gene-expression signature with <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TRM    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>  cells that is associated with <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Runx3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> activity. In a mouse model of adoptive T cell therapy for melanoma, Runx3-deficient CD8+  tumour-infiltrating lymphocytes failed to accumulate in tumours, resulting in greater rates of tumour growth and mortality. Conversely, overexpression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Runx3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> enhanced tumour-specific CD8+  T cell abundance, delayed tumour growth, and prolonged survival. In addition to establishing <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Runx3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> as a central regulator of TRM  cell differentiation, these results provide insight into the signals that promote T cell residency in non-lymphoid sites, which could be used to enhance vaccine efficacy or adoptive cell therapy treatments that target cancer.</div></details></details></td>
    </tr>
    <tr>
      <th>3</th>
      <td>STAT5A</td>
      <td>4</td>
      <td>TREG:3, TCM:1, TEFF:1</td>
      <td>0.939717</td>
      <td>ENSG00000126561</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/26224887">26224887</a><div class="entities" style="line-height: 2.5"><h3>Natural Variation in Interleukin-2 Sensitivity Influences Regulatory T Cell Frequency and Function in Individuals With Long-standing Type 1 Diabetes.</h3></br>Defective immune homeostasis in the balance between FOXP3+ regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) and effector T cells is a likely contributing factor in the loss of self-tolerance observed in type 1 diabetes (T1D). Given the importance of interleukin-2 (IL-2) signaling in the generation and function of Tregs, observations that polymorphisms in genes in the IL-2 pathway associate with T1D and that some individuals with T1D exhibit reduced IL-2 signaling indicate that impairment of this pathway may play a role in Treg dysfunction and the pathogenesis of T1D. Here, we have examined IL-2 sensitivity in CD4+ T cell subsets in 70 individuals with long-standing T1D, allowing us to investigate the effect of low IL-2 sensitivity on Treg frequency and function. IL-2 responsiveness, measured by <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT5a    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> phosphorylation, was a very stable phenotype within individuals but exhibited considerable interindividual variation and was influenced by T1D-associated PTPN2 gene polymorphisms. Tregs from individuals with lower IL-2 signaling were reduced in frequency, were less able to maintain expression of FOXP3 under limiting concentrations of IL-2, and displayed reduced suppressor function. These results suggest that reduced IL-2 signaling may be used to identify patients with the highest Treg dysfunction and who may benefit most from IL-2 immunotherapy.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/22461703">22461703</a><div class="entities" style="line-height: 2.5"><h3>Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function.</h3></br>Numerous reports have demonstrated that CD4(+)CD25(+) regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) from individuals with a range of human autoimmune diseases, including type 1 diabetes, are deficient in their ability to control autologous proinflammatory responses when compared with nondiseased, control individuals. Treg dysfunction could be a primary, causal event or may result from perturbations in the immune system during disease development. Polymorphisms in genes associated with Treg function, such as IL2RA, confer a higher risk of autoimmune disease. Although this suggests a primary role for defective Tregs in autoimmunity, a link between IL2RA gene polymorphisms and Treg function has not been examined. We addressed this by examining the impact of an IL2RA haplotype associated with type 1 diabetes on Treg fitness and suppressive function. Studies were conducted using healthy human subjects to avoid any confounding effects of disease. We demonstrated that the presence of an autoimmune disease-associated IL2RA haplotype correlates with diminished IL-2 responsiveness in Ag-experienced CD4(+) T cells, as measured by phosphorylation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT5a    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, and is associated with lower levels of FOXP3 expression by Tregs and a reduction in their ability to suppress proliferation of autologous effector T cells. These data offer a rationale that contributes to the molecular and cellular mechanisms through which polymorphisms in the IL-2RA gene affect immune regulation, and consequently upon susceptibility to autoimmune and inflammatory diseases.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/18270368">18270368</a><div class="entities" style="line-height: 2.5"><h3>STAT5-signaling cytokines regulate the expression of FOXP3 in CD4+CD25+ regulatory T cells and CD4+CD25- effector T cells.</h3></br>Forkhead box P3 (FOXP3) is considered a specific marker for CD4(+)CD25(+) regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, but increasing evidence suggests that human CD4(+)CD25(-) effector T (Teff) cells can transiently express FOXP3 upon activation. We demonstrate that the signal transducer and activator of transcription 5 (STAT5)-signaling cytokines, IL-2, IL-15 and to a lesser extent IL-7, induce FOXP3 up-regulation in vitro in activated human Teff cells. In contrast, cytokines which do not activate STAT5, such as IL-4 or transforming growth factor-beta alone, do not directly induce FOXP3 expression in activated Teff cells. Moreover, expression of a constitutively active form of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT5a    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is sufficient to induce FOXP3 expression in Teff cells. Expression of FOXP3 in activated Teff cells requires both TCR-mediated activation and endogenous IL-2, but is not dependent on cell division and does not induce suppressive function. The presence of STAT5-activating cytokines is also required to maintain high FOXP3 expression and suppressive activity of Treg cells in vitro. These data indicate that activation of STAT5 sustains FOXP3 expression in both <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Teff cells and contribute to our understanding of how cytokines affect the expression of FOXP3.</div></details><details><summary>TCM</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/17190839">17190839</a><div class="entities" style="line-height: 2.5"><h3>Convergence of TCR and cytokine signaling leads to FOXO3a phosphorylation and drives the survival of CD4+ central memory T cells.</h3></br>The molecular events involved in the establishment and maintenance of CD4+ central memory and effector memory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TCM    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and TEM, respectively) are poorly understood. In this study, we demonstrate that ex vivo isolated TCM are more resistant to both spontaneous and Fas-induced apoptosis than TEM and have an increased capacity to proliferate and persist in vitro. Using global gene expression profiling, single cell proteomics, and functional assays, we show that the survival of CD4+ TCM depends, at least in part, on the activation and phosphorylation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    signal transducer and activator of transcription 5a    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT5a    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) and forkhead box O3a (FOXO3a). TCM showed a significant increase in the levels of phosphorylation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT5a    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> compared with TEM in response to both IL-2 (P<0.04) and IL-7 (P<0.002); the latter is well known for its capacity to enhance T cell survival. Moreover, ex vivo TCM express higher levels of the transcriptionally inactive phosphorylated forms of FOXO3a and concomitantly lower levels of the proapoptotic FOXO3a target, Bim. Experiments aimed at blocking FOXO3a phosphorylation confirmed the role of this phosphoprotein in protecting TCM from apoptosis. Our results provide, for the first time in humans, an insight into molecular mechanisms that could be responsible for the longevity and persistence of CD4+ TCM.</div></details><details><summary>TEFF</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/18270368">18270368</a><div class="entities" style="line-height: 2.5"><h3>STAT5-signaling cytokines regulate the expression of FOXP3 in CD4+CD25+ regulatory T cells and CD4+CD25- effector T cells.</h3></br>Forkhead box P3 (FOXP3) is considered a specific marker for CD4(+)CD25(+) regulatory T (Treg) cells, but increasing evidence suggests that human CD4(+)CD25(-) effector T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Teff    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells can transiently express FOXP3 upon activation. We demonstrate that the signal transducer and activator of transcription 5 (STAT5)-signaling cytokines, IL-2, IL-15 and to a lesser extent IL-7, induce FOXP3 up-regulation in vitro in activated human Teff cells. In contrast, cytokines which do not activate STAT5, such as IL-4 or transforming growth factor-beta alone, do not directly induce FOXP3 expression in activated Teff cells. Moreover, expression of a constitutively active form of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT5a    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is sufficient to induce FOXP3 expression in Teff cells. Expression of FOXP3 in activated Teff cells requires both TCR-mediated activation and endogenous IL-2, but is not dependent on cell division and does not induce suppressive function. The presence of STAT5-activating cytokines is also required to maintain high FOXP3 expression and suppressive activity of Treg cells in vitro. These data indicate that activation of STAT5 sustains FOXP3 expression in both Treg and Teff cells and contribute to our understanding of how cytokines affect the expression of FOXP3.</div></details></details></td>
    </tr>
    <tr>
      <th>4</th>
      <td>CEBPD</td>
      <td>1</td>
      <td>TEM:1</td>
      <td>0.840937</td>
      <td>ENSG00000221869</td>
      <td><details><summary>Subtypes</summary><details><summary>TEM</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28219889">28219889</a><div class="entities" style="line-height: 2.5"><h3>Rapid and Rigorous IL-17A Production by a Distinct Subpopulation of Effector Memory T Lymphocytes Constitutes a Novel Mechanism of Toxic Shock Syndrome Immunopathology.</h3></br>Toxic shock syndrome (TSS) is caused by staphylococcal and streptococcal superantigens (SAgs) that provoke a swift hyperinflammatory response typified by a cytokine storm. The precipitous decline in the host's clinical status and the lack of targeted therapies for TSS emphasize the need to identify key players of the storm's initial wave. Using a humanized mouse model of TSS and human cells, we herein demonstrate that SAgs elicit in vitro and in vivo IL-17A responses within hours. SAg-triggered human IL-17A production was characterized by remarkably high mRNA stability for this cytokine. A distinct subpopulation of CD4+  effector memory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TEM    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> ) cells that secrete IL-17A, but not IFN-γ, was responsible for early IL-17A production. We found mouse "<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TEM    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> -17" cells to be enriched within the intestinal epithelium and among lamina propria lymphocytes. Furthermore, interfering with IL-17A receptor signaling in human PBMCs attenuated the expression of numerous inflammatory mediators implicated in the TSS-associated cytokine storm. IL-17A receptor blockade also abrogated the secondary effect of SAg-stimulated PBMCs on human dermal fibroblasts as judged by <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    C/EBP δ    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression. Finally, the early IL-17A response to SAgs was pathogenic because in vivo neutralization of IL-17A in humanized mice ameliorated hepatic and intestinal damage and reduced mortality. Together, our findings identify CD4+  TEM  cells as a key effector of TSS and reveal a novel role for IL-17A in TSS immunopathogenesis. Our work thus elucidates a pathogenic, as opposed to protective, role for IL-17A during Gram-positive bacterial infections. Accordingly, the IL-17-IL-17R axis may provide an attractive target for the management of SAg-mediated illnesses.</div></details></details></td>
    </tr>
    <tr>
      <th>5</th>
      <td>BCL6</td>
      <td>64</td>
      <td>TFH:57, TH:9, TFREG:6, TREG:5, TH1:3, TH17:2, TEFF:1</td>
      <td>0.699334</td>
      <td>ENSG00000113916</td>
      <td><details><summary>Subtypes</summary><details><summary>TFH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/29870918">29870918</a><div class="entities" style="line-height: 2.5"><h3>The prevalence and function of CD4+ CXCR5+ Foxp3+  follicular regulatory T cells in diffuse large B cell lymphoma.</h3></br>CD4+ CXCR5+ Foxp3+  follicular regulatory T (Tfr) cells possess critical roles in suppressing the germinal center reaction, B cell activation, and follicular helper T cell (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cytokine secretion. Since diffuse large B cell lymphoma (DLBCL) can arise from B cells undergoing germinal center reaction and/or differentiation, we hypothesized that Tfr cells might be involved in DLBCL. In the present study, we recruited thirty-five DLBCL patients and twenty-five healthy controls. Data showed that DLBCL patients presented an enrichment of circulating CD4+ CXCR5+ Foxp3+  Tfr cells compared to controls. In the primary tumor isolated from enlarged lymph nodes, Tfr cells made up of roughly 3% to 16% of infiltrating T cells. Higher levels of tumor-infiltrating Tfr cells were observed in patients with less advanced DLBCL stages, and in patients that stayed in remission 24 months after the initial R-CHOP treatment. High <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and high FOXP3 expression was observed in Tfr cells ex vivo. After anti-CD3/CD28 and IL-2 stimulation, the Tfr cells more closely resembled Treg cells and presented high IL10 and TGFB1 expression. CD4+ CD25+ CXCR5+  Tfr cells and CD4+ CD25+ CXCR5-  non-Tfr Treg cells could suppress CD4+ CD25-  Tconv cell and CD8+  T cell proliferation with similar capacity. However, Tfr cells were less capable of suppressing IFNG expression than Treg cells, and although both cell types supported CD19+  tumor cell proliferation, Tfr cells were less supportive than the non-Tfr Treg cells. Overall, this study suggested that Tfr cells were involved in intratumoral immunity, were likely beneficial to DLBCL patients, and were functionally distinctive from non-Tfr Treg cells. The distribution pattern and the prognostic value of Tfr cells in DLBCL should be examined in further studies.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/29563292">29563292</a><div class="entities" style="line-height: 2.5"><h3>Activation and Induction of Antigen-Specific T Follicular Helper Cells Play a Critical Role in Live-Attenuated Influenza Vaccine-Induced Human Mucosal Anti-influenza Antibody Response.</h3></br>There is increasing interest recently in developing intranasal vaccines against respiratory tract infections. The antibody response is critical for vaccine-induced protection, and T follicular helper cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TFH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> ) are considered important for mediating the antibody response. Most data supporting the role for TFH  in the antibody response are from animal studies, and direct evidence from humans is limited, apart from the presence of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TFH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> -like cells in blood. We studied the activation and induction of TFH  and their role in the anti-influenza antibody response induced by a live-attenuated influenza vaccine (LAIV) in human nasopharynx-associated lymphoid tissue (NALT). TFH  activation in adenotonsillar tissues was analyzed by flow cytometry, and anti-hemagglutinin (anti-HA) antibodies were examined following LAIV stimulation of tonsillar mononuclear cells (MNC). Induction of antigen-specific TFH  by LAIV was studied by flow cytometry analysis of induced TFH  and CD154 expression. LAIV induced TFH  proliferation, which correlated with anti-HA antibody production, and TFH  were shown to be critical for the antibody response. Induction of TFH  from naive T cells by LAIV was shown in newly induced TFH  expressing <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and CD21, followed by the detection of anti-HA antibodies. Antigen specificity of LAIV-induced TFH  was demonstrated by expression of the antigen-specific T cell activation marker CD154 upon challenge by H1N1 virus antigen or HA. LAIV-induced TFH  differentiation was inhibited by <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, interleukin-21 (IL-21), ICOS, and CD40 signaling blocking, and that diminished anti-HA antibody production. In conclusion, we demonstrated the induction by LAIV of antigen-specific TFH  in human NALT that provide critical support for the anti-influenza antibody response. Promoting antigen-specific TFH  in NALT by use of intranasal vaccines may provide an effective vaccination strategy against respiratory infections in humans.<b>IMPORTANCE</b> Airway infections, such as influenza, are common in humans. Intranasal vaccination has been considered a biologically relevant and effective way of immunization against airway infection. The vaccine-induced antibody response is crucial for protection against infection. Recent data from animal studies suggest that one type of T cells, TFH , are important for the antibody response. However, data on whether TFH -mediated help for antibody production operates in humans are limited due to the lack of access to human immune tissue containing TFH  In this study, we demonstrate the induction of TFH  in human immune tissue, providing critical support for the anti-influenza antibody response, by use of an intranasal influenza vaccine. Our findings provide direct evidence that TFH  play a critical role in vaccine-induced immunity in humans and suggest a novel strategy for promoting such cells by use of intranasal vaccines against respiratory infections.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/29212666">29212666</a><div class="entities" style="line-height: 2.5"><h3>STAT4 and T-bet control follicular helper T cell development in viral infections.</h3></br>Follicular helper T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells promote germinal center (GC) B cell survival and proliferation and guide their differentiation and immunoglobulin isotype switching by delivering contact-dependent and soluble factors, including IL-21, IL-4, IL-9, and IFN-γ. IL-21 and IFN-γ are coexpressed by Tfh cells during viral infections, but transcriptional regulation of these cytokines is not completely understood. In this study, we show that the T helper type 1 cell (Th1 cell) transcriptional regulators T-bet and STAT4 are coexpressed with <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Bcl6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in Tfh cells after acute viral infection, with a temporal decline in T-bet in the waning response. T-bet is important for Tfh cell production of IFN-γ, but not IL-21, and for a robust GC reaction. STAT4, phosphorylated in Tfh cells upon infection, is required for expression of T-bet and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Bcl6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and for IFN-γ and IL-21. These data indicate that T-bet is expressed with <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Bcl6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in Tfh cells and is required alongside STAT4 to coordinate Tfh cell IL-21 and IFN-γ production and for promotion of the GC response after acute viral challenge.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/29186193">29186193</a><div class="entities" style="line-height: 2.5"><h3>RIG-I-like receptor activation by dengue virus drives follicular T helper cell formation and antibody production.</h3></br>Follicular T helper cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TFH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) are fundamental in orchestrating effective antibody-mediated responses critical for immunity against viral infections and effective vaccines. However, it is unclear how virus infection leads to TFH induction. We here show that dengue virus (DENV) infection of human dendritic cells (DCs) drives TFH formation via crosstalk of RIG-I-like receptor (RLR) RIG-I and MDA5 with type I Interferon (IFN) signaling. DENV infection leads to RLR-dependent IKKε activation, which phosphorylates IFNα/β receptor-induced STAT1 to drive IL-27 production via the transcriptional complex ISGF3. Inhibiting RLR activation as well as neutralizing antibodies against IL-27 prevented TFH formation. DENV-induced <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    CXCR5+PD-1+Bcl-6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+ TFH cells secreted IL-21 and activated B cells to produce IgM and IgG. Notably, RLR activation by synthetic ligands also induced IL-27 secretion and TFH polarization. These results identify an innate mechanism by which antibodies develop during viral disease and identify RLR ligands as potent adjuvants for TFH-promoting vaccination strategies.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/29133396">29133396</a><div class="entities" style="line-height: 2.5"><h3>Repression of miR-31 by <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> stabilizes the helper function of human follicular helper T cells.</h3></br>Follicular helper T cells (TFH s) are a key component of adaptive immune respons<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    es a    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>s they help antibody production by B cells. Differentiation and function of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TFH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>  cells are controlled by the master gene <i>BCL6</i>, but it is largely unclear how this transcription repressor specifies the TFH  program. Here we asked whether <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> controlled helper function through down-regulation of specific microRNAs (miRNAs). We first assessed miRNA expression in <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TFH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>  cells and defined a TFH -specific miRNA signature. We report that hsa-miR-31-5p (miR-31) is down-regulated in TFH ; we showed that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> suppresses miR-31 expression by binding to its promoter; and we demonstrated that miR-31 inhibits the expression of molecules that control T-helper function, such as CD40L and SAP. These findings identify a BCL6-initiated inhibitory circuit that stabilizes the follicular helper T cell program at least in part through the control of miRNA transcription. Although <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> controls TFH  activity in human and mouse, the role of miR-31 is restricted to human TFH  cell differentiation, reflecting a species specificity of the miR-31 action. Our findings highlight miR-31 as a possible target to modulate human T cell dependent antibody responses in the settings of infection, vaccination, or immune dysregulation.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28943543">28943543</a><div class="entities" style="line-height: 2.5"><h3>Expression of Master Regulators of T cell, Helper T cell and Follicular Helper T cell Differentiation in Angioimmunoblastic T cell Lymphoma.</h3></br>Objective It has been postulated that the normal counterpart of angioimmunoblastic T cell lymphoma (AITL) is the follicular helper T cell (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TFH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>). Recent immunological studies have identified several transcription factors responsible for T cell differentiation. The master regulators associated with T cell, helper T cell (Th), and TFH differentiation are reportedly BCL11B, Th-POK, and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, respectively. We explored the postulated normal counterpart of AITL with respect to the expression of the master regulators of T cell differentiation. Methods We performed an immunohistochemical analysis in 15 AITL patients to determine the expression of the master regulators and several surface markers associated with T cell differentiation. Results BCL11B was detected in 10 patients (67%), and the surface marker of T cells (CD3) was detected in all patients. Only 2 patients (13%) expressed the marker of naïve T cells (CD45RA), but all patients expressed the marker of effector T cells (CD45RO). Nine patients expressed Th-POK (60%), and 7 (47%) expressed a set of surface antigens of Th (CD4-positive and CD8-negative). In addition, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and the surface markers of TFH (CXCL13, PD-1, and SAP) were detected in 11 (73%), 8 (53%), 14 (93%), and all patients, respectively. Th-POK-positive/BCL6-negative patients showed a significantly shorter overall survival (OS) than the other patients (median OS: 33.0 months vs. 74.0 months, p=0.020; log-rank test). Conclusion Many of the AITL patients analyzed in this study expressed the master regulators of T cell differentiation. The clarification of the diagnostic significance and pathophysiology based on the expression of these master regulators in AITL is expected in the future.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28728856">28728856</a><div class="entities" style="line-height: 2.5"><h3>Achaete-scute complex homologue 2 accelerates the development of Sjögren's syndrome-like disease in the NOD/ShiLtJ mouse.</h3></br>Achaete-scute complex homologue 2 (Ascl2) has been reported to induce the differentiation and activation of follicular helper T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TFH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> ) cells, which are essential for development of Sjögren's syndrome (SS). This study examined whether Ascl2 plays a role in the development of SS. NOD/ShiLtJ mice were injected with an Ascl2-overexpression vector, and the infiltration of lymphocytes into salivary and lacrimal glands was assessed. The expression of inflammatory cytokines and chemoattractants for T or B cells was measured. The activation of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TFH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>  cells was assessed using a specific marker of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TFH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>  cells. Ascl2 level was also measured in SS patients. Overexpression of Ascl2 increased the expression of C-X-C chemokine receptor type 5 (CXCR5) in both salivary and lacrimal glands (p<0.0001). Overexpression of Ascl2 also increased the expression of proinflammatory cytokines and chemoattractants including interleukin 6 (IL-6), tumor necrosis factor-α, IL-8, programmed cell death 1 (PD-1), IL-21, and B-cell lymphoma 6 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Bcl-6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>). Overexpression of Ascl2 increased the populations of CD4+ CXCR5+ , CD4+ ICOS+ , and CD4+ PD-1+  cells. The Ascl2 level was higher in peripheral blood mononuclear cells from SS patients compared with those from healthy controls. Our findings suggest that Ascl2 may play a role in the development and progression of SS and may be a therapeutic target in the treatment of SS.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28550121">28550121</a><div class="entities" style="line-height: 2.5"><h3><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> represses antiviral resistance in follicular T helper cells.</h3></br>Follicular Th (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are a distinct subset of Th cells that help B cells produce class-switched antibodies. Studies have demonstrated that Tfh cells are highly prone to HIV infection and replication. However, the molecular mechanisms underlying this phenomenon are largely unclear. Here, we show that murine and human Tfh cells have diminished constitutive expression of IFN-stimulated genes (ISGs) inclusive of antiviral resistance factor MX dynamin-like GTPase 2 (MX2) and IFN-induced transmembrane 3 (IFITM3) compared with non-Tfh cells. A lower antiviral resistance in Tfh was consistent with a higher susceptibility to retroviral infections. Mechanistically, we found that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, a master regulator of Tfh cell development, binds to ISG loci and inhibits the expression of MX2 and IFITM3 in Tfh cells. We demonstrate further that inhibition of the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> BR-C, ttk, and bab (BTB) domain function increases the expression of ISGs and suppresses HIV infection and replication in Tfh cells. Our data reveal a regulatory role of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in inhibiting antiviral resistance factors in Tfh cells, thereby promoting the susceptibility Tfh cells to viral infections. Our results indicate that the modulation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> function in Tfh cells could be a potential strategy to enhance Tfh cell resistance to retroviral infections and potentially decrease cellular reservoirs of HIV infection.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28263097">28263097</a><div class="entities" style="line-height: 2.5"><h3>Transcriptional and epigenetic regulation of follicular T-helper cells and their role in autoimmunity.</h3></br>T-follicular helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are a specialized subset of T cells that provide help to B cells and promote the formation of germinal centers (GCs). Tfh cells transmit important signals to B cells that drive class switch recombination, somatic hyper-mutation, the<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">     gene    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>ration of high-affinity antibodies, immunological memory and their differentiation into plasma cells or memory B cells in the GCs. Tfh-cell differentiation is regulated by the coordinated functions of distinct cytokines, including interleukin (IL)-6, IL-21, IL-12, IL-23, IL-2, IL-7 and transforming growth factor-β (TGF-β), as well as transcription factors, including B-cell lymphoma 6 protein (Bcl-6), Signal transducers and activators of transcription (STAT)1, STAT3, STAT4, B-cell activating transcription factor (Batf), interferon regulatory factor 4 (IRF4), v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog (C-Maf), T cell-specific transcription factor 1 (TCF-1) and Achaete-scute homolog 2 (Acl2), which have been shown to form a complex transcriptional network. In addition, increasing evidence indicates that epigenetic regulations, such as DNA methylation, histone modifications and non-coding RNA regulations, also coordinately control the differentiation and function of Tfh cells along with transcription factors. Furthermore, abnormalities in the regulation of Tfh cells have been associated with several autoimmune diseases, such as systemic lupus erythematosus (SLE), multiple sclerosis (MS) and rheumatoid arthritis (RA). Herein, this review aims to summarize the coordinate regulation and interaction of transcription factors, cytokines and epigenetic modifications that control Tfh-cell differentiation as well as the mechanism of dysregulation of Tfh cells in pathogenesis of autoimmune diseases, which highlight potential therapeutic targets.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28153782">28153782</a><div class="entities" style="line-height: 2.5"><h3>Rapid de novo generation of antigen specific human B cells with expression of Blimp-1 and AID by in vitro immunization.</h3></br>In vitro immunization with antigens and cytokines triggers specific human B-cell response in short periods and is therefore superior to conventional in vivo immunization for antibody development. However, this new technology is limited by low efficiency, poor reproducibility, and requirement of pre-immunized lymphocytes. In this study, we demonstrate a novel method for de novo inducing antigen-specific human B cells in vitro. Unlike previous in vitro immunization of unfractionated PBMCs, we firstly optimized the conditions for inducing monocyte-derived dendritic cells (DCs) to efficiently capture, process, and present antigens. Instead of using the conventional method to activate Th2 cells for in vitro immunization, we succeeded to differentiate naïve CD4+  T cells into T follicular helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells using antigen-sensitized DCs and cytokine cocktail. We discovered the differentiated T cells expressed ICOS, PD-1, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL-6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, and IL-21 at high levels. After 12 days of T-B co-culture, we observed induced T cells efficiently promoted naïve B cells to differentiate into plasmablasts secreting antigen-specific antibodies, with expression of Blimp-1 and AID related to affinity maturation and class switching. Thus, we established a new co-culture system with naïve lymphocyte populations for de novo acquisition of specifically in vitro immunized B cells potentially for development of therapeutic antibodies, which also provides novel insights into understanding the complex interactions among immune cells in lymph nodes.</div></details><details><summary>TH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28943543">28943543</a><div class="entities" style="line-height: 2.5"><h3>Expression of Master Regulators of T cell, Helper T cell and Follicular Helper T cell Differentiation in Angioimmunoblastic T cell Lymphoma.</h3></br>Objective It has been postulated that the normal counterpart of angioimmunoblastic T cell lymphoma (AITL) is the follicular helper T cell (TFH). Recent immunological studies have identified several transcription factors responsible for T cell differentiation. The master regulators associated with T cell, helper T cell (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>), and TFH differentiation are reportedly BCL11B, Th-POK, and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, respectively. We explored the postulated normal counterpart of AITL with respect to the expression of the master regulators of T cell differentiation. Methods We performed an immunohistochemical analysis in 15 AITL patients to determine the expression of the master regulators and several surface markers associated with T cell differentiation. Results BCL11B was detected in 10 patients (67%), and the surface marker of T cells (CD3) was detected in all patients. Only 2 patients (13%) expressed the marker of naïve T cells (CD45RA), but all patients expressed the marker of effector T cells (CD45RO). Nine patients expressed Th-POK (60%), and 7 (47%) expressed a set of surface antigens of Th (CD4-positive and CD8-negative). In addition, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and the surface markers of TFH (CXCL13, PD-1, and SAP) were detected in 11 (73%), 8 (53%), 14 (93%), and all patients, respectively. Th-POK-positive/BCL6-negative patients showed a significantly shorter overall survival (OS) than the other patients (median OS: 33.0 months vs. 74.0 months, p=0.020; log-rank test). Conclusion Many of the AITL patients analyzed in this study expressed the master regulators of T cell differentiation. The clarification of the diagnostic significance and pathophysiology based on the expression of these master regulators in AITL is expected in the future.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28550121">28550121</a><div class="entities" style="line-height: 2.5"><h3><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> represses antiviral resistance in follicular T helper cells.</h3></br>Follicular <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> (Tfh) cells are a distinct subset of Th cells that help B cells produce class-switched antibodies. Studies have demonstrated that Tfh cells are highly prone to HIV infection and replication. However, the molecular mechanisms underlying this phenomenon are largely unclear. Here, we show that murine and human Tfh cells have diminished constitutive expression of IFN-stimulated genes (ISGs) inclusive of antiviral resistance factor MX dynamin-like GTPase 2 (MX2) and IFN-induced transmembrane 3 (IFITM3) compared with non-Tfh cells. A lower antiviral resistance in Tfh was consistent with a higher susceptibility to retroviral infections. Mechanistically, we found that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, a master regulator of Tfh cell development, binds to ISG loci and inhibits the expression of MX2 and IFITM3 in Tfh cells. We demonstrate further that inhibition of the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> BR-C, ttk, and bab (BTB) domain function increases the expression of ISGs and suppresses HIV infection and replication in Tfh cells. Our data reveal a regulatory role of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in inhibiting antiviral resistance factors in Tfh cells, thereby promoting the susceptibility Tfh cells to viral infections. Our results indicate that the modulation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> function in Tfh cells could be a potential strategy to enhance Tfh cell resistance to retroviral infections and potentially decrease cellular reservoirs of HIV infection.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/22885524">22885524</a><div class="entities" style="line-height: 2.5"><h3>The darker side of follicular helper T cells: from autoimmunity to immunodeficiency.</h3></br>Follicular helper T (T(FH)) cells represent a distinct subset of CD4⁺ helper T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(H)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells specialized in providing help to B cells. They are characterized by their unique transcriptional profile (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Bcl6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>), surface marker expression (CXCR5, PD-1, ICOS and CD40L) and cytokine production pattern (IL-21 and IL-6). T(FH) cells provide help to B cells both to form germinal centers (GCs) and to differentiate into memory B cells and plasma cells for generation of humoral responses. However, there is emerging evidence that implicates T(FH) cells in the development of various human pathologies, such as autoimmune diseases, immunodeficiency and lymphoma. This review focuses on the current progress in this area including mouse and human studies. A clearer understanding of the mechanisms of T(FH) cell-mediated immunity and pathology may be exploited for rational development of therapeutic strategies.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21511186">21511186</a><div class="entities" style="line-height: 2.5"><h3>A subset of interleukin-21+ chemokine receptor CCR9+ T helper cells target accessory organs of the digestive system in autoimmunity.</h3></br>This study describes a CD4+ T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cell subset marked by coexpression of the cytokine interleukin 21 (IL-21) and the gut-homing chemokine receptor CCR9. Although CCR9+ Th cells were observed in healthy mice and humans, they were enriched in the inflamed pancreas and salivary glands of NOD mice and in the circulation of Sjögren's syndrome patients. CCR9+ Th cells expressed large amounts of IL-21, inducible T cell costimulator (ICOS), and the transcription factors <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Bcl6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and Maf, and also supported antibody production from B cells, thereby resembling T follicular B helper (Tfh) cells. However, in contrast to Tfh cells, CCR9+ Th cells displayed limited expression of CXCR5 and the targets of CCR9+ Th cells were CD8+ T cells whose responsiveness to IL-21 was necessary for the development of diabetes. Thus, CCR9+ Th cells are a subset of IL-21-producing T helper cells that influence regional specification of autoimmune diseases that affect accessory organs of the digestive system.</div></details><details><summary>TFREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/24324208">24324208</a><div class="entities" style="line-height: 2.5"><h3>Foxp3⁺ T(reg) cells in humoral immunity.</h3></br>T(reg) cells are essential for the maintenance of immune homeostasis and prevention of autoimmunity. In humoral immune responses, loss of T(reg) cell function causes increased levels of serum autoantibodies, hyper-IgE, spontaneous generation of germinal centres, and enhanced numbers of specialised T follicular helper cells (T(fh) cells) controlled by the lineage-defining transcription factor <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL-6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (B-cell lymphoma 6). Recent studies have demonstrated that a subset of T(reg) cells [T follicular regulatory (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(freg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells] are able to co-opt the follicular T cell program by gaining expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL-6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and travelling to the follicle where they have an important role in the control of expansion of T(fh) cells and the germinal centre reaction. However, the mechanisms by which they exert this control are still under investigation. In this review, we discuss the effects of T(reg) cells on humoral immunity and the mechanisms by which they exert their regulatory function.</div></details><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27436361">27436361</a><div class="entities" style="line-height: 2.5"><h3>ROCK2 signaling is required to induce a subset of T follicular helper cells through opposing effects on STATs in autoimmune settings.</h3></br>Rho-associated kinase 2 (ROCK2) determines the balance between human T helper 17 (TH17) cells and regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. We investigated its role in the generation of T follicular helper (TFH) cells, which help to generate antibody-producing B cells under normal and autoimmune conditions. Inhibiting ROCK2 in normal human T cells or peripheral blood mononuclear cells from patients with active systemic lupus erythematosus (SLE) decreased the number and function of TFH cells induced by activation ex vivo. Moreover, inhibition of ROCK2 activity decreased the abundance of the transcriptional regulator <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Bcl6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (B cell lymphoma 6) and increased that of Blimp1 by reducing the binding of signal transducer and activator of transcription 3 (STAT3) and increasing that of STAT5 to the promoters of the genes <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Bcl6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and PRDM1, respectively. In the MRL/lpr murine model of SLE, oral administration of the selective ROCK2 inhibitor KD025 resulted in a twofold reduction in the numbers of TFH cells and antibody-producing plasma cells in the spleen, as well as a decrease in the size of splenic germinal centers, which are the sites of interaction between TFH cells and B cells. KD025-treated mice showed a substantial improvement in both histological and clinical scores compared to those of untreated mice and had reduced amounts of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Bcl6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and phosphorylated STAT3, as well as increased STAT5 phosphorylation. Together, these data suggest that ROCK2 signaling plays a critical role in controlling the development of TFH cells induced by autoimmune conditions through reciprocal regulation of STAT3 and STAT5 activation.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/24324208">24324208</a><div class="entities" style="line-height: 2.5"><h3>Foxp3⁺ <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells in humoral immunity.</h3></br><mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells are essential for the maintenance of immune homeostasis and prevention of autoimmunity. In humoral immune responses, loss of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cell function causes increased levels of serum autoantibodies, hyper-IgE, spontaneous generation of germinal centres, and enhanced numbers of specialised T follicular helper cells (T(fh) cells) controlled by the lineage-defining transcription factor <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL-6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (B-cell lymphoma 6). Recent studies have demonstrated that a subset of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells [T follicular regulatory (T(freg)) cells] are able to co-opt the follicular T cell program by gaining expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL-6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and travelling to the follicle where they have an important role in the control of expansion of T(fh) cells and the germinal centre reaction. However, the mechanisms by which they exert this control are still under investigation. In this review, we discuss the effects of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells on humoral immunity and the mechanisms by which they exert their regulatory function.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21785430">21785430</a><div class="entities" style="line-height: 2.5"><h3>Follicular regulatory T cells expressing Foxp3 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Bcl-6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> suppress germinal center reactions.</h3></br>Foxp3(+) regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells suppress different types of immune responses to help maintain homeostasis in the body. How <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells regulate humoral immunity, including germinal center reactions, is unclear. Here we identify a subset of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells expressing CXCR5 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Bcl-6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> that localize to the germinal centers in mice and humans. The expression of CXCR5 on <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells depends on <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Bcl-6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. These <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    CXCR5(+)Bcl-6(+) T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> cells are absent in the thymus but can be generated de novo from CXCR5(-)Foxp3(+) natural T(reg) precursors. A lack of CXCR5(+) T(reg) cells leads to greater germinal center reactions including germinal center B cells, affinity maturation of antibodies and the differentiation of plasma cells. These results unveil a Bcl-6-CXCR5 axis in <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells that drives the development of follicular regulatory T (T(FR)) cells that function to inhibit the germinal center reactions.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21785433">21785433</a><div class="entities" style="line-height: 2.5"><h3>Foxp3+ follicular regulatory T cells control the germinal center response.</h3></br>Follicular helper (T(FH)) cells provide crucial signals to<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">     germ    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>inal center B cells undergoing somatic hypermutation and selection that results in affinity maturation. Tight control of T(FH) numbers maintains self tolerance. We describe a population of Foxp3(+)Blimp-1(+)CD4(+) T cells constituting 10-25% of the CXCR5(high)PD-1(high)CD4(+) T cells found in the germinal center after immunization with protein antigens. These follicular regulatory T (T(FR)) cells share phenotypic characteristics with T(FH) and conventional Foxp3(+) regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells yet are distinct from both. Similar to T(FH) cells, T(FR) cell development depends on Bcl-6, SLAM-associated protein (SAP), CD28 and B cells; however, T(FR) cells originate from thymic-derived Foxp3(+) precursors, not naive or T(FH) cells. T(FR) cells are suppressive in vitro and limit T(FH) cell and germinal center B cell numbers in vivo. In the absence of T(FR) cells, an outgrowth of non-antigen-specific B cells in germinal centers leads to fewer antigen-specific cells. Thus, the T(FH) differentiation pathway is co-opted by <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells to control the germinal center response.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/18231910">18231910</a><div class="entities" style="line-height: 2.5"><h3>Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis.</h3></br>Tumor-infiltrating immune cells perform a crucial function in host immune reactions against diffuse large B-cell lymphoma (DLBCL). In this study, we have identified a subset of tumor-infiltrating FOXP3-positive regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) in the initial DLBCL biopsy specimens, and have evaluated their prognostic significance. Ninety six patients with DLBCL were evaluated retrospectively. The pattern of FOXP3 protein expression was evaluated using standard immunohistochemistry in paraffin-embedded tissue samples. Sixty seven of all 96 specimens were stained with antibodies for CD-10, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    bcl-6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and MUM1 via tissue microarray (TMA) to classify the cases into a germinal center B-cell like (GCB) group and a non-GCB group. The median overall survival (OS) was 28 months. As compared with the others, the patients with higher percentages of FOXP3-positive Tregs on initial tumor biopsy evidenced a significantly longer OS (p = 0.003). Patients classified into the GCB group evidenced a significantly longer OS as compared with the non-GCB group (p = 0.008). When the prognostic factors were evaluated via a multivariate model, the international prognostic index and the percentage of infiltrating FOXP3-positive Tregs in the initial biopsy were identified as independent predictors of OS. In conclusion, the presence of an increased percentage of FOXP3-positive Tregs in DLBCL is predictive of better prognoses.</div></details><details><summary>TH1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/25485678">25485678</a><div class="entities" style="line-height: 2.5"><h3>Follicular helper T cell signature in type 1 diabetes.</h3></br>The strong genetic association between particular HLA alleles and type 1 diabetes (T1D) indicates a key role for CD4+ T cells in disease; however, the differentiation state of the responsible T cells is unclear. T cell differentiation originally was considered a dichotomy between <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells, with Th1 cells deemed culpable for autoimmune islet destruction. Now, multiple additional T cell differentiation fates are recognized with distinct roles. Here, we used a transgenic mouse model of diabetes to probe the gene expression profile of islet-specific T cells by microarray and identified a clear follicular helper T (Tfh) cell differentiation signature. Introduction of T cells with a Tfh cell phenotype from diabetic animals efficiently transferred diabetes to recipient animals. Furthermore, memory T cells from patients with T1D expressed elevated levels of Tfh cell markers, including CXCR5, ICOS, PDCD1, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, and IL21. Defects in the IL-2 pathway are associated with T1D, and IL-2 inhibits Tfh cell differentiation in mice. Consistent with these previous observations, we found that IL-2 inhibited human Tfh cell differentiation and identified a relationship between IL-2 sensitivity in T cells from patients with T1D and acquisition of a Tfh cell phenotype. Together, these findings identify a Tfh cell signature in autoimmune diabetes and suggest that this population could be used as a biomarker and potentially targeted for T1D interventions. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/24463518">24463518</a><div class="entities" style="line-height: 2.5"><h3>Transcription factor achaete-scute homologue 2 initiates follicular T-helper-cell development.</h3></br>In immune responses, activated T cells migrate to B-cell follicles and develop into follicular T-helper (TFH) cells, a recently identified subset of CD4(+) T cells specialized in providing help to B lymphocytes in the induction of germinal centres. Although <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Bcl6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> has been shown to be essential in TFH-cell function, it may not regulate the initial migration of T cells or the induction of the TFH program, as exemplified by C-X-C chemokine receptor type 5 (CXCR5) upregulation. Here we show that expression of achaete-scute homologue 2 (Ascl2)--a basic helix-loop-helix (bHLH) transcription factor--is selectively upregulated in TFH cells. Ectopic expression of Ascl2 upregulates CXCR5 but not <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Bcl6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, and downregulates C-C chemokine receptor 7 (CCR7) expression in T cells in vitro, as well as accelerating T cell migration to the follicles and TFH-cell development in vivo in mice. Genome-wide analysis indicates that Ascl2 directly regulates TFH-related genes whereas it inhibits expression of T-helper cell 1 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) and TH17 signature genes. Acute deletion of Ascl2, as well as blockade of its function with the Id3 protein in CD4(+) T cells, results in impaired TFH-cell development and germinal centre response. Conversely, mutation of Id3, known to cause antibody-mediated autoimmunity, greatly enhances TFH-cell generation. Thus, Ascl2 directly initiates TFH-cell development.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/12672077">12672077</a><div class="entities" style="line-height: 2.5"><h3>Kinetics and STAT4- or STAT6-mediated regulation of genes involved in lymphocyte polarization to <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells.</h3></br>Many genes implicated in Th1 and Th2 differentiation have been identified in both human and mouse. However, the functional roles and hierarchy of these factors in the signaling pathways leading to either Th1 or Th2 responses are less clear. To explore at which stage of polarization the differences between <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells occur, we have studied the expression of 23 key genes implicated in the process during the first week of polarization from human precursor T helper cells using quantitative real-time reverse transcription-PCR. According to our results, 14 of the genes were clearly regulated differentially in Th1 and Th2 conditions in distinct time-dependent patterns, either during the first 2 days or after 1 week of polarization. Furthermore, 6 of these genes were identified to be targets of STAT4/6 regulation. Thus, for the first time we demonstrate expression kinetics of a number of key genes involved in Th1 and Th2 differentiation during the first week of polarization in both human and mouse. In addition, our study shows for the first time that the genes <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL-6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and TRADD are differentially regulated during the polarization of human <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells.</div></details><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27436361">27436361</a><div class="entities" style="line-height: 2.5"><h3>ROCK2 signaling is required to induce a subset of T follicular helper cells through opposing effects on STATs in autoimmune settings.</h3></br>Rho-associated kinase 2 (ROCK2) determines the balance between human T helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells and regulatory T (Treg) cells. We investigated its role in the generation of T follicular helper (TFH) cells, which help to generate antibody-producing B cells under normal and autoimmune conditions. Inhibiting ROCK2 in normal human T cells or peripheral blood mononuclear cells from patients with active systemic lupus erythematosus (SLE) decreased the number and function of TFH cells induced by activation ex vivo. Moreover, inhibition of ROCK2 activity decreased the abundance of the transcriptional regulator <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Bcl6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (B cell lymphoma 6) and increased that of Blimp1 by reducing the binding of signal transducer and activator of transcription 3 (STAT3) and increasing that of STAT5 to the promoters of the genes <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Bcl6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and PRDM1, respectively. In the MRL/lpr murine model of SLE, oral administration of the selective ROCK2 inhibitor KD025 resulted in a twofold reduction in the numbers of TFH cells and antibody-producing plasma cells in the spleen, as well as a decrease in the size of splenic germinal centers, which are the sites of interaction between TFH cells and B cells. KD025-treated mice showed a substantial improvement in both histological and clinical scores compared to those of untreated mice and had reduced amounts of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Bcl6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and phosphorylated STAT3, as well as increased STAT5 phosphorylation. Together, these data suggest that ROCK2 signaling plays a critical role in controlling the development of TFH cells induced by autoimmune conditions through reciprocal regulation of STAT3 and STAT5 activation.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/26062018">26062018</a><div class="entities" style="line-height: 2.5"><h3>Pathogenic Transdifferentiation of Th17 Cells Contribute to Perpetuation of Rheumatoid Arthritis during Anti-TNF Treatment.</h3></br>T-helper cells producing interleukin (IL)-17A and IL-17F cytokines (Th17 cells) are considered the source of autoimmunity in rheumatoid arthritis (RA). In this study, we characterized specific pathogenic features of Th17 cells in RA. By using nano-string technology, we analyzed transcription of 419 genes in the peripheral blood CCR6(+)CXCR3(-) CD4(+) cells of 14 RA patients and 6 healthy controls and identified 109 genes discriminating Th17 cells of RA patients from the controls. Th17 cells of RA patients had an aggressive pathogenic profile and in addition to signature cytokines IL-17, IL-23 and IL-21, and transcriptional regulators RAR-related orphan receptor gamma of T cells (RORγt) and Janus kinase 2 (JAK2), they produced high levels of IL-23R, C-C chemokine ligand type 20 (CCL20), granulocyte-monocyte colony-stimulating factor (GM-CSF ) and transcription factor Tbet required for synovial homing. We showed that Th17 cells are enriched with Helios-producing Foxp3- and IL2RA-deficient cells, indicating altered regulatory profile. The follicular T-helper (Tfh) cells presented a functional profile of adaptor molecules, transcriptional regulator <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Bcl-6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and B-cell activating cytokines IL-21, IL-31 and leukemia inhibitory factor (LIF ). We observed that anti-tumor necrosis factor (TNF) treatment had a limited effect on the transcription signature of Th17 cells. Patients in remission retained the machinery of receptors (IL-23R and IL-1R1), proinflammatory cytokines (IL-17F, IL-23, IL-21 and TNF ) and adaptor molecules (C-X-C chemokine receptor 5 [CXCR5] and cytotoxic T lymphocyte-associated protein 4 [CTLA-4]), essential for efficient transdifferentiation and accumulation of Th17 cells. This study convincingly shows that the peripheral blood CCR6(+)CXCR3(-) CD4(+) cells of RA patients harbor pathogenic subsets of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Tfh cells, which may transdifferentiate from Tregs and contribute to perpetuation of the disease. </div></details><details><summary>TEFF</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/17981205">17981205</a><div class="entities" style="line-height: 2.5"><h3>The expansion and maintenance of antigen-selected CD8(+) T cell clones.</h3></br>The biological purpose of the mature, postthymic CD8(+) T cell is to respond to microbial antigens with a developmental program of clonal expansion and concomitant differentiation leading to effector cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(EFF)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) that provide antimicrobial defense. Because many microbial infections persist into a chronic phase, this antigen-stimulated developmental program must be capable of continually generating T(EFF), perhaps for the lifetime of the individual. This chapter proposes that the ability of a CD8(+) T cell clone to maintain the continual production of T(EFF) during periods of persistent antigenic stimulation is based on a program that has two sequential phases of clonal expansion: an initial stage that occurs mainly in the secondary lymphoid tissues and is mediated by ligation of the T cell receptor (TCR) and CD27, and a subsequent, IL-2-dependent phase that occurs predominantly in peripheral, nonlymphoid tissues. The TCR/CD27-dependent phase establishes a nondifferentiating, self-renewing pool of clonally expanding cells, and the IL-2-dependent phase mediates continued clonal expansion that is coupled to the development of T(EFF). The two pools are linked by the process of asymmetrical division within the self-renewing subset so that, at steady state of cellular replication in this TCR/CD27-dependent subset, one daughter cell remains undifferentiated and the other initiates its commitment to IL-2-dependent terminal differentiation. Superimposed on this basic scheme are a shift in the CD8(+) T cell response to type I and II interferon (IFN) from anti- to pro-proliferative and transcriptional control of replicative senescence by Bmi-1, Blimp-1, and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>/BCL6b. This developmental program ensures that despite the occurrence of cellular senescence antiviral CD8(+) T cell clones are maintained for the duration of persistent viral infections.</div></details></details></td>
    </tr>
    <tr>
      <th>6</th>
      <td>ZBTB16</td>
      <td>1</td>
      <td>MAIT:1, NKT:1</td>
      <td>0.688304</td>
      <td>ENSG00000109906</td>
      <td><details><summary>Subtypes</summary><details><summary>MAIT</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/23223428">23223428</a><div class="entities" style="line-height: 2.5"><h3>Human iNKT and MAIT cells exhibit a PLZF-dependent proapoptotic propensity that is counterbalanced by XIAP.</h3></br>Invariant natural killer (iNKT) T cells and mucosal-associated invariant T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    MAIT    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells represent peculiar T lymphocyte subpopulations with innate-like properties that differ from conventional T cells. iNKT are reduced in the primary immunodeficiency caused by mutations in the X-linked inhibitor of apoptosis (XIAP). By studying the mechanism of this depletion, we herein report that iNKT cells exhibit a high susceptibility to apoptosis that is not observed with conventional T cells. Elevated expression of caspases 3 and 7 accounts for the proapoptotic phenotype of iNKT cells, which is inhibited by XIAP although it exerts a moderate effect in conventional T cells. Similarly, MAIT cells exhibit a proapoptotic propensity with elevated expression of activated caspases and are decreased in XIAP-deficient individuals. Knockdown of the transcription factor PLZF/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    ZBTB-16    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, which is involved in the effector program of iNKT cells, diminishes their proapoptotic phenotype. Conversely, overexpression of PLZF/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    ZBTB-16    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in conventional T cells leads to a proapoptotic phenotype. Our findings identify a previously unknown pathway of regulation of innate-like T cell homeostasis depending on XIAP and PLZF. The proapoptotic feature of iNKT cells also gives a reliable explanation of their exhaustion observed in different human conditions including the XIAP immunodeficiency.</div></details></details></td>
    </tr>
    <tr>
      <th>7</th>
      <td>WT1</td>
      <td>3</td>
      <td>TREG:2, TC1:1</td>
      <td>0.572034</td>
      <td>ENSG00000184937</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/18793383">18793383</a><div class="entities" style="line-height: 2.5"><h3>In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells.</h3></br>Human hepatocellular carcinoma (HCC) cells express <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    WT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and/or carcinoembryonic antigen (CEA) as potential targets for the induction of antitumor immunity. In this study, generation of cytotoxic T lymphocytes (CTL) and regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) by fusions of dendritic cells (DCs) and HCC cells was examined.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21654520">21654520</a><div class="entities" style="line-height: 2.5"><h3>Tumor-infiltrating cytotoxic T lymphocytes as independent prognostic factor in epithelial ovarian cancer with wilms tumor protein 1 overexpression.</h3></br>Immune response characterization at the primary tumor site enables the design of therapeutic vaccination strategies with higher efficacy in epithelial ovarian cancer (EOC). In this study, we related Wilms tumor protein 1 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    WT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) overexpression, a well-established immunotherapeutic target, to clinicopathological characteristics, immunological parameters, and survival in primary EOC. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    WT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> overexpression was evaluated in primary EOC tissue of 270 patients by immunohistochemistry on tissue microarrays (TMAs). Clinicopathological characteristics, follow-up, and data on infiltration of CD8⁺ cytotoxic T lymphocytes (CTLs), FoxP3⁺ regulatory T lymphocytes (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>), major histocompatibility complex (MHC) class I, and II molecule expression, were derived from a previously published dataset. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    WT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> overexpression was defined as positive immunostaining for WT1. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    WT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> overexpression, present in 56.3% of EOC, was associated with infiltration of Tregs [odds ratio (OR), 2.7; 95% confidence interval (95% CI), 1.6-4.7; P<0.001] and up-regulation of MHC class II (OR, 2.2; 95% CI, 1.2-4.1; P=0.014). Advanced stage (OR, 4.0; 95% CI, 1.9-8.6; P<0.001) and serous histology (OR, 6.7; 95% CI, 3.2-13.6; P<0.001) were independent predictors of WT1 overexpressing EOC. High number of CTL was an independent prognostic factor for progression-free survival (hazard ratio, 0.5; 95% CI, 0.3-0.8; P=0.006) in WT1 overexpressing EOC. As WT1 overexpressing EOC is associated with CTL and Treg infiltration next to MHC class II up-regulation, future clinical trials should evaluate the combination of therapeutic WT1 vaccines with strategies depleting Tregs and/or up-regulating MHC class I, in an attempt to enhance clinical efficacy in EOC patients.</div></details><details><summary>TC1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/15790789">15790789</a><div class="entities" style="line-height: 2.5"><h3>Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T cell receptor genes.</h3></br>Tumor antigen-specific CD4+ and CD8+ T lymphocytes, especially interferon-gamma (IFN-gamma)-producing type-1 helper T (Th1) and type-1 cytotoxic T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tc1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, play a crucial role in tumor eradication. Adoptive transfer using tumor-specific Th1 and Tc1 cells is a promising therapeutic strategy for tumor immunotherapy. However, its clinical application has been hampered because of difficulties in generating tumor-specific Th1 cells from patients with tumors. To overcome this problem, we have developed an efficient method to prepare tumor-specific Th1 and Tc1 cells. T cell receptor (TCR) alpha and beta genes obtained from an HLA-A24-restricted, Wilms tumor 1 (WT1) peptide-specific Tc clone were lentivirally transduced to polyclonally activated Th1 and Tc1 cells. As expected, TCR gene-modified Tc1 cells showed cytotoxicity and IFN-gamma production in response to peptide-loaded lymphoblastoid cell lines, WT1 gene-transduced cells, and freshly isolated leukemia cells expressing both <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    WT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and HLA-A24. Surprisingly, we further demonstrated that Th1 cells transduced with HLA-class I-restricted TCR genes also showed both cytotoxicity and cytokine production in an HLA-A24-restricted manner. In contrast to gene-modified Tc1 cells, Th1 cells produced high amounts of interleukin-2 (IL-2) in addition to IFN-gamma, which is beneficial for induction of antitumor cellular immunity. Thus, TCR gene-modified HLA-class I-restricted Th1 and Tc1 cells are a powerful strategy for the application to adoptive immunotherapy of human cancer.</div></details></details></td>
    </tr>
    <tr>
      <th>8</th>
      <td>RORA</td>
      <td>9</td>
      <td>TH17:5, TREG:3, TH:2, TH1:2, THP:1</td>
      <td>0.567572</td>
      <td>ENSG00000069667</td>
      <td><details><summary>Subtypes</summary><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/25732870">25732870</a><div class="entities" style="line-height: 2.5"><h3>Gαq controls rheumatoid arthritis via regulation of Th17 differentiation.</h3></br>Gαq, the α-subunit of Gq protein, is ubiquitously expressed in mammalian cells. It initially attracted attention for its physiological significance in cardiovascular system. In recent years, studies have also indicated the important roles of Gαq in regulating immunity, supplying us a new insight into the mechanism of immune regulation. T helper type 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are potent inducers of tissue inflammation. Many studies have shown that Th17 cells are major effector cells in the pathogenesis of many experimental autoimmune diseases and human inflammatory conditions such as rheumatoid arthritis (RA). One of our previous studies has shown that Gαq negatively controls the disease activity of RA. However, how Gαq controls the pathogenesis of autoimmune disease is not clear. Whether this effect is via the regulation of Th17 differentiation is still not known. We aimed to find out the role of Gαq in control of Th17 differentiation. We investigated the relationship between Gαq and Th17 in RA patients. We then investigated the mechanism of how Gαq regulated Th17 differentiation by using Gnaq(-/-) mice. We observed that the expression of Gαq was negatively associated with interleukin-17A expression in RA patients, indicating that Gαq negatively controlled the differentiation of Th17 cells. By using Gnaq(-/-) mice, we demonstrated that Gαq inhibited the differentiation of Th17 cell via regulating the activity of extracellular signal-regulated kinase-1/2 to control the expression of STAT3 (signal transducer and activator of transcription 3) and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORα    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (RAR-related orphan receptor-α). These data suggest the possibility of targeting Gαq to develop a novel therapeutic regimen for autoimmune disease. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/23653308">23653308</a><div class="entities" style="line-height: 2.5"><h3>Roles of T helper 17 cells and interleukin-17 in neuroautoimmune diseases with emphasis on multiple sclerosis and Guillain-Barré syndrome as well as their animal models.</h3></br>The identification of T helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells challenges the Th1/Th2 paradigm of the immune response and invites intensive exploration of their mechanisms and functions in the field of autoimmune diseases, host defense, allergy, etc. The collective data have shown that transforming growth factor-β (TGF-β), interleukin (IL)-6, IL-1β, IL-21, and IL-23 are involved in the differentiation program of Th17 cells. The transcription factors RORγT, STAT3, RORγ, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORα    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, and IRF4 exert regulatory effects on the development of Th17 cells. Among the Th17-related effector cytokines, such as IL-17, IL-17F, IL-21, and IL-22, IL-17 is regarded as a key cytokine to induce inflammatory responses. This review outlines the cytokines and transcription factors involved in the differentiation of Th17 cells and their effector functions, with specific focus on the roles of Th17 cells and IL-17 in neuroautoimmune diseases, especially in multiple sclerosis and Guillain-Barré syndrome, as well as in their animal models, experimental autoimmune encephalomyelitis and experimental autoimmune neuritis.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/22048764">22048764</a><div class="entities" style="line-height: 2.5"><h3>Human Th1 and Th17 cells exhibit epigenetic stability at signature cytokine and transcription factor loci.</h3></br>The linear model of Th cell lineage commitment is being revised due to reports that mature Th cells can trans-differentiate into alternate lineages. This ability of Th cells to reprogram is thought to be regulated by epigenetic mechanisms that control expression of transcription factors characteristic of opposing lineages. It is unclear, however, to what extent this new model of Th cell plasticity holds true in human Th cell subsets that develop under physiological conditions in vivo. We isolated in vivo-differentiated human Th1 and Th17 cells, as well as intermediate Th1/17 cells, and identified distinct epigenetic signatures at cytokine (IFNG and IL17A) and transcription factor (TBX21, RORC, and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORA    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) loci. We also examined the phenotypic and epigenetic stability of human Th17 cells exposed to Th1-polarizing conditions and found that although they could upregulate TBX21 and IFN-γ, this occurred without loss of IL-17 or RORC expression, and resulted in cells with a Th1/17 phenotype. Similarly, Th1 cells could upregulate IL-17 upon enforced expression of RORC2, but did not lose expression of IFN-γ or TBX21. Despite alterations in expression of these signature genes, epigenetic modifications were remarkably stable aside from the acquisition of active histone methylation marks at cytokine gene promoters. The limited capacity of human <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th1 cells to undergo complete lineage conversion suggests that the bipotent Th1/17 cells may arise from Th1 and/or Th17 cells. These data also question the broad applicability of the new model of Th cell lineage plasticity to in vivo-polarized human Th cell subsets.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/19261692">19261692</a><div class="entities" style="line-height: 2.5"><h3>Th17 cells: from precursors to players in inflammation and infection.</h3></br>Upon activation, naive CD4(+) T cells differentiate into different lineages of effector T(h) subsets. Each subset is characterized by its unique cytokine profile and biological functions. T(h)17, a newly described T(h) subset that produces IL-17, IL-17F and IL-22 in preference to other cytokines, has been shown to play an important role in clearing specific pathogens and in inducing autoimmune tissue inflammations. Over the last 2-3 years, significant progress has been made to understand the development and biological functions of T(h)17 subset. Transforming growth factor beta (TGF) together with IL-6 or IL-21 initiates the differentiation while IL-23 stabilizes the generation of T(h)17 cells. The transcription factors of T(h)17 cells [retinoid-related orphan receptor (ROR) gammat, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    ROR-alpha    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and signal transducer and activator of transcription-3] have been described recently. Since TGF-beta is essential for the generation of both T(h)17 and regulatory T (T(reg)) cells from naive T cells, which suggests a developmental link between <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(h)17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and T(reg) cells. Functions of these two subsets of T cells are, however, opposite to each other; <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(h)17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells are highly pathogenic during the inflammatory process while T(reg) cells are crucial for inhibiting tissue inflammation and maintaining self-tolerance. Here, we review the recent information on differentiation and effector functions of T(h)17 cells during inflammatory conditions.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/24068736">24068736</a><div class="entities" style="line-height: 2.5"><h3>IL-29 is produced by T(H)17 cells and mediates the cutaneous antiviral competence in psoriasis.</h3></br>Psoriasis and atopic dermatitis (AD) are the most common chronic inflammatory skin diseases. Although both patient groups show strongly impaired skin barrier function, only AD patients frequently suffer from cutaneous viral infections. The mechanisms underlying the distinct susceptibilities to these pathogenetic and often life-threatening infections are unknown. We show that antiviral proteins (AVPs) such as MX1, BST2, ISG15, and OAS2 were strongly elevated in psoriatic compared to AD lesions and healthy skin. Of 30 individually quantified cytokines in psoriatic lesions, interleukin-29 (IL-29) was the only mediator whose expression correlated with the AVP levels. IL-29 was absent in AD lesions, and neutralization of IL-29 in psoriatic skin reduced AVP expression. Accordingly, IL-29 raised AVP levels in isolated keratinocytes, epidermis models, and human skin explants, but did not influence antibacterial protein production. AVP induction correlated with increased antiviral defense of IL-29-treated keratinocytes. Furthermore, IL-29 elevated the expression of signaling elements, resulting in increased sensitivity of keratinocytes toward its own action. We identified T helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(H)17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells as IL-29 producers and demonstrated their ability to increase the antiviral competence of keratinocytes in an IL-29-dependent manner. Transforming growth factor-β and the activity of RORγt/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORα    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> were most critical for the development of IL-29-producing T(H)17 cells. IL-29 secretion by these cells was dependent on NFAT and c-Jun N-terminal kinase and was inhibited by IL-4. These data suggest that T(H)17 cell-derived IL-29, which is absent in AD, mediates the robust antiviral state on psoriatic skin, and demonstrate a new function of T(H)17 cells.</div></details><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/19261692">19261692</a><div class="entities" style="line-height: 2.5"><h3>Th17 cells: from precursors to players in inflammation and infection.</h3></br>Upon activation, naive CD4(+) T cells differentiate into different lineages of effector T(h) subsets. Each subset is characterized by its unique cytokine profile and biological functions. T(h)17, a newly described T(h) subset that produces IL-17, IL-17F and IL-22 in preference to other cytokines, has been shown to play an important role in clearing specific pathogens and in inducing autoimmune tissue inflammations. Over the last 2-3 years, significant progress has been made to understand the development and biological functions of T(h)17 subset. Transforming growth factor beta (TGF) together with IL-6 or IL-21 initiates the differentiation while IL-23 stabilizes the generation of T(h)17 cells. The transcription factors of T(h)17 cells [retinoid-related orphan receptor (ROR) gammat, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    ROR-alpha    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and signal transducer and activator of transcription-3] have been described recently. Since TGF-beta is essential for the generation of both T(h)17 and regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells from naive T cells, which suggests a developmental link between T(h)17 and T(reg) cells. Functions of these two subsets of T cells are, however, opposite to each other; T(h)17 cells are highly pathogenic during the inflammatory process while <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells are crucial for inhibiting tissue inflammation and maintaining self-tolerance. Here, we review the recent information on differentiation and effector functions of T(h)17 cells during inflammatory conditions.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/29500225">29500225</a><div class="entities" style="line-height: 2.5"><h3>RORα-expressing T regulatory cells restrain allergic skin inflammation.</h3></br>Atopic dermatitis is an allergic inflammatory skin disease characterized <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    by t    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>he production of the type 2 cytokines in the skin by type 2 innate lymphoid cells (ILC2s) and T helper 2 (TH 2) cells, and tissue eosinophilia. Using two distinct mouse models of atopic dermatitis, we show that expression of retinoid-related orphan receptor α (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORα    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) in skin-resident T regulatory cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> ) is important for restraining allergic skin inflammation. In both models, targeted deletion of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORα    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in mouse Tregs  led to exaggerated eosinophilia driven by interleukin-5 (IL-5) production by ILC2s and TH 2 cells. Expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORα    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in skin-resident Tregs  suppressed IL-4 expression and enhanced expression of death receptor 3 (DR3), which is the receptor for tumor necrosis factor (TNF) family cytokine, TNF ligand-related molecule 1 (TL1A), which promotes Treg  functions. DR3 is expressed on both ILC2s and skin-resident Tregs  Upon deletion of RORα in skin-resident Tregs , we found that Tregs  were no longer able to sequester TL1A, resulting in enhanced ILC2 activation. We also documented higher expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORα    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in skin-resident Tregs  than in peripheral blood circulating Tregs  in humans, suggesting that RORα and the TL1A-DR3 circuit could be therapeutically targeted in atopic dermatitis.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21462833">21462833</a><div class="entities" style="line-height: 2.5"><h3>Plasticity of regulatory T cells under cytokine pressure.</h3></br>CD4+ T helper (Th) cells have been divided into different subsets as defined by their cytokine products and functions after their activation. CD4+ T cell subsets are continuously discovered and until now Th1, Th2, Th9, Th17, and regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells have been almost unanimously recognized but yet not completely characterized. The selective production of cytokines by each of the subsets is probably the master key of the mechanisms of immune regulation. The cytokine milieu is extremely important on deciding the fate of T cells. Generally, more than one cytokine is needed for differentiating to a particular lineage and just recently it was shown that this status quo of commitment could be challenged. It is well known that cytokines bind to Type I/II cytokine receptors signaling via Janus kinases (JAKs) followed by activation of Signal Transducer and Activator of Transcription (STAT). STAT molecules work together with other transcription factors (Foxp3, RORgammat and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORalpha    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, T-bet, GATA3, Runx 1, NFAT, etc.) also controlled by cytokines, in modulating the Th phenotype and functions. In this review, we analyze the plasticity of Treg population focusing on the most recent discoveries on how microenvironmental cytokines refine/modify Treg phenotype and function, thus changing their fate.</div></details><details><summary>TH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/29500225">29500225</a><div class="entities" style="line-height: 2.5"><h3>RORα-expressing T regulatory cells restrain allergic skin inflammation.</h3></br>Atopic dermatitis is an allergic inflammatory skin disease characterized <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    by t    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>he production of the type 2 cytokines in the skin by type 2 innate lymphoid cells (ILC2s) and T helper 2 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> 2) cells, and tissue eosinophilia. Using two distinct mouse models of atopic dermatitis, we show that expression of retinoid-related orphan receptor α (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORα    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) in skin-resident T regulatory cells (Tregs ) is important for restraining allergic skin inflammation. In both models, targeted deletion of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORα    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in mouse Tregs  led to exaggerated eosinophilia driven by interleukin-5 (IL-5) production by ILC2s and TH 2 cells. Expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORα    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in skin-resident Tregs  suppressed IL-4 expression and enhanced expression of death receptor 3 (DR3), which is the receptor for tumor necrosis factor (TNF) family cytokine, TNF ligand-related molecule 1 (TL1A), which promotes Treg  functions. DR3 is expressed on both ILC2s and skin-resident Tregs  Upon deletion of RORα in skin-resident Tregs , we found that Tregs  were no longer able to sequester TL1A, resulting in enhanced ILC2 activation. We also documented higher expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORα    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in skin-resident Tregs  than in peripheral blood circulating Tregs  in humans, suggesting that RORα and the TL1A-DR3 circuit could be therapeutically targeted in atopic dermatitis.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21462833">21462833</a><div class="entities" style="line-height: 2.5"><h3>Plasticity of regulatory T cells under cytokine pressure.</h3></br>CD4+ T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells have been divided into different subsets as defined by their cytokine products and functions after their activation. CD4+ T cell subsets are continuously discovered and until now Th1, Th2, Th9, Th17, and regulatory T (Treg) cells have been almost unanimously recognized but yet not completely characterized. The selective production of cytokines by each of the subsets is probably the master key of the mechanisms of immune regulation. The cytokine milieu is extremely important on deciding the fate of T cells. Generally, more than one cytokine is needed for differentiating to a particular lineage and just recently it was shown that this status quo of commitment could be challenged. It is well known that cytokines bind to Type I/II cytokine receptors signaling via Janus kinases (JAKs) followed by activation of Signal Transducer and Activator of Transcription (STAT). STAT molecules work together with other transcription factors (Foxp3, RORgammat and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORalpha    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, T-bet, GATA3, Runx 1, NFAT, etc.) also controlled by cytokines, in modulating the Th phenotype and functions. In this review, we analyze the plasticity of Treg population focusing on the most recent discoveries on how microenvironmental cytokines refine/modify Treg phenotype and function, thus changing their fate.</div></details><details><summary>TH1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/19912251">19912251</a><div class="entities" style="line-height: 2.5"><h3>Translational mini-review series on Th17 cells: induction of interleukin-17 production by regulatory T cells.</h3></br>Uncommitted (naive) CD4(+) T helper cells (Thp) can be induced to differentiate to specific lineages according to the local cytokine milieu, towards T helper type 1 (Th1), Th2, Th17 and regulatory T cell (T(reg)) phenotypes in a mutually exclusive manner. Each phenotype is characterized by unique signalling pathways and expression of specific transcription factors, notably T-bet for Th1, GATA-3 for Th2, forkhead box P3 (FoxP3) for T(regs) and receptor-related orphan receptor (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    ROR)alpha    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and RORgammat for Th17 cells. T(regs) and Th17 cells have been demonstrated to arise from common precursors in a reciprocal manner based on exposure to transforming growth factor (TGF)-beta or TGF-beta plus interleukin (IL)-6 and carry out diametrically opposing functions, namely suppression or propagation of inflammation, respectively. However, while epigenetic modifications in <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 differentiated cells prevents their conversion to other phenotypes, Th17 cells generated in vitro using TGF-beta and IL-6 are unstable and can convert to other phenotypes, especially Th1, both in vitro and in vivo. T(regs) are generated from naive precursors both in the thymus (natural, nT(regs)) and in the periphery (induced, iT(regs)). The highly suppressive function of T(regs) enables them to control many inflammatory diseases in animals and makes them particularly attractive candidates for immunotherapy in humans. The stability of the T(reg) phenotype is therefore of paramount importance in this context. Recent descriptions of T(reg) biology have suggested that components of pathogens or inflammatory mediators may subvert the suppressive function of T(regs) in order to allow propagation of adequate immune responses. Unexpectedly, however, a number of groups have now described conversion of T(regs) to the Th17 phenotype induced by appropriate inflammatory stimuli. These observations are particularly relevant in the context of cell therapy but may also explain some of the dysregulation seen in autoimmune diseases. In this paper, we review T(reg) to Th17 conversion and propose some potential mechanisms for this phenomenon.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/19132915">19132915</a><div class="entities" style="line-height: 2.5"><h3>IL-17 and Th17 Cells.</h3></br>CD4+ T cells, upon activation and expansion, develop into different T helper cell subsets with different cytokine profiles and distinct effector functions. Until recently, T cells were divided into <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> or Th2 cells, depending on the cytokines they produce. A third subset of IL-17-producing effector T helper cells, called Th17 cells, has now been discovered and characterized. Here, we summarize the current information on the differentiation and effector functions of the Th17 lineage. Th17 cells produce IL-17, IL-17F, and IL-22, thereby inducing a massive tissue reaction owing to the broad distribution of the IL-17 and IL-22 receptors. Th17 cells also secrete IL-21 to communicate with the cells of the immune system. The differentiation factors (TGF-beta plus IL-6 or IL-21), the growth and stabilization factor (IL-23), and the transcription factors (STAT3, RORgammat, and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORalpha    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) involved in the development of Th17 cells have just been identified. The participation of TGF-beta in the differentiation of Th17 cells places the Th17 lineage in close relationship with CD4+CD25+Foxp3+ regulatory T cells (Tregs), as TGF-beta also induces differentiation of naive T cells into Foxp3+ Tregs in the peripheral immune compartment. The investigation of the differentiation, effector function, and regulation of Th17 cells has opened up a new framework for understanding T cell differentiation. Furthermore, we now appreciate the importance of Th17 cells in clearing pathogens during host defense reactions and in inducing tissue inflammation in autoimmune disease.</div></details><details><summary>THP</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/19912251">19912251</a><div class="entities" style="line-height: 2.5"><h3>Translational mini-review series on Th17 cells: induction of interleukin-17 production by regulatory T cells.</h3></br>Uncommitted (naive) CD4(+) T helper cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Thp    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) can be induced to differentiate to specific lineages according to the local cytokine milieu, towards T helper type 1 (Th1), Th2, Th17 and regulatory T cell (T(reg)) phenotypes in a mutually exclusive manner. Each phenotype is characterized by unique signalling pathways and expression of specific transcription factors, notably T-bet for Th1, GATA-3 for Th2, forkhead box P3 (FoxP3) for T(regs) and receptor-related orphan receptor (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    ROR)alpha    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and RORgammat for Th17 cells. T(regs) and Th17 cells have been demonstrated to arise from common precursors in a reciprocal manner based on exposure to transforming growth factor (TGF)-beta or TGF-beta plus interleukin (IL)-6 and carry out diametrically opposing functions, namely suppression or propagation of inflammation, respectively. However, while epigenetic modifications in Th1 and Th2 differentiated cells prevents their conversion to other phenotypes, Th17 cells generated in vitro using TGF-beta and IL-6 are unstable and can convert to other phenotypes, especially Th1, both in vitro and in vivo. T(regs) are generated from naive precursors both in the thymus (natural, nT(regs)) and in the periphery (induced, iT(regs)). The highly suppressive function of T(regs) enables them to control many inflammatory diseases in animals and makes them particularly attractive candidates for immunotherapy in humans. The stability of the T(reg) phenotype is therefore of paramount importance in this context. Recent descriptions of T(reg) biology have suggested that components of pathogens or inflammatory mediators may subvert the suppressive function of T(regs) in order to allow propagation of adequate immune responses. Unexpectedly, however, a number of groups have now described conversion of T(regs) to the Th17 phenotype induced by appropriate inflammatory stimuli. These observations are particularly relevant in the context of cell therapy but may also explain some of the dysregulation seen in autoimmune diseases. In this paper, we review T(reg) to Th17 conversion and propose some potential mechanisms for this phenomenon.</div></details></details></td>
    </tr>
    <tr>
      <th>9</th>
      <td>RORC</td>
      <td>31</td>
      <td>TH17:13, TREG:12, TH:6, TH1:4, TH22:4</td>
      <td>0.560262</td>
      <td>ENSG00000143365</td>
      <td><details><summary>Subtypes</summary><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27255270">27255270</a><div class="entities" style="line-height: 2.5"><h3>Tolerance to the Intestinal Microbiota Mediated by ROR(γt)(+) Cells.</h3></br>Harmless microbes colonizing the gut require the establishment of a well-equilibrated symbiosis between this microbiota and its host. However, the immune system is primed to recognize both conserved microbial patterns and foreign antigens, and therefore developed strong tolerance mechanisms to prevent potential fatal immune reactivity to symbiotic microbes. The transcription factor RAR-related orphan-like γt [ROR(γt); encoded by <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Rorc    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>] plays a key role in the gut for lymphoid tissue organogenesis, development of innate lymphoid cells type 3 (ILC3s) and proinflammatory type 17 T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. Surprisingly, recent research has revealed a contribution of ROR(γt)-expressing cells in a variety of tolerance mechanisms in both the innate and adaptive immune system.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/26878233">26878233</a><div class="entities" style="line-height: 2.5"><h3>Transient inhibition of ROR-γt therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cells.</h3></br>RAR-related orphan receptor-γt (ROR-γt) directs differentiation of proinflammatory T helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells and is a potential therapeutic target in chronic autoimmune and inflammatory diseases. However, ROR-γt-dependent group 3 innate lymphoid cells ILC3s provide essential immunity and tissue protection in the intestine, suggesting that targeting ROR-γt could also result in impaired host defense after infection or enhanced tissue damage. Here, we demonstrate that transient chemical inhibition of ROR-γt in mice selectively reduces cytokine production from TH17 but not ILCs in the context of intestinal infection with Citrobacter rodentium, resulting in preserved innate immunity. Temporal deletion of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Rorc    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (encoding ROR-γt) in mature ILCs also did not impair cytokine response in the steady state or during infection. Finally, pharmacologic inhibition of ROR-γt provided therapeutic benefit in mouse models of intestinal inflammation and reduced the frequency of TH17 cells but not ILCs isolated from primary intestinal samples of individuals with inflammatory bowel disease (IBD). Collectively, these results reveal differential requirements for ROR-γt in the maintenance of TH17 cell and ILC3 responses and suggest that transient inhibition of ROR-γt is a safe and effective therapeutic approach during intestinal inflammation. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/24363794">24363794</a><div class="entities" style="line-height: 2.5"><h3>The metalloprotease ADAM12 regulates the effector function of human Th17 cells.</h3></br>A key modulator of immune homeostasis, TGFβ has an important role in the differentiation of regulatory T cells (Tregs) and IL-17-secreting T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>). How TGFβ regulates these functionally opposing T cell subsets is not well understood. We determined that an ADAM family metalloprotease called ADAM12 is specifically and highly expressed in both Tregs and CCR6+ Th17 cells. ADAM12 is induced in vitro upon differentiation of naïve T cells to Th17 cells or IL-17-secreting Tregs. Remarkably, silencing ADAM12 expression in CCR6+ memory T cells enhances the production of Th17 cytokines, similar to suppressing TGFβ signaling. Further, ADAM12 knockdown in naïve human T cells polarized towards Th17/Treg cells, or ectopically expressing <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, greatly enhances IL-17-secreting cell differentiation, more potently then inhibiting TGFβ signals. Together, our findings reveal a novel regulatory role for ADAM12 in Th17 cell differentiation or function and may have implications in regulating their aberrant responses during immune pathologies. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/24211040">24211040</a><div class="entities" style="line-height: 2.5"><h3>Reasons for rarity of Th17 cells in inflammatory sites of human disorders.</h3></br>T helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells have been reported to be responsible for several chronic inflammatory diseases. However, a peculiar feature of human Th17 cells is that they are very rare in the inflammatory sites in comparison with Th1 cells. The first reason for this rarity is the existence of some self-regulatory mechanisms that limit their expansion. The limited expansion of human Th17 cells is related to the retinoic acid orphan (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    ROR)C    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>-dependent up-regulation of the interleukin (IL)-4 induced gene 1 (IL4I1), which encodes for a l-phenylalanine oxidase, that has been shown to down-regulate CD3ζ expression in T cells. This results in abnormalities of the molecular pathway which is responsible for the impairment of IL-2 production and therefore for the lack of cell proliferation in response to T cell receptor (TCR) signalling. IL4I1 up-regulation also associates with the increased expression of Tob1, a member of the Tob/BTG anti-proliferative protein family, which is involved in cell cycle arrest. A second reason for the rarity of human Th17 cells in the inflammatory sites is their rapid shifting into the Th1 phenotype, which is mainly related to the activity of IL-12 and TNF-α. We have named these Th17-derived Th1 cells as non-classic because they differ from classic Th1 cells for the expression of molecules specific for Th17 cells, such as <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, CD161, CCR6, IL4I1, and IL-17 receptor E. This distinction may be important for defining the respective pathogenic role of Th17, non-classic Th1 and classic Th1 cells in many human inflammatory disorders. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/22537755">22537755</a><div class="entities" style="line-height: 2.5"><h3>Elevated profiles of Th22 cells and correlations with Th17 cells in patients with immune thrombocytopenia.</h3></br>T-helper (Th) 22 and Th17 cells are implicated in the pathogenesis of autoimmune diseases. However, the role of Th22 cells in the pathophysiology of immune thrombocytopenia (ITP) remains unclear. Th22, <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th1 cells in both ITP patients and healthy controls were examined by flow cytometry. Plasma interleukin-22 (IL-22) level was measured by enzyme linked immunosorbent assay (ELISA). Signal transducers and activators of transcription 3 (STAT-3) and transcription factor RAR-related organ receptor C (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) messenger RNA (mRNA) expressions were examined by quantitative reverse transcription polymerase chain reaction (RT-PCR). Th22 cells, Th17 cells, Th1 cells and plasma IL-22 were significantly higher in ITP patients than in healthy controls. Moreover, Th22 cells showed a positive correlation with the levels of plasma IL-22 as well as <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th1 cells in ITP patients. Significant up-regulations of both STAT-3 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> transcription factors were also observed. Additionally, the percentage of Th22 cells was higher in autoantibody-negative ITP patients than in autoantibody-positive patients. Our results demonstrate a possible role of Th22 cells in ITP, and thus, the blockade of IL-22 may be a reasonable therapeutic strategy for ITP.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/22326581">22326581</a><div class="entities" style="line-height: 2.5"><h3>Rarity of human T helper 17 cells is due to retinoic acid orphan receptor-dependent mechanisms that limit their expansion.</h3></br>The reason why CD4(+) T helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, despite their well-known pathogenic role in chronic inflammatory disorders, are very rare in the inflammatory sites remains unclear. We demonstrate that human Th17 cells exhibit low ability to proliferate and to produce the T cell growth factor interleukin-2 (IL-2), in response to combined CD3 and CD28 stimulation. This was due to the upregulated expression of IL-4-induced gene 1 (IL4I1) mRNA, a secreted L-phenylalanine oxidase, which associated with a decrease in CD3ζ chain expression and consequent abnormalities in the molecular pathway that allows IL-2 production and cell proliferation. High IL4I1 mRNA expression was detectable in Th17 cell precursors and was strictly dependent on Th17 cell master gene, the retinoid acid related orphan receptor (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>). Th17 cells also exhibited <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>-dependent CD28 hyperexpression and the ability to produce IL-17A after CD28 stimulation without CD3 triggering. Our findings suggest that the rarity of human Th17 cells in inflamed tissues results from <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>-dependent mechanisms limiting their expansion.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/22048764">22048764</a><div class="entities" style="line-height: 2.5"><h3>Human Th1 and Th17 cells exhibit epigenetic stability at signature cytokine and transcription factor loci.</h3></br>The linear model of Th cell lineage commitment is being revised due to reports that mature Th cells can trans-differentiate into alternate lineages. This ability of Th cells to reprogram is thought to be regulated by epigenetic mechanisms that control expression of transcription factors characteristic of opposing lineages. It is unclear, however, to what extent this new model of Th cell plasticity holds true in human Th cell subsets that develop under physiological conditions in vivo. We isolated in vivo-differentiated human Th1 and Th17 cells, as well as intermediate Th1/17 cells, and identified distinct epigenetic signatures at cytokine (IFNG and IL17A) and transcription factor (TBX21, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, and RORA) loci. We also examined the phenotypic and epigenetic stability of human Th17 cells exposed to Th1-polarizing conditions and found that although they could upregulate TBX21 and IFN-γ, this occurred without loss of IL-17 or <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression, and resulted in cells with a Th1/17 phenotype. Similarly, Th1 cells could upregulate IL-17 upon enforced expression of RORC2, but did not lose expression of IFN-γ or TBX21. Despite alterations in expression of these signature genes, epigenetic modifications were remarkably stable aside from the acquisition of active histone methylation marks at cytokine gene promoters. The limited capacity of human <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th1 cells to undergo complete lineage conversion suggests that the bipotent Th1/17 cells may arise from Th1 and/or Th17 cells. These data also question the broad applicability of the new model of Th cell lineage plasticity to in vivo-polarized human Th cell subsets.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21367463">21367463</a><div class="entities" style="line-height: 2.5"><h3><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and Foxp3 axis in cerebrospinal fluid of patients with neuro-Behçet's disease.</h3></br>Neurological manifestations are present in 5% to 30% of patients with Behçet's disease (BD). Neuro-Behçet's Disease (NBD) is hypothetically caused by T helper (Th) cells, which development is dependent on the expression of lineage-specific transcription factors. Cerebrospinal fluid (CSF) mRNA expression of TBX21, GATA3, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, FOXP3 and EBI3 were assessed in 18 NBD patients and 26 controls disease [16 noninflammatory neurological disease (NIND) and 10 headache attributed to Behçet's disease (HaBD)]. Expression of TBX21 (Th1), RORC (Th17) and Foxp3 (Treg) were increased in NBD patients compared to HaBD and NIND patients. EBI3 and Th2-associated GATA3 expressions were found to be decreased (P<0.0001 and P<0.0001) in NBD patients. Analysis of transcription factor ratios, revealed an increase in the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>/FOXP3 and TBX21/GATA3 ratios in NBD patients (P<0.0001; P<0.0003). Our findings indicate that both Th1 and Th17 mRNA expressions involving a possible impairment of Treg cells. This might play a role in CSF-NBD inflammation, permitting activation of harmful T cell subpopulations. The TBX21/GATA3 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>/FOXP3 ratios dysregulations in NBD are consistent with those reported in other inflammatory diseases and indicating the plasticity existing between Th1, <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Treg cells during inflammation.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/20106535">20106535</a><div class="entities" style="line-height: 2.5"><h3>Increased prevalence of T helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells in peripheral blood and decidua in unexplained recurrent spontaneous abortion patients.</h3></br>T helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells and regulatory T (Treg) cells are two distinct subsets of CD4(+) T cells which have opposite effects on inflammation, autoimmunity and immunological rejection of foreign tissue. Treg cells have been shown to be important in maintaining materno-fetal tolerance, but the role of Th17 cells in human pregnancy and pathological pregnancy, especially in relation to unexplained recurrent spontaneous abortion (RSA), has not been investigated. In this study, we showed that the proportion of Th17 cells in the peripheral blood and decidua was significantly higher in unexplained RSA patients compared to normal, early pregnant women. Meanwhile, there was an inverse relationship between Th17 cells and Treg cells in the peripheral blood lymphocytes (PBL) and decidua in unexplained RSA. The expression of Th17 related factors, IL-17, IL-23 and retinoid orphan nuclear receptor (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>), in PBL and decidua in unexplained RSA patients was significantly higher than normal, early pregnant women. This study is the first to define the occurrence of Th17 cells in unexplained RSA patients and in normal, early pregnant women. We suggest that these highly pro-inflammatory cells contribute to unexplained RSA, and the balance between Th17 cells and Treg cells may be critical to pregnancy outcomes.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/19965648">19965648</a><div class="entities" style="line-height: 2.5"><h3>Regulating human Th17 cells via differential expression of IL-1 receptor.</h3></br>In humans, interleukin-1beta (IL-1beta) has been suggested as an essential cytokine for developing IL-17- or IL-17A-producing CD4(+) T helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. However, little is known about the relationship of IL-1 receptor expression and Th17 cell differentiation. We report here the presence of 2 distinct CD4(+) T cell populations with and without expression of IL-1RI that correlates with the capacity to produce IL-17 in naive and memory CD4(+) T cells of human peripheral blood. IL-1RI(+) memory CD4(+) T cells had increased gene expression of IL17, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, and IRF4 even before T cell receptor triggering, indicating that the effect of IL-1beta is programmed in these cells via IL-1RI. Although CD4(+) T cells from umbilical cord blood did not express IL-1RI, the cytokines IL-7, IL-15, and transforming growth factor-beta (TGF-beta) up-regulated IL-1RI expression on naive CD4(+) T cells, suggesting that IL-1RI(+) naive CD4(+) T cells develop in periphery. Furthermore, IL-17 production from the cytokine-treated naive CD4(+) T cells was induced by IL-1beta and this induction was blocked by IL-1R antagonist. These results indicate that human Th17 cell differentiation is regulated via differential expression of IL-1RI, which is controlled by IL-7 and IL-15.</div></details><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27902985">27902985</a><div class="entities" style="line-height: 2.5"><h3>Disease Manifestation and Inflammatory Activity as Modulators of Th17/Treg Balance and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>/FoxP3 Methylation in Systemic Sclerosis.</h3></br>There is much evidence that T cells are strongly involved in the pathogenesis of localized and systemic forms of scleroderma (SSc). A dysbalance between FoxP3+ regulatory CD4+ T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) and inflammatory T-helper (Th) 17 cells has been suggested.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27479084">27479084</a><div class="entities" style="line-height: 2.5"><h3>An asthma-associated IL4R variant exacerbates airway inflammation by promoting conversion of regulatory T cells to TH17-like cells.</h3></br>Mechanisms by which regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells fail to control inflammation in asthma remain poorly understood. We show that a severe asthma-associated polymorphism in the gene encoding the interleukin (IL)-4 receptor alpha chain (Il4ra(R576)) promotes conversion of induced <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> (iTreg) cells toward a T helper 17 (TH17) cell fate. This skewing is mediated by the recruitment by IL-4Rα(R576) of the growth-factor-receptor-bound protein 2 (GRB2) adaptor protein, which drives IL-17 expression by activating a pathway that involves extracellular-signal-regulated kinase, IL-6 and the transcription factor STAT3. Treg cell-specific deletion of genes that regulate TH17 cell differentiation, including Il6ra and RAR-related orphan receptor gamma (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Rorc    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>), but not of Il4 or Il13, prevented exacerbated airway inflammation in mice expressing Il4ra(R576) (hereafter referred to as Il4ra(R576) mice). Furthermore, treatment of Il4ra(R576) mice with a neutralizing IL-6-specific antibody prevented iTreg cell reprogramming into TH17-like cells and protected against severe airway inflammation. These findings identify a previously unknown mechanism for the development of mixed TH2-TH17 cell inflammation in genetically prone individuals and point to interventions that stabilize iTreg cells as potentially effective therapeutic strategies.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/25828206">25828206</a><div class="entities" style="line-height: 2.5"><h3>The role and modulation of CCR6+ Th17 cell populations in rheumatoid arthritis.</h3></br>The IL-17A producing T-helper-17 (Th17) cell population plays a major role in rheumatoid arthritis (RA) pathogenesis and has gained wide interest as treatment target. IL-17A expressing Th cells are characterized by the expression of the chemokine receptor CCR6 and the transcription factor <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. In RA, CCR6+ Th cells were identified in peripheral blood, synovial fluid and inflamed synovial tissue. CCR6+ Th cells might drive the progression of an early inflammation towards a persistent arthritis. The CCR6+ Th cell population is heterogeneous and several subpopulations can be distinguished, including Th17, Th22, Th17.1 (also called non-classic Th1 cells), and unclassified or intermediate populations. Interestingly, some of these populations produce low levels of IL-17A but are still very pathogenic. Furthermore, the CCR6+ Th cells phenotype is unstable and plasticity exists between CCR6+ Th cells and T-regulatory (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells and within the CCR6+ Th cell subpopulations. In this review, characteristics of the different CCR6+ Th cell populations, their plasticity, and their potential impact on rheumatoid arthritis are discussed. Moreover, current approaches to target CCR6+ Th cells and future directions of research to find specific CCR6+ Th cell targets in the treatment of patients with RA and other CCR6+ Th cell mediated autoimmune diseases are highlighted. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/24363794">24363794</a><div class="entities" style="line-height: 2.5"><h3>The metalloprotease ADAM12 regulates the effector function of human Th17 cells.</h3></br>A key modulator of immune homeostasis, TGFβ has an important role in the differentiation of regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) and IL-17-secreting T cells (Th17). How TGFβ regulates these functionally opposing T cell subsets is not well understood. We determined that an ADAM family metalloprotease called ADAM12 is specifically and highly expressed in both Tregs and CCR6+ Th17 cells. ADAM12 is induced in vitro upon differentiation of naïve T cells to Th17 cells or IL-17-secreting Tregs. Remarkably, silencing ADAM12 expression in CCR6+ memory T cells enhances the production of Th17 cytokines, similar to suppressing TGFβ signaling. Further, ADAM12 knockdown in naïve human T cells polarized towards Th17/Treg cells, or ectopically expressing <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, greatly enhances IL-17-secreting cell differentiation, more potently then inhibiting TGFβ signals. Together, our findings reveal a novel regulatory role for ADAM12 in Th17 cell differentiation or function and may have implications in regulating their aberrant responses during immune pathologies. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/23529856">23529856</a><div class="entities" style="line-height: 2.5"><h3>Co-activation through TLR4 and TLR9 but not TLR2 skews Treg-mediated modulation of Igs and induces IL-17 secretion in Treg: B cell co-cultures.</h3></br>Whereas Th17 cells are associated with aggravated inflammation, regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) provide an environment to control overt responses. Nevertheless, Tregs display a certain degree of plasticity demonstrating that T cell differentiation processes are not absolute. Previously, we showed that human Treg clones induced B cells to produce IgG4. Here we focus on the actions of freshly isolated CD4(+)CD25(+)Foxp3(+)CD127(dim) Tregs on Ig production by B cells and the consequences of prior TLR activation of B cells. In the absence of TLR stimuli, Tregs, but not conventional T cells, dampened B cell proliferation, plasma cell formation and, with the exception of IgG4, all other Ig production. Although IgG4 levels were unchanged in total B cell:Treg co-cultures, levels were increased in Treg co-cultures of naive, but not memory, B cells. Triggering TLR on B cells skewed both Ig and cytokine secretion patterns and, surprisingly, Tregs within TLR4- and TLR9- but not TLR2-triggered B cell co-cultures up-regulated retinoic acid related orphan receptor (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) and produced IL-17. These data indicate that under conditions like bacterial or viral infections, B cells can escape Treg control, and provides an explanation as to why patients suffering from allergy or helminth infections display polar immunopathological symptoms despite being exposed to the same agent. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21469109">21469109</a><div class="entities" style="line-height: 2.5"><h3>Epigenetic reprogramming of the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> locus during in vitro expansion is a distinctive feature of human memory but not naïve Treg.</h3></br>The adoptive transfer of in vitro expanded Treg is a promising treatment option for autoimmune as well as alloantigen-induced diseases. Yet, concerns about the phenotypic and functional stability of Tregs upon in vitro culture command both careful selection of the starting population and thorough characterization of the final cell product. Recently, a high degree of developmental plasticity has been described for murine <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th17 cells. Similarly, IL-17-producing FOXP3(+) cells have been detected among the CD45RA(-) memory-type subpopulation of human Tregs ex vivo. This prompted us to investigate the predisposition of human naïve and memory Tregs to develop into Th17 cells during polyclonal in vitro expansion. Here, we show that stimulation-induced DNA demethylation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, which encodes the lineage-defining transcription factor for Th17 cells, occurs selectively in CD45RA(-) memory-type Tregs, irrespective of their FOXP3 expression level. On the contrary, naïve CD45RA(+) Tregs retain stable CpG methylation across the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> locus even upon prolonged ex vivo expansion and in consequence show only a marginal tendency to express <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and develop into IL-17-producing cells. These findings are highly relevant for the generation of therapeutic Treg products.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21303976">21303976</a><div class="entities" style="line-height: 2.5"><h3>Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer.</h3></br>The tumor microenvironment includes a complex network of immune T cell subpopulations. In this study, we systematically analyzed the balance between cytotoxic T cells and different subsets of helper T cells in human colorectal cancers and we correlated their impact on disease-free survival. A panel of immune related genes were analyzed in 125 frozen colorectal tumor specimens. Infiltrating cytotoxic T cells, <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>, Th1, and Th17 cells were also quantified in the center and the invasive margin of the tumors. By hierarchical clustering of a correlation matrix we identified functional clusters of genes associated with Th17 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, IL17A), Th2 (IL4, IL5, IL13), Th1 (Tbet, IRF1, IL12Rb2, STAT4), and cytotoxicity (GNLY, GZMB, PRF1). Patients with high expression of the Th17 cluster had a poor prognosis, whereas patients with high expression of the Th1 cluster had prolonged disease-free survival. In contrast, none of the Th2 clusters were predictive of prognosis. Combined analysis of cytotoxic/Th1 and Th17 clusters improved the ability to discriminate relapse. In situ analysis of the density of IL17+ cells and CD8+ cells in tumor tissues confirmed the results. Our findings argue that functional Th1 and Th17 clusters yield opposite effects on patient survival in colorectal cancer, and they provide complementary information that may improve prognosis.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/20106535">20106535</a><div class="entities" style="line-height: 2.5"><h3>Increased prevalence of T helper 17 (Th17) cells in peripheral blood and decidua in unexplained recurrent spontaneous abortion patients.</h3></br>T helper 17 (Th17) cells and regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are two distinct subsets of CD4(+) T cells which have opposite effects on inflammation, autoimmunity and immunological rejection of foreign tissue. Treg cells have been shown to be important in maintaining materno-fetal tolerance, but the role of Th17 cells in human pregnancy and pathological pregnancy, especially in relation to unexplained recurrent spontaneous abortion (RSA), has not been investigated. In this study, we showed that the proportion of Th17 cells in the peripheral blood and decidua was significantly higher in unexplained RSA patients compared to normal, early pregnant women. Meanwhile, there was an inverse relationship between Th17 cells and Treg cells in the peripheral blood lymphocytes (PBL) and decidua in unexplained RSA. The expression of Th17 related factors, IL-17, IL-23 and retinoid orphan nuclear receptor (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>), in PBL and decidua in unexplained RSA patients was significantly higher than normal, early pregnant women. This study is the first to define the occurrence of Th17 cells in unexplained RSA patients and in normal, early pregnant women. We suggest that these highly pro-inflammatory cells contribute to unexplained RSA, and the balance between Th17 cells and Treg cells may be critical to pregnancy outcomes.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/19499249">19499249</a><div class="entities" style="line-height: 2.5"><h3>The prevalence of Th17 cells and FOXP3 regulate T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) in children with primary nephrotic syndrome.</h3></br>The aim of this study was to investigate the prevalence of interleukin (IL)-17-producing CD4+ T cells (Th17) and regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells in children with primary nephrotic syndrome. The study cohort consisted of 62 children who were randomly divided into control, primary nephrotic syndrome, and isolated hematuria groups. Flow cytometric analysis revealed the presence of Th17 cells in the peripheral blood mononuclear cells (PBMCs) of 35 children and Tregs in the PBMCs of all children. In addition, mRNA expression of Th17-related factors [IL-17, -23p19 and retinoid orphan nuclear receptor (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORc    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>)] and the concentration of plasma inflammatory mediators such as IL-6 and IL-1beta were consistently detected in all children. Protein expression of IL-17 and transforming growth factor-beta1 were also detected in renal biopsy tissue and compared between different groups. Patients with PNS were found to have an increased number of Th17 cells and decreased numbers of Tregs in their PBMCs, and there was significant difference in the prevalence of Th17 and Tregs between the patients with PNS and those with isolated hematuria. Our data show that among our study cohort, there was a dynamic equilibrium between Th17 and Treg cells in children with PNS following the development of PNS with apparent renal tubular epithelial cell and interstitium lesions. The dynamic interaction between Th17 and Treg cells may be important in the development of PNS.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27559094">27559094</a><div class="entities" style="line-height: 2.5"><h3>Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses.</h3></br>Resolution of inflammation is a finely regulated process mediated by specialized proresolving lipid mediators (SPMs), including docosahexaenoic acid (DHA)-derived resolvins and maresins. The immunomodulatory role of SPMs in adaptive immune cells is of interest. We report that D-series resolvins (resolvin D1 and resolvin D2) and maresin 1 modulate adaptive immune responses in human peripheral blood lymphocytes. These lipid mediators reduce cytokine production by activated CD8(+) T cells and CD4(+) T helper 1 (TH1) and TH17 cells but do not modulate T cell inhibitory receptors or abrogate their capacity to proliferate. Moreover, these SPMs prevented naïve CD4(+) T cell differentiation into TH1 and TH17 by down-regulating their signature transcription factors, T-bet and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Rorc    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, in a mechanism mediated by the GPR32 and ALX/FPR2 receptors; they concomitantly enhanced de novo generation and function of Foxp3(+) regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells via the GPR32 receptor. These results were also supported in vivo in a mouse deficient for DHA synthesis (Elovl2(-/-)) that showed an increase in TH1/TH17 cells and a decrease in Treg cells compared to wild-type mice. Additionally, either DHA supplementation in Elovl2(-/-) mice or in vivo administration of resolvin D1 significantly reduced cytokine production upon specific stimulation of T cells. These findings demonstrate actions of specific SPMs on adaptive immunity and provide a new avenue for SPM-based approaches to modulate chronic inflammation.</div></details><details><summary>TH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27902985">27902985</a><div class="entities" style="line-height: 2.5"><h3>Disease Manifestation and Inflammatory Activity as Modulators of Th17/Treg Balance and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>/FoxP3 Methylation in Systemic Sclerosis.</h3></br>There is much evidence that T cells are strongly involved in the pathogenesis of localized and systemic forms of scleroderma (SSc). A dysbalance between FoxP3+ regulatory CD4+ T cells (Tregs) and inflammatory T-helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) 17 cells has been suggested.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/26553345">26553345</a><div class="entities" style="line-height: 2.5"><h3>Benzoxazepines Achieve Potent Suppression of IL-17 Release in Human T-Helper 17 (TH 17) Cells through an Induced-Fit Binding Mode to the Nuclear Receptor RORγ.</h3></br>RORγt, an isoform of the retinoic acid-related orphan receptor gamma (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORc    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, RORγ), has been identified as the master regulator of T-helper 17 (TH 17) cell function and development, making it an attractive target for the treatment of autoimmune diseases. Validation for this target comes from antibodies targeting interleukin-17 (IL-17), the signature cytokine produced by <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> 17 cells, which have shown impressive results in clinical trials. Through focused screening of our compound collection, we identified a series of N-sulfonylated benzoxazepines, which displayed micromolar affinity for the RORγ ligand-binding domain (LBD) in a radioligand binding assay. Optimization of these initial hits resulted in potent binders, which dose-dependently decreased the ability of the RORγ-LBD to interact with a peptide derived from steroid receptor coactivator 1, and inhibited the release of IL-17 secretion from isolated and cultured human <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> 17 cells with nanomolar potency. A cocrystal structure of inverse agonist 15 (2-chloro-6-fluoro-N-(4-{[3-(trifluoromethyl)phenyl]sulfonyl}-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)benzamide) bound to the RORγ-LBD illustrated that both hydrophobic interactions, leading to an induced fit around the substituted benzamide moiety of 15, as well as a hydrogen bond from the amide NH to His479 seemed to be important for the mechanism of action. This structure is compared with the structure of agonist 25 (N-(2-fluorophenyl)-4-[(4-fluorophenyl)sulfonyl]-2,3,4,5-tetrahydro-1,4-benzoxazepin-6-amine ) and structures of other known RORγ modulators.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/26261240">26261240</a><div class="entities" style="line-height: 2.5"><h3>SUMOylation-disrupting WAS mutation converts WASp from a transcriptional activator to a repressor of NF-κB response genes in T cells.</h3></br>In Wiskott-Aldrich syndrome (WAS), immunodeficiency and autoimmunity often comanifest, yet how WAS mutations misregulate chromatin-signaling in Thelper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells favoring development of auto-inflammation over protective immunity is unclear. Previously, we identified an essential promoter-specific, coactivator role of nuclear-WASp in TH1 gene transcription. Here we identify small ubiquitin-related modifier (SUMO)ylation as a novel posttranslational modification of WASp, impairment of which converts nuclear-WASp from a transcriptional coactivator to a corepressor of nuclear factor (NF)-κB response genes in human (TH)1-differentiating cells. V75M, one of many disease-causing mutations occurring in SUMO*motif (72-ψψψψKDxxxxSY-83) of WASp, compromises WASp-SUMOylation, associates with COMMD1 to attenuate NF-κB signaling, and recruits histone deacetylases-6 (HDAC6) to p300-marked promoters of NF-κB response genes that pattern immunity but not inflammation. Consequently, proteins mediating adaptive immunity (IFNG, STAT1, TLR1) are deficient, whereas those mediating auto-inflammation (GM-CSF, TNFAIP2, IL-1β) are paradoxically increased in TH1 cells expressing SUMOylation-deficient WASp. Moreover, SUMOylation-deficient WASp favors ectopic development of the TH17-like phenotype (↑IL17A, IL21, IL22, IL23R, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, and CSF2) under TH1-skewing conditions, suggesting a role for WASp in modulating TH1/TH17 plasticity. Notably, pan-histone deacetylase inhibitors lift promoter-specific repression imposed by SUMOylation-deficient WASp and restore misregulated gene expression. Our findings uncovering a SUMOylation-based mechanism controlling WASp's dichotomous roles in transcription may have implications for personalized therapy for patients carrying mutations that perturb WASp-SUMOylation. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21968241">21968241</a><div class="entities" style="line-height: 2.5"><h3>Th17 cells in Behçet's disease: a new immunoregulatory axis.</h3></br>Accumulating evidence suggests that the abnormality of innate and adaptive immunity responses plays an important role in Behçet's disease (BD). T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells have a central role in modulating immune responses. Traditionally, BD is regarded as a Th1-mediated inflammatory disease. Recently, Th17 cells were identified as a new subset of Th cells unrelated to Th1 or Th2 cells, and several cytokines are involved in regulating their activation and differentiation. Naïve murine CD4+ Th can be induced to differentiate towards Th1, Th2, Th17 and Treg phenotypes according to the local cytokine milieu. The committed cells are characterised by expression of specific transcription factors, T bet for Th1, GATA-3 for Th2, Foxp3 for Tregs and RORγt (RORγt/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) for Th17 cells. It has been demonstrated that the skewing of murine Th towards Th17 and Treg is mutually exclusive. Th17 cells regulate inflammation via production of distinct cytokines such as interleukin (IL)-17. There is growing evidence that Th17 cells are pathological in many human autoimmune and inflammatory diseases, leading to intense interest in defining their origins, functions and developing strategies to block their pathological effects. Evidence from human disease such as BD suggests that specialised antigen-presenting cells drive their in vivo development. Knowledge of how Th17 cells interact with other immune cells is limited, but recent data suggest that Th17 cells may not be subject to strict cellular regulation by T regulatory cells. Notably, Th17 cells and Treg cells appear to share common developmental pathways and both cell types retain significant plasticity. Herein, we will discuss the molecular and cellular regulation of Th17 cells with an emphasis on BD. The identification of Th17 cells helps us to explain some of the anomalies seen in the Th1/Th2 axis and has broadened our understanding of the immunopathological effects of Th17 cells in the development of BD.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21710691">21710691</a><div class="entities" style="line-height: 2.5"><h3>The molecular pathogenesis of STAT3-driven gastric tumourigenesis in mice is independent of IL-17.</h3></br>Chronic activation of the gastric mucosal adaptive immune response is a characteristic trait of gastric cancer. It has recently emerged that a new class of T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, defined by their ability to produce interleukin (IL)-17A (Th17), is associated with a host of inflammatory responses, including gastritis. However, the role of these Th17 cells in the pathogenesis of gastric cancer is less clear. To formally address this, we employed gp130(F/F) mice, which spontaneously develop gastric inflammation-associated tumours akin to human intestinal-type gastric cancer. At the molecular level, these tumours demonstrate hyper-activation of the latent transcription factor signal transducer and activator of transcription (STAT)3 via the IL-6 cytokine family member, IL-11. In gp130(F/F) mice, the generation of Th17 cells, as well as the gastric expression of IL-17a and other Th17-related factors (Rorγt, IL-23), were augmented compared to wild-type gp130(+/+) mice. Consistent with a role for IL-6 and STAT3 in regulating IL-17A, increased Th17 generation and gastric expression of Th17-related factors in gp130(F/F) mice were reduced to wild-type levels in gp130(F/F) :Stat3(-/+) mice displaying normalized STAT3 activity, and also in gp130(F/F) :IL-6(-/-) mice. Importantly, genetic ablation of IL-17A in gp130(F/F) :IL-17a(-/-) mice did not suppress the initiation and growth of gastric tumours. Furthermore, IL-17A and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> gene expression was strongly increased in human gastric biopsies from patients with gastritis, but not gastric cancer. Collectively, our data suggest that increased expression of Th17-related factors does not correlate with the molecular pathogenesis of gastric tumourigenesis.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21367463">21367463</a><div class="entities" style="line-height: 2.5"><h3><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and Foxp3 axis in cerebrospinal fluid of patients with neuro-Behçet's disease.</h3></br>Neurological manifestations are present in 5% to 30% of patients with Behçet's disease (BD). Neuro-Behçet's Disease (NBD) is hypothetically caused by T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, which development is dependent on the expression of lineage-specific transcription factors. Cerebrospinal fluid (CSF) mRNA expression of TBX21, GATA3, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, FOXP3 and EBI3 were assessed in 18 NBD patients and 26 controls disease [16 noninflammatory neurological disease (NIND) and 10 headache attributed to Behçet's disease (HaBD)]. Expression of TBX21 (Th1), RORC (Th17) and Foxp3 (Treg) were increased in NBD patients compared to HaBD and NIND patients. EBI3 and Th2-associated GATA3 expressions were found to be decreased (P<0.0001 and P<0.0001) in NBD patients. Analysis of transcription factor ratios, revealed an increase in the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>/FOXP3 and TBX21/GATA3 ratios in NBD patients (P<0.0001; P<0.0003). Our findings indicate that both Th1 and Th17 mRNA expressions involving a possible impairment of Treg cells. This might play a role in CSF-NBD inflammation, permitting activation of harmful T cell subpopulations. The TBX21/GATA3 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>/FOXP3 ratios dysregulations in NBD are consistent with those reported in other inflammatory diseases and indicating the plasticity existing between Th1, Th17 and Treg cells during inflammation.</div></details><details><summary>TH1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/22965818">22965818</a><div class="entities" style="line-height: 2.5"><h3>Distinctive features of classic and nonclassic (Th17 derived) human Th1 cells.</h3></br>T helper17 (Th17) lymphocytes represent a third arm of the CD4(+)  T cell effector responses, in addition to <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells. Th17 cells have been found to exhibit high plasticity because they rapidly shift into the Th1 phenotype in inflammatory sites. In humans, Th1 cells derived from Th17 cells express CD161, whereas classic Th1 cells do not; these Th17-derived Th1 cells have been termed nonclassic Th1 cells. In this study, we examined similarities and differences between classic and nonclassic human Th1 cells by assessing a panel of T cell clones, as well as CD161(+)  or CD161(-)  CD4(+)  T cells derived ex vivo from the circulation of healthy subjects or the synovial fluid of patients with juvenile idiopathic arthritis. The results show that nonclassic Th1 cells can be identified based on CD161 expression, as well as the consistent expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    retinoic acid orphan receptor C    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, IL-17 receptor E, CCR6, and IL-4-induced gene 1, which are all virtually absent in classic Th1 cells. The possibility to distinguish these two-cell subsets by using such a panel of markers may allow the opportunity to better establish the respective pathogenic roles of classic and nonclassic (Th17 derived) Th1 cells in different chronic inflammatory disorders.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21968241">21968241</a><div class="entities" style="line-height: 2.5"><h3>Th17 cells in Behçet's disease: a new immunoregulatory axis.</h3></br>Accumulating evidence suggests that the abnormality of innate and adaptive immunity responses plays an important role in Behçet's disease (BD). T helper (Th) cells have a central role in modulating immune responses. Traditionally, BD is regarded as a Th1-mediated inflammatory disease. Recently, Th17 cells were identified as a new subset of Th cells unrelated to <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> or Th2 cells, and several cytokines are involved in regulating their activation and differentiation. Naïve murine CD4+ Th can be induced to differentiate towards Th1, Th2, Th17 and Treg phenotypes according to the local cytokine milieu. The committed cells are characterised by expression of specific transcription factors, T bet for Th1, GATA-3 for Th2, Foxp3 for Tregs and RORγt (RORγt/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) for Th17 cells. It has been demonstrated that the skewing of murine Th towards Th17 and Treg is mutually exclusive. Th17 cells regulate inflammation via production of distinct cytokines such as interleukin (IL)-17. There is growing evidence that Th17 cells are pathological in many human autoimmune and inflammatory diseases, leading to intense interest in defining their origins, functions and developing strategies to block their pathological effects. Evidence from human disease such as BD suggests that specialised antigen-presenting cells drive their in vivo development. Knowledge of how Th17 cells interact with other immune cells is limited, but recent data suggest that Th17 cells may not be subject to strict cellular regulation by T regulatory cells. Notably, Th17 cells and Treg cells appear to share common developmental pathways and both cell types retain significant plasticity. Herein, we will discuss the molecular and cellular regulation of Th17 cells with an emphasis on BD. The identification of Th17 cells helps us to explain some of the anomalies seen in the Th1/Th2 axis and has broadened our understanding of the immunopathological effects of Th17 cells in the development of BD.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21303976">21303976</a><div class="entities" style="line-height: 2.5"><h3>Clinical impact of different classes of infiltrating T cytotoxic and helper cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>, th2, treg, th17) in patients with colorectal cancer.</h3></br>The tumor microenvironment includes a complex network of immune T cell subpopulations. In this study, we systematically analyzed the balance between cytotoxic T cells and different subsets of helper T cells in human colorectal cancers and we correlated their impact on disease-free survival. A panel of immune related genes were analyzed in 125 frozen colorectal tumor specimens. Infiltrating cytotoxic T cells, Treg, Th1, and Th17 cells were also quantified in the center and the invasive margin of the tumors. By hierarchical clustering of a correlation matrix we identified functional clusters of genes associated with Th17 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, IL17A), Th2 (IL4, IL5, IL13), Th1 (Tbet, IRF1, IL12Rb2, STAT4), and cytotoxicity (GNLY, GZMB, PRF1). Patients with high expression of the Th17 cluster had a poor prognosis, whereas patients with high expression of the Th1 cluster had prolonged disease-free survival. In contrast, none of the Th2 clusters were predictive of prognosis. Combined analysis of cytotoxic/Th1 and Th17 clusters improved the ability to discriminate relapse. In situ analysis of the density of IL17+ cells and CD8+ cells in tumor tissues confirmed the results. Our findings argue that functional Th1 and Th17 clusters yield opposite effects on patient survival in colorectal cancer, and they provide complementary information that may improve prognosis.</div></details><details><summary>TH22</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/26000313">26000313</a><div class="entities" style="line-height: 2.5"><h3>The alteration and clinical significance of Th22/Th17/Th1 cells in patients with chronic myeloid leukemia.</h3></br>T helper- (Th-) cell immunodeficiency plays important roles in tumor development and their effects in chronic myeloid leukemia (CML) remain unclear. In the present study, we mainly investigated the role of Th22, Th17, and Th1 cell and their related cytokines (IL-22, IL-17, and IFN-r) in the pathophysiology of CML. Bone marrow (BM) and peripheral blood (PB) were extracted from newly diagnosed (ND), chronic phase- (CP-) CML patients, and controls. Th subsets were examined by flow cytometry. Plasma IL-22, IL-17, and IFN-r concentrations were measured by ELISA. AHR and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mRNA expressions were examined by RT-PCR. The frequencies of Th22, Th17, and Th1 cells, along with the expression of specific transcription factors <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and AHR, were significantly decreased in ND patients compared with healthy controls, while all these abnormality recovered in CP patients. In addition, there existed a significantly positive relationship between <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th22    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th17 cells in PB or BM. A significantly negative relationship was found between Th cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th22    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>, Th17, or Th1) and BCR-ABL (%) IS or the number of PB white blood cells. All these results demonstrated that Th22, Th17, and Th1 cells might be important therapeutic targets in CML and could facilitate a better outcome for tumor immunotherapy. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/24473142">24473142</a><div class="entities" style="line-height: 2.5"><h3>Elevated Th22 cells correlated with Th17 cells in peripheral blood of patients with acute myeloid leukemia.</h3></br>Acute myeloid leukemia (AML) is a hematological tumor in which progress T helper (Th) subsets including Th22, Th17, and Th1 cells play a pivotal role. However, the role of T helper (Th) subsets in the immune pathogenesis of AML remains unclear. Here, we investigated frequencies of Th22, Th17, pure Th17, and Th1 cells in the peripheral blood (PB) of AML patients. We demonstrated that Th22, Th17, and pure Th17 in newly-diagnosed (ND) and non-complete remission (Non-CR) AML patients and plasma IL-22 in ND AML patients were significantly increased. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Retinoid-related orphan receptor C    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) expression was significantly elevated in CR and Non-CR AML patients. However, Th1 in ND AML patients and IL-17 in ND, Non-CR or CR AML patients was significantly decreased compared with controls. Moreover, Th22 and IL-22 showed positive correlation with pure Th17, but Th22 showed negative correlation with Th1 in ND AML patients. RORC showed positive correlation with Th22 and approximately positive correlation with pure Th17 in Non-CR patients. PB blast cell showed positive correlation with Th22 and negative correlation with Th1 in ND AML patients. Our results indicate that <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th22    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and pure Th17 cells conjointly contribute to the pathogenesis of AML and might be promising novel clinical index for AML. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/22537755">22537755</a><div class="entities" style="line-height: 2.5"><h3>Elevated profiles of Th22 cells and correlations with Th17 cells in patients with immune thrombocytopenia.</h3></br>T-helper (Th) 22 and Th17 cells are implicated in the pathogenesis of autoimmune diseases. However, the role of Th22 cells in the pathophysiology of immune thrombocytopenia (ITP) remains unclear. <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th22    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>, Th17 and Th1 cells in both ITP patients and healthy controls were examined by flow cytometry. Plasma interleukin-22 (IL-22) level was measured by enzyme linked immunosorbent assay (ELISA). Signal transducers and activators of transcription 3 (STAT-3) and transcription factor RAR-related organ receptor C (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) messenger RNA (mRNA) expressions were examined by quantitative reverse transcription polymerase chain reaction (RT-PCR). <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th22    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells, Th17 cells, Th1 cells and plasma IL-22 were significantly higher in ITP patients than in healthy controls. Moreover, Th22 cells showed a positive correlation with the levels of plasma IL-22 as well as Th17 and Th1 cells in ITP patients. Significant up-regulations of both STAT-3 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> transcription factors were also observed. Additionally, the percentage of Th22 cells was higher in autoantibody-negative ITP patients than in autoantibody-positive patients. Our results demonstrate a possible role of Th22 cells in ITP, and thus, the blockade of IL-22 may be a reasonable therapeutic strategy for ITP.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/26255628">26255628</a><div class="entities" style="line-height: 2.5"><h3>Elevated Th22 as well as Th17 cells associated with therapeutic outcome and clinical stage are potential targets in patients with multiple myeloma.</h3></br>T helper (Th) cell imbalance plays important roles in tumor development and their effects in Multiple myeloma (MM) remain unclear. In the present study, we investigated the levels and clinical significance of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th22    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>, Th17 and Th1 cells in patients with MM. Th subsets were examined by flow cytometry. Plasma IL-22, IL-17A and IFN-γ concentrations were measured by ELISA. AHR and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RORC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mRNA expression was examined by RT-PCR. Here, we found that the frequency of Th22 cells was significantly elevated in peripheral blood (PB) and bone marrow (BM) of newly-diagnosed MM patients, and recovered in complete remission patients after chemotherapy. The circulating Th17 cells accompanied by IL-17A levels were also up-regulated in MM patients and decreased after remission. We also found that there was a significantly positive correlation between Th22 and Th17 cells in MM patients. Moreover, the frequencies of Th22 and Th17 cells were higher in stage III than in stage I+II of MM. Our data demonstrated that Th22 and Th17 cells might be important therapeutic targets in multiple myeloma and could facilitate the effect of antitumor immunotherapy.</div></details></details></td>
    </tr>
    <tr>
      <th>10</th>
      <td>IRF1</td>
      <td>9</td>
      <td>TH1:3, TREG:3, TH:2, TEFF:1, TH2:1, γδT:1</td>
      <td>0.518724</td>
      <td>ENSG00000125347</td>
      <td><details><summary>Subtypes</summary><details><summary>TH1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/21303976">21303976</a><div class="entities" style="line-height: 2.5"><h3>Clinical impact of different classes of infiltrating T cytotoxic and helper cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>, th2, treg, th17) in patients with colorectal cancer.</h3></br>The tumor microenvironment includes a complex network of immune T cell subpopulations. In this study, we systematically analyzed the balance between cytotoxic T cells and different subsets of helper T cells in human colorectal cancers and we correlated their impact on disease-free survival. A panel of immune related genes were analyzed in 125 frozen colorectal tumor specimens. Infiltrating cytotoxic T cells, Treg, Th1, and Th17 cells were also quantified in the center and the invasive margin of the tumors. By hierarchical clustering of a correlation matrix we identified functional clusters of genes associated with Th17 (RORC, IL17A), Th2 (IL4, IL5, IL13), Th1 (Tbet, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, IL12Rb2, STAT4), and cytotoxicity (GNLY, GZMB, PRF1). Patients with high expression of the Th17 cluster had a poor prognosis, whereas patients with high expression of the Th1 cluster had prolonged disease-free survival. In contrast, none of the Th2 clusters were predictive of prognosis. Combined analysis of cytotoxic/Th1 and Th17 clusters improved the ability to discriminate relapse. In situ analysis of the density of IL17+ cells and CD8+ cells in tumor tissues confirmed the results. Our findings argue that functional Th1 and Th17 clusters yield opposite effects on patient survival in colorectal cancer, and they provide complementary information that may improve prognosis.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/10037767">10037767</a><div class="entities" style="line-height: 2.5"><h3>Interleukin-12 induces expression of interferon regulatory factor-1 via signal transducer and activator of transcription-4 in human T helper type 1 cells.</h3></br>IRF-1-deficient mice show a striking defect in the development of T helper 1 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. In the present report, we investigate the expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> during differentiation of human T helper cells. No significant differences of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mRNA expression were found in established <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells; however, interleukin 12 (IL-12) induced a strong up-regulation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> transcripts in Th1 but not in Th2 cells. We demonstrate that IL-12-induced up-regulation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is mediated by signal transducer and activator of transcription-4, which binds to the interferon (IFN)-gamma-activated sequence present in the promoter of the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> gene. Strong IL-12-dependent activation of a reporter gene construct containing the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> IFN-gamma-activated sequence element provides further evidence for the key role of signal transducer and activator of transcription-4 in the IL-12-induced up-regulation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> transcripts in T cells. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression was strongly induced after stimulation of naive CD4(+) T cells via the T cell receptor, irrespective of the cytokines present at priming, indicating that this transcription factor does not play a major role in initiating a Th1-specific transcriptional cascade in differentiating helper T cells. However, our finding that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is a target gene of IL-12 suggests that some of the IL-12-induced effector functions of Th1 cells may be mediated by <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/10622632">10622632</a><div class="entities" style="line-height: 2.5"><h3>Experimental murine leishmaniasis and the Th1/Th2 cell concept.</h3></br>Herein, the current knowledge about the immune response during murine cutaneous leishmaniasis is summarized. Special regard is given to the characteristics and generation of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells during this disease. Originally established on the basis of different cytokines produced by T cell clones, it is now known that the Th1/Th2 concept really defines totally different immune pathways that affect most, if not all cells of the immune system. Murine experimental leishmaniasis was the first model to confirm the relevance of the Th1/Th2 concept in vivo. In particular, data from this laboratory will be presented on the role of different IL-4 receptor allotypes, on the role of the transcription factor interferon-regulatory-factor-1 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) and the importance of the enzyme inducible NO synthase (iNOS). This work was supported by the SFB 263 and the Fonds der Chemischen Industrie.</div></details><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28113084">28113084</a><div class="entities" style="line-height: 2.5"><h3>Increase of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> gene expression and impairment of T regulatory cells suppression activity on patients with myelodysplastic syndrome: A longitudinal one-year study.</h3></br>Studies have demonstrated that abnormalities in interferon regulatory factor-1 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) expression might develop myelodysplastic syndromes (MDS). <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> was described as modulator of T regulatory (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells by suppressing Foxp3 on mice. We aimed to determine the role of Treg and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in MDS. Thirty-eight MDS patients fulfilling WHO criteria and classified according to risk scores were evaluated at time 0 (T0) and after 12 months (T12) for: Treg suppression activity in coculture with T effector (Teff) cells; <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and Foxp3 genetic expression by qRT-PCR; IL-2, -4, -6, -10, -17, TNFα and IFNγ production by Cytometric Bead Array. No differences in Foxp3 expression (T0=0.06±0.06 vs T12=0.06±0.12, p=0.5), Treg number (T0=5.62±2.84×105  vs T12=4.87±2.62×105 ; p=0.3) and Teff percentage (T0=16.8±9.56% vs T12=13.1±6.3%; p=0.06) were observed on T12. Low risk MDS patients showed a higher number of Treg (5.2±2.6×105 ) versus high risk group (2.6±1.2×105 , p=0.03). Treg suppression activity was impaired on T0 and T12.Cytokine production and IRF-1 expression were increased on T12. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    The c    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>orrelation between IRF-1 and FoxP3 was negative (r2 =0.317,<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">     p=0.    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>045) on T0. These results suggest a hyper activity of the immune system, probably secondary to Treg suppression activity impairment. This state may induce the loss of tolerance culminating in the proliferation of MDS clones.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27063510">27063510</a><div class="entities" style="line-height: 2.5"><h3>Common variable immunodeficiency, impaired neurological development and reduced numbers of T regulatory cells in a 10-year-old boy with a STAT1 gain-of-function mutation.</h3></br>Recently, gain-of-function (GOF) mutations in the gene encoding signal transducer and activator of transcription 1 (STAT1) have been associated with chronic mucocutaneous candidiasis (CMC). This case report describes a 10-year-old boy presenting with signs of common variable immunodeficiency (CVID), failure to thrive, impaired neurological development, and a history of recurrent mucocutaneous Candida infections. Sequencing of the STAT1 gene identified a heterozygous missense mutation in exon 7 encoding the STAT1 coiled-coil domain (c.514T>C, p.Phe172Leu). In addition to hypogammaglobulinemia with B-cell deficiency, and a low percentage of Th17 cells, immunological analysis of the patient revealed a marked depletion of forkhead-box P3(+)-expressing regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>). In vitro stimulation of T cells from the patient with interferon-α (IFNα) and/or IFNɣ resulted in a significantly increased expression of STAT1-regulated target genes such as MIG1, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, MX1, MCP1/CCL2, IFI-56K, and CXCL10 as compared to IFN-treated cells from a healthy control, while no IFNα/ɣ-mediated up-regulation of the FOXP3 gene was found. These data demonstrate that the STAT1 GOF mutation F172L, which results in impaired stability of the antiparallel STAT1 dimer conformation, is associated with inhibited Treg cell development and neurological symptoms. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21303976">21303976</a><div class="entities" style="line-height: 2.5"><h3>Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer.</h3></br>The tumor microenvironment includes a complex network of immune T cell subpopulations. In this study, we systematically analyzed the balance between cytotoxic T cells and different subsets of helper T cells in human colorectal cancers and we correlated their impact on disease-free survival. A panel of immune related genes were analyzed in 125 frozen colorectal tumor specimens. Infiltrating cytotoxic T cells, <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>, Th1, and Th17 cells were also quantified in the center and the invasive margin of the tumors. By hierarchical clustering of a correlation matrix we identified functional clusters of genes associated with Th17 (RORC, IL17A), Th2 (IL4, IL5, IL13), Th1 (Tbet, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, IL12Rb2, STAT4), and cytotoxicity (GNLY, GZMB, PRF1). Patients with high expression of the Th17 cluster had a poor prognosis, whereas patients with high expression of the Th1 cluster had prolonged disease-free survival. In contrast, none of the Th2 clusters were predictive of prognosis. Combined analysis of cytotoxic/Th1 and Th17 clusters improved the ability to discriminate relapse. In situ analysis of the density of IL17+ cells and CD8+ cells in tumor tissues confirmed the results. Our findings argue that functional Th1 and Th17 clusters yield opposite effects on patient survival in colorectal cancer, and they provide complementary information that may improve prognosis.</div></details><details><summary>TH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/20177960">20177960</a><div class="entities" style="line-height: 2.5"><h3>Inhibition of IFN regulatory factor-1 down-regulate Th1 cell function in patients with acute coronary syndrome.</h3></br>The crucial role of T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells and chronic inflammation in atherosclerosis and coronary artery disease is no longer controversial. Evidence has revealed that Th cell type 1 (Th1) is closely associated with the pathogenesis of acute coronary syndrome (ACS). But the mechanisms involved in the generation of Th1 cells have not been fully elucidated. IFN regulatory factor (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF)-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is a pleiotropic transcription factor involved in innate immunity and chronic inflammation disease. The study was undertaken to investigate the potential effect of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> on the Th1 cell function in patients with ACS in vitro.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/11348014">11348014</a><div class="entities" style="line-height: 2.5"><h3>Neuropeptides as modulators of macrophage functions. Regulation of cytokine production and antigen presentation by VIP and PACAP.</h3></br>Vasoactive intestinal peptide (VIP) and the structurally related neuropeptide pituitary adenylate cyclase activating polypeptide (PACAP), present in the microenvironment of lymphoid organs, modulate the function of inflammatory cells through specific receptors. VIP and PACAP inhibit the production of pro-inflammatory agents and stimulate the production of anti-inflammatory cytokines in activated macrophages. The effect is mediated through specific receptors and involves shedding of the CD14 lipopolysaccharide (LPS) receptor and the transcriptional regulation of cytokine genes through effects on de novo expression or nuclear translocation of NFkappaB, cAMP-element binding protein (CREB), c-Jun, and interferon regulatory factor 1 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>). The in vivo administration of VIP/PACAP results in a similar pattern of cytokine modulation which, presumably, mediates the protective effect of VIP/PACAP in a high-endotoxic murine model for septic shock. VIP/PACAP reduce the expression of the costimulatory B7.1/B7.2 molecules and the subsequent stimulatory activity for T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells in stimulated macrophages. In contrast, in unstimulated macrophages, VIP/PACAP induce specific B7.2 expression and promote Th2 cell differentiation. We propose that VIP/PACAP act as endogenous factors that regulate immune homeostasis and that the physiological consequences of VIP/PACAP presence in the immune microenvironment depend on the timing of the neuropeptide release and the activation stage of the neighboring immune cells.</div></details><details><summary>TEFF</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28113084">28113084</a><div class="entities" style="line-height: 2.5"><h3>Increase of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> gene expression and impairment of T regulatory cells suppression activity on patients with myelodysplastic syndrome: A longitudinal one-year study.</h3></br>Studies have demonstrated that abnormalities in interferon regulatory factor-1 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) expression might develop myelodysplastic syndromes (MDS). <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> was described as modulator of T regulatory (Treg) cells by suppressing Foxp3 on mice. We aimed to determine the role of Treg and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in MDS. Thirty-eight MDS patients fulfilling WHO criteria and classified according to risk scores were evaluated at time 0 (T0) and after 12 months (T12) for: Treg suppression activity in coculture with T effector (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Teff    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells; <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and Foxp3 genetic expression by qRT-PCR; IL-2, -4, -6, -10, -17, TNFα and IFNγ production by Cytometric Bead Array. No differences in Foxp3 expression (T0=0.06±0.06 vs T12=0.06±0.12, p=0.5), Treg number (T0=5.62±2.84×105  vs T12=4.87±2.62×105 ; p=0.3) and Teff percentage (T0=16.8±9.56% vs T12=13.1±6.3%; p=0.06) were observed on T12. Low risk MDS patients showed a higher number of Treg (5.2±2.6×105 ) versus high risk group (2.6±1.2×105 , p=0.03). Treg suppression activity was impaired on T0 and T12.Cytokine production and IRF-1 expression were increased on T12. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    The c    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>orrelation between IRF-1 and FoxP3 was negative (r2 =0.317,<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">     p=0.    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>045) on T0. These results suggest a hyper activity of the immune system, probably secondary to Treg suppression activity impairment. This state may induce the loss of tolerance culminating in the proliferation of MDS clones.</div></details><details><summary>TH2</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/12479817">12479817</a><div class="entities" style="line-height: 2.5"><h3>IFN-gamma represses IL-4 expression via <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and IRF-2.</h3></br>Polarization of CD4(+) T helper cells toward either a Th1 or Th2 response can significantly influence host immunity to pathogens. IL-4 and IFN-gamma are the signature cytokines of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th1 cells, respectively. IFN-gamma was shown to assist Th1 development by promoting IL-12 and IL-12 receptor expression. So far, direct influence of Th2 cytokine expression by IFN-gamma has not been described. We show here that IFN-gamma directly suppresses IL-4 gene expression. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and IRF-2 induced by IFN-gamma bind to three distinct IL-4 promoter sites and function as transcriptional repressors. Our data demonstrate a direct negative feedback of IFN-gamma on expression of the Th2 cytokine gene IL-4 and, thus, provide evidence for another important mechanism by which IFNgamma assists Th1 and attenuates Th2 responses.</div></details></details></td>
    </tr>
    <tr>
      <th>11</th>
      <td>STAT4</td>
      <td>23</td>
      <td>TH1:10, TFH:5, TH2:4, TREG:3, TH:2, TFH1LIKE:1, TH17:1</td>
      <td>0.464554</td>
      <td>ENSG00000138378</td>
      <td><details><summary>Subtypes</summary><details><summary>TH1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/21684616">21684616</a><div class="entities" style="line-height: 2.5"><h3>Lesional skin in atopic dogs shows a mixed Type-1 and Type-2 immune responsiveness.</h3></br>Canine atopic dermatitis (AD) is a chronic inflammatory and pruritic skin disease which shares several characteristics with its human counterpart. In chronic patch test lesions of human with AD mainly a Th1-type cellular response is found. Besides, non-lesional AD skin is already skewed for inflammation and therefore different from healthy skin. The goal of this study was to characterize local immune responsiveness in chronic canine AD lesions as compared to that in non-lesional AD skin by defining T cell subset relevant cytokine- and transcription factor expression profiles. The gene expression of the Th1 cytokines IL-12p35, IL-12p40 and IFN-γ and their related transcription factors <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, SOCS5 and T-bet, the Th2 cytokines IL-4 and IL-13 and transcription factors STAT6, SOCS3 and GATA-3 and the regulatory cytokines IL-10 and TGF-β and the transcription factor FOXP3 was evaluated in healthy control and atopic dogs. In non-lesional (NLS) and chronic lesional skin (LS) of atopic dogs and control skin (CS) from healthy dogs mRNA expression of cytokines and transcription factors were measured by quantitative real-time PCR. Significantly different values were found for the following factors: IL-12p40 mRNA was lower in LS when compared to NLS. Expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> was higher in LS compared to CS and NLS. More IL-13 and SOCS3 were found in LS and NLS when compared to CS and also in LS compared to NLS. GATA-3 was lower in LS compared to NLS. IL-10 expression was higher in both LS and NLS compared to CS and more IL-10 was present in LS compared to NLS. These findings indicate that both <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1-    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2-type as well as T regulatory cells are present in NLS and LS in canine atopic skin.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21303976">21303976</a><div class="entities" style="line-height: 2.5"><h3>Clinical impact of different classes of infiltrating T cytotoxic and helper cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>, th2, treg, th17) in patients with colorectal cancer.</h3></br>The tumor microenvironment includes a complex network of immune T cell subpopulations. In this study, we systematically analyzed the balance between cytotoxic T cells and different subsets of helper T cells in human colorectal cancers and we correlated their impact on disease-free survival. A panel of immune related genes were analyzed in 125 frozen colorectal tumor specimens. Infiltrating cytotoxic T cells, Treg, Th1, and Th17 cells were also quantified in the center and the invasive margin of the tumors. By hierarchical clustering of a correlation matrix we identified functional clusters of genes associated with Th17 (RORC, IL17A), Th2 (IL4, IL5, IL13), Th1 (Tbet, IRF1, IL12Rb2, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>), and cytotoxicity (GNLY, GZMB, PRF1). Patients with high expression of the Th17 cluster had a poor prognosis, whereas patients with high expression of the Th1 cluster had prolonged disease-free survival. In contrast, none of the Th2 clusters were predictive of prognosis. Combined analysis of cytotoxic/Th1 and Th17 clusters improved the ability to discriminate relapse. In situ analysis of the density of IL17+ cells and CD8+ cells in tumor tissues confirmed the results. Our findings argue that functional Th1 and Th17 clusters yield opposite effects on patient survival in colorectal cancer, and they provide complementary information that may improve prognosis.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21205293">21205293</a><div class="entities" style="line-height: 2.5"><h3>Attenuated expression of tenascin-C in ovalbumin-challenged <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT4-    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>/- mice.</h3></br>Asthma leads to structural changes in the airways, including the modification of extracellular matrix proteins such as tenascin-C. The role of tenascin-C is unclear, but it might act as an early initiator of airway wall remodelling, as its expression is increased in the mouse and human airways during allergic inflammation. In this study, we examined whether <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> or Th2 cells are important regulators of tenascin-C in experimental allergic asthma utilizing mice with impaired Th1 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT4-    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>/-) or Th2 (STAT6-/-) immunity.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/17361203">17361203</a><div class="entities" style="line-height: 2.5"><h3>Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response.</h3></br>Interferon lambda-1 (IFN-lambda1/IL-29) is a member of the Type-III interferon family, which contains three ligands: IFN-lambda1, 2 and 3. These three ligands use the same unique heterodimeric receptor composed of CRF2-12 (IFN-lambda-R1/IL-28Ralpha) and CRF2-4 (IL10-R-beta) chains. Like their close relatives, the Type-I interferons, IFN-lambda1, 2 and 3, promote the phosphorylation of STAT1 and STAT2, induce the ISRE3 complex, elevate OAS and MxA expression and exhibit antiviral activity in vitro. Their use of the IL10-R-beta chain and their ability to phosphorylate STAT3, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and STAT5 suggested that they may also exhibit immunomodulatory activity; their antiviral action led us to hypothesize that this activity might be directed toward the Th1/Th2 system. Here, we have demonstrated that IFN-lambda1 altered the activity of Th cells in three separate experimental systems: (i) mitogen stimulation, (ii) mixed-lymphocyte reaction (MLR) and (iii) stimulation of naive T cells by monocyte-derived dendritic cells (mDC). In Con-A stimulation assays, the inclusion of IFN-lambda1 consistently led to markedly diminished levels of secreted interleukin (IL-13) with occasional coincident, modest elevation of secreted IFN-gamma. IL-13 secretion was 100-fold more sensitive to IFN-lambda1 than was IFN-gamma secretion. These observations were also made in the allogeneic two-way MLR. IFN-lambda1 was able to alter cytokine-mediated Th biasing and when naive T cells were exposed to allogeneic mDC that had been matured in the presence of IFN-lambda1, secreted IL-13 was again markedly and consistently reduced, whereas secreted IFN-gamma was largely unaltered. These functions were independent of IL-10. Our data support a hitherto unsuspected role for IFN-lambda1 in modulating the development of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells, with an apparent emphasis on the diminution of IL-13 secretion.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/16285008">16285008</a><div class="entities" style="line-height: 2.5"><h3>IL-12-independent Th1 polarization in human mononuclear cells infected with varicella-zoster virus.</h3></br>T helper type 1 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells perform a critical role in fighting intracellular organisms, and interleukin-12 (IL-12) is known to promote a Thl response. This study was conducted to identify whether an IL-12-independent Th1 reaction is induced by the varicella-zoster virus (VZV) in human beings. It was found that different intracellular microorganisms could induce IFNgamma but not IL-12 production. Induction of IFNgamma production by VZV was associated with IFNalpha production and phosphorylation of both the signal transducer and activator of transcription-1 (STAT-1) and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT-4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in lymphocytes. In contrast, Bacillus Calmette-Guerin (BCG) induced IL-12 production in association with <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT-4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> but not STAT-1 activation. Anti-IFNalpha but not anti-IL-12 antibodies blocked the VZV-induced Th1 polarization. A patient with an IL-12 receptor beta1 chain deficiency showed a normal VZV- but not a normal BCG-induced Th1 reaction, further supporting the concept of an IFNalpha-mediated, IL-12-independent Th1 reaction in response to certain intracellular infections. Identification of the early Th1 polarization induced by IFNalpha versus IL-12 in response to specific viruses may enable the development of better therapeutic strategies tailored to different infections.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/12672077">12672077</a><div class="entities" style="line-height: 2.5"><h3>Kinetics and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT4-    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> or STAT6-mediated regulation of genes involved in lymphocyte polarization to <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells.</h3></br>Many genes implicated in Th1 and Th2 differentiation have been identified in both human and mouse. However, the functional roles and hierarchy of these factors in the signaling pathways leading to either Th1 or Th2 responses are less clear. To explore at which stage of polarization the differences between <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells occur, we have studied the expression of 23 key genes implicated in the process during the first week of polarization from human precursor T helper cells using quantitative real-time reverse transcription-PCR. According to our results, 14 of the genes were clearly regulated differentially in Th1 and Th2 conditions in distinct time-dependent patterns, either during the first 2 days or after 1 week of polarization. Furthermore, 6 of these genes were identified to be targets of STAT4/6 regulation. Thus, for the first time we demonstrate expression kinetics of a number of key genes involved in Th1 and Th2 differentiation during the first week of polarization in both human and mouse. In addition, our study shows for the first time that the genes BCL-6 and TRADD are differentially regulated during the polarization of human <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/11894097">11894097</a><div class="entities" style="line-height: 2.5"><h3>Involvement of receptor-interacting protein 2 in innate and adaptive immune responses.</h3></br>Host defences to microorganisms rely on a coordinated interplay between the innate and adaptive responses of immunity. Infection with intracellular bacteria triggers an immediate innate response requiring macrophages, neutrophils and natural killer cells, whereas subsequent activation of an adaptive response through development of T-helper subtype 1 cells (TH1) proceeds during persistent infection. To understand the physiological role of receptor-interacting protein 2 (Rip2), also known as RICK and CARDIAK, we generated mice with a targeted disruption of the gene coding for Rip2. Here we show that Rip2-deficient mice exhibit a profoundly decreased ability to defend against infection by the intracellular pathogen Listeria monocytogenes. Rip2-deficient macrophages infected with L. monocytogenes or treated with lipopolysaccharide (LPS) have decreased activation of NF-kappaB, whereas dominant negative Rip2 inhibited NF-kappaB activation mediated by Toll-like receptor 4 and Nod1. In vivo, Rip2-deficient mice were resistant to the lethal effects of LPS-induced endotoxic shock. Furthermore, Rip2 deficiency results in impaired interferon-gamma production in both <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and natural killer cells, attributed in part to defective interleukin-12-induced <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> activation. Our data reflect requirements for Rip2 in multiple pathways regulating immune and inflammatory responses.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/10064070">10064070</a><div class="entities" style="line-height: 2.5"><h3>Induction of interferon-gamma production in <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> CD4+ T cells: evidence for two distinct pathways for promoter activation.</h3></br>IFN-gamma produced by CD4+ T helper 1 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells promotes protection against intracellular pathogens. Antigen activation of Th1 cells is an important mode of IFN-gamma induction, but here we analyze a second, antigen-nonspecific pathway capable of inducing full IFN-gamma transcription. IL-12 or IL-18 alone do not induce IFN-gamma mRNA, and only modestly augment antigen-induced IFN-gamma mRNA from Th1 cells. However, IL-12 and IL-18 together fully induce IFN-gamma transcription independently of TCR-activated signals, by a mechanism that does not simply involve <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and NF-kappaB activation, but requires additional protein synthesis. Cyclosporin A inhibits TCR-induced IFN-gamma production, but not IL-12/IL-18-induced IFN-gamma production, biochemically discriminating between these pathways. These results suggest that the two pathways induce IFN-gamma production through functionally segregated but spatially overlapping cis-acting elements, similar to other genes under the control of two or more promoters.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/9834059">9834059</a><div class="entities" style="line-height: 2.5"><h3>Differentiation of human NK cells into NK1 and NK2 subsets.</h3></br>Human NK cells cultured in the presence of IL-12 or IL-4 differentiate into cell populations with distinct patterns of cytokine secretion similar to <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells. NK cells grown in IL-12 (NK1) produce IL-10 and IFN-gamma, whereas NK cells grown in IL-4 (NK2) produce IL-5 and IL-13. Although these NK cell subsets do not differ in cytotoxic activity, NK1 cells express higher levels of cell surface CD95 (Fas) Ag than NK2 cells and are more sensitive to Ab or chemically induced apoptosis. Like Th1 cells, NK1 cells accumulate much higher levels of the IL-12Rbeta2-chain mRNA and are significantly more responsive to IL-12 than NK2 cells at the level of activation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> transcription factor. The identification of NK cell subsets that are analogous to T cell subsets suggests a new role for NK cells in innate inflammatory responses and in their effect on adaptive immunity.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/9531298">9531298</a><div class="entities" style="line-height: 2.5"><h3>Activation of STAT proteins and cytokine genes in human <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells generated in the absence of IL-12 and IL-4.</h3></br>We have shown previously that human CD4+ 45RO- T cells could be primed for a Th2 phenotype independent of IL-4 if they were activated by anti-CD28 mAb plus IL-2. If additional TCR signals were provided, the cells differentiated toward Th1 independent of IL-12. Here we show that anti-CD28/IL-2-primed Th2 cells expressed high levels of activated STAT6, but no cytokine mRNA. Moreover, both <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells expressed active STAT1 and -3, but not STAT2, -4, and -5. Restimulation of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> or Th2 cells via CD3 plus CD28 induced production of IFN-gamma or IL-4, respectively, but did not alter the activation status/DNA binding activity of STATs. Addition of IL-4 (or anti-IL-4 mAb) to restimulated Th2 cells did not modulate STAT6 activation or IL-4 expression, confirming the full commitment. However, Th2 cells remained responsive to IL-12, which repressed STAT6 DNA binding but activated <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, and this coincided with a suppression of IL-4/IL-5 and an induction of IFN-gamma. In Th1 cells, IL-12 activated both STAT6 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, and IL-4 activated STAT6, but in both cases the Th1 phenotype remained. Together the data show that CD28/IL-2-dependent Th2 priming activated STAT6 without inducing IL-4 expression. The primed Th cells resembled memory cells and produced IL-4 upon the first CD3/CD28 costimulus without detectable modulation of STATs. Th2 cells remained responsive to IL-12, which repressed STAT6 DNA binding and activated <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, and switched the cells to Th1. The effects of IL-12 may depend on the commitment of the cells, since IL-12 phosphorylated STAT6 in Th1 and dephosphorylated STAT6 in Th2 cells.</div></details><details><summary>TFH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/29212666">29212666</a><div class="entities" style="line-height: 2.5"><h3><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and T-bet control follicular helper T cell development in viral infections.</h3></br>Follicular helper T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells promote germinal center (GC) B cell survival and proliferation and guide their differentiation and immunoglobulin isotype switching by delivering contact-dependent and soluble factors, including IL-21, IL-4, IL-9, and IFN-γ. IL-21 and IFN-γ are coexpressed by Tfh cells during viral infections, but transcriptional regulation of these cytokines is not completely understood. In this study, we show that the T helper type 1 cell (Th1 cell) transcriptional regulators T-bet and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> are coexpressed with Bcl6 in Tfh cells after acute viral infection, with a temporal decline in T-bet in the waning response. T-bet is important for Tfh cell production of IFN-γ, but not IL-21, and for a robust GC reaction. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, phosphorylated in Tfh cells upon infection, is required for expression of T-bet and Bcl6 and for IFN-γ and IL-21. These data indicate that T-bet is expressed with Bcl6 in Tfh cells and is required alongside <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> to coordinate Tfh cell IL-21 and IFN-γ production and for promotion of the GC response after acute viral challenge.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/29055004">29055004</a><div class="entities" style="line-height: 2.5"><h3>STAT4 Regulates the CD8+  Regulatory T Cell/T Follicular Helper Cell Axis and Promotes Atherogenesis in Insulin-Resistant <i>Ldlr<sup>-/-</sup></i> Mice.<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    The     <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>metabolic syndrome and diabetic conditions su<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    pport    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> atherosclerosis, but the exact mechanisms for accelerated atherogenesis remain unclear. Although the proinflammato<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    ry ro    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>le of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in atherosclerosis and diet-induced insulin resistance (IR) was recently established, the impact of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> on atherogenesis in conditions of IR is not known. In this study, we generated <i>Stat4<sup>-/-</sup>Ldlr<sup>-/-</sup></i> mice that were fed a diabetogenic diet with added cholesterol (DDC). DDC-fed <i>Stat4<sup>-/-</sup>Ldlr<sup>-/-</sup></i> mice demonstrated improved glucose tolerance, insulin sensitivity, and a 36% reduction in atherosclerosis compared with <i>Ldlr<sup>-/-</sup></i> controls. Interestingly, we detected a reduction in T follicular helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells and plasma B cells but a sharp elevation in CD8+  regulatory T cells (Tregs) in spleens and aortas of <i>Stat4<sup>-/-</sup>Ldlr<sup>-/-</sup></i> mice compared with <i>Ldlr<sup>-/-</sup></i> mice. Similarly, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> deficiency supported CD8+  Treg differentiation in vitro. STAT4-deficient CD8+  Tregs suppressed Tfh cell and germinal center B cell development upon immunization with keyhole limpet hemocyanin, indicating an important role for STAT4 in CD8+  Treg functions in vivo. Furthermore, adoptive transfer of <i>Stat4<sup>-/-</sup>Ldlr<sup>-/-</sup></i> CD8+  Tregs versus <i>Ldlr<sup>-/-</sup></i> CD8+  Tregs resulted in a significant reduction in plaque burden and suppression of Tfh cell and germinal center B cells in DDC-fed <i>Ldlr<sup>-/-</sup></i> recipients. STAT4 expression in macrophages (MΦs) also affected the Tfh/CD8+  Treg axis, because conditioned media from <i>Stat4<sup>-/-</sup>Ldlr<sup>-/-</sup></i> MΦs supported CD8+  Treg differentiation, but not Tfh cell differentiation, in a TGF-β-dependent manner. These findings suggest a novel mechanism by which STAT4 supports atherosclerosis in IR <i>Ldlr<sup>-/-</sup></i> mice via STAT4-dependent MΦs, as well as cell-intrinsic suppression of CD8+  Treg generation and functions and maintenance of Tfh cell generation and the accompanying humoral immune response.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28263097">28263097</a><div class="entities" style="line-height: 2.5"><h3>Transcriptional and epigenetic regulation of follicular T-helper cells and their role in autoimmunity.</h3></br>T-follicular helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are a specialized subset of T cells that provide help to B cells and promote the formation of germinal centers (GCs). Tfh cells transmit important signals to B cells that drive class switch recombination, somatic hyper-mutation, the generation of high-affinity antibodies, immunological memory and their dif<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    feren    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>tiation into plasma cells or memory B cells in the GCs. Tfh-cell differentiation is regulated by the coordinated functions of distinct cytokines, including interleukin (IL)-6, IL-21, IL-12, IL-23, IL-2, IL-7 and transforming growth factor-β (TGF-β), as well as transcription factors, including B-cell lymphoma 6 protein (Bcl-6), Signal transducers and activators of transcription (STAT)1, STAT3, STAT4, B-cell activating transcription factor (Batf), interferon regulatory factor 4 (IRF4), v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog (C-Maf), T cell-specific transcription factor 1 (TCF-1) and Achaete-scute homolog 2 (Acl2), which have been shown to form a complex transcriptional network. In addition, increasing evidence indicates that epigenetic regulations, such as DNA methylation, histone modifications and non-coding RNA regulations, also coordinately control the differentiation and function of Tfh cells along with transcription factors. Furthermore, abnormalities in the regulation of Tfh cells have been associated with several autoimmune diseases, such as systemic lupus erythematosus (SLE), multiple sclerosis (MS) and rheumatoid arthritis (RA). Herein, this review aims to summarize the coordinate regulation and interaction of transcription factors, cytokines and epigenetic modifications that control Tfh-cell differentiation as well as the mechanism of dysregulation of Tfh cells in pathogenesis of autoimmune diseases, which highlight potential therapeutic targets.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/23476048">23476048</a><div class="entities" style="line-height: 2.5"><h3>IL-12 receptor β1 deficiency alters in vivo T follicular helper cell response in humans.</h3></br>Antibody responses represent a key immune protection mechanism. T follicular helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are the major CD4(+) T cell subset that provides help to B cells to generate an antibody response. Tfh cells together with B cells form germinal centers (GCs), the site where high-affinity B cells are selected and differentiate into either memory B cells or long-lived plasma cells. We show here that interleukin-12 receptor β1 (IL-12Rβ1)-mediated signaling is important for in vivo Tfh response in humans. Although not prone to B cell-deficient-associated infections, subjects lacking functional IL-12Rβ1, a receptor for IL-12 and IL-23, displayed substantially less circulating memory <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and memory B cells than control subjects. GC formation in lymph nodes was also impaired in IL-12Rβ1-deficient subjects. Consistently, the avidity of tetanus toxoid-specific serum antibodies was substantially lower in these subjects than in age-matched controls. Tfh cells in tonsils from control individuals displayed the active form of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    signal transducer and activator of transcription 4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>), demonstrating that IL-12 is also acting on Tfh cells in GCs. Thus, our study shows that the IL-12-STAT4 axis is associated with the development and the functions of Tfh cells in vivo in humans.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/19592276">19592276</a><div class="entities" style="line-height: 2.5"><h3>Human dendritic cells induce the differentiation of interleukin-21-producing T follicular helper-like cells through interleukin-12.</h3></br>T follicular helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells help development of antibody responses via interleukin-21 (IL-21). Here we show that activated human dendritic cells (DCs) induced naive CD4(+) T cells to become IL-21-producing Tfh-like cells through IL-12. CD4(+) T cells primed with IL-12 induced B cells to produce immunoglobulins in a fashion dependent on IL-21 and inducible costimulator (ICOS), thus sharing fundamental characteristics with Tfh cells. The induction of Tfh-like cells by activated DCs was inhibited by neutralizing IL-12. IL-12 induced two different IL-21-producers: IL-21(+)IFN-gamma(+)T-bet(+) Th1 cells and IL-21(+)IFN-gamma(-)T-bet(-) non-Th1 cells, in a manner dependent on <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    signal transducer and activator of transcription 4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>). IL-12 also regulated IL-21 secretion by memory CD4(+) T cells. Thus, IL-12 produced by activated DCs regulates antibody responses via developing IL-21-producing Tfh-like cells and inducing IL-21 secretion from memory CD4(+) T cells. These data suggest that the developmental pathway of Tfh cells differs between mice and humans, which have considerable implications for vaccine development.</div></details><details><summary>TH2</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/20086239">20086239</a><div class="entities" style="line-height: 2.5"><h3>Distinct signal codes generate dendritic cell functional plasticity.</h3></br>Our adaptive immune system induces distinct responses to different pathogens because of the functional plasticity of dendritic cells (DCs); however, how DCs program unique responses remains unclear. Here, we found that the cytokine thymic stromal lymphopoietin (TSLP) potently transduced a unique T helper type 2 (T(H)2)-inducing compound signal in DCs. Whereas activation of nuclear factor kappaB (predominantly p50) drove DCs to produce OX40L to induce T(H)2 differentiation, the activation of signal transducer and activator of transcription 6 (STAT6) triggered DCs to secrete chemokines necessary for the recruitment of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(H)2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells. In addition, TSLP signaling limited the activation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and interferon regulatory factor 8 (IRF-8), which are essential factors for the production of the T(H)1-polarizing cytokine interleukin-12 (IL-12). By contrast, Toll-like receptor ligands and CD40 ligand did not activate STAT6 in myeloid DCs, but instead increased the abundance of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and IRF-8 to induce T(H)1 responses through the production of IL-12. Therefore, we propose that the functional plasticity of DCs relies on elaborate signal codes that are generated by different stimuli.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/18691059">18691059</a><div class="entities" style="line-height: 2.5"><h3>Role of GATA-3 in allergic diseases.</h3></br>GATA-3 is a transcription factor that is specifically expressed in T helper 2 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells and plays a critical role in the differentiation of Th2 cells from uncommitted CD4+ lymphocytes. In addition GATA-3 is essential for the gene expression of the cytokines IL-4, IL-5 and IL-13 that mediate allergic inflammation. In human T lymphocytes GATA-3 is normally localized to the cytoplasm, but on activation by antigen-presenting cells via the T cell receptor (CD3) and co-stimulatory receptor CD28 GATA-3 is phosphorylated by p38 MAP kinase and translocates to the nucleus via the nuclear import protein importin-alpha. Corticosteroids bound to glucocorticoid receptors inhibit GATA-3 function by competing for nuclear entry via importin-alpha and also by inhibiting p38 MAP kinase through the induction of MAP kinase phosphatase-1. GATA-3 is inhibited by the Th1 master regulatory transcription T-bet but in turn inhibits <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT-4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and thus T-bet so that Th2 polarization is maintained. Since GATA-3 appears to be a critical transcription factor for allergic inflammation it is an obvious target for inhibition. However, direct inhibition by inhaled specific oligonucleotides or interference RNA is not yet possible. Corticosteroids act as indirect inhibitors and in patients with corticosteroid resistance p38 MAP kinase inhibitors may also prove to be useful in the future.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/11359632">11359632</a><div class="entities" style="line-height: 2.5"><h3>Molecular aspects of T cell differentiation.</h3></br>Differentiated T helper 1 (Th1) and T helper 2 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) T cells show striking differences in their patterns of cytokine expression. This process is initiated by stimulation with antigen and the cytokines IL-12 and IL-4, respectively, and requires antigen-induced transcription factors such as NFAT and cytokine-induced transcription factors such as <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, induced by IL-12, and STAT6, induced by IL-4. This results in induction and maintained expression of subset-specific transcription factors including T-bet in Th1 cells and GATA3 in Th2 cells, which are involved in ensuring the commitment of T cells to Th1 or Th2 lineages. Here we review the signalling pathways and transcription factors that mediate T cell differentiation, and describe the epigenetic changes in chromatin structure, locus accessibility and DNA methylation that are known to accompany this process.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/9095224">9095224</a><div class="entities" style="line-height: 2.5"><h3>Regulation of interleukin-12 signalling during T helper phenotype development.</h3></br>The experiments described above have allowed us to define the molecular events in IL-12 signalling. Within minutes after IL-12 treatment of responsive cells, Stat1, Stat3, and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> are tyrosine phosphorylated. These molecules form nuclear DNA-binding complexes consisting of homodimeric Stat1 and heterodimeric Stat3-Stat4 complexes. In a murine in vitro phenotype development model, T cells rapidly and selectively lose their capacity to respond to IL-12 upon acquisition of the Th2 phenotype. This hyporesponsiveness is manifested by the inability of IL-12 to induce IFN gamma production in differentiated Th2 cells, as well as the inability of IL-12 to induce the activation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. Despite the functional defect of IL-12 signalling in Th2 cells, all known components of the IL-12 signal transduction pathway are present. We speculate that in Th2 cells, the second receptor chain may be absent or one of the other components may be modified. Genetic experiments in Balb/c and B10.D2 strains of mice have demonstrated several differences in T helper differentiation in vitro. Stimulation of T cells under neutral conditions results in a bias of Balb/c T cells toward the <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> extreme and B10 T cells toward the Th1 extreme of cytokine production. Following stimulation under neutral conditions, B10 T cells retain the ability to respond to IL-12 while Balb/c T cells lose IL-12 responsiveness. Mating experiments have demonstrated that the B10 genetic effect is dominant in F1 mice. Analysis of backcrossed animals has suggested that the ability to respond to IL-12 in the secondary stimulation may be controlled by a single dominant B10 gene. The results we describe may have profound implications for allergy. Since allergic responses are largely due to the activation of the Th2 subset of T lymphocytes, a better understanding of T cell phenotype development may reveal multiple targets for therapeutic intervention. First, a better understanding of Th1 phenotype induction in response to IL-12 may allow prevention of in vivo allergic responses using pharmacological tools which bias allergen-specific responses to the Th1 subset. Second, a molecular explantation of why Th2 cells fail to reverse phenotype in response to IL-12 may allow treatment of atopic individuals to remove the disease-promoting T lymphocyte compartment. Finally, a better understanding of the basis for genetic differences in murine T helper cell differentiation may allow us to identify a causative genetic element in humans, yielding better diagnostic and therapeutic methods.</div></details><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/29055004">29055004</a><div class="entities" style="line-height: 2.5"><h3>STAT4 Regulates the CD8+  Regulatory T Cell/T Follicular Helper Cell Axis and Promotes Atherogenesis in Insulin-Resistant <i>Ldlr<sup>-/-</sup></i> Mice.<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    The     <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>metabolic syndrome and diabetic conditions su<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    pport    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> atherosclerosis, but the exact mechanisms for accelerated atherogenesis remain unclear. Although the proinflammato<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    ry ro    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>le of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in atherosclerosis and diet-induced insulin resistance (IR) was recently established, the impact of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> on atherogenesis in conditions of IR is not known. In this study, we generated <i>Stat4<sup>-/-</sup>Ldlr<sup>-/-</sup></i> mice that were fed a diabetogenic diet with added cholesterol (DDC). DDC-fed <i>Stat4<sup>-/-</sup>Ldlr<sup>-/-</sup></i> mice demonstrated improved glucose tolerance, insulin sensitivity, and a 36% reduction in atherosclerosis compared with <i>Ldlr<sup>-/-</sup></i> controls. Interestingly, we detected a reduction in T follicular helper (Tfh) cells and plasma B cells but a sharp elevation in CD8+  regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) in spleens and aortas of <i>Stat4<sup>-/-</sup>Ldlr<sup>-/-</sup></i> mice compared with <i>Ldlr<sup>-/-</sup></i> mice. Similarly, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> deficiency supported CD8+  Treg differentiation in vitro. STAT4-deficient CD8+  Tregs suppressed Tfh cell and germinal center B cell development upon immunization with keyhole limpet hemocyanin, indicating an important role for STAT4 in CD8+  Treg functions in vivo. Furthermore, adoptive transfer of <i>Stat4<sup>-/-</sup>Ldlr<sup>-/-</sup></i> CD8+  Tregs versus <i>Ldlr<sup>-/-</sup></i> CD8+  Tregs resulted in a significant reduction in plaque burden and suppression of Tfh cell and germinal center B cells in DDC-fed <i>Ldlr<sup>-/-</sup></i> recipients. STAT4 expression in macrophages (MΦs) also affected the Tfh/CD8+  Treg axis, because conditioned media from <i>Stat4<sup>-/-</sup>Ldlr<sup>-/-</sup></i> MΦs supported CD8+  Treg differentiation, but not Tfh cell differentiation, in a TGF-β-dependent manner. These findings suggest a novel mechanism by which STAT4 supports atherosclerosis in IR <i>Ldlr<sup>-/-</sup></i> mice via STAT4-dependent MΦs, as well as cell-intrinsic suppression of CD8+  Treg generation and functions and maintenance of Tfh cell generation and the accompanying humoral immune response.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21303976">21303976</a><div class="entities" style="line-height: 2.5"><h3>Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer.</h3></br>The tumor microenvironment includes a complex network of immune T cell subpopulations. In this study, we systematically analyzed the balance between cytotoxic T cells and different subsets of helper T cells in human colorectal cancers and we correlated their impact on disease-free survival. A panel of immune related genes were analyzed in 125 frozen colorectal tumor specimens. Infiltrating cytotoxic T cells, <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>, Th1, and Th17 cells were also quantified in the center and the invasive margin of the tumors. By hierarchical clustering of a correlation matrix we identified functional clusters of genes associated with Th17 (RORC, IL17A), Th2 (IL4, IL5, IL13), Th1 (Tbet, IRF1, IL12Rb2, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>), and cytotoxicity (GNLY, GZMB, PRF1). Patients with high expression of the Th17 cluster had a poor prognosis, whereas patients with high expression of the Th1 cluster had prolonged disease-free survival. In contrast, none of the Th2 clusters were predictive of prognosis. Combined analysis of cytotoxic/Th1 and Th17 clusters improved the ability to discriminate relapse. In situ analysis of the density of IL17+ cells and CD8+ cells in tumor tissues confirmed the results. Our findings argue that functional Th1 and Th17 clusters yield opposite effects on patient survival in colorectal cancer, and they provide complementary information that may improve prognosis.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/17328715">17328715</a><div class="entities" style="line-height: 2.5"><h3>The role of T helper 17 (Th17) and regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) in human organ transplantation and autoimmune disease.</h3></br>Uncommitted (naive) murine CD4+ T helper cells (Thp) can be induced to differentiate towards T helper 1 (Th1), Th2, Th17 and regulatory (Treg) phenotypes according to the local cytokine milieu. This can be demonstrated most readily both in vitro and in vivo in murine CD4+ T cells. The presence of interleukin (IL)-12 [signalling through signal transduction and activator of transcription (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT)-4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>] skews towards Th1, IL-4 (signalling through STAT-6) towards Th2, transforming growth factor (TGF)-beta towards Treg and IL-6 and TGF-beta towards Th17. The committed cells are characterized by expression of specific transcription factors, T-bet for Th1, GATA-3 for Th2, forkhead box P3 (FoxP3) for Tregs and RORgammat for Th17 cells. Recently, it has been demonstrated that the skewing of murine Thp towards Th17 and Treg is mutually exclusive. Although human Thp can also be skewed towards Th1 and Th2 phenotypes there is as yet no direct evidence for the existence of discrete Th17 cells in humans nor of mutually antagonistic development of Th17 cells and <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>. There is considerable evidence, however, both in humans and in mice for the importance of interferon (IFN)-gamma and IL-17 in the development and progression of inflammatory and autoimmune diseases (AD). Unexpectedly, some models of autoimmunity thought traditionally to be solely Th1-dependent have been demonstrated subsequently to have a non-redundant requirement for Th17 cells, notably experimental allergic encephalomyelitis and collagen-induced arthritis. In contrast, Tregs have anti-inflammatory properties and can cause quiescence of autoimmune diseases and prolongation of transplant function. As a result, it can be proposed that skewing of responses towards Th17 or Th1 and away from Treg may be responsible for the development and/or progression of AD or acute transplant rejection in humans. Blocking critical cytokines in vivo, notably IL-6, may result in a shift from a Th17 towards a regulatory phenotype and induce quiescence of AD or prevent transplant rejection. In this paper we review Th17/IL-17 and Treg biology and expand on this hypothesis.</div></details><details><summary>TH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/23555662">23555662</a><div class="entities" style="line-height: 2.5"><h3>Tissue inhibitor of metalloproteinase 1 is preferentially expressed in Th1 and Th17 T-helper cell subsets and is a direct STAT target gene.</h3></br>CD4(+) T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells differentiate into distinct effector subsets that are critical for host defense, but are also implicated in the pathogenesis of autoimmune disorders. Thelper17 (Th17) cells in particular are emerging as important drivers of multiple diseases including psoriasis, spondyloarthropathy and multiple sclerosis. To gain insight into the function of Th17 cells, we performed transcriptional profiling in hopes of elucidating products not previously recognized as being functionally relevant in these T cells. Herein, we demonstrate that tissue inhibitor of metalloproteinase 1 (TIMP1), a secreted protein with pleiotropic effects on cellular growth, survival and integrity of the extracellular matrix, is preferentially produced by Th17 and Th1 cells. We further show that Th1 and Th17 cell TIMP1 regulation follows separate mechanisms with a requirement for <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in the former and STAT3 in the latter. Finally, we demonstrate that when restricted to T cells, expression of TIMP1 promotes neuropathology in experimental allergic encephalomyelitis.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/10566142">10566142</a><div class="entities" style="line-height: 2.5"><h3>Regulation of the IL-12/IL-12R axis: a critical step in T-helper cell differentiation and effector function.</h3></br>Interleukin (IL)-12 is required for the development of T-helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) 1 cells, which have been shown to be important for protective cell-mediated immune responses against a variety of intracellular pathogens. Recent studies have clarified the sources and the regulation of IL-12 production leading to Th1 development against microbes. Expression of IL-12R is necessary for maintaining IL-12 responsiveness and controlling Th1 lineage commitment. Advances in this area have included a broader understanding of the factors involved in the regulation of the IL-12R beta 2 signaling component. Expression of this receptor subunit in humans is critically influenced by IL-12 and type I interferons. IL-12 signaling results in <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> activation and interferon (IFN)-gamma production. Recent evidence suggests that IL-12 also modulates a number of genes involved in leukocyte trafficking. Thus, IL-12 is not only an important proinflammatory cytokine, which induces production of IFN-gamma and subsequent activation of phagocytic cells but also plays a major role in regulating the migration and proper positioning of effector cells.</div></details><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/23555662">23555662</a><div class="entities" style="line-height: 2.5"><h3>Tissue inhibitor of metalloproteinase 1 is preferentially expressed in Th1 and Th17 T-helper cell subsets and is a direct STAT target gene.</h3></br>CD4(+) T helper (Th) cells differentiate into distinct effector subsets that are critical for host defense, but are also implicated in the pathogenesis of autoimmune disorders. Thelper17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells in particular are emerging as important drivers of multiple diseases including psoriasis, spondyloarthropathy and multiple sclerosis. To gain insight into the function of Th17 cells, we performed transcriptional profiling in hopes of elucidating products not previously recognized as being functionally relevant in these T cells. Herein, we demonstrate that tissue inhibitor of metalloproteinase 1 (TIMP1), a secreted protein with pleiotropic effects on cellular growth, survival and integrity of the extracellular matrix, is preferentially produced by <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th1 cells. We further show that Th1 and Th17 cell TIMP1 regulation follows separate mechanisms with a requirement for <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in the former and STAT3 in the latter. Finally, we demonstrate that when restricted to T cells, expression of TIMP1 promotes neuropathology in experimental allergic encephalomyelitis.</div></details></details></td>
    </tr>
    <tr>
      <th>12</th>
      <td>STAT6</td>
      <td>22</td>
      <td>TH2:8, TH1:6, TREG:6, TH:4, TC9:1, TH17:1, TH9:1</td>
      <td>0.352826</td>
      <td>ENSG00000166888</td>
      <td><details><summary>Subtypes</summary><details><summary>TH2</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27858144">27858144</a><div class="entities" style="line-height: 2.5"><h3>Th9 and other IL-9-producing cells in allergic asthma.</h3></br>Allergic asthma is a worldwide increasing chronic disease of the airways which affects more than 300 million people. It is associated with increased IgE, mast cell activation, airway hyperresponsiveness (AHR), mucus overproduction and remodeling of the airways. Previously, this pathological trait has been associated with T helper type 2 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. Recently, different CD4+  T cell subsets (Th17, Th9) as well as cells of innate immunity, like mast cells and innate lymphoid cells type 2 (ILC2s), which are all capable of producing the rediscovered cytokine IL-9, are known to contribute to this disease. Regarding Th9 cells, it is known that naïve T cells develop into IL-9-producing cells in the presence of interleukin-4 (IL-4) and transforming growth factor beta (TGFβ). Downstream of IL-4, several transcription factors like <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    signal transducer and activator of transcription 6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>), interferon regulatory factor 4 (IRF4), GATA binding protein 3 (GATA3), basic leucine zipper transcription factor, ATF-like (BATF) and nuclear factor of activated T cells (NFAT) are activated. Additionally, the transcription factor PU.1, which is downstream of TGFβ signaling, also seems to be crucial in the development of Th9 cells. IL-9 is a pleiotropic cytokine that influences various distinct functions of different target cells such as T cells, B cells, mast cells and airway epithelial cells by activating STAT1, STAT3 and STAT5. Because of its pleiotropic functions, IL-9 has been demonstrated to be involved in several diseases, such as cancer, autoimmunity and other pathogen-mediated immune-regulated diseases. In this review, we focus on the role of Th9 and IL-9-producing cells in allergic asthma.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21646394">21646394</a><div class="entities" style="line-height: 2.5"><h3>SOCS2 regulates T helper type 2 differentiation and the generation of type 2 allergic responses.</h3></br>The incidence of allergy and asthma in developed countries is on the increase and this trend looks likely to continue. CD4(+) T helper 2 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are major drivers of these diseases and their commitment is controlled by cytokines such as interleukin 4, which are in turn regulated by the suppressor of cytokine signaling (SOCS) proteins. We report that SOCS2(-/-) CD4(+) T cells show markedly enhanced Th2 differentiation. SOCS2(-/-) mice, as well as RAG-1(-/-) mice transferred with SOCS2(-/-) CD4(+) T cells, exhibit elevated type 2 responses after helminth antigen challenge. Moreover, in in vivo models of atopic dermatitis and allergen-induced airway inflammation, SOCS2(-/-) mice show significantly elevated IgE, eosinophilia, type 2 responses, and inflammatory pathology relative to wild-type mice. Finally, after T cell activation, markedly enhanced <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and STAT5 phosphorylation is observed in SOCS2(-/-) T cells, whereas STAT3 phosphorylation is blunted. Thus, we provide the first evidence that SOCS2 plays an important role in regulating Th2 cell expansion and development of the type 2 allergic responses.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/20086239">20086239</a><div class="entities" style="line-height: 2.5"><h3>Distinct signal codes generate dendritic cell functional plasticity.</h3></br>Our adaptive immune system induces distinct responses to different pathogens because of the functional plasticity of dendritic cells (DCs); however, how DCs program unique responses remains unclear. Here, we found that the cytokine thymic stromal lymphopoietin (TSLP) potently transduced a unique T helper type 2 (T(H)2)-inducing compound signal in DCs. Whereas activation of nuclear factor kappaB (predominantly p50) drove DCs to produce OX40L to induce T(H)2 differentiation, the activation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    signal transducer and activator of transcription 6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) triggered DCs to secrete chemokines necessary for the recruitment of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(H)2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells. In addition, TSLP signaling limited the activation of STAT4 and interferon regulatory factor 8 (IRF-8), which are essential factors for the production of the T(H)1-polarizing cytokine interleukin-12 (IL-12). By contrast, Toll-like receptor ligands and CD40 ligand did not activate <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in myeloid DCs, but instead increased the abundance of STAT4 and IRF-8 to induce T(H)1 responses through the production of IL-12. Therefore, we propose that the functional plasticity of DCs relies on elaborate signal codes that are generated by different stimuli.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/23668241">23668241</a><div class="entities" style="line-height: 2.5"><h3>'All things considered': transcriptional regulation of T helper type 2 cell differentiation from precursor to effector activation.</h3></br>T helper type 2 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are critical to host defence against helminth infection and the pathogenesis of allergic diseases. The differentiation of Th2 cells from naive CD4 T cells is controlled by intricate transcriptional mechanisms. At the precursor stage of naive CD4 T cells, transcriptional mechanisms maintain the potential and in the meantime prevent spontaneous differentiation to Th2 fate. In addition, intrachromosomal interactions important for co-ordinated expression of Th2 cytokines pre-exist in naive CD4 T cells. Upon T cell receptor (TCR) engagement, naive CD4 T cells are induced by polarizing signals of the interleukin-4/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and Jagged/Notch pathways to up-regulate the expression of GATA-3. Once up-regulated, GATA-3 drives Th2 and suppresses Th1 differentiation in a cell autonomous fashion. In this stage of differentiation, the Th2 cytokine locus, as well as the interferon-γ locus, undergoes chromatin remodelling and epigenetic modifications that contribute to the somatic memory of Th2 cytokine gene expression pattern. Once differentiated, Th2 effector cells promptly produce Th2 cytokines upon TCR stimulation, which is regulated by concerted actions of GATA-3, TCR signalling, enhancers and the Th2 locus control region. This review provides a detailed account of the transcriptional regulatory events at these different stages of Th2 differentiation. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21514424">21514424</a><div class="entities" style="line-height: 2.5"><h3>Type 2 helper T cell cytokines induce morphologic and molecular characteristics of atopic dermatitis in human skin equivalent.</h3></br>Both the immune system and the epidermis likely have an important role in the pathogenesis of atopic dermatitis (AD). The objective of the present study was to develop a human skin equivalent model exhibiting morphologic and molecular characteristics of AD in a controlled manner. Skin equivalents generated from normal adult human keratinocytes were stimulated with type 2 T-helper cell (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cytokines IL-4 and IL-13, and morphologic features and gene expression of the epidermis were studied. Th2 cytokines induced intercellular edema similar to spongiotic changes observed in lesional AD as assessed at histopathologic analysis and electron microscopy. Furthermore, genes known to be specifically expressed in epidermis of patients with AD such as CAII and NELL2 were induced. In contrast, expression of psoriasis-associated genes such as elafin and hBD2 was not changed. Th2 cytokines caused DNA fragmentation in the keratinocytes, which could be inhibited by the caspase inhibitor Z-VAD, which suggests that apoptosis was induced. In addition, up-regulation of the death receptor Fas was observed in keratinocytes after Th2 cytokine stimulation. IL-4 and IL-13 induced phosphorylation of the signaling molecule <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. It was concluded that the skin equivalent model described herein may be useful in investigation of the epidermal aspects of AD and for study of drugs that act at the level of keratinocyte biology.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/11804871">11804871</a><div class="entities" style="line-height: 2.5"><h3>The Th2 lymphocyte products IL-4 and IL-13 rapidly induce airway hyperresponsiveness through direct effects on resident airway cells.</h3></br>Airway inflammation and airway hyperresponsiveness (AHR) are hallmarks of asthma. Cytokines produced by T helper type 2 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    ) lym    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>phocytes have been implicated in both processes. There is strong support for the idea that Th2 cytokines can produce AHR indirectly by promoting the recruitment of inflammatory cells. Less attention has been given to the possibility that Th2 cytokines might induce AHR by acting directly on resident airway cells. To investigate this, we polarized and activated CD4(+) T cells in vitro and analyzed airway function after administration of lymphocyte-conditioned media to the airways of naive mice. Th2-lymphocyte-conditioned medium induced AHR within 6 h. This finding was reproduced in masT cell-deficient and in T- and B-lymphocyte-deficient mice. AHR did not occur when Th2-lymphocyte-conditioned medium was administered to mice lacking the IL-4 receptor alpha subunit or Stat6, suggesting a critical role for interleukin (IL)-4 and/or IL-13. This was confirmed by the finding that recombinant IL-4 and IL-13 both induced AHR within 6 h. The induction of AHR occurred in the absence of inflammatory cell recruitment or mucus production. These results strongly suggest that products of activated Th2 lymphocytes can rapidly perturb airway function through direct effects on resident airway cells.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/11359632">11359632</a><div class="entities" style="line-height: 2.5"><h3>Molecular aspects of T cell differentiation.</h3></br>Differentiated T helper 1 (Th1) and T helper 2 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) T cells show striking differences in their patterns of cytokine expression. This process is initiated by stimulation with antigen and the cytokines IL-12 and IL-4, respectively, and requires antigen-induced transcription factors such as NFAT and cytokine-induced transcription factors such as STAT4, induced by IL-12, and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, induced by IL-4. This results in induction and maintained expression of subset-specific transcription factors including T-bet in Th1 cells and GATA3 in Th2 cells, which are involved in ensuring the commitment of T cells to Th1 or Th2 lineages. Here we review the signalling pathways and transcription factors that mediate T cell differentiation, and describe the epigenetic changes in chromatin structure, locus accessibility and DNA methylation that are known to accompany this process.</div></details><details><summary>TH1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/21684616">21684616</a><div class="entities" style="line-height: 2.5"><h3>Lesional skin in atopic dogs shows a mixed Type-1 and Type-2 immune responsiveness.</h3></br>Canine atopic dermatitis (AD) is a chronic inflammatory and pruritic skin disease which shares several characteristics with its human counterpart. In chronic patch test lesions of human with AD mainly a Th1-type cellular response is found. Besides, non-lesional AD skin is already skewed for inflammation and therefore different from healthy skin. The goal of this study was to characterize local immune responsiveness in chronic canine AD lesions as compared to that in non-lesional AD skin by defining T cell subset relevant cytokine- and transcription factor expression profiles. The gene expression of the Th1 cytokines IL-12p35, IL-12p40 and IFN-γ and their related transcription factors STAT4, SOCS5 and T-bet, the Th2 cytokines IL-4 and IL-13 and transcription factors <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, SOCS3 and GATA-3 and the regulatory cytokines IL-10 and TGF-β and the transcription factor FOXP3 was evaluated in healthy control and atopic dogs. In non-lesional (NLS) and chronic lesional skin (LS) of atopic dogs and control skin (CS) from healthy dogs mRNA expression of cytokines and transcription factors were measured by quantitative real-time PCR. Significantly different values were found for the following factors: IL-12p40 mRNA was lower in LS when compared to NLS. Expression of STAT4 was higher in LS compared to CS and NLS. More IL-13 and SOCS3 were found in LS and NLS when compared to CS and also in LS compared to NLS. GATA-3 was lower in LS compared to NLS. IL-10 expression was higher in both LS and NLS compared to CS and more IL-10 was present in LS compared to NLS. These findings indicate that both <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1-    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2-type as well as T regulatory cells are present in NLS and LS in canine atopic skin.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21205293">21205293</a><div class="entities" style="line-height: 2.5"><h3>Attenuated expression of tenascin-C in ovalbumin-challenged STAT4-/- mice.</h3></br>Asthma leads to structural changes in the airways, including the modification of extracellular matrix proteins such as tenascin-C. The role of tenascin-C is unclear, but it might act as an early initiator of airway wall remodelling, as its expression is increased in the mouse and human airways during allergic inflammation. In this study, we examined whether <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> or Th2 cells are important regulators of tenascin-C in experimental allergic asthma utilizing mice with impaired Th1 (STAT4-/-) or Th2 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6-    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>/-) immunity.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/17546034">17546034</a><div class="entities" style="line-height: 2.5"><h3>Dynamic changes in histone-methylation 'marks' across the locus encoding interferon-gamma during the differentiation of T helper type 2 cells.</h3></br>The 'histone-code' hypothesis proposes that cell fate 'decisions' are achieved through the creation of stable epigenetic histone 'marks' at gene loci. Here we explored the formation of marks of repressive methylation of histone 3 at lysine 9 (H3-K9) and of H3-K27 at the locus encoding interferon-gamma (Ifng locus) during the commitment of naive T cells to the T helper type 1 (TH1) and TH2 lineages. Methylation of H3-K9 across the Ifng locus was rapidly induced in differentiating <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and TH2 cells and was sustained in TH1 cells. In contrast, TH2 differentiation caused loss of methylation of H3-K9 and gain of methylation of H3-K27 by mechanisms dependent on the transcription factors GATA-3 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. Thus, histone-methylation marks at the Ifng locus are highly dynamic, which may ensure higher-order transcriptional regulation during early lineage commitment.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/16516225">16516225</a><div class="entities" style="line-height: 2.5"><h3>Enrichment of nucleofected primary human CD4+ T cells: a novel and efficient method for studying gene function and role in human primary T helper cell differentiation.</h3></br>Identification of key factors mediating the differentiation of naïve CD4(+) T helper cells into Th1 and Th2 subsets is important for understanding the molecular mechanisms of the development of autoimmune diseases as well as asthma and allergy. Functional importance of a given gene in the initiation of human T helper cell differentiation has been hard to study due to the difficulty in transfecting primary resting human T lymphocytes. In this study we have successfully transfected human primary CD4(+) T helper cells using Amaxa's Nucleofection technology. To overcome the background caused by untransfected cells, we have developed a system for enriching nucleofected unstimulated human primary T helper cells that express the gene of interest. This is achieved by introducing a plasmid construct containing a bicistronic unit coding for a truncated mouse MHC class l H-2K(k) cell surface marker followed by selection of H-2K(k) positive cells using antibody coated beads. We demonstrate that the nucleofected and enriched H-2K(k) positive T helper cells differentiate into <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells as well as the non-transfected control cells. We also show that by using this novel method, introduction of an shRNA targeting <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, a key molecule driving the Th2 cell development, results in impaired Th2 cell differentiation, as expected. The method described here, enables fast and feasible preparation of highly pure transfected primary CD4(+) T cell cultures ideal for studying the influence of overexpression or knockdown of a given gene on T helper cell differentiation and other primary human T cell functions.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/9531298">9531298</a><div class="entities" style="line-height: 2.5"><h3>Activation of STAT proteins and cytokine genes in human <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells generated in the absence of IL-12 and IL-4.</h3></br>We have shown previously that human CD4+ 45RO- T cells could be primed for a Th2 phenotype independent of IL-4 if they were activated by anti-CD28 mAb plus IL-2. If additional TCR signals were provided, the cells differentiated toward Th1 independent of IL-12. Here we show that anti-CD28/IL-2-primed Th2 cells expressed high levels of activated <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, but no cytokine mRNA. Moreover, both <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells expressed active STAT1 and -3, but not STAT2, -4, and -5. Restimulation of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> or Th2 cells via CD3 plus CD28 induced production of IFN-gamma or IL-4, respectively, but did not alter the activation status/DNA binding activity of STATs. Addition of IL-4 (or anti-IL-4 mAb) to restimulated Th2 cells did not modulate <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> activation or IL-4 expression, confirming the full commitment. However, Th2 cells remained responsive to IL-12, which repressed <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> DNA binding but activated STAT4, and this coincided with a suppression of IL-4/IL-5 and an induction of IFN-gamma. In Th1 cells, IL-12 activated both <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and STAT4, and IL-4 activated <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, but in both cases the Th1 phenotype remained. Together the data show that CD28/IL-2-dependent Th2 priming activated <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> without inducing IL-4 expression. The primed Th cells resembled memory cells and produced IL-4 upon the first CD3/CD28 costimulus without detectable modulation of STATs. Th2 cells remained responsive to IL-12, which repressed <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> DNA binding and activated STAT4, and switched the cells to Th1. The effects of IL-12 may depend on the commitment of the cells, since IL-12 phosphorylated <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in Th1 and dephosphorylated <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in Th2 cells.</div></details><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/24053457">24053457</a><div class="entities" style="line-height: 2.5"><h3><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> polymorphisms are associated with neonatal regulatory T cells and cytokines and atopic diseases at 3 years.</h3></br>The transcription factor <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is crucial for activation of the interleukin (IL)-4/IL-13 pathway and has been linked to regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>). Associations of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> polymorphisms with IgE levels were described; however, their impact on neonatal immune responses and early disease development is unknown.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/20335310">20335310</a><div class="entities" style="line-height: 2.5"><h3>Regulation of the T helper cell type 2 (Th2)/T regulatory cell (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) balance by IL-4 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>.</h3></br>During the development of immune responses to pathogens, self-antigens, or environmental allergens, naive CD4(+) T cells differentiate into subsets of effector cells including Th1, Th2, and Th17 cells. The differentiation into these subsets is controlled by specific transcription factors. The activity of these effector cells is limited by nTregs and iTregs, whose differentiation and maintenance are dependent on the transcription factor Foxp3. The regulation of autoimmune diseases mediated by Th1 and Th17 cells by Tregs has been studied and reviewed extensively. However, much less has been presented about the interplay between <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells and their contribution to allergic disease. In this perspective, we discuss the regulation of Th2 cells by Tregs and vice versa, focusing on the interplay between the IL-4-activated <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>/GATA3 pathway and Foxp3.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/19961539">19961539</a><div class="entities" style="line-height: 2.5"><h3>Identification and characterization of the transcription factors involved in T cell development, t-bet, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    stat6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and foxp3, within the zebrafish, Danio rerio.</h3></br>The discovery of cytokines expressed by T-helper 1 (Th1), Th2, Th17 and T-regulatory (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells has prompted speculation that these types of responses may exist in fish, arising early in vertebrate evolution. In this investigation, we cloned three zebrafish transcription factors, T-box expressed in T cells (t-bet), <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    signal transducer and activator of transcription 6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    stat6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) and fork-head box p3 (foxp3), in which two transcripts are present, that are important in the development of a number of these cell types. They were found within the zebrafish genome, using a synteny approach in the case of t-bet and foxp3. Multiple alignments of zebrafish t-bet, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    stat6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and foxp3 amino acids with known vertebrate homologues revealed regions of high conservation, subsequently identified to be protein domains important in the functioning of these transcription factors. The gene organizations of zebrafish t-bet and foxp3 were identical to those of the human genes, with the second foxp3 transcript lacking exons 5, 6, 7 and 8. Zebrafish <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    stat6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (21 exons and 20 introns) was slightly different from the human gene, which contained 22 exons and 21 introns. Immunostimulation of zebrafish head kidney and spleen cells with phytohaemagglutinin, lipopolysaccharide or Poly I:C, showed a correlation between the expression of t-bet, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    stat6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and foxp3 with other genes involved in Th and T(reg) responses using quantitative PCR. These transcription factors, together with many of the cytokines that are expressed by different T cell subtypes, will aid future investigations into the Th and T(reg) cell types that exist in teleosts.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/25034833">25034833</a><div class="entities" style="line-height: 2.5"><h3>The alteration and clinical significance of Th1/Th2/Th17/Treg cells in patients with multiple myeloma.</h3></br>Immunological T cells and associated cytokines have been shown to be involved in the pathogenesis of multiple myeloma (MM). However, the abnormal immune imbalance of T lymphocyte subsets on MM remains unknown. We investigate the proportions of T helper 1 (Th1)/Th2/Th17/T regulatory (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells in peripheral blood mononuclear cells (PBMCs) by flow cytometry (FCM), and serum levels of relevant cytokines in MM patients and controls were detected by enzyme-linked immunosorbent assay (ELISA). The messenger RNA (mRNA) expression of T-bet, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, RORgammat, and Foxp3 was measured by real-time quantitative polymerase chain reaction (PCR). The CD4+ Th1 and CD4+ Th17 cells in patients with MM were significantly higher than those in health controls as well as the expression of T-bet and RORgammat mRNA. Furthermore, serum levels of interferon gamma (IFN-γ), IL-6, and IL-17A in MM group were greatly increased and significantly associated with each other. Significant differences on Th cells, cytokines, and transcription factors were observed on MM patients. The imbalance of T lymphocyte subsets was thought to contribute to the pathogenesis and underlying mechanisms of MM. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/22892452">22892452</a><div class="entities" style="line-height: 2.5"><h3>Induction of antitumor immunity ex vivo using dendritic cells transduced with fowl pox vector expressing MUC1, CEA, and a triad of costimulatory molecules (rF-PANVAC).</h3></br>The fowl pox vector expressing the tumor-associated antigens, mucin-1 and carcinoembryonic antigen in the context of costimulatory molecules (rF-PANVAC) has shown promise as a tumor vaccine. However, vaccine-mediated expansion of suppressor T cell populations may blunt clinical efficacy. We characterized the cellular immune response induced by ex vivo dendritic cells (DCs) transduced with (rF)-PANVAC. Consistent with the functional characteristics of potent antigen-presenting cells, rF-PANVAC-DCs demonstrated strong expression of mucin-1 and carcinoembryonic antigen and costimulatory molecules, CD80, CD86, and CD83; decreased levels of phosphorylated STAT3, and increased levels of Tyk2, Janus kinase 2, and STAT1. rF-PANVAC-DCs stimulated expansion of tumor antigen-specific T cells with potent cytolytic capacity. However, rF-PANVAC-transduced DCs also induced the concurrent expansion of FOXP3 expressing CD4CD25 regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) that inhibited T cell activation. Moreover, Tregs expressed high levels of Th2 cytokines [interleukin (IL)-10, IL-4, IL-5, and IL-13] together with phosphorylated STAT3 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. In contrast, the vaccine-expanded Treg population expressed high levels of Th1 cytokines IL-2 and interferon-γ and the proinflammatory receptor-related orphan receptor γt (RORγt) and IL-17A suggesting that these cells may share effector functions with conventional TH17 T cells. These data suggest that Tregs expanded by rF-PANVAC-DCs, exhibit immunosuppressive properties potentially mediated by Th2 cytokines, but simultaneous expression of Th1 and Th17-associated factors suggests a high degree of plasticity.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/17328715">17328715</a><div class="entities" style="line-height: 2.5"><h3>The role of T helper 17 (Th17) and regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) in human organ transplantation and autoimmune disease.</h3></br>Uncommitted (naive) murine CD4+ T helper cells (Thp) can be induced to differentiate towards T helper 1 (Th1), Th2, Th17 and regulatory (Treg) phenotypes according to the local cytokine milieu. This can be demonstrated most readily both in vitro and in vivo in murine CD4+ T cells. The presence of interleukin (IL)-12 [signalling through signal transduction and activator of transcription (STAT)-4] skews towards Th1, IL-4 (signalling through <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT-6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) towards Th2, transforming growth factor (TGF)-beta towards Treg and IL-6 and TGF-beta towards Th17. The committed cells are characterized by expression of specific transcription factors, T-bet for Th1, GATA-3 for Th2, forkhead box P3 (FoxP3) for Tregs and RORgammat for Th17 cells. Recently, it has been demonstrated that the skewing of murine Thp towards Th17 and Treg is mutually exclusive. Although human Thp can also be skewed towards Th1 and Th2 phenotypes there is as yet no direct evidence for the existence of discrete Th17 cells in humans nor of mutually antagonistic development of Th17 cells and <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>. There is considerable evidence, however, both in humans and in mice for the importance of interferon (IFN)-gamma and IL-17 in the development and progression of inflammatory and autoimmune diseases (AD). Unexpectedly, some models of autoimmunity thought traditionally to be solely Th1-dependent have been demonstrated subsequently to have a non-redundant requirement for Th17 cells, notably experimental allergic encephalomyelitis and collagen-induced arthritis. In contrast, Tregs have anti-inflammatory properties and can cause quiescence of autoimmune diseases and prolongation of transplant function. As a result, it can be proposed that skewing of responses towards Th17 or Th1 and away from Treg may be responsible for the development and/or progression of AD or acute transplant rejection in humans. Blocking critical cytokines in vivo, notably IL-6, may result in a shift from a Th17 towards a regulatory phenotype and induce quiescence of AD or prevent transplant rejection. In this paper we review Th17/IL-17 and Treg biology and expand on this hypothesis.</div></details><details><summary>TH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/26466682">26466682</a><div class="entities" style="line-height: 2.5"><h3>p-<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, PU.1, and NF-κB are involved in allergen-induced late-phase airway inflammation in asthma patients.</h3></br>Previous in vitro and animal studies demonstrated that transcription factors p-<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and PU.1 are required to induce interleukin (IL)-9 secretion by T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) 9 cells. It is believed that n factor-kappaB (NF-κB) plays a role in eosinophil survival. The importance of these transcription factors in the pathogenesis of allergic asthma (AA) in humans is poorly understood. We evaluated p-<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and PU.1 expression in peripheral blood Th9 cells and NF-κB expression in eosinophils during late-phase airway inflammation in AA patients.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/23254356">23254356</a><div class="entities" style="line-height: 2.5"><h3>Tc9 cells, a new subset of CD8(+) T cells, support Th2-mediated airway inflammation.</h3></br>Similar to T-helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, CD8(+) T cells also differentiate into distinct subpopulations. However, the existence of IL-9-producing CD8(+) T (Tc9) cells has not been elucidated so far. We show that murine CD8(+) T cells activated in the presence of IL-4 plus TGF-β develop into transient IL-9 producers characterized by specific IFN-γ and IL-10 expression patterns as well as by low cytotoxic function along with diminished expression of the CTL-associated transcription factors T-bet and Eomesodermin. Similarly to the CD4(+) counterpart, Tc9 cells required for their differentiation <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and IRF4. Tc9 cells deficient for these master regulators displayed increased levels of Foxp3 that in turn suppressed IL-9 production. In an allergic airway disease model, Tc9 cells promoted the onset of airway inflammation, mediated by subpathogenic numbers of Th2 cells. This support was specific for Tc9 cells because CTLs failed to exert this function. We detected increased Tc9 frequency in the periphery in mice and humans with atopic dermatitis, a Th2-associated skin disease that often precedes asthma. Thus, our data point to the existence of Tc9 cells and to their supportive function in Th2-dependent airway inflammation, suggesting that these cells might be a therapeutic target in allergic disorders.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/20620947">20620947</a><div class="entities" style="line-height: 2.5"><h3>Genome-wide profiling of interleukin-4 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> transcription factor regulation of human Th2 cell programming.</h3></br>Dissecting the molecular mechanisms by which T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells differentiate to effector Th2 cells is important for understanding the pathogenesis of immune-mediated diseases, such as asthma and allergy. Because the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> transcription factor is an upstream mediator required for interleukin-4 (IL-4)-induced Th2 cell differentiation, its targets include genes important for this process. Using primary human CD4(+) T cells, and by blocking <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> with RNAi, we identified a number of direct and indirect targets of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> with ChIP sequencing. The integration of these data sets with detailed kinetics of IL-4-driven transcriptional changes showed that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> was predominantly needed for the activation of transcription leading to the Th2 cell phenotype. This integrated genome-wide data on IL-4- and STAT6-mediated transcription provide a unique resource for studies on Th cell differentiation and, in particular, for designing interventions of human Th2 cell responses.</div></details><details><summary>TC9</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/23254356">23254356</a><div class="entities" style="line-height: 2.5"><h3>Tc9 cells, a new subset of CD8(+) T cells, support Th2-mediated airway inflammation.</h3></br>Similar to T-helper (Th) cells, CD8(+) T cells also differentiate into distinct subpopulations. However, the existence of IL-9-producing CD8(+) T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tc9    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells has not been elucidated so far. We show that murine CD8(+) T cells activated in the presence of IL-4 plus TGF-β develop into transient IL-9 producers characterized by specific IFN-γ and IL-10 expression patterns as well as by low cytotoxic function along with diminished expression of the CTL-associated transcription factors T-bet and Eomesodermin. Similarly to the CD4(+) counterpart, Tc9 cells required for their differentiation <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and IRF4. Tc9 cells deficient for these master regulators displayed increased levels of Foxp3 that in turn suppressed IL-9 production. In an allergic airway disease model, Tc9 cells promoted the onset of airway inflammation, mediated by subpathogenic numbers of Th2 cells. This support was specific for Tc9 cells because CTLs failed to exert this function. We detected increased Tc9 frequency in the periphery in mice and humans with atopic dermatitis, a Th2-associated skin disease that often precedes asthma. Thus, our data point to the existence of Tc9 cells and to their supportive function in Th2-dependent airway inflammation, suggesting that these cells might be a therapeutic target in allergic disorders.</div></details><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/19505891">19505891</a><div class="entities" style="line-height: 2.5"><h3>Gfi1 negatively regulates T(h)17 differentiation by inhibiting RORgammat activity.</h3></br>T(h) cells have long been divided into two subsets, T(h)1 and T(h)2; however, recently, T(h)17 and inducible regulatory T (iTreg) cells were identified as new T(h) cell subsets. Although T(h)1- and T(h)2-polarizing cytokines have been shown to suppress T(h)17 and iTreg development, transcriptional regulation of T(h)17 and iTreg differentiation by cytokines remains to be clarified. In this study, we found that expression of the growth factor independent 1 (Gfi1) gene, which has been implicated in T(h)2 development, was repressed in <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(h)17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and iTreg cells compared with T(h)1 and T(h)2 lineages. Gfi1 expression was enhanced by the IFN-gamma/STAT1 and IL-4/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> pathways, whereas it was repressed by the transforming growth factor-beta1 stimulation at the promoter level. Over-expression of Gfi1 strongly reduced IL-17A transcription in the EL4 T cell line, as well as in primary T cells. This was due to the blockade of recruitment of retinoid-related orphan receptor gammat to the IL-17A promoter. In contrast, IL-17A expression was significantly enhanced in Gfi1-deficient T cells under T(h)17-promoting differentiation conditions as compared with wild-type T cells. In contrast, the impacts of Gfi1 in iTregs were not as strong as in T(h)17 cells. Taken together, these data strongly suggest that Gfi1 is a negative regulator of T(h)17 differentiation, which represents a novel mechanism for the regulation of T(h)17 development by cytokines.</div></details><details><summary>TH9</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27858144">27858144</a><div class="entities" style="line-height: 2.5"><h3>Th9 and other IL-9-producing cells in allergic asthma.</h3></br>Allergic asthma is a worldwide increasing chronic disease of the airways which affects more than 300 million people. It is associated with increased IgE, mast cell activation, airway hyperresponsiveness (AHR), mucus overproduction and remodeling of the airways. Previously, this pathological trait has been associated with T helper type 2 (Th2) cells. Recently, different CD4+  T cell subsets (Th17, Th9) as well as cells of innate immunity, like mast cells and innate lymphoid cells type 2 (ILC2s), which are all capable of producing the rediscovered cytokine IL-9, are known to contribute to this disease. Regarding Th9 cells, it is known that naïve T cells develop into IL-9-producing cells in the presence of interleukin-4 (IL-4) and transforming growth factor beta (TGFβ). Downstream of IL-4, several transcription factors like <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    signal transducer and activator of transcription 6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT6    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>), interferon regulatory factor 4 (IRF4), GATA binding protein 3 (GATA3), basic leucine zipper transcription factor, ATF-like (BATF) and nuclear factor of activated T cells (NFAT) are activated. Additionally, the transcription factor PU.1, which is downstream of TGFβ signaling, also seems to be crucial in the development of Th9 cells. IL-9 is a pleiotropic cytokine that influences various distinct functions of different target cells such as T cells, B cells, mast cells and airway epithelial cells by activating STAT1, STAT3 and STAT5. Because of its pleiotropic functions, IL-9 has been demonstrated to be involved in several diseases, such as cancer, autoimmunity and other pathogen-mediated immune-regulated diseases. In this review, we focus on the role of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th9    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and IL-9-producing cells in allergic asthma.</div></details></details></td>
    </tr>
    <tr>
      <th>13</th>
      <td>RAG1</td>
      <td>8</td>
      <td>TREG:3, TH1:2, TC17:1, TH2:1, TH9:1</td>
      <td>0.328900</td>
      <td>ENSG00000166349</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/20208000">20208000</a><div class="entities" style="line-height: 2.5"><h3>Regulatory T cells inhibit T cell proliferation and decrease demyelination in mice chronically infected with a coronavirus.</h3></br>Mice infected with the neurotropic JHM strain of mouse hepatitis virus (JHMV) develop acute and chronic demyelinating diseases with histopathological similarities to multiple sclerosis. The process of demyelination is largely immune-mediated, as immunodeficient mice (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RAG1(-/-)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mice) do not develop demyelination upon infection; however, demyelination develops if these mice are reconstituted with either JHMV-immune CD4 or CD8 T cells. Because myelin destruction is a consequence of the inflammatory response associated with virus clearance, we reasoned that decreasing the amount of inflammation would diminish clinical disease and demyelination. Given that regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) have potent anti-inflammatory effects, we adoptively transferred Tregs into infected C57BL/6 and RAG1(-/-) mice. In both instances, transfer of Tregs decreased weight loss, clinical scores, and demyelination. Transferred Tregs were not detected in the CNS of infected <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RAG1(-/-)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mice, but rather appeared to mediate their effects in the draining cervical lymph nodes. We show that Tregs dampen the inflammatory response mediated by transferred JHMV-immune splenocytes in infected <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RAG1(-/-)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mice by decreasing T cell proliferation, dendritic cell activation, and proinflammatory cytokine/chemokine production, without inducing apoptosis. By extension, decreasing inflammation, whether by Treg transfer or by otherwise enhancing the anti-inflammatory milieu, could contribute to improved clinical outcomes in patients with virus-induced demyelination.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/24666246">24666246</a><div class="entities" style="line-height: 2.5"><h3>Co-existence of clonal expanded autologous and transplacental-acquired maternal T cells in recombination activating gene-deficient severe combined immunodeficiency.</h3></br>It is commonly accepted that the presence of high amounts of maternal T cells excludes Omenn syndrome (OS) in severe combined immunodeficiency (SCID). We report a SCID patient with a novel mutation in the recombination activating gene (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RAG)1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> gene (4-BP DEL.1406 TTGC) who presented with immunodeficiency and OS. Several assays, including representatives of specific T cell receptors (TCR), Vβ families and TCR-γ rearrangements, were performed in order to understand more clearly the nature and origin of the patient's T cells. The patient had oligoclonal T cells which, based on the patient-mother human leucocyte antigen (HLA)-B50 mismatch, were either autologous or of maternal origin. These cell populations were different in their numbers of regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) and the diversity of TCR repertoires. This is the first description of the co-existence of large amounts of clonal expanded autologous and transplacental-acquired maternal T cells in RAG1-deficient SCID.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/15668741">15668741</a><div class="entities" style="line-height: 2.5"><h3>The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo.</h3></br>The cytokine IL-6 acts via a specific receptor complex that consists of the membrane-bound IL-6 receptor (mIL-6R) or the soluble IL-6 receptor (sIL-6R) and glycoprotein 130 (gp130). In this study, we investigated the role of IL-6R components in asthma. We observed increased levels of sIL-6R in the airways of patients with allergic asthma as compared to those in controls. In addition, local blockade of the sIL-6R in a murine model of late-phase asthma after OVA sensitization by gp130-fraction constant led to suppression of Th2 cells in the lung. By contrast, blockade of mIL-6R induced local expansion of Foxp3-positive CD4+CD25+ Tregs with increased immunosuppressive capacities. CD4+CD25+ but not CD4+CD25- lung T cells selectively expressed the IL-6R alpha chain and showed IL-6-dependent STAT-3 phosphorylation. Finally, in an in vivo transfer model of asthma in immunodeficient <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Rag1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mice, CD4+CD25+ T cells isolated from anti-IL-6R antibody-treated mice exhibited marked immunosuppressive and antiinflammatory functions. IL-6 signaling therefore controls the balance between effector cells and <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> in the lung by means of different receptor components. Furthermore, inhibition of IL-6 signaling emerges as a novel molecular approach for the treatment of allergic asthma.</div></details><details><summary>TH1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/19502389">19502389</a><div class="entities" style="line-height: 2.5"><h3>Innate immune processes are sufficient for driving cigarette smoke-induced inflammation in mice.</h3></br>The objective of this study was to characterize the impact of cigarette smoke exposure on lung immune and inflammatory processes. BALB/c and C57BL/6 mice were exposed to cigarette smoke for 4 days (acute) or at least 5 weeks (prolonged). Both mouse strains manifested an inflammatory response after acute smoke exposure, characterized by an influx of neutrophils and mononuclear cells. Multiplex analysis revealed a greater than twofold increase of the cytokines IL-1alpha, -5, -6, and -18, as well as the chemokines monocyte chemotactic protein-1 and -3, macrophage inflammatory protein-1alpha, -beta, and -gamma, -2, -3beta, macrophage defined chemokine, granulocyte chemotactic protein-2, and interferon-gamma-inducible protein-10. In BALB/c mice, neutrophilia persisted after prolonged exposure, whereas C57BL/6 showed evidence of attenuated neutrophilia both in the bronchoalveolar lavage and the lungs. In both mouse strains, cigarette smoke exposure was associated with an expansion of mature (CD11c(hi)/major histocompatibility complex class II(hi)) myeloid dendritic cells; we observed no changes in plasmacytoid dendritic cells. Lymphocytes in the lungs displayed an activated phenotype that persisted for CD4 T cells only after prolonged exposure. In BALB/c mice, T cells acquired T helper (Th) 1 and Th2 effector function after 5 weeks of smoke exposure, whereas, in C57BL/6 mice, neither <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> nor Th2 cells were detected. In both mouse strains, cigarette smoke exposure led to an accumulation of FoxP3+ T regulatory cells in the lungs. Studies in <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RAG1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> knockout mice suggest that these regulatory cells may participate in controlling smoke-induced inflammation. Acute and prolonged cigarette smoke exposure was associated with inflammation, activation of the adaptive immune system, and expansion of T regulatory cells in the lungs.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/8724834">8724834</a><div class="entities" style="line-height: 2.5"><h3>T cells and cytokines in intracellular bacterial infections: experiences with Mycobacterium bovis BCG.</h3></br>Intracellular bacteria reside in mononuclear phagocytes, and protective immunity is dominated by T lymphocytes. Mycobacterium bovis bacillus Calmette-Guéin (BCG) infection of mice represents an excellent model for studying immune mechanisms involved in defence against persistent intracellular bacteria that cause chronic disease. Gene disruption mutant mice include: A beta-/-, which lack conventional CD4+ T cell receptor alpha/beta (TCR alpha/beta) T lymphocytes; beta 2 microglobulin -/-, which lack conventional CD8+ TCR alpha/beta lymphocytes; TCR beta-/-, which lack all TCR alpha/beta lymphocytes; TCR delta-/-, which lack all TCR gamma/delta lymphocytes; and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RAG-1-    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>/- mutants, which lack mature T and B lymphocytes. Studies of these mutants suggest that CD4+ TCR alpha/beta, CD8+ TCR alpha/beta and TCR gamma/delta T lymphocytes all contribute to immunity against M. bovis BCG. Activation of antibacterial effector functions in macrophages by T helper 1 (Th1) cell-derived gamma-interferon (IFN-gamma) is central to protection. In contrast, Th2 cells are only marginally involved. Activation of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells is regulated by interleukin 10 (IL-10) and IL-12, which are induced early in infection with M. bovis BCG. Although IL-12 is stimulated by M. bovis BCG in immunocompetent mice, studies with IFN-gamma receptor-deficient and tumour necrosis factor alpha (TNF-alpha) receptor-deficient mutant mice suggest that M. bovis BCG-induced IL-12 secretion depends on IFN-gamma and TNF-alpha. Hence, IL-12 cannot be the first cytokine produced during M. bovis BCG infection.</div></details><details><summary>TC17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/23250275">23250275</a><div class="entities" style="line-height: 2.5"><h3>Th17 cells confer long-term adaptive immunity to oral mucosal Candida albicans infections.</h3></br>Oropharyngeal candidiasis (OPC) is an opportunistic infection caused by Candida albicans. Despite its prevalence, little is known about C. albicans-specific immunity in the oral mucosa. Vaccines against Candida generate both T helper type 1 (Th1) and Th17 responses, and considerable evidence implicates interleukin (IL)-17 in immunity to OPC. However, IL-17 is also produced by innate immune cells that are remarkably similar to Th17 cells, expressing the same markers and localizing to similar mucosal sites. To date, the relative contribution(s) of Th1, Th17, and innate IL-17-producing cells in OPC have not been clearly defined. Here, we sought to determine the nature and function of adaptive T cell responses to OPC, using a new recall infection model. Mice subjected to infection and re-challenge with Candida mounted a robust and stable antigen-specific IL-17 response in CD4+ but not CD8+ T cells. There was little evidence for Th1 or Th1/Th17 responses. The Th17 response promoted accelerated fungal clearance, and Th17 cells could confer protection in <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Rag1-    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>/- mice upon adoptive transfer. Surprisingly, CD4 deficiency did not cause OPC but was instead associated with compensatory IL-17 production by <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tc17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and CD3+CD4-CD8- cells. Therefore, classic CD4+Th17 cells protect from OPC but can be compensated by other IL-17-producing cells in CD4-deficient hosts.</div></details><details><summary>TH2</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/21646394">21646394</a><div class="entities" style="line-height: 2.5"><h3>SOCS2 regulates T helper type 2 differentiation and the generation of type 2 allergic responses.</h3></br>The incidence of allergy and asthma in developed countries is on the increase and this trend looks likely to continue. CD4(+) T helper 2 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are major drivers of these diseases and their commitment is controlled by cytokines such as interleukin 4, which are in turn regulated by the suppressor of cytokine signaling (SOCS) proteins. We report that SOCS2(-/-) CD4(+) T cells show markedly enhanced Th2 differentiation. SOCS2(-/-) mice, as well as <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RAG-1(-/-)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mice transferred with SOCS2(-/-) CD4(+) T cells, exhibit elevated type 2 responses after helminth antigen challenge. Moreover, in in vivo models of atopic dermatitis and allergen-induced airway inflammation, SOCS2(-/-) mice show significantly elevated IgE, eosinophilia, type 2 responses, and inflammatory pathology relative to wild-type mice. Finally, after T cell activation, markedly enhanced STAT6 and STAT5 phosphorylation is observed in SOCS2(-/-) T cells, whereas STAT3 phosphorylation is blunted. Thus, we provide the first evidence that SOCS2 plays an important role in regulating Th2 cell expansion and development of the type 2 allergic responses.</div></details><details><summary>TH9</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/22772464">22772464</a><div class="entities" style="line-height: 2.5"><h3>Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells.</h3></br>Interleukin-9 (IL-9) is a T cell cytokine that acts through a γC-family receptor on target cells and is associated with inflammation and allergy. We determined that T cells from mice deficient in the T helper type 17 (T(H)17) pathway genes encoding retinoid-related orphan receptor γ (ROR-γ) and IL-23 receptor (IL-23R) produced abundant IL-9, and we found substantial growth inhibition of B16F10 melanoma in these mice. IL-9-blocking antibodies reversed this tumor growth inhibition and enhanced tumor growth in wild-type (WT) mice. Il9r(-/-) mice showed accelerated tumor growth, and administration of recombinant IL-9 (rIL-9) to tumor-bearing WT and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Rag1(-/-    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) mice inhibited melanoma as well as lung carcinoma growth. Adoptive transfer of tumor-antigen-specific <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(H)9    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells into both WT and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Rag1(-/-    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) mice suppressed melanoma growth; this effect was abrogated by treatment with neutralizing antibodies to IL-9. Exogenous rIL-9 inhibited tumor growth in <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Rag1(-/-)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mice but not in masT cell-deficient mice, suggesting that the targets of IL-9 in this setting include mast cells but not T or B cells. In addition, we found higher numbers of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(H)9    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells in normal human skin and blood compared to metastatic lesions of subjects with progressive stage IV melanoma. These results suggest a role for IL-9 in tumor immunity and offer insight into potential therapeutic strategies. </div></details></details></td>
    </tr>
    <tr>
      <th>14</th>
      <td>HIF1A</td>
      <td>7</td>
      <td>TREG:4, TC1:1, TC17:1, TH9:1, TREG1:1</td>
      <td>0.328900</td>
      <td>ENSG00000100644</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28382159">28382159</a><div class="entities" style="line-height: 2.5"><h3>A Crucial Role of CXCL14 for Promoting Regulatory T Cells Activation in Stroke.</h3></br>Inflammatory processes have a detrimental role in the pathophysiology of ischemic stroke. However, little is known about the endogenous anti-inflammatory mechanisms in ischemic brain. Here, we identify CXCL14 as a critical mediator of these mechanisms. CXCL14 levels were upregulated in the ischemic brains of humans and rodents. Moreover, hypoxia inducible factor-1α (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    HIF-1α    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) drives hypoxia- or cerebral ischemia (CI)-dependent CXCL14 expression via directly binding to the CXCL14 promoter. Depletion of CXCL14 inhibited the accumulation of immature dendritic cells (iDC) or regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) and increased the infarct volume, whereas the supplementation of CXCL14 had the opposite effects. CXCL14 promoted the adhesion, migration, and homing of circulating CD11c+  iDC to the ischemic tissue via the upregulation of the cellular prion protein (PrPC ), PECAM-1, and MMPs. The accumulation of Treg in ischemic areas of the brain was mediated through a cooperative effect of CXCL14 and iDC-secreted IL-2-induced Treg differentiation. Interestingly, CXCL14 largely promoted IL-2-induced Treg differentiation. These findings indicate that CXCL14 is a critical immunomodulator involved in the stroke-induced inflammatory reaction. Passive CXCL14 supplementation provides a tractable path for clinical translation in the improvement of stroke-induced neuroinflammation.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27918097">27918097</a><div class="entities" style="line-height: 2.5"><h3>Sugars and fat - A healthy way to generate functional regulatory T cells.</h3></br>Cellular metabolism has emerged as an important regulator of adaptive immunity. While the metabolic requirements of conventional T cells are increasingly understood, the role of cellular metabolism in Foxp3+  regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells is less clear. Although it is well accepted that repression of Akt/mTOR, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    HIF-1α    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and aerobic glycolysis are important for the efficient generation of Treg cells in vitro, clear evidence how these pathways impact on Treg-cell development in vivo is limited. Furthermore, newer studies have shown that the same pathways that appear to suppress Treg-cell development are active in and required for functionally mature Treg cells. Thus, it becomes increasingly evident that development and function of regulatory T cells require different wiring of metabolic pathways. Finally, it is likely that critical differences remain to be uncovered between the metabolism of resting or 'naïve' Treg cells and those fully differentiated and actively engaged in suppression. In this comment, we briefly discuss our current understanding of Treg-cell metabolism and the need to address this area with new approaches based on in vivo models.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27716621">27716621</a><div class="entities" style="line-height: 2.5"><h3>Hypoxia-induced CCL28 promotes recruitment of regulatory T cells and tumor growth in liver cancer.</h3></br>Tumor cells craft microenvironment to overcome growth disadvantages and adjust to escape the immunosurveillance during tumorigenesis and metastasis. The evolving adaption to the changing microenvironment is exemplified by the development of strategies to deal with hypoxia resulted from fast proliferation of the tumor cells. In this study, we found that hypoxia hepatocellular carcinoma (HCC) cells recruited Regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) and expressed more Chemokine (C-C motif) ligand 28 (CCL28). Deletion of CCL28 inhibited Treg recruitment. Furthermore, overexpression of CCL28 promoted tumor growth and Treg infiltration in vivo. Enhanced angiogenesis and VEGF expression was also observed. Moreover, inhibition of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    HIF1α    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> reversed hypoxia-induced CCL28 upregulation. Taken together, our results demonstrate that HCC recruits Tregs to promote angiogenesis under hypoxic condition by upregulating CCL28 expression. These findings establish a link between Tregs and hypoxia in HCC growth and may provide a new potential therapeutic target for treating HCC.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/18792019">18792019</a><div class="entities" style="line-height: 2.5"><h3>Hypoxia controls CD4+CD25+ regulatory T cell homeostasis via hypoxia-inducible factor-1alpha.</h3></br>Recent data suggest that hypoxia and its principal molecular signature HIF-1 (hypoxia-inducing factor-1) may tune down inflammation by dictating anti-inflammatory programs. We tested the effects of hypoxia and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    HIF-1alpha    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> on the homeostasis of naturally occurring regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) and their transcriptional activator Foxp3. Hypoxia induced a time-dependent increase in <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    HIF-1alpha    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in mouse and human T cells. Hypoxia upregulated the expression of Foxp3 in Jurkat T cells, human and murine mononuclear cells. The effects of hypoxia on Foxp3 expression were <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    HIF-1alpha    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>-dependent as they were abolished upon transfection with short-interfering RNAs for <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    HIF-1alpha    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and promoted by <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    HIF-1alpha    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> overexpression. Hypoxia increased the potency of Treg, as hypoxic CD4(+)CD25(+) lymphocytes were more effective than normoxic cells in suppressing the proliferation of CD4(+)CD25(-) effectors. In vivo expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    HIF-1alpha    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> achieved by hydrodynamic injection of the respective naked DNA similarly induced an increase in Foxp3 expression and an increase in the number of functionally active Foxp3(+)CD4(+)CD25(+) Treg. Thus, hypoxia dictates an anti-inflammatory program by driving expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    HIF-1alpha    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> that acts to increase the number and suppressive properties of naturally occurring CD4(+)CD25(+) Treg.</div></details><details><summary>TC1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28542595">28542595</a><div class="entities" style="line-height: 2.5"><h3>Antifungal Tc17 cells are durable and stable, persisting as long-lasting vaccine memory without plasticity towards IFNγ cells.</h3></br>Our understanding of persistence and plasticity of IL-17A+ memory T cells is clouded by conflicting results in models analyzing T helper 17 cells. We studied memory IL-17A+ CD8+ T cell (Tc17) homeostasis, persistence and plasticity during fungal vaccine immunity. We report that vaccine-induced memory Tc17 cells persist with high fidelity to the type 17 phenotype. Tc17 cells persisted durably for a year as functional IL-17A+ memory cells without converting to IFNγ+ (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tc1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, although they produced multiple type I cytokines in the absence of residual vaccine antigen. Memory Tc17 cells were canonical CD8+ T cells with phenotypic features distinct from Tc1 cells, and were Ror(γ)thi, TCF-1hi, T-betlo and EOMESlo. In investigating the bases of Tc17 persistence, we observed that memory Tc17 cells had much higher levels of basal homeostatic proliferation than did Tc1 cells. Conversely, memory Tc17 cells displayed lower levels of anti-apoptotic molecules Bcl-2 and Bcl-xL than Tc1 cells, yet were resistant to apoptosis. Tc1 cells required Bcl-2 for their survival, but Bcl-2 was dispensable for the maintenance of Tc17 cells. Tc17 and Tc1 cells displayed different requirements for <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    HIF-1α    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> during effector differentiation and sustenance and memory persistence. Thus, antifungal vaccination induces durable and stable memory Tc17 cells with distinct requirements for long-term persistence that distinguish them from memory Tc1 cells.</div></details><details><summary>TC17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28542595">28542595</a><div class="entities" style="line-height: 2.5"><h3>Antifungal Tc17 cells are durable and stable, persisting as long-lasting vaccine memory without plasticity towards IFNγ cells.</h3></br>Our understanding of persistence and plasticity of IL-17A+ memory T cells is clouded by conflicting results in models analyzing T helper 17 cells. We studied memory IL-17A+ CD8+ T cell (Tc17) homeostasis, persistence and plasticity during fungal vaccine immunity. We report that vaccine-induced memory Tc17 cells persist with high fidelity to the type 17 phenotype. Tc17 cells persisted durably for a year as functional IL-17A+ memory cells without converting to IFNγ+ (Tc1) cells, although they produced multiple type I cytokines in the absence of residual vaccine antigen. Memory Tc17 cells were canonical CD8+ T cells with phenotypic features distinct from Tc1 cells, and were Ror(γ)thi, TCF-1hi, T-betlo and EOMESlo. In investigating the bases of Tc17 persistence, we observed that memory Tc17 cells had much higher levels of basal homeostatic proliferation than did Tc1 cells. Conversely, memory Tc17 cells displayed lower levels of anti-apoptotic molecules Bcl-2 and Bcl-xL than Tc1 cells, yet were resistant to apoptosis. Tc1 cells required Bcl-2 for their survival, but Bcl-2 was dispensable for the maintenance of Tc17 cells. <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tc17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Tc1 cells displayed different requirements for <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    HIF-1α    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> during effector differentiation and sustenance and memory persistence. Thus, antifungal vaccination induces durable and stable memory Tc17 cells with distinct requirements for long-term persistence that distinguish them from memory Tc1 cells.</div></details><details><summary>TH9</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27317260">27317260</a><div class="entities" style="line-height: 2.5"><h3>Histone Deacetylase SIRT1 Negatively Regulates the Differentiation of Interleukin-9-Producing CD4(+) T Cells.</h3></br>Distinct metabolic programs support the differentiation of CD4(+) T cells into separate functional subsets. In this study, we investigated metabolic mechanisms underlying the differentiation of IL-9-producing CD4(+) T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th9    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) in allergic airway inflammation and cancerous tumors. We found that histone deacetylase SIRT1 negatively regulated Th9 cell differentiation. A deficiency of SIRT1 induced by either conditional deletion in mouse CD4(+) T cells or the use of small interfering RNA (siRNA) in mouse or human T cells increased IL-9 production, whereas ectopic SIRT1 expression inhibited it. Notably, SIRT1 inhibited Th9 cell differentiation that regulated anti-tumor immunity and allergic pulmonary inflammation. Glycolytic activation through the mTOR-hypoxia-inducible factor-1α (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    HIF1α    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) was required for the differentiation of Th9 cells that conferred protection against tumors and is involved in allergic airway inflammation. Our results define the essential features of SIRT1-mTOR-<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    HIF1α    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> signaling-coupled glycolytic pathway in inducing Th9 cell differentiation, with implications for metabolic reprogramming as an immunotherapeutic approach.</div></details></details></td>
    </tr>
    <tr>
      <th>15</th>
      <td>SATB1</td>
      <td>5</td>
      <td>TREG:4, TEFF:2</td>
      <td>0.321621</td>
      <td>ENSG00000182568</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/30560927">30560927</a><div class="entities" style="line-height: 2.5"><h3>Interleukin 2 modulates thymic-derived regulatory T cell epigenetic landscape.</h3></br>Foxp3+ CD4+  regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> ) cells are essential for preventing fatal autoimmunity and safeguard immune homeostasis in vivo. While expression of the transcription factor Foxp3 and IL-2 signals are both required for the development and function of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>  cells, the commitment to the Treg  cell lineage occurs during thymic selection upon T cell receptor (TCR) triggering, and precedes the expression of Foxp3. Whether signals beside TCR contribute to establish <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>  cell epigenetic and functional identity is still unknown. Here, using a mouse model with reduced IL-2 signaling, we show that IL-2 regulates the positioning of the pioneer factor <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    SATB1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in CD4+  thymocytes and controls genome wide chromatin accessibility of thymic-derived Treg  cells. We also show that <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>  cells receiving only low IL-2 signals can suppress endogenous but not WT autoreactive T cell responses in vitro and in vivo. Our findings have broad implications for potential therapeutic strategies to reprogram Treg  cells in vivo.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/25338958">25338958</a><div class="entities" style="line-height: 2.5"><h3>Inhibition of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    SATB1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression in regulatory T cells contributes to hepatitis B virus-related chronic liver inflammation.</h3></br>Regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) contribute to the pathogenesis of chronic hepatitis B (CHB). Special AT-rich sequence-binding protein 1 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    SATB1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) may be a key component of this process. In the present study, Tregs and conventional T cells (Tconvs) were isolated by magnetic cell sorting of peripheral blood from CHB patients (n=57), individuals with resolved hepatitis B virus (HBV) infections (n=15), and healthy controls (n=29). <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    SATB1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression was studied by reverse transcription-quantitative PCR, flow cytometry and immunofluorescence microscopy, and the correlation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    SATB1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression to the expression of liver inflammation serum markers and the HBV DNA load was assessed. CHB patients showed significantly reduced <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    SATB1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression in Tregs than healthy controls and individuals with resolved HBV infections. Moreover, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    SATB1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression in Tregs was significantly lower than in Tconvs of patients with chronic HBV infection. Serum HBV DNA and liver inflammation markers were inversely correlated to the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    SATB1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mRNA level in Tregs. Antiviral treatment was accompanied by increased expression of the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    SATB1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> gene in Tregs. Thus, Tregs from CHB patients have reduced levels of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    SATB1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, which is resolved with antiviral therapy. Inhibition of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    SATB1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression may impair the hepatic inflammatory response and contribute to HBV persistence.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/22961053">22961053</a><div class="entities" style="line-height: 2.5"><h3>A multiply redundant genetic switch 'locks in' the transcriptional signature of regulatory T cells.</h3></br>The transcription factor Foxp3 participates dominantly in the specification and function of Foxp3(+)CD4(+) regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells) but is neither strictly necessary nor sufficient to determine the characteristic <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cell signature. Here we used computational network inference and experimental testing to assess the contribution of other transcription factors to this. Enforced expression of Helios or Xbp1 elicited distinct signatures, but Eos, IRF4, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Satb1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, Lef1 and GATA-1 elicited exactly the same outcome, acting in synergy with Foxp3 to activate expression of most of the <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cell signature, including key transcription factors, and enhancing occupancy by Foxp3 at its genomic targets. Conversely, the T(reg) cell signature was robust after inactivation of any single cofactor. A redundant genetic switch thus 'locked in' the <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cell phenotype, a model that would account for several aspects of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cell physiology, differentiation and stability.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21841785">21841785</a><div class="entities" style="line-height: 2.5"><h3>Repression of the genome organizer <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    SATB1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in regulatory T cells is required for suppressive function and inhibition of effector differentiation.</h3></br>Regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells) are essential for self-tolerance and immune homeostasis. Lack of effector T cell (T(eff) cell) function and gain of suppressive activity by <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells are dependent on the transcriptional program induced by Foxp3. Here we report that repression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    SATB1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, a genome organizer that regulates chromatin structure and gene expression, was crucial for the phenotype and function of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells. Foxp3, acting as a transcriptional repressor, directly suppressed the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    SATB1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> locus and indirectly suppressed it through the induction of microRNAs that bound the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    SATB1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> 3' untranslated region. Release of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    SATB1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> from the control of Foxp3 in <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells caused loss of suppressive function, establishment of transcriptional T(eff) cell programs and induction of T(eff) cell cytokines. Our data support the proposal that inhibition of SATB1-mediated modulation of global chromatin remodeling is pivotal for maintaining <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cell functionality.</div></details><details><summary>TEFF</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/21841785">21841785</a><div class="entities" style="line-height: 2.5"><h3>Repression of the genome organizer <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    SATB1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in regulatory T cells is required for suppressive function and inhibition of effector differentiation.</h3></br>Regulatory T cells (T(reg) cells) are essential for self-tolerance and immune homeostasis. Lack of effector T cell (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(eff)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cell) function and gain of suppressive activity by T(reg) cells are dependent on the transcriptional program induced by Foxp3. Here we report that repression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    SATB1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, a genome organizer that regulates chromatin structure and gene expression, was crucial for the phenotype and function of T(reg) cells. Foxp3, acting as a transcriptional repressor, directly suppressed the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    SATB1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> locus and indirectly suppressed it through the induction of microRNAs that bound the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    SATB1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> 3' untranslated region. Release of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    SATB1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> from the control of Foxp3 in T(reg) cells caused loss of suppressive function, establishment of transcriptional T(eff) cell programs and induction of T(eff) cell cytokines. Our data support the proposal that inhibition of SATB1-mediated modulation of global chromatin remodeling is pivotal for maintaining T(reg) cell functionality.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28801365">28801365</a><div class="entities" style="line-height: 2.5"><h3>Overexpression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    SATB1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> Gene Inhibits the Immunosuppressive Function of Regulatory T Cells in Chronic Hepatitis B.</h3></br>Special AT-rich sequence-binding protein 1 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    SATB1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) is a class of nuclear matrix binding protein expressed by T cells and plays an important role in regulatory T cells (Tregs) mediated immune regulation. The immunosuppressive function of Tregs in chronic hepatitis B (CHB) being inhibited by <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    SATB1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> has been shown in our previous studies. The objective of this study was to learn the impact of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    SATB1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> on the cellular immune function of CHB. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    SATB1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> isolated from human peripheral blood mononuclear cells (PBMCs) was used as a template of PCR and its product was connected to vector PLV-EF1α-EGFP-N. Reconstructed vector PLV-EF1α-SATB1/EGFP was used to create highly infectious virions and then transduced to Tregs isolated from the CHB patients. Cytokine secreted by Tregs with and without <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    SATB1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> overexpression were determined. The results showed that there was a significant increase of Th1 (IFN-γ) and Th2 (IL-4 and IL-5) cytokines following <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    SATB1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> overexpression in CHB derived Tregs. It means that overexpression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    SATB1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> can promote the conversion from Tregs to effector T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Teffs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) that lose suppressive function and stimulate the secretion of effective cytokines. These data provide the basis for further research on the mechanism of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    SATB1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in regulating specific immune response of CHB patients.</div></details></details></td>
    </tr>
    <tr>
      <th>16</th>
      <td>EOMES</td>
      <td>8</td>
      <td>MAIT:2, TH17:2, NKT:1, TC9:1, TEM:1, TFH:1, TH:1, TREG:1</td>
      <td>0.308723</td>
      <td>ENSG00000163508</td>
      <td><details><summary>Subtypes</summary><details><summary>MAIT</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28630305">28630305</a><div class="entities" style="line-height: 2.5"><h3>Multiple layers of heterogeneity and subset diversity in human MAIT cell responses to distinct microorganisms and to innate cytokines.</h3></br>Mucosa-associated invariant T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    MAIT    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are a large innate-like T cell subset in humans defined by invariant TCR Vα7.2 use and expression of CD161. <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    MAIT    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells recognize microbial riboflavin metabolites of bacterial or fungal origin presented by the monomorphic MR1 molecule. The extraordinary level of evolutionary conservation of MR1 and the limited known diversity of riboflavin metabolite antigens have suggested that MAIT cells are relatively homogeneous and uniform in responses against diverse microbes carrying the riboflavin biosynthesis pathway. The ability of MAIT cells to exhibit microbe-specific functional specialization has not been thoroughly investigated. Here, we found that MAIT cell responses against <i>Escherichia coli</i> and <i>Candida albicans</i> displayed microbe-specific polyfunctional response profiles, antigen sensitivity, and response magnitudes. MAIT cell effector responses against <i>E. coli</i> and <i>C. albicans</i> displayed differential MR1 dependency and TCR β-chain bias, consistent with possible divergent antigen subspecificities between these bacterial and fungal organisms. Finally, although the MAIT cell immunoproteome was overall relatively homogenous and consistent with an effector memory-like profile, it still revealed diversity in a set of natural killer cell-associated receptors. Among these, CD56, CD84, and CD94 defined a subset with higher expression of the transcription factors promyelocytic leukemia zinc finger (PLZF), <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    eomesodermin    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, and T-bet and enhanced capacity to respond to IL-12 and IL-18 stimulation. Thus, the conserved and innate-like MAIT cells harbor multiple layers of functional heterogeneity as they respond to bacterial or fungal organisms or innate cytokines and adapt their antimicrobial response patterns in a stimulus-specific manner.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/26220166">26220166</a><div class="entities" style="line-height: 2.5"><h3>CD161(int)CD8+ T cells: a novel population of highly functional, memory CD8+ T cells enriched within the gut.</h3></br>The C-type lectin-like receptor CD161 is expressed by lymphocytes found in human gut and liver, as well as blood, especially natural killer (NK) cells, T helper 17 (Th17) cells, and a population of unconventional T cells known as mucosal-associated invariant T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    MAIT    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. The association of high CD161 expression with innate T cell populations including MAIT cells is established. Here we show that CD161 is also expressed, at intermediate levels, on a prominent subset of polyclonal CD8+ T cells, including antiviral populations that display a memory phenotype. These memory CD161(int)CD8+ T cells are enriched within the colon and express both CD103 and CD69, markers associated with tissue residence. Furthermore, this population was characterized by enhanced polyfunctionality, increased levels of cytotoxic mediators, and high expression of the transcription factors T-bet and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    eomesodermin    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    EOMES    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>). Such populations were induced by novel vaccine strategies based on adenoviral vectors, currently in trial against hepatitis C virus. Thus, intermediate CD161 expression marks potent polyclonal, polyfunctional tissue-homing CD8+ T cell populations in humans. As induction of such responses represents a major aim of T cell prophylactic and therapeutic vaccines in viral disease and cancer, analysis of these populations could be of value in the future. </div></details><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/26511769">26511769</a><div class="entities" style="line-height: 2.5"><h3>CCR2 defines in vivo development and homing of IL-23-driven GM-CSF-producing Th17 cells.</h3></br>IL-17-producing helper T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are critical for host defense against extracellular pathogens but also drive numerous autoimmune diseases. Th17 cells that differ in their inflammatory potential have been described including IL-10-producing Th17 cells that are weak inducers of inflammation and highly inflammatory, IL-23-driven, GM-CSF/IFNγ-producing Th17 cells. However, their distinct developmental requirements, functions and trafficking mechanisms in vivo remain poorly understood. Here we identify a temporally regulated IL-23-dependent switch from CCR6 to CCR2 usage by developing Th17 cells that is critical for pathogenic Th17 cell-driven inflammation in experimental autoimmune encephalomyelitis (EAE). This switch defines a unique in vivo cell surface signature (CCR6(-)CCR2(+)) of GM-CSF/IFNγ-producing Th17 cells in EAE and experimental persistent extracellular bacterial infection, and in humans. Using this signature, we identify an IL-23/IL-1/IFNγ/TNFα/T-bet/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Eomesodermin    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>-driven circuit driving GM-CSF/IFNγ-producing Th17 cell formation in vivo. Thus, our data identify a unique cell surface signature, trafficking mechanism and T cell intrinsic regulators of GM-CSF/IFNγ-producing Th17 cells. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/26220166">26220166</a><div class="entities" style="line-height: 2.5"><h3>CD161(int)CD8+ T cells: a novel population of highly functional, memory CD8+ T cells enriched within the gut.</h3></br>The C-type lectin-like receptor CD161 is expressed by lymphocytes found in human gut and liver, as well as blood, especially natural killer (NK) cells, T helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, and a population of unconventional T cells known as mucosal-associated invariant T (MAIT) cells. The association of high CD161 expression with innate T cell populations including MAIT cells is established. Here we show that CD161 is also expressed, at intermediate levels, on a prominent subset of polyclonal CD8+ T cells, including antiviral populations that display a memory phenotype. These memory CD161(int)CD8+ T cells are enriched within the colon and express both CD103 and CD69, markers associated with tissue residence. Furthermore, this population was characterized by enhanced polyfunctionality, increased levels of cytotoxic mediators, and high expression of the transcription factors T-bet and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    eomesodermin    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    EOMES    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>). Such populations were induced by novel vaccine strategies based on adenoviral vectors, currently in trial against hepatitis C virus. Thus, intermediate CD161 expression marks potent polyclonal, polyfunctional tissue-homing CD8+ T cell populations in humans. As induction of such responses represents a major aim of T cell prophylactic and therapeutic vaccines in viral disease and cancer, analysis of these populations could be of value in the future. </div></details><details><summary>NKT</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/26157173">26157173</a><div class="entities" style="line-height: 2.5"><h3>A Subset of CD8αβ+ Invariant NKT Cells in a Humanized Mouse Model.</h3></br>Invariant <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NKT    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> (iNKT) cells are unconventional innate-like T cells demonstrating potent antitumor function in conventional mouse models. However, the iNKT cell ligands have had limited efficacy in human antitumor clinical trials, mostly due to the profound differences in the properties and compositions of iNKT cells between the two species, including the presence of a CD8(+) subset of iNKT cells only in humans. To build reliable in vivo models for studying human iNKT cells, we recently developed the first humanized mouse model (hCD1d-KI) with human CD1d knocked in. To further humanize the mouse model, we now introduced the human invariant NKT TCRα-chain (Vα24Jα18) into the hCD1d-knockin mice. Similar to humans, this humanized mouse model developed a subset of CD8αβ(+) iNKT cells among other human-like iNKT subsets. The presence of the CD8αβ(+) iNKT cells in the thymus suggests that these cells developed in the thymus. In the periphery, these NKT cells showed a strong Th1-biased cytokine response and potent cytotoxicity for syngeneic tumor cells upon activation, as do human CD8αβ(+) iNKT cells. The low binding avidity of iNKT TCRs to the human CD1d/lipid complex and high prevalence of Vβ7 TCRβ among the CD8(+) iNKT cells strongly point to a low avidity-based developmental program for these iNKT cells, which included the suppression of Th-POK and upregulation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    eomesodermin    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> transcriptional factors. Our establishment of this extensively humanized mouse model phenotypically and functionally reflecting the human CD1d/iNKT TCR system will greatly facilitate the future design and optimization of iNKT cell-based immunotherapies. </div></details><details><summary>TC9</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/23254356">23254356</a><div class="entities" style="line-height: 2.5"><h3>Tc9 cells, a new subset of CD8(+) T cells, support Th2-mediated airway inflammation.</h3></br>Similar to T-helper (Th) cells, CD8(+) T cells also differentiate into distinct subpopulations. However, the existence of IL-9-producing CD8(+) T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tc9    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells has not been elucidated so far. We show that murine CD8(+) T cells activated in the presence of IL-4 plus TGF-β develop into transient IL-9 producers characterized by specific IFN-γ and IL-10 expression patterns as well as by low cytotoxic function along with diminished expression of the CTL-associated transcription factors T-bet and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Eomesodermin    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. Similarly to the CD4(+) counterpart, Tc9 cells required for their differentiation STAT6 and IRF4. Tc9 cells deficient for these master regulators displayed increased levels of Foxp3 that in turn suppressed IL-9 production. In an allergic airway disease model, Tc9 cells promoted the onset of airway inflammation, mediated by subpathogenic numbers of Th2 cells. This support was specific for Tc9 cells because CTLs failed to exert this function. We detected increased Tc9 frequency in the periphery in mice and humans with atopic dermatitis, a Th2-associated skin disease that often precedes asthma. Thus, our data point to the existence of Tc9 cells and to their supportive function in Th2-dependent airway inflammation, suggesting that these cells might be a therapeutic target in allergic disorders.</div></details><details><summary>TEM</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28924369">28924369</a><div class="entities" style="line-height: 2.5"><h3>IL-12 Influence mTOR to Modulate CD8+  T Cells Differentiation through T-bet and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Eomesodermin    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in Response to Invasive Pulmonary Aspergillosis.</h3></br><b>Objective:</b> To investigate whether mTOR signaling pathway regulate the proliferation and differentiation of CD8+  T cells by transcription factors T-bet and Eomes, and explore the role of IL-12 in this biological procedure. <b>Methods:</b> Aspergillus fumigatus spore suspension nasal inhalation was used to establish the invasive pulmonary aspergillosis (IPA) mouse model. After inoculation, rapamycin (2mg/kg) each day or IL-12 (5ug/kg) every other day was given for 7 days. The blood samples were obtained before the mice sacrificed and lung specimens were taken. Pathological sections were stained with hematoxylin and eosin (HE). The number of CD8+ effective memory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tem    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) and the expression of IFN-γ, mTOR, ribosomal protein S6 kinase (S6K), T-bet and EOMES were measured by flow cytometry. The levels of IL-6, IL-10 and Galactomannan (GM) were determined by ELISA. <b>Results:</b> After IL-12 treatment, the number of CD8+  Tem and the expression of IFN-γ increased significantly; while quite the opposite results were observed when the mTOR pathway was blocked by rapamycin. The expression of mTOR and S6K as well as the level of IFN-γ of the IL-12 treatment group were significantly higher than those in IPA and IPA + rapamycin groups. In addition, IL-12 promoted increasing T-bet and down regulating Eomes to make the Tem transformation. The final immune effector was high level of inflammatory cytokines (IL-6) and low level of anti-inflammatory factors (IL-10) and this strengthened immune response to the Aspergillus infection. <b>Conclusions:</b> The biological effects of Tem could significantly affect IPA infection host immune regulation, which depended on the activation of mTOR signaling pathway by IL-12.</div></details><details><summary>TFH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27425607">27425607</a><div class="entities" style="line-height: 2.5"><h3>Molecular Mechanisms Regulating T Helper 1 versus T Follicular Helper Cell Differentiation in Humans.</h3></br>IL-12 is important for the differentiation of T follicular helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, as well as Th1 cells in humans. Still, how IL-12 signals regulate Tfh versus Th1 cell differentiation remains poorly characterized. Here we aimed to determine the molecular mechanisms that regulate the differentiation and the function of IL-12-stimulated human naive CD4(+) T cells. We found that T-bet promoted the expression of CXCR5 in human CD4(+) T cells. We provide evidence that T-bet does not strongly inhibit the Tfh cell differentiation program per se but diminishes the functions to provide help to B cells. This study also suggests that IRF4 plays an important role in driving the early differentiation of IL-12-stimulated CD4(+) T cells toward Tfh and away from Th1 by inhibiting the expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Eomesodermin    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. Thus, the fate of IL-12-stimulated CD4(+) T cells is determined through interplay of multiple transcription factors at early stages.</div></details><details><summary>TH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/23254356">23254356</a><div class="entities" style="line-height: 2.5"><h3>Tc9 cells, a new subset of CD8(+) T cells, support Th2-mediated airway inflammation.</h3></br>Similar to T-helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, CD8(+) T cells also differentiate into distinct subpopulations. However, the existence of IL-9-producing CD8(+) T (Tc9) cells has not been elucidated so far. We show that murine CD8(+) T cells activated in the presence of IL-4 plus TGF-β develop into transient IL-9 producers characterized by specific IFN-γ and IL-10 expression patterns as well as by low cytotoxic function along with diminished expression of the CTL-associated transcription factors T-bet and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Eomesodermin    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. Similarly to the CD4(+) counterpart, Tc9 cells required for their differentiation STAT6 and IRF4. Tc9 cells deficient for these master regulators displayed increased levels of Foxp3 that in turn suppressed IL-9 production. In an allergic airway disease model, Tc9 cells promoted the onset of airway inflammation, mediated by subpathogenic numbers of Th2 cells. This support was specific for Tc9 cells because CTLs failed to exert this function. We detected increased Tc9 frequency in the periphery in mice and humans with atopic dermatitis, a Th2-associated skin disease that often precedes asthma. Thus, our data point to the existence of Tc9 cells and to their supportive function in Th2-dependent airway inflammation, suggesting that these cells might be a therapeutic target in allergic disorders.</div></details><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27197194">27197194</a><div class="entities" style="line-height: 2.5"><h3>Rapalogs Efficacy Relies on the Modulation of Antitumor T cell Immunity.</h3></br>The rapalogs everolimus and temsirolimus that inhibit mTOR signaling are used as antiproliferative drugs in several cancers. Here we investigated the influence of rapalogs-mediated immune modulation on their antitumor efficacy. Studies in metastatic renal cell carcinoma patients showed that everolimus promoted high expansion of FoxP3 (+)Helios(+)Ki67(+) regulatory CD4 T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>). In these patients, rapalogs strongly enhanced the suppressive functions of Tregs, mainly in a contact-dependent manner. Paradoxically, a concurrent activation of spontaneous tumor-specific Th1 immunity also occurred. Furthermore, a high rate of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Eomes(+)CD8(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> T cells was detected in patients after a long-term mTOR inhibition. We found that early changes in the Tregs/antitumor Th1 balance can differentially shape the treatment efficacy. Patients presenting a shift toward decreased Tregs levels and high expansion of antitumor Th1 cells showed better clinical responses. Studies conducted in tumor-bearing mice confirmed the deleterious effect of rapalogs-induced Tregs via a mechanism involving the inhibition of antitumor T cell immunity. Consequently, the combination of temsirolimus plus CCR4 antagonist, a receptor highly expressed on rapalogs-exposed Tregs, was more effective than monotherapy. Altogether, our results describe for the first time a dual impact of host adaptive antitumor T cell immunity on the clinical effectiveness of rapalogs and prompt their association with immunotherapies. Cancer Res; 76(14); 4100-12. ©2016 AACR.</div></details></details></td>
    </tr>
    <tr>
      <th>17</th>
      <td>STAT3</td>
      <td>92</td>
      <td>TREG:42, TH17:28, TH:12, TH1:8, TH2:7, TFH:6, TEFF:3, TH22:2, TREG1:2, MAIT:1, NKT:1, TC17:1, TFH1LIKE:1, TH9:1, TREG17:1</td>
      <td>0.304352</td>
      <td>ENSG00000168610</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28940360">28940360</a><div class="entities" style="line-height: 2.5"><h3>Lys63-polyubiquitination by the E3 ligase casitas B-lineage lymphoma-b (Cbl-b) modulates peripheral regulatory T cell tolerance in patients with systemic lupus erythematosus.</h3></br>T cells from systemic lupus erythematosus (SLE) patients display a wide array of anomalies in peripheral immune tolerance mechanisms. The role of ubiquitin ligases such as Cbl-b has been described recently in these phenomena. However, its role in resistance to suppression phenotype in SLE has not been characterized, which was the aim of the present study. Thirty SLE patients (20 with active disease and 10 with complete remission) and 30 age- and sex-matched healthy controls were recruited. Effector (CD4+  CD25-  ) and regulatory (CD4+  CD25+  ) T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>  ) were purified from peripheral blood mononuclear cells (PBMCs) by magnetic selection. Suppression assays were performed in autologous and allogeneic co-cultures and analysed by a flow cytometry assay. Cbl-b expression and lysine-63 (K63)-specific polyubiquitination profile were assessed by Western blotting. We found a defective Cbl-b expression in Tregs  from lupus patients in contrast to healthy controls (1·1 ± 0·9 versus 2·5 ± 1·8, P = 0·003), which was related with resistance to suppression (r = 0·633, P = 0·039). Moreover, this feature was associated with deficient K63 polyubiquitination substrates and enhanced expression of phosphorylated signal transducer and activation of transcription 3 (pSTAT-3) in Tregs  from lupus patients. Our findings support that Cbl-b modulates resistance to suppression by regulating the K63 polyubiquitination profile in lupus Tregs  . In addition, defective K63 polyubiquitination of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is related to increased pSTAT-3 expression, and might promote the loss of suppressive capacity of Tregs  in lupus patients.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28817117">28817117</a><div class="entities" style="line-height: 2.5"><h3>Increased tumor-infiltrating CD45RA- CCR7-  regulatory T cell subset with immunosuppressive properties foster gastric cancer progress.</h3></br>Regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) are major components of tumor-infiltrating immune cells with potent immunosuppressive properties in gastric cancer (GC) microenvironment. However, different subsets of the Tregs and their relevance to GC are unknown. Here, we found that patients with GC showed a significantly higher Tregs infiltration in tumors, and CD45RA- CCR7-  Treg subset constituted most tumor-infiltrating Tregs. Tumor-infiltrating CD45RA- CCR7-  Treg subset with an effector/memory phenotype accumulated in tumors and expressed low level of HLA-DR. Gastric tumor-derived TNF-α induced CD45RA- CCR7-  Treg subset with similar phenotype to their status in tumors and inhibited their HLA-DR expression via activating <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> phosphorylation. These tumor-associated CD45RA- CCR7-  Treg subset exerted superior immunosuppressive properties to effectively suppress CD8+  T cells' anti-tumor function including CD8+  T cell IFN-γ and granzyme B (GrB) production as well as CD8+  T cell proliferation in vitro, and also contributed to the growth and progression of human gastric tumors in vivo, via IL-10 secretion and cell-cell contact mechanisms. Moreover, increased tumor-infiltrating CD45RA- CCR7-  Treg subset as well as higher intratumoral CD45RA- CCR7-  Treg/CD8+  T cell ratio was associated with advanced disease progression and reduced GC patient survival. This study therefore identifies a novel immunosuppressive pathway involving CD45RA- CCR7-  Treg subset development within the GC microenvironment. Efforts to inhibit this pathway may therefore prove a valuable strategy to prevent, and to treat this immune suppressive of GC.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28735449">28735449</a><div class="entities" style="line-height: 2.5"><h3>Therapy with omeprazole modulates regulatory T cell/T helper 17 immune response in children with duodenal ulcers.</h3></br>The purpose of this study was to determine the effect of omeprazole on the regulatory T cell (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) and T helper 17 (Th17)-mediated response in patients with duodenal ulcers (DUs). DU patients were randomly divided into omeprazole and colloid bismuth subcitrate treatment groups. The ratios of Th17 and Treg in peripheral blood mononuclear cells (PBMCs) were measured. Cytokine production and Foxp3+ - and RORγt-positive cells were detected. The expressions of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, p-<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, STAT5 and p-STAT5 were detected by Western blot. The results showed that DU patients had an imbalanced Treg/Th17 response, as reflected by the higher IL-17 level and Th17 ratio and lower IL-10 level and Treg proportion in serum compared with those in the healthy volunteers. The administration of omeprazole to the patients significantly increased Treg and IL-10 levels and reduced Th17 and IL-17 levels. Omeprazole markedly increased the number of Foxp3-positive cells, decreased the number of RORγt-positive cells and restored the balanced ratio of IL-10/IL-17 in the ulcer tissue. Interestingly, we observed a negative correlation between the ratios of Treg/Th17 and the pathological scores in damaged tissues. Of note, H. pylori-infected PBMCs showed decreased Treg and an increased Th17 proportion, which could be reversed by omeprazole. Finally, omeprazole increased the expression of p-STAT5 and reduced the level of p-STAT3 without any effects on the total expression of STAT5 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. Our data suggest that omeprazole treatment restores the equilibrium of the Treg/Th17-mediated response in DU patients. Moreover, the modulation of p-<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and p-STAT5 expression by omeprazole induced balanced polarisation of Treg/Th17.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28644966">28644966</a><div class="entities" style="line-height: 2.5"><h3>An immunosuppressive function of interleukin-35 in chronic hepatitis C virus infection.</h3></br>Interleukin (IL)-35, a newly identified member of the IL-12 cytokine family, has been reported to suppress inflammation and induce immunotolerance. However, little is known regarding the role of IL-35 during chronic hepatitis C virus (HCV) infection. Herein, we measured the serum IL-35 concentration of 73 patients with hepatitis C and 22 healthy individuals, as well as further investigated the modulatory function of IL-35 on CD4+ CD25+ CD127<sup>dim/-</sup> regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) and on hepatocytes infected with HCV in cell culture (HCVcc). IL-35 expression was significantly increased in patients with chronic hepatitis C and was positively correlated with the levels of HCV RNA. Inhibition of viral replication led to decreases in the serum levels of IL-35. IL-35 stimulation not only elevated the percentage of Tregs but also robustly inhibited cellular proliferation and up-regulated the production of anti-inflammatory cytokines (e.g., IL-10 and IL-35) in a HCV-specific and non-specific manner, which indicates enhancement of the suppressive function of Tregs. Although IL-35 did not exert anti-HCV activity in HCVcc-infected Huh7.5 cells, it reduced inflammatory cytokine secretion from Huh7.5 cells. This was probably via inhibition of the STAT1 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> signaling pathways, which could suppress subsequent liver damage due to chronic hepatitis C. The current data suggested that IL-35 contributes to persistent HCV infection by inhibiting antiviral immune activity. Moreover, IL-35 might also protect against HCV-induced liver injury by down-regulating the expression of proinflammatory cytokines. Thus, the immunosuppressive properties of IL-35 might play contradictory roles in maintaining viral persistence and reducing the inflammatory responses in chronic HCV infection.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28468969">28468969</a><div class="entities" style="line-height: 2.5"><h3>Protein Kinase CK2 Controls the Fate between Th17 Cell and Regulatory T Cell Differentiation.</h3></br>CK2 is a highly conserved and pleiotropic serine/threonine kinase that promotes many prosurvival and proinflammatory signaling pathways, including PI3K/Akt/mTOR and JAK/STAT. These pathways are essential for CD4+  T cell activation and polarization, but little is known about how CK2 functions in T cells. In this article, we demonstrate that CK2 expression and kinase activity are induced upon CD4+  T cell activation. Targeting the catalytic activity of CK2 using the next-generation small molecule inhibitor CX-4945 in vitro significantly and specifically inhibited mouse and human Th17 cell differentiation while promoting the generation of Foxp3+  regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>). These findings were associated with suppression of PI3K/Akt/mTOR activation and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> phosphorylation upon CX-4945 treatment. Furthermore, we demonstrate that CX-4945 treatment inhibits the maturation of Th17 cells into inflammatory IFN-γ-coproducing effector cells. The Th17/Treg axis and maturation of Th17 cells are major contributing factors to the pathogenesis of many autoimmune disorders, including multiple sclerosis. Using a murine model of multiple sclerosis, experimental autoimmune encephalomyelitis, we demonstrate that in vivo administration of CX-4945 targets Akt/mTOR signaling in CD4+  T cells and the Th17/Treg axis throughout disease. Importantly, CX-4945 treatment after disease initiation significantly reduced disease severity, which was associated with a significant decrease in the frequency of pathogenic IFN-γ+  and GM-CSF+  Th17 cells in the CNS. Our data implicate CK2 as a regulator of the Th17/Treg axis and Th17 cell maturation and suggest that CK2 could be targeted for the treatment of Th17 cell-driven autoimmune disorders.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28387597">28387597</a><div class="entities" style="line-height: 2.5"><h3>Human CD39+  Treg  Cells Express Th17-Associated Surface Markers and Suppress IL-17 via a Stat3-Dependent Mechanism.</h3></br>Human CD4+  T regulatory cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> ) are a population of phenotypically and functionally diverse cells that downre<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    gulat    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>e inflammatory and autoimmune responses. As <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17     <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>cells play an important role in the pathogenesis of autoimmune diseases, it is critical to elucidate the mechanisms regulating these cells. In this study, we examined the molecular basis underlying the phenotypic and functional diversity of human Tregs  expressing the ectonucleotidase CD39. CD4+ CD25hi CD39+  Tregs  inhibit the proliferative response and the secretion of IL-17 and IFN-γ of autologous CD4+  T effector cells, while CD4+ CD25hi CD39-  Tregs  only suppress IFN-γ production. We demonstrate that activated human CD4+ CD25hi CD39+  Tregs  express the Th17-associated surface markers CCR6 and IL-23R, and phosphorylate the transcription factor Stat3. Moreover, suppression of IL-17 by CD4+ CD25hi CD39+  Tregs  occurs via a Stat3-dependent mechanism as inhibition of Stat3 activation in the CD39+  Tregs  reverses their ability to suppress IL-17. CD4+ CD25hi CD39-  Tregs  are not endowed with the ability to inhibit IL-17 as they do not upregulate CCR6 or the IL-23R, and furthermore, they secrete IL-17. Our findings provide the first evidence that human Treg  functional diversity is matched to the type of immune response being regulated and reveal a new role for <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in controlling Treg  function.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28213589">28213589</a><div class="entities" style="line-height: 2.5"><h3>SH479, a Betulinic Acid Derivative, Ameliorates Experimental Autoimmune Encephalomyelitis by Regulating the T Helper 17/Regulatory T Cell Balance.</h3></br>CD4+  T helper cells, especially T helper 17 (TH 17) cells, combined with i<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    mmune regulatory network dysfunction, play key rol    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>es<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">     in a    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>utoimmune diseases including multiple sclerosis (MS). Betulinic acid (BA), a natural pentacyclic triterpenoid, has been reported to be involved in anti-inflammation, in particular having an inhibitory effect on proinflammatory cytokine interleukin 17 (IL-17) and interferon-<i>γ</i> (IFN-<i>γ</i>) production. In this study, we screened BA derivatives and found a BA derivative, SH479, that had a greater inhibitory effect on TH 17 differentiation. Our further analysis showed that SH479 had a greater inhibitory effect on TH 17 and TH 1, and a more stimulatory effect on regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. To evaluate the effects of SH479 on autoimmune diseases in vivo, we employed the extensively used MS mouse model experimental autoimmune encephalomyelitis (EAE). Our results showed that SH479 ameliorated clinical and histologic signs of EAE in both prevention and therapeutic protocols by regulating the TH 17/Treg balance. SH479 dose-dependently reduced splenic lymphocyte proinflammatory factors and increased anti-inflammatory factors. Moreover, SH479 specifically inhibited splenic lymphocyte viability from EAE mice but not normal splenic lymphocyte viability. At the molecular level, SH479 inhibited TH 17 differentiation by regulating signal transducer and activator of transcription-3 (STAT3) phosphorylation, DNA binding activity, and recruitment to the <i>Il-17a</i> promoter in CD4+  T cells. Furthermore, SH479 promoted the STAT5 signaling pathway and inhibited the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-<i>κ</i>B) signaling pathway. Together, our data demonstrated that SH479 ameliorated EAE by regulating the TH 17/Treg balance through inhibiting the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and NF-<i>κ</i>B pathways while activating the STAT5 pathway, suggesting that SH479 is a potential novel drug candidate for autoimmune diseases including MS.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28108629">28108629</a><div class="entities" style="line-height: 2.5"><h3>Myeloid <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> Promotes Lung Tumorigenesis by Transforming Tumor Immunosurveillance into Tumor-Promoting Inflammation.</h3></br>One of the most fundamental and challenging questions in the cancer field is how immunity in patients with cancer is transformed from tumor immunosurveillance to tumor-promoting inflammation. Here, we identify the transcription factor <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> as the culprit responsible for this pathogenic event in lung cancer development. We found that antitumor type 1 CD4+  T-helper (Th1) cells and CD8+  T cells were directly counter balanced in lung cancer development with tumor-promoting myeloid-derived suppressor cells (MDSCs) and suppressive macrophages, and that activation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in MDSCs and macrophages promoted tumorigenesis through pulmonary recruitment and increased resistance of suppressive cells to CD8+  T cells, enhancement of cytotoxicity toward CD4+  and CD8+  T cells, induction of regulatory T cell (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>), inhibition of dendritic cells (DC), and polarization of macrophages toward the M2 phenotype. The deletion of myeloid <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> boosted antitumor immunity and suppressed lung tumorigenesis. These findings increase our understanding of immune programming in lung tumorigenesis and provide a mechanistic basis for developing STAT3-based immunotherapy against this and other solid tumors. <i>Cancer Immunol Res; 5(3); 257-68. ©2017 AACR</i>.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27752897">27752897</a><div class="entities" style="line-height: 2.5"><h3>Foxp3 expression in CD4+ CD25+ Foxp3+  regulatory T cells promotes development of colorectal cancer by inhibiting tumor immunity.</h3></br>The mechanism underlying CD4+ CD25+ Foxp3+  regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) promoting the development of colorectal cancer (CRC) was elucidated in the present study. Forty-eight cases of colorectal carcinomas, 22 cases of colon polyps and 21 cases of normal colorectal tissues were collected. The correlation among Foxp3, IL-10 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, and the clinical relevance of these three indexes were analyzed. The results showed that the levels of Foxp3 expressed in infiltrating CD4+ CD25+ Foxp3+ Tregs, and IL-10 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in CRC tissues were all significantly higher than those in polypus tissues and normal colon tissues (P< 0.01). Pearson correlation analysis indicated that the expression level of Foxp3 was positively correlated with <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> at mRNA level (r=0.526, P=0.036), and was positively correlated with IL-10 at protein level (r=0.314, P=0.030). The Foxp3 expressed in CD4+ CD25+ Foxp3+ Tregs was correlated with the histological grade, lymph node metastasis and TNM stage of CRC (P<0.05 for all). The IL-10 expression was correlated with the histological grade and TNM stage (both P<0.05). The <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression was correlated with the lymph node metastasis and TNM stage (both P<0.05). It was concluded that CD4+ CD25+ Foxp3+ Tregs can inhibit tumor immunity in combination with some other related inhibitory cytokines and that Foxp3 expression in CD4+ CD25+ Foxp3+ Tregs correlates with CRC progression.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27576175">27576175</a><div class="entities" style="line-height: 2.5"><h3>The paracrine immunomodulatory interactions between the human dental pulp derived mesenchymal stem cells and CD4 T cell subsets.</h3></br>Mesenchymal stem cells (MSCs) have strong immunomodulatory properties, however these properties may show some di<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    fferen    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>ces according to the tissue type of their isolate. In this study we investigated the paracrine interactions between human DP derived MSCs (hDP-MSCs) and the CD4+  T helper cell subsets to establish their immunomodulatory mechanisms. We found that the CD4+ -Tbet+  (Th1) and CD4+ -Gata3+  (Th2) cells were suppressed by the hDP-MSCs, but the CD4+ -Stat3+  (Th17) and CD4+ -CD25+ -FoxP3+  (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells were stimulated. The expressions of T cell specific cytokines interferon gamma (IFN-g), interleukin (IL)-4 and IL-17a decreased, but IL-10 and transforming growth factor beta-1 (TGF-b1) increased with the hDP-MSCs. The expressions of indoleamine-pyrrole 2,3-dioxygenase (IDO), prostaglandin E2 (PGE2), soluble human leukocyte antigen G (sHLA-G) derived from hDP-MSCs slightly increased, but hepatocyte growth factor (HGF) significantly increased in the co-culture groups. According to our findings, the hDP-MSCs can suppress the Th1 and Th2 subsets but stimulate the Th17 and Treg subsets. The <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression of Th17 cells may have been stimulated by the HGF, and thus the pro-inflammatory Th17 cells may have altered into the immunosuppressive regulatory Th17 cells. Further prospective studies are needed to confirm our findings.</div></details><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28652396">28652396</a><div class="entities" style="line-height: 2.5"><h3>TLR7 Signaling Regulates Th17 Cells and Autoimmunity: Novel Potential for Autoimmune Therapy.</h3></br>Innate regulation through TLR signaling has been shown to be important for promoting T cell subset development and function. However, limited information is known about whether differential TLR signaling can selectively inhibit <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and/or Th1 cells, which are important for controlling excessive inflammation and autoimmune responses. In this article, we demonstrate that activation of TLR7 signaling in T cells can inhibit Th17 cell differentiation from naive T cells and IL-17 production in established Th17 cells. We further report that downregulation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> signaling is responsible for TLR7-mediated inhibition of Th17 cells due to induction of suppressor of cytokine signaling 3 and 5. TLR7-mediated suppression of Th17 cells does not require dendritic cell involvement. In addition, we show that TLR7 signaling can suppress Th1 cell development and function through a mechanism different from Th17 cell suppression. Importantly, our complementary in vivo studies demonstrate that treatment with the TLR7 ligand imiquimod can inhibit Th1 and Th17 cells, resulting in the prevention of, and an immunotherapeutic reduction in, experimental autoimmune encephalomyelitis. These studies identify a new strategy to manipulate Th17/Th1 cells through TLR7 signaling, with important implications for successful immunotherapy against autoimmune and inflammatory diseases.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28050571">28050571</a><div class="entities" style="line-height: 2.5"><h3>How Does Interleukin-22 Mediate Liver Regeneration and Prevent Injury and Fibrosis?</h3></br>Interleukin-22 (IL-22) is a pluripotent T cell-derived cytokine which is a member of IL-10 cytokine family. It is the only interleukin produced by immune cells but does not target immune system components. IL-22 is mainly produced by dendritic cells (DCs) and <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>, TH22, NK, and NKT cells and targets a number of body tissues including liver, pancreas, and other epithelial tissues. It provokes a series of downstream signaling pathways upon binding with IL-22R complex which protects liver damage through <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> activation. IL-22BP is an inhibitor of IL-22 which has 20-1000x more affinity to bind with IL-22 compared to IL-22R1 that inhibits IL-22 activity. Its level was found to be positively correlated with the severity of liver damage and fibrosis. So, the present review is an effort to reveal the exact mechanism lying in the hepatoprotective activity of IL-22 and some of its future therapeutic implications.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27555590">27555590</a><div class="entities" style="line-height: 2.5"><h3>Protein kinase CK2 governs the molecular decision between encephalitogenic TH17 cell and Treg cell development.</h3></br>T helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells represent a discrete TH cell subset instrumental in the immune response to extracellular bacteria and fungi. However, TH17 cells are considered to be detrimentally involved in autoimmune diseases like multiple sclerosis (MS). In contrast to TH17 cells, regulatory T (Treg) cells were shown to be pivotal in the maintenance of peripheral tolerance. Thus, the balance between Treg cells and TH17 cells determines the severity of a TH17 cell-driven disease and therefore is a promising target for treating autoimmune diseases. However, the molecular mechanisms controlling this balance are still unclear. Here, we report that pharmacological inhibition as well as genetic ablation of the protein kinase CK2 (CK2) ameliorates experimental autoimmune encephalomyelitis (EAE) severity and relapse incidence. Furthermore, CK2 inhibition or genetic ablation prevents TH17 cell development and promotes the generation of Treg cells. Molecularly, inhibition of CK2 leads to reduced <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> phosphorylation and strongly attenuated expression of the IL-23 receptor, IL-17, and GM-CSF. Thus, these results identify CK2 as a nodal point in TH17 cell development and suggest this kinase as a potential therapeutic target to treat TH17 cell-driven autoimmune responses.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27436361">27436361</a><div class="entities" style="line-height: 2.5"><h3>ROCK2 signaling is required to induce a subset of T follicular helper cells through opposing effects on STATs in autoimmune settings.</h3></br>Rho-associated kinase 2 (ROCK2) determines the balance between human T helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells and regulatory T (Treg) cells. We investigated its role in the generation of T follicular helper (TFH) cells, which help to generate antibody-producing B cells under normal and autoimmune conditions. Inhibiting ROCK2 in normal human T cells or peripheral blood mononuclear cells from patients with active systemic lupus erythematosus (SLE) decreased the number and function of TFH cells induced by activation ex vivo. Moreover, inhibition of ROCK2 activity decreased the abundance of the transcriptional regulator Bcl6 (B cell lymphoma 6) and increased that of Blimp1 by reducing the binding of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    signal transducer and activator of transcription 3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) and increasing that of STAT5 to the promoters of the genes Bcl6 and PRDM1, respectively. In the MRL/lpr murine model of SLE, oral administration of the selective ROCK2 inhibitor KD025 resulted in a twofold reduction in the numbers of TFH cells and antibody-producing plasma cells in the spleen, as well as a decrease in the size of splenic germinal centers, which are the sites of interaction between TFH cells and B cells. KD025-treated mice showed a substantial improvement in both histological and clinical scores compared to those of untreated mice and had reduced amounts of Bcl6 and phosphorylated <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, as well as increased STAT5 phosphorylation. Together, these data suggest that ROCK2 signaling plays a critical role in controlling the development of TFH cells induced by autoimmune conditions through reciprocal regulation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and STAT5 activation.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27221197">27221197</a><div class="entities" style="line-height: 2.5"><h3>MicroRNAs: New regulators of IL-22.</h3></br>Interleukin-22 (IL-22) is a cytokine that belongs to the IL-10 family of interleukins. It can be produced by T helper 22 (Th22) cells, T helper 1 (Th1) cells, T helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, natural killer 22 (NK22) cells, natural killer T (NKT) cells, innate lymphoid cells (ILCs), and γδ T cells. IL-22 acts via binding to a heterodimeric transmembrane receptor complex that consists of IL-22R1 and IL-10R2 and mainly contributes to the tissue repair and host defense. Transcription factors such as retinoid orphan receptor γt (RORγt) and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    signal transducer and activator of transcription 3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>), have been reported to play important roles in regulation of IL-22 expression. Recently, it has been demonstrated in several studies that microRNAs (miRNAs) potently regulate expression of interleukins, including production of IL-22. Here, we review current knowledge about regulators of IL-22 expression with a particular emphasis on the role of miRNAs.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/25732870">25732870</a><div class="entities" style="line-height: 2.5"><h3>Gαq controls rheumatoid arthritis via regulation of Th17 differentiation.</h3></br>Gαq, the α-subunit of Gq protein, is ubiquitously expressed in mammalian cells. It initially attracted attention for its physiological significance in cardiovascular system. In recent years, studies have also indicated the important roles of Gαq in regulating immunity, supplying us a new insight into the mechanism of immune regulation. T helper type 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are potent inducers of tissue inflammation. Many studies have shown that Th17 cells are major effector cells in the pathogenesis of many experimental autoimmune diseases and human inflammatory conditions such as rheumatoid arthritis (RA). One of our previous studies has shown that Gαq negatively controls the disease activity of RA. However, how Gαq controls the pathogenesis of autoimmune disease is not clear. Whether this effect is via the regulation of Th17 differentiation is still not known. We aimed to find out the role of Gαq in control of Th17 differentiation. We investigated the relationship between Gαq and Th17 in RA patients. We then investigated the mechanism of how Gαq regulated Th17 differentiation by using Gnaq(-/-) mice. We observed that the expression of Gαq was negatively associated with interleukin-17A expression in RA patients, indicating that Gαq negatively controlled the differentiation of Th17 cells. By using Gnaq(-/-) mice, we demonstrated that Gαq inhibited the differentiation of Th17 cell via regulating the activity of extracellular signal-regulated kinase-1/2 to control the expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    signal transducer and activator of transcription 3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) and RORα (RAR-related orphan receptor-α). These data suggest the possibility of targeting Gαq to develop a novel therapeutic regimen for autoimmune disease. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/25572535">25572535</a><div class="entities" style="line-height: 2.5"><h3>Modulation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and STAT5 activity rectifies the imbalance of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Treg cells in patients with acute coronary syndrome.</h3></br>The signal transducer and activator of transcription (STAT) activity plays an important role in the differentiation and imbalance of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Treg cells in acute coronary syndrome (ACS) patients. We determined that the basal <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> phosphorylation level was significantly increased and exhibited a positive relationship with Th17 cells but was negatively correlated with Treg cells in ACS patients. Opposite effects were observed for STAT5 activity. Using the pharmaceutical inhibitor TG101348 or knockdown of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> reduced the number of Th17 cells while promoting the number and function of Treg cells via the Janus kinase2 (JAK2)/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> pathway in ACS patients. Significantly more STAT5 bound to the Foxp3 locus when <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> was knocked down, and overexpression of STAT5 led to an increased number of Treg cells but a decreased number of Th17 cells in ACS patients. Our findings demonstrate that modulation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>/STAT5 activity rectifies the imbalance of Th17/Treg cells in ACS patients. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/25263529">25263529</a><div class="entities" style="line-height: 2.5"><h3>Suppression of human and mouse Th17 differentiation and autoimmunity by an endogenous Interleukin 23 receptor cytokine-binding homology region.</h3></br>T-helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, a recently identified CD4+ T subset with a unique characteristic to produce Interleukin-17 (IL-17), are critical for the development of autoimmune diseases such as multiple sclerosis, in which IL-23 plays an important role in the differentiation of Th17 cells through IL-23/IL-23-receptor/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> pathway. Previously, soluble recombinant human IL-23 receptor cytokine-binding homology region (hIL23R-CHR) was constructed in our laboratory to neutralize IL-23 and inhibit murine Th17 development in vitro. Herein we present that hIL23R-CHR could inhibit both differentiation and function of human/murine Th17 cells. The present in vivo study further demonstrated that hIL23R-CHR inhibited murine Th17 cell development by down regulating IL-17 gene expression and protected mice against the development of experimental autoimmune encephalomyelitis (EAE) through suppression of CNS inflammation and pro-inflammatory cytokine production. In addition to the in vitro inhibition of human Th17 cells in a dose-dependent manner, the antagonizing effect of hIL23R-CHR was confirmed by reduced levels of IL-23 in both blood and brain of EAE mice and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> phosphorylation in vivo. Taken together, our data demonstrated that hIL23R-CHR could be an effective and specific immunosuppressive molecule for the treatment of Th17-related autoimmune diseases. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/25164131">25164131</a><div class="entities" style="line-height: 2.5"><h3>Decreased expression of microRNA-21 correlates with the imbalance of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Treg cells in patients with rheumatoid arthritis.</h3></br>The imbalance of Th17/Treg cell populations has been suggested to be involved in the regulation of rheumatoid arthritis (RA) pathogenesis; however, the mechanism behind this phenomenon remains unclear. Recent studies have shown how microRNAs (miRNAs) are important regulators of immune responses and are involved in the development of a variety of inflammatory diseases, including RA. In this study, we demonstrated that the frequencies of CD3(+) CD4(+) IL-17(+) Th17 cells were significantly higher, and CD4(+) CD25(+) FOXP3(+) Treg cells significantly lower in peripheral blood mononuclear cells from RA patients. Detection of cytokines from RA patients revealed an elevated panel of pro-inflammatory cytokines, including IL-17, IL-6, IL-1β, TNF-α and IL-22, which carry the inflammatory signature of RA and are crucial in the differentiation and maintenance of pathogenic Th17 cells and dysfunction of Treg cells. However, the level of miR-21 was significantly lower in RA patients, accompanied by the increase in <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression and activation, and decrease in STAT5/pSTAT5 protein and Foxp3 mRNA levels. Furthermore, lipopolysaccharide stimulation up-regulated miR-21 expression from healthy controls, but down-regulated miR-21 expression from RA patients. Therefore, we speculate that miR-21 may be part of a negative feedback loop in the normal setting. However, miR-21 levels decrease significantly in RA patients, suggesting that this feedback loop is dysregulated and may contribute to the imbalance of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Treg cells. MiR-21 may thus serve as a novel regulator in T cell differentiation and homoeostasis, and provides a new therapeutic target for the treatment of RA. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/24469975">24469975</a><div class="entities" style="line-height: 2.5"><h3>Boswellic acids reduce Th17 differentiation via blockade of IL-1β-mediated IRAK1 signaling.</h3></br>Interferon-gamma producing CD4(+) T (Th1) cells and IL-17-producing CD4(+) T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are involved in the pathogenesis of several autoimmune diseases including multiple sclerosis. Therefore, the development of treatment strategies controlling the generation and expansion of these effector cells is of high interest. Frankincense, the resin from trees of the genus Boswellia, and particularly its prominent bioactive compound acetyl-11-keto-β-boswellic acid (AKBA), have potent anti-inflammatory properties. Here, we demonstrate that AKBA is able to reduce the differentiation of human CD4(+) T cells to Th17 cells, while slightly increasing Th2- and Treg-cell differentiation. Furthermore, AKBA reduces the IL-1β-triggered IL-17A release of memory Th17 cells. AKBA may affect IL-1β signaling by preventing IL-1 receptor-associated kinase 1 phosphorylation and subsequently decreasing <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> phosphorylation at Ser727, which is required for Th17-cell differentiation. The effects of AKBA on Th17 differentiation and IL-17A release make the compound a good candidate for potential treatment of Th17-driven diseases. </div></details><details><summary>TH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28612433">28612433</a><div class="entities" style="line-height: 2.5"><h3>Musculin inhibits human T-helper 17 cell response to interleukin 2 by controlling STAT5B activity.</h3></br>We recently demonstrated that human T-helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) 17 cells, unlike Th1 cells, do not proliferate in response to T cell receptor stimulation, mainly because of their reduced capacity to produce and respond to IL-2. In this study, we show that their lower responsiveness to IL-2 is due to the selective expression of Musculin (MSC), a member of the basic helix-loop-helix transcription factors. We show that MSC expression in human Th17 cells is retinoic acid orphan receptor (ROR)γt-dependent, and allows the upregulation of PPP2R2B, a regulatory member of the protein phosphatase 2A (PP2A) enzyme. High PPP2R2B levels in human Th17 cells were responsible for the reduced STAT5B Ser-193 phosphorylation upon IL-2 signalling and, therefore, impaired STAT5B DNA binding and transcriptional activity on IL-2 target genes. PP2A, observed in Th17 cells, controls also <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, dephosphorylating Ser727, thus increasing its activity that plays a crucial role in Th17 development and/or maintenance. Thus, our findings identify an additional mechanism responsible for the limited expansion of human Th17 cells, and could provide a further explanation for the rarity of these cells in inflamed tissues.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28213589">28213589</a><div class="entities" style="line-height: 2.5"><h3>SH479, a Betulinic Acid Derivative, Ameliorates Experimental Autoimmune Encephalomyelitis by Regulating the T Helper 17/Regulatory T Cell Balance.</h3></br>CD4+  T helper cells, especially T helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> 17) cells, combined with i<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    mmune regulatory network dysfunction, play key rol    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>es<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">     in a    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>utoimmune diseases including multiple sclerosis (MS). Betulinic acid (BA), a natural pentacyclic triterpenoid, has been reported to be involved in anti-inflammation, in particular having an inhibitory effect on proinflammatory cytokine interleukin 17 (IL-17) and interferon-<i>γ</i> (IFN-<i>γ</i>) production. In this study, we screened BA derivatives and found a BA derivative, SH479, that had a greater inhibitory effect on TH 17 differentiation. Our further analysis showed that SH479 had a greater inhibitory effect on TH 17 and TH 1, and a more stimulatory effect on regulatory T (Treg) cells. To evaluate the effects of SH479 on autoimmune diseases in vivo, we employed the extensively used MS mouse model experimental autoimmune encephalomyelitis (EAE). Our results showed that SH479 ameliorated clinical and histologic signs of EAE in both prevention and therapeutic protocols by regulating the TH 17/Treg balance. SH479 dose-dependently reduced splenic lymphocyte proinflammatory factors and increased anti-inflammatory factors. Moreover, SH479 specifically inhibited splenic lymphocyte viability from EAE mice but not normal splenic lymphocyte viability. At the molecular level, SH479 inhibited TH 17 differentiation by regulating signal transducer and activator of transcription-3 (STAT3) phosphorylation, DNA binding activity, and recruitment to the <i>Il-17a</i> promoter in CD4+  T cells. Furthermore, SH479 promoted the STAT5 signaling pathway and inhibited the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-<i>κ</i>B) signaling pathway. Together, our data demonstrated that SH479 ameliorated EAE by regulating the TH 17/Treg balance through inhibiting the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and NF-<i>κ</i>B pathways while activating the STAT5 pathway, suggesting that SH479 is a potential novel drug candidate for autoimmune diseases including MS.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27225664">27225664</a><div class="entities" style="line-height: 2.5"><h3>Cucurbitacin E Potently Modulates the Activity of Encephalitogenic Cells.</h3></br>Cucurbitacin E (CucE) is a highly oxidized steroid consisting of a tetracyclic triterpene. It is a member of a Cucurbitacin family of biomolecules that are predominantly found in Cucurbitaceae plants. CucE has already been identified as a potent anti-inflammatory compound. Here, its effects on CD4(+) T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells and macrophages, as the major encephalitogenic cells in the autoimmunity of the central nervous system, were investigated. Production of major pathogenic Th cell cytokines: interferon-gamma and interleukin-17 were inhibited under the influence of CucE. The effects of CucE on CD4(+) T cells were mediated through the modulation of aryl hydrocarbon receptor, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, NFκB, p38 MAPK, and miR-146 signaling. Further, production of nitric oxide and reactive oxygen species, as well as phagocytic ability, were inhibited in macrophages treated with CucE. These results imply that CucE possesses powerful antiencephalitogenic activity. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/23555662">23555662</a><div class="entities" style="line-height: 2.5"><h3>Tissue inhibitor of metalloproteinase 1 is preferentially expressed in Th1 and Th17 T-helper cell subsets and is a direct STAT target gene.</h3></br>CD4(+) T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells differentiate into distinct effector subsets that are critical for host defense, but are also implicated in the pathogenesis of autoimmune disorders. Thelper17 (Th17) cells in particular are emerging as important drivers of multiple diseases including psoriasis, spondyloarthropathy and multiple sclerosis. To gain insight into the function of Th17 cells, we performed transcriptional profiling in hopes of elucidating products not previously recognized as being functionally relevant in these T cells. Herein, we demonstrate that tissue inhibitor of metalloproteinase 1 (TIMP1), a secreted protein with pleiotropic effects on cellular growth, survival and integrity of the extracellular matrix, is preferentially produced by Th17 and Th1 cells. We further show that Th1 and Th17 cell TIMP1 regulation follows separate mechanisms with a requirement for STAT4 in the former and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in the latter. Finally, we demonstrate that when restricted to T cells, expression of TIMP1 promotes neuropathology in experimental allergic encephalomyelitis.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/23403044">23403044</a><div class="entities" style="line-height: 2.5"><h3>Blood CD4+CD45RO+CXCR5+ T cells are decreased but partially functional in <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    signal transducer and activator of transcription 3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> deficiency.</h3></br>The generation of high-affinity antibodies requires the presence of a population of CD4+ T cells (follicular <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> [TFH] cells) in the lymph node follicles. These cells differ from TH1, TH2, and TH17 effector cells in that they strongly express activation markers and the chemokine receptor CXCR5 and secrete large amounts of IL-21 and CXCL13. Small numbers of nonactivated CD4+CD45RO+CXCR5+ T cells are also found in the blood.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21710691">21710691</a><div class="entities" style="line-height: 2.5"><h3>The molecular pathogenesis of STAT3-driven gastric tumourigenesis in mice is independent of IL-17.</h3></br>Chronic activation of the gastric m<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    ucosa    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>l adaptive immune response is a characteristic trait of gastric cancer. It has recently emerged that a new class of T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, defined by their ability to<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">     produc    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>e interleukin (IL)-17A (Th17), <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    is as    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>sociated with a host of inflammatory responses, including gastritis. However, the role of these Th17 cells in the pathogenesis of gastric cancer is less clear. To formally address this, we employed gp130(F/F) mice, which spontaneously develop gastric inflammation-associated tumours akin to human intestinal-type gastric cancer. At the molecular level, these tumours demonstrate hyper-activation of the latent transcription factor signal transducer and activator of transcription (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT)3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> via the IL-6 cytokine family member, IL-11. In gp130(F/F) mice, the generation of Th17 cells, as well as the gastric expression of IL-17a and other Th17-related factors (Rorγt, IL-23), were augmented compared to wild-type gp130(+/+) mice. Consistent with a role for IL-6 and STAT3 in regulating IL-17A, increased Th17 generation and gastric expression of Th17-related factors in gp130(F/F) mice were reduced to wild-type levels in gp130(F/F) :Stat3(-/+) mice displaying normalized STAT3 activity, and also in gp130(F/F) :IL-6(-/-) mice. Importantly, genetic ablation of IL-17A in gp130(F/F) :IL-17a(-/-) mice did not suppress the initiation and growth of gastric tumours. Furthermore, IL-17A and RORC gene expression was strongly increased in human gastric biopsies from patients with gastritis, but not gastric cancer. Collectively, our data suggest that increased expression of Th17-related factors does not correlate with the molecular pathogenesis of gastric tumourigenesis.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27931536">27931536</a><div class="entities" style="line-height: 2.5"><h3>Advances in atopic dermatitis in 2015.</h3></br>This review aims to highlight recently published articles on atopic dermatitis (AD). Updated are the insights into epidemiology, pathology, diagnostics, and therapy. Epidemiologic studies have revealed a positive correlation between AD and systemic conditions, such as rheumatoid arthritis, inflammatory bowel disease, and neonatal adiposity. Pathologic findings highlight the involvement of novel barrier factors (desmoplakin and claudin), novel immune cell subsets (pathogenic effector <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> 2 cells and group 2 innate lymphoid cells), and differential skewing of helper T cells (eg, TH 17 dominance in Asians with AD). As diagnostics, noninvasive examinations of the transepidermal water loss of neonates, the density of epidermal Staphylococcus species, and the gut flora might prognosticate the onset of AD. As for therapy, various methods are proposed, including conventional (petrolatum and UV) and molecule-oriented regimens targeting Janus kinase, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    signal transducer and activator of transcription 3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, extracellular signal-regulated kinase, sirtuin 1, or aryl hydrocarbon receptor.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/25123282">25123282</a><div class="entities" style="line-height: 2.5"><h3>Complex interactions of transcription factors in mediating cytokine biology in T cells.</h3></br>T-helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells play critical roles within the mammalian immune system, and the differentiation of naive CD4(+) T cells into distinct T-helper subsets is critical for normal immunoregulation and host defense. These carefully regulated differentiation processes are controlled by networks of cytokines, transcription factors, and epigenetic modifications, resulting in the generation of multiple CD4(+) T cell subsets, including Th1, Th2, Th9, Th17, Treg, and Tfh cells. In this review, we discuss the roles of transcription factors in determining the specific type of differentiation and in particular the role of interleukin-2 (IL-2) in promoting or inhibiting Th differentiation. In addition to discussing master regulators and subset-specific transcription factors for distinct T-helper cell populations, we focus on signal transducer and activator of transcription (STAT) proteins and on the cooperative action of interferon regulatory factor 4 (IRF4) with activator protein 1 (AP-1) family proteins and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in the assembly of complexes that broadly influence T cell differentiation. </div></details><details><summary>TH1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28683082">28683082</a><div class="entities" style="line-height: 2.5"><h3>The herbal decoction modified Danggui Buxue Tang attenuates immune-mediated bone marrow failure by regulating the differentiation of T lymphocytes in an immune-induced aplastic anemia mouse model.</h3></br>Angelicae Sinensis, Radix Astragali and Rhizoma Coptidis are all herbs of modified Danggui Buxue Tang (DGBX) and are extensively applied herbs in traditional Chinese medicine for the treatment of anemia and inflammation. In this study, immune-induced AA mice were used as an animal model, and the immunosuppressive agent, Ciclosporin A (CsA), was used as a positive control. Multiple pro-inflammatory cytokines were examined by bead-based multiplex flow cytometry. The T cell subsets were assessed using a fluorescence-activated cell sorter (FACS). Western blot analysis was used to estimate the protein expression levels of specific transcription factors for T helper cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>, Th2 and Th17) and key molecules of the Janus-activated kinase (Jak)/signal transducer and activator of transcription (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) signaling pathway. DGBX treatment could significantly increase the production of whole blood cells in peripheral blood (PB); inhibit the expansion of Th1 and Th17 cells; increase the differentiation of Th2 and Tregs cells; regulate the expression levels of T-bet, GATA-3, RORγ and proinflammatory cytokines; and decrease the expression levels of key molecules in the Jak/Stat signaling pathway. These results indicate that DGBX can regulate the differentiation of T lymphocytes, resulting in immunosuppressive and hematogenic functions on AA mice. DGBX might be a good candidate for inclusion in a randomized study for AA with more data on the possible side effects and doses used in humans. Ultimately, it may be used for applications of traditional medicine against AA in modern complementary and alternative immunosuppressive therapeutics.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27221197">27221197</a><div class="entities" style="line-height: 2.5"><h3>MicroRNAs: New regulators of IL-22.</h3></br>Interleukin-22 (IL-22) is a cytokine that belongs to the IL-10 family of interleukins. It can be produced by T helper 22 (Th22) cells, T helper 1 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, T helper 17 (Th17) cells, natural killer 22 (NK22) cells, natural killer T (NKT) cells, innate lymphoid cells (ILCs), and γδ T cells. IL-22 acts via binding to a heterodimeric transmembrane receptor complex that consists of IL-22R1 and IL-10R2 and mainly contributes to the tissue repair and host defense. Transcription factors such as retinoid orphan receptor γt (RORγt) and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    signal transducer and activator of transcription 3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>), have been reported to play important roles in regulation of IL-22 expression. Recently, it has been demonstrated in several studies that microRNAs (miRNAs) potently regulate expression of interleukins, including production of IL-22. Here, we review current knowledge about regulators of IL-22 expression with a particular emphasis on the role of miRNAs.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/24469975">24469975</a><div class="entities" style="line-height: 2.5"><h3>Boswellic acids reduce Th17 differentiation via blockade of IL-1β-mediated IRAK1 signaling.</h3></br>Interferon-gamma producing CD4(+) T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells and IL-17-producing CD4(+) T (Th17) cells are involved in the pathogenesis of several autoimmune diseases including multiple sclerosis. Therefore, the development of treatment strategies controlling the generation and expansion of these effector cells is of high interest. Frankincense, the resin from trees of the genus Boswellia, and particularly its prominent bioactive compound acetyl-11-keto-β-boswellic acid (AKBA), have potent anti-inflammatory properties. Here, we demonstrate that AKBA is able to reduce the differentiation of human CD4(+) T cells to Th17 cells, while slightly increasing Th2- and Treg-cell differentiation. Furthermore, AKBA reduces the IL-1β-triggered IL-17A release of memory Th17 cells. AKBA may affect IL-1β signaling by preventing IL-1 receptor-associated kinase 1 phosphorylation and subsequently decreasing <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> phosphorylation at Ser727, which is required for Th17-cell differentiation. The effects of AKBA on Th17 differentiation and IL-17A release make the compound a good candidate for potential treatment of Th17-driven diseases. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/23203924">23203924</a><div class="entities" style="line-height: 2.5"><h3>Early growth response gene-2 controls IL-17 expression and Th17 differentiation by negatively regulating Batf.</h3></br>Early growth response gene (Egr)-2 is important for the maintenance of T cell homeostasis and controls the development of autoimmune disease. However, the underlying mechanisms are unknown. We have now discovered that Egr-2, which is induced by TGF-β and IL-6, negatively regulates the expression of IL-17, but not IL-2 or IFN-γ, in effector T cells. In the absence of Egr-2, CD4 T cells produce high levels of Th17 cytokines, which renders mice susceptible to experimental autoimmune encephalomyelitis induction. T cells lacking Egr-2 show increased propensity for Th17, but not <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> or Th2, differentiation. Control of IL-17 expression and Th17 differentiation by Egr-2 is due to inhibition of Batf, a transcription factor that regulates IL-17 expression and Th17 differentiation. Egr-2 interacts with Batf in CD4 T cells and suppresses its interaction with DNA sequences derived from the IL-17 promoter, whereas the activation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and expression of retinoic acid-related orphan receptor γt are unchanged in Th17 cells in the absence of Egr-2. Thus, Egr-2 plays an important role to intrinsically control Th17 differentiation. We also found that CD4 T cells from multiple sclerosis patients have reduced expression of Egr-2 and increased expression of IL-17 following stimulation with anti-CD3 in vitro. Collectively, our results demonstrate that Egr-2 is an intrinsic regulator that controls Th17 differentiation by inhibiting Batf activation, which may be important for the control of multiple sclerosis development.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/20032993">20032993</a><div class="entities" style="line-height: 2.5"><h3>Circulating Th17, Th22, and Th1 cells are increased in psoriasis.</h3></br>Th17, Th22, and Th1 cells are detected in psoriatic skin lesions and implicated in psoriasis pathogenesis, but inflammatory T cell numbers in blood, as well as the relative importance of each cell type, is unclear. Using 7-color flow cytometry, circulating Th17, Th22, and Th1 cells were quantified in 21 untreated psoriatics and 17 healthy individuals. CCR6 was the best cell surface marker for IL-17A+ cells when compared with IL-23R or CD161. CCR6+, IL-17A+, IL-22+, CCR6+IL-17A+, CCR6+IL-22+, CCR6+tumor necrosis factor-alpha+, IL-17A+IFN-gamma-, IL-17A+IL-22+IFN-gamma-, and IL-17A+IL-22-IFN-gamma- cells were increased in psoriatics (all values P<0.001), indicating elevations in circulating Th17 cells, using multiple criteria to define these cells. Th22 (IL-17A-IL-22+IFN-gamma-, P<0.05) and <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> (IL-17A-IFN-gamma+, P<0.05) cells were also increased in psoriatics, but to a lesser extent. Inhibition of either NF-kappaB or <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in vitro blocked cytokine production by both Th17 and Th1 cells. Circulating levels of Th17 and Th1 cells decreased in a subset of five psoriasis patients serially evaluated following induction therapy with infliximab. In summary, elevated numbers of circulating inflammatory T cells may contribute to cutaneous inflammation and systemic inflammatory disease that occurs in individuals with psoriasis.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/17361203">17361203</a><div class="entities" style="line-height: 2.5"><h3>Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response.</h3></br>Interferon lambda-1 (IFN-lambda1/IL-29) is a member of the Type-III interferon family, which contains three ligands: IFN-lambda1, 2 and 3. These three ligands use the same unique heterodimeric receptor composed of CRF2-12 (IFN-lambda-R1/IL-28Ralpha) and CRF2-4 (IL10-R-beta) chains. Like their close relatives, the Type-I interferons, IFN-lambda1, 2 and 3, promote the phosphorylation of STAT1 and STAT2, induce the ISRE3 complex, elevate OAS and MxA expression and exhibit antiviral activity in vitro. Their use of the IL10-R-beta chain and their ability to phosphorylate <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, STAT4 and STAT5 suggested that they may also exhibit immunomodulatory activity; their antiviral action led us to hypothesize that this activity might be directed toward the Th1/Th2 system. Here, we have demonstrated that IFN-lambda1 altered the activity of Th cells in three separate experimental systems: (i) mitogen stimulation, (ii) mixed-lymphocyte reaction (MLR) and (iii) stimulation of naive T cells by monocyte-derived dendritic cells (mDC). In Con-A stimulation assays, the inclusion of IFN-lambda1 consistently led to markedly diminished levels of secreted interleukin (IL-13) with occasional coincident, modest elevation of secreted IFN-gamma. IL-13 secretion was 100-fold more sensitive to IFN-lambda1 than was IFN-gamma secretion. These observations were also made in the allogeneic two-way MLR. IFN-lambda1 was able to alter cytokine-mediated Th biasing and when naive T cells were exposed to allogeneic mDC that had been matured in the presence of IFN-lambda1, secreted IL-13 was again markedly and consistently reduced, whereas secreted IFN-gamma was largely unaltered. These functions were independent of IL-10. Our data support a hitherto unsuspected role for IFN-lambda1 in modulating the development of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells, with an apparent emphasis on the diminution of IL-13 secretion.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/19132915">19132915</a><div class="entities" style="line-height: 2.5"><h3>IL-17 and Th17 Cells.</h3></br>CD4+ T cells, upon activation and expansion, develop into different T helper cell subsets with different cytokine profiles and distinct effector functions. Until recently, T cells were divided into <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> or Th2 cells, depending on the cytokines they produce. A third subset of IL-17-producing effector T helper cells, called Th17 cells, has now been discovered and characterized. Here, we summarize the current information on the differentiation and effector functions of the Th17 lineage. Th17 cells produce IL-17, IL-17F, and IL-22, thereby inducing a massive tissue reaction owing to the broad distribution of the IL-17 and IL-22 receptors. Th17 cells also secrete IL-21 to communicate with the cells of the immune system. The differentiation factors (TGF-beta plus IL-6 or IL-21), the growth and stabilization factor (IL-23), and the transcription factors (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, RORgammat, and RORalpha) involved in the development of Th17 cells have just been identified. The participation of TGF-beta in the differentiation of Th17 cells places the Th17 lineage in close relationship with CD4+CD25+Foxp3+ regulatory T cells (Tregs), as TGF-beta also induces differentiation of naive T cells into Foxp3+ Tregs in the peripheral immune compartment. The investigation of the differentiation, effector function, and regulation of Th17 cells has opened up a new framework for understanding T cell differentiation. Furthermore, we now appreciate the importance of Th17 cells in clearing pathogens during host defense reactions and in inducing tissue inflammation in autoimmune disease.</div></details><details><summary>TH2</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28683082">28683082</a><div class="entities" style="line-height: 2.5"><h3>The herbal decoction modified Danggui Buxue Tang attenuates immune-mediated bone marrow failure by regulating the differentiation of T lymphocytes in an immune-induced aplastic anemia mouse model.</h3></br>Angelicae Sinensis, Radix Astragali and Rhizoma Coptidis are all herbs of modified Danggui Buxue Tang (DGBX) and are extensively applied herbs in traditional Chinese medicine for the treatment of anemia and inflammation. In this study, immune-induced AA mice were used as an animal model, and the immunosuppressive agent, Ciclosporin A (CsA), was used as a positive control. Multiple pro-inflammatory cytokines were examined by bead-based multiplex flow cytometry. The T cell subsets were assessed using a fluorescence-activated cell sorter (FACS). Western blot analysis was used to estimate the protein expression levels of specific transcription factors for T helper cells (Th1, Th2 and Th17) and key molecules of the Janus-activated kinase (Jak)/signal transducer and activator of transcription (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) signaling pathway. DGBX treatment could significantly increase the production of whole blood cells in peripheral blood (PB); inhibit the expansion of Th1 and Th17 cells; increase the differentiation of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Tregs cells; regulate the expression levels of T-bet, GATA-3, RORγ and proinflammatory cytokines; and decrease the expression levels of key molecules in the Jak/Stat signaling pathway. These results indicate that DGBX can regulate the differentiation of T lymphocytes, resulting in immunosuppressive and hematogenic functions on AA mice. DGBX might be a good candidate for inclusion in a randomized study for AA with more data on the possible side effects and doses used in humans. Ultimately, it may be used for applications of traditional medicine against AA in modern complementary and alternative immunosuppressive therapeutics.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27858144">27858144</a><div class="entities" style="line-height: 2.5"><h3>Th9 and other IL-9-producing cells in allergic asthma.</h3></br>Allergic asthma is a worldwide increasing chronic disease of the airways which affects more than 300 million people. It is associated with increased IgE, mast cell activation, airway hyperresponsiveness (AHR), mucus overproduction and remodeling of the airways. Previously, this pathological trait has been associated with T helper type 2 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. Recently, different CD4+  T cell subsets (Th17, Th9) as well as cells of innate immunity, like mast cells and innate lymphoid cells type 2 (ILC2s), which are all capable of producing the rediscovered cytokine IL-9, are known to contribute to this disease. Regarding Th9 cells, it is known that naïve T cells develop into IL-9-producing cells in the presence of interleukin-4 (IL-4) and transforming growth factor beta (TGFβ). Downstream of IL-4, several transcription factors like signal transducer and activator of transcription 6 (STAT6), interferon regulatory factor 4 (IRF4), GATA binding protein 3 (GATA3), basic leucine zipper transcription factor, ATF-like (BATF) and nuclear factor of activated T cells (NFAT) are activated. Additionally, the transcription factor PU.1, which is downstream of TGFβ signaling, also seems to be crucial in the development of Th9 cells. IL-9 is a pleiotropic cytokine that influences various distinct functions of different target cells such as T cells, B cells, mast cells and airway epithelial cells by activating STAT1, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and STAT5. Because of its pleiotropic functions, IL-9 has been demonstrated to be involved in several diseases, such as cancer, autoimmunity and other pathogen-mediated immune-regulated diseases. In this review, we focus on the role of Th9 and IL-9-producing cells in allergic asthma.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27576175">27576175</a><div class="entities" style="line-height: 2.5"><h3>The paracrine immunomodulatory interactions between the human dental pulp derived mesenchymal stem cells and CD4 T cell subsets.</h3></br>Mesenchymal stem cells (MSCs) have strong immunomodulatory properties, however these properties may show some di<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    fferen    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>ces according to the tissue type of their isolate. In this study we investigated the paracrine interactions between human DP derived MSCs (hDP-MSCs) and the CD4+  T helper cell subsets to establish their immunomodulatory mechanisms. We found that the CD4+ -Tbet+  (Th1) and CD4+ -Gata3+  (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells were suppressed by the hDP-MSCs, but the CD4+ -Stat3+  (Th17) and CD4+ -CD25+ -FoxP3+  (Treg) cells were stimulated. The expressions of T cell specific cytokines interferon gamma (IFN-g), interleukin (IL)-4 and IL-17a decreased, but IL-10 and transforming growth factor beta-1 (TGF-b1) increased with the hDP-MSCs. The expressions of indoleamine-pyrrole 2,3-dioxygenase (IDO), prostaglandin E2 (PGE2), soluble human leukocyte antigen G (sHLA-G) derived from hDP-MSCs slightly increased, but hepatocyte growth factor (HGF) significantly increased in the co-culture groups. According to our findings, the hDP-MSCs can suppress the Th1 and Th2 subsets but stimulate the Th17 and Treg subsets. The <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression of Th17 cells may have been stimulated by the HGF, and thus the pro-inflammatory Th17 cells may have altered into the immunosuppressive regulatory Th17 cells. Further prospective studies are needed to confirm our findings.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/22750414">22750414</a><div class="entities" style="line-height: 2.5"><h3>Human epithelial cells stimulated with Vibrio cholerae produce thymic stromal lymphopoietin and promote dendritic cell-mediated inflammatory Th2 response.</h3></br>Vibrio cholerae induces acute inflammatory response at intestinal epithelial surface; the underlying cellular immune mechanisms for such effects are largely unexplored. Mucosal immune response is controlled by crosstalk between the intestinal epithelial cells (ECs) and dendritic cells (DCs). An EC-derived cytokine thymic stromal lymphopoietin (TSLP) has been found a critical regulator of several human inflammatory conditions. TSLP is highly elevated in ECs stimulated with V. cholerae and its recombinant flagellin (rFlaA). V. cholerae treated human ECs produce DC-attracting chemokine MIP-3α (CCL20). Flagellin, a potent V. cholerae factor was responsible for maximum stimulation of epithelial CCL20 production and subsequent DC activation. Activated DCs express high levels of costimulatory molecules and secrete inflammatory cytokines TNF-α, IL-6 and IL-1β. Bacteria stimulated ECs conditioned DCs to produce Th2 cell-attracting chemokines CCL17 and CCL22. TSLP and other mediators present in the V. cholerae stimulated EC-culture filtrate potently activated DCs, which subsequently primed CD4(+)T cells to differentiate into T helper type 2 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells that produce high amounts of IL-4, IL-13 and TNF-α and low IFN-γ. TSLP-induced proinflammatory response in DCs involved the transcriptional mechanisms, MAPKs (ERK1/2, p38 and JNK) and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> activation. This study suggests TSLP and other mediators released from ECs in response to V. cholerae colonization actively influence DCs in initiating inflammatory response.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21646394">21646394</a><div class="entities" style="line-height: 2.5"><h3>SOCS2 regulates T helper type 2 differentiation and the generation of type 2 allergic responses.</h3></br>The incidence of allergy and asthma in developed countries is on the increase and this trend looks likely to continue. CD4(+) T helper 2 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are major drivers of these diseases and their commitment is controlled by cytokines such as interleukin 4, which are in turn regulated by the suppressor of cytokine signaling (SOCS) proteins. We report that SOCS2(-/-) CD4(+) T cells show markedly enhanced Th2 differentiation. SOCS2(-/-) mice, as well as RAG-1(-/-) mice transferred with SOCS2(-/-) CD4(+) T cells, exhibit elevated type 2 responses after helminth antigen challenge. Moreover, in in vivo models of atopic dermatitis and allergen-induced airway inflammation, SOCS2(-/-) mice show significantly elevated IgE, eosinophilia, type 2 responses, and inflammatory pathology relative to wild-type mice. Finally, after T cell activation, markedly enhanced STAT6 and STAT5 phosphorylation is observed in SOCS2(-/-) T cells, whereas <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> phosphorylation is blunted. Thus, we provide the first evidence that SOCS2 plays an important role in regulating Th2 cell expansion and development of the type 2 allergic responses.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/18172584">18172584</a><div class="entities" style="line-height: 2.5"><h3>Th17 cells: a new fate for differentiating helper T cells.</h3></br>Classically naïve CD4(+) have been thought to differentiate into two possible lineages, T helper 1 (Th1) or T helper 2 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. Within this paradigm the pathogenesis of autoimmunity was suggested to predominantly relate to Th1 cells and the production of IFN-gamma. However, there were many aspects of this model that did not seem to fit, not the least of which was that IFN-gamma was protective in some models of autoimmunity. During the past 2 years, remarkable progress has been made to characterize a new lineage of helper T cells. Designated Th17 cells, this lineage selectively produces proinflammatory cytokines including IL-17, IL-21, and IL-22. In the mouse, the differentiation of this new lineage is initiated by TGFbeta-1 and IL-6 and IL-21, which activate <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and induce the expression of the transcription factor retinoic acid-related orphan receptor (RORgammat). IL-23, which also activates <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, apparently serves to maintain Th17 cells in vivo. In human cells, IL-1, IL-6, and IL-23 promote human Th17 differentiation, but TGFbeta-1 is reportedly not needed. Emerging data have suggested that Th17 plays an essential role in the host defense against extracellular bacteria and fungi and in pathogenesis of autoimmune diseases. Selectively targeting the Th17 lineage may be beneficial for the treatment of inflammatory and autoimmune diseases.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/9095224">9095224</a><div class="entities" style="line-height: 2.5"><h3>Regulation of interleukin-12 signalling during T helper phenotype development.</h3></br>The experiments described above have allowed us to define the molecular events in IL-12 signalling. Within minutes after IL-12 treatment of responsive cells, Stat1, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, and Stat4 are tyrosine phosphorylated. These molecules form nuclear DNA-binding complexes consisting of homodimeric Stat1 and heterodimeric Stat3-Stat4 complexes. In a murine in vitro phenotype development model, T cells rapidly and selectively lose their capacity to respond to IL-12 upon acquisition of the Th2 phenotype. This hyporesponsiveness is manifested by the inability of IL-12 to induce IFN gamma production in differentiated Th2 cells, as well as the inability of IL-12 to induce the activation of Stat4. Despite the functional defect of IL-12 signalling in Th2 cells, all known components of the IL-12 signal transduction pathway are present. We speculate that in Th2 cells, the second receptor chain may be absent or one of the other components may be modified. Genetic experiments in Balb/c and B10.D2 strains of mice have demonstrated several differences in T helper differentiation in vitro. Stimulation of T cells under neutral conditions results in a bias of Balb/c T cells toward the <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> extreme and B10 T cells toward the Th1 extreme of cytokine production. Following stimulation under neutral conditions, B10 T cells retain the ability to respond to IL-12 while Balb/c T cells lose IL-12 responsiveness. Mating experiments have demonstrated that the B10 genetic effect is dominant in F1 mice. Analysis of backcrossed animals has suggested that the ability to respond to IL-12 in the secondary stimulation may be controlled by a single dominant B10 gene. The results we describe may have profound implications for allergy. Since allergic responses are largely due to the activation of the Th2 subset of T lymphocytes, a better understanding of T cell phenotype development may reveal multiple targets for therapeutic intervention. First, a better understanding of Th1 phenotype induction in response to IL-12 may allow prevention of in vivo allergic responses using pharmacological tools which bias allergen-specific responses to the Th1 subset. Second, a molecular explantation of why Th2 cells fail to reverse phenotype in response to IL-12 may allow treatment of atopic individuals to remove the disease-promoting T lymphocyte compartment. Finally, a better understanding of the basis for genetic differences in murine T helper cell differentiation may allow us to identify a causative genetic element in humans, yielding better diagnostic and therapeutic methods.</div></details><details><summary>TFH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28263097">28263097</a><div class="entities" style="line-height: 2.5"><h3>Transcriptional and epigenetic regulation of follicular T-helper cells and their role in autoimmunity.</h3></br>T-follicular helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are a specialized subset of T cells that provide help to B cells and promote the formation of germinal centers (GCs). Tfh cells transmit important signals to B cells that drive class switch recombination, somatic hyper-mutation, the generation of high-affinity antibodies, immunological memory and th<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    eir d    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>ifferentiation into plasma cells or memory B cells in the GCs. Tfh-cell differentiation is regulated by the coordinated functions of distinct cytokines, including interleukin (IL)-6, IL-21, IL-12, IL-23, IL-2, IL-7 and transforming growth factor-β (TGF-β), as well as transcription factors, including B-cell lymphoma 6 protein (Bcl-6), Signal transducers and activators of transcription (STAT)1, STAT3, STAT4, B-cell activating transcription factor (Batf), interferon regulatory factor 4 (IRF4), v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog (C-Maf), T cell-specific transcription factor 1 (TCF-1) and Achaete-scute homolog 2 (Acl2), which have been shown to form a complex transcriptional network. In addition, increasing evidence indicates that epigenetic regulations, such as DNA methylation, histone modifications and non-coding RNA regulations, also coordinately control the differentiation and function of Tfh cells along with transcription factors. Furthermore, abnormalities in the regulation of Tfh cells have been associated with several autoimmune diseases, such as systemic lupus erythematosus (SLE), multiple sclerosis (MS) and rheumatoid arthritis (RA). Herein, this review aims to summarize the coordinate regulation and interaction of transcription factors, cytokines and epigenetic modifications that control Tfh-cell differentiation as well as the mechanism of dysregulation of Tfh cells in pathogenesis of autoimmune diseases, which highlight potential therapeutic targets.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27436361">27436361</a><div class="entities" style="line-height: 2.5"><h3>ROCK2 signaling is required to induce a subset of T follicular helper cells through opposing effects on STATs in autoimmune settings.</h3></br>Rho-associated kinase 2 (ROCK2) determines the balance between human T helper 17 (TH17) cells and regulatory T (Treg) cells. We investigated its role in the generation of T follicular helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TFH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, which help to generate antibody-producing B cells under normal and autoimmune conditions. Inhibiting ROCK2 in normal human T cells or peripheral blood mononuclear cells from patients with active systemic lupus erythematosus (SLE) decreased the number and function of TFH cells induced by activation ex vivo. Moreover, inhibition of ROCK2 activity decreased the abundance of the transcriptional regulator Bcl6 (B cell lymphoma 6) and increased that of Blimp1 by reducing the binding of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    signal transducer and activator of transcription 3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) and increasing that of STAT5 to the promoters of the genes Bcl6 and PRDM1, respectively. In the MRL/lpr murine model of SLE, oral administration of the selective ROCK2 inhibitor KD025 resulted in a twofold reduction in the numbers of TFH cells and antibody-producing plasma cells in the spleen, as well as a decrease in the size of splenic germinal centers, which are the sites of interaction between TFH cells and B cells. KD025-treated mice showed a substantial improvement in both histological and clinical scores compared to those of untreated mice and had reduced amounts of Bcl6 and phosphorylated <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, as well as increased STAT5 phosphorylation. Together, these data suggest that ROCK2 signaling plays a critical role in controlling the development of TFH cells induced by autoimmune conditions through reciprocal regulation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and STAT5 activation.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27401342">27401342</a><div class="entities" style="line-height: 2.5"><h3>Unique and shared signaling pathways cooperate to regulate the differentiation of human CD4+ T cells into distinct effector subsets.</h3></br>Naive CD4(+) T cells differentiate into specific effector subsets-Th1, Th2, Th17, and T follicular helper (Tfh)-that provide immunity against pathogen infection. The signaling pathways involved in generating these effector cells are partially known. However, the effects of mutations underlying human primary immunodeficiencies on these processes, and how they compromise specific immune responses, remain unresolved. By studying individuals with mutations in key signaling pathways, we identified nonredundant pathways regulating human CD4(+) T cell differentiation in vitro. IL12Rβ1/TYK2 and IFN-γR/STAT1 function in a feed-forward loop to induce Th1 cells, whereas IL-21/IL-21R/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> signaling is required for Th17, Tfh, and IL-10-secreting cells. IL12Rβ1/TYK2 and NEMO are also required for Th17 induction. Strikingly, gain-of-function STAT1 mutations recapitulated the impact of dominant-negative <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mutations on <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th17 cells, revealing a putative inhibitory effect of hypermorphic STAT1 over <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. These findings provide mechanistic insight into the requirements for human T cell effector function, and explain clinical manifestations of these immunodeficient conditions. Furthermore, they identify molecules that could be targeted to modulate CD4(+) T cell effector function in the settings of infection, vaccination, or immune dysregulation.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/23403044">23403044</a><div class="entities" style="line-height: 2.5"><h3>Blood CD4+CD45RO+CXCR5+ T cells are decreased but partially functional in <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    signal transducer and activator of transcription 3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> deficiency.</h3></br>The generation of high-affinity antibodies requires the presence of a population of CD4+ T cells (follicular TH [<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TFH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>] cells) in the lymph node follicles. These cells differ from TH1, TH2, and TH17 effector cells in that they strongly express activation markers and the chemokine receptor CXCR5 and secrete large amounts of IL-21 and CXCL13. Small numbers of nonactivated CD4+CD45RO+CXCR5+ T cells are also found in the blood.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/22403255">22403255</a><div class="entities" style="line-height: 2.5"><h3>Functional <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> deficiency compromises the generation of human T follicular helper cells.</h3></br>T follicular helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are critical for providing the necessary signals to induce differentiation of B cells into memory and Ab-secreting cells. Accordingly, it is important to identify the molecular requirements for Tfh cell development and function. We previously found that IL-12 mediates the differentiation of human CD4(+) T cells to the Tfh lineage, because IL-12 induces naive human CD4(+) T cells to acquire expression of IL-21, BCL6, ICOS, and CXCR5, which typify Tfh cells. We have now examined CD4(+) T cells from patients deficient in IL-12Rβ1, TYK2, STAT1, and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> to further explore the pathways involved in human Tfh cell differentiation. Although STAT1 was dispensable, mutations in IL12RB1, TYK2, or <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> compromised IL-12-induced expression of IL-21 by human CD4(+) T cells. Defective expression of IL-21 by STAT3-deficient CD4(+) T cells resulted in diminished B-cell helper activity in vitro. Importantly, mutations in <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, but not IL12RB1 or TYK2, also reduced Tfh cell generation in vivo, evidenced by decreased circulating CD4(+)CXCR5(+) T cells. These results highlight the nonredundant role of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in human Tfh cell differentiation and suggest that defective Tfh cell development and/or function contributes to the humoral defects observed in STAT3-deficient patients.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/22250083">22250083</a><div class="entities" style="line-height: 2.5"><h3>Cutting edge: IL-21 derived from human follicular helper T cells acts as a survival factor for secondary lymphoid organ, but not for bone marrow, plasma cells.</h3></br>IL-21 induces the differentiation of activated B lymphocytes into plasma cells (PC), but its direct effect on PC remains uncertain. This study analyzes the role of IL-21 on human in vivo-generated PC. IL-21R was clearly expressed on PC from the human tonsil, the lymph node, and the spleen (secondary lymphoid organs [SLO]) but barely on terminally mature bone marrow PC. IL-21 enhanced Ig secretion by isolated SLO PC but not bone marrow PC. Tonsillar T follicular helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) lymphocytes are known to secrete IL-21. Purified Tfh cells induced a marked increase of Ig production by tonsillar PC, and this effect was impaired when endogenous IL-21 production was blocked. IL-21 provoked a rapid and transient phosphorylation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in tonsillar PC. Tfh cells or exogenous IL-21 reduce tonsillar PC apoptosis and increases PC recovery but does not modify their nonproliferating status. These results suggest that IL-21 derived from Tfh cells acts as a survival factor for SLO PC in vivo.</div></details><details><summary>TEFF</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27149428">27149428</a><div class="entities" style="line-height: 2.5"><h3>Hepatitis C virus-induced myeloid-derived suppressor cells regulate T cell differentiation and function via the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    signal transducer and activator of transcription 3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> pathway.</h3></br>T cells play a pivotal role in controlling viral infection; however, the precise mechanisms responsible for regulating T cell differentiation and function during infections are incompletely understood. In this study, we demonstrated an expansion of myeloid-derived suppressor cells (MDSCs), in particular the monocytic MDSCs (M-MDSCs; CD14(+) CD33(+) CD11b(+) HLA-DR(-/low) ), in patients with chronic hepatitis C virus (HCV) infection. Notably, HCV-induced M-MDSCs express high levels of phosphorylated <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    signal transducer and activator of transcription 3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (pSTAT3) and interleukin-10 (IL-10) compared with healthy subjects. Blocking <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> signalling reduced HCV-mediated M-MDSC expansion and decreased IL-10 expression. Importantly, we observed a significant increase in the numbers of CD4(+) CD25(+) Foxp3(+) regulatory T (Treg) cells following incubation of healthy peripheral blood mononuclear cells (PBMCs) with MDSCs derived from HCV-infected patients or treated with HCV core protein. In addition, depletion of MDSCs from PBMCs led to a significant reduction of Foxp3(+) Treg cells developed during chronic HCV infection. Moreover, depletion of MDSCs from PBMCs significantly increased interferon-γ production by CD4(+) T effector (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Teff    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells derived from HCV patients. These results suggest that HCV-induced MDSCs promote Treg cell development and inhibit Teff cell function, suggesting a novel mechanism for T cell regulation and a new strategy for immunotherapy against human viral diseases.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/24838857">24838857</a><div class="entities" style="line-height: 2.5"><h3>Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T cells.</h3></br>T cell immunoglobulin and mucin domain 3 (TIM-3) is an Ig-superfamily member expressed on IFN-γ-secreting Th1 and Tc1 cells and was identified as a negative regulator of immune tolerance. TIM-3 is expressed by a subset of activated CD4(+) T cells, and anti-CD3/anti-CD28 stimulation increases both the level of expression and the number of TIM-3(+) T cells. In mice, TIM-3 is constitutively expressed on natural regulatory T (Treg) cells and has been identified as a regulatory molecule of alloimmunity through its ability to modulate CD4(+) T cell differentiation. Here, we examined TIM-3 expression on human Treg cells to determine its role in T cell suppression. In contrast to mice, TIM-3 is not expressed on Treg cells ex vivo but is upregulated after activation. While TIM-3(+) Treg cells with increased gene expression of LAG3, CTLA4, and FOXP3 are highly efficient suppressors of effector T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Teff    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, TIM-3(-) Treg cells poorly suppressed Th17 cells as compared with their suppression of Th1 cells; this decreased suppression ability was associated with decreased <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression and phosphorylation and reduced gene expression of IL10, EBI3, GZMB, PRF1, IL1Rα, and CCR6. Thus, our results suggest that TIM-3 expression on Treg cells identifies a population highly effective in inhibiting pathogenic Th1- and Th17-cell responses. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21307288">21307288</a><div class="entities" style="line-height: 2.5"><h3><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> phosphorylation mediates resistance of primary human T cells to regulatory T cell suppression.</h3></br>Human autoimmune diseases are characterized by systemic T cell dysfunction, resulting in chronically activated Th1 and Th17 cells that are inadequately suppressed by regulatory T cells (Tregs). IL-6, which is overexpressed in tissue and serum of patients with autoimmune diseases, inhibits human Treg function. We sought to determine the mechanism for the antitolerogenic properties of IL-6 by examining the signaling pathways downstream of IL-6R in primary human T cells. Inhibition of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> signaling in MLCs containing IL-6 restores Treg-mediated suppression, demonstrating that IL-6-mediated loss of Treg suppression requires phosphorylation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. Cultures in which either effector T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Teffs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) or Tregs were pretreated with <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> inhibitors indicate that phosphorylated (p)Stat3 is required in both T cell populations for IL-6-mediated reversal of Treg function. IL-21, which signals preferentially through pStat3, also reverses Treg suppression, in contrast to IL-27 and IFN-γ, which signal preferentially through Stat1 and do not inhibit Treg function. Interestingly, both Teffs and Tregs respond to IL-6 stimulation through strong <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> phosphorylation with minimal MAPK/Erk activation and moderate Stat1 phosphorylation. Finally, Teffs stimulated strongly through the TCR are also resistant to suppression by Tregs and show concurrent <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> phosphorylation. In these cultures, inhibition of pStat3 restores functional suppression by Tregs. Taken together, our findings suggest that an early dominance of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> signaling, prior to subsequent T cell activation, is required for the loss of functional Treg suppression and that kinase-specific inhibitors may hold therapeutic promise in the treatment of autoimmune and chronic inflammatory diseases.</div></details><details><summary>TH22</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27221197">27221197</a><div class="entities" style="line-height: 2.5"><h3>MicroRNAs: New regulators of IL-22.</h3></br>Interleukin-22 (IL-22) is a cytokine that belongs to the IL-10 family of interleukins. It can be produced by T helper 22 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th22    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, T helper 1 (Th1) cells, T helper 17 (Th17) cells, natural killer 22 (NK22) cells, natural killer T (NKT) cells, innate lymphoid cells (ILCs), and γδ T cells. IL-22 acts via binding to a heterodimeric transmembrane receptor complex that consists of IL-22R1 and IL-10R2 and mainly contributes to the tissue repair and host defense. Transcription factors such as retinoid orphan receptor γt (RORγt) and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    signal transducer and activator of transcription 3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>), have been reported to play important roles in regulation of IL-22 expression. Recently, it has been demonstrated in several studies that microRNAs (miRNAs) potently regulate expression of interleukins, including production of IL-22. Here, we review current knowledge about regulators of IL-22 expression with a particular emphasis on the role of miRNAs.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/22537755">22537755</a><div class="entities" style="line-height: 2.5"><h3>Elevated profiles of Th22 cells and correlations with Th17 cells in patients with immune thrombocytopenia.</h3></br>T-helper (Th) 22 and Th17 cells are implicated in the pathogenesis of autoimmune diseases. However, the role of Th22 cells in the pathophysiology of immune thrombocytopenia (ITP) remains unclear. <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th22    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>, Th17 and Th1 cells in both ITP patients and healthy controls were examined by flow cytometry. Plasma interleukin-22 (IL-22) level was measured by enzyme linked immunosorbent assay (ELISA). Signal transducers and activators of transcription 3 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) and transcription factor RAR-related organ receptor C (RORC) messenger RNA (mRNA) expressions were examined by quantitative reverse transcription polymerase chain reaction (RT-PCR). <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th22    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells, Th17 cells, Th1 cells and plasma IL-22 were significantly higher in ITP patients than in healthy controls. Moreover, Th22 cells showed a positive correlation with the levels of plasma IL-22 as well as Th17 and Th1 cells in ITP patients. Significant up-regulations of both <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and RORC transcription factors were also observed. Additionally, the percentage of Th22 cells was higher in autoantibody-negative ITP patients than in autoantibody-positive patients. Our results demonstrate a possible role of Th22 cells in ITP, and thus, the blockade of IL-22 may be a reasonable therapeutic strategy for ITP.</div></details><details><summary>MAIT</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27167980">27167980</a><div class="entities" style="line-height: 2.5"><h3>Mucosal-Associated Invariant T (MAIT) Cells Are Impaired in Th17 Associated Primary and Secondary Immunodeficiencies.</h3></br>The recently described Mucosal Associated Invariant T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    MAIT    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells mediate specific recognition of bacterial and fungal vitamin B2 metabolites. As innate T cells, they possess broad effector responses, including IFN- including Iproduction, that are comparable to conventional T cell responses. Immunodeficiencies associated with systemic Th17 deficiency may also be compounded by defects in MAIT immunity. We evaluated Th17 immunity in this innate T cell compartment in primary (AD-HIES) and secondary immunodeficiency (thymoma) patients with conventional Th17 deficiency and susceptibility to fungal and bacterial disease. Our results suggest that <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    MAIT    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells are both reduced and functional deficient in <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> deficiency and thymoma patients with IL-12/23 autoantibodies. In contrast, thymoma patients without autoantibodies preserved the normal number and functional MAIT cells.</div></details><details><summary>NKT</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27221197">27221197</a><div class="entities" style="line-height: 2.5"><h3>MicroRNAs: New regulators of IL-22.</h3></br>Interleukin-22 (IL-22) is a cytokine that belongs to the IL-10 family of interleukins. It can be produced by T helper 22 (Th22) cells, T helper 1 (Th1) cells, T helper 17 (Th17) cells, natural killer 22 (NK22) cells, natural killer T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NKT    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, innate lymphoid cells (ILCs), and γδ T cells. IL-22 acts via binding to a heterodimeric transmembrane receptor complex that consists of IL-22R1 and IL-10R2 and mainly contributes to the tissue repair and host defense. Transcription factors such as retinoid orphan receptor γt (RORγt) and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    signal transducer and activator of transcription 3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>), have been reported to play important roles in regulation of IL-22 expression. Recently, it has been demonstrated in several studies that microRNAs (miRNAs) potently regulate expression of interleukins, including production of IL-22. Here, we review current knowledge about regulators of IL-22 expression with a particular emphasis on the role of miRNAs.</div></details><details><summary>TC17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/25259411">25259411</a><div class="entities" style="line-height: 2.5"><h3>Tc17 Cells in Immunity and Systemic Autoimmunity.</h3></br>Tc17 cells-a subset of CD8(+)T cells-have recently been identified that are characterized by the production of interleukin (IL)-17. Cytokines IL-6 and transforming growth factor-beta 1 (TGF-β1) and transcription factors signaling transducers and activators of transcription (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT)3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, retinoic acid receptor-related orphan nuclear receptor gamma (RORγt), and interferon regulatory factor (IRF)4 are necessary for differentiation of Tc17 cells, controlling expression of molecules essential for Tc17 cell trafficking and function. Current human researches have determined the significance of CD161 expression as either a marker of Tc17 cells or as an effector and regulator of Tc17 cell function. Noncytotoxic Tc17 cells possess a high plasticity to convert into IFN-γ producing cells, which exhibit strong cytotoxic activity. The importance of in vivo plasticity of Tc17 cells for the induction of autoimmune diseases has been demonstrated and Tc17 cells potentially represent novel therapeutic targets in autoimmune diseases. The involvement of interleukin (IL)-17-producing CD8(+)T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tc17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) in various conditions, such as infection, cancer, and autoimmune inflammation, has been documented in both humans and mice; however, Tc17 cells have received only marginal attention. Here, we provide an overview of the cytokines and chemokines that characterize the murine and human Tc17 cells. Moreover, we discuss signaling pathways, molecular interactions, and transcriptional events that contribute to Tc17 differentiation and acquisition of effector functions. Also considered is the basis of Tc17 cell plasticity toward the Tc1 lineage, and we suggest that in vivo plasticity of Tc17 cells may be a key feature of Tc17 cell biology in autoimmune diseases. Furthermore, current human researches have revealed that Tc17 cells are different than that in mice because all of them express CD161 and exclusively originate from CD161 precursors present in umbilical cord blood. Finally, we focus on the recent evidence for long-lived Tc17 memory cell populations in mouse models and humans, and their functional roles in mediating disease memory. Hopefully, the information obtained will benefit for developing novel therapeutic strategies. </div></details><details><summary>TH9</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27858144">27858144</a><div class="entities" style="line-height: 2.5"><h3>Th9 and other IL-9-producing cells in allergic asthma.</h3></br>Allergic asthma is a worldwide increasing chronic disease of the airways which affects more than 300 million people. It is associated with increased IgE, mast cell activation, airway hyperresponsiveness (AHR), mucus overproduction and remodeling of the airways. Previously, this pathological trait has been associated with T helper type 2 (Th2) cells. Recently, different CD4+  T cell subsets (Th17, Th9) as well as cells of innate immunity, like mast cells and innate lymphoid cells type 2 (ILC2s), which are all capable of producing the rediscovered cytokine IL-9, are known to contribute to this disease. Regarding Th9 cells, it is known that naïve T cells develop into IL-9-producing cells in the presence of interleukin-4 (IL-4) and transforming growth factor beta (TGFβ). Downstream of IL-4, several transcription factors like signal transducer and activator of transcription 6 (STAT6), interferon regulatory factor 4 (IRF4), GATA binding protein 3 (GATA3), basic leucine zipper transcription factor, ATF-like (BATF) and nuclear factor of activated T cells (NFAT) are activated. Additionally, the transcription factor PU.1, which is downstream of TGFβ signaling, also seems to be crucial in the development of Th9 cells. IL-9 is a pleiotropic cytokine that influences various distinct functions of different target cells such as T cells, B cells, mast cells and airway epithelial cells by activating STAT1, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and STAT5. Because of its pleiotropic functions, IL-9 has been demonstrated to be involved in several diseases, such as cancer, autoimmunity and other pathogen-mediated immune-regulated diseases. In this review, we focus on the role of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th9    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and IL-9-producing cells in allergic asthma.</div></details><details><summary>TREG17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/24511136">24511136</a><div class="entities" style="line-height: 2.5"><h3><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> programs Th17-specific regulatory T cells to control GN.</h3></br>A pathogenic role for Th17 cells in inflammatory renal disease is well established. The mechanisms underlying their counter-regulation are, however, largely unknown. Recently, Th17 lineage-specific regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) that depend on activation of the transcription factor <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> were identified. We studied the function of Treg17 in the nephrotoxic nephritis (NTN) model of crescentic GN. The absence of Treg17 cells in <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3(Cre)×Stat3(fl/fl)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mice resulted in the aggravation of NTN and skewing of renal and systemic immune responses toward Th17. Detailed analysis of Stat3-deficient Tregs revealed that the survival, activation, proliferation, and suppressive function of these cells remained intact. However, Tregs from <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp3(Cre)×Stat3(fl/fl)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mice lacked surface expression of the chemokine receptor CCR6, which resulted in impaired renal trafficking. Furthermore, aggravation of NTN was reversible in the absence of Th17 responses, as shown in <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    CD4(Cre)×Stat3(fl/fl)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mice lacking both Treg17 and Th17 cells, suggesting that Th17 cells are indeed the major target of Treg17 cells. Notably, immunohistochemistry revealed CCR6-bearing Treg17 cells in kidney biopsy specimens of patients with GN. CCR6 expression on human Treg17 cells also appears dependent on <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, as shown by analysis of Tregs from patients with dominant-negative <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mutations. Our data indicate the presence and involvement of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>/STAT3-dependent Treg17 cells that specifically target Th17 cells in murine and human crescentic GN, and suggest the kidney-specific action of these Treg17 cells is regulated by CCR6-directed migration into areas of Th17 inflammation.</div></details></details></td>
    </tr>
    <tr>
      <th>18</th>
      <td>GATA3</td>
      <td>65</td>
      <td>TH2:22, TH1:18, TREG:17, TH:15, TH17:4, γδT:2, TC1:1, TH9:1, THP:1, TREG1:1</td>
      <td>0.283786</td>
      <td>ENSG00000107485</td>
      <td><details><summary>Subtypes</summary><details><summary>TH2</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/29700302">29700302</a><div class="entities" style="line-height: 2.5"><h3>Bcl11b is essential for licensing Th2 differentiation during helminth infection and allergic asthma.</h3></br>During helminth infection and allergic asthma, naive CD4+  T cells differentiate into cytokine-producing Type-2 helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells that resolve the infection or induce asthma-associated pathology. Mechanisms regulating the Th2 differentiation in vivo remain poorly understood. Here we report that mice lacking Bcl11b in mature T cells have a diminished capacity to mount Th2 responses during helminth infection and allergic asthma, showing reduced Th2 cytokines and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Gata3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, and elevated Runx3. We provide evidence that Bcl11b is required to maintain chromatin accessibility at Th2-cytokine promoters and locus-control regions, and binds the Il4 HS IV silencer, reducing its accessibility. Bcl11b also binds Gata3-intronic and downstream-noncoding sites, sustaining the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Gata3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression. In addition, Bcl11b binds and deactivates upstream enhancers at Runx3 locus, restricting the Runx3 expression and its availability to act at the Il4 HS IV silencer. Thus, our results establish novel roles for Bcl11b in the regulatory loop that licenses Th2 program in vivo.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28683082">28683082</a><div class="entities" style="line-height: 2.5"><h3>The herbal decoction modified Danggui Buxue Tang attenuates immune-mediated bone marrow failure by regulating the differentiation of T lymphocytes in an immune-induced aplastic anemia mouse model.</h3></br>Angelicae Sinensis, Radix Astragali and Rhizoma Coptidis are all herbs of modified Danggui Buxue Tang (DGBX) and are extensively applied herbs in traditional Chinese medicine for the treatment of anemia and inflammation. In this study, immune-induced AA mice were used as an animal model, and the immunosuppressive agent, Ciclosporin A (CsA), was used as a positive control. Multiple pro-inflammatory cytokines were examined by bead-based multiplex flow cytometry. The T cell subsets were assessed using a fluorescence-activated cell sorter (FACS). Western blot analysis was used to estimate the protein expression levels of specific transcription factors for T helper cells (Th1, Th2 and Th17) and key molecules of the Janus-activated kinase (Jak)/signal transducer and activator of transcription (Stat3) signaling pathway. DGBX treatment could significantly increase the production of whole blood cells in peripheral blood (PB); inhibit the expansion of Th1 and Th17 cells; increase the differentiation of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Tregs cells; regulate the expression levels of T-bet, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, RORγ and proinflammatory cytokines; and decrease the expression levels of key molecules in the Jak/Stat signaling pathway. These results indicate that DGBX can regulate the differentiation of T lymphocytes, resulting in immunosuppressive and hematogenic functions on AA mice. DGBX might be a good candidate for inclusion in a randomized study for AA with more data on the possible side effects and doses used in humans. Ultimately, it may be used for applications of traditional medicine against AA in modern complementary and alternative immunosuppressive therapeutics.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28676845">28676845</a><div class="entities" style="line-height: 2.5"><h3>Th2/1 Hybrid Cells Occurring in Murine and Human Strongyloidiasis Share Effector Functions of Th1 Cells.</h3></br>Infections by the soil-transmitted threadworm <i>Strongyloides stercoralis</i> affect 30-100 million people worldwide, predominantly in tropic and sub-tropic regions. Here we assessed the T helper cell phenotypes in threadworm-infected patients and experimental murine infections with focus on CD4+  T cells co-expressing markers of Th2 and Th1 differentiation. We show that mice infected with the close relative <i>S. ratti</i> generate strong Th2 responses characterized by the expansion of CD4+  <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+  cells expressing IL-4/-5/-13 in blood, spleen, gut-draining lymph nodes, lung and gut tissue. In addition to conventional Th2 cells, significantly increased frequencies of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+ T-bet+  Th2/1-hybrid cells were detected in all organs and co-expressed Th2- and Th1-cytokines at intermediate levels. Assessing the phenotype of blood-derived CD4+  T cells from South Indian patients infected with <i>S. stercoralis</i> and local uninfected control donors we found that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expressing Th2 cells were significantly increased in the patient cohort, coinciding with elevated eosinophil and IgE/IgG4 levels. A fraction of IL-4+ CD4+  T cells simultaneously expressed IFN-γ hence displaying a Th2/1 hybrid phenotype. In accordance with murine Th2/1 cells, human Th2/1 cells expressed intermediate levels of Th2 cytokines. Contrasting their murine counterparts, human Th2/1 hybrids were marked by high levels of IFN-γ and rather low <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression. Assessing the effector function of murine Th2/1 cells <i>in vitro</i> we found that Th2/1 cells were qualified for driving the classical activation of macrophages. Furthermore, Th2/1 cells shared innate, cytokine-driven effector functions with Th1 cells. Hence, the key findings of our study are that T helper cells with combined characteristics of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th1 cells are integral to immune responses of helminth-infected mice, but also occur in helminth-infected humans and we suggest that Th2/1 cells are poised for the instruction of balanced immune responses during nematode infections.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28411045">28411045</a><div class="entities" style="line-height: 2.5"><h3>Pro-inflammatory effects of the Th1 chemokine CXCL10 in acquired aplastic anaemia.</h3></br>CXCL10/IFN-γ-induced protein 10 (IP-10) and its corresponding receptor CXCR3 have long been considered to be involved in the pathophysiology of type 1 T (Th1) cell-orientated autoimmune diseases. However, the exact role of CXCL10 in the pathogenesis of aplastic anaemia (AA) has not been thoroughly studied. The aim of our study was to evaluate the plasma level of CXCL10 and its effects on CD4+  T cell differentiation in AA. In our study, we found that an elevated plasma level of CXCL10 was negatively correlated with platelet, absolute neutrophil and reticulocyte counts, while it was positively correlated with the proportion of lymphocytes in white blood cells in AA patients. To confirm the pro-inflammatory effects of CXCL10 in AA, we isolated CD4+  T cells and evaluated the function of CXCL10 in CD4+  T cell differentiation. In vitro stimulation experiments further revealed the pro-inflammatory role of CXCL10 in AA, partially by promoting the secretion of interferon (IFN)-γ and IL-17. In addition, CXCL10 significantly skewed CD4+  T cell differentiation to Th1 cells and T helper 17 (Th17) cells in AA patients, while it inhibited the differentiation of type 2 T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells only in controls. The mRNA expression of transcription factors representative of T cell differentiation was detected by RT-PCR. Consistently, our results showed that after CXCL10 treatment, the expression of T-bet and RORγt was significantly enhanced, while the expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> was inhibited. In conclusion, our results indicated that CXCL10, a pro-inflammatory chemokine, might be involved in the abnormal immune response in AA.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27858144">27858144</a><div class="entities" style="line-height: 2.5"><h3>Th9 and other IL-9-producing cells in allergic asthma.</h3></br>Allergic asthma is a worldwide increasing chronic disease of the airways which affects more than 300 million people. It is associated with increased IgE, mast cell activation, airway hyperresponsiveness (AHR), mucus overproduction and remodeling of the airways. Previously, this pathological trait has been associated with T helper type 2 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. Recently, different CD4+  T cell subsets (Th17, Th9) as well as cells of innate immunity, like mast cells and innate lymphoid cells type 2 (ILC2s), which are all capable of producing the rediscovered cytokine IL-9, are known to contribute to this disease. Regarding Th9 cells, it is known that naïve T cells develop into IL-9-producing cells in the presence of interleukin-4 (IL-4) and transforming growth factor beta (TGFβ). Downstream of IL-4, several transcription factors like signal transducer and activator of transcription 6 (STAT6), interferon regulatory factor 4 (IRF4), GATA binding protein 3 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>), basic leucine zipper transcription factor, ATF-like (BATF) and nuclear factor of activated T cells (NFAT) are activated. Additionally, the transcription factor PU.1, which is downstream of TGFβ signaling, also seems to be crucial in the development of Th9 cells. IL-9 is a pleiotropic cytokine that influences various distinct functions of different target cells such as T cells, B cells, mast cells and airway epithelial cells by activating STAT1, STAT3 and STAT5. Because of its pleiotropic functions, IL-9 has been demonstrated to be involved in several diseases, such as cancer, autoimmunity and other pathogen-mediated immune-regulated diseases. In this review, we focus on the role of Th9 and IL-9-producing cells in allergic asthma.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27576175">27576175</a><div class="entities" style="line-height: 2.5"><h3>The paracrine immunomodulatory interactions between the human dental pulp derived mesenchymal stem cells and CD4 T cell subsets.</h3></br>Mesenchymal stem cells (MSCs) have strong imm<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    unomod    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>ulatory properties, however these properties may show some differences according to the tissue type of their isolate. In this study we investigated the paracrine interactions between human DP derived MSCs (hDP-MSCs) and the CD4+  T helper cell subsets to establish their immunomodulatory mechanisms. We found that the CD4+ -Tbet+  (Th1) and CD4+ -Gata3+  (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells were suppressed by the hDP-MSCs, but the CD4+ -Stat3+  (Th17) and CD4+ -CD25+ -FoxP3+  (Treg) cells were stimulated. The expressions of T cell specific cytokines interferon gamma (IFN-g), interleukin (IL)-4 and IL-17a decreased, but IL-10 and transforming growth factor beta-1 (TGF-b1) increased with the hDP-MSCs. The expressions of indoleamine-pyrrole 2,3-dioxygenase (IDO), prostaglandin E2 (PGE2), soluble human leukocyte antigen G (sHLA-G) derived from hDP-MSCs slightly increased, but hepatocyte growth factor (HGF) significantly increased in the co-culture groups. According to our findings, the hDP-MSCs can suppress the Th1 and Th2 subsets but stimulate the Th17 and Treg subsets. The Stat3 expression of Th17 cells may have been stimulated by the HGF, and thus the pro-inflammatory Th17 cells may have altered into the immunosuppressive regulatory Th17 cells. Further prospective studies are needed to confirm our findings.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/26872695">26872695</a><div class="entities" style="line-height: 2.5"><h3>The Wnt Antagonist Dickkopf-1 Promotes Pathological Type 2 Cell-Mediated Inflammation.</h3></br>Exposure to a plethora of environmental challenges commonly triggers pathological type 2 cell-mediated inflammation. Here we report the pathological role of the Wnt antagonist Dickkopf-1 (Dkk-1) upon allergen challenge or non-healing parasitic infection. The increased circulating amounts of Dkk-1 polarized T cells to T helper 2 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, stimulating a marked simultaneous induction of the transcription factors c-Maf and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Gata-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, mediated by the kinases p38 MAPK and SGK-1, resulting in Th2 cell cytokine production. Circulating Dkk-1 was primarily from platelets, and the increase of Dkk-1 resulted in formation of leukocyte-platelet aggregates (LPA) that facilitated leukocyte infiltration to the affected tissue. Functional inhibition of Dkk-1 impaired Th2 cell cytokine production and leukocyte infiltration, protecting mice from house dust mite (HDM)-induced asthma or Leishmania major infection. These results highlight that Dkk-1 from thrombocytes is an important regulator of leukocyte infiltration and polarization of immune responses in pathological type 2 cell-mediated inflammation. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/22112437">22112437</a><div class="entities" style="line-height: 2.5"><h3><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> regulates contact hyperresponsiveness in a murine model of allergic dermatitis.</h3></br>Contact hypersensitivity (CHS) is thought to be associated mainly with the activation of T helper (Th) type 1 cells. However, evidence also suggests that Th type 2 cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) and cytokines play roles in the development of CHS in humans. The present study examines the Th2 response during the development of CHS in response to 2,4,6-trinitrochlorobenzene (TNCB) in GATA-3-transgenic (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> Tg) mice. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> Tg mice were immunized with 7% TNCB applied to abdominal shaved skin. Seven days later, the mice were challenged with 1% TNCB applied to the left ear. Ear swelling, cytokine production in the skin of the ear, and the levels of IgE, IgG1 and IgG2a were measured. Furthermore, we examined the effects of medical treatment on TNCB-induced contact dermatitis using this model. The ear-swelling responses of TNCB-sensitized/challenged <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> Tg mice were significantly greater than those of similarly treated wild-type (WT) mice. The expression of both IL-5 and IL-13 in TNCB sensitized/challenged skin tissues and the IgE response after challenge were obviously increased in the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> Tg mice, whereas the expression of IFN-γ was identical in the challenged skin tissues of GATA-3-Tg and WT mice. When TNCB-sensitized <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> Tg mice were treated with a high dose of tacrolimus, ear swelling was not significantly decreased, compared with the results in WT mice. These results suggest that GATA-3-induced Th2-dominant responses play a critical role in the pathogenesis of allergic types of dermatitis, such as atopic dermatitis, and may lead to useful new drug development in the future.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/20921287">20921287</a><div class="entities" style="line-height: 2.5"><h3>A novel subset of CD4(+) <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(H)2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> memory/effector cells that produce inflammatory IL-17 cytokine and promote the exacerbation of chronic allergic asthma.</h3></br>The inflammatory cytokine interleukin (IL)-17 is involved in the pathogenesis of allergic diseases. However, the identity and functions of IL-17-producing T cells during the pathogenesis of allergic diseases remain unclear. Here, we report a novel subset of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(H)2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> memory/effector cells that coexpress the transcription factors <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and RORγt and coproduce T(H)17 and T(H)2 cytokines. Classical <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(H)2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> memory/effector cells had the potential to produce IL-17 after stimulation with proinflammatory cytokines IL-1β, IL-6, and IL-21. The number of IL-17-T(H)2 cells was significantly increased in blood of patients with atopic asthma. In a mouse model of allergic lung diseases, IL-17-producing CD4(+) T(H)2 cells were induced in the inflamed lung and persisted as the dominant IL-17-producing T cell population during the chronic stage of asthma. Treating cultured bronchial epithelial cells with IL-17 plus T(H)2 cytokines induced strong up-regulation of chemokine eotaxin-3, Il8, Mip1b, and Groa gene expression. Compared with classical T(H)17 and T(H)2 cells, antigen-specific IL-17-producing <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(H)2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells induced a profound influx of heterogeneous inflammatory leukocytes and exacerbated asthma. Our findings highlight the plasticity of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(H)2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> memory cells and suggest that IL-17-producing <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(H)2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells may represent the key pathogenic T(H)2 cells promoting the exacerbation of allergic asthma.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/20808283">20808283</a><div class="entities" style="line-height: 2.5"><h3>NBR1 is a new PB1 signalling adapter in Th2 differentiation and allergic airway inflammation in vivo.</h3></br>Allergic airway inflammation is a disease in which T helper 2 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells have a critical function. The molecular mechanisms controlling Th2 differentiation and function are of paramount importance in biology and immunology. Recently, a network of PB1-containing adapters and kinases has been shown to be essential in this process owing to its function in regulating cell polarity and the activation of critical transcription factors. Here, we show in vivo data showing that T cell-specific NBR1-deficient mice show impaired lung inflammation and have defective Th2 differentiation ex vivo with alterations in T cell polarity and the selective inhibition of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Gata3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and nuclear factor of activated T c1 activation. These results establish NBR1 as a novel PB1 adapter in Th2 differentiation and asthma.</div></details><details><summary>TH1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28683082">28683082</a><div class="entities" style="line-height: 2.5"><h3>The herbal decoction modified Danggui Buxue Tang attenuates immune-mediated bone marrow failure by regulating the differentiation of T lymphocytes in an immune-induced aplastic anemia mouse model.</h3></br>Angelicae Sinensis, Radix Astragali and Rhizoma Coptidis are all herbs of modified Danggui Buxue Tang (DGBX) and are extensively applied herbs in traditional Chinese medicine for the treatment of anemia and inflammation. In this study, immune-induced AA mice were used as an animal model, and the immunosuppressive agent, Ciclosporin A (CsA), was used as a positive control. Multiple pro-inflammatory cytokines were examined by bead-based multiplex flow cytometry. The T cell subsets were assessed using a fluorescence-activated cell sorter (FACS). Western blot analysis was used to estimate the protein expression levels of specific transcription factors for T helper cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>, Th2 and Th17) and key molecules of the Janus-activated kinase (Jak)/signal transducer and activator of transcription (Stat3) signaling pathway. DGBX treatment could significantly increase the production of whole blood cells in peripheral blood (PB); inhibit the expansion of Th1 and Th17 cells; increase the differentiation of Th2 and Tregs cells; regulate the expression levels of T-bet, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, RORγ and proinflammatory cytokines; and decrease the expression levels of key molecules in the Jak/Stat signaling pathway. These results indicate that DGBX can regulate the differentiation of T lymphocytes, resulting in immunosuppressive and hematogenic functions on AA mice. DGBX might be a good candidate for inclusion in a randomized study for AA with more data on the possible side effects and doses used in humans. Ultimately, it may be used for applications of traditional medicine against AA in modern complementary and alternative immunosuppressive therapeutics.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27815970">27815970</a><div class="entities" style="line-height: 2.5"><h3>Granulocyte colony-stimulating factor decreases the Th1/Th2 ratio in peripheral blood mononuclear cells from patients with chronic immune thrombocytopenic purpura in vitro.</h3></br>Chronic immune thrombocytopenia purpura (ITP) is an autoimmune disease that exhibits an abnormally high<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">     Th1/T    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>h2 ratio. Granulocyte colony-stimulating factor (G-CSF) has been shown to decrease the Th1/Th2 ratio in healthy donors. In this study, we investigated the effects of G-CSF treatment on the Th1/Th2 cells and the underlying mechanisms in patients with ITP in vitro. Peripheral blood mononuclear cells (PBMCs) isolated from patients with ITP and healthy controls were treated with G-CSF. Expression levels of interferon (IFN)-γ, interleukin (IL)-2, IL-4, and IL-13 in supernatants were measured by enzyme-linked immunosorbent assays. The expression of IFN-γ, IL-4, and G-CSF receptor (G-CSFR) on <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells were examined by flow cytometry and confocal microscopy. The mRNA expression of IFN-γ, IL-2, IL-4, IL-13, and T-box expressed in T cells (T-bet) and GATA-binding protein 3 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) in PBMCs was evaluated by reverse transcription polymerase chain reaction. The results showed that G-CSF could significantly reduce the Th1/Th2 ratio in PBMCs from patients with ITP in vitro. As the concentration of G-CSF increased, Th1/Th2 ([IFN-γ+IL-2]/[IL-4+IL-13]) cytokine ratios and T-bet/GATA-3 mRNA ratios decreased in a concentration-dependent manner. Th1 cells and Th2 cells both expressed G-CSFR. These results suggest that G-CSF could decrease the Th1/Th2 ratio in the context of ITP, and elucidate the direct and indirect immunomodulatory mechanisms underlying G-CSF functions in Th1/Th2 cells, thus supporting the therapeutic potential of G-CSF in the treatment of patients with ITP.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/25627813">25627813</a><div class="entities" style="line-height: 2.5"><h3>Glycogen synthase kinase-3 controls IL-10 expression in CD4(+) effector T cell subsets through epigenetic modification of the IL-10 promoter.</h3></br>The serine/threonine kinase glycogen synthase kinase-3 (GSK3) plays an important role in balancing pro- and anti-inflammatory cytokines. We have examined the role of GSK3 in production of IL-10 by subsets of CD4(+) T helper cells. Treatment of naive murine CD4(+) T cells with GSK3 inhibitors did not affect their production of IL-10. However, treatment of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells with GSK3 inhibitors dramatically increased production of IL-10. GSK3 inhibition also led to upregulation of IL-10 among Th1, Th2, and Th17 subsets isolated from human blood. The encephalitogenic potential of GSK3 inhibitor treated murine Th1 cells was significantly reduced in adoptive transfer experiments by an IL-10-dependent mechanism. Analysis of the murine IL-10 promoter in response to inhibition of GSK3 in Th1 cells showed modification to a transcriptionally active state indicated by changes in histone H3 acetylation and methylation. Additionally, GSK3 inhibition increased expression of the transcription factors c-Maf, Nfil3, and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, correlating with the increase in IL-10. These findings are important in the context of autoimmune disease since they show that it is possible to reprogram disease-causing cells through GSK3 inhibition. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/23976879">23976879</a><div class="entities" style="line-height: 2.5"><h3>Hybrid T-helper cells: stabilizing the moderate center in a polarized system.</h3></br>Polarization of cell phenotypes, a common strategy to achieve cell type diversity in metazoa, results from binary cell-fate decisions in the branching pedigree of development. Such "either-or" fate decisions are controlled by two opposing cell fate-determining transcription factors. Each of the two distinct "master regulators" promotes differentiation of its respective sister lineage. But they also suppress one other, leading to their mutually exclusive expression in the two ensuing lineages. Thus, promiscuous coexistence of the antagonist regulators in the same cell, the hallmark of the common "undecided" progenitor of two sister lineages, is considered unstable. This antagonism ensures robust polarization into two discretely distinct cell types. But now the immune system's T-helper (Th) cells and their two canonical subtypes, Th1 and Th2 cells, tell a different story, as revealed in three papers recently published in PLOS Biology. The intermediate state that co-expresses the two opposing master regulators of the Th1 and Th2 subtypes, T-bet and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Gata3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, is highly stable and is not necessarily an undecided precursor. Instead, the Th1/Th2 hybrid cell is a robust new type with properties of both <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells. These hybrid cells are functionally active and possess the benefit of moderation: self-limitation of effector T cell function to prevent excessive inflammation, a permanent risk in host defense that can cause tissue damage or autoimmunity. Gene regulatory network analysis suggests that stabilization of the intermediate center in a polarizing system can be achieved by minor tweaking of the architecture of the mutual suppression gene circuit, and thus is a design option readily available to evolution. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21968241">21968241</a><div class="entities" style="line-height: 2.5"><h3>Th17 cells in Behçet's disease: a new immunoregulatory axis.</h3></br>Accumulating evidence suggests that the abnormality of innate and adaptive immunity responses plays an important role in Behçet's disease (BD). T helper (Th) cells have a central role in modulating immune responses. Traditionally, BD is regarded as a Th1-mediated inflammatory disease. Recently, Th17 cells were identified as a new subset of Th cells unrelated to <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> or Th2 cells, and several cytokines are involved in regulating their activation and differentiation. Naïve murine CD4+ Th can be induced to differentiate towards Th1, Th2, Th17 and Treg phenotypes according to the local cytokine milieu. The committed cells are characterised by expression of specific transcription factors, T bet for Th1, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> for Th2, Foxp3 for Tregs and RORγt (RORγt/RORC) for Th17 cells. It has been demonstrated that the skewing of murine Th towards Th17 and Treg is mutually exclusive. Th17 cells regulate inflammation via production of distinct cytokines such as interleukin (IL)-17. There is growing evidence that Th17 cells are pathological in many human autoimmune and inflammatory diseases, leading to intense interest in defining their origins, functions and developing strategies to block their pathological effects. Evidence from human disease such as BD suggests that specialised antigen-presenting cells drive their in vivo development. Knowledge of how Th17 cells interact with other immune cells is limited, but recent data suggest that Th17 cells may not be subject to strict cellular regulation by T regulatory cells. Notably, Th17 cells and Treg cells appear to share common developmental pathways and both cell types retain significant plasticity. Herein, we will discuss the molecular and cellular regulation of Th17 cells with an emphasis on BD. The identification of Th17 cells helps us to explain some of the anomalies seen in the Th1/Th2 axis and has broadened our understanding of the immunopathological effects of Th17 cells in the development of BD.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21684616">21684616</a><div class="entities" style="line-height: 2.5"><h3>Lesional skin in atopic dogs shows a mixed Type-1 and Type-2 immune responsiveness.</h3></br>Canine atopic dermatitis (AD) is a chronic inflammatory and pruritic skin disease which shares several characteristics with its human counterpart. In chronic patch test lesions of human with AD mainly a Th1-type cellular response is found. Besides, non-lesional AD skin is already skewed for inflammation and therefore different from healthy skin. The goal of this study was to characterize local immune responsiveness in chronic canine AD lesions as compared to that in non-lesional AD skin by defining T cell subset relevant cytokine- and transcription factor expression profiles. The gene expression of the Th1 cytokines IL-12p35, IL-12p40 and IFN-γ and their related transcription factors STAT4, SOCS5 and T-bet, the Th2 cytokines IL-4 and IL-13 and transcription factors STAT6, SOCS3 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and the regulatory cytokines IL-10 and TGF-β and the transcription factor FOXP3 was evaluated in healthy control and atopic dogs. In non-lesional (NLS) and chronic lesional skin (LS) of atopic dogs and control skin (CS) from healthy dogs mRNA expression of cytokines and transcription factors were measured by quantitative real-time PCR. Significantly different values were found for the following factors: IL-12p40 mRNA was lower in LS when compared to NLS. Expression of STAT4 was higher in LS compared to CS and NLS. More IL-13 and SOCS3 were found in LS and NLS when compared to CS and also in LS compared to NLS. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> was lower in LS compared to NLS. IL-10 expression was higher in both LS and NLS compared to CS and more IL-10 was present in LS compared to NLS. These findings indicate that both <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1-    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2-type as well as T regulatory cells are present in NLS and LS in canine atopic skin.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/19912251">19912251</a><div class="entities" style="line-height: 2.5"><h3>Translational mini-review series on Th17 cells: induction of interleukin-17 production by regulatory T cells.</h3></br>Uncommitted (naive) CD4(+) T helper cells (Thp) can be induced to differentiate to specific lineages according to the local cytokine milieu, towards T helper type 1 (Th1), Th2, Th17 and regulatory T cell (T(reg)) phenotypes in a mutually exclusive manner. Each phenotype is characterized by unique signalling pathways and expression of specific transcription factors, notably T-bet for Th1, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> for Th2, forkhead box P3 (FoxP3) for T(regs) and receptor-related orphan receptor (ROR)alpha and RORgammat for Th17 cells. T(regs) and Th17 cells have been demonstrated to arise from common precursors in a reciprocal manner based on exposure to transforming growth factor (TGF)-beta or TGF-beta plus interleukin (IL)-6 and carry out diametrically opposing functions, namely suppression or propagation of inflammation, respectively. However, while epigenetic modifications in <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 differentiated cells prevents their conversion to other phenotypes, Th17 cells generated in vitro using TGF-beta and IL-6 are unstable and can convert to other phenotypes, especially Th1, both in vitro and in vivo. T(regs) are generated from naive precursors both in the thymus (natural, nT(regs)) and in the periphery (induced, iT(regs)). The highly suppressive function of T(regs) enables them to control many inflammatory diseases in animals and makes them particularly attractive candidates for immunotherapy in humans. The stability of the T(reg) phenotype is therefore of paramount importance in this context. Recent descriptions of T(reg) biology have suggested that components of pathogens or inflammatory mediators may subvert the suppressive function of T(regs) in order to allow propagation of adequate immune responses. Unexpectedly, however, a number of groups have now described conversion of T(regs) to the Th17 phenotype induced by appropriate inflammatory stimuli. These observations are particularly relevant in the context of cell therapy but may also explain some of the dysregulation seen in autoimmune diseases. In this paper, we review T(reg) to Th17 conversion and propose some potential mechanisms for this phenomenon.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/19805038">19805038</a><div class="entities" style="line-height: 2.5"><h3>The transcription factors T-bet and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> control alternative pathways of T cell differentiation through a shared set of target genes.</h3></br>Upon detection of antigen, CD4(+) T helper (Th) cells can differentiate into a number of effector types that tailor the immune response to different pathogens. Alternative Th1 and Th2 cell fates are specified by the transcription factors T-bet and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, respectively. Only a handful of target genes are known for these two factors and because of this, the mechanism through which T-bet and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> induce differentiation toward alternative cell fates is not fully understood. Here, we provide a genomic map of T-bet and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> binding in primary human T cells and identify their target genes, most of which are previously unknown. In Th1 cells, T-bet associates with genes of diverse function, including those with roles in transcriptional regulation, chemotaxis and adhesion. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> occupies genes in both <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells and, unexpectedly, shares a large proportion of targets with T-bet. Re-complementation of T-bet alters the expression of these genes in a manner that mirrors their differential expression between Th1 and Th2 lineages. These data show that the choice between Th1 and Th2 lineage commitment is the result of the opposing action of T-bet and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> at a shared set of target genes and may provide a general paradigm for the interaction of lineage-specifying transcription factors.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/18772129">18772129</a><div class="entities" style="line-height: 2.5"><h3>Cyclic AMP-induced chromatin changes support the NFATc-mediated recruitment of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> to the interleukin 5 promoter.</h3></br>Elevated intracellular cyclic AMP levels, which suppress the proliferation of naive T cells and type 1 T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are a property of T helper 2 (Th2) cells and regulatory T cells. While cyclic AMP signals interfere with the IL-2 promoter induction, they support the induction of Th2-type genes, in particular of il-5 gene. We show here that cyclic AMP signals support the generation of three inducible DNase I hypersensitive chromatin sites over the il-5 locus, including its promoter region. In addition, cyclic AMP signals enhance histone H3 acetylation at the IL-5 promoter and the concerted binding of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and NFATc to the promoter. This is facilitated by direct protein-protein interactions involving the C-terminal Zn(2+)-finger of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and the C-terminal region of the NFATc1 DNA binding domain. Because inhibition of NFATc binding to the IL-5 promoter in vivo also affects the binding of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, one may conclude that upon induction of Th2 effector cells NFATc recruits <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> to Th2-type genes. These data demonstrate the functional importance of cyclic AMP signals for the interplay between <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and NFATc factors in the transcriptional control of lymphokine expression in Th2 effector cells.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/17546034">17546034</a><div class="entities" style="line-height: 2.5"><h3>Dynamic changes in histone-methylation 'marks' across the locus encoding interferon-gamma during the differentiation of T helper type 2 cells.</h3></br>The 'histone-code' hypothesis proposes that cell fate 'decisions' are achieved through the creation of stable epigenetic histone 'marks' at gene loci. Here we explored the formation of marks of repressive methylation of histone 3 at lysine 9 (H3-K9) and of H3-K27 at the locus encoding interferon-gamma (Ifng locus) during the commitment of naive T cells to the T helper type 1 (TH1) and TH2 lineages. Methylation of H3-K9 across the Ifng locus was rapidly induced in differentiating <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and TH2 cells and was sustained in TH1 cells. In contrast, TH2 differentiation caused loss of methylation of H3-K9 and gain of methylation of H3-K27 by mechanisms dependent on the transcription factors <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and STAT6. Thus, histone-methylation marks at the Ifng locus are highly dynamic, which may ensure higher-order transcriptional regulation during early lineage commitment.</div></details><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28945272">28945272</a><div class="entities" style="line-height: 2.5"><h3>CD4+  T helper cells and regulatory T cells in active lupus nephritis: an imbalance towards a predominant Th1 response?</h3></br>The objective of this study was to evaluate the frequency of CD4+  T cell subsets in peripheral blood mononuclear cells (PBMC), urine and renal tissue from patients with lupus nephritis (LN). PBMC and urinary cells were collected from 17 patients with active LN, 20 disease controls (DC) with primary glomerulonephritis and 10 healthy controls (HC) and were analysed by flow cytometry with markers for T helper type 1 (Th1), Th2, Th17 and regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>  ) cells. T cell subsets were assessed by immunohistochemistry from LN biopsy specimens from 12 LN patients. T cell subtypes in PBMC were re-evaluated at 6 months of therapy. CD4+  T cells were decreased in PBMC in LN compared with DC and HC (P = 0·0001). No differences were observed in urinary CD4+  T cell subsets between LN and DC. The frequency of urinary Th17 cells was higher in patients with non-proliferative than in proliferative LN (P = 0·041). CD3+  and T-box 21 ( Tbet+) cells were found in glomeruli and interstitium of LN patients, while forkhead box protein 3 (FoxP3), retinoid-related orphan receptor gamma (ROR-γ) and GATA binding protein 3 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) were present only in glomeruli. Th1 cells in PBMC were correlated negatively with urinary Th1 cells (Rho = -0·531; P = 0·028) and with Tbet  in renal interstitium (Rho = -0·782; P = 0·004). At 6 months, LN patients showed an increase in Th17 cells in PBMC. In conclusion, the inverse association between Th1 cells from PBMC and urinary/renal tissue indicate a role for Th1 in LN pathophysiology. Urinary Th17 cells were associated with less severe LN, and Th17 increased in PBMC during therapy. Urinary CD4+  T cells were not different between LN and DC.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27602995">27602995</a><div class="entities" style="line-height: 2.5"><h3>Medium-dose estrogen ameliorates experimental autoimmune encephalomyelitis in ovariectomized mice.</h3></br>Estrogen is a neuro-protective hormone in various central nervous system (CNS) disorders. The present study evaluated the role of estrogen during experimental autoimmune encephalomyelitis (EAE) at doses selected to mimic any suppressive potential from the hormone during pregnancy. Here, mice were ovariectomized and then 2 weeks later treated with MOG antigen to induce EAE. Concurrently, mice then received (subcutaneously) an implanted pellet to deliver varying estrogen amounts over a 21-day period. Clinical scores and other parameters were monitored daily for the 21 days. At the end of the period, brain/spinal cord histology was performed to measure lymphocyte infiltration; T cell profiles were determined through ELISA, flow cytometry, and real-time PCR. Transcription factor expression levels in the CNS were assessed using real-time PCR; T cell differentiation was evaluated via flow cytometry. The results demonstrated that estrogen inhibited development of EAE. Histological studies revealed limited leukocyte infiltration into the CNS. High and medium dose of estrogen increased TH 2 and Treg  cell production of interleukin (IL)-4, IL-10, and transforming growth factor (TGF)-β, but concurrently resulted in a significant reduction in production of interferon (IFN)-γ, IL-17, and IL-6. Flow cytometry revealed there were also significant decreases in the percentages of TH 1 and TH 17 cells, as well as significant increase in percentages of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>  and TH 2 cells in the spleen and lymph nodes. Real-time PCR results indicated that high- and medium-dose estrogen treatments reduced T-bet and ROR-γt factor expression, but enhanced Foxp3 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression. Collectively, these results demonstrated that a medium dose of estrogen - similar to a pregnancy level of estrogen - could potentially reduce the incidence and severity of autoimmune EAE and possibly other autoimmune pathologies.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27576175">27576175</a><div class="entities" style="line-height: 2.5"><h3>The paracrine immunomodulatory interactions between the human dental pulp derived mesenchymal stem cells and CD4 T cell subsets.</h3></br>Mesenchymal stem cells (MSCs) have strong imm<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    unomod    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>ulatory properties, however these properties may show some differences according to the tissue type of their isolate. In this study we investigated the paracrine interactions between human DP derived MSCs (hDP-MSCs) and the CD4+  T helper cell subsets to establish their immunomodulatory mechanisms. We found that the CD4+ -Tbet+  (Th1) and CD4+ -Gata3+  (Th2) cells were suppressed by the hDP-MSCs, but the CD4+ -Stat3+  (Th17) and CD4+ -CD25+ -FoxP3+  (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells were stimulated. The expressions of T cell specific cytokines interferon gamma (IFN-g), interleukin (IL)-4 and IL-17a decreased, but IL-10 and transforming growth factor beta-1 (TGF-b1) increased with the hDP-MSCs. The expressions of indoleamine-pyrrole 2,3-dioxygenase (IDO), prostaglandin E2 (PGE2), soluble human leukocyte antigen G (sHLA-G) derived from hDP-MSCs slightly increased, but hepatocyte growth factor (HGF) significantly increased in the co-culture groups. According to our findings, the hDP-MSCs can suppress the Th1 and Th2 subsets but stimulate the Th17 and Treg subsets. The Stat3 expression of Th17 cells may have been stimulated by the HGF, and thus the pro-inflammatory Th17 cells may have altered into the immunosuppressive regulatory Th17 cells. Further prospective studies are needed to confirm our findings.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27344332">27344332</a><div class="entities" style="line-height: 2.5"><h3>Dysregulation of Th1, Th2, Th17, and T regulatory cell-related transcription factor signaling in children with autism.</h3></br>Autism is a neurodevelopmental disorder characterized by stereotypic repetitive behaviors, impaired social interactions, and communication deficits. Numerous immune system abnormalities have been described in individuals with autism including abnormalities in the ratio of Th1/Th2/Th17 cells; however, the expression of the transcription factors responsible for the regulation and differentiation of Th1/Th2/Th17/Treg cells has not previously been evaluated. Peripheral blood mononuclear cells (PBMCs) from children with autism (AU) or typically developing (TD) control children were stimulated with phorbol-12-myristate 13-acetate (PMA) and ionomycin in the presence of brefeldin A. The expressions of Foxp3, RORγt, STAT-3, T-bet, and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mRNAs and proteins were then assessed. Our study shows that children with AU displayed altered immune profiles and function, characterized by a systemic deficit of Foxp3+  T regulatory (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells and increased RORγt+ , T-bet+ , <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+ , and production by CD4+  T cells as compared to TD. This was confirmed by real-time PCR (RT-PCR) and western blot analyses. Our results suggest that autism impacts transcription factor signaling, which results in an immunological imbalance. Therefore, the restoration of transcription factor signaling may have a great therapeutic potential in the treatment of autistic disorders.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/25154413">25154413</a><div class="entities" style="line-height: 2.5"><h3>Two histone/protein acetyltransferases, CBP and p300, are indispensable for Foxp3+ T-regulatory cell development and function.</h3></br>T-regulatory (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are important to immune homeostasis, and Treg cell deficiency or dysfunction leads to autoimmune disease. A histone/protein acetyltransferase (HAT), p300, was recently found to be important for Treg function and stability, but further insights into the mechanisms by which p300 or other HATs affect Treg biology are needed. Here we show that CBP, a p300 paralog, is also important in controlling Treg function and stability. Thus, while mice with Treg-specific deletion of CBP or p300 developed minimal autoimmune disease, the combined deletion of CBP and p300 led to fatal autoimmunity by 3 to 4 weeks of age. The effects of CBP and p300 deletion on Treg development are dose dependent and involve multiple mechanisms. CBP and p300 cooperate with several key Treg transcription factors that act on the Foxp3 promoter to promote Foxp3 production. CBP and p300 also act on the Foxp3 conserved noncoding sequence 2 (CNS2) region to maintain Treg stability in inflammatory environments by regulating pCREB function and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression, respectively. Lastly, CBP and p300 regulate the epigenetic status and function of Foxp3. Our findings provide insights into how HATs orchestrate multiple aspects of Treg development and function and identify overlapping but also discrete activities for p300 and CBP in control of Treg cells. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/24995608">24995608</a><div class="entities" style="line-height: 2.5"><h3>The immunomodulatory effects of human mesenchymal stem cells on peripheral blood mononuclear cells in ALS patients.</h3></br>In a previous study, we reported that intrathecal injection of mesenchymal stem cells (MSCs) slowed disease progression in G93A mutant superoxide dismutase1 transgenic mice. In this study, we found that intrathecal MSC administration vastly increased the infiltration of peripheral immune cells into the spinal cord of Amyotrophic lateral sclerosis (ALS) mice (G93A mutant superoxide dismutase1 transgenic). Thus, we investigated the immunomodulatory effect of MSCs on peripheral blood mononuclear cells (PBMCs) in ALS patients, focusing on regulatory T lymphocytes (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> ; CD4(+) /CD25(high) /FoxP3(+) ) and the mRNA expression of several cytokines (IFN-γ, TNF-α, IL-17, IL-4, IL-10, IL-13, and TGF-β). Peripheral blood samples were obtained from nine healthy controls (HC) and sixteen patients who were diagnosed with definite or probable ALS. Isolated PBMCs from the blood samples of all subjects were co-cultured with MSCs for 24 or 72 h. Based on a fluorescence-activated cell sorting analysis, we found that co-culture with MSCs increased the Treg /total T lymphocyte ratio in the PBMCs from both groups according to the co-culture duration. Co-culture of PBMCs with MSCs for 24 h led to elevated mRNA levels of IFN-γ and IL-10 in the PBMCs from both groups. However, after co-culturing for 72 h, although the IFN-γ mRNA level had returned to the basal level in co-cultured HC PBMCs, the IFN-γ mRNA level in co-cultured ALS PBMCs remained elevated. Additionally, the levels of IL-4 and TGF-β were markedly elevated, along with <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Gata3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mRNA, a Th2 transcription factor mRNA, in both HC and ALS PBMCs co-cultured for 72 h. The elevated expression of these cytokines in the co-culture supernatant was confirmed via ELISA. Furthermore, we found that the increased mRNA level of indoleamine 2,3-dioxygenase (IDO) in the co-cultured MSCs was correlated with the increase in Treg induction. These findings of Treg induction and increased anti-inflammatory cytokine expression in co-cultured ALS PBMCs provide indirect evidence that MSCs may play a role in the immunomodulation of inflammatory responses when MSC therapy is targeted to ALS patients. We propose the following mechanism for the effect of mesenchymal stem cells (MSCs) administered intrathecally in amyotrophic lateral sclerosis (ALS): MSCs increase infiltration of peripheral immune cells into CNS and skew the infiltrated immune cells toward regulatory T lymphocytes (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> ) and Th2 lymphocytes. Treg and Th2 secret anti-inflammatory cytokines such as IL-4, IL-10, and TGF-β. A series of immunomodulatory mechanism provides a new strategy for ALS treatment. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/23143995">23143995</a><div class="entities" style="line-height: 2.5"><h3>Regulatory T lymphocytes mediate amyotrophic lateral sclerosis progression and survival.</h3></br>In amyotrophic lateral sclerosis (ALS) mice, regulatory T lymphocytes (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) are neuroprotective, slowing disease progression. To address whether Tregs and FoxP3, a transcription factor required for Treg function, similarly influence progression rates of ALS patients, T lymphocytes from patients were assessed by flow cytometry. Both numbers of Tregs and their FoxP3 protein expressions were reduced in rapidly progressing ALS patients and inversely correlated with progression rates. The mRNA levels of FoxP3, TGF-β, IL4 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Gata3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, a Th2 transcription factor, were reduced in rapidly progressing patients and inversely correlated with progression rates. Both FoxP3 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Gata3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> were accurate indicators of progression rates. No differences in IL10, Tbx21, a Th1 transcription factor or IFN-γ expression were found between slow and rapidly progressing patients. A 3.5-year prospective study with a second larger cohort revealed that early reduced FoxP3 levels were indicative of progression rates at collection and predictive of future rapid progression and attenuated survival. Collectively, these data suggest that Tregs and Th2 lymphocytes influence disease progression rates. Importantly, early reduced FoxP3 levels could be used to identify rapidly progressing patients.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/22922362">22922362</a><div class="entities" style="line-height: 2.5"><h3>Transcription factor Foxp3 and its protein partners form a complex regulatory network.</h3></br>The transcription factor Foxp3 is indispensible for the differentiation and function of regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells). To gain insights into the molecular mechanisms of Foxp3-mediated gene expression, we purified Foxp3 complexes and explored their composition. Biochemical and mass-spectrometric analyses revealed that Foxp3 forms multiprotein complexes of 400-800 kDa or larger and identified 361 associated proteins, ∼30% of which were transcription related. Foxp3 directly regulated expression of a large proportion of the genes encoding its cofactors. Some transcription factor partners of Foxp3 facilitated its expression. Functional analysis of the cooperation of Foxp3 with one such partner, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, provided additional evidence for a network of transcriptional regulation afforded by Foxp3 and its associates to control distinct aspects of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cell biology.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21114556">21114556</a><div class="entities" style="line-height: 2.5"><h3>FoxP3, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and T-bet expression in elderly asthma.</h3></br>Asthma is a chronic inflammatory disorder in which Th2, Th1 and suppressive T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) play a role. The transcription factor FoxP3 plays a role in Treg differentiation while T-bet is important for Th1 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> for Th2 differentiation from naïve T cells. Recent data show that age-related deregulation of Treg cells is a mechanism of senescence affecting several chronic diseases. It is crucial to understand the behaviour of these cell populations in asthma for elderly patients.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21079691">21079691</a><div class="entities" style="line-height: 2.5"><h3>The female lower genital tract is a privileged compartment with IL-10 producing dendritic cells and poor Th1 immunity following Chlamydia trachomatis infection.</h3></br>While a primary genital tract infection with C. trachomatis stimulates partial-protection against re-infection, it may also result in severe inflammation and tissue destruction. Here we have dissected whether functional compartments exist in the genital tract that restrict Th1-mediated protective immunity. Apart from the Th1-subset, little is known about the role of other CD4(+) T cell subsets in response to a genital tract chlamydial infection. Therefore, we investigated CD4(+) T cell subset differentiation in the genital tract using RT-PCR for expression of critical transcription factors and cytokines in the upper (UGT) and lower genital tract (LGT) of female C57BL/6 mice in response to C. trachomatis serovar D infection. We found that the Th1 subset dominated the UGT, as IFN-γ and T-bet mRNA expression were high, while <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> was low following genital infection with C. trachomatis serovar D. By contrast, IL-10 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mRNA dominated the LGT, suggesting the presence of Th2 cells. These functional compartments also attracted regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) differently as increased FoxP3 mRNA expression was seen primarily in the UGT. Although IL-17A mRNA was somewhat up-regulated in the LGT, no significant change in RORγ-t mRNA expression was observed, suggesting no involvement of Th17 cells. The dichotomy between the LGT and UGT was maintained during infection by IL-10 because in IL-10-deficient mice the distinction between the two compartments was completely lost and a dramatic shift to the predominance of Th1 cells in the LGT occurred. Unexpectedly, the major source of IL-10 was CD11c(+) CD11b(+) DC, probably creating an anti-inflammatory privileged site in the LGT.</div></details><details><summary>TH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/29038009">29038009</a><div class="entities" style="line-height: 2.5"><h3>Advances in mechanisms of allergic disease in 2016.</h3></br>This review highlights advances in mechanisms of allergic disease, particularly type 2 innate lymphoid cells; <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> 2 lymphocytes; eicosanoid regulation of inflammation; extracellular vesicles in allergic responses; IL-33; microbiome properties, especially as they relate to mucosal barrier function; and a series of findings concerning the allergic inflammatory cells eosinophils, basophils, and mast cells. During the last year, mechanistic advances occurred in understanding type 2 innate lymphoid cells, particularly related to their response to ozone, involvement with experimental food allergy responses, and regulation by IL-33. Novel ways of regulating <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> 2 cells through epigenetic regulation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> through sirtuin-1, a class III histone deacetylase, were published. The understanding of eicosanoid regulation of inflammation increased and focused on additional properties of phospholipase A2  and the role of prostaglandin D2  and its receptors and inhibitory prostaglandin E2  pathways. Mechanisms through which extracellular vesicles are released and contribute to allergic responses were reported. There was a deeper appreciation of mucosal barrier function, the epithelial alarmin IL-33, and the microbiome. Finally, there were advances concerning allergic inflammatory cells (mast cells, basophils, and eosinophils) that will undoubtedly have an effect on disease understanding and new therapeutic strategies.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28108952">28108952</a><div class="entities" style="line-height: 2.5"><h3>Transcriptional regulators dictate innate lymphoid cell fates.</h3></br>Research on innate lymphoid cells (ILC) has recently been a fast paced topic of immunological research. As ILCs are able to produce signature Th cytokine, ILCs have garnered considerable attention and have been described to represent the innate counterpart of the CD4+  T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. The development and function of ILCs are precisely regulated by a network of crucial transcription factors, which are also involved in the development or differentiation of conventional natural killer (cNK) cells and T cells. In this review, we will summarize the key transcriptional regulators and their functions through each phases of ILC development. With the phase of ILC lineage commitment, we will focus in particular on the roles of the transcription regulators Id2 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, which in collaboration with other transcriptional factors, are critically involved in the generation of ILC fate determined progenitors. Once an ILC lineage has been established, several other transcription factors are required for the specification and functional regulation of distinct mature ILC subsets. Thus, a comprehensive understanding of the interactions and regulatory mechanisms mediated by these transcription factors will help us to further understand how ILCs exert their helper-like functions and bridge the innate and adaptive immunity.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27912316">27912316</a><div class="entities" style="line-height: 2.5"><h3>Th2 Cells in Health and Disease.</h3></br>Helper T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cell subsets direct immune responses by producing signature cytokines. Th2 cells produce IL-4, IL-5, and IL-13, which are important in humoral immunity and protection from helminth infection and are central to the pathogenesis of many allergic inflammatory diseases. Molecular analysis of Th2 cell differentiation and maintenance of function has led to recent discoveries that have refined our understanding of Th2 cell biology. Epigenetic regulation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Gata3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression by chromatin remodeling complexes such as Polycomb and Trithorax is crucial for maintaining Th2 cell identity. In the context of allergic diseases, memory-type pathogenic Th2 cells have been identified in both mice and humans. To better understand these disease-driving cell populations, we have developed a model called the pathogenic Th population disease induction model. The concept of defined subsets of pathogenic Th cells may spur new, effective strategies for treating intractable chronic inflammatory disorders.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27602995">27602995</a><div class="entities" style="line-height: 2.5"><h3>Medium-dose estrogen ameliorates experimental autoimmune encephalomyelitis in ovariectomized mice.</h3></br>Estrogen is a neuro-protective hormone in various central nervous system (CNS) disorders. The present study evaluated the role of estrogen during experimental autoimmune encephalomyelitis (EAE) at doses selected to mimic any suppressive potential from the hormone during pregnancy. Here, mice were ovariectomized and then 2 weeks later treated with MOG antigen to induce EAE. Concurrently, mice then received (subcutaneously) an implanted pellet to deliver varying estrogen amounts over a 21-day period. Clinical scores and other parameters were monitored daily for the 21 days. At the end of the period, brain/spinal cord histology was performed to measure lymphocyte infiltration; T cell profiles were determined through ELISA, flow cytometry, and real-time PCR. Transcription factor expression levels in the CNS were assessed using real-time PCR; T cell differentiation was evaluated via flow cytometry. The results demonstrated that estrogen inhibited development of EAE. Histological studies revealed limited leukocyte infiltration into the CNS. High and medium dose of estrogen increased TH 2 and Treg  cell production of interleukin (IL)-4, IL-10, and transforming growth factor (TGF)-β, but concurrently resulted in a significant reduction in production of interferon (IFN)-γ, IL-17, and IL-6. Flow cytometry revealed there were also significant decreases in the percentages of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> 1 and TH 17 cells, as well as significant increase in percentages of Treg  and TH 2 cells in the spleen and lymph nodes. Real-time PCR results indicated that high- and medium-dose estrogen treatments reduced T-bet and ROR-γt factor expression, but enhanced Foxp3 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression. Collectively, these results demonstrated that a medium dose of estrogen - similar to a pregnancy level of estrogen - could potentially reduce the incidence and severity of autoimmune EAE and possibly other autoimmune pathologies.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/25019384">25019384</a><div class="entities" style="line-height: 2.5"><h3>The regulation and role of c-FLIP in human Th cell differentiation.</h3></br>The early differentiation of T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells is a tightly controlled and finely balanced process, which involves several factors including cytokines, transcription factors and co-stimulatory molecules. Recent studies have shown that in addition to the regulation of apoptosis, caspase activity is also needed for Th cell proliferation and activation and it might play a role in Th cell differentiation. The isoforms of the cellular FLICE inhibitory protein (c-FLIP) are regulators of CASPASE-8 activity and the short isoform, c-FLIPS, has been shown to be up-regulated by IL-4, the Th2 driving cytokine. In this work, we have studied the expression and functional role of three c-FLIP isoforms during the early Th cell differentiation. Only two of the isoforms, c-FLIPS and c-FLIPL, were detected at the protein level although c-FLIPR was expressed at the mRNA level. The knockdown of c-FLIPL led to enhanced Th1 differentiation and elevated IL-4 production by Th2 cells, whereas the knockdown of c-FLIPS diminished <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression and IL-4 production by Th2 cells. In summary, our results provide new insight into the role of c-FLIP proteins in the early differentiation of human Th cells. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/24040751">24040751</a><div class="entities" style="line-height: 2.5"><h3>Functional plasticity of Th17 cells: implications in gastrointestinal tract function.</h3></br>The gastrointestinal tract is an active player of the human immune system, participating in the innate and adaptive immune responses, keeping the homeostasis of the human being in a healthy status. However, most intestinal conditions are associated with an altered immune response, which implies the activation of CD4(+) T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. Based on their cytokine secretion, transcription factor expression and immunological functions, the differentiated Th cells were initially subdivided into different lineages: Th1 (that express the transcription factor T-box (T-bet), secrete interferon (IFN)-γ and protect the host against intracellular infections) and Th2 (that express GATA binding protein 3 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>), secrete interleukin (IL)-4, IL-5 and IL-13, and mediate host defense against helminths). Later, a new subset was identified, the Th17, which selectively produces IL-17A and is crucial for host defense against extracellular pathogens. More recently, a functional plasticity between the Th1 and Th17 lineages has been described, a process sometimes controversial that seems to play a key role in different inflammatory conditions, including those affecting the gastrointestinal system. This review will summarize the current knowledge regarding the regulation and functional role of Th17 cells in the gut, focusing on these newly identified features of this T cell subset, including plasticity, their relationship with regulatory T cells and their heterogeneity in the inflammatory microenvironment. A better understanding of these issues is critical to elucidate the role of Th17 cells in intestine immunity, and so for the design of novel therapeutic approaches for intestinal diseases specifically targeting Th17 cells. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/23976879">23976879</a><div class="entities" style="line-height: 2.5"><h3>Hybrid T-helper cells: stabilizing the moderate center in a polarized system.</h3></br>Polarization of cell phenotypes, a common strategy to achieve cell type diversity in metazoa, results from binary cell-fate decisions in the branching pedigree of development. Such "either-or" fate decisions are controlled by two opposing cell fate-determining transcription factors. Each of the two distinct "master regulators" promotes differentiation of its respective sister lineage. But they also suppress one other, leading to their mutually exclusive expression in the two ensuing lineages. Thus, promiscuous coexistence of the antagonist regulators in the same cell, the hallmark of the common "undecided" progenitor of two sister lineages, is considered unstable. This antagonism ensures robust polarization into two discretely distinct cell types. But now the immune system's T-helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells and their two canonical subtypes, Th1 and Th2 cells, tell a different story, as revealed in three papers recently published in PLOS Biology. The intermediate state that co-expresses the two opposing master regulators of the Th1 and Th2 subtypes, T-bet and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Gata3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, is highly stable and is not necessarily an undecided precursor. Instead, the Th1/Th2 hybrid cell is a robust new type with properties of both Th1 and Th2 cells. These hybrid cells are functionally active and possess the benefit of moderation: self-limitation of effector T cell function to prevent excessive inflammation, a permanent risk in host defense that can cause tissue damage or autoimmunity. Gene regulatory network analysis suggests that stabilization of the intermediate center in a polarizing system can be achieved by minor tweaking of the architecture of the mutual suppression gene circuit, and thus is a design option readily available to evolution. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21968241">21968241</a><div class="entities" style="line-height: 2.5"><h3>Th17 cells in Behçet's disease: a new immunoregulatory axis.</h3></br>Accumulating evidence suggests that the abnormality of innate and adaptive immunity responses plays an important role in Behçet's disease (BD). T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells have a central role in modulating immune responses. Traditionally, BD is regarded as a Th1-mediated inflammatory disease. Recently, Th17 cells were identified as a new subset of Th cells unrelated to Th1 or Th2 cells, and several cytokines are involved in regulating their activation and differentiation. Naïve murine CD4+ Th can be induced to differentiate towards Th1, Th2, Th17 and Treg phenotypes according to the local cytokine milieu. The committed cells are characterised by expression of specific transcription factors, T bet for Th1, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> for Th2, Foxp3 for Tregs and RORγt (RORγt/RORC) for Th17 cells. It has been demonstrated that the skewing of murine Th towards Th17 and Treg is mutually exclusive. Th17 cells regulate inflammation via production of distinct cytokines such as interleukin (IL)-17. There is growing evidence that Th17 cells are pathological in many human autoimmune and inflammatory diseases, leading to intense interest in defining their origins, functions and developing strategies to block their pathological effects. Evidence from human disease such as BD suggests that specialised antigen-presenting cells drive their in vivo development. Knowledge of how Th17 cells interact with other immune cells is limited, but recent data suggest that Th17 cells may not be subject to strict cellular regulation by T regulatory cells. Notably, Th17 cells and Treg cells appear to share common developmental pathways and both cell types retain significant plasticity. Herein, we will discuss the molecular and cellular regulation of Th17 cells with an emphasis on BD. The identification of Th17 cells helps us to explain some of the anomalies seen in the Th1/Th2 axis and has broadened our understanding of the immunopathological effects of Th17 cells in the development of BD.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21367463">21367463</a><div class="entities" style="line-height: 2.5"><h3>RORC and Foxp3 axis in cerebrospinal fluid of patients with neuro-Behçet's disease.</h3></br>Neurological manifestations are present in 5% to 30% of patients with Behçet's disease (BD). Neuro-Behçet's Disease (NBD) is hypothetically caused by T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, which development is dependent on the expression of lineage-specific transcription factors. Cerebrospinal fluid (CSF) mRNA expression of TBX21, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, RORC, FOXP3 and EBI3 were assessed in 18 NBD patients and 26 controls disease [16 noninflammatory neurological disease (NIND) and 10 headache attributed to Behçet's disease (HaBD)]. Expression of TBX21 (Th1), RORC (Th17) and Foxp3 (Treg) were increased in NBD patients compared to HaBD and NIND patients. EBI3 and Th2-associated <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expressions were found to be decreased (P<0.0001 and P<0.0001) in NBD patients. Analysis of transcription factor ratios, revealed an increase in the RORC/FOXP3 and TBX21/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> ratios in NBD patients (P<0.0001; P<0.0003). Our findings indicate that both Th1 and Th17 mRNA expressions involving a possible impairment of Treg cells. This might play a role in CSF-NBD inflammation, permitting activation of harmful T cell subpopulations. The TBX21/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and RORC/FOXP3 ratios dysregulations in NBD are consistent with those reported in other inflammatory diseases and indicating the plasticity existing between Th1, Th17 and Treg cells during inflammation.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/19805038">19805038</a><div class="entities" style="line-height: 2.5"><h3>The transcription factors T-bet and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> control alternative pathways of T cell differentiation through a shared set of target genes.</h3></br>Upon detection of antigen, CD4(+) T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells can differentiate into a number of effector types that tailor the immune response to different pathogens. Alternative Th1 and Th2 cell fates are specified by the transcription factors T-bet and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, respectively. Only a handful of target genes are known for these two factors and because of this, the mechanism through which T-bet and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> induce differentiation toward alternative cell fates is not fully understood. Here, we provide a genomic map of T-bet and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> binding in primary human T cells and identify their target genes, most of which are previously unknown. In Th1 cells, T-bet associates with genes of diverse function, including those with roles in transcriptional regulation, chemotaxis and adhesion. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> occupies genes in both Th1 and Th2 cells and, unexpectedly, shares a large proportion of targets with T-bet. Re-complementation of T-bet alters the expression of these genes in a manner that mirrors their differential expression between Th1 and Th2 lineages. These data show that the choice between Th1 and Th2 lineage commitment is the result of the opposing action of T-bet and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> at a shared set of target genes and may provide a general paradigm for the interaction of lineage-specifying transcription factors.</div></details><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28411045">28411045</a><div class="entities" style="line-height: 2.5"><h3>Pro-inflammatory effects of the Th1 chemokine CXCL10 in acquired aplastic anaemia.</h3></br>CXCL10/IFN-γ-induced protein 10 (IP-10) and its corresponding receptor CXCR3 have long been considered to be involved in the pathophysiology of type 1 T (Th1) cell-orientated autoimmune diseases. However, the exact role of CXCL10 in the pathogenesis of aplastic anaemia (AA) has not been thoroughly studied. The aim of our study was to evaluate the plasma level of CXCL10 and its effects on CD4+  T cell differentiation in AA. In our study, we found that an elevated plasma level of CXCL10 was negatively correlated with platelet, absolute neutrophil and reticulocyte counts, while it was positively correlated with the proportion of lymphocytes in white blood cells in AA patients. To confirm the pro-inflammatory effects of CXCL10 in AA, we isolated CD4+  T cells and evaluated the function of CXCL10 in CD4+  T cell differentiation. In vitro stimulation experiments further revealed the pro-inflammatory role of CXCL10 in AA, partially by promoting the secretion of interferon (IFN)-γ and IL-17. In addition, CXCL10 significantly skewed CD4+  T cell differentiation to Th1 cells and T helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells in AA patients, while it inhibited the differentiation of type 2 T (Th2) cells only in controls. The mRNA expression of transcription factors representative of T cell differentiation was detected by RT-PCR. Consistently, our results showed that after CXCL10 treatment, the expression of T-bet and RORγt was significantly enhanced, while the expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> was inhibited. In conclusion, our results indicated that CXCL10, a pro-inflammatory chemokine, might be involved in the abnormal immune response in AA.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/23994430">23994430</a><div class="entities" style="line-height: 2.5"><h3>Correction of abnormal T cell subsets by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura.</h3></br>Idiopathic thrombocytopenic purpura (ITP) is an acquired autoimmune disorder. Both impaired platelet production and T cell-mediated effects play a role in ITP thrombocytopenia. A Th1 polarization of the immune response, up-regulation of Th17 cells and decreased number of Treg cells have been demonstrated in ITP patients. High-dose dexamethasone was administered as first-line therapy in adult patients with ITP. However, the mechanism of effects of dexamethasone on ITP is still unclear. In this study, we tested the effectiveness of high-dose dexamethasone as initial treatment in adults with immune thrombocytopenic purpura. PBMCs were isolated from Donors, ITP and Treatment groups. T cell subsets were analyzed by FCM and transcriptional factors were checked by Real-time PCR. We found that dexamethasone returned the ratio of Th1/Th2 and the number of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Treg cells to the normal levels. Furthermore, we identified that dexamethasone corrected the T cell subset levels through inhibiting <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and FOXp3 expression and promoting RORγt expression. Taken together, we reported a previously unrecognized mechanism on dexamethasone in the ITP treatment. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/23269607">23269607</a><div class="entities" style="line-height: 2.5"><h3>Downregulation of IL-17-producing T cells is associated with regulatory T cell expansion and disease progression in chronic lymphocytic leukemia.</h3></br>Little is known about the immunobiology of interleukin-17 (IL-17)-producing T cells and regulatory T cells (Treg) in chronic lymphocytic leukemia (CLL). In this study, the frequencies of Th17, Tc17, and CD39(+) Treg cells were enumerated in peripheral T cells isolated from 40 CLL patients and 15 normal subjects by flow cytometry. Our results showed a lower frequency of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Tc17 cells in progressive (0.99 ± 0.12 % of total CD3(+)CD4(+) cells; 0.44 ± 0.09 % of total CD8(+) cells) compared to indolent patients (1.57 ± 0.24 %, p = 0.042; 0.82 ± 0.2 %, p = 0.09) and normal subjects (1.78 ± 0.2 %, p = 0.003; 0.71 ± 0.09 %, p = 0.04). Decrease in IL-17-producing T cells was associated with CD39(+) Treg cells expansion. Variation of IL-17-producing cells and Treg cells in indolent and progressive patients was neither associated to the expression levels of Th1- and Th2-specific transcription factors T-bet and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> nor to the frequencies of IFN-γ and IL-4-producing CD4(+) T cells in a selected number of samples. Additionally, suppressive potential of CD4(+) Treg was similar in CLL patients and normal subjects. Our data indicate that progression of CLL is associated with downregulation of IL-17-producing T cells and expansion of Treg cells, implying contribution of these subsets of T cells in the progression of CLL.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21367463">21367463</a><div class="entities" style="line-height: 2.5"><h3>RORC and Foxp3 axis in cerebrospinal fluid of patients with neuro-Behçet's disease.</h3></br>Neurological manifestations are present in 5% to 30% of patients with Behçet's disease (BD). Neuro-Behçet's Disease (NBD) is hypothetically caused by T helper (Th) cells, which development is dependent on the expression of lineage-specific transcription factors. Cerebrospinal fluid (CSF) mRNA expression of TBX21, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, RORC, FOXP3 and EBI3 were assessed in 18 NBD patients and 26 controls disease [16 noninflammatory neurological disease (NIND) and 10 headache attributed to Behçet's disease (HaBD)]. Expression of TBX21 (Th1), RORC (Th17) and Foxp3 (Treg) were increased in NBD patients compared to HaBD and NIND patients. EBI3 and Th2-associated <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expressions were found to be decreased (P<0.0001 and P<0.0001) in NBD patients. Analysis of transcription factor ratios, revealed an increase in the RORC/FOXP3 and TBX21/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> ratios in NBD patients (P<0.0001; P<0.0003). Our findings indicate that both Th1 and Th17 mRNA expressions involving a possible impairment of Treg cells. This might play a role in CSF-NBD inflammation, permitting activation of harmful T cell subpopulations. The TBX21/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and RORC/FOXP3 ratios dysregulations in NBD are consistent with those reported in other inflammatory diseases and indicating the plasticity existing between Th1, <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Treg cells during inflammation.</div></details><details><summary>TC1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/25528359">25528359</a><div class="entities" style="line-height: 2.5"><h3>The 3 major types of innate and adaptive cell-mediated effector immunity.</h3></br>The immune system has tailored its effector functions to optimally respond to distinct species of microbes. Based on emerging knowledge on the different effector T cell and innate lymphoid cell (ILC) lineages, it is clear that the innate and adaptive immune systems converge into 3 major kinds of cell-mediated effector immunity, which we propose to categorize as type 1, type 2, and type 3. Type 1 immunity consists of T-bet(+) IFN-γ-producing group 1 ILCs (ILC1 and natural killer cells), CD8(+) cytotoxic T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TC1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>), and CD4(+) TH1 cells, which protect against intracellular microbes through activation of mononuclear phagocytes. Type 2 immunity consists of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> ILC2s, TC2 cells, and TH2 cells producing IL-4, IL-5, and IL-13, which induce mast cell, basophil, and eosinophil activation, as well as IgE antibody production, thus protecting against helminthes and venoms. Type 3 immunity is mediated by retinoic acid-related orphan receptor γt(+) ILC3s, TC17 cells, and TH17 cells producing IL-17, IL-22, or both, which activate mononuclear phagocytes but also recruit neutrophils and induce epithelial antimicrobial responses, thus protecting against extracellular bacteria and fungi. On the other hand, type 1 and 3 immunity mediate autoimmune diseases, whereas type 2 responses can cause allergic diseases. </div></details><details><summary>TH9</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27858144">27858144</a><div class="entities" style="line-height: 2.5"><h3>Th9 and other IL-9-producing cells in allergic asthma.</h3></br>Allergic asthma is a worldwide increasing chronic disease of the airways which affects more than 300 million people. It is associated with increased IgE, mast cell activation, airway hyperresponsiveness (AHR), mucus overproduction and remodeling of the airways. Previously, this pathological trait has been associated with T helper type 2 (Th2) cells. Recently, different CD4+  T cell subsets (Th17, Th9) as well as cells of innate immunity, like mast cells and innate lymphoid cells type 2 (ILC2s), which are all capable of producing the rediscovered cytokine IL-9, are known to contribute to this disease. Regarding Th9 cells, it is known that naïve T cells develop into IL-9-producing cells in the presence of interleukin-4 (IL-4) and transforming growth factor beta (TGFβ). Downstream of IL-4, several transcription factors like signal transducer and activator of transcription 6 (STAT6), interferon regulatory factor 4 (IRF4), GATA binding protein 3 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>), basic leucine zipper transcription factor, ATF-like (BATF) and nuclear factor of activated T cells (NFAT) are activated. Additionally, the transcription factor PU.1, which is downstream of TGFβ signaling, also seems to be crucial in the development of Th9 cells. IL-9 is a pleiotropic cytokine that influences various distinct functions of different target cells such as T cells, B cells, mast cells and airway epithelial cells by activating STAT1, STAT3 and STAT5. Because of its pleiotropic functions, IL-9 has been demonstrated to be involved in several diseases, such as cancer, autoimmunity and other pathogen-mediated immune-regulated diseases. In this review, we focus on the role of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th9    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and IL-9-producing cells in allergic asthma.</div></details><details><summary>THP</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/19912251">19912251</a><div class="entities" style="line-height: 2.5"><h3>Translational mini-review series on Th17 cells: induction of interleukin-17 production by regulatory T cells.</h3></br>Uncommitted (naive) CD4(+) T helper cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Thp    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) can be induced to differentiate to specific lineages according to the local cytokine milieu, towards T helper type 1 (Th1), Th2, Th17 and regulatory T cell (T(reg)) phenotypes in a mutually exclusive manner. Each phenotype is characterized by unique signalling pathways and expression of specific transcription factors, notably T-bet for Th1, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> for Th2, forkhead box P3 (FoxP3) for T(regs) and receptor-related orphan receptor (ROR)alpha and RORgammat for Th17 cells. T(regs) and Th17 cells have been demonstrated to arise from common precursors in a reciprocal manner based on exposure to transforming growth factor (TGF)-beta or TGF-beta plus interleukin (IL)-6 and carry out diametrically opposing functions, namely suppression or propagation of inflammation, respectively. However, while epigenetic modifications in Th1 and Th2 differentiated cells prevents their conversion to other phenotypes, Th17 cells generated in vitro using TGF-beta and IL-6 are unstable and can convert to other phenotypes, especially Th1, both in vitro and in vivo. T(regs) are generated from naive precursors both in the thymus (natural, nT(regs)) and in the periphery (induced, iT(regs)). The highly suppressive function of T(regs) enables them to control many inflammatory diseases in animals and makes them particularly attractive candidates for immunotherapy in humans. The stability of the T(reg) phenotype is therefore of paramount importance in this context. Recent descriptions of T(reg) biology have suggested that components of pathogens or inflammatory mediators may subvert the suppressive function of T(regs) in order to allow propagation of adequate immune responses. Unexpectedly, however, a number of groups have now described conversion of T(regs) to the Th17 phenotype induced by appropriate inflammatory stimuli. These observations are particularly relevant in the context of cell therapy but may also explain some of the dysregulation seen in autoimmune diseases. In this paper, we review T(reg) to Th17 conversion and propose some potential mechanisms for this phenomenon.</div></details></details></td>
    </tr>
    <tr>
      <th>19</th>
      <td>LIN28B</td>
      <td>2</td>
      <td>NKT:1, TREG:1</td>
      <td>0.280415</td>
      <td>ENSG00000187772</td>
      <td><details><summary>Subtypes</summary><details><summary>NKT</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/22345399">22345399</a><div class="entities" style="line-height: 2.5"><h3><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Lin28b    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> reprograms adult bone marrow hematopoietic progenitors to mediate fetal-like lymphopoiesis.</h3></br>The immune system develops in waves during ontogeny; it is initially populated by cells generated from fetal hematopoietic stem cells (HSCs) and later by cells derived from adult HSCs. Remarkably, the genetic programs that control these two distinct stem cell fates remain poorly understood. We report that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Lin28b    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is specifically expressed in mouse and human fetal liver and thymus, but not in adult bone marrow or thymus. We demonstrate that ectopic expression of Lin28 reprograms hematopoietic stem/progenitor cells (HSPCs) from adult bone marrow, which endows them with the ability to mediate multilineage reconstitution that resembles fetal lymphopoiesis, including increased development of B-1a, marginal zone B, gamma/delta (γδ) T cells, and natural killer T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NKT    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells.</div></details><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27793996">27793996</a><div class="entities" style="line-height: 2.5"><h3><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Lin28b    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> Regulates Fetal Regulatory T Cell Differentiation through Modulation of TGF-β Signaling.</h3></br>Immune tolerance between the fetus and mother represents an active process by which the developing fetus must not mount immune responses to noninherited Ags on chimeric maternal cells that reside in fetal tissue. This is, in part, mediated by the suppressive influence of CD4+ FOXP3+ CD25+  regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>). Fetal secondary lymphoid organs have an increased frequency of Tregs and, as compared with adult T cells, fetal naive CD4+  T cells exhibit a strong predisposition to differentiate into Tregs when stimulated. This effect is mediated by the TCR and TGF-β pathways, and fetal T cells show significantly increased Treg differentiation in response to anti-CD3 and TGF-β stimulation. Naive fetal T cells also exhibit increased signaling through the TGF-β pathway, with these cells demonstrating increased expression of the signaling mediators TGF-βRI, TGF-βRIII, and SMAD2, and higher levels of SMAD2/SMAD3 phosphorylation. Increased fetal Treg differentiation is mediated by the RNA-binding protein <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Lin28b    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, which is overexpressed in fetal T cells as compared with adult cells. When <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Lin28b    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression is decreased in naive fetal T cells, they exhibit decreased Treg differentiation that is associated with decreased TGF-β signaling and lowered expression of TGF-βRI, TGF-βRIII, and SMAD2. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Lin28b    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> regulates the maturation of let-7 microRNAs, and these TGF-β signaling mediators are let-7 targets. We hypothesize that loss of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Lin28b    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression in fetal T cells leads to increased mature let-7, which causes decreased expression of TGF-βRI, TGF-βRIII, and SMAD2 proteins. A reduction in TGF-β signaling leads to reduced Treg numbers.</div></details></details></td>
    </tr>
    <tr>
      <th>20</th>
      <td>AHR</td>
      <td>30</td>
      <td>TREG:10, TH:4, TH17:4, TH22:4, TREG1:4, NKT:3, TH2:3, TH1:2, TH9:1, γδT:1</td>
      <td>0.259351</td>
      <td>ENSG00000106546</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/29553094">29553094</a><div class="entities" style="line-height: 2.5"><h3>Role of Regulatory T cells in Airway Inflammation in Asthma.</h3></br>Asthma is an allergic disease characterized by chronic airway inflammation, airway hyperresponsiveness (AHR), reversibility and remodeling. Inhaled corticosteroids (ICS) are effective in many patients with asthma. However, ICS are a controlling, but not but curative treatment, and there are still many patients with refractory and difficult-to-treat asthma. The evaluation of airway inflammation by induced sputum, non-specific <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> by methacholine, and asthmatic reactions by specific allergen challenge techniques are useful not only to investigate the pathogenesis of asthma but also to help develop new drugs for asthma management. Interactions between inflammation and regulation, such as between regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>), and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> were investigated using these techniques. The phenotypes are Tregs characterized by expression of the forkhead box P3 (Foxp3) and cytotoxic T lymphocyte antigen 4 (CTLA4), which are potent mediators of dominant self-tolerance. Foxp3 and CTLA4 interact with each other. In patients with mild asthma, airway Tregs were decreased and airway eosinophilic inflammation was activated with accelerated <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. Human asthmatic attack models by allergen challenge demonstrated that airway Tregs were decreased from the baseline with late asthmatic response (LAR) in patients with dual-responder asthma, and there was a significant correlation between change in airway Tregs and LAR. Airway Tregs were increased with escalation of interleukin-10 by ICS. The investigation of Tregs may lead to new strategies for management of asthma and other allergic diseases.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28550042">28550042</a><div class="entities" style="line-height: 2.5"><h3>T cell expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AhR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> inhibits the maintenance of pTreg  cells in the gastrointestinal tract in acute GVHD.</h3></br>The aryl hydrocarbon receptor (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AhR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) is a ligand-activated transcription factor that affects the function and development of immune cells. Here, we show that recipient mice receiving AhR<sup>-/-</sup> T cells have improved survival and decreased acute graft-versus-host disease (aGVHD) in 2 different murine allogeneic bone marrow transplant (BMT) models. We also show that CD4+  T cells lacking <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AhR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> demonstrate reduced accumulation in secondary lymphoid tissue because of low levels of proliferation 4 days after BMT. Additionally, we found a significant increase in the quantity of peripherally induced regulatory donor T (pTreg ) cells in the colon of recipients transplanted with AhR<sup>-/-</sup> T cells 14 days after transplant. Blockade of AhR using a clinically available <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AhR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> antagonist greatly enhanced the in vitro generation of inducible <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>  (iTreg ) cells from naïve CD4+  human T cells. We have identified <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AhR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> as a novel target on donor T cells that is critical to the pathogenesis of aGVHD.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27330188">27330188</a><div class="entities" style="line-height: 2.5"><h3>Tolerogenic nanoparticles inhibit T cell-mediated autoimmunity through SOCS2.</h3></br>Type 1 diabetes (T1D) is a T cell-dependent autoimmune disease that is characterized by the destruction of insulin-producing β cells in the pancreas. The administration to patients of ex vivo-differentiated FoxP3(+) regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells or tolerogenic dendritic cells (DCs) that promote Treg cell differentiation is considered a potential therapy for T1D; however, cell-based therapies cannot be easily translated into clinical practice. We engineered nanoparticles (NPs) to deliver both a tolerogenic molecule, the aryl hydrocarbon receptor (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AhR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) ligand 2-(1'H-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE), and the β cell antigen proinsulin (NPITE+Ins) to induce a tolerogenic phenotype in DCs and promote Treg cell generation in vivo. NPITE+Ins administration to 8-week-old nonobese diabetic mice suppressed autoimmune diabetes. NPITE+Ins induced a tolerogenic phenotype in DCs, which was characterized by a decreased ability to activate inflammatory effector T cells and was concomitant with the increased differentiation of FoxP3(+) Treg cells. The induction of a tolerogenic phenotype in DCs by NPs was mediated by the AhR-dependent induction of Socs2, which resulted in inhibition of nuclear factor κB activation and proinflammatory cytokine production (properties of tolerogenic DCs). Together, these data suggest that NPs constitute a potential tool to reestablish tolerance in T1D and potentially other autoimmune disorders.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/25701076">25701076</a><div class="entities" style="line-height: 2.5"><h3>Systems biologic analysis of T regulatory cells genetic pathways in murine primary biliary cirrhosis.</h3></br>CD4(+)Foxp3(+) regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) play a non-redundant role in control of excessive immune responses, and defects in Tregs have been shown both in patients and murine models of primary biliary cirrhosis (PBC), a progressive autoimmune biliary disease. Herein, we took advantage of a murine model of PBC, the dominant negative transforming growth factor β receptor II (dnTGFβRII) mice, to assess Treg genetic defects and their functional effects in PBC. By using high-resolution microarrays with verification by PCR and protein expression, we found profound and wide-ranging differences between dnTGFβRII and normal, wild type Tregs. Critical transcription factors were down-regulated including Eos, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ahr    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, Klf2, Foxp1 in dnTGFβRII Tregs. Functionally, dnTGFβRII Tregs expressed an activated, pro-inflammatory phenotype with upregulation of Ccl5, Granzyme B and IFN-γ. Genetic pathway analysis suggested that the primary effect of loss of TGFβ pathway signaling was to down regulate immune regulatory processes, with a secondary upregulation of inflammatory processes. These findings provide new insights into T regulatory genetic defects; aberrations of the identified genes or genetic pathways should be investigated in human PBC Tregs. This approach which takes advantage of biologic pathway analysis illustrates the ability to identify genes/pathways that are affected both independently and dependent on abnormalities in TGFβ signaling. Such approaches will become increasingly useful in human autoimmunity. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/24527450">24527450</a><div class="entities" style="line-height: 2.5"><h3>Toward understanding the role of aryl hydrocarbon receptor in the immune system: current progress and future trends.</h3></br>The immune system is regulated by distinct signaling pathways that control the development and function of the immune cells. Accumulating evidence suggest that ligation of aryl hydrocarbon receptor (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ahr    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>), an environmentally responsive transcription factor, results in multiple cross talks that are capable of modulating these pathways and their downstream responsive genes. Most of the immune cells respond to such modulation, and many inflammatory response-related genes contain multiple xenobiotic-responsive elements (XREs) boxes upstream. Active research efforts have investigated the physiological role of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ahr    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in inflammation and autoimmunity using different animal models. Recently formed paradigm has shown that activation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ahr    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or 3,3'-diindolylmethane (DIM) prompts the differentiation of CD4(+)Foxp3(+) regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) and inhibits T helper (Th)-17 suggesting that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ahr    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is an innovative therapeutic strategy for autoimmune inflammation. These promising findings generate a basis for future clinical practices in humans. This review addresses the current knowledge on the role of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ahr    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in different immune cell compartments, with a particular focus on inflammation and autoimmunity. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/23319400">23319400</a><div class="entities" style="line-height: 2.5"><h3>Possible role of the 'IDO-<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AhR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> axis' in maternal-foetal tolerance.</h3></br>The induction<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">     an    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>d maintenance of immunologic tolerance at the feto-maternal interface is necessary for a successful pregnancy. The most accepted hypothesis for the mechanism underlying this tolerance is that pregnancy-induced foetal antigen-specific maternal T regulatory (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> ) cells mediate maternal tolerance to the foetus. The aryl hydrocarbon receptor (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AhR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>), which is highly expressed in the placenta, is widely studied in female reproductive biology and immunology. Activation of AhR can promote immune tolerance by controlling the differentiation of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>  cells in some autoimmune disorders. However, the specific mechanisms underlying tolerance are poorly understood. Indoleamine 2,3-dioxygenase (IDO) is the initial and rate-limiting enzyme of tryptophan catabolism in human placental trophoblasts. IDO produces kynurenine, an endogenous <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AhR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> ligand that directly activates <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AhR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and is proposed to be central to the establishment and maintenance of immunologic tolerance at the maternal-foetal interface. We propose that kynurenine activates <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AhR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, leading to the AhR-dependent <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>  cells generation, which in turn critically regulates immunological tolerance at the feto-maternal interface. This hypothesis must be tested and the proof of this hypothesis may provide a potential therapeutic target for the treatment of infertility and other adverse pregnancy outcomes resulted from inadequate immunological tolerance at the feto-maternal interface.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/20676092">20676092</a><div class="entities" style="line-height: 2.5"><h3>Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells.</h3></br>The aryl hydrocarbon receptor (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AhR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) participates in the differentiation of mouse regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells) and interleukin 17 (IL-17)-producing helper T cells (T(H)17 cells), but its role in human T cell differentiation is unknown. We investigated the role of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AhR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in the differentiation of human induced <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells (iT(reg) cells). We found that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AhR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> activation promoted the differentiation of CD4(+)Foxp3(-) T cells, which produce IL-10 and control responder T cells through granzyme B. However, activation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AhR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in the presence of transforming growth factor-beta1 induced Foxp3(+) iT(reg) cells, which suppress responder T cells through the ectonucleoside triphosphate diphosphohydrolase CD39. The induction of functional Foxp3(+) iT(reg) cells required coordinated action of the transcriptional regulators Smad1 and Aiolos. Thus, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AhR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is a potential target through which functional iT(reg) cells could be induced in human autoimmune disorders.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/19811658">19811658</a><div class="entities" style="line-height: 2.5"><h3>GITR signaling potentiates airway hyperresponsiveness by enhancing Th2 cell activity in a mouse model of asthma.</h3></br>Allergic asthma is characterized by airway hyperresponsiveness (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) and allergic inflammation of the airways, driven by allergen-specific Th2 cells. The asthma phenotypes and especially <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> are sensitive to the presence and activity of regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells in the lung. Glucocorticoid-induced tumor necrosis factor receptor (GITR) is known to have a co-stimulatory function on effector CD4+ T cells, rendering these cells insensitive to Treg suppression. However, the effects of GITR signaling on polarized Th1 and Th2 cell effector functions are not well-established. We sought to evaluate the effect of GITR signaling on fully differentiated Th1 and Th2 cells and to determine the effects of GITR activation at the time of allergen provocation on AHR and airway inflammation in a Th2-driven mouse model of asthma.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27783946">27783946</a><div class="entities" style="line-height: 2.5"><h3><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> Activation Is Protective against Colitis Driven by T Cells in Humanized Mice.</h3></br>Existing therapies for inflammatory bowel disease that are based on broad suppression of inflammation result in variable clinical benefit and unwanted side effects. A potential therapeutic approach for promoting immune tolerance is the in vivo induction of regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>). Here we report that activation of the aryl hydrocarbon receptor using the non-toxic agonist 2-(1'H-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) induces human Tregs in vitro that suppress effector T cells through a mechanism mediated by CD39 and Granzyme B. We then developed a humanized murine system whereby human CD4+  T cells drive colitis upon exposure to 2,4,6-trinitrobenzenesulfonic acid and assessed ITE as a potential therapeutic. ITE administration ameliorated colitis in humanized mice with increased CD39, Granzyme B, and IL10-secreting human Tregs. These results develop an experimental model to investigate human CD4+  T responses in vivo and identify the non-toxic <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> agonist ITE as a potential therapy for promoting immune tolerance in the intestine.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/26226672">26226672</a><div class="entities" style="line-height: 2.5"><h3>[Serum Levels of Regulatory T Cell in the Yusho Patients].</h3></br>Dioxin and dioxin-like compounds receptor (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ahr    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) mainly expressed on the surface of regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cell and Th17 cell could regulate immunological functions in the Yusho patients. We prospectively analyzed data obtained in a total of 56 cases of Yusho, which include patients identified ('Nintei' ) or non-identified ( 'Minintei') or identified as a family member, at the annual health check in 2014. The number of Treg cell showed lower among identified patients compared with non-identified group or family identified group (p = 0.4184 and p = 0.291, respectively). There was also a strong correlation between serum levels of neutral fat and the number of Treg cells (p = 0.0313). These results suggest that Treg cell plays a principal role in the immune response among Yusho patients.</div></details><details><summary>TH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28276465">28276465</a><div class="entities" style="line-height: 2.5"><h3>Cytochrome P450s in human immune cells regulate IL-22 and c-Kit via an <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> feedback loop.</h3></br>The mechanisms how environmental compounds influence the human immune system are unknown. The environmentally sensitive transcription factor aryl hydrocarbon receptor (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) has immune-modulating functions and responds to small molecules. Cytochrome P4501 enzymes (CYP1) act downstream of the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and metabolize small molecules. However, it is currently unknown whether CYP1 activity is relevant for immune modulation. We studied the interdependence of CYP1 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in human primary immune cells using pharmacological methods. CYP1 inhibition increased the expression levels of the stem cell factor receptor (c-Kit) and interleukin (IL)-22 but decreased IL-17. Single cell analyses showed that CYP1 inhibition especially promoted CD4+  helper T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells that co-express c-Kit and IL-22 simultaneously. The addition of an <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> antagonist reversed all these effects. In addition to T cells, we screened other human immune cells for CYP and found cell-specific fingerprints, suggesting that similar mechanisms are present in multiple immune cells. We describe a feedback loop yet unknown in human immune cells where CYP1 inhibition resulted in an altered <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>-dependent immune response. This mechanism relates CYP1-dependent metabolism of environmental small molecules to human immunity.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/24737285">24737285</a><div class="entities" style="line-height: 2.5"><h3>Increased circulating T‑helper 22 cells in patients with dilated cardiomyopathy.</h3></br>Recently, the newly determined interleukin (IL)‑22‑producing T-helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) 22 cell has been implicated to be involved in the pathogenesis of autoimmune diseases. However, its role in the pathogenesis of dilated cardiomyopathy (DCM) has yet to be elucidated. A total of 30 patients with DCM and 30 healthy controls were enrolled in the present study. The levels of Th22, Th17 and Th1 cells in the peripheral blood were analyzed by flow cytometry. Levels of plasma IL‑22 and autoantibody adenine nucleotide translocator (ANT) were assessed using the ELISA. The key transcription factor of Th22, aryl hydrocarbon receptor (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>), was assessed using quantitative polymerase chain reaction. Additionally, clinical data on the brain natriuretic peptide (BNP), C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were collected. In comparison with those in the control group, significantly elevated levels of Th22, Th17 and Th1 cells were detected in patients with DCM (all P<0.01). Similarly, elevated mRNA levels of peripheral <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> were detected in patients with DCM. The percentage of Th22 cells was higher in ANT‑positive compared with ANT‑negative patients with DCM. The levels of BNP and CRP, but not ESR, showed a significant positive correlation with those of Th22 cells. With regard to the concentrations of plasma IL‑22, no statistical difference was found between patients with DCM and the healthy controls, nor did it demonstrate a statistical correlation with the percentage of Th22 cells. In conclusion, the present study showed that patients with DCM, particularly those of the ANT autoantibody positive subjects, exhibit elevated levels of peripheral Th22 cells, indicating that a Th22 immune response may be implicated in the pathogenesis of DCM. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28658543">28658543</a><div class="entities" style="line-height: 2.5"><h3>Modeling TH  2 responses and airway inflammation to understand fundamental mechanisms regulating the pathogenesis of asthma.</h3></br>In this review, we highlight experiments conducted in our laboratories that have elucidated functional roles for CD4+  T-helper type-2 lymphocytes (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>  2 cells), their associated cytokines, and eosinophils in the regulation of hallmark features of allergic asthma. Notably, we consider the complexity of type-2 responses and studies that have explored integrated signaling among classical TH  2 cytokines (IL-4, IL-5, and IL-13), which together with CCL11 (eotaxin-1) regulate critical aspects of eosinophil recruitment, allergic inflammation, and airway hyper-responsiveness (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>). Among our most important findings, we have provided evidence that the initiation of TH  2 responses is regulated by airway epithelial cell-derived factors, including TRAIL and MID1, which promote TH  2 cell development via STAT6-dependent pathways. Further, we highlight studies demonstrating that microRNAs are key regulators of allergic inflammation and potential targets for anti-inflammatory therapy. On the background of TH  2 inflammation, we have demonstrated that innate immune cells (notably, airway macrophages) play essential roles in the generation of steroid-resistant inflammation and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> secondary to allergen- and pathogen-induced exacerbations. Our work clearly indicates that understanding the diversity and spatiotemporal role of the inflammatory response and its interactions with resident airway cells is critical to advancing knowledge on asthma pathogenesis and the development of new therapeutic approaches.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/11292022">11292022</a><div class="entities" style="line-height: 2.5"><h3>IL-5-induced airway eosinophilia--the key to asthma?</h3></br>Bronchial asthma is a chronic inflammatory airway disease defined by reversible airway obstruction and non-specific airway hyper-responsiveness (AHR). Although profound insights have been made into the pathophysiology of asthma, the exact mechanisms inducing and regulating the disease are still not fully understood. Yet, it is generally accepted that the pathological changes in asthma are induced by a chronic inflammatory process which is characterized by infiltration of the bronchial mucosa with lymphocytes and eosinophils, increased mucus production and submucosal edema. There is increasing evidence that an imbalance in the T-helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cell response of genetically predisposed individuals to common environmental antigens plays a pivotal role in the pathogenesis of allergic bronchial asthma and other atopic disorders. Following allergic sensitization, T cells from atopic patients tend to produce elevated levels of Th2-type cytokines, especially interleukin (IL)-4, IL-13, IL-5 and IL-6, which induce and regulate IgE production and eosinophil airway infiltration. In this review, the role of Th2-type cytokines, IgE and airway eosinophils in the induction of airway inflammation and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is discussed, and animal studies of asthma and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, mainly in rodents will be considered. A better understanding of the underlying mechanisms leading to asthma pathology may yield more specific immunological strategies for the treatment of this disease which is increasing worldwide.</div></details><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/26511867">26511867</a><div class="entities" style="line-height: 2.5"><h3>The emerging role of aryl hydrocarbon receptor in the activation and differentiation of Th17 cells.</h3></br>The aryl hydrocarbon receptor (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) is a cytoplasmic transcription factor, which plays an essential role in the xenobiotic metabolism in a wide variety of cells. The <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> gene is evolutionarily conserved and it has a central role not only in the differentiation and maturation of many tissues, but also in the toxicological metabolism of the cell by the activation of metabolizing enzymes. Several lines of evidence support that both <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> agonists and antagonists have profound immunological effects; and recently, the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> has been implicated in antibacterial host defense. According to recent studies, the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is essential for the differentiation and activation of T helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. It is well known that Th17 cells have a central role in the development of inflammation, which is crucial in the defense against pathogens. In addition, Th17 cells play a major role in the pathogenesis of several autoimmune diseases such as rheumatoid arthritis. Therefore, the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> may provide connection between the environmental chemicals, the immune regulation, and autoimmunity. In the present review, we summarize the role of the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in the Th17 cell functions. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/24498387">24498387</a><div class="entities" style="line-height: 2.5"><h3>Identification of cinnabarinic acid as a novel endogenous aryl hydrocarbon receptor ligand that drives IL-22 production.</h3></br>The aryl hydrocarbon receptor (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) binds to environmental toxicants including synthetic halogenated aromatic hydrocarbons and is involved in a diverse array of biological processes. Recently, the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> was shown to control host immunity by affecting the balance between inflammatory T cells that produce IL-17 (Th17) and IL-22 versus regulatory T cells (Treg) involved in tolerance. While environmental <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> ligands can mediate this effect, endogenous ligands are likely to be more relevant in host immune responses. We investigated downstream metabolites of tryptophan as potential <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> ligands because (1) tryptophan metabolites have been implicated in regulating the balance between <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Treg cells and (2) many of the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> ligands identified thus far are derivatives of tryptophan. We characterized the ability of tryptophan metabolites to bind and activate the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and to increase IL-22 production in human T cells. We report that the tryptophan metabolite, cinnabarinic acid (CA), is an <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> ligand that stimulates the differentiation of human and mouse T cells producing IL-22. We compare the IL-22-stimulating activity of CA to that of other tryptophan metabolites and define stimulation conditions that lead to CA production from immune cells. Our findings link tryptophan metabolism to <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> activation and define a novel endogenous <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> agonist with potentially broad biological functions. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/24083809">24083809</a><div class="entities" style="line-height: 2.5"><h3>Yusho patients show increased serum IL-17, IL-23, IL-1β, and TNFα levels more than 40 years after accidental polychlorinated biphenyl poisoning.</h3></br>The Yusho poisoning incident, caused by rice oil contaminated with polychlorinated biphenyls (PCBs), polychlorinated quarterphenyls (PCQs), and polychlorinated dibenzofurans (PCDFs) generated by heat-denatured PCBs, occurred in 1968 in western Japan. Although severe symptoms are rarely observed today, the levels of PCBs and PCDFs in the sera of Yusho patients remain high. The aryl hydrocarbon receptor (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AhR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>), which also acts as a dioxin receptor, is a transcriptional regulator that mediates dioxin toxicity. Recent studies show that dioxin mediates its immune toxic effects via <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AhR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AhR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> activation induces dysregulation of interleukin (IL)-17- producing T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. This study therefore hypothesized that Yusho patients would show dysregulated TH17 cell-mediated immune responses. To validate the hypothesis, levels of IL-17 and IL-22, each secreted by TH17 cells, along with IL-1β and IL-23 were measured in serum samples from 40 Yusho patients and 40 age-matched controls. Levels of tumor necrosis factor (TNF)-α potentially secreted by TH17 cell-stimulated neutrophils and macrophages were also measured. The results indicated that serum IL-17 levels, as well as those of IL-1β, IL-23, and TNFα, were significantly higher in Yusho patients than in controls. In contrast, serum IL-22 levels were significantly lower in the Yusho patients. These results suggest that Yusho patients have dysregulated TH17 cell-mediated immune responses that may be linked to inflammation.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/20450290">20450290</a><div class="entities" style="line-height: 2.5"><h3>Emerging roles of T helper subsets in the pathogenesis of asthma.</h3></br>The cardinal features of asthma include pulmonary inflammation and airway hyperresponsiveness (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>). Classically, asthma, specifically allergic asthma, has been attributed to a hyperactive Th2 cell immune response. However, the Th2 cell-mediated inflammation model has failed to adequately explain many of the clinical and molecular aspects of asthma. In addition, the outcomes of Th2-targeted therapeutic trials have been disappointing. Thus, asthma is now believed to be a complex and heterogeneous disorder, with several molecular mechanisms underlying the airway inflammation and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> that is associated with asthma. The original classification of Th1 and Th2 pathways has recently been expanded to include additional effector Th cell subsets. These include <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>, Th9 and Treg cells. Emerging data highlight the involvement of these new Th cell subsets in the initiation and augmentation of airway inflammation and asthmatic responses. We now review the roles of these recently classified effector Th cell subsets in asthmatic inflammation and the insights they may provide in addition to the traditional Th2 paradigm. The hope is that a clearer understanding of the inflammatory pathways involved and the mediators of inflammation will yield better targeted therapeutics.</div></details><details><summary>TH22</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/26000313">26000313</a><div class="entities" style="line-height: 2.5"><h3>The alteration and clinical significance of Th22/Th17/Th1 cells in patients with chronic myeloid leukemia.</h3></br>T helper- (Th-) cell immunodeficiency plays important roles in tumor development and their effects in chronic myeloid leukemia (CML) remain unclear. In the present study, we mainly investigated the role of Th22, Th17, and Th1 cell and their related cytokines (IL-22, IL-17, and IFN-r) in the pathophysiology of CML. Bone marrow (BM) and peripheral blood (PB) were extracted from newly diagnosed (ND), chronic phase- (CP-) CML patients, and controls. Th subsets were examined by flow cytometry. Plasma IL-22, IL-17, and IFN-r concentrations were measured by ELISA. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and RORC mRNA expressions were examined by RT-PCR. The frequencies of Th22, Th17, and Th1 cells, along with the expression of specific transcription factors RORC and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, were significantly decreased in ND patients compared with healthy controls, while all these abnormality recovered in CP patients. In addition, there existed a significantly positive relationship between <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th22    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th17 cells in PB or BM. A significantly negative relationship was found between Th cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th22    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>, Th17, or Th1) and BCR-ABL (%) IS or the number of PB white blood cells. All these results demonstrated that Th22, Th17, and Th1 cells might be important therapeutic targets in CML and could facilitate a better outcome for tumor immunotherapy. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/24737285">24737285</a><div class="entities" style="line-height: 2.5"><h3>Increased circulating T‑helper 22 cells in patients with dilated cardiomyopathy.</h3></br>Recently, the newly determined interleukin (IL)‑22‑producing T-helper (Th) 22 cell has been implicated to be involved in the pathogenesis of autoimmune diseases. However, its role in the pathogenesis of dilated cardiomyopathy (DCM) has yet to be elucidated. A total of 30 patients with DCM and 30 healthy controls were enrolled in the present study. The levels of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th22    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>, Th17 and Th1 cells in the peripheral blood were analyzed by flow cytometry. Levels of plasma IL‑22 and autoantibody adenine nucleotide translocator (ANT) were assessed using the ELISA. The key transcription factor of Th22, aryl hydrocarbon receptor (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>), was assessed using quantitative polymerase chain reaction. Additionally, clinical data on the brain natriuretic peptide (BNP), C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were collected. In comparison with those in the control group, significantly elevated levels of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th22    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>, Th17 and Th1 cells were detected in patients with DCM (all P<0.01). Similarly, elevated mRNA levels of peripheral <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> were detected in patients with DCM. The percentage of Th22 cells was higher in ANT‑positive compared with ANT‑negative patients with DCM. The levels of BNP and CRP, but not ESR, showed a significant positive correlation with those of Th22 cells. With regard to the concentrations of plasma IL‑22, no statistical difference was found between patients with DCM and the healthy controls, nor did it demonstrate a statistical correlation with the percentage of Th22 cells. In conclusion, the present study showed that patients with DCM, particularly those of the ANT autoantibody positive subjects, exhibit elevated levels of peripheral Th22 cells, indicating that a Th22 immune response may be implicated in the pathogenesis of DCM. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/26255628">26255628</a><div class="entities" style="line-height: 2.5"><h3>Elevated Th22 as well as Th17 cells associated with therapeutic outcome and clinical stage are potential targets in patients with multiple myeloma.</h3></br>T helper (Th) cell imbalance plays important roles in tumor development and their effects in Multiple myeloma (MM) remain unclear. In the present study, we investigated the levels and clinical significance of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th22    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>, Th17 and Th1 cells in patients with MM. Th subsets were examined by flow cytometry. Plasma IL-22, IL-17A and IFN-γ concentrations were measured by ELISA. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and RORC mRNA expression was examined by RT-PCR. Here, we found that the frequency of Th22 cells was significantly elevated in peripheral blood (PB) and bone marrow (BM) of newly-diagnosed MM patients, and recovered in complete remission patients after chemotherapy. The circulating Th17 cells accompanied by IL-17A levels were also up-regulated in MM patients and decreased after remission. We also found that there was a significantly positive correlation between Th22 and Th17 cells in MM patients. Moreover, the frequencies of Th22 and Th17 cells were higher in stage III than in stage I+II of MM. Our data demonstrated that Th22 and Th17 cells might be important therapeutic targets in multiple myeloma and could facilitate the effect of antitumor immunotherapy.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/26159476">26159476</a><div class="entities" style="line-height: 2.5"><h3><mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th22    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells in autoimmunity: a review of current knowledge.</h3></br>Newly identified T helper cell 22 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th22    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) is a subset of CD4+ T cells with specific properties apart from other known CD4+ T cell subsets. Th22 is obviously discrete from Th17 and Th1 subsets by production of interleukin (IL)-22 but not IL-17 or IFN-γ, and also with distinguished expression of aryl hydrocarbon receptor (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) as the key transcription factor. This T helper subset, by producing pro-inflammatory cytokines such as IL-22 and tumor necrosis factor-α (TNF-α), is implicated in the pathogenesis of inflammatory and autoimmune disorder. This review discusses the role of Th22 and its cytokine IL-22 in the immunopathogenesis of autoimmune disease including acute coronary syndrome, psoriasis, atopic dermatitis, rheumatoid arthritis, systemic lupus erythematosus, Behçet's disease, type 1 and 2 diabetes and immune thrombocytopenia. </div></details><details><summary>NKT</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/19015310">19015310</a><div class="entities" style="line-height: 2.5"><h3>A novel subset of mouse NKT cells bearing the IL-17 receptor B responds to IL-25 and contributes to airway hyperreactivity.</h3></br>Airway hypersensitive reaction (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) is an animal model for asthma, which is caused or enhanced by environmental factors such as allergen exposure. However, the precise mechanisms that drive <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> remain unclear. We identified a novel subset of natural killer T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NKT    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells that expresses the interleukin 17 receptor B (IL-17RB) for IL-25 (also known as IL-17E) and is essential for the induction of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. IL-17RB is preferentially expressed on a fraction of CD4(+) NKT cells but not on other splenic leukocyte populations tested. IL-17RB(+) CD4(+) NKT cells produce predominantly IL-13 and Th2 chemokines upon stimulation with IL-25 in vitro. IL-17RB(+) NKT cells were detected in the lung, and depletion of IL-17RB(+) NKT cells by IL-17RB-specific monoclonal antibodies or NKT cell-deficient Jalpha18(-/-) mice failed to develop IL-25-dependent <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. Cell transfer of IL-17RB(+) but not IL-17RB(-) NKT cells into Jalpha18(-/-) mice also successfully reconstituted <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> induction. These results strongly suggest that IL-17RB(+) CD4(+) NKT cells play a crucial role in the pathogenesis of asthma.</div></details><details><summary>TH2</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27858144">27858144</a><div class="entities" style="line-height: 2.5"><h3>Th9 and other IL-9-producing cells in allergic asthma.</h3></br>Allergic asthma is a worldwide increasing chronic disease of the airways which affects more than 300 million people. It is associated with increased IgE, mast cell activation, airway hyperresponsiveness (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>), mucus overproduction and remodeling of the airways. Previously, this pathological trait has been associated with T helper type 2 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. Recently, different CD4+  T cell subsets (Th17, Th9) as well as cells of innate immunity, like mast cells and innate lymphoid cells type 2 (ILC2s), which are all capable of producing the rediscovered cytokine IL-9, are known to contribute to this disease. Regarding Th9 cells, it is known that naïve T cells develop into IL-9-producing cells in the presence of interleukin-4 (IL-4) and transforming growth factor beta (TGFβ). Downstream of IL-4, several transcription factors like signal transducer and activator of transcription 6 (STAT6), interferon regulatory factor 4 (IRF4), GATA binding protein 3 (GATA3), basic leucine zipper transcription factor, ATF-like (BATF) and nuclear factor of activated T cells (NFAT) are activated. Additionally, the transcription factor PU.1, which is downstream of TGFβ signaling, also seems to be crucial in the development of Th9 cells. IL-9 is a pleiotropic cytokine that influences various distinct functions of different target cells such as T cells, B cells, mast cells and airway epithelial cells by activating STAT1, STAT3 and STAT5. Because of its pleiotropic functions, IL-9 has been demonstrated to be involved in several diseases, such as cancer, autoimmunity and other pathogen-mediated immune-regulated diseases. In this review, we focus on the role of Th9 and IL-9-producing cells in allergic asthma.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/17172648">17172648</a><div class="entities" style="line-height: 2.5"><h3>TH2 cells in the pathogenesis of airway remodeling: regulatory T cells a plausible panacea for asthma.</h3></br>T-helper type 2 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are one of the hallmarks of airway remodeling. The daunting task of regaining tolerance will be to regulate airway hyperresponsiveness (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) and remodeling in chronic asthma by balancing the ballet of TH1 and TH2 cells. The mechanism of tolerance appears to be modulated by a specialized subset of T cells called regulatory T cells (Tregs). Currently there are six subtypes of Tregs including CD4+CD25+ naturally occurring (N-Tregs), inducible naïve CD4+CD25- T cells (TR1), TR1 memory phenotype, T-helper type 3 (TH3), CD4-CD25+DX5+ natural killer T cells (TRNKT), and CD4-CD25+CD8+ cytotoxic T cells (TRCTC). The development of Tregs is controversial as to whether they occur in the thymus or peripheral lymphoid tissue. Studies have shown that NTregs are generated in the thymus and TR1 cells occur in the periphery. Nevertheless, Tregs express an arsenal of molecular membrane markers: CD3, CD25, CD62L, CD69, BTLA, GITR, ICOS, Neuroplin- 1 (Nrp-1), and PD-1. However, the most definitive marker is Forkhead Winged-Helix Transcriptional Factor Box p3 (Foxp3). The suppression of N-Tregs occurs by cell-to-cell contact, and low levels of IL-10 and moderate levels of TGF-beta, but the primary mechanism involves the sequestration and activation of neighboring naïve CD4+CD25- T cells to become TR1 cells. In contrast, TR1 cells exert their suppressive properties by copious secretion of IL-10 and TGF- beta. These suppressive mechanisms occur by the inhibition of IL-2 production and the promotion of cell cycle arrest. The development of this specialized subset of T cells is an enigma, but their understanding will provide a plausible panacea for asthma.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/11804871">11804871</a><div class="entities" style="line-height: 2.5"><h3>The Th2 lymphocyte products IL-4 and IL-13 rapidly induce airway hyperresponsiveness through direct effects on resident airway cells.<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ai    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>rway inflammation and airway hyperresponsiveness (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) are hallmarks of asthma. Cytokines produced by T helper type 2 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) lymphocytes have been implicated in both processes. There is strong support for the idea that Th2 cytokines can produce <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> indirectly by promoting the recruitment of inflammatory cells. Less attention has been given to the possibility that Th2 cytokines might induce <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> by acting directly on resident airway cells. To investigate this, we polarized and activated CD4(+) T cells in vitro and analyzed airway function after administration of lymphocyte-conditioned media to the airways of naive mice. Th2-lymphocyte-conditioned medium induced <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> within 6 h. This finding was reproduced in masT cell-deficient and in T- and B-lymphocyte-deficient mice. AHR did not occur when Th2-lymphocyte-conditioned medium was administered to mice lacking the IL-4 receptor alpha subunit or Stat6, suggesting a critical role for interleukin (IL)-4 and/or IL-13. This was confirmed by the finding that recombinant IL-4 and IL-13 both induced <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> within 6 h. The induction of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> occurred in the absence of inflammatory cell recruitment or mucus production. These results strongly suggest that products of activated Th2 lymphocytes can rapidly perturb airway function through direct effects on resident airway cells.</div></details><details><summary>TH1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/19811658">19811658</a><div class="entities" style="line-height: 2.5"><h3>GITR signaling potentiates airway hyperresponsiveness by enhancing Th2 cell activity in a mouse model of asthma.</h3></br>Allergic asthma is characterized by airway hyperresponsiveness (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) and allergic inflammation of the airways, driven by allergen-specific Th2 cells. The asthma phenotypes and especially <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> are sensitive to the presence and activity of regulatory T (Treg) cells in the lung. Glucocorticoid-induced tumor necrosis factor receptor (GITR) is known to have a co-stimulatory function on effector CD4+ T cells, rendering these cells insensitive to Treg suppression. However, the effects of GITR signaling on polarized Th1 and Th2 cell effector functions are not well-established. We sought to evaluate the effect of GITR signaling on fully differentiated <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells and to determine the effects of GITR activation at the time of allergen provocation on AHR and airway inflammation in a Th2-driven mouse model of asthma.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/17172648">17172648</a><div class="entities" style="line-height: 2.5"><h3>TH2 cells in the pathogenesis of airway remodeling: regulatory T cells a plausible panacea for asthma.</h3></br>T-helper type 2 (TH2) cells are one of the hallmarks of airway remodeling. The daunting task of regaining tolerance will be to regulate airway hyperresponsiveness (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) and remodeling in chronic asthma by balancing the ballet of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and TH2 cells. The mechanism of tolerance appears to be modulated by a specialized subset of T cells called regulatory T cells (Tregs). Currently there are six subtypes of Tregs including CD4+CD25+ naturally occurring (N-Tregs), inducible naïve CD4+CD25- T cells (TR1), TR1 memory phenotype, T-helper type 3 (TH3), CD4-CD25+DX5+ natural killer T cells (TRNKT), and CD4-CD25+CD8+ cytotoxic T cells (TRCTC). The development of Tregs is controversial as to whether they occur in the thymus or peripheral lymphoid tissue. Studies have shown that NTregs are generated in the thymus and TR1 cells occur in the periphery. Nevertheless, Tregs express an arsenal of molecular membrane markers: CD3, CD25, CD62L, CD69, BTLA, GITR, ICOS, Neuroplin- 1 (Nrp-1), and PD-1. However, the most definitive marker is Forkhead Winged-Helix Transcriptional Factor Box p3 (Foxp3). The suppression of N-Tregs occurs by cell-to-cell contact, and low levels of IL-10 and moderate levels of TGF-beta, but the primary mechanism involves the sequestration and activation of neighboring naïve CD4+CD25- T cells to become TR1 cells. In contrast, TR1 cells exert their suppressive properties by copious secretion of IL-10 and TGF- beta. These suppressive mechanisms occur by the inhibition of IL-2 production and the promotion of cell cycle arrest. The development of this specialized subset of T cells is an enigma, but their understanding will provide a plausible panacea for asthma.</div></details><details><summary>TH9</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27858144">27858144</a><div class="entities" style="line-height: 2.5"><h3>Th9 and other IL-9-producing cells in allergic asthma.</h3></br>Allergic asthma is a worldwide increasing chronic disease of the airways which affects more than 300 million people. It is associated with increased IgE, mast cell activation, airway hyperresponsiveness (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AHR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>), mucus overproduction and remodeling of the airways. Previously, this pathological trait has been associated with T helper type 2 (Th2) cells. Recently, different CD4+  T cell subsets (Th17, Th9) as well as cells of innate immunity, like mast cells and innate lymphoid cells type 2 (ILC2s), which are all capable of producing the rediscovered cytokine IL-9, are known to contribute to this disease. Regarding Th9 cells, it is known that naïve T cells develop into IL-9-producing cells in the presence of interleukin-4 (IL-4) and transforming growth factor beta (TGFβ). Downstream of IL-4, several transcription factors like signal transducer and activator of transcription 6 (STAT6), interferon regulatory factor 4 (IRF4), GATA binding protein 3 (GATA3), basic leucine zipper transcription factor, ATF-like (BATF) and nuclear factor of activated T cells (NFAT) are activated. Additionally, the transcription factor PU.1, which is downstream of TGFβ signaling, also seems to be crucial in the development of Th9 cells. IL-9 is a pleiotropic cytokine that influences various distinct functions of different target cells such as T cells, B cells, mast cells and airway epithelial cells by activating STAT1, STAT3 and STAT5. Because of its pleiotropic functions, IL-9 has been demonstrated to be involved in several diseases, such as cancer, autoimmunity and other pathogen-mediated immune-regulated diseases. In this review, we focus on the role of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th9    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and IL-9-producing cells in allergic asthma.</div></details></details></td>
    </tr>
    <tr>
      <th>21</th>
      <td>EGR2</td>
      <td>7</td>
      <td>TREG:4, TH1:2, TREG1:1</td>
      <td>0.258560</td>
      <td>ENSG00000122877</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/25582080">25582080</a><div class="entities" style="line-height: 2.5"><h3>Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.</h3></br>The cytotoxic T lymphocyte antigen-4 (CTLA-4)-blocking antibody ipilimumab induces immune-mediated long-term control of metastatic melanoma in a fraction of patients. Although ipilimumab undoubtedly exerts its therapeutic effects via immunostimulation, thus far clinically useful, immunologically relevant biomarkers that predict treatment efficiency have been elusive. Here, we show that neutralization of IL-2 or blocking the α and β subunits of the IL-2 receptor (CD25 and CD122, respectively) abolished the antitumor effects and the accompanying improvement of the ratio of intratumoral T effector versus regulatory cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>), which were otherwise induced by CTLA-4 blockade in preclinical mouse models. CTLA-4 blockade led to the reduction of a suppressive CD4(+) T cell subset expressing Lag3, ICOS, IL-10 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Egr2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> with a concomitant rise in IL-2-producing effector cells that lost FoxP3 expression and accumulated in regressing tumors. While recombinant IL-2 improved the therapeutic efficacy of CTLA-4 blockade, the decoy IL-2 receptor α (IL-2Rα, sCD25) inhibited the anticancer effects of CTLA-4 blockade. In 262 metastatic melanoma patients receiving ipilimumab, baseline serum concentrations of sCD25 represented an independent indicator of overall survival, with high levels predicting resistance to therapy. Altogether, these results unravel a role for IL-2 and IL-2 receptors in the anticancer activity of CTLA-4 blockade. Importantly, our study provides the first immunologically relevant biomarker, namely elevated serum sCD25, that predicts resistance to CTLA-4 blockade in patients with melanoma. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/25381473">25381473</a><div class="entities" style="line-height: 2.5"><h3>The roles of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Egr-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in autoimmune diseases.</h3></br>Being a member of the early growth response (Egr) family of transcription factors, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Egr-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is expressed in a variety of cell types of the immune system. Recent findings imply that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Egr-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is important in the development and function of T helper (Th) 17 cell, regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cell, as well as dendritic cell (DC). Although these cells perform significantly in the pathogenesis of autoimmune diseases, such as systemic lupus erythematosus, multiple sclerosis, and systemic sclerosis, the roles of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Egr-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in the pathogenesis of autoimmune diseases can not be neglected. In this article, we will discuss recent findings about the important roles of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Egr-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in immune cells and the possible pathological roles of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Egr-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in autoimmune diseases. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/22460149">22460149</a><div class="entities" style="line-height: 2.5"><h3>Roles of LAG3 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    EGR2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in regulatory T cells.</h3></br>Regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) participate in the maintenance of tolerance to self-antigens and suppressive control of excessive immune responses to exogenous antigens. A lack or dysfunction of these cells is responsible for the pathogenesis and development of many autoimmune diseases. It is well known that CD4 Tregs play a major role in controlling immune responses and can be classified into two main populations: thymus-derived naturally occurring Tregs (nTregs) and induced Tregs (iTregs) generated from CD4(+)CD25(-) precursors in the peripheral lymphoid organs. The most extensively studied Tregs are the nTregs, which express the interleukin 2 (IL-2) receptor CD25 and the transcription factor Forkhead box P3 (Foxp3). On the other hand, iTregs contain multiple heterogeneous subsets, including interleukin (IL)-10-producing CD4 type I Tregs (Tr1 cells) and transforming growth factor -β-producing Th3 cells, and so on. However, the extent of the contribution of iTregs to immunoregulation in normal animals has been difficult to evaluate because of the lack of suitable cell surface markers. It has been found recently that IL-10-secreting iTregs can be delineated as CD4(+)CD25(-)Foxp3(-) T cells that characteristically express both the lymphocyte activation gene-3 (LAG3) and the early growth response gene-2 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    EGR2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>). In this review, opinions about the roles of LAG3 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    EGR2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in Tregs are presented.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/20453445">20453445</a><div class="entities" style="line-height: 2.5"><h3>CD4+CD25-LAG-3+ T cells in mouse and human.</h3></br>We have recently reported a murine novel regulatory T cell population, CD4(+)CD25(-)LAG-3(+) regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>). Microarray analysis revealed that CD4(+)CD25(-)LAG-3(+) Tregs had a unique mRNA expression profile that was different from the conventional CD4(+)CD25(+) regulatory T cells. In particular, CD4(+)CD25(-)LAG-3(+) Tregs characteristically expressed early growth response gene 2 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Egr-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) that was reported to be associated with the induction of anergy. CD4(+)CD25(-)LAG-3(+) Tregs produced high-amount of IL-10 in response to TCR stimulation and showed immunosuppressive activity in vitro and in vivo. Retroviral gene transfer of Eg-2 converted naïve CD4(+) T cells into IL-10-secreting and LAG-3-expressing T cells, and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Egr-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> transduced CD4(+) T cells exhibited antigen-specific immunosuppressive capacity in vivo. On the basis of these observations, we have attempted to identify a human counterpart of murine CD4(+)CD25(-)LAG-3(+) Tregs in human. CD4(+)CD25(-)LAG-3(+) T cells were found in human in similar pattern as murine CD4(+)CD25(-)LAG-3(+) Tregs. In the quantitative PCR, human CD4(+)CD25(-)LAG-3(+) T cells expressed high levels of IL-10. From the microarray analysis, we found the close similarity between human CD4(+)CD25(-)LAG-3(+) T cells and murine CD4(+)CD25(-)LAG-3(+) <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>. Therefore, human CD4(+)CD25(-)LAG-3(+) T cells might be a human counterpart of murine CD4(+)CD25(-)LAG-3(+) Tregs.</div></details><details><summary>TH1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/23203924">23203924</a><div class="entities" style="line-height: 2.5"><h3>Early growth response gene-2 controls IL-17 expression and Th17 differentiation by negatively regulating Batf.</h3></br>Early growth response gene (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Egr)-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is important for the maintenance of T cell homeostasis and controls the development of autoimmune disease. However, the underlying mechanisms are unknown. We have now discovered that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Egr-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, which is induced by TGF-β and IL-6, negatively regulates the expression of IL-17, but not IL-2 or IFN-γ, in effector T cells. In the absence of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Egr-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, CD4 T cells produce high levels of Th17 cytokines, which renders mice susceptible to experimental autoimmune encephalomyelitis induction. T cells lacking <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Egr-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> show increased propensity for Th17, but not <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> or Th2, differentiation. Control of IL-17 expression and Th17 differentiation by <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Egr-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is due to inhibition of Batf, a transcription factor that regulates IL-17 expression and Th17 differentiation. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Egr-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> interacts with Batf in CD4 T cells and suppresses its interaction with DNA sequences derived from the IL-17 promoter, whereas the activation of STAT3 and expression of retinoic acid-related orphan receptor γt are unchanged in Th17 cells in the absence of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Egr-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. Thus, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Egr-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> plays an important role to intrinsically control Th17 differentiation. We also found that CD4 T cells from multiple sclerosis patients have reduced expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Egr-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and increased expression of IL-17 following stimulation with anti-CD3 in vitro. Collectively, our results demonstrate that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Egr-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is an intrinsic regulator that controls Th17 differentiation by inhibiting Batf activation, which may be important for the control of multiple sclerosis development.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/11254710">11254710</a><div class="entities" style="line-height: 2.5"><h3>Differential expression of Fas ligand in <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells is regulated by early growth response gene and NF-AT family members.</h3></br>Inducible expression of Fas ligand (CD95 ligand) by activated T cells and the resulting apoptosis of CD95-bearing cells is a critical component of peripheral T cell homeostasis and cytotoxic effector mechanisms. Transcriptional control of the expression of Fas ligand has been attributed to a number of factors, including early growth response gene 2 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Egr2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>), Egr3, Sp1, and NF-AT, although a direct contribution of NF-AT is controversial. The present study confirms a role for Egr factors and indicates that NF-AT is essential for optimal expression of murine Fas ligand through a direct interaction with an NF-AT consensus element. The role of these factors was further defined by studying the differential expression of Fas ligand in Th1 and Th2 lines derived from DO11.10 TCR transgenic mice. EMSA analyses of a composite Egr/NF-AT site showed recruitment of Sp1 to this site in Th2 cells, but not in Th1 cells. Furthermore, gel-shift analyses demonstrated the binding of Egr1, 2, and 3 in Th2 cells and Egr1 and 2, but not Egr3 in Th1 cells at a known Egr site. Northern analysis corroborated the lack of Egr3 in Th1 cells. Differential usage of these transcription factors by <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells suggests a potential mechanism underlying the differential expression of Fas ligand by distinct T cell lineages.</div></details></details></td>
    </tr>
    <tr>
      <th>22</th>
      <td>IRF4</td>
      <td>19</td>
      <td>TH17:5, TH:4, TREG:4, TFH:3, TC17:2, TH1:2, TC9:1, TH2:1, TH9:1, TREG1:1</td>
      <td>0.246978</td>
      <td>ENSG00000137265</td>
      <td><details><summary>Subtypes</summary><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/23664832">23664832</a><div class="entities" style="line-height: 2.5"><h3><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> transcription-factor-dependent CD103(+)CD11b(+) dendritic cells drive mucosal T helper 17 cell differentiation.</h3></br>CD103(+)CD11b(+) dendritic cells (DCs) represent the major migratory DC population within the small intestinal lamina propria (SI-LP), but their in vivo function remains unclear. Here we demonstrate that intestinal CD103(+)CD11b(+) DC survival was dependent on interferon regulatory factor 4 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>). Mice with a DC deletion in <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Irf4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> displayed reduced numbers of intestinal interleukin 17 (IL-17)-secreting helper T 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells and failed to support Th17 cell differentiation in draining mesenteric lymph nodes (MLN) following immunization. The latter was associated with a selective reduction in CD103(+)CD11b(+) MLN DCs and DC derived IL-6. Immunized Il6(-/-) mice failed to support Th17 cell differentiation in MLN in vivo and CD103(+)CD11b(+) MLN DCs supported IL-6-dependent Th17 cell differentiation in vitro. Together, our results suggest a central role for IRF4-dependent, IL-6 producing CD103(+)CD11b(+) DCs in intestinal Th17 cell differentiation.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/23653308">23653308</a><div class="entities" style="line-height: 2.5"><h3>Roles of T helper 17 cells and interleukin-17 in neuroautoimmune diseases with emphasis on multiple sclerosis and Guillain-Barré syndrome as well as their animal models.</h3></br>The identification of T helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells challenges the Th1/Th2 paradigm of the immune response and invites intensive exploration of their mechanisms and functions in the field of autoimmune diseases, host defense, allergy, etc. The collective data have shown that transforming growth factor-β (TGF-β), interleukin (IL)-6, IL-1β, IL-21, and IL-23 are involved in the differentiation program of Th17 cells. The transcription factors RORγT, STAT3, RORγ, RORα, and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> exert regulatory effects on the development of Th17 cells. Among the Th17-related effector cytokines, such as IL-17, IL-17F, IL-21, and IL-22, IL-17 is regarded as a key cytokine to induce inflammatory responses. This review outlines the cytokines and transcription factors involved in the differentiation of Th17 cells and their effector functions, with specific focus on the roles of Th17 cells and IL-17 in neuroautoimmune diseases, especially in multiple sclerosis and Guillain-Barré syndrome, as well as in their animal models, experimental autoimmune encephalomyelitis and experimental autoimmune neuritis.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/23221338">23221338</a><div class="entities" style="line-height: 2.5"><h3>IL-17A secretion by CD8+ T cells supports Th17-mediated autoimmune encephalomyelitis.</h3></br>IL-17-producing CD8+ T (Tc17) cells are detectible in multiple sclerosis (MS) lesions; however, their contribution to the disease is unknown. To identify functions of Tc17 cells, we induced EAE, a murine model of MS, in mice lacking IFN regulatory factor 4 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>). IRF4-deficient mice failed to generate Tc17 and Th17 cells and were resistant to EAE. After adoptive transfer of WT CD8+ T cells and subsequent immunization for EAE induction in these mice, the CD8+ T cells developed a Tc17 phenotype in the periphery but could not infiltrate the CNS. Similarly, transfer of small numbers of WT CD4+ T cells alone did not evoke EAE, but when transferred together with CD8+ T cells, IL-17-producing CD4+ (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) T cells accumulated in the CNS and mice developed severe disease. Th17 accumulation and development of EAE required IL-17A production by CD8+ T cells, suggesting that Tc17 cells are required to promote CD4+ T cell-mediated induction of EAE. Accordingly, patients with early-stage MS harbored a greater number of Tc17 cells in the cerebrospinal fluid than in peripheral blood. Our results reveal that Tc17 cells contribute to the initiation of CNS autoimmunity in mice and humans by supporting Th17 cell pathogenicity.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/22983707">22983707</a><div class="entities" style="line-height: 2.5"><h3>A genomic regulatory element that directs assembly and function of immune-specific AP-1-IRF complexes.</h3></br>Interferon regulatory factor 4 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) and IRF8 regulate B, T, macrophage, and dendritic cell differentiation. They are recruited to cis-regulatory Ets-IRF composite elements by PU.1 or Spi-B. How these IRFs target genes in most T cells is enigmatic given the absence of specific Ets partners. Chromatin immunoprecipitation sequencing in T helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(H)17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells reveals that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> targets sequences enriched for activating protein 1 (AP-1)-IRF composite elements (AICEs) that are co-bound by BATF, an AP-1 factor required for T(H)17, B, and dendritic cell differentiation. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and BATF bind cooperatively to structurally divergent AICEs to promote gene activation and T(H)17 differentiation. The AICE motif directs assembly of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> or IRF8 with BATF heterodimers and is also used in T(H)2, B, and dendritic cells. This genomic regulatory element and cognate factors appear to have evolved to integrate diverse immunomodulatory signals.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/19965648">19965648</a><div class="entities" style="line-height: 2.5"><h3>Regulating human Th17 cells via differential expression of IL-1 receptor.</h3></br>In humans, interleukin-1beta (IL-1beta) has been suggested as an essential cytokine for developing IL-17- or IL-17A-producing CD4(+) T helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. However, little is known about the relationship of IL-1 receptor expression and Th17 cell differentiation. We report here the presence of 2 distinct CD4(+) T cell populations with and without expression of IL-1RI that correlates with the capacity to produce IL-17 in naive and memory CD4(+) T cells of human peripheral blood. IL-1RI(+) memory CD4(+) T cells had increased gene expression of IL17, RORC, and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> even before T cell receptor triggering, indicating that the effect of IL-1beta is programmed in these cells via IL-1RI. Although CD4(+) T cells from umbilical cord blood did not express IL-1RI, the cytokines IL-7, IL-15, and transforming growth factor-beta (TGF-beta) up-regulated IL-1RI expression on naive CD4(+) T cells, suggesting that IL-1RI(+) naive CD4(+) T cells develop in periphery. Furthermore, IL-17 production from the cytokine-treated naive CD4(+) T cells was induced by IL-1beta and this induction was blocked by IL-1R antagonist. These results indicate that human Th17 cell differentiation is regulated via differential expression of IL-1RI, which is controlled by IL-7 and IL-15.</div></details><details><summary>TH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/23254356">23254356</a><div class="entities" style="line-height: 2.5"><h3>Tc9 cells, a new subset of CD8(+) T cells, support Th2-mediated airway inflammation.</h3></br>Similar to T-helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, CD8(+) T cells also differentiate into distinct subpopulations. However, the existence of IL-9-producing CD8(+) T (Tc9) cells has not been elucidated so far. We show that murine CD8(+) T cells activated in the presence of IL-4 plus TGF-β develop into transient IL-9 producers characterized by specific IFN-γ and IL-10 expression patterns as well as by low cytotoxic function along with diminished expression of the CTL-associated transcription factors T-bet and Eomesodermin. Similarly to the CD4(+) counterpart, Tc9 cells required for their differentiation STAT6 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. Tc9 cells deficient for these master regulators displayed increased levels of Foxp3 that in turn suppressed IL-9 production. In an allergic airway disease model, Tc9 cells promoted the onset of airway inflammation, mediated by subpathogenic numbers of Th2 cells. This support was specific for Tc9 cells because CTLs failed to exert this function. We detected increased Tc9 frequency in the periphery in mice and humans with atopic dermatitis, a Th2-associated skin disease that often precedes asthma. Thus, our data point to the existence of Tc9 cells and to their supportive function in Th2-dependent airway inflammation, suggesting that these cells might be a therapeutic target in allergic disorders.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/22515488">22515488</a><div class="entities" style="line-height: 2.5"><h3>Elevated interferon regulatory factor 4 levels in patients with allergic asthma.</h3></br>Allergic asthma is a common inflammatory disease regulated by the T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. Interferon regulatory factor 4 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) plays an important role in the differentiation of Th cells. This study investigated whether <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is involved in the systemic immune responses in allergic asthma patients.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/25700150">25700150</a><div class="entities" style="line-height: 2.5"><h3>T helper 9 cells induced by plasmacytoid dendritic cells regulate interleukin-17 in multiple sclerosis.</h3></br>Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS) characterized by persistent inflammation orchestrated by cluster of differentiation (CD) 4 T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. In particular, Th1 and Th17 cells amplify, whereas T regulatory (Treg) cells moderate inflammation. The role of other Th subsets in MS is not clear. In the present study, we investigated the generation of different Th responses by human dendritic cells (DCs) in MS. We compared the production of several Th cytokines by naive CD4+ T cells polarized with myeloid and plasmacytoid DCs (mDCs and pDCs) in healthy donors (HD) and relapsing-remitting (RR)-MS patients. We found that resiquimod-stimulated mDCs were able to activate Th17 differentiation, whereas pDCs induced interleukin (IL)-10-producing Th cells. Surprisingly, resiquimod-stimulated pDCs from MS patients also significantly induced the differentiation of Th9 cells, which produce IL-9 and are known to be involved in allergic diseases. We investigated the potential role of IL-9 in MS. We found that IL-9 activated signal transducer and activator of transcription (STAT) 1 and STAT5 phosphorylation and interfered with IL-17 and interferon (IFN) regulatory transcription factor (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF)-4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression in Th17-polarized cells. Moreover, in the cerebrospinal fluid (CSF) of 107 RR-MS patients, IL-9 inversely correlated with indexes of inflammatory activity, neurodegeneration and disability progression of MS. High levels of IL-9 were associated with the absence of IL-17 in the CSF of RR-MS patients. Our results demonstrate a Th9-inducing potential of pDCs in MS, suggesting an immunoregulatory role leading to attenuation of the exaggerated Th17 inflammatory response.</div></details><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/29844370">29844370</a><div class="entities" style="line-height: 2.5"><h3>mTOR coordinates transcriptional programs and mitochondrial metabolism of activated Treg  subsets to protect tissue homeostasis.</h3></br>Regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> ) cells derived from the thymus (tTreg ) and periphery (pTreg ) have central and distinct functions in immunosuppression, but mechanisms for the generation and activation of Treg  subsets in vivo are unclear. Here, we show that mechanistic target of rapamycin (mTOR) unexpectedly supports the homeostasis and functional activation of tTreg  and pTreg  cells. mTOR signaling is crucial for programming activated Treg -cell function to protect immune tolerance and tissue homeostasis. Treg -specific deletion of mTOR drives spontaneous effector T cell activation and inflammation in barrier tissues and is associated with reduction in both thymic-derived effector Treg  (eTreg ) and pTreg  cells. Mechanistically, mTOR functions downstream of antigenic signals to drive <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression and mitochondrial metabolism, and accordingly, deletion of mitochondrial transcription factor A (Tfam) severely impairs Treg -cell suppressive function and eTreg -cell generation. Collectively, our results show that mTOR coordinates transcriptional and metabolic programs in activated Treg  subsets to mediate tissue homeostasis.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/22961053">22961053</a><div class="entities" style="line-height: 2.5"><h3>A multiply redundant genetic switch 'locks in' the transcriptional signature of regulatory T cells.</h3></br>The transcription factor Foxp3 participates dominantly in the specification and function of Foxp3(+)CD4(+) regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells) but is neither strictly necessary nor sufficient to determine the characteristic <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cell signature. Here we used computational network inference and experimental testing to assess the contribution of other transcription factors to this. Enforced expression of Helios or Xbp1 elicited distinct signatures, but Eos, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, Satb1, Lef1 and GATA-1 elicited exactly the same outcome, acting in synergy with Foxp3 to activate expression of most of the <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cell signature, including key transcription factors, and enhancing occupancy by Foxp3 at its genomic targets. Conversely, the T(reg) cell signature was robust after inactivation of any single cofactor. A redundant genetic switch thus 'locked in' the <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cell phenotype, a model that would account for several aspects of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cell physiology, differentiation and stability.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28723546">28723546</a><div class="entities" style="line-height: 2.5"><h3>Local Modulation of Antigen-Presenting Cell Development after Resolution of Pneumonia Induces Long-Term Susceptibility to Secondary Infections.</h3></br>Lung infections cause prolonged immune alterations and elevated susceptibility to secondary pneumonia. We found that, after resolution of primary viral or bacterial pneumonia, dendritic cells (DC), and macrophages exhibited poor antigen-presentation capacity and secretion of immunogenic cytokines. Development of these "paralyzed" DCs and macrophages depended on the immunosuppressive microenvironment established upon resolution of primary infection, which involved regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells and the cytokine TGF-β. Paralyzed DCs secreted TGF-β and induced local Treg cell accumulation. They also expressed lower amounts of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, a transcription factor associated with increased antigen-presentation capacity, and higher amounts of Blimp1, a transcription factor associated with tolerogenic functions, than DCs present during primary infection. Blimp1 expression in DC of humans suffering sepsis or trauma correlated with severity and complicated outcomes. Our findings describe mechanisms underlying sepsis- and trauma-induced immunosuppression, reveal prognostic markers of susceptibility to secondary infections and identify potential targets for therapeutic intervention.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/25700150">25700150</a><div class="entities" style="line-height: 2.5"><h3>T helper 9 cells induced by plasmacytoid dendritic cells regulate interleukin-17 in multiple sclerosis.</h3></br>Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS) characterized by persistent inflammation orchestrated by cluster of differentiation (CD) 4 T helper (Th) cells. In particular, Th1 and Th17 cells amplify, whereas T regulatory (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells moderate inflammation. The role of other Th subsets in MS is not clear. In the present study, we investigated the generation of different Th responses by human dendritic cells (DCs) in MS. We compared the production of several Th cytokines by naive CD4+ T cells polarized with myeloid and plasmacytoid DCs (mDCs and pDCs) in healthy donors (HD) and relapsing-remitting (RR)-MS patients. We found that resiquimod-stimulated mDCs were able to activate Th17 differentiation, whereas pDCs induced interleukin (IL)-10-producing Th cells. Surprisingly, resiquimod-stimulated pDCs from MS patients also significantly induced the differentiation of Th9 cells, which produce IL-9 and are known to be involved in allergic diseases. We investigated the potential role of IL-9 in MS. We found that IL-9 activated signal transducer and activator of transcription (STAT) 1 and STAT5 phosphorylation and interfered with IL-17 and interferon (IFN) regulatory transcription factor (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF)-4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression in Th17-polarized cells. Moreover, in the cerebrospinal fluid (CSF) of 107 RR-MS patients, IL-9 inversely correlated with indexes of inflammatory activity, neurodegeneration and disability progression of MS. High levels of IL-9 were associated with the absence of IL-17 in the CSF of RR-MS patients. Our results demonstrate a Th9-inducing potential of pDCs in MS, suggesting an immunoregulatory role leading to attenuation of the exaggerated Th17 inflammatory response.</div></details><details><summary>TFH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28263097">28263097</a><div class="entities" style="line-height: 2.5"><h3>Transcriptional and epigenetic regulation of follicular T-helper cells and their role in autoimmunity.</h3></br>T-follicular helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are a specialized subset of T cells that provide help to B cells and promote the formation of germinal centers (GCs). Tfh cells transmit important signals to B cells that drive class switch recombination, somatic hyper-mutation, the generation of high-affinity antibodies, immunological memory and their differentiation into plasma cells or memory B cells in the GCs. Tfh-cell differentiation <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    is r    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>egulated by the coordinated functions of distinct cytokines, including interleukin (IL)-6, IL-21, IL-12, IL-23, IL-2, IL-7 and transforming growth factor-β (TGF-β), as well as transcription factors, including B-cell lymphoma 6 protein (Bcl-6), Signal transducers and activators of transcription (STAT)1, STAT3, STAT4, B-cell activating transcription factor (Batf), interferon regulatory factor 4 (IRF4), v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog (C-Maf), T cell-specific transcription factor 1 (TCF-1) and Achaete-scute homolog 2 (Acl2), which have been shown to form a complex transcriptional network. In addition, increasing evidence indicates that epigenetic regulations, such as DNA methylation, histone modifications and non-coding RNA regulations, also coordinately control the differentiation and function of Tfh cells along with transcription factors. Furthermore, abnormalities in the regulation of Tfh cells have been associated with several autoimmune diseases, such as systemic lupus erythematosus (SLE), multiple sclerosis (MS) and rheumatoid arthritis (RA). Herein, this review aims to summarize the coordinate regulation and interaction of transcription factors, cytokines and epigenetic modifications that control Tfh-cell differentiation as well as the mechanism of dysregulation of Tfh cells in pathogenesis of autoimmune diseases, which highlight potential therapeutic targets.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27425607">27425607</a><div class="entities" style="line-height: 2.5"><h3>Molecular Mechanisms Regulating T Helper 1 versus T Follicular Helper Cell Differentiation in Humans.</h3></br>IL-12 is important for the differentiation of T follicular helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, as well as Th1 cells in humans. Still, how IL-12 signals regulate Tfh versus Th1 cell differentiation remains poorly characterized. Here we aimed to determine the molecular mechanisms that regulate the differentiation and the function of IL-12-stimulated human naive CD4(+) T cells. We found that T-bet promoted the expression of CXCR5 in human CD4(+) T cells. We provide evidence that T-bet does not strongly inhibit the Tfh cell differentiation program per se but diminishes the functions to provide help to B cells. This study also suggests that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> plays an important role in driving the early differentiation of IL-12-stimulated CD4(+) T cells toward Tfh and away from Th1 by inhibiting the expression of Eomesodermin. Thus, the fate of IL-12-stimulated CD4(+) T cells is determined through interplay of multiple transcription factors at early stages.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/23405901">23405901</a><div class="entities" style="line-height: 2.5"><h3>Transcriptional regulation of follicular T-helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells.</h3></br>T-follicular helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are a new subset of effector CD4(+)  T cells that are specialized in helping B cells in the germinal center reaction. Tfh cells are distinct from other established CD4(+)  T cell lineages, Th1, Th2, Th17, and T-regulatory cells, in their gene expression profiles. Tfh cell differentiation results from a network of transcriptional regulation by a master transcriptional factor Bcl6 as well as <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, c-Maf, Batf, and STAT3/5. During Tfh cell ontogeny, increased CXCR5 expression directs activated T cell migration to the follicles, and their interaction with B cells leads to Bcl6 upregulation, which helps establish effector and memory Tfh cell program. This review summarizes the recent progress in molecular mechanisms underlying Tfh differentiation and discusses the future perspectives for this important area of research.</div></details><details><summary>TC17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/25259411">25259411</a><div class="entities" style="line-height: 2.5"><h3>Tc17 Cells in Immunity and Systemic Autoimmunity.</h3></br>Tc17 cells-a subset of CD8(+)T cells-have recently been identified that are characterized by the production of interleukin (IL)-17. Cytokines IL-6 and transforming growth factor-beta 1 (TGF-β1) and transcription factors signaling transducers and activators of transcription (STAT)3, retinoic acid receptor-related orphan nuclear receptor gamma (RORγt), and interferon regulatory factor (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF)4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> are necessary for differentiation of Tc17 cells, controlling expression of molecules essential for Tc17 cell trafficking and function. Current human researches have determined the significance of CD161 expression as either a marker of Tc17 cells or as an effector and regulator of Tc17 cell function. Noncytotoxic Tc17 cells possess a high plasticity to convert into IFN-γ producing cells, which exhibit strong cytotoxic activity. The importance of in vivo plasticity of Tc17 cells for the induction of autoimmune diseases has been demonstrated and Tc17 cells potentially represent novel therapeutic targets in autoimmune diseases. The involvement of interleukin (IL)-17-producing CD8(+)T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tc17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) in various conditions, such as infection, cancer, and autoimmune inflammation, has been documented in both humans and mice; however, Tc17 cells have received only marginal attention. Here, we provide an overview of the cytokines and chemokines that characterize the murine and human Tc17 cells. Moreover, we discuss signaling pathways, molecular interactions, and transcriptional events that contribute to Tc17 differentiation and acquisition of effector functions. Also considered is the basis of Tc17 cell plasticity toward the Tc1 lineage, and we suggest that in vivo plasticity of Tc17 cells may be a key feature of Tc17 cell biology in autoimmune diseases. Furthermore, current human researches have revealed that Tc17 cells are different than that in mice because all of them express CD161 and exclusively originate from CD161 precursors present in umbilical cord blood. Finally, we focus on the recent evidence for long-lived Tc17 memory cell populations in mouse models and humans, and their functional roles in mediating disease memory. Hopefully, the information obtained will benefit for developing novel therapeutic strategies. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/23221338">23221338</a><div class="entities" style="line-height: 2.5"><h3>IL-17A secretion by CD8+ T cells supports Th17-mediated autoimmune encephalomyelitis.</h3></br>IL-17-producing CD8+ T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tc17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are detectible in multiple sclerosis (MS) lesions; however, their contribution to the disease is unknown. To identify functions of Tc17 cells, we induced EAE, a murine model of MS, in mice lacking IFN regulatory factor 4 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>). IRF4-deficient mice failed to generate <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tc17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th17 cells and were resistant to EAE. After adoptive transfer of WT CD8+ T cells and subsequent immunization for EAE induction in these mice, the CD8+ T cells developed a Tc17 phenotype in the periphery but could not infiltrate the CNS. Similarly, transfer of small numbers of WT CD4+ T cells alone did not evoke EAE, but when transferred together with CD8+ T cells, IL-17-producing CD4+ (Th17) T cells accumulated in the CNS and mice developed severe disease. Th17 accumulation and development of EAE required IL-17A production by CD8+ T cells, suggesting that Tc17 cells are required to promote CD4+ T cell-mediated induction of EAE. Accordingly, patients with early-stage MS harbored a greater number of Tc17 cells in the cerebrospinal fluid than in peripheral blood. Our results reveal that Tc17 cells contribute to the initiation of CNS autoimmunity in mice and humans by supporting Th17 cell pathogenicity.</div></details><details><summary>TH1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/21440248">21440248</a><div class="entities" style="line-height: 2.5"><h3><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> regulates IL-10 gene expression in CD4(+) T cells through differential nuclear translocation.</h3></br>CD4(+) T cells play critical roles in the generation of protective immunity against a variety of pathogens. The main two types of effector CD4(+) T cells, <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 are characterized by their ability to produce signature cytokines. Among them, IL-10 is a multi-functional cytokine that plays a crucial role in maintaining the balance between immunity and tolerance. Although IL-10 is produced by both differentiated primary <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells, Th2 cells produce much higher levels of IL-10 upon stimulation. However, little information is available on the molecular mechanisms of IL-10 gene regulation at the transcriptional level. Interferon regulatory factor <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is a member of the IRF family of transcription factors and plays critical roles in the development of CD4(+) T cells into Th2 cells. In this present study, we elucidate the underlying mechanism of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mediated IL-10 gene transcription in primary CD4(+) T cells. Th2 specific binding of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> to the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> responsive elements in IL-10 locus potentiated IL-10 expression in Th2 cells. Knockdown of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> by siRNA decreased IL-10 expression level in Th2 cells. Nuclear translocation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> was much higher in Th2 cells upon stimulation, which contribute to maintain IL-10(high) phenotype of Th2 cells. Collectively, our results suggest that stimulation driven quantitative differences of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in the nucleus and its binding to IL-10 regulatory elements are crucial mechanisms to induce IL-10(high) gene expression in Th2 cells.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/18962896">18962896</a><div class="entities" style="line-height: 2.5"><h3>A distal cis-regulatory element, CNS-9, controls NFAT1 and IRF4-mediated IL-10 gene activation in T helper cells.</h3></br>IL-10 is a multifunctional cytokine that plays a critical role in maintaining the balance between immunity and tolerance. Previously, we identified proximal regulatory elements and alterations of chromatin structure in the IL-10 gene loci of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells. We have now characterized a crucial cis-regulatory element, CNS-9, located 9kb upstream of the transcription start site in IL-10 gene loci. The CNS-9 region is highly conserved in vertebrate genomes, and contains clustered NFAT and IRF binding motifs. In vitro binding of NFAT1 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> to the CNS-9 region was observed by EMSA. Furthermore, Th2-preferential in vivo binding of NFAT1 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> to the CNS-9 region was observed by ChIP. Cyclosporine A treatment on wild type Th2 cells or Th2 cells derived from NFAT1 knockout (NFAT1(-/-)) mice showed significantly reduced trans-activity of CNS-9. The Th2 subset-specific enhancer activity of CNS-9 was upregulated synergistically by NFAT1 and its partner <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. Mutations in the binding sites for NFAT1 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> abrogated its enhancer activity of CNS-9. Collectively, our results establish crucial roles for enhancer element CNS-9, and NFAT1 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> that bind to it, for IL-10 expression in differential T helper subsets.</div></details><details><summary>TC9</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/23254356">23254356</a><div class="entities" style="line-height: 2.5"><h3>Tc9 cells, a new subset of CD8(+) T cells, support Th2-mediated airway inflammation.</h3></br>Similar to T-helper (Th) cells, CD8(+) T cells also differentiate into distinct subpopulations. However, the existence of IL-9-producing CD8(+) T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tc9    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells has not been elucidated so far. We show that murine CD8(+) T cells activated in the presence of IL-4 plus TGF-β develop into transient IL-9 producers characterized by specific IFN-γ and IL-10 expression patterns as well as by low cytotoxic function along with diminished expression of the CTL-associated transcription factors T-bet and Eomesodermin. Similarly to the CD4(+) counterpart, Tc9 cells required for their differentiation STAT6 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. Tc9 cells deficient for these master regulators displayed increased levels of Foxp3 that in turn suppressed IL-9 production. In an allergic airway disease model, Tc9 cells promoted the onset of airway inflammation, mediated by subpathogenic numbers of Th2 cells. This support was specific for Tc9 cells because CTLs failed to exert this function. We detected increased Tc9 frequency in the periphery in mice and humans with atopic dermatitis, a Th2-associated skin disease that often precedes asthma. Thus, our data point to the existence of Tc9 cells and to their supportive function in Th2-dependent airway inflammation, suggesting that these cells might be a therapeutic target in allergic disorders.</div></details><details><summary>TH2</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27858144">27858144</a><div class="entities" style="line-height: 2.5"><h3>Th9 and other IL-9-producing cells in allergic asthma.</h3></br>Allergic asthma is a worldwide increasing chronic disease of the airways which affects more than 300 million people. It is associated with increased IgE, mast cell activation, airway hyperresponsiveness (AHR), mucus overproduction and remodeling of the airways. Previously, this pathological trait has been associated with T helper type 2 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. Recently, different CD4+  T cell subsets (Th17, Th9) as well as cells of innate immunity, like mast cells and innate lymphoid cells type 2 (ILC2s), which are all capable of producing the rediscovered cytokine IL-9, are known to contribute to this disease. Regarding Th9 cells, it is known that naïve T cells develop into IL-9-producing cells in the presence of interleukin-4 (IL-4) and transforming growth factor beta (TGFβ). Downstream of IL-4, several transcription factors like signal transducer and activator of transcription 6 (STAT6), interferon regulatory factor 4 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>), GATA binding protein 3 (GATA3), basic leucine zipper transcription factor, ATF-like (BATF) and nuclear factor of activated T cells (NFAT) are activated. Additionally, the transcription factor PU.1, which is downstream of TGFβ signaling, also seems to be crucial in the development of Th9 cells. IL-9 is a pleiotropic cytokine that influences various distinct functions of different target cells such as T cells, B cells, mast cells and airway epithelial cells by activating STAT1, STAT3 and STAT5. Because of its pleiotropic functions, IL-9 has been demonstrated to be involved in several diseases, such as cancer, autoimmunity and other pathogen-mediated immune-regulated diseases. In this review, we focus on the role of Th9 and IL-9-producing cells in allergic asthma.</div></details><details><summary>TH9</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27858144">27858144</a><div class="entities" style="line-height: 2.5"><h3>Th9 and other IL-9-producing cells in allergic asthma.</h3></br>Allergic asthma is a worldwide increasing chronic disease of the airways which affects more than 300 million people. It is associated with increased IgE, mast cell activation, airway hyperresponsiveness (AHR), mucus overproduction and remodeling of the airways. Previously, this pathological trait has been associated with T helper type 2 (Th2) cells. Recently, different CD4+  T cell subsets (Th17, Th9) as well as cells of innate immunity, like mast cells and innate lymphoid cells type 2 (ILC2s), which are all capable of producing the rediscovered cytokine IL-9, are known to contribute to this disease. Regarding Th9 cells, it is known that naïve T cells develop into IL-9-producing cells in the presence of interleukin-4 (IL-4) and transforming growth factor beta (TGFβ). Downstream of IL-4, several transcription factors like signal transducer and activator of transcription 6 (STAT6), interferon regulatory factor 4 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>), GATA binding protein 3 (GATA3), basic leucine zipper transcription factor, ATF-like (BATF) and nuclear factor of activated T cells (NFAT) are activated. Additionally, the transcription factor PU.1, which is downstream of TGFβ signaling, also seems to be crucial in the development of Th9 cells. IL-9 is a pleiotropic cytokine that influences various distinct functions of different target cells such as T cells, B cells, mast cells and airway epithelial cells by activating STAT1, STAT3 and STAT5. Because of its pleiotropic functions, IL-9 has been demonstrated to be involved in several diseases, such as cancer, autoimmunity and other pathogen-mediated immune-regulated diseases. In this review, we focus on the role of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th9    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and IL-9-producing cells in allergic asthma.</div></details></details></td>
    </tr>
    <tr>
      <th>23</th>
      <td>BATF</td>
      <td>6</td>
      <td>TFH:2, TH9:2, TH:1, TH1:1, TH17:1, TH2:1</td>
      <td>0.225702</td>
      <td>ENSG00000156127</td>
      <td><details><summary>Subtypes</summary><details><summary>TFH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28263097">28263097</a><div class="entities" style="line-height: 2.5"><h3>Transcriptional and epigenetic regulation of follicular T-helper cells and their role in autoimmunity.</h3></br>T-follicular helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are a specialized subset of T cells that provide help to B cells and promote the formation of germinal centers (GCs). Tfh cells transmit important signals to B cells that drive class switch recombination, somatic hyper-mutation, the generation of high-affinity antibodies, immunological memory and their differentiation into plasma cells or memory B cell<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    s in    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> the GCs. Tfh-cell differentiation is regulated by the coordinated functions of distinct cytokines, including interleukin (IL)-6, IL-21, IL-12, IL-23, IL-2, IL-7 and transforming growth factor-β (TGF-β), as well as transcription factors, including B-cell lymphoma 6 protein (Bcl-6), Signal transducers and activators of transcription (STAT)1, STAT3, STAT4, B-cell activating transcription factor (Batf), interferon regulatory factor 4 (IRF4), v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog (C-Maf), T cell-specific transcription factor 1 (TCF-1) and Achaete-scute homolog 2 (Acl2), which have been shown to form a complex transcriptional network. In addition, increasing evidence indicates that epigenetic regulations, such as DNA methylation, histone modifications and non-coding RNA regulations, also coordinately control the differentiation and function of Tfh cells along with transcription factors. Furthermore, abnormalities in the regulation of Tfh cells have been associated with several autoimmune diseases, such as systemic lupus erythematosus (SLE), multiple sclerosis (MS) and rheumatoid arthritis (RA). Herein, this review aims to summarize the coordinate regulation and interaction of transcription factors, cytokines and epigenetic modifications that control Tfh-cell differentiation as well as the mechanism of dysregulation of Tfh cells in pathogenesis of autoimmune diseases, which highlight potential therapeutic targets.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/23405901">23405901</a><div class="entities" style="line-height: 2.5"><h3>Transcriptional regulation of follicular T-helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells.</h3></br>T-follicular helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are a new subset of effector CD4(+)  T cells that are specialized in helping B cells in the germinal center reaction. Tfh cells are distinct from other established CD4(+)  T cell lineages, Th1, Th2, Th17, and T-regulatory cells, in their gene expression profiles. Tfh cell differentiation results from a network of transcriptional regulation by a master transcriptional factor Bcl6 as well as IRF4, c-Maf, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Batf    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, and STAT3/5. During Tfh cell ontogeny, increased CXCR5 expression directs activated T cell migration to the follicles, and their interaction with B cells leads to Bcl6 upregulation, which helps establish effector and memory Tfh cell program. This review summarizes the recent progress in molecular mechanisms underlying Tfh differentiation and discusses the future perspectives for this important area of research.</div></details><details><summary>TH9</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27858144">27858144</a><div class="entities" style="line-height: 2.5"><h3>Th9 and other IL-9-producing cells in allergic asthma.</h3></br>Allergic asthma is a worldwide increasing chronic disease of the airways which affects more than 300 million people. It is associated with increased IgE, mast cell activation, airway hyperresponsiveness (AHR), mucus overproduction and remodeling of the airways. Previously, this pathological trait has been associated with T helper type 2 (Th2) cells. Recently, different CD4+  T cell subsets (Th17, Th9) as well as cells of innate immunity, like mast cells and innate lymphoid cells type 2 (ILC2s), which are all capable of producing the rediscovered cytokine IL-9, are known to contribute to this disease. Regarding Th9 cells, it is known that naïve T cells develop into IL-9-producing cells in the presence of interleukin-4 (IL-4) and transforming growth factor beta (TGFβ). Downstream of IL-4, several transcription factors like signal transducer and activator of transcription 6 (STAT6), interferon regulatory factor 4 (IRF4), GATA binding protein 3 (GATA3), basic leucine zipper transcription factor, ATF-like (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BATF    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) and nuclear factor of activated T cells (NFAT) are activated. Additionally, the transcription factor PU.1, which is downstream of TGFβ signaling, also seems to be crucial in the development of Th9 cells. IL-9 is a pleiotropic cytokine that influences various distinct functions of different target cells such as T cells, B cells, mast cells and airway epithelial cells by activating STAT1, STAT3 and STAT5. Because of its pleiotropic functions, IL-9 has been demonstrated to be involved in several diseases, such as cancer, autoimmunity and other pathogen-mediated immune-regulated diseases. In this review, we focus on the role of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th9    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and IL-9-producing cells in allergic asthma.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/24216482">24216482</a><div class="entities" style="line-height: 2.5"><h3>Th9 cell development requires  a <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BATF    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>-regulated transcriptional network.</h3></br>T helper 9 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th9    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are specialized for the production of IL-9, promote allergic inflammation in mice, and are associated with allergic disease in humans. It has not been determined whether Th9 cells express a characteristic transcriptional signature. In this study, we performed microarray analysis to identify genes enriched in Th9 cells compared with other Th subsets. This analysis defined a transcriptional regulatory network required for the expression of a subset of Th9-enriched genes. The activator protein 1 (AP1) family transcription factor <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BATF    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (B cell, activating transcription factor–like) was among the genes enriched in Th9 cells and was required for the expression of IL-9 and other Th9-associated genes in both human and mouse T cells. The expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BATF    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> was increased in Th9 cultures derived from atopic infants compared with Th9 cultures from control infants. T cells deficient in <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BATF    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression had a diminished capacity to promote allergic inflammation compared with wild-type controls. Moreover, mouse Th9 cells ectopically expressing <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BATF    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> were more efficient at promoting allergic inflammation than control transduced cells. These data indicate that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BATF    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is a central regulator of the Th9 phenotype and contributes to the development of allergic inflammation.</div></details><details><summary>TH1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/23203924">23203924</a><div class="entities" style="line-height: 2.5"><h3>Early growth response gene-2 controls IL-17 expression and Th17 differentiation by negatively regulating <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Batf    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>.</h3></br>Early growth response gene (Egr)-2 is important for the maintenance of T cell homeostasis and controls the development of autoimmune disease. However, the underlying mechanisms are unknown. We have now discovered that Egr-2, which is induced by TGF-β and IL-6, negatively regulates the expression of IL-17, but not IL-2 or IFN-γ, in effector T cells. In the absence of Egr-2, CD4 T cells produce high levels of Th17 cytokines, which renders mice susceptible to experimental autoimmune encephalomyelitis induction. T cells lacking Egr-2 show increased propensity for Th17, but not <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> or Th2, differentiation. Control of IL-17 expression and Th17 differentiation by Egr-2 is due to inhibition of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Batf    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, a transcription factor that regulates IL-17 expression and Th17 differentiation. Egr-2 interacts with <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Batf    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in CD4 T cells and suppresses its interaction with DNA sequences derived from the IL-17 promoter, whereas the activation of STAT3 and expression of retinoic acid-related orphan receptor γt are unchanged in Th17 cells in the absence of Egr-2. Thus, Egr-2 plays an important role to intrinsically control Th17 differentiation. We also found that CD4 T cells from multiple sclerosis patients have reduced expression of Egr-2 and increased expression of IL-17 following stimulation with anti-CD3 in vitro. Collectively, our results demonstrate that Egr-2 is an intrinsic regulator that controls Th17 differentiation by inhibiting <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Batf    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> activation, which may be important for the control of multiple sclerosis development.</div></details><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/22983707">22983707</a><div class="entities" style="line-height: 2.5"><h3>A genomic regulatory element that directs assembly and function of immune-specific AP-1-IRF complexes.</h3></br>Interferon regulatory factor 4 (IRF4) and IRF8 regulate B, T, macrophage, and dendritic cell differentiation. They are recruited to cis-regulatory Ets-IRF composite elements by PU.1 or Spi-B. How these IRFs target genes in most T cells is enigmatic given the absence of specific Ets partners. Chromatin immunoprecipitation sequencing in T helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(H)17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells reveals that IRF4 targets sequences enriched for activating protein 1 (AP-1)-IRF composite elements (AICEs) that are co-bound by <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BATF    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, an AP-1 factor required for T(H)17, B, and dendritic cell differentiation. IRF4 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BATF    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> bind cooperatively to structurally divergent AICEs to promote gene activation and T(H)17 differentiation. The AICE motif directs assembly of IRF4 or IRF8 with <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BATF    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> heterodimers and is also used in T(H)2, B, and dendritic cells. This genomic regulatory element and cognate factors appear to have evolved to integrate diverse immunomodulatory signals.</div></details><details><summary>TH2</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27858144">27858144</a><div class="entities" style="line-height: 2.5"><h3>Th9 and other IL-9-producing cells in allergic asthma.</h3></br>Allergic asthma is a worldwide increasing chronic disease of the airways which affects more than 300 million people. It is associated with increased IgE, mast cell activation, airway hyperresponsiveness (AHR), mucus overproduction and remodeling of the airways. Previously, this pathological trait has been associated with T helper type 2 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. Recently, different CD4+  T cell subsets (Th17, Th9) as well as cells of innate immunity, like mast cells and innate lymphoid cells type 2 (ILC2s), which are all capable of producing the rediscovered cytokine IL-9, are known to contribute to this disease. Regarding Th9 cells, it is known that naïve T cells develop into IL-9-producing cells in the presence of interleukin-4 (IL-4) and transforming growth factor beta (TGFβ). Downstream of IL-4, several transcription factors like signal transducer and activator of transcription 6 (STAT6), interferon regulatory factor 4 (IRF4), GATA binding protein 3 (GATA3), basic leucine zipper transcription factor, ATF-like (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BATF    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) and nuclear factor of activated T cells (NFAT) are activated. Additionally, the transcription factor PU.1, which is downstream of TGFβ signaling, also seems to be crucial in the development of Th9 cells. IL-9 is a pleiotropic cytokine that influences various distinct functions of different target cells such as T cells, B cells, mast cells and airway epithelial cells by activating STAT1, STAT3 and STAT5. Because of its pleiotropic functions, IL-9 has been demonstrated to be involved in several diseases, such as cancer, autoimmunity and other pathogen-mediated immune-regulated diseases. In this review, we focus on the role of Th9 and IL-9-producing cells in allergic asthma.</div></details></details></td>
    </tr>
    <tr>
      <th>24</th>
      <td>NFKB2</td>
      <td>1</td>
      <td>TFH:1</td>
      <td>0.171971</td>
      <td>ENSG00000077150</td>
      <td><details><summary>Subtypes</summary><details><summary>TFH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/24888602">24888602</a><div class="entities" style="line-height: 2.5"><h3>Novel <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NFKB2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mutation in early-onset CVID.</h3></br>Common variable immunodeficiency (CVID) is heterogeneous, clinically, immunologically and genetically. The majority of genetic mechanisms leading to CVID remain elusive. We studied a Greek Cypriot family of non-consanguineous parents. Two children were diagnosed with CVID at an early age. Whole exome sequencing revealed 8bp deletion in the C-terminal part of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NFKB2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> gene associated with disease. The mutation leads to a frameshift (p.Asp865Valfs*17) altering 17 C-terminal amino acids from residue 865, and creating a premature stop-codon resulting in a truncated protein, 19 amino acids shorter than wild type (p100Δ19). We validated the results with Dye-termination sequencing and Western blot, and confirmed that the conserved residue at 866 is mutated from serine to arginine in p100Δ19, leaving the mutant protein unphosphorylated at this critical regulatory position. Consequently, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NFKB2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>/p100 processing and nuclear translocation were abrogated. Using flow cytometry, we further demonstrated that there was a reduction in B cells (CD19+), switched memory B cells (CD27+IgD-) and T follicular helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells (both CD4+CXCR5+ and CD4+CXCR5Hi) in a CVID patient with <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NFKB2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>/p100Δ19, compared to healthy controls. These data support the notion that the non-canonical NFκB pathway plays an important role in B cell differentiation and the development of Tfh cells, and may pave the way for better understanding of the pathology of CVID. </div></details></details></td>
    </tr>
    <tr>
      <th>25</th>
      <td>JUNB</td>
      <td>2</td>
      <td>TH2:1, TREG:1</td>
      <td>0.153753</td>
      <td>ENSG00000171223</td>
      <td><details><summary>Subtypes</summary><details><summary>TH2</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/9889198">9889198</a><div class="entities" style="line-height: 2.5"><h3>Regulation of IL-4 expression by the transcription factor <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    JunB    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> during T helper cell differentiation.</h3></br>The molecular basis for restricted cytokine expression by T helper 1 (Th1) and T helper 2 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells is unclear. Previous studies found that P1, an element of the interleukin 4 (IL-4) promoter that binds AP-1, is important for Th2-restricted IL-4 expression. Here we show that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    JunB    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, but not the other Jun family members, was selectively induced in Th2 cells and not in Th1 cells during differentiation. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    JunB    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> has previously been considered to be a negative regulator of transcription. However, we show that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    JunB    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> binds directly to the P1 site and synergizes with c-Maf to activate an IL-4 luciferase reporter gene. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    JunB    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>-control of IL-4 expression is mediated by the phosphorylation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    JunB    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> at Thr102 and -104 by JNK MAP kinase. The synergy between c-Maf and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    JunB    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> can be attributed to cooperative DNA binding, which is facilitated by <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    JunB    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> phosphorylation. In transgenic mice, elevated <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    JunB    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> levels caused increased expression of several Th2 cytokines in developing Th1 cells. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    JunB    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> also upregulated IL-4 expression in response to immunization. Thus, the early increase of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    JunB    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> protein in Th2 cells can provide the specificity for c-Maf in IL-4 expression during T cell development and directs thereby Th2 differentiation.</div></details><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/18223166">18223166</a><div class="entities" style="line-height: 2.5"><h3>FoxP3 maintains Treg unresponsiveness by selectively inhibiting the promoter DNA-binding activity of AP-1.</h3></br>Regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) have been shown to play a crucial role in maintaining self-tolerance and suppressing autoimmunity. The forkhead transcription factor, FoxP3, is a key molecule necessary and sufficient for Tregs development and function. However, the molecular mechanisms by which FoxP3 regulates the phenotypic (anergic) and the functional (suppressive) characteristics of Tregs are not well defined. Here we found that the promoter DNA-binding activity of AP-1 transcription factors is selectively inhibited in the naturally occurring CD4+ CD25+ Tregs from mice. The impaired AP-1 DNA binding is not the result of the decreased nuclear translocation of AP-1 family transcription factors, including c-Jun, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    JunB    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, and c-Fos. FoxP3 significantly suppresses both the transcriptional activity and promoter DNA-binding of AP-1 by interacting with c-Jun. The N-terminus of FoxP3, but not its C-terminus forkhead domain, specifically interacts with phosphorylated c-Jun and alters c-Jun subnuclear distribution. This N-terminus of FoxP3 with nuclear localization signals (FoxP3N/NLS) is able to suppress AP-1 transcriptional activity. Ectopic expression of FoxP3N/NLS sufficiently induces the unresponsiveness of mouse primary CD4+ CD25- T cells, whereas the full-length FoxP3 is required for the suppressive functions of Tregs. These findings uncover one of the mechanisms underlying how FoxP3 maintains the unresponsiveness of Tregs.</div></details></details></td>
    </tr>
    <tr>
      <th>26</th>
      <td>IRF2</td>
      <td>1</td>
      <td>TH2:1</td>
      <td>0.131121</td>
      <td>ENSG00000168310</td>
      <td><details><summary>Subtypes</summary><details><summary>TH2</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/12479817">12479817</a><div class="entities" style="line-height: 2.5"><h3>IFN-gamma represses IL-4 expression via IRF-1 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>.</h3></br>Polarization of CD4(+) T helper cells toward either a Th1 or Th2 response can significantly influence host immunity to pathogens. IL-4 and IFN-gamma are the signature cytokines of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th1 cells, respectively. IFN-gamma was shown to assist Th1 development by promoting IL-12 and IL-12 receptor expression. So far, direct influence of Th2 cytokine expression by IFN-gamma has not been described. We show here that IFN-gamma directly suppresses IL-4 gene expression. IRF-1 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> induced by IFN-gamma bind to three distinct IL-4 promoter sites and function as transcriptional repressors. Our data demonstrate a direct negative feedback of IFN-gamma on expression of the Th2 cytokine gene IL-4 and, thus, provide evidence for another important mechanism by which IFNgamma assists Th1 and attenuates Th2 responses.</div></details></details></td>
    </tr>
    <tr>
      <th>27</th>
      <td>FOXO1</td>
      <td>8</td>
      <td>TREG:3, TFH:2, TEFF:1, TH:1, TH17:1</td>
      <td>0.128648</td>
      <td>ENSG00000150907</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/29309928">29309928</a><div class="entities" style="line-height: 2.5"><h3>FOXOs in cancer immunity: Knowns and unknowns.</h3></br>In the tumor microenvironment (TME), cancer cells, stromal cells, and immune cells, along with their extracellular factors, have profound effects on either promoting or repressing anti-cancer immunity. Accumulating evidence has shown the paradoxical intrinsic role of the Forkhead box O (FOXO) family of transcription factors in cancer, which can act as a tumor repressor while also maintaining cancer stem cells. FOXOs also regulate cancer immunity. FOXOs promote antitumor activity through negatively regulating the expression of immunosuppressive proteins, such as programmed death 1 ligand 1 (PD-L1), and vascular endothelial growth factor (VEGF) in tumor cells or stromal cells, which can shape an immunotolerant state in the TME. FOXOs also intrinsically control the anti-tumor immune response as well as the homeostasis and development of immune cells, including T cells, B cells, natural killer (NK) cells, macrophages, and dendritic cells. As a cancer repressor, reviving the activity of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxo1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> forces tumor-infiltrating activated regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> ) cells to egress from tumor tissues. As a promoter of cancer development, Foxo3 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxo1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> negatively regulate cytotoxicity of both CD8+  T cells and NK cells against tumor cells. In this review, we focus on the complex role of FOXOs in regulating cancer immunity due to the various roles that they play in cancer cells, stromal cells, and immune cells. We also speculate on some possible additional roles of FOXOs in cancer immunity based on findings regarding FOXOs in non-cancer settings, such as infectious disease.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27878235">27878235</a><div class="entities" style="line-height: 2.5"><h3>Accelerated cell cycle progression of human regulatory T cell-like cell line caused by continuous exposure to asbestos fibers.</h3></br>Asbestos exposure causes malignant tumors such as lung cancer and malignant mesothelioma. Based on our hypothesis in which continuous exposure to asbestos of immune cells cause reduction of antitumor immunity, the decrease of natural killer cell killing activity with reduction of NKp46 activating receptor expression, inhibition of cytotoxic T cell clonal expansion, reduced CXCR3 chemokine receptor expression and production of interferon-γ production in CD4+ T cells were reported using cell line models, freshly isolated peripheral blood immune cells from health donors as well as asbestos exposed patients such as pleural plaque and mesothelioma. In addition to these findings, regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) showed enhanced function through cell-cell contact and increased secretion of typical soluble factors, interleukin (IL)-10 and transforming growth factor (TGF)-β, in a cell line model using the MT-2 human polyclonal T cells and its sublines exposed continuously to asbestos fibers. Since these sublines showed a remarkable reduction of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxO1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> transcription factor, which regulates various cell cycle regulators in asbestos-exposed sublines, the cell cycle progression in these sublines was examined and compared with that of the original MT-2 cells. Results showed that cyclin D1 expression was markedly enhanced, and various cyclin-dependent kinase-inhibitors were reduced with increased S phases in the sublines. Furthermore, the increase of cyclin D1 expression was regulated by <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxO1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. The overall findings indicate that antitumor immunity in asbestos-exposed individuals may be reduced in Treg through changes in the function and volume of Treg.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/24016547">24016547</a><div class="entities" style="line-height: 2.5"><h3>Transcriptional control of regulatory T cell development and function.</h3></br>Regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells differentiate from thymocytes or peripheral T cells in response to host and environmental cues, culminating in induction of the transcription factor forkhead box P3 (Foxp3) and the Treg cell-specific epigenome. An intermediate amount of antigen stimulation is required to induce Foxp3 expression by engaging T cell receptor (TCR)-activated [e.g., nuclear factor (NF)-κB] and TCR-inhibited (e.g., Foxo) transcription factors. Furthermore, Treg cell differentiation is associated with attenuated Akt signaling, resulting in enhanced nuclear retention of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxo1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, which is indispensable for Treg cell function. These findings reveal that Treg cell lineage commitment is not only controlled by genetic and epigenetic imprinting, but also modulated by transcriptional programs responding to extracellular signals. </div></details><details><summary>TFH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27791035">27791035</a><div class="entities" style="line-height: 2.5"><h3>miRNA92a targets KLF2 and the phosphatase PTEN signaling to promote human T follicular helper precursors in T1D islet autoimmunity.</h3></br>Aberrant immune activation mediated by T effector cell populations is pivotal in the onset of autoimmunity in type 1 diabetes (T1D). T follicular helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TFH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are essential in the induction of high-affinity antibodies, and their precursor memory compartment circulates in the blood. The role of TFH precursors in the onset of islet autoimmunity and signaling pathways regulating their differentiation is incompletely understood. Here, we provide direct evidence that during onset of islet autoimmunity, the insulin-specific target T cell population is enriched with a C-X-C chemokine receptor type 5 (CXCR5)+ CD4+  TFH precursor phenotype. During onset of islet autoimmunity, the frequency of TFH precursors was controlled by high expression of microRNA92a (miRNA92a). miRNA92a-mediated TFH precursor induction was regulated by phosphatase and tension homolog (PTEN) - phosphoinositol-3-kinase (PI3K) signaling involving PTEN and forkhead box protein O1 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxo1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>), supporting autoantibody generation and triggering the onset of islet autoimmunity. Moreover, we identify Krueppel-like factor 2 (KLF2) as a target of miRNA92a in regulating human TFH precursor induction. Importantly, a miRNA92a antagomir completely blocked induction of human TFH precursors in vitro. More importantly, in vivo application of a miRNA92a antagomir to nonobese diabetic (NOD) mice with ongoing islet autoimmunity resulted in a significant reduction of TFH precursors in peripheral blood and pancreatic lymph nodes. Moreover, miRNA92a antagomir application reduced immune infiltration and activation in pancreata of NOD mice as well as humanized NOD Scid IL2 receptor gamma chain knockout (NSG) human leucocyte antigen (HLA)-DQ8 transgenic animals. We therefore propose that miRNA92a and the PTEN-PI3K-KLF2 signaling network could function as targets for innovative precision medicines to reduce T1D islet autoimmunity.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/25646266">25646266</a><div class="entities" style="line-height: 2.5"><h3>ICOS maintains the T follicular helper cell phenotype by down-regulating Krüppel-like factor 2.</h3></br>The co-stimulators ICOS (inducible T cell co-stimulator) and CD28 are both important for T follicular helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TFH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, yet their individual contributions are unclear. Here, we show that each molecule plays an exclusive role at different stages of TFH cell development. While CD28 regulated early expression of the master transcription factor Bcl-6, ICOS co-stimulation was essential to maintain the phenotype by regulating the novel TFH transcription factor Klf2 via <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxo1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. Klf2 directly binds to Cxcr5, Ccr7, Psgl-1, and S1pr1, and low levels of Klf2 were essential to maintain this typical TFH homing receptor pattern. Blocking ICOS resulted in relocation of fully developed TFH cells back to the T cell zone and reversion of their phenotype to non-TFH effector cells, which ultimately resulted in breakdown of the germinal center response. Our study describes for the first time the exclusive role of ICOS and its downstream signaling in the maintenance of TFH cells by controlling their anatomical localization in the B cell follicle. </div></details><details><summary>TEFF</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/29337047">29337047</a><div class="entities" style="line-height: 2.5"><h3>Imaging flow cytometry: A method for examining dynamic native <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FOXO1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> localization in human lymphocytes.</h3></br>While flow cytometry can reliably assess surface and intracellular marker expression within small cell populations, it does not provide any information on protein localization. Several key transcription factors (TF) downstream of lymphocyte surface receptors are regulated by nuclear versus cytoplasmic localization, and one such TF is Forkhead box O1 (FOXO1). <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FOXO1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> integrates antigen-binding, co-receptor activation and metabolic signals in lymphocytes, leading to proliferation and differentiation. Importantly, the nuclear or cytoplasmic localization of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FOXO1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is key for gene expression leading to different lymphocyte phenotypes. In effector lymphocytes (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Teff    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>), for example, lymphocyte receptor (TCR) signaling leads to an Akt-dependent phosphorylation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FOXO1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. Phosphorylated <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FOXO1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is excluded from the nucleus, promoting proliferation and effector functions. In contrast, nuclear retention of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FOXO1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is essential for early and late development of T and B cells and for the thymic development and stability of regulatory T cells. Given the critical role of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FOXO1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> localization as an indicator and determinant of function, quantification of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FOXO1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> cellular localization in human lymphocytes can help determine immune cell activation and activity in experimental and clinical scenarios. The standard method used to determine subcellular protein localization is the analysis of nuclear and cytoplasmic protein extracts by Western blotting (WB). However, available techniques, such as WB, are limited by a requirement for a large number of cells and inability to determine <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FOXO1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> localization in individual cells or sub-populations. In contrast, a standardized method using an imaging flow cytometer (IFC) such as the Amnis ImagestreamX  Mark II, would provide both qualitative, per-cell localization information, as well as quantitative data on gated sub-populations. To this end, we report the development and optimization of an IFC protocol to examine native <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FOXO1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> localization in human lymphocytes. A human CD4+ lymphocyte line, HuT102, as well as primary human T cells, were assessed for dynamic <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FOXO1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> localization after treatment with a lymphocyte receptor signaling mimic (PMA/Ionomycin). IFC nuclear translocation analysis permitted us to precisely quantify the alterations over time in nuclear and cytoplasmic localization of native <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FOXO1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> on a per cell basis, including within specific, user-defined sub-populations of cells. For human lymphocytes, using IFC to assess and quantify dynamic <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FOXO1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> localization allows the user to simultaneously study multiple lymphocyte subpopulations as well as to delineate differing effects of dynamic <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FOXO1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> localization that may be lost when other available methods are used.</div></details><details><summary>TH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/29018172">29018172</a><div class="entities" style="line-height: 2.5"><h3><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxo1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and Foxp1 play opposing roles in regulating the differentiation and antitumor activity of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> 9 cells programmed by IL-7.</h3></br>Tumor-specific CD4+  T helper 9 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH 9)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark><mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> 9) cel<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    ls, s    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>o-called because of their production of the cytokine interleukin-9 (IL-9), are a powerful effector T cell subset for cancer immunothera<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    py. W    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>e found that pretreatment of naïve CD4+  T cells with IL-7 further enhanced their differentiation into <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> 9 cells and augmented their antitumor activity. IL-7 markedly increased the abundance of the histone acetyltransferase p300 by activating the STAT5 and PI3K-AKT-mTOR signaling pathways and promoting the acetylation of histones at the <i>Il9</i> promoter. As a result, the transcriptional regulator Foxo1 was dephosphorylated and translocated to the nucleus, bound to the <i>Il9</i> promoter, and induced the production of IL-9 protein. In contrast, Foxp1, which bound to the <i>Il9</i> promoter in naïve CD4+  T cells and inhibited <i>Il9</i> expression, was outcompeted for binding to the <i>Il9</i> promoter by Foxo1 and translocated to the cytoplasm. Furthermore, forced expression of Foxo1 or a deficiency in <i>Foxp1</i> in CD4+  T cells markedly increased the production of IL-9, whereas a deficiency in <i>Foxo1</i> inhibited the ability of IL-7 to enhance the differentiation and antitumor activity of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> 9 cells. Thus, we identified the roles of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxo1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> as a positive regulator and Foxp1 as a negative regulator of TH 9 cell differentiation and antitumor activity, which may provide potential targets for cancer immunotherapy.</div></details><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/21825017">21825017</a><div class="entities" style="line-height: 2.5"><h3>Cytokine signals through PI-3 kinase pathway modulate Th17 cytokine production by CCR6+ human memory T cells.</h3></br>Human memory T cells (T(M) cells) that produce IL-17 or IL-22 are currently defined as <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> or Th22 cells, respectively. These T cell lineages are almost exclusively CCR6(+) and are important mediators of chronic inflammation and autoimmunity. However, little is known about the mechanisms controlling IL-17/IL-22 expression in memory Th17/Th22 subsets. We show that common γ chain (γc)-using cytokines, namely IL-2, IL-7, and IL-15, potently induce Th17-signature cytokine expression (Il17a, Il17f, Il22, and Il26) in CCR6(+), but not CCR6(-), T(M) cells, even in CCR6(+) cells lacking IL-17 expression ex vivo. Inhibition of phosphoinositide 3-kinase (PI-3K) or Akt signaling selectively prevents Th17 cytokine induction by γc-cytokines, as does ectopic expression of the transcription factors <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FOXO1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> or KLF2, which are repressed by PI-3K signaling. These results indicate that Th17 cytokines are tuned by PI-3K signaling in CCR6(+) T(M) cells, which may contribute to chronic or autoimmune inflammation. Furthermore, these findings suggest that ex vivo analysis of IL-17 expression may greatly underestimate the frequency and pathogenic potential of the human Th17 compartment.</div></details></details></td>
    </tr>
    <tr>
      <th>28</th>
      <td>MAF</td>
      <td>2</td>
      <td>TFH:2, TH:1</td>
      <td>0.113748</td>
      <td>ENSG00000178573</td>
      <td><details><summary>Subtypes</summary><details><summary>TFH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/22427637">22427637</a><div class="entities" style="line-height: 2.5"><h3>Bcl6 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Maf    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> cooperate to instruct human follicular helper CD4 T cell differentiation.</h3></br>Follicular helper CD4 T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells provide B cells with signals that are important for the generation of high-affinity Abs and immunological memory and, therefore, are critical for the protective immunity elicited by most human vaccines. Transcriptional regulators of human Tfh cell differentiation are poorly understood. In this article, we demonstrate that Bcl6 controls specific gene modules for human Tfh cell differentiation. The introduction of Bcl6 expression in primary human CD4 T cells resulted in the regulation of a core set of migration genes that enable trafficking to germinal centers: CXCR4, CXCR5, CCR7, and EBI2. Bcl6 expression also induced a module of protein expression critical for T-B interactions, including SAP, CD40L, PD-1, ICOS, and CXCL13. This constitutes direct evidence for Bcl6 control of most of these functions and includes three genes known to be loci of severe human genetic immunodeficiencies (CD40L, SH2D1A, and ICOS). Introduction of Bcl6 did not alter the expression of IL-21 or IL-4, the primary cytokines of human Tfh cells. We show in this article that introduction of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Maf    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (c-Maf) does induce the capacity to express IL-21. Surprisingly, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Maf    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> also induced CXCR5 expression. Coexpression of Bcl6 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Maf    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> revealed that Bcl6 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Maf    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> cooperate in the induction of CXCR4, PD-1, and ICOS. Altogether, these findings reveal that Bcl6 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Maf    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> collaborate to orchestrate a suite of genes that define core characteristics of human Tfh cell biology.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21511186">21511186</a><div class="entities" style="line-height: 2.5"><h3>A subset of interleukin-21+ chemokine receptor CCR9+ T helper cells target accessory organs of the digestive system in autoimmunity.</h3></br>This study describes a CD4+ T helper (Th) cell subset marked by coexpression of the cytokine interleukin 21 (IL-21) and the gut-homing chemokine receptor CCR9. Although CCR9+ Th cells were observed in healthy mice and humans, they were enriched in the inflamed pancreas and salivary glands of NOD mice and in the circulation of Sjögren's syndrome patients. CCR9+ Th cells expressed large amounts of IL-21, inducible T cell costimulator (ICOS), and the transcription factors Bcl6 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Maf    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, and also supported antibody production from B cells, thereby resembling T follicular B helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. However, in contrast to Tfh cells, CCR9+ Th cells displayed limited expression of CXCR5 and the targets of CCR9+ Th cells were CD8+ T cells whose responsiveness to IL-21 was necessary for the development of diabetes. Thus, CCR9+ Th cells are a subset of IL-21-producing T helper cells that influence regional specification of autoimmune diseases that affect accessory organs of the digestive system.</div></details><details><summary>TH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/21511186">21511186</a><div class="entities" style="line-height: 2.5"><h3>A subset of interleukin-21+ chemokine receptor CCR9+ T helper cells target accessory organs of the digestive system in autoimmunity.</h3></br>This study describes a CD4+ T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cell subset marked by coexpression of the cytokine interleukin 21 (IL-21) and the gut-homing chemokine receptor CCR9. Although CCR9+ Th cells were observed in healthy mice and humans, they were enriched in the inflamed pancreas and salivary glands of NOD mice and in the circulation of Sjögren's syndrome patients. CCR9+ Th cells expressed large amounts of IL-21, inducible T cell costimulator (ICOS), and the transcription factors Bcl6 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Maf    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, and also supported antibody production from B cells, thereby resembling T follicular B helper (Tfh) cells. However, in contrast to Tfh cells, CCR9+ Th cells displayed limited expression of CXCR5 and the targets of CCR9+ Th cells were CD8+ T cells whose responsiveness to IL-21 was necessary for the development of diabetes. Thus, CCR9+ Th cells are a subset of IL-21-producing T helper cells that influence regional specification of autoimmune diseases that affect accessory organs of the digestive system.</div></details></details></td>
    </tr>
    <tr>
      <th>29</th>
      <td>RXRA</td>
      <td>2</td>
      <td>TH1:2</td>
      <td>0.107790</td>
      <td>ENSG00000186350</td>
      <td><details><summary>Subtypes</summary><details><summary>TH1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/19307772">19307772</a><div class="entities" style="line-height: 2.5"><h3>Differential expression of nuclear receptors in T helper cells.</h3></br>Steroid hormones have long been known to have a profound influence on the immune system. Although the functions of these nuclear receptors in the development of T cells are fairly well studied, the differential expression of these receptors in T helper cells is poorly understood. Here, we investigated the differential expression of nuclear receptors and coregulators in <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells by genomewide microarray analysis. The result showed that several nuclear receptors and coregulators are differentially expressed in these cells. The result was confirmed by RT-PCR. The result showed that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RXRalpha    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is highly expressed in Th2 cells. Overexpression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RXRalpha    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in a Jurkat human T cell line induced IL4 but not IFN-gamma gene expression, suggesting that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RXRalpha    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> plays a selective role in Th1 and Th2 differentiation. In summary, these results suggest that Th1/Th2 differentiation may be influenced by differential regulation of nuclear receptors and coregulators.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/16331704">16331704</a><div class="entities" style="line-height: 2.5"><h3>Twisting the Th1/Th2 immune response via the retinoid X receptor: lessons from a genetic approach.</h3></br>The immune system is influenced by environmental factors such as hormones and nutrients. Previous studies have suggested that vitamins A and D influence the process of naive T helper (Th) cell differentiation into <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> or Th2 cells. Vitamins A and D signal through the retinoid X receptor (RXR), which partners with either the retinoic acid receptor or the vitamin D receptor. Most previous studies into the role of RXR in Th differentiation have been performed in vitro and it was necessary for these to be verified in a physiological environment. However, in vivo study has been hindered since <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RXRalpha    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> deficient mice are embryonic lethal. Du et al. in this issue of the European Journal of Immunology, overcome this obstacle using "pinkie" mice that harbor a hypomorphic mutation in the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Rxralpha    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> gene. The authors report that the mutant mice have an exaggerated Th1 immune response which is attributed to the aberrant antigen-presenting cell and CD4 T cell function. This study confirms previous studies indicating that RXR signaling plays an important role in Th cell differentiation and also provides a valuable tool with which to study the mechanisms and the in vivo functions of this signaling pathway.</div></details></details></td>
    </tr>
    <tr>
      <th>30</th>
      <td>STAT1</td>
      <td>33</td>
      <td>TREG:11, TH:7, TH1:5, TFH:4, TH17:4, TH2:2, TREG1:2, TEFF:1, TH9:1</td>
      <td>0.099520</td>
      <td>ENSG00000115415</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28644966">28644966</a><div class="entities" style="line-height: 2.5"><h3>An immunosuppressive function of interleukin-35 in chronic hepatitis C virus infection.</h3></br>Interleukin (IL)-35, a newly identified member of the IL-12 cytokine family, has been reported to suppress inflammation and induce immunotolerance. However, little is known regarding the role of IL-35 during chronic hepatitis C virus (HCV) infection. Herein, we measured the serum IL-35 concentration of 73 patients with hepatitis C and 22 healthy individuals, as well as further investigated the modulatory function of IL-35 on CD4+ CD25+ CD127<sup>dim/-</sup> regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) and on hepatocytes infected with HCV in cell culture (HCVcc). IL-35 expression was significantly increased in patients with chronic hepatitis C and was positively correlated with the levels of HCV RNA. Inhibition of viral replication led to decreases in the serum levels of IL-35. IL-35 stimulation not only elevated the percentage of Tregs but also robustly inhibited cellular proliferation and up-regulated the production of anti-inflammatory cytokines (e.g., IL-10 and IL-35) in a HCV-specific and non-specific manner, which indicates enhancement of the suppressive function of Tregs. Although IL-35 did not exert anti-HCV activity in HCVcc-infected Huh7.5 cells, it reduced inflammatory cytokine secretion from Huh7.5 cells. This was probably via inhibition of the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and STAT3 signaling pathways, which could suppress subsequent liver damage due to chronic hepatitis C. The current data suggested that IL-35 contributes to persistent HCV infection by inhibiting antiviral immune activity. Moreover, IL-35 might also protect against HCV-induced liver injury by down-regulating the expression of proinflammatory cytokines. Thus, the immunosuppressive properties of IL-35 might play contradictory roles in maintaining viral persistence and reducing the inflammatory responses in chronic HCV infection.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28256939">28256939</a><div class="entities" style="line-height: 2.5"><h3>Increased Levels of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> Protein in Blood CD4 T Cells from Systemic Lupus Erythematosus Patients Are Associated with Perturbed Homeostasis of Activated CD45RA- FOXP3hi  Regulatory Subset and Follow-Up Disease Severity.</h3></br>In murine systemic lupus erythematosus (SLE), aberrant regulation of interferon (IFN)-alpha-<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> signaling and perturb<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    ed ho    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>meostasis of CD4+ FOXP3+  regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) were described. In the present study, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> signaling and circulating Treg subsets were assessed by flow cytometry in 39 SLE patients and their potential association with disease course was examined during long-term follow-up. Levels of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> protein as measured by median fluorescence intensity (MFI) were significantly increased in SLE CD4 T cells when compared with rheumatoid arthritis patients and healthy controls and were positively correlated with disease activity. The highest STAT1 MFI was found in CD45RA- FOXP3hi -activated Treg (aTreg) subset, which demonstrated the highest <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> phosphorylation responses among SLE CD4 T cells and significant decrease in proliferation marker Ki-67 expression after IFN-alpha stimulation. Percentage of Ki-67+  aTregs was significantly decreased in SLE patients and was negatively correlated with CD4 T cell STAT1 MFI. A subgroup of SLE patients characterized by lower aTreg counts experienced more severe relapsing disease course during 1,000 days of follow-up. Mean CD4 T cell <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> MFI in follow-up samples from SLE patients was negatively correlated with mean of follow-up aTreg counts. Our findings indicate that augmented <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> signaling may be involved in perturbed aTreg homeostasis, which could represent a possible marker of SLE disease severity.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27063510">27063510</a><div class="entities" style="line-height: 2.5"><h3>Common variable immunodeficiency, impaired neurological development and reduced numbers of T regulatory cells in a 10-year-old boy with a <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> gain-of-function mutation.</h3></br>Recently, gain-of-function (GOF) mutations in the gene encoding <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    signal transducer and activator of transcription 1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) have been associated with chronic mucocutaneous candidiasis (CMC). This case report describes a 10-year-old boy presenting with signs of common variable immunodeficiency (CVID), failure to thrive, impaired neurological development, and a history of recurrent mucocutaneous Candida infections. Sequencing of the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> gene identified a heterozygous missense mutation in exon 7 encoding the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> coiled-coil domain (c.514T>C, p.Phe172Leu). In addition to hypogammaglobulinemia with B-cell deficiency, and a low percentage of Th17 cells, immunological analysis of the patient revealed a marked depletion of forkhead-box P3(+)-expressing regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>). In vitro stimulation of T cells from the patient with interferon-α (IFNα) and/or IFNɣ resulted in a significantly increased expression of STAT1-regulated target genes such as MIG1, IRF1, MX1, MCP1/CCL2, IFI-56K, and CXCL10 as compared to IFN-treated cells from a healthy control, while no IFNα/ɣ-mediated up-regulation of the FOXP3 gene was found. These data demonstrate that the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> GOF mutation F172L, which results in impaired stability of the antiparallel <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> dimer conformation, is associated with inhibited Treg cell development and neurological symptoms. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/25138378">25138378</a><div class="entities" style="line-height: 2.5"><h3>Ganoderic acid Me induces the apoptosis of competent T cells and increases the proportion of Treg cells through enhancing the expression and activation of indoleamine 2,3-dioxygenase in mouse lewis lung cancer cells.</h3></br>The indoleamine 2,3-dioxygenase-(IDO-) mediated microenvironment plays an important role in tumor immune escape. It is known that ganoderic acid Me can enhance IFN-γ expression and IDO is preferentially induced by IFN-γ. However, whether GA-Me can induce IDO expression has not been clarified yet. We established stable clones of IDO-overexpressing 2 LL cells (2LL-EGFP-IDO). After co-culturing with IDO expressing or control vector-transfected 2LL-EGFP cells, T cell apoptosis was determined and the proportion of the regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) and CD8+ T cell subset was measured. The total cellular protein samples of 2 LL-EGFP-IDO cells were isolated for detecting JAK-<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> signalling pathway. Co-culture supernatants were used to detect amino acids and cytokines. IDO transfected 2 LL cells yielded high level of IDO enzymatic activity, resulting in complete depletion of tryptophan from the culture medium. We found that apoptosis occurred in T cells after cocultured with IDO+2LL cells and the proportion of CD4+CD25+ cells and FoxP3+ cells increased while CD8+ cells decreased. The specific inhibitor of IDO, 1-D-MT and GA-Me efficiently enhanced T cell apoptosis, increased Tregs, and reduced CD8+ T cells in vitro. Increased expression of IDO, p-JAK1 and p-<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> were confirmed by Western blot analysis. The levels of IFN-γ, IL-10, LDH and kynurenine in co-culture supernatant correspondingly increased, while tryptophan reduced. These results suggest that GA-Me contributing to IDO helps to create a tolerogenic milieu in lung tumors by directly inducing T cell apoptosis, restraining CD8+ T cell activation, and enhancing Treg-mediated immunosuppression.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21345084">21345084</a><div class="entities" style="line-height: 2.5"><h3>Immunohistochemical analysis reveals an influx of regulatory T cells and focal trophoblastic <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> phosphorylation in chronic villitis of unknown etiology.</h3></br>Maternal T cells and fetal macrophages constitute the primary infiltrate of chronic villitis of unknown etiology (CVUE), but the role of CD25(+)/FOXP3(+) regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells in CVUE has not been examined. Moreover, little is known about the expression of immune markers, such as the major histocompatibility complex (MHC) class II antigen, human leukocyte antigen-DR (HLA-DR), in trophoblasts in this disease. We, therefore, examined CVUE placentas for the presence of Treg cells and aberrant activation of HLA-DR in trophoblasts. Sequential formalin-fixed, paraffin-embedded tissue sections from 8 CVUE placentas and 10 control placentas were stained by immunohistochemistry with antibodies for CD3, CD4, CD8, CD20, CD25, FOXP3, CD56, CD68, HLA-DR, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, and phosphorylated <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> [P-(Y701)-STAT-1]. T cells and histiocytes were confirmed as the inflammatory infiltrate in CVUE. In areas of CVUE, histiocytes strongly expressed HLA-DR and nuclear P-(Y701)-STAT-1, and the relative numbers of CD25(+)/FOXP3(+) Treg cells were increased, compared with control placentas. In 5 of 8 CVUE cases, there was patchy nuclear expression of P-(Y701)-STAT-1 in syncytiotrophoblast most extensively involved by villitis, but no other marker examined was detected in the trophoblast cell layer. We confirmed the influx of T cells and histiocytes in CVUE. Our results are the 1st, to our knowledge, to identify increased numbers of Treg cells in CVUE vs noninflamed placentas. However, we were unable to verify HLA-DR expression in trophoblasts of placentas with CVUE, suggesting that this does not contribute to the influx of T cells. Our observation that P-(Y701)-STAT-1 expression in a syncytiotrophoblast is restricted to regions of inflammation suggests that the JAK-<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> pathway is aberrantly activated in these cells.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21307288">21307288</a><div class="entities" style="line-height: 2.5"><h3>Stat3 phosphorylation mediates resistance of primary human T cells to regulatory T cell suppression.</h3></br>Human autoimmune diseases are characterized by systemic T cell dysfunction, resulting in chronically activated Th1 and Th17 cells that are inadequately suppressed by regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>). IL-6, which is overexpressed in tissue and serum of patients with autoimmune diseases, inhibits human Treg function. We sought to determine the mechanism for the antitolerogenic properties of IL-6 by examining the signaling pathways downstream of IL-6R in primary human T cells. Inhibition of Stat3 signaling in MLCs containing IL-6 restores Treg-mediated suppression, demonstrating that IL-6-mediated loss of Treg suppression requires phosphorylation of Stat3. Cultures in which either effector T cells (Teffs) or Tregs were pretreated with Stat3 inhibitors indicate that phosphorylated (p)Stat3 is required in both T cell populations for IL-6-mediated reversal of Treg function. IL-21, which signals preferentially through pStat3, also reverses Treg suppression, in contrast to IL-27 and IFN-γ, which signal preferentially through <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and do not inhibit Treg function. Interestingly, both Teffs and Tregs respond to IL-6 stimulation through strong Stat3 phosphorylation with minimal MAPK/Erk activation and moderate <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> phosphorylation. Finally, Teffs stimulated strongly through the TCR are also resistant to suppression by Tregs and show concurrent Stat3 phosphorylation. In these cultures, inhibition of pStat3 restores functional suppression by Tregs. Taken together, our findings suggest that an early dominance of Stat3 signaling, prior to subsequent T cell activation, is required for the loss of functional Treg suppression and that kinase-specific inhibitors may hold therapeutic promise in the treatment of autoimmune and chronic inflammatory diseases.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27538493">27538493</a><div class="entities" style="line-height: 2.5"><h3>Exosomal miR-24-3p impedes T cell function by targeting FGF11 and serves as a potential prognostic biomarker for nasopharyngeal carcinoma.</h3></br>Recent studies have shown that extracellular microRNAs are not only potential biomarkers but are also involved in cell interactions to regulate the intercommunication between cancer cells and their microenvironments in various types of malignancies. In this study, we isolated exosomes from nasopharyngeal carcinoma (NPC) cell lines and patient sera (T-EXOs), or control NP69 cells and healthy donor sera (HD-EXOs). We found that miR-24-3p was markedly enriched in T-EXOs as compared with HD-EXOs; the serum exosomal miR-24-3p level was correlated with worse disease-free survival of patients (p < 0.05). Knockdown of exosomal miR-24-3p (miR-24-3p-sponge-T-EXOs) by a sponge RNA targeting miR-24-3p restored the T-EXO-mediated (control-sponge-T-EXO) inhibition of T cell proliferation and Th1 and Th17 differentiation, and the induction of regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>). Mechanistic analyses revealed that administration of exosomal miR-24-3p increased P-ERK, P-<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and P-STAT3 expression while decreasing P-STAT5 expression during T cell proliferation and differentiation. Moreover, by in vivo and in vitro assessments, we found FGF11 to be a direct target of miR-24-3p. However, both miR-24-3p-sponge-T-EXOs and T-EXOs (control-sponge-T-EXOs) impeded proliferation and Th1 and Th17 differentiation, but induced Treg differentiation, of lenti-shFGF11-transfected T cells. The levels of phosphorylated ERK and STAT proteins were different in lenti-ScshRNA-transfected T cells and lenti-shFGF11-transfected T cells following administration of miR-24-3p-sponge-T-EXO. Interestingly, tumour FGF11 expression was positively correlated with the number of CD4+  and CD8+  T cells in vivo, and predicted favourable patient DFS (p < 0.05). Additionally, hypoxia increased cellular and exosomal miR-24-3p levels and enhanced the inhibitory effect of T-EXO on T cell proliferation and differentiation. Collectively, our findings suggest that exosomal miR-24-3p is involved in tumour pathogenesis by mediating T cell suppression via repression of FGF11, and may serve as a potential prognostic biomarker in NPC. Copyright © 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/26523057">26523057</a><div class="entities" style="line-height: 2.5"><h3>Ex Vivo Signaling Protein Mapping in T Lymphocytes in the Psoriatic Arthritis Joints.</h3></br>We assessed signaling protein mapping in total T cells, to analyze the proportions of T regulatory (Treg) and TCD4+ effector (Teff) cell phenotypes, and the respective interleukin 6Rα (IL-6Rα) expression in the inflammatory microenvironment of synovial fluid (SF) of patients with sustained psoriatic arthritis (PsA). Our approach was to measure the IL-6 level in SF using a multiplex bead immunoassay. Reverse-phase protein array was used to assess Janus kinase (JAK) 1 and JAK2, extra-cellular regulated kinase (ERK) 1 and 2, protein kinase Cδ (PKCδ), signal transducer and activator and transcription (STAT) 1, STAT3, and STAT5 phosphoproteins in total T cell lysates from SF of patients with PsA. Frequencies of CD4+IL-17A-F+IL-23+ CD4+ Th cells producing IL-17A and IL-17F (Th17) and CD4+CD25high intracellular forkhead box transcription factor+ (FOXP3+) phenotypes, and the percentage of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg-    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Teff- cells were quantified in SF and matched peripheral blood (PB) of patients with PsA and PB of healthy controls (HC) by flow cytometry. Our results were the following: In PsA SF samples, a coordinate increase of JAK1, ERK1/2, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, STAT3, and STAT5 phosphoproteins was found in total T cells in SF of PsA; where IL-6 levels were higher than in PB from HC. Expanded CD4+IL-17A-F+IL-23+ Th17, CD4+ CD25- Teff- and CD4+CD25(high) FoxP3+Treg subsets, showing similar levels of enhanced IL-6Rδ expression, were confined to PsA joints. In our studies, the transcriptional network profile identified by ex vivo signaling protein mapping in T lymphocytes in PsA joints revealed the complex interplay between IL-1, IL-6, and IL-23 signaling and differentiation of Th17 cells and CD4+Tregs in sustained joint inflammation in PsA.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/25700150">25700150</a><div class="entities" style="line-height: 2.5"><h3>T helper 9 cells induced by plasmacytoid dendritic cells regulate interleukin-17 in multiple sclerosis.</h3></br>Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS) characterized by persistent inflammation orchestrated by cluster of differentiation (CD) 4 T helper (Th) cells. In particular, Th1 and Th17 cells amplify, whereas T regulatory (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells moderate inflammation. The role of other Th subsets in MS is not clear. In the present study, we investigated the generation of different Th responses by human dendritic cells (DCs) in MS. We compared the production of several Th cytokines by naive CD4+ T cells polarized with myeloid and plasmacytoid DCs (mDCs and pDCs) in healthy donors (HD) and relapsing-remitting (RR)-MS patients. We found that resiquimod-stimulated mDCs were able to activate Th17 differentiation, whereas pDCs induced interleukin (IL)-10-producing Th cells. Surprisingly, resiquimod-stimulated pDCs from MS patients also significantly induced the differentiation of Th9 cells, which produce IL-9 and are known to be involved in allergic diseases. We investigated the potential role of IL-9 in MS. We found that IL-9 activated <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    signal transducer and activator of transcription (STAT) 1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and STAT5 phosphorylation and interfered with IL-17 and interferon (IFN) regulatory transcription factor (IRF)-4 expression in Th17-polarized cells. Moreover, in the cerebrospinal fluid (CSF) of 107 RR-MS patients, IL-9 inversely correlated with indexes of inflammatory activity, neurodegeneration and disability progression of MS. High levels of IL-9 were associated with the absence of IL-17 in the CSF of RR-MS patients. Our results demonstrate a Th9-inducing potential of pDCs in MS, suggesting an immunoregulatory role leading to attenuation of the exaggerated Th17 inflammatory response.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/23572151">23572151</a><div class="entities" style="line-height: 2.5"><h3>Comparison of immunosuppressive and immunomodulatory cells in keratoacanthoma and cutaneous squamous cell carcinoma.</h3></br>An imbalance of immunosuppressive and immunomodulatory cells plays an important role in inhibiting the anti-tumour immune response in a tumour-bearing host. Among such cells, regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>), together with immunosuppressive macrophages, such as CD163+ M2 macrophages, play roles in maintaining the tumour microenvironment. In contrast, interleukin-27 (IL-27) induces <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and STAT3 activation, thus resulting in the enhancement of naive CD4 T cell proliferation, the promotion of early Th1 differentiation, and the induction of the anti-tumour immune response. The purpose of this study was to investigate the involvement of immunosuppressive cells, such as Tregs and CD163+ macrophages, as well as immunomodulatory cells (i.e. IL-27-producing cells) in keratoacanthoma (KA) and invasive squamous cell carcinoma (SCC). We also examined the presence of CD3+ Foxp3+ Tregs cells in lesional skin from 10 patients with KA and 18 patients with SCC. Increased numbers of CD3+ Foxp3+ Tregs were observed in SCC compared with KA. In parallel with Tregs, higher numbers of CD163+ macrophages and MMP-9+ cells were detected only in SCC. In contrast, IL-27-producing cells were increased only in KA. In addition, the expression of pSTAT1 on tumour cells was observed only in KA. These findings suggest that the induction of immunosuppressive and immunomodulatory cells differs between KA and SCC. </div></details><details><summary>TH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/26525134">26525134</a><div class="entities" style="line-height: 2.5"><h3>Age-Related Differences in Percentages of Regulatory and Effector T Lymphocytes and Their Subsets in Healthy Individuals and Characteristic <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>/STAT5 Signalling Response in Helper T Lymphocytes.</h3></br>The dynamic process of the development of the immune system can in itself result in age-related immune malfunctions. In this study, we analysed lymphocyte subsets in the peripheral blood of 60 healthy donors, divided into groups of children, adolescents, and adults, focusing on effector (Teff) and regulatory (Treg) T lymphocytes and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>/STAT5 signalling response in helper T lymphocytes (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) in adults, using flow cytometry. Our results demonstrate a decrease in the percentage of total Tregs and an increase in the percentage of total Teffs with age and a consequential immense increase in the Teff/Treg ratio. The increase of Teffs was most apparent in Th1, Th1Th17, and Th17CD161- subsets. Significant Th lymphocyte <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression differences were observed between children and adolescents, which were associated with the decrease in activated Tregs. Higher expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> was found in FoxP3hi than in FoxP3low Th lymphocytes, while significant IL-2 induced STAT5 phosphorylation differences were found among the subsets of Th lymphocytes in adults. Our study demonstrates age-related changes in circulating Teff and Treg, as well as significant differences in STAT5/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> signalling among FoxP3+ Th lymphocytes, providing new advances in the understanding of immunosenescence. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/26261240">26261240</a><div class="entities" style="line-height: 2.5"><h3>SUMOylation-disrupting WAS mutation converts WASp from a transcriptional activator to a repressor of NF-κB response genes in T cells.</h3></br>In Wiskott-Aldrich syndrome (WAS), immunodeficiency and autoimmunity often comanifest, yet how WAS mutations misregulate chromatin-signaling in Thelper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells favoring development of auto-inflammation over protective immunity is unclear. Previously, we identified an essential promoter-specific, coactivator role of nuclear-WASp in TH1 gene transcription. Here we identify small ubiquitin-related modifier (SUMO)ylation as a novel posttranslational modification of WASp, impairment of which converts nuclear-WASp from a transcriptional coactivator to a corepressor of nuclear factor (NF)-κB response genes in human (TH)1-differentiating cells. V75M, one of many disease-causing mutations occurring in SUMO*motif (72-ψψψψKDxxxxSY-83) of WASp, compromises WASp-SUMOylation, associates with COMMD1 to attenuate NF-κB signaling, and recruits histone deacetylases-6 (HDAC6) to p300-marked promoters of NF-κB response genes that pattern immunity but not inflammation. Consequently, proteins mediating adaptive immunity (IFNG, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, TLR1) are deficient, whereas those mediating auto-inflammation (GM-CSF, TNFAIP2, IL-1β) are paradoxically increased in TH1 cells expressing SUMOylation-deficient WASp. Moreover, SUMOylation-deficient WASp favors ectopic development of the TH17-like phenotype (↑IL17A, IL21, IL22, IL23R, RORC, and CSF2) under TH1-skewing conditions, suggesting a role for WASp in modulating TH1/TH17 plasticity. Notably, pan-histone deacetylase inhibitors lift promoter-specific repression imposed by SUMOylation-deficient WASp and restore misregulated gene expression. Our findings uncovering a SUMOylation-based mechanism controlling WASp's dichotomous roles in transcription may have implications for personalized therapy for patients carrying mutations that perturb WASp-SUMOylation. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/22510470">22510470</a><div class="entities" style="line-height: 2.5"><h3>Quantifying crosstalk among interferon-γ, interleukin-12, and tumor necrosis factor signaling pathways within a TH1 cell model.</h3></br>T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(H)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells integrate biochemical cues present in the tissue microenvironment and produce cytokines that orchestrate immune responses. Previous discoveries have revealed a qualitative understanding of how T(H) cells process this biochemical information; however, the lack of methods to quantify how well these depictions apply to a particular cell type limits our ability to translate our knowledge of the immune response from one biological system to another. We used model-based inference methods and quantitative flow cytometric analysis in mouse T(H)1 cells to determine the relative contributions of different putative branches in the signaling network that responds to the cytokine interleukin-12 (IL-12), which links innate and adaptive immunity. The response of T(H)1 cells to IL-12 exhibited hysteresis because it depended on both current and past exposure and engaged a positive feedback mechanism through the direct activation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    signal transducer and activator of transcription 1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. The hysteresis in the dose-response curve to IL-12 created a transient "memory" by sustaining cytokine secretion after the withdrawal of the stimulus. In summary, this combined experimental and computational approach illustrates how model-based inference can be used to better understand how cells process and act upon biochemical cues present in the tissue microenvironment.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/18418398">18418398</a><div class="entities" style="line-height: 2.5"><h3>Onecut transcription factor OC2 is a direct target of T-bet in type-1 T-helper cells.</h3></br>T-box transcription factor, T-bet, has a central role in the differentiation of T-helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) progenitor cells to Th1 or Th2 effector cells, partly by regulating the expression of genes such as interferon-gamma (IFN-gamma). However, the direct target genes, especially those mediating the transcriptional network initiated by T-bet, are not yet fully understood. By combining chromatin immunoprecipitation from Th1 cells with human cytosine-phosphate-guanine-island array analysis, Onecut 2 (OC2), which encodes a member of the ONECUT class of transcriptional activators, was identified as a direct target gene of T-bet. OC2 is expressed in Th1 but not Th2 cells and reporter assays showed that T-bet transactivates OC2 transcription through putative T-bet half-sites locating -451 to -347 of OC2 promoter region. Moreover, we found that OC2 binds and transactivates human T-bet promoter. These results suggest that not only cell-extrinsic regulation via the IFN-gamma/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> pathway, but also cell-intrinsic transcriptional positive feedback loop between T-bet and OC2 could be involved in Th1 development.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/25700150">25700150</a><div class="entities" style="line-height: 2.5"><h3>T helper 9 cells induced by plasmacytoid dendritic cells regulate interleukin-17 in multiple sclerosis.</h3></br>Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS) characterized by persistent inflammation orchestrated by cluster of differentiation (CD) 4 T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. In particular, Th1 and Th17 cells amplify, whereas T regulatory (Treg) cells moderate inflammation. The role of other Th subsets in MS is not clear. In the present study, we investigated the generation of different Th responses by human dendritic cells (DCs) in MS. We compared the production of several Th cytokines by naive CD4+ T cells polarized with myeloid and plasmacytoid DCs (mDCs and pDCs) in healthy donors (HD) and relapsing-remitting (RR)-MS patients. We found that resiquimod-stimulated mDCs were able to activate Th17 differentiation, whereas pDCs induced interleukin (IL)-10-producing Th cells. Surprisingly, resiquimod-stimulated pDCs from MS patients also significantly induced the differentiation of Th9 cells, which produce IL-9 and are known to be involved in allergic diseases. We investigated the potential role of IL-9 in MS. We found that IL-9 activated <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    signal transducer and activator of transcription (STAT) 1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and STAT5 phosphorylation and interfered with IL-17 and interferon (IFN) regulatory transcription factor (IRF)-4 expression in Th17-polarized cells. Moreover, in the cerebrospinal fluid (CSF) of 107 RR-MS patients, IL-9 inversely correlated with indexes of inflammatory activity, neurodegeneration and disability progression of MS. High levels of IL-9 were associated with the absence of IL-17 in the CSF of RR-MS patients. Our results demonstrate a Th9-inducing potential of pDCs in MS, suggesting an immunoregulatory role leading to attenuation of the exaggerated Th17 inflammatory response.</div></details><details><summary>TH1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/25972481">25972481</a><div class="entities" style="line-height: 2.5"><h3>CD155 (PVR/Necl5) mediates a costimulatory signal in CD4+ T cells and regulates allergic inflammation.</h3></br>Although <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells are known to be involved in allergic inflammatory diseases, the molecular mechanisms underlying their differentiation are incompletely understood. In this study, we identified CD155 as a costimulatory molecule on CD4(+) T cells. Importantly, CD155-mediated signaling induced Th1 development in both humans and mice, as evidenced by production of IFN-γ and upregulation of Tbx21 transcription; these effects were independent of IL-12 but dependent on NF-κB-induced autocrine IFN-γ that triggered positive feedback via <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> activation. Mice genetically deficient in CD155 or treated with anti-CD155 Ab exhibited attenuated Th1-type contact hypersensitivity. Thus, CD155 plays an important regulatory role in helper T cell differentiation and allergic diseases. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/17361203">17361203</a><div class="entities" style="line-height: 2.5"><h3>Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response.</h3></br>Interferon lambda-1 (IFN-lambda1/IL-29) is a member of the Type-III interferon family, which contains three ligands: IFN-lambda1, 2 and 3. These three ligands use the same unique heterodimeric receptor composed of CRF2-12 (IFN-lambda-R1/IL-28Ralpha) and CRF2-4 (IL10-R-beta) chains. Like their close relatives, the Type-I interferons, IFN-lambda1, 2 and 3, promote the phosphorylation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and STAT2, induce the ISRE3 complex, elevate OAS and MxA expression and exhibit antiviral activity in vitro. Their use of the IL10-R-beta chain and their ability to phosphorylate STAT3, STAT4 and STAT5 suggested that they may also exhibit immunomodulatory activity; their antiviral action led us to hypothesize that this activity might be directed toward the Th1/Th2 system. Here, we have demonstrated that IFN-lambda1 altered the activity of Th cells in three separate experimental systems: (i) mitogen stimulation, (ii) mixed-lymphocyte reaction (MLR) and (iii) stimulation of naive T cells by monocyte-derived dendritic cells (mDC). In Con-A stimulation assays, the inclusion of IFN-lambda1 consistently led to markedly diminished levels of secreted interleukin (IL-13) with occasional coincident, modest elevation of secreted IFN-gamma. IL-13 secretion was 100-fold more sensitive to IFN-lambda1 than was IFN-gamma secretion. These observations were also made in the allogeneic two-way MLR. IFN-lambda1 was able to alter cytokine-mediated Th biasing and when naive T cells were exposed to allogeneic mDC that had been matured in the presence of IFN-lambda1, secreted IL-13 was again markedly and consistently reduced, whereas secreted IFN-gamma was largely unaltered. These functions were independent of IL-10. Our data support a hitherto unsuspected role for IFN-lambda1 in modulating the development of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells, with an apparent emphasis on the diminution of IL-13 secretion.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/16325585">16325585</a><div class="entities" style="line-height: 2.5"><h3>TWEAK attenuates the transition from innate to adaptive immunity.</h3></br>Innate immunity is the first line of defense against infection, protecting the host during the development of adaptive immunity and critically affecting the nature of the adaptive response. We show that, in contrast to tumor necrosis factor alpha (TNF-alpha), the related protein TWEAK attenuates the transition from innate to adaptive mechanisms. TWEAK-/- mice had overabundant natural killer (NK) cells and displayed hypersensitivity to bacterial endotoxin, with their innate immune cells producing excess interferon (IFN)-gamma and interleukin (IL)-12. TWEAK inhibited stimulation of the transcriptional activator <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and induced p65 nuclear factor (NF)-kappaB association with histone deacetylase 1, repressing cytokine production. TWEAK-/- mice developed oversized spleens with expanded memory and T helper 1 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) subtype cells upon aging and mounted stronger innate and adaptive TH1-based responses against tumor challenge. Thus, TWEAK suppresses production of IFN-gamma and IL-12, curtailing the innate response and its transition to adaptive TH1 immunity.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/16285008">16285008</a><div class="entities" style="line-height: 2.5"><h3>IL-12-independent Th1 polarization in human mononuclear cells infected with varicella-zoster virus.</h3></br>T helper type 1 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells perform a critical role in fighting intracellular organisms, and interleukin-12 (IL-12) is known to promote a Thl response. This study was conducted to identify whether an IL-12-independent Th1 reaction is induced by the varicella-zoster virus (VZV) in human beings. It was found that different intracellular microorganisms could induce IFNgamma but not IL-12 production. Induction of IFNgamma production by VZV was associated with IFNalpha production and phosphorylation of both the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    signal transducer and activator of transcription-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) and STAT-4 in lymphocytes. In contrast, Bacillus Calmette-Guerin (BCG) induced IL-12 production in association with STAT-4 but not <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> activation. Anti-IFNalpha but not anti-IL-12 antibodies blocked the VZV-induced Th1 polarization. A patient with an IL-12 receptor beta1 chain deficiency showed a normal VZV- but not a normal BCG-induced Th1 reaction, further supporting the concept of an IFNalpha-mediated, IL-12-independent Th1 reaction in response to certain intracellular infections. Identification of the early Th1 polarization induced by IFNalpha versus IL-12 in response to specific viruses may enable the development of better therapeutic strategies tailored to different infections.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/9531298">9531298</a><div class="entities" style="line-height: 2.5"><h3>Activation of STAT proteins and cytokine genes in human <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells generated in the absence of IL-12 and IL-4.</h3></br>We have shown previously that human CD4+ 45RO- T cells could be primed for a Th2 phenotype independent of IL-4 if they were activated by anti-CD28 mAb plus IL-2. If additional TCR signals were provided, the cells differentiated toward Th1 independent of IL-12. Here we show that anti-CD28/IL-2-primed Th2 cells expressed high levels of activated STAT6, but no cytokine mRNA. Moreover, both <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells expressed active <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and -3, but not STAT2, -4, and -5. Restimulation of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> or Th2 cells via CD3 plus CD28 induced production of IFN-gamma or IL-4, respectively, but did not alter the activation status/DNA binding activity of STATs. Addition of IL-4 (or anti-IL-4 mAb) to restimulated Th2 cells did not modulate STAT6 activation or IL-4 expression, confirming the full commitment. However, Th2 cells remained responsive to IL-12, which repressed STAT6 DNA binding but activated STAT4, and this coincided with a suppression of IL-4/IL-5 and an induction of IFN-gamma. In Th1 cells, IL-12 activated both STAT6 and STAT4, and IL-4 activated STAT6, but in both cases the Th1 phenotype remained. Together the data show that CD28/IL-2-dependent Th2 priming activated STAT6 without inducing IL-4 expression. The primed Th cells resembled memory cells and produced IL-4 upon the first CD3/CD28 costimulus without detectable modulation of STATs. Th2 cells remained responsive to IL-12, which repressed STAT6 DNA binding and activated STAT4, and switched the cells to Th1. The effects of IL-12 may depend on the commitment of the cells, since IL-12 phosphorylated STAT6 in Th1 and dephosphorylated STAT6 in Th2 cells.</div></details><details><summary>TFH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/29186193">29186193</a><div class="entities" style="line-height: 2.5"><h3>RIG-I-like receptor activation by dengue virus drives follicular T helper cell formation and antibody production.</h3></br>Follicular T helper cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TFH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) are fundamental in orchestrating effective antibody-mediated responses critical for immunity against viral infections and effective vaccines. However, it is unclear how virus infection leads to TFH induction. We here show that dengue virus (DENV) infection of human dendritic cells (DCs) drives TFH formation via crosstalk of RIG-I-like receptor (RLR) RIG-I and MDA5 with type I Interferon (IFN) signaling. DENV infection leads to RLR-dependent IKKε activation, which phosphorylates IFNα/β receptor-induced <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> to drive IL-27 production via the transcriptional complex ISGF3. Inhibiting RLR activation as well as neutralizing antibodies against IL-27 prevented TFH formation. DENV-induced CXCR5+PD-1+Bcl-6+ TFH cells secreted IL-21 and activated B cells to produce IgM and IgG. Notably, RLR activation by synthetic ligands also induced IL-27 secretion and TFH polarization. These results identify an innate mechanism by which antibodies develop during viral disease and identify RLR ligands as potent adjuvants for TFH-promoting vaccination strategies.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28263097">28263097</a><div class="entities" style="line-height: 2.5"><h3>Transcriptional and epigenetic regulation of follicular T-helper cells and their role in autoimmunity.</h3></br>T-follicular helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are a specialized subset of T cells that provide help to B cells and promote the formation of germinal centers (GCs). Tfh cells transmit important signals to B cells that drive class switch recombination, somatic hyper-mutation, the generation of high-affinity antibodies, immunological memor<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    y and     <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>their differentiation into plasma cells or memory B cells in the GCs. Tfh-cell differentiation is regulated by the coordinated functions of distinct cytokines, including interleukin (IL)-6, IL-21, IL-12, IL-23, IL-2, IL-7 and transforming growth factor-β (TGF-β), as well as transcription factors, including B-cell lymphoma 6 protein (Bcl-6), Signal transducers and activators of transcription (STAT)1, STAT3, STAT4, B-cell activating transcription factor (Batf), interferon regulatory factor 4 (IRF4), v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog (C-Maf), T cell-specific transcription factor 1 (TCF-1) and Achaete-scute homolog 2 (Acl2), which have been shown to form a complex transcriptional network. In addition, increasing evidence indicates that epigenetic regulations, such as DNA methylation, histone modifications and non-coding RNA regulations, also coordinately control the differentiation and function of Tfh cells along with transcription factors. Furthermore, abnormalities in the regulation of Tfh cells have been associated with several autoimmune diseases, such as systemic lupus erythematosus (SLE), multiple sclerosis (MS) and rheumatoid arthritis (RA). Herein, this review aims to summarize the coordinate regulation and interaction of transcription factors, cytokines and epigenetic modifications that control Tfh-cell differentiation as well as the mechanism of dysregulation of Tfh cells in pathogenesis of autoimmune diseases, which highlight potential therapeutic targets.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27401342">27401342</a><div class="entities" style="line-height: 2.5"><h3>Unique and shared signaling pathways cooperate to regulate the differentiation of human CD4+ T cells into distinct effector subsets.</h3></br>Naive CD4(+) T cells differentiate into specific effector subsets-Th1, Th2, Th17, and T follicular helper (Tfh)-that provide immunity against pathogen infection. The signaling pathways involved in generating these effector cells are partially known. However, the effects of mutations underlying human primary immunodeficiencies on these processes, and how they compromise specific immune responses, remain unresolved. By studying individuals with mutations in key signaling pathways, we identified nonredundant pathways regulating human CD4(+) T cell differentiation in vitro. IL12Rβ1/TYK2 and IFN-γR/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> function in a feed-forward loop to induce Th1 cells, whereas IL-21/IL-21R/STAT3 signaling is required for Th17, Tfh, and IL-10-secreting cells. IL12Rβ1/TYK2 and NEMO are also required for Th17 induction. Strikingly, gain-of-function <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mutations recapitulated the impact of dominant-negative STAT3 mutations on <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th17 cells, revealing a putative inhibitory effect of hypermorphic <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> over STAT3. These findings provide mechanistic insight into the requirements for human T cell effector function, and explain clinical manifestations of these immunodeficient conditions. Furthermore, they identify molecules that could be targeted to modulate CD4(+) T cell effector function in the settings of infection, vaccination, or immune dysregulation.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/22403255">22403255</a><div class="entities" style="line-height: 2.5"><h3>Functional STAT3 deficiency compromises the generation of human T follicular helper cells.</h3></br>T follicular helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tfh    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are critical for providing the necessary signals to induce differentiation of B cells into memory and Ab-secreting cells. Accordingly, it is important to identify the molecular requirements for Tfh cell development and function. We previously found that IL-12 mediates the differentiation of human CD4(+) T cells to the Tfh lineage, because IL-12 induces naive human CD4(+) T cells to acquire expression of IL-21, BCL6, ICOS, and CXCR5, which typify Tfh cells. We have now examined CD4(+) T cells from patients deficient in IL-12Rβ1, TYK2, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, and STAT3 to further explore the pathways involved in human Tfh cell differentiation. Although <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> was dispensable, mutations in IL12RB1, TYK2, or STAT3 compromised IL-12-induced expression of IL-21 by human CD4(+) T cells. Defective expression of IL-21 by STAT3-deficient CD4(+) T cells resulted in diminished B-cell helper activity in vitro. Importantly, mutations in STAT3, but not IL12RB1 or TYK2, also reduced Tfh cell generation in vivo, evidenced by decreased circulating CD4(+)CXCR5(+) T cells. These results highlight the nonredundant role of STAT3 in human Tfh cell differentiation and suggest that defective Tfh cell development and/or function contributes to the humoral defects observed in STAT3-deficient patients.</div></details><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/23741351">23741351</a><div class="entities" style="line-height: 2.5"><h3>TGF-β enhanced IL-21-induced differentiation of human IL-21-producing CD4+ T cells via Smad3.</h3></br>IL-21 has pleiotropic effects on innate and adaptive immune response, and plays an important role in the development of autoimmune disease and antitumor activity. It has been reported that IL-21 is produced by CD4(+) T cells and NKT cells. However, the differentiation of IL-21-producing CD4(+) T cells in humans remains largely unclear. In the present study, we showed that cytokines of IL-1β, IL-6 or IL-21 induced differentiation of human IL-21-producing CD4(+) T cells, and TGF-β enhanced the effect of inflammatory cytokines on the development of IL-21-producing CD4(+) T cells. Furthermore, we found that the majority of IL-21-producing cells were distinct from Th17 cells and Th1 cells since they did not co-express IL-17 and IFN-γ. TGF-β significantly inhibited the production of IFN-γ and enhanced the effect of IL-21 on the development of IL-21-producing CD4(+) T cells. In addition, we found that IL-21 inhibited the differentiation of CD4(+) Foxp3(+) T cells induced by TGF-β. Further study indicated that IL-21 induced phosphorylation of transcriptional factors of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, STAT3 and STAT5, and TGF-β induced phosphorylation of Smad3 in CD4(+) T cells. Taken together, our data indicated that TGF-β enhanced IL-21-induced differentiation of IL-21-producing CD4(+) T cells, and the majority of IL-21-producing cells were different from <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th1 cells. Our results provide a new sight regarding the differentiation of human CD4(+) T cells.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21893418">21893418</a><div class="entities" style="line-height: 2.5"><h3>Induction of regulatory Tr1 cells and inhibition of T(H)17 cells by IL-27.</h3></br>Accumulating evidence indicates that IL-27, a member of the IL-12 family of cytokines, alleviates the severity of autoimmune diseases in both mice and men. The IL-27-induced activation of signal transducer and activator of transcription (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat)1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and Stat3 promotes the generation of IL-10- producing type 1 regulatory T (Tr1) cells that inhibit effector T cells. In addition, IL-27 also suppresses the development of pathogenic IL-17-producing CD4(+) T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(H)17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells suggesting that pharmacological manipulations of IL-27 signaling pathway could be exploited therapeutically in regulating tissue inflammation. Here, we review how IL-27 controls inflammation through the regulation of Tr1 and T(H)17 responses.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/19505891">19505891</a><div class="entities" style="line-height: 2.5"><h3>Gfi1 negatively regulates T(h)17 differentiation by inhibiting RORgammat activity.</h3></br>T(h) cells have long been divided into two subsets, T(h)1 and T(h)2; however, recently, T(h)17 and inducible regulatory T (iTreg) cells were identified as new T(h) cell subsets. Although T(h)1- and T(h)2-polarizing cytokines have been shown to suppress T(h)17 and iTreg development, transcriptional regulation of T(h)17 and iTreg differentiation by cytokines remains to be clarified. In this study, we found that expression of the growth factor independent 1 (Gfi1) gene, which has been implicated in T(h)2 development, was repressed in <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(h)17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and iTreg cells compared with T(h)1 and T(h)2 lineages. Gfi1 expression was enhanced by the IFN-gamma/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and IL-4/STAT6 pathways, whereas it was repressed by the transforming growth factor-beta1 stimulation at the promoter level. Over-expression of Gfi1 strongly reduced IL-17A transcription in the EL4 T cell line, as well as in primary T cells. This was due to the blockade of recruitment of retinoid-related orphan receptor gammat to the IL-17A promoter. In contrast, IL-17A expression was significantly enhanced in Gfi1-deficient T cells under T(h)17-promoting differentiation conditions as compared with wild-type T cells. In contrast, the impacts of Gfi1 in iTregs were not as strong as in T(h)17 cells. Taken together, these data strongly suggest that Gfi1 is a negative regulator of T(h)17 differentiation, which represents a novel mechanism for the regulation of T(h)17 development by cytokines.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/17496900">17496900</a><div class="entities" style="line-height: 2.5"><h3>TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>.</h3></br>T-helper type 17 cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(H)17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) are implicated in rodent models of immune-mediated diseases. Here we report their involvement in human uveitis and scleritis, and validate our findings in experimental autoimmune uveoretinitis (EAU), a model of uveitis. T(H)17 cells were present in human peripheral blood mononuclear cells (PBMC), and were expanded by interleukin (IL)-2 and inhibited by interferon (IFN)-gamma. Their numbers increased during active uveitis and scleritis and decreased following treatment. IL-17 was elevated in EAU and upregulated tumor necrosis factor (TNF)-alpha in retinal cells, suggesting a mechanism by which T(H)17 may contribute to ocular pathology. Furthermore, IL-27 was constitutively expressed in retinal ganglion and photoreceptor cells, was upregulated by IFN-gamma and inhibited proliferation of T(H)17. These findings suggest that T(H)1 cells may mitigate uveitis by antagonizing the T(H)17 phenotype through the IFN-gamma-mediated induction of IL-27 in target tissue. The finding that IL-2 promotes T(H)17 expansion provides explanations for the efficacy of IL-2R antibody therapy in uveitis, and suggests that antagonism of T(H)17 by IFN-gamma and/or IL-27 could be used for the treatment of chronic inflammation.</div></details><details><summary>TH2</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27858144">27858144</a><div class="entities" style="line-height: 2.5"><h3>Th9 and other IL-9-producing cells in allergic asthma.</h3></br>Allergic asthma is a worldwide increasing chronic disease of the airways which affects more than 300 million people. It is associated with increased IgE, mast cell activation, airway hyperresponsiveness (AHR), mucus overproduction and remodeling of the airways. Previously, this pathological trait has been associated with T helper type 2 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. Recently, different CD4+  T cell subsets (Th17, Th9) as well as cells of innate immunity, like mast cells and innate lymphoid cells type 2 (ILC2s), which are all capable of producing the rediscovered cytokine IL-9, are known to contribute to this disease. Regarding Th9 cells, it is known that naïve T cells develop into IL-9-producing cells in the presence of interleukin-4 (IL-4) and transforming growth factor beta (TGFβ). Downstream of IL-4, several transcription factors like signal transducer and activator of transcription 6 (STAT6), interferon regulatory factor 4 (IRF4), GATA binding protein 3 (GATA3), basic leucine zipper transcription factor, ATF-like (BATF) and nuclear factor of activated T cells (NFAT) are activated. Additionally, the transcription factor PU.1, which is downstream of TGFβ signaling, also seems to be crucial in the development of Th9 cells. IL-9 is a pleiotropic cytokine that influences various distinct functions of different target cells such as T cells, B cells, mast cells and airway epithelial cells by activating <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, STAT3 and STAT5. Because of its pleiotropic functions, IL-9 has been demonstrated to be involved in several diseases, such as cancer, autoimmunity and other pathogen-mediated immune-regulated diseases. In this review, we focus on the role of Th9 and IL-9-producing cells in allergic asthma.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/9095224">9095224</a><div class="entities" style="line-height: 2.5"><h3>Regulation of interleukin-12 signalling during T helper phenotype development.</h3></br>The experiments described above have allowed us to define the molecular events in IL-12 signalling. Within minutes after IL-12 treatment of responsive cells, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, Stat3, and Stat4 are tyrosine phosphorylated. These molecules form nuclear DNA-binding complexes consisting of homodimeric <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and heterodimeric Stat3-Stat4 complexes. In a murine in vitro phenotype development model, T cells rapidly and selectively lose their capacity to respond to IL-12 upon acquisition of the Th2 phenotype. This hyporesponsiveness is manifested by the inability of IL-12 to induce IFN gamma production in differentiated Th2 cells, as well as the inability of IL-12 to induce the activation of Stat4. Despite the functional defect of IL-12 signalling in Th2 cells, all known components of the IL-12 signal transduction pathway are present. We speculate that in Th2 cells, the second receptor chain may be absent or one of the other components may be modified. Genetic experiments in Balb/c and B10.D2 strains of mice have demonstrated several differences in T helper differentiation in vitro. Stimulation of T cells under neutral conditions results in a bias of Balb/c T cells toward the <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> extreme and B10 T cells toward the Th1 extreme of cytokine production. Following stimulation under neutral conditions, B10 T cells retain the ability to respond to IL-12 while Balb/c T cells lose IL-12 responsiveness. Mating experiments have demonstrated that the B10 genetic effect is dominant in F1 mice. Analysis of backcrossed animals has suggested that the ability to respond to IL-12 in the secondary stimulation may be controlled by a single dominant B10 gene. The results we describe may have profound implications for allergy. Since allergic responses are largely due to the activation of the Th2 subset of T lymphocytes, a better understanding of T cell phenotype development may reveal multiple targets for therapeutic intervention. First, a better understanding of Th1 phenotype induction in response to IL-12 may allow prevention of in vivo allergic responses using pharmacological tools which bias allergen-specific responses to the Th1 subset. Second, a molecular explantation of why Th2 cells fail to reverse phenotype in response to IL-12 may allow treatment of atopic individuals to remove the disease-promoting T lymphocyte compartment. Finally, a better understanding of the basis for genetic differences in murine T helper cell differentiation may allow us to identify a causative genetic element in humans, yielding better diagnostic and therapeutic methods.</div></details><details><summary>TEFF</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/21307288">21307288</a><div class="entities" style="line-height: 2.5"><h3>Stat3 phosphorylation mediates resistance of primary human T cells to regulatory T cell suppression.</h3></br>Human autoimmune diseases are characterized by systemic T cell dysfunction, resulting in chronically activated Th1 and Th17 cells that are inadequately suppressed by regulatory T cells (Tregs). IL-6, which is overexpressed in tissue and serum of patients with autoimmune diseases, inhibits human Treg function. We sought to determine the mechanism for the antitolerogenic properties of IL-6 by examining the signaling pathways downstream of IL-6R in primary human T cells. Inhibition of Stat3 signaling in MLCs containing IL-6 restores Treg-mediated suppression, demonstrating that IL-6-mediated loss of Treg suppression requires phosphorylation of Stat3. Cultures in which either effector T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Teffs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) or Tregs were pretreated with Stat3 inhibitors indicate that phosphorylated (p)Stat3 is required in both T cell populations for IL-6-mediated reversal of Treg function. IL-21, which signals preferentially through pStat3, also reverses Treg suppression, in contrast to IL-27 and IFN-γ, which signal preferentially through <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and do not inhibit Treg function. Interestingly, both Teffs and Tregs respond to IL-6 stimulation through strong Stat3 phosphorylation with minimal MAPK/Erk activation and moderate <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Stat1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> phosphorylation. Finally, Teffs stimulated strongly through the TCR are also resistant to suppression by Tregs and show concurrent Stat3 phosphorylation. In these cultures, inhibition of pStat3 restores functional suppression by Tregs. Taken together, our findings suggest that an early dominance of Stat3 signaling, prior to subsequent T cell activation, is required for the loss of functional Treg suppression and that kinase-specific inhibitors may hold therapeutic promise in the treatment of autoimmune and chronic inflammatory diseases.</div></details><details><summary>TH9</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27858144">27858144</a><div class="entities" style="line-height: 2.5"><h3>Th9 and other IL-9-producing cells in allergic asthma.</h3></br>Allergic asthma is a worldwide increasing chronic disease of the airways which affects more than 300 million people. It is associated with increased IgE, mast cell activation, airway hyperresponsiveness (AHR), mucus overproduction and remodeling of the airways. Previously, this pathological trait has been associated with T helper type 2 (Th2) cells. Recently, different CD4+  T cell subsets (Th17, Th9) as well as cells of innate immunity, like mast cells and innate lymphoid cells type 2 (ILC2s), which are all capable of producing the rediscovered cytokine IL-9, are known to contribute to this disease. Regarding Th9 cells, it is known that naïve T cells develop into IL-9-producing cells in the presence of interleukin-4 (IL-4) and transforming growth factor beta (TGFβ). Downstream of IL-4, several transcription factors like signal transducer and activator of transcription 6 (STAT6), interferon regulatory factor 4 (IRF4), GATA binding protein 3 (GATA3), basic leucine zipper transcription factor, ATF-like (BATF) and nuclear factor of activated T cells (NFAT) are activated. Additionally, the transcription factor PU.1, which is downstream of TGFβ signaling, also seems to be crucial in the development of Th9 cells. IL-9 is a pleiotropic cytokine that influences various distinct functions of different target cells such as T cells, B cells, mast cells and airway epithelial cells by activating <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, STAT3 and STAT5. Because of its pleiotropic functions, IL-9 has been demonstrated to be involved in several diseases, such as cancer, autoimmunity and other pathogen-mediated immune-regulated diseases. In this review, we focus on the role of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th9    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and IL-9-producing cells in allergic asthma.</div></details></details></td>
    </tr>
    <tr>
      <th>31</th>
      <td>ASCL2</td>
      <td>2</td>
      <td>TFH:2, TH:1, TH1:1</td>
      <td>0.099287</td>
      <td>ENSG00000183734</td>
      <td><details><summary>Subtypes</summary><details><summary>TFH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28728856">28728856</a><div class="entities" style="line-height: 2.5"><h3>Achaete-scute complex homologue 2 accelerates the development of Sjögren's syndrome-like disease in the NOD/ShiLtJ mouse.</h3></br>Achaete-scute complex homologue 2 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ascl2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) has been reported to induce the differentiation and activation of follicular helper T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TFH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> ) cells, which are essential for development of Sjögren's syndrome (SS). This study examined whether <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ascl2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> plays a role in the development of SS. NOD/ShiLtJ mice were injected with an Ascl2-overexpression vector, and the infiltration of lymphocytes into salivary and lacrimal glands was assessed. The expression of inflammatory cytokines and chemoattractants for T or B cells was measured. The activation of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TFH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>  cells was assessed using a specific marker of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TFH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>  cells. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ascl2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> level was also measured in SS patients. Overexpression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ascl2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> increased the expression of C-X-C chemokine receptor type 5 (CXCR5) in both salivary and lacrimal glands (p<0.0001). Overexpression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ascl2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> also increased the expression of proinflammatory cytokines and chemoattractants including interleukin 6 (IL-6), tumor necrosis factor-α, IL-8, programmed cell death 1 (PD-1), IL-21, and B-cell lymphoma 6 (Bcl-6). Overexpression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ascl2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> increased the populations of CD4+ CXCR5+ , CD4+ ICOS+ , and CD4+ PD-1+  cells. The <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ascl2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> level was higher in peripheral blood mononuclear cells from SS patients compared with those from healthy controls. Our findings suggest that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ascl2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> may play a role in the development and progression of SS and may be a therapeutic target in the treatment of SS.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/24463518">24463518</a><div class="entities" style="line-height: 2.5"><h3>Transcription factor achaete-scute homologue 2 initiates follicular T-helper-cell development.</h3></br>In immune responses, activated T cells migrate to B-cell follicles and develop into follicular T-helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TFH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, a recently identified subset of CD4(+) T cells specialized in providing help to B lymphocytes in the induction of germinal centres. Although Bcl6 has been shown to be essential in TFH-cell function, it may not regulate the initial migration of T cells or the induction of the TFH program, as exemplified by C-X-C chemokine receptor type 5 (CXCR5) upregulation. Here we show that expression of achaete-scute homologue 2 (Ascl2)--a basic helix-loop-helix (bHLH) transcription factor--is selectively upregulated in TFH cells. Ectopic expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ascl2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> upregulates CXCR5 but not Bcl6, and downregulates C-C chemokine receptor 7 (CCR7) expression in T cells in vitro, as well as accelerating T cell migration to the follicles and TFH-cell development in vivo in mice. Genome-wide analysis indicates that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ascl2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> directly regulates TFH-related genes whereas it inhibits expression of T-helper cell 1 (TH1) and TH17 signature genes. Acute deletion of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ascl2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, as well as blockade of its function with the Id3 protein in CD4(+) T cells, results in impaired TFH-cell development and germinal centre response. Conversely, mutation of Id3, known to cause antibody-mediated autoimmunity, greatly enhances TFH-cell generation. Thus, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ascl2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> directly initiates TFH-cell development.</div></details><details><summary>TH1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/24463518">24463518</a><div class="entities" style="line-height: 2.5"><h3>Transcription factor achaete-scute homologue 2 initiates follicular T-helper-cell development.</h3></br>In immune responses, activated T cells migrate to B-cell follicles and develop into follicular T-helper (TFH) cells, a recently identified subset of CD4(+) T cells specialized in providing help to B lymphocytes in the induction of germinal centres. Although Bcl6 has been shown to be essential in TFH-cell function, it may not regulate the initial migration of T cells or the induction of the TFH program, as exemplified by C-X-C chemokine receptor type 5 (CXCR5) upregulation. Here we show that expression of achaete-scute homologue 2 (Ascl2)--a basic helix-loop-helix (bHLH) transcription factor--is selectively upregulated in TFH cells. Ectopic expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ascl2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> upregulates CXCR5 but not Bcl6, and downregulates C-C chemokine receptor 7 (CCR7) expression in T cells in vitro, as well as accelerating T cell migration to the follicles and TFH-cell development in vivo in mice. Genome-wide analysis indicates that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ascl2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> directly regulates TFH-related genes whereas it inhibits expression of T-helper cell 1 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) and TH17 signature genes. Acute deletion of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ascl2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, as well as blockade of its function with the Id3 protein in CD4(+) T cells, results in impaired TFH-cell development and germinal centre response. Conversely, mutation of Id3, known to cause antibody-mediated autoimmunity, greatly enhances TFH-cell generation. Thus, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ascl2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> directly initiates TFH-cell development.</div></details></details></td>
    </tr>
    <tr>
      <th>32</th>
      <td>TWIST1</td>
      <td>1</td>
      <td>TH1:1</td>
      <td>0.096410</td>
      <td>ENSG00000122691</td>
      <td><details><summary>Subtypes</summary><details><summary>TH1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/25486906">25486906</a><div class="entities" style="line-height: 2.5"><h3>miR-148a is upregulated by <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Twist1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and T-bet and promotes Th1-cell survival by regulating the proapoptotic gene Bim.</h3></br>Repeatedly activated T helper 1 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells present during chronic inflammation can efficiently adapt to the inflammatory milieu, for example, by expressing the transcription factor <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Twist1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, which limits the immunopathology caused by Th1 cells. Here, we show that in repeatedly activated murine Th1 cells, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Twist1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and T-bet induce expression of microRNA-148a (miR-148a). miR-148a regulates expression of the proapoptotic gene Bim, resulting in a decreased Bim/Bcl2 ratio. Inhibition of miR-148a by antagomirs in repeatedly activated Th1 cells increases the expression of Bim, leading to enhanced apoptosis. Knockdown of Bim expression by siRNA in miR-148a antagomir-treated cells restores viability of the Th1 cells, demonstrating that miR-148a controls survival by regulating Bim expression. Thus, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Twist1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and T-bet not only control the differentiation and function of Th1 cells, but also their persistence in chronic inflammation. </div></details></details></td>
    </tr>
    <tr>
      <th>33</th>
      <td>ETS2</td>
      <td>2</td>
      <td>TH:1, TREG:1</td>
      <td>0.094194</td>
      <td>ENSG00000157557</td>
      <td><details><summary>Subtypes</summary><details><summary>TH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27815505">27815505</a><div class="entities" style="line-height: 2.5"><h3>Transcription Factor <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ets-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> Acts as a Preinduction Repressor of Interleukin-2 (IL-2) Transcription in Naive T Helper Lymphocytes.</h3></br>IL-2 is the first cytokine produced when naive T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are activated and differentiate into dividing pre-Th0 proliferating precursors. IL-2 expression is blocked in naive, but not activated or memory, Th cells by the transcription factor <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ets-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> that binds to the antigen receptor response element (ARRE)-2 of the proximal IL-2 promoter. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ets-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> acts as an independent preinduction repressor in naive Th cells and does not interact physically with the transcription factor NFAT (nuclear factor of activated T cells) that binds to the ARRE-2 in activated Th cells. In naive Th cells, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ets-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mRNA expression, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ets-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> protein levels, and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ets-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> binding to ARRE-2 decrease upon cell activation followed by the concomitant expression of IL-2. Cyclosporine A stabilizes <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ets-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mRNA and protein when the cells are activated. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ets-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> silences directly constitutive or induced IL-2 expression through the ARRE-2. Conversely, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ets-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> silencing allows for constitutive IL-2 expression in unstimulated cells. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ets-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> binding to ARRE-2 in chromatin is stronger in naive compared with activated or memory Th cells; in the latter, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ets-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> participates in a change of the IL-2 promoter architecture, possibly to facilitate a quick response when the cells re-encounter antigen. We propose that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ets-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression and protein binding to the ARRE-2 of the IL-2 promoter are part of a strictly regulated process that results in a physiological transition of naive Th cells to Th0 cells upon antigenic stimulation. Malfunction of such a repression mechanism at the molecular level could lead to a disturbance of later events in Th cell plasticity, leading to autoimmune diseases or other pathological conditions.</div></details><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/20427269">20427269</a><div class="entities" style="line-height: 2.5"><h3>Valproate treatment of human cord blood CD4-positive effector T cells confers on them the molecular profile (microRNA signature and FOXP3 expression) of natural regulatory CD4-positive cells through inhibition of histone deacetylase.</h3></br>Regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) play a key role in immune system homeostasis and tolerance to antigens, thereby preventing autoimmunity, and may be partly responsible for the lack of an appropriate immune response against tumor cells. Although not sufficient, a high expression of forkhead box P3 (FOXP3) is necessary for their suppressive function. Recent reports have shown that histones deacetylase inhibitors increased FOXP3 expression in T cells. We therefore decided to investigate in non-Tregs CD4-positive cells, the mechanisms by which an aspecific opening of the chromatin could lead to an increased FOXP3 expression. We focused on binding of potentially activating transcription factors to the promoter region of FOXP3 and on modifications in the five miRs constituting the Tregs signature. Valproate treatment induced binding of Ets-1 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ets-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> to the FOXP3 promoter and acted positively on its expression, by increasing the acetylation of histone H4 lysines. Valproate treatment also induced the acquisition of the miRs Tregs signature. To elucidate whether the changes in the miRs expression could be due to the increased FOXP3 expression, we transduced these non-Tregs with a FOXP3 lentiviral expression vector, and found no changes in miRs expression. Therefore, the modification in their miRs expression profile is not due to an increased expression of FOXP3 but directly results from histones deacetylase inhibition. Rather, the increased FOXP3 expression results from the additive effects of Ets factors binding and the change in expression level of miR-21 and miR-31. We conclude that valproate treatment of human non-Tregs confers on them a molecular profile similar to that of their regulatory counterpart.</div></details></details></td>
    </tr>
    <tr>
      <th>34</th>
      <td>JUN</td>
      <td>1</td>
      <td>TH2:1</td>
      <td>0.092716</td>
      <td>ENSG00000177606</td>
      <td><details><summary>Subtypes</summary><details><summary>TH2</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/9889198">9889198</a><div class="entities" style="line-height: 2.5"><h3>Regulation of IL-4 expression by the transcription factor JunB during T helper cell differentiation.</h3></br>The molecular basis for restricted cytokine expression by T helper 1 (Th1) and T helper 2 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells is unclear. Previous studies found that P1, an element of the interleukin 4 (IL-4) promoter that binds AP-1, is important for Th2-restricted IL-4 expression. Here we show that JunB, but not the other <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Jun family    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> members, was selectively induced in Th2 cells and not in Th1 cells during differentiation. JunB has previously been considered to be a negative regulator of transcription. However, we show that JunB binds directly to the P1 site and synergizes with c-Maf to activate an IL-4 luciferase reporter gene. JunB-control of IL-4 expression is mediated by the phosphorylation of JunB at Thr102 and -104 by JNK MAP kinase. The synergy between c-Maf and JunB can be attributed to cooperative DNA binding, which is facilitated by JunB phosphorylation. In transgenic mice, elevated JunB levels caused increased expression of several Th2 cytokines in developing Th1 cells. JunB also upregulated IL-4 expression in response to immunization. Thus, the early increase of JunB protein in Th2 cells can provide the specificity for c-Maf in IL-4 expression during T cell development and directs thereby Th2 differentiation.</div></details></details></td>
    </tr>
    <tr>
      <th>35</th>
      <td>PPARG</td>
      <td>1</td>
      <td>TEFF:1, TREG:1</td>
      <td>0.085957</td>
      <td>ENSG00000132170</td>
      <td><details><summary>Subtypes</summary><details><summary>TEFF</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/24957461">24957461</a><div class="entities" style="line-height: 2.5"><h3>p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T cell-mediated immunosuppression.</h3></br>Dendritic cell (DC)-based cancer immunotherapy is a promising method, but so far has demonstrated limited clinical benefits. Regulatory T cells (Tregs) represent a major obstacle to cancer immunotherapy approaches. Here we show that inhibiting p38 MAPK during DC differentiation enables DCs to activate tumour-specific effector T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Teff    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>), inhibiting the conversion of Treg and compromising Treg inhibitory effects on Teff. Inhibition of p38 MAPK in DCs lowers expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    PPARγ    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, activating p50 and upregulating OX40L expression in DCs. OX40L/OX40 interactions between DCs and Teff and/or Treg are critical for priming effective and therapeutic antitumour responses. Similarly, p38 MAPK inhibition also augments the T cell stimulatory capacity of human monocyte-derived DCs in the presence of Treg. These findings contribute to ongoing efforts to improve DC-based immunotherapy in human cancers. </div></details><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/24957461">24957461</a><div class="entities" style="line-height: 2.5"><h3>p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T cell-mediated immunosuppression.</h3></br>Dendritic cell (DC)-based cancer immunotherapy is a promising method, but so far has demonstrated limited clinical benefits. Regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) represent a major obstacle to cancer immunotherapy approaches. Here we show that inhibiting p38 MAPK during DC differentiation enables DCs to activate tumour-specific effector T cells (Teff), inhibiting the conversion of Treg and compromising Treg inhibitory effects on Teff. Inhibition of p38 MAPK in DCs lowers expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    PPARγ    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, activating p50 and upregulating OX40L expression in DCs. OX40L/OX40 interactions between DCs and Teff and/or Treg are critical for priming effective and therapeutic antitumour responses. Similarly, p38 MAPK inhibition also augments the T cell stimulatory capacity of human monocyte-derived DCs in the presence of Treg. These findings contribute to ongoing efforts to improve DC-based immunotherapy in human cancers. </div></details></details></td>
    </tr>
    <tr>
      <th>36</th>
      <td>MYC</td>
      <td>2</td>
      <td>TREG:2, TEFF:1</td>
      <td>0.085957</td>
      <td>ENSG00000136997</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28416194">28416194</a><div class="entities" style="line-height: 2.5"><h3>Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments.</h3></br>Immune cells function in diverse metabolic environments. Tissues with low glucose and high lactate concentrations, such as the intestinal tract or ischemic tissues, frequently require immune responses to be more pro-tolerant, avoiding unwanted reactions against self-antigens or commensal bacteria. T-regulatory cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) maintain peripheral tolerance, but how Tregs function in low-glucose, lactate-rich environments is unknown. We report that the Treg transcription factor Foxp3 reprograms T cell metabolism by suppressing <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Myc    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and glycolysis, enhancing oxidative phosphorylation, and increasing nicotinamide adenine dinucleotide oxidation. These adaptations allow Tregs a metabolic advantage in low-glucose, lactate-rich environments; they resist lactate-mediated suppression of T cell function and proliferation. This metabolic phenotype may explain how Tregs promote peripheral immune tolerance during tissue injury but also how cancer cells evade immune destruction in the tumor microenvironment. Understanding Treg metabolism may therefore lead to novel approaches for selective immune modulation in cancer and autoimmune diseases.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27712958">27712958</a><div class="entities" style="line-height: 2.5"><h3>Nutrients and the microenvironment to feed a T cell army.</h3></br>T cells have dramatic functional and proliferative shifts in the course of maintaining immune protection from pathogens and cancer. To support these changes, T cells undergo metabolic reprogramming upon stimulation and again after antigen clearance. Depending on the extrinsic cell signals, T cells can differentiate into functionally distinct subsets that utilize and require diverse metabolic programs. Effector T cells (Teff) enhance glucose and glutamine uptake, whereas regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) do not rely on significant rates of glycolysis. The dependence of these subsets on specific metabolic programs makes T cells reliant on these signaling pathways and nutrients. Metabolic pathways, such as those regulated by mTOR and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Myc    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, augment T cell glycolysis and glutaminolysis programs to promote T cell activity. These pathways respond to signals and control metabolism through both transcriptional or post-transcriptional mechanisms. Epigenetic modifications also play an important role by stabilizing the transcription factors that define subset specific reprogramming. In addition, circadian rhythm cycling may also influence energy use, immune surveillance, and function of T cells. In this review, we focus on the metabolic and nutrient requirements of T cells, and how canonical pathways of growth and metabolism regulate nutrients that are essential for T cell function.</div></details><details><summary>TEFF</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27712958">27712958</a><div class="entities" style="line-height: 2.5"><h3>Nutrients and the microenvironment to feed a T cell army.</h3></br>T cells have dramatic functional and proliferative shifts in the course of maintaining immune protection from pathogens and cancer. To support these changes, T cells undergo metabolic reprogramming upon stimulation and again after antigen clearance. Depending on the extrinsic cell signals, T cells can differentiate into functionally distinct subsets that utilize and require diverse metabolic programs. Effector T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Teff    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) enhance glucose and glutamine uptake, whereas regulatory T cells (Treg) do not rely on significant rates of glycolysis. The dependence of these subsets on specific metabolic programs makes T cells reliant on these signaling pathways and nutrients. Metabolic pathways, such as those regulated by mTOR and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Myc    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, augment T cell glycolysis and glutaminolysis programs to promote T cell activity. These pathways respond to signals and control metabolism through both transcriptional or post-transcriptional mechanisms. Epigenetic modifications also play an important role by stabilizing the transcription factors that define subset specific reprogramming. In addition, circadian rhythm cycling may also influence energy use, immune surveillance, and function of T cells. In this review, we focus on the metabolic and nutrient requirements of T cells, and how canonical pathways of growth and metabolism regulate nutrients that are essential for T cell function.</div></details></details></td>
    </tr>
    <tr>
      <th>37</th>
      <td>BCL6B</td>
      <td>2</td>
      <td>TEFF:1, TFH:1</td>
      <td>0.085957</td>
      <td>ENSG00000161940</td>
      <td><details><summary>Subtypes</summary><details><summary>TEFF</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/17981205">17981205</a><div class="entities" style="line-height: 2.5"><h3>The expansion and maintenance of antigen-selected CD8(+) T cell clones.</h3></br>The biological purpose of the mature, postthymic CD8(+) T cell is to respond to microbial antigens with a developmental program of clonal expansion and concomitant differentiation leading to effector cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(EFF)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) that provide antimicrobial defense. Because many microbial infections persist into a chronic phase, this antigen-stimulated developmental program must be capable of continually generating T(EFF), perhaps for the lifetime of the individual. This chapter proposes that the ability of a CD8(+) T cell clone to maintain the continual production of T(EFF) during periods of persistent antigenic stimulation is based on a program that has two sequential phases of clonal expansion: an initial stage that occurs mainly in the secondary lymphoid tissues and is mediated by ligation of the T cell receptor (TCR) and CD27, and a subsequent, IL-2-dependent phase that occurs predominantly in peripheral, nonlymphoid tissues. The TCR/CD27-dependent phase establishes a nondifferentiating, self-renewing pool of clonally expanding cells, and the IL-2-dependent phase mediates continued clonal expansion that is coupled to the development of T(EFF). The two pools are linked by the process of asymmetrical division within the self-renewing subset so that, at steady state of cellular replication in this TCR/CD27-dependent subset, one daughter cell remains undifferentiated and the other initiates its commitment to IL-2-dependent terminal differentiation. Superimposed on this basic scheme are a shift in the CD8(+) T cell response to type I and II interferon (IFN) from anti- to pro-proliferative and transcriptional control of replicative senescence by Bmi-1, Blimp-1, and BCL6/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL6b    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. This developmental program ensures that despite the occurrence of cellular senescence antiviral CD8(+) T cell clones are maintained for the duration of persistent viral infections.</div></details><details><summary>TFH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/25177110">25177110</a><div class="entities" style="line-height: 2.5"><h3>The histopathology of labial salivary glands in primary Sjögren's syndrome: focusing on follicular helper T cells in the inflammatory infiltrates.</h3></br>Recently, we revealed the importance of follicular helper T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(FH)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) in the pathogenesis of primary Sjögren's syndrome (pSS). In the present study, we focused on the site of the inflammation and determined the composition of lymphocyte infiltration in labial salivary gland (LSG) biopsies with special emphasis on <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(FH)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and germinal center B cells. We selected tissue blocks obtained from ten patients at the time of disease onset. Detection of cell specific markers was performed with immunohistochemical and immunofluorescence stainings. We evaluated patients' clinical and laboratory features retrospectively and assessed the relation between disease course and early histopathological findings. LSG biopsies were graded based on the extension and arrangement level of periductal inflammatory cell infiltrates. T(FH) cell markers (CD84, PD-1, and Bcl-6) occurred predominantly in more organized structures with higher focus scores. The coexpression of CD3 and Bcl-6 markers clearly identified T(FH) cells close to <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Bcl-6(+) B    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> cells with the typical formation of germinal centers. Systemic features were developed later in the disease course only in patients with highly structured infiltrates and the presence of T(FH) cells. Our observations suggest that the presence of T(FH) cells in LSGs at the disease onset may predict a more pronounced clinical course of pSS.</div></details></details></td>
    </tr>
    <tr>
      <th>38</th>
      <td>AR</td>
      <td>15</td>
      <td>TREG:9, TH:3, TH17:2, TH1:1, TH2:1, TH9:1</td>
      <td>0.085307</td>
      <td>ENSG00000169083</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/23843861">23843861</a><div class="entities" style="line-height: 2.5"><h3>Regulatory T cells in the immunodiagnosis and outcome of kidney allograft rejection.</h3></br>Acute rejection (AR) is responsible for up to 12% of graft loss with the highest risk generally occurring during the first six months after transplantation. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> may be broadly classified into humoral as well as cellular rejection. Cellular rejection develops when donor alloantigens, presented by antigen-presenting cells (APCs) through class I or class II HLA molecules, activate the immune response against the allograft, resulting in activation of naive T cells that differentiate into subsets including cytotoxic CD8(+) and helper CD4(+) T cells type 1 (TH1) and TH2 cells or into cytoprotective immunoregulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>). The immune reaction directed against a renal allograft has been suggested to be characterized by two major components: a destructive one, mediated by CD4(+) helper and CD8(+) cytotoxic T cells, and a protective response, mediated by Tregs. The balance between these two opposite immune responses can significantly affect the graft survival. Many studies have been performed in order to define the role of Tregs either in the immunodiagnosis of transplant rejection or as predictor of the clinical outcome. However, information available from the literature shows a contradictory picture that deserves further investigation. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21091665">21091665</a><div class="entities" style="line-height: 2.5"><h3>Forkhead box P3+ T cells express interleukin-17 in nasal mucosa of patients with both allergic rhinitis and polyposis.</h3></br>The pathogenesis of nasal polyposis remains unclear; it severely affects patients' quality of life and complicates inflammation in adjacent organs such as sinusitis and asthma. Aberrant immune regulatory function in these patients is proposed. The present study aims to examine the regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> ) in nasal mucosa of patients with allergic rhinitis (AR) and nasal polyposis (NP). Patients with <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> or <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>/NP were treated with inferior turbinectomy for their inferior turbinate hyperplasia. Surgically removed nasal mucosa was collected to examine the T(reg) by immunohistochemistry and flow cytometry. The results showed that more forkhead box P3 (FoxP3)(+) cells were found in <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> with polyps than in those with <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> alone. Further studies revealed that these FoxP3(+) T cells from <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>/NP group also expressed interleukin (IL)-17. In vitro study showed that staphylococcal enterotoxin B (SEB) induced CD4(+) FoxP3(+) T cells to become FoxP3(+) IL-17(+) cells via facilitating the expression of IL-6, that in synergy with transforming growth factor-beta, induce the expression of IL-17 in FoxP3(+) cells. We conclude that FoxP3(+) IL-17(+) T cells were localized in the nasal mucosa of patients with <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and NP. SEB may play a role in converting FoxP3(+) T(reg) to FoxP3(+) IL-17(+) T cells. The presence of IL-17(+) FoxP3(+) T cells may play a role in the remodelling of the nasal airways in certain people who develop polyps, irrespective of whether or not they are atopic.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/19357258">19357258</a><div class="entities" style="line-height: 2.5"><h3>Regulatory, effector, and cytotoxic T cell profiles in long-term kidney transplant patients.</h3></br>Animal studies have suggested a potential role for regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) in allograft tolerance, but these FOXP3+ cells seem to be an inherent component of acute rejection (AR) in human recipients of renal transplants. The balance between regulatory cells and effector/cytotoxic cells may determine graft outcome; this balance has not been described for chronic allograft injury. We investigated the expression of key regulatory, effector, and cytotoxic transcripts (i.e., FOXP3, T-bet, and granzyme B, respectively) in the grafts and peripheral blood of long-term-surviving renal transplant patients. We found that, whereas neither intragraft nor peripheral blood FOXP3 or T-bet mRNA could distinguish between rejection and nonrejection status, granzyme B (GrzB) mRNA could: It was significantly increased in the graft and significantly decreased in the peripheral blood of patients with chronic antibody-mediated rejection (CAMR). Quantifying peripheral blood GrzB mRNA demonstrated potential to aid in the noninvasive diagnosis of CAMR. In summary, these data affirm GrzB as a marker not only for <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> but also for CAMR. In addition, we identified several previously unreported clinical or demographic factors influencing regulatory/effector/cytotoxic profiles in the peripheral blood, highlighting the necessity to consider confounding variables when considering the use of potential biomarkers, such as FOXP3, for diagnosis or prognosis in kidney transplantation.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/17161354">17161354</a><div class="entities" style="line-height: 2.5"><h3>Peripheral CD4+ CD25+ Treg cell expansion in lung transplant recipients is not affected by calcineurin inhibitors.</h3></br>CD4+CD25+ regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells have been shown to play a role in allograft tolerance and their peripheral counts vary according to the degre<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    e     <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>of graft acceptance in lung<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">     t    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>ransplant recipients (LTR). Recent studies demonstrate that certain drugs might modulate generation, expansion and activity of Treg cells. Aim of this study was to evaluate the effect of therapeutic regimens used in our institution on peripheral CD4+CD25(high)CD69- Treg cell numbers in a group of 51 LTR with stable clinical conditions. They were treated with standard immunosuppression: calcineurin inhibitor (CNI)+azathioprine (AZA)+steroids (n=28) or with CNI+mycophenolate mofetil (MMF)+steroids (n=11) or with CNI+steroids (n=12). These stable LTR were compared with age-matched healthy controls (n=35) and with 19 LTR who developed bronchiolitis obliterans syndrome (BOS) and were treated analogously. Stable LTR showed higher peripheral Treg cell counts with respect to age-matched healthy controls (59.9+/-31.8/mul versus 42.1+/-16.9/mul, respectively; p<0.05). This increase was detectable in all patients treated with CNI either in association with AZA or MMF. During these treatments a significant expansion of Treg cell counts was detectable during acute rejection (AR) episodes (86.03+/-26.6/mul during AR versus 36.34+/-7.6 before AR; p<0,05). Moreover, the development of BOS was associated to a significant decrease of Treg cell counts irrespective to the immunosuppressive regimen used. In conclusion, therapeutic regimens based on CNI seem to allow a certain degree of peripheral Treg cell expansion in stable LTR.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/29122078">29122078</a><div class="entities" style="line-height: 2.5"><h3>The role of regulatory T cells in the regulation of upper airway inflammation.</h3></br>Allergic rhinitis (AR) and chronic rhinosinusitis with nasal polyps (CRSwNP) are inflammatory diseases of the upper airway, with a similar immunologic profile, characterized by aberrant and persistent type 2 inflammation. One cell population that has been identified as altered in both disease types is regulatory T cell (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>). Tregs have the capacity to modulate T-effector function and suppress inflammatory cytokine production in a broad range of cell types. Given the ability of Tregs to control inflammation, the role of Tregs in respiratory diseases has attracted much attention. As discussed in this article, alterations in the Treg numbers and function, or both, have been identified in <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and CRSwNP, although much of the data is conflicting. Here, we explored what is known and, in many cases, unknown about the mechanisms by which Tregs differentiate and function, and how these functions can be controlled in the mucosal microenvironment. By gaining a greater understanding of these processes, it may be possible to harness the natural immunosuppressive activity of Tregs to ameliorate the chronic inflammation associated with <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and CRSwNP.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/28423590">28423590</a><div class="entities" style="line-height: 2.5"><h3>Neutralization of interleukin-17 suppresses allergic rhinitis symptoms by downregulating Th2 and Th17 responses and upregulating the Treg response.</h3></br>Allergic rhinitis (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) has long been considered to predominantly involve the actions of Th2 cells, with relatively small contributions from Th1 cells. In recent years, the discovery of Th17 and regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells has rendered the Th1/Th2 balance paradigm more complex and expanded our understanding of the pathogenesis of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. IL-17, a key cytokine produced by Th17 cells, is known to induce allergen-specific Th2 cell activation, eosinophil and neutrophil accumulation, and serum IgE production in asthma; all of these features may play important roles in <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. To the best of our knowledge, only a few studies have assessed the feasibility of using IL-17 antagonists to treat <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. Thus, the principal objectives of the present study were, first, to determine the status of Th17 and Treg cells in the nasal mucosa of a mouse model of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, and, second, to investigate the effects of IL-17 on such cells and the therapeutic efficacy of anti-IL-17 antibodies (Abs) in the context of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. Anti-IL-17 Abs were given intranasally during the re-challenge of BALB/c mice with ovalbumin (OVA)-induced <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. We measured the numbers of nasal rubbing motions and sneezes, eosinophil and neutrophil levels, Th1, Th2, Th17, and Treg parameters in the nasal mucosa. Anti-IL-17 Abs markedly reduced the number of nasal rubbing motions and sneezes, decreased eosinophil and neutrophil infiltration, reduced Th2 and Th17 responses, and increased the Treg response. Anti-IL-17 Ab treatment protects against <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. These results will improve our understanding of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> pathogenesis and may lead to the development of novel therapeutic approaches for management of the condition.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/26546895">26546895</a><div class="entities" style="line-height: 2.5"><h3>Imbalance of Peripheral Th17 and Regulatory T Cells in Children with Allergic Rhinitis and Bronchial Asthma.</h3></br>The purpose of the present study is to investigate the prevalence of Th17 and regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells in children with allergic rhinitis (AR) accompanying with bronchial asthma (BA). 24 children with AR, 22 children with BA, 18 children with AR accompanying with BA, and 20 healthy controls were recruited. The prevalence of peripheral blood Th17 and Treg cells were determined by flow cytometry. mRNA expression of retinoid-acid receptor-related orphan receptor (ROR)-γt and forkhead box P3 (Foxp3) were determined by realtime polymerase chain reaction. Cytokine expressions in plasma were determined by enzyme linked immunosorbent assay. The frequency of Th17 cells, ROR-γt mRNA expression, and the plasma levels of IL-17 were significantly higher, while Treg cells and Transforming growth factor (TGF)-β1 were significantly lower in children with AR accompanying with BA compared with those in children with <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> or BA alone or control subjects. In children with allergic airway disease, total IgE levels were positively correlated to the frequency of Th17 cells (r=0.607, p<0.01), plasma IL-17 levels, and negatively correlated to the frequency of Treg cells (r=-0.429, p<0.01) and TGF-β1 levels (r=-0.224, p<0.01). While Forced expiratory volume in one second (FEV1) (% predicted) was negatively correlated to the frequency of Th17 cells (r=-0.602, p<0.01), plasma IL-17 levels (r=-0.577, p<0.01), and positively correlated to the frequency of Treg cells r=0.504, p<0.01) and TGF-β1 levels (r=0.231, p<0.05). Our results demonstrate that the imbalance of peripheral Th17/Treg cells plays an important role in the pathogenesis of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> accompanying with BA.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/23451486">23451486</a><div class="entities" style="line-height: 2.5"><h3>[Advances in cytokine immune mechanisms of allergic rhinitis].</h3></br>Allergic rhinitis is a common disease, which was released by the IgE-mediated atopic individuals exposed to allergens in the earlier researches. However, there are variety of immunocompetent cells and cytokines involved in the nasal mucosa immunologic mechanism in nowadays researches. The mechanism of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is caused by the imbalance of the Th1/Th2, a kind of allergic inflammation who is characterized by the nasal Th2 immune response dominant. Th1 cells mainly produce of IFN-gamma (does not include IL-4 and IL-5), Th2 cells produce IL-4, IL-5, IL-9 and IL-13 (not including IFN-gamma). Recently it was found that regulatory T cells (T regulatory cells, <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) and Th17 cell research played a crucial role in the occurrence of allergic inflammation.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/19545671">19545671</a><div class="entities" style="line-height: 2.5"><h3>The role of Foxp3+ regulatory T cells in kidney transplantation.</h3></br>Our project aimed to investigate the relation between the level of pretransplantation and posttransplantation peripheral CD4(+)CD25(+)Foxp3(+) T-regulatory lymphocytes (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) and the development of acute rejection (AR) episodes in 44 patients after kidney transplantation. During the 6-month period following transplantation, AR was diagnosed in 11 patients. Peripheral blood samples were collected 1 day before and 10 days after transplantation and tested for concentrations of CD4(+)CD25(+)Foxp3(+) cells by means of flow cytometry. The pretransplantation analysis showed significantly lower mean levels of peripheral Tregs in AR patients versus control group (P < .05). A lower level of Tregs was also observed in nonrejection (NONAR) patients versus control group (P < .05); however, it was still higher than in the AR group (P < .05). The 10-day posttransplantation analysis showed a similar pattern; however, a significant increase in the concentration of peripheral Tregs in NONAR patients was observed (P < .05), whereas no change was recorded in AR patients (P > .05). We found lower pretransplantation levels of peripheral Tregs in both <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and NONAR groups, versus control group. The deficiency of peripheral Tregs in patients with end-stage renal failure might be due to the long-term inflammatory processes adversely affecting the peripheral regulatory mechanisms. However, significantly lower levels of Tregs observed in <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> patients might also be related to genetic predispositions. Our observation suggests that the size and possibly the functionality of Tregs in the AR group was not sufficient to successfully control the immune response after kidney transplantation, leading to acute rejection episodes.</div></details><details><summary>TH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/19262506">19262506</a><div class="entities" style="line-height: 2.5"><h3>A2A adenosine receptor (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) activation inhibits pro-inflammatory cytokine production by human CD4+ helper T cells and regulates Helicobacter-induced gastritis and bacterial persistence.</h3></br>Helicobacter pylori causes a lifelong infection and provides a model of bacterial adaptation and persistent colonization. Adenosine is an anti-inflammatory mediator that limits tissue damage during inflammation. We studied the role of adenosine in the T cell-mediated regulation of gastritis and bacterial persistence. After 4 h of activation, human T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells increased A(2A) adenosine receptor (A(2A)AR) mRNA level (sevenfold). A(2A)AR was the predominant subtype expressed in resting and stimulated gastric or peripheral Th cells. Stimulation with ATL313, an A(2A)AR agonist, increased cyclic AMP (cAMP) accumulation and reduced interleukin-2 (IL-2) production by 20-50%. ATL313 also attenuated tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma) production, which was inhibited by an A(2A)AR antagonist. Infection of IL-10-deficient mice with H. pylori is cleared spontaneously due to the marked inflammation. Administration of ATL313 during infection reduced gastritis and pro-inflammatory cytokine responses while bacterial load increased. In contrast, infection of A(2A)AR-deficient mice enhanced gastritis. Thus, A(2A)AR limits the pro-inflammatory effects of Th cells and favor chronic Helicobacter infection.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/20005391">20005391</a><div class="entities" style="line-height: 2.5"><h3>Increased T-bet to GATA-3 ratio during acute allograft rejection in the rat lung.</h3></br>Acute allograft rejection (AR) remains a major problem in solid organ transplantation. The pivotal mechanism hinges on alloantigen recognition by recipient T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(h)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells that differentiate into T(h)1 and T(h)2. This study investigated the association of mRNA levels of the transcription factors T-box expressed in T cells and GATA-binding protein 3 with the development of T(h)1/T(h)2-directed immune responses. We investigated the expression of T-bet and GATA-3 mRNA levels and the protein levels of their marker cytokines interleukin (IL)-2 and IL-4 in orthotopically transplanted rat lungs during <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. We observed a nonsignificant increase in T-bet expression following allografting at days 3 and 5 but there was a significant reduction in GATA-3 expression on day 5 compared with controls. The ratio of T-bet to GATA-3 expression showed a trend to increase at day 3 following allografting reaching significance at 5 days. These changes were associated with a significant increase in the expression of IL-2 over IL-4 on days 3 and 5. This study suggests that T(h)1 responses play a major role during <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in the rat lung, and that this differentiation can be monitored by measuring mRNA levels of T-bet and GATA-3.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/15941684">15941684</a><div class="entities" style="line-height: 2.5"><h3>Effects of glucan treatment on the Th1/Th2 balance in patients with allergic rhinitis: a double-blind placebo-controlled study.</h3></br>Allergic rhinitis (AR) is a disease characterized by IgE-mediated, allergic inflammation of the nasal mucosa. T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) 2 cells play an important role in the development of IgE-mediated diseases such as <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, with local overproduction of Th2 cytokines (IL-4, IL-5 and IL-13) at the site of allergic inflammation. Th1 cytokines (IL-12 and IFN-gamma) are known to suppress this Th2 immune response, aiding the treatment of these diseases. Beta-1,3-1,6-glucan (Glucan) is an immunomodulator stimulating particularly the antitumor response. An efficient antitumor stimulation can be achieved through a Th1-mediated immune response.</div></details><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28423590">28423590</a><div class="entities" style="line-height: 2.5"><h3>Neutralization of interleukin-17 suppresses allergic rhinitis symptoms by downregulating Th2 and Th17 responses and upregulating the Treg response.</h3></br>Allergic rhinitis (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) has long been considered to predominantly involve the actions of Th2 cells, with relatively small contributions from Th1 cells. In recent years, the discovery of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and regulatory T (Treg) cells has rendered the Th1/Th2 balance paradigm more complex and expanded our understanding of the pathogenesis of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. IL-17, a key cytokine produced by Th17 cells, is known to induce allergen-specific Th2 cell activation, eosinophil and neutrophil accumulation, and serum IgE production in asthma; all of these features may play important roles in <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. To the best of our knowledge, only a few studies have assessed the feasibility of using IL-17 antagonists to treat <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. Thus, the principal objectives of the present study were, first, to determine the status of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Treg cells in the nasal mucosa of a mouse model of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, and, second, to investigate the effects of IL-17 on such cells and the therapeutic efficacy of anti-IL-17 antibodies (Abs) in the context of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. Anti-IL-17 Abs were given intranasally during the re-challenge of BALB/c mice with ovalbumin (OVA)-induced <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. We measured the numbers of nasal rubbing motions and sneezes, eosinophil and neutrophil levels, Th1, Th2, Th17, and Treg parameters in the nasal mucosa. Anti-IL-17 Abs markedly reduced the number of nasal rubbing motions and sneezes, decreased eosinophil and neutrophil infiltration, reduced Th2 and Th17 responses, and increased the Treg response. Anti-IL-17 Ab treatment protects against <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. These results will improve our understanding of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> pathogenesis and may lead to the development of novel therapeutic approaches for management of the condition.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/26546895">26546895</a><div class="entities" style="line-height: 2.5"><h3>Imbalance of Peripheral Th17 and Regulatory T Cells in Children with Allergic Rhinitis and Bronchial Asthma.</h3></br>The purpose of the present study is to investigate the prevalence of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and regulatory T (Treg) cells in children with allergic rhinitis (AR) accompanying with bronchial asthma (BA). 24 children with AR, 22 children with BA, 18 children with AR accompanying with BA, and 20 healthy controls were recruited. The prevalence of peripheral blood <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Treg cells were determined by flow cytometry. mRNA expression of retinoid-acid receptor-related orphan receptor (ROR)-γt and forkhead box P3 (Foxp3) were determined by realtime polymerase chain reaction. Cytokine expressions in plasma were determined by enzyme linked immunosorbent assay. The frequency of Th17 cells, ROR-γt mRNA expression, and the plasma levels of IL-17 were significantly higher, while Treg cells and Transforming growth factor (TGF)-β1 were significantly lower in children with AR accompanying with BA compared with those in children with <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> or BA alone or control subjects. In children with allergic airway disease, total IgE levels were positively correlated to the frequency of Th17 cells (r=0.607, p<0.01), plasma IL-17 levels, and negatively correlated to the frequency of Treg cells (r=-0.429, p<0.01) and TGF-β1 levels (r=-0.224, p<0.01). While Forced expiratory volume in one second (FEV1) (% predicted) was negatively correlated to the frequency of Th17 cells (r=-0.602, p<0.01), plasma IL-17 levels (r=-0.577, p<0.01), and positively correlated to the frequency of Treg cells r=0.504, p<0.01) and TGF-β1 levels (r=0.231, p<0.05). Our results demonstrate that the imbalance of peripheral Th17/Treg cells plays an important role in the pathogenesis of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> accompanying with BA.</div></details><details><summary>TH1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/23477548">23477548</a><div class="entities" style="line-height: 2.5"><h3>Ovalbumin induced allergic rhinitis and development of prediabetes to rats: possible role of Th2 cytokines.</h3></br>Diabetes is known to be regulated by cytokines secreted from Th1 cells, while allergic rhinitis (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) is mainly regulated by Th2 cytokines. In recent past we have reported the development of diabetes in response to parthinium induced <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> to rats. These results were contradictory to Th1/Th2 paradigm which suggests that <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells reciprocally counteract each other. Subsequently in silico interactome analysis further revealed that Th2 cytokines may signal to increase the level of Th1 along with the proteins involved in the development of diabetes. In present study we tried to understand the diabetogenic changes on the background of ovalbumin induced allergic rhinitis (OVA). Three groups of seven rats were considered; group I control (Ctrl); group II OVA and group III OVA+L-cetrizine (OVA+ D). The study continued for 48 days and the experiment was terminated on day 49, while L-cetrizine was administered for last 07 days (42-48 days). Group II showed increased levels of Th1 (IL-2) and Th2 cytokines, induction of allergic rhinitis and changes in the proteins involved in diabetes. In group III, most of the changes were reverted back towards normalcy. Induction of allergic rhinitis triggers Th2 cytokines that result increase IL-2 (Th1) and alterations in the metabolic parameters led to the condition of prediabetes. </div></details><details><summary>TH2</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/22532281">22532281</a><div class="entities" style="line-height: 2.5"><h3>[Mechanism of action of nasal glucocorticosteroids in the treatment of allergic rhinitis. Part 1: Pathophysiology, molecular basis].</h3></br>Allergic rhinitis (AR) is a common airway disease characterized by mucosal swelling leading to congestion, mucosal hyperreactivity and increased secretions. Inflammatory processes in the mucosa are responsible for most symptoms and are characterized by mucosal remodeling after longer time periods. The early phase response, which is characterized by sneezing, rhinorrhea and nasal congestion, is the response of the sensory nerve terminals and blood vessels in the nasal mucosa to chemical mediators such as histamine, prostaglandins and leukotrienes. Nasal exposure to allergens leads to infiltration of inflammatory cells, such as activated eosinophils and T helper type 2 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, into the nasal mucosa by chemoattractant factors such as cytokines including interleukin 5 (IL-5), chemical mediators including cysLTs and chemokines including eotaxin. Edema of the nasal mucosa develops as a secondary reaction with inflammatory cells. This inflammation, referred to as the late-phase response, develops 6-10 h after allergen challenge and causes prolonged nasal congestion. In addition, a neurogenic mechanism is activated after liberation of substance P and others. Therefore, allergic rhinitis is a complex immunogenic disease that also activates mechanisms of the immune system in general. Antiallergic and antiinflammatory medications such as nasal glucocorticosteroids (nGCS) are thought to be the most effective treatment for controlling the symptoms and inflammatory mechanisms of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. The antiinflammatory action of nGCS depends on at least two different mechanisms: transactivation and transrepression. Moreover, they regulate immune functions by inducing regulatory cytokines and forkhead box P3 (Foxp3). Foxp3 is of upmost importance as a transcription factor of regulatory T cells, allowing the inhibition of effector function and proliferation of other CD4+ cells.</div></details><details><summary>TH9</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/26708394">26708394</a><div class="entities" style="line-height: 2.5"><h3>High frequency of T helper type 9 cells in Chinese patients with allergic rhinitis.</h3></br>T helper type 9 cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th9    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) are the most recently discovered subset of Th cells, and are involved in the pathology of several autoimmune and allergic diseases. The significance of Th9 cells in allergic rhinitis (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AR    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) in Chinese patients is unclear.</div></details></details></td>
    </tr>
    <tr>
      <th>39</th>
      <td>CEBPB</td>
      <td>1</td>
      <td>TH17:1</td>
      <td>0.083559</td>
      <td>ENSG00000172216</td>
      <td><details><summary>Subtypes</summary><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/26631268">26631268</a><div class="entities" style="line-height: 2.5"><h3>Stromal Fibroblasts Induce CCL20 through IL6/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    C/EBPβ    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> to Support the Recruitment of Th17 Cells during Cervical Cancer Progression.</h3></br>Cervical cancer is a consequence of persistent infection with human papillomaviruses (HPV). Progression to malignancy is linked to an inflammatory microenvironment comprising T-helper-17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, a T cell subset with protumorigenic properties. Neoplastic cells express only low endogenous levels of the Th17 chemoattractant CCL20, and therefore, it is unclear how Th17 cells are recruited to the cervical cancer tissue. In this study, we demonstrate that CCL20 was predominantly expressed in the stroma of cervical squamous cell carcinomas in situ. This correlated with stromal infiltration of CD4(+)/IL17(+) cells and with advancing International Federation of Gynecology and Obstetrics (FIGO) stage. Furthermore, we show that cervical cancer cells instructed primary cervical fibroblasts to produce high levels of CCL20 and to attract CD4/IL17/CCR6-positive cells, generated in vitro, in a CCL20/CCR6-dependent manner. Further mechanistic investigations identified cervical cancer cell-derived IL6 as an important mediator of paracrine CCL20 induction at the promoter, mRNA, and protein level in fibroblasts. CCL20 was upregulated through the recently described CCAAT/enhancer-binding protein β (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    C/EBPβ    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) pathway as shown with a dominant-negative version of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    C/EBPβ    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and through siRNA-mediated knockdown. In summary, our study defines a novel molecular mechanism by which cervical neoplastic cells shape their local microenvironment by instructing fibroblasts to support Th17 cell infiltration in a paracrine IL6/C/EBPβ-dependent manner. Th17 cells may in turn maintain chronic inflammation within high-grade cervical lesions to further promote cancer progression.</div></details></details></td>
    </tr>
    <tr>
      <th>40</th>
      <td>EGR3</td>
      <td>1</td>
      <td>TH1:1</td>
      <td>0.083494</td>
      <td>ENSG00000179388</td>
      <td><details><summary>Subtypes</summary><details><summary>TH1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/11254710">11254710</a><div class="entities" style="line-height: 2.5"><h3>Differential expression of Fas ligand in <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells is regulated by early growth response gene and NF-AT family members.</h3></br>Inducible expression of Fas ligand (CD95 ligand) by activated T cells and the resulting apoptosis of CD95-bearing cells is a critical component of peripheral T cell homeostasis and cytotoxic effector mechanisms. Transcriptional control of the expression of Fas ligand has been attributed to a number of factors, including early growth response gene 2 (Egr2), <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Egr3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, Sp1, and NF-AT, although a direct contribution of NF-AT is controversial. The present study confirms a role for Egr factors and indicates that NF-AT is essential for optimal expression of murine Fas ligand through a direct interaction with an NF-AT consensus element. The role of these factors was further defined by studying the differential expression of Fas ligand in Th1 and Th2 lines derived from DO11.10 TCR transgenic mice. EMSA analyses of a composite Egr/NF-AT site showed recruitment of Sp1 to this site in Th2 cells, but not in Th1 cells. Furthermore, gel-shift analyses demonstrated the binding of Egr1, 2, and 3 in Th2 cells and Egr1 and 2, but not <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Egr3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in Th1 cells at a known Egr site. Northern analysis corroborated the lack of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Egr3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in Th1 cells. Differential usage of these transcription factors by <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells suggests a potential mechanism underlying the differential expression of Fas ligand by distinct T cell lineages.</div></details></details></td>
    </tr>
    <tr>
      <th>41</th>
      <td>NR4A2</td>
      <td>2</td>
      <td>TH17:1, TREG:1</td>
      <td>0.080001</td>
      <td>ENSG00000153234</td>
      <td><details><summary>Subtypes</summary><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/23437182">23437182</a><div class="entities" style="line-height: 2.5"><h3>Nuclear receptor <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NR4A2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> orchestrates Th17 cell-mediated autoimmune inflammation via IL-21 signalling.</h3></br>IL-17-producing CD4(+) T helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are pathogenic in a range of human autoimmune diseases and corresponding animal models. We now demonstrate that such T cells infiltrating the target organ during the induction of experimental autoimmune encephalomyelitis (EAE) and experimental autoimmune uveoretinitis (EAU) specifically express <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NR4A2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. Further, we reveal a critical involvement of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NR4A2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in Th17 cell functions and Th17 cell-driven autoimmune diseases. When <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NR4A2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression was blocked with siRNA, full Th17 differentiation was prevented in vitro: although cells expressed the master Th17 regulator, RORγt, they expressed reduced levels of IL-23R and were unable to produce IL-17 and IL-21. Notably, Th17 differentiation in the absence of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NR4A2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> was restored by exogenous IL-21, indicating that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NR4A2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> controls full maturation of Th17 cells via autocrine IL-21 signalling. Preventing <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NR4A2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression in vivo by systemic treatment with NR4A2-specific siRNA also reduced Th17 effector responses and furthermore protected mice from EAE induction. In addition, the lack of disease was associated with a reduction in autocrine IL-21 production and IL-23R expression. Similar modulation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NR4A2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression was also effective as an intervention, reversing established autoimmune responses and ameliorating clinical disease symptoms. Thus, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NR4A2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> appears to control Th17 differentiation and so plays an essential role in the development of Th17-mediated autoimmune disease. As <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NR4A2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is also upregulated during human autoimmune disease, targeting <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NR4A2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> may provide a new therapeutic approach in treating autoimmune disease.</div></details><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27778276">27778276</a><div class="entities" style="line-height: 2.5"><h3>Transcriptional modulation of regulatory T cell development by novel regulators NR4As.</h3></br>Regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells with high expression of both CD25 and Foxp3 are developed in the thymus and also peripheral tissues. Treg cells suppress the activation and functions of effector T cells raised against specific antigens and are crucial for maintaining immune homeostasis. Treg cell development is associated with the induction of and epigenetic alterations of forkhead transcription factor Foxp3. Foxp3 expression is increased by the activation of several transcription factors including nuclear factor-kappa B (NF-κB), nuclear factor of activated T cells (NFAT), and Smad3 in response to various signals such as TGFβ, retinoic acid, and rapamycin. Recently, the orphan nuclear receptor 4A proteins (NR4As) including NR4A1 (Nur77), <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NR4A2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (Nurr1), and NR4A3 (Nor1) are reported to regulate Treg cell development through activation of Foxp3 and have therapeutic potentials in treating immune disorders. This review summarizes the function and regulatory mechanisms of Treg cells and also implicates current advances in immunomodulatory functions of NR4As and their therapeutic potentials in inflammation and cancer.</div></details></details></td>
    </tr>
    <tr>
      <th>42</th>
      <td>KLF2</td>
      <td>5</td>
      <td>TFH:2, TREG:2, TH17:1</td>
      <td>0.070207</td>
      <td>ENSG00000127528</td>
      <td><details><summary>Subtypes</summary><details><summary>TFH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27791035">27791035</a><div class="entities" style="line-height: 2.5"><h3>miRNA92a targets <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    KLF2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and the phosphatase PTEN signaling to promote human T follicular helper precursors in T1D islet autoimmunity.</h3></br>Aberrant immune activation mediated by T effector cell populations is pivotal in the onset of autoimmunity in type 1 diabetes (T1D). T follicular helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TFH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are essential in the induction of high-affinity antibodies, and their precursor memory compartment circulates in the blood. The role of TFH precursors in the onset of islet autoimmunity and signaling pathways regulating their differentiation is incompletely understood. Here, we provide direct evidence that during onset of islet autoimmunity, the insulin-specific target T cell population is enriched with a C-X-C chemokine receptor type 5 (CXCR5)+ CD4+  TFH precursor phenotype. During onset of islet autoimmunity, the frequency of TFH precursors was controlled by high expression of microRNA92a (miRNA92a). miRNA92a-mediated TFH precursor induction was regulated by phosphatase and tension homolog (PTEN) - phosphoinositol-3-kinase (PI3K) signaling involving PTEN and forkhead box protein O1 (Foxo1), supporting autoantibody generation and triggering the onset of islet autoimmunity. Moreover, we identify Krueppel-like factor 2 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    KLF2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) as a target of miRNA92a in regulating human TFH precursor induction. Importantly, a miRNA92a antagomir completely blocked induction of human TFH precursors in vitro. More importantly, in vivo application of a miRNA92a antagomir to nonobese diabetic (NOD) mice with ongoing islet autoimmunity resulted in a significant reduction of TFH precursors in peripheral blood and pancreatic lymph nodes. Moreover, miRNA92a antagomir application reduced immune infiltration and activation in pancreata of NOD mice as well as humanized NOD Scid IL2 receptor gamma chain knockout (NSG) human leucocyte antigen (HLA)-DQ8 transgenic animals. We therefore propose that miRNA92a and the PTEN-PI3K-<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    KLF2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> signaling network could function as targets for innovative precision medicines to reduce T1D islet autoimmunity.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/25646266">25646266</a><div class="entities" style="line-height: 2.5"><h3>ICOS maintains the T follicular helper cell phenotype by down-regulating Krüppel-like factor 2.</h3></br>The co-stimulators ICOS (inducible T cell co-stimulator) and CD28 are both important for T follicular helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TFH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, yet their individual contributions are unclear. Here, we show that each molecule plays an exclusive role at different stages of TFH cell development. While CD28 regulated early expression of the master transcription factor Bcl-6, ICOS co-stimulation was essential to maintain the phenotype by regulating the novel TFH transcription factor <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Klf2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> via Foxo1. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Klf2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> directly binds to Cxcr5, Ccr7, Psgl-1, and S1pr1, and low levels of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Klf2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> were essential to maintain this typical TFH homing receptor pattern. Blocking ICOS resulted in relocation of fully developed TFH cells back to the T cell zone and reversion of their phenotype to non-TFH effector cells, which ultimately resulted in breakdown of the germinal center response. Our study describes for the first time the exclusive role of ICOS and its downstream signaling in the maintenance of TFH cells by controlling their anatomical localization in the B cell follicle. </div></details><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/25701076">25701076</a><div class="entities" style="line-height: 2.5"><h3>Systems biologic analysis of T regulatory cells genetic pathways in murine primary biliary cirrhosis.</h3></br>CD4(+)Foxp3(+) regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) play a non-redundant role in control of excessive immune responses, and defects in Tregs have been shown both in patients and murine models of primary biliary cirrhosis (PBC), a progressive autoimmune biliary disease. Herein, we took advantage of a murine model of PBC, the dominant negative transforming growth factor β receptor II (dnTGFβRII) mice, to assess Treg genetic defects and their functional effects in PBC. By using high-resolution microarrays with verification by PCR and protein expression, we found profound and wide-ranging differences between dnTGFβRII and normal, wild type Tregs. Critical transcription factors were down-regulated including Eos, Ahr, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Klf2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, Foxp1 in dnTGFβRII Tregs. Functionally, dnTGFβRII Tregs expressed an activated, pro-inflammatory phenotype with upregulation of Ccl5, Granzyme B and IFN-γ. Genetic pathway analysis suggested that the primary effect of loss of TGFβ pathway signaling was to down regulate immune regulatory processes, with a secondary upregulation of inflammatory processes. These findings provide new insights into T regulatory genetic defects; aberrations of the identified genes or genetic pathways should be investigated in human PBC Tregs. This approach which takes advantage of biologic pathway analysis illustrates the ability to identify genes/pathways that are affected both independently and dependent on abnormalities in TGFβ signaling. Such approaches will become increasingly useful in human autoimmunity. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/22178876">22178876</a><div class="entities" style="line-height: 2.5"><h3>CD4+CD25+Foxp3+ regulatory T cells protect endothelial function impaired by oxidized low density lipoprotein via the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    KLF-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> transcription factor.</h3></br>To investigate the regulation of CD4(+)CD25(+) Regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) on pro-inflammatory adhesion molecules, Krüppel-Like Factor-2 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    KLF-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) and its downstream transcriptional targets in human umbilical vein endothelial cells (HUVECs) impaired by ox-LDL and the mechanisms of it.</div></details><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/21825017">21825017</a><div class="entities" style="line-height: 2.5"><h3>Cytokine signals through PI-3 kinase pathway modulate Th17 cytokine production by CCR6+ human memory T cells.</h3></br>Human memory T cells (T(M) cells) that produce IL-17 or IL-22 are currently defined as <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> or Th22 cells, respectively. These T cell lineages are almost exclusively CCR6(+) and are important mediators of chronic inflammation and autoimmunity. However, little is known about the mechanisms controlling IL-17/IL-22 expression in memory Th17/Th22 subsets. We show that common γ chain (γc)-using cytokines, namely IL-2, IL-7, and IL-15, potently induce Th17-signature cytokine expression (Il17a, Il17f, Il22, and Il26) in CCR6(+), but not CCR6(-), T(M) cells, even in CCR6(+) cells lacking IL-17 expression ex vivo. Inhibition of phosphoinositide 3-kinase (PI-3K) or Akt signaling selectively prevents Th17 cytokine induction by γc-cytokines, as does ectopic expression of the transcription factors FOXO1 or <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    KLF2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, which are repressed by PI-3K signaling. These results indicate that Th17 cytokines are tuned by PI-3K signaling in CCR6(+) T(M) cells, which may contribute to chronic or autoimmune inflammation. Furthermore, these findings suggest that ex vivo analysis of IL-17 expression may greatly underestimate the frequency and pathogenic potential of the human Th17 compartment.</div></details></details></td>
    </tr>
    <tr>
      <th>43</th>
      <td>SP1</td>
      <td>1</td>
      <td>TH1:1</td>
      <td>0.068172</td>
      <td>ENSG00000185591</td>
      <td><details><summary>Subtypes</summary><details><summary>TH1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/11254710">11254710</a><div class="entities" style="line-height: 2.5"><h3>Differential expression of Fas ligand in <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells is regulated by early growth response gene and NF-AT family members.</h3></br>Inducible expression of Fas ligand (CD95 ligand) by activated T cells and the resulting apoptosis of CD95-bearing cells is a critical component of peripheral T cell homeostasis and cytotoxic effector mechanisms. Transcriptional control of the expression of Fas ligand has been attributed to a number of factors, including early growth response gene 2 (Egr2), Egr3, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Sp1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, and NF-AT, although a direct contribution of NF-AT is controversial. The present study confirms a role for Egr factors and indicates that NF-AT is essential for optimal expression of murine Fas ligand through a direct interaction with an NF-AT consensus element. The role of these factors was further defined by studying the differential expression of Fas ligand in Th1 and Th2 lines derived from DO11.10 TCR transgenic mice. EMSA analyses of a composite Egr/NF-AT site showed recruitment of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Sp1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> to this site in Th2 cells, but not in Th1 cells. Furthermore, gel-shift analyses demonstrated the binding of Egr1, 2, and 3 in Th2 cells and Egr1 and 2, but not Egr3 in Th1 cells at a known Egr site. Northern analysis corroborated the lack of Egr3 in Th1 cells. Differential usage of these transcription factors by <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells suggests a potential mechanism underlying the differential expression of Fas ligand by distinct T cell lineages.</div></details></details></td>
    </tr>
    <tr>
      <th>44</th>
      <td>PBX1</td>
      <td>2</td>
      <td>TFH:1, TREG:1</td>
      <td>0.060801</td>
      <td>ENSG00000185630</td>
      <td><details><summary>Subtypes</summary><details><summary>TFH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27296664">27296664</a><div class="entities" style="line-height: 2.5"><h3>The Lupus Susceptibility Gene Pbx1 Regulates the Balance between Follicular Helper T Cell and Regulatory T Cell Differentiation.</h3></br><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Pbx1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> controls chromatin accessibility to a large number of genes and is entirely conserved between mice and humans. The Pbx1-d dominant-negative isoform is more frequent in CD4(+) T cells from lupus patients than from healthy controls. Pbx1-d is associated with the production of autoreactive T cells in mice carrying the Sle1a1 lupus-susceptibility locus. Transgenic (Tg) expression of Pbx1-d in CD4(+) T cells reproduced the phenotypes of Sle1a1 mice, with increased inflammatory functions of CD4(+) T cells and impaired Foxp3(+) regulatory T cell (Treg) homeostasis. Pbx1-d-Tg expression also expanded the number of follicular helper T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TFHs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) in a cell-intrinsic and Ag-specific manner, which was enhanced in recall responses and resulted in Th1-biased Abs. Moreover, Pbx1-d-Tg CD4(+) T cells upregulated the expression of miR-10a, miR-21, and miR-155, which were implicated in Treg and follicular helper T cell homeostasis. Our results suggest that Pbx1-d impacts lupus development by regulating effector T cell differentiation and promoting TFHs at the expense of Tregs. In addition, our results identify <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Pbx1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> as a novel regulator of CD4(+) T cell effector function.</div></details><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/21708033">21708033</a><div class="entities" style="line-height: 2.5"><h3>Defective response of CD4(+) T cells to retinoic acid and TGFβ in systemic lupus erythematosus.</h3></br>CD25(+) FOXP3(+) CD4(+) regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) are induced by transforming growth factor β (TGFβ) and further expanded by retinoic acid (RA). We have previously shown that this process was defective in T cells from lupus-prone mice expressing the novel isoform of the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Pbx1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> gene, Pbx1-d. This study tested the hypothesis that CD4(+) T cells from systemic lupus erythematosus (SLE) patients exhibited similar defects in Treg induction in response to TGFβ and RA, and that PBX1-d expression is associated with this defect.</div></details></details></td>
    </tr>
    <tr>
      <th>45</th>
      <td>GFI1</td>
      <td>3</td>
      <td>TREG:2, TH17:1</td>
      <td>0.059085</td>
      <td>ENSG00000162676</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/23986534">23986534</a><div class="entities" style="line-height: 2.5"><h3>Differential response of regulatory and conventional CD4⁺ lymphocytes to CD3 engagement: clues to a possible mechanism of anti-CD3 action?</h3></br>Several clinical trials have shown anti-CD3 treatment to be a promising therapy for autoimmune diabetes, but its mechanism of action remains unclear. Foxp3(+) regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) are likely to be involved, but through unknown mechanistic pathways. We profiled the transcriptional consequences in CD4(+) Tregs and conventional T cells (Tconvs) in the first hours and days after anti-CD3 treatment of NOD mice. Anti-CD3 treatment led to a transient transcriptional response, terminating faster than most Ag-induced responses. Most transcripts were similarly induced in Tregs and Tconvs, but several were differential, in particular, those encoding the IL-7R and transcription factors Id2/3 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Gfi1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, upregulated in Tregs but repressed in Tconvs. Because IL-7R was a plausible candidate for driving the homeostatic response of Tregs to anti-CD3, we tested its relevance by supplementation of anti-CD3 treatment with IL-7/anti-IL-7 complexes. Although ineffective alone, IL-7 significantly improved the rate of remission induced by anti-CD3. Four anti-human CD3 mAbs exhibited the same differential effect on IL-7R expression in human as in mouse cells, suggesting that the mechanism also underlies therapeutic effect in human cells, and perhaps a rationale for testing a combination of anti-CD3 and IL-7 for the treatment of recent-onset human type 1 diabetes. Thus, systems-level analysis of the response to anti-CD3 in the early phase of the treatment demonstrates different responses in Tregs and Tconvs, and provides new leads to a mechanistic understanding of its mechanism of action in reverting recent-onset diabetes. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/24152290">24152290</a><div class="entities" style="line-height: 2.5"><h3>Histone methylation mediates plasticity of human FOXP3(+) regulatory T cells by modulating signature gene expressions.</h3></br>CD4(+) FOXP3(+) regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells constitute a heterogeneous and plastic T cell lineage that plays a pivotal role in maintaining immune homeostasis and immune tolerance. However, the fate of human Treg cells after loss of FOXP3 expression and the epigenetic mechanisms contributing to such a phenotype switch remain to be fully elucidated. In the current study, we demonstrate that human CD4(+) CD25(high) CD127(low/-) Treg cells convert to two subpopulations with distinctive FOXP3(+) and FOXP3(-) phenotypes following in vitro culture with anti-CD3/CD28 and interleukin-2. Digital gene expression analysis showed that upon in vitro expansion, human Treg cells down-regulated Treg cell signature genes, such as FOXP3, CTLA4, ICOS, IKZF2 and LRRC32, but up-regulated a set of T helper lineage-associated genes, especially T helper type 2 (Th2)-associated, such as GATA3, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GFI1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and IL13. Subsequent chromatin immunoprecipitation-sequencing of these subpopulations yielded genome-wide maps of their H3K4me3 and H3K27me3 profiles. Surprisingly, reprogramming of Treg cells was associated with differential histone modifications, as evidenced by decreased abundance of permissive H3K4me3 within the down-regulated Treg cell signature genes, such as FOXP3, CTLA4 and LRRC32 loci, and increased abundance of H3K4me3 within the Th2-associated genes, such as IL4 and IL5; however, the H3K27me3 modification profile was not significantly different between the two subpopulations. In conclusion, this study revealed that loss of FOXP3 expression from human Treg cells during in vitro expansion can induce reprogramming to a T helper cell phenotype with a gene expression signature dominated by Th2 lineage-associated genes, and that this cell type conversion may be mediated by histone methylation events.</div></details><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/19505891">19505891</a><div class="entities" style="line-height: 2.5"><h3><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Gfi1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> negatively regulates T(h)17 differentiation by inhibiting RORgammat activity.</h3></br>T(h) cells have long been divided into two subsets, T(h)1 and T(h)2; however, recently, T(h)17 and inducible regulatory T (iTreg) cells were identified as new T(h) cell subsets. Although T(h)1- and T(h)2-polarizing cytokines have been shown to suppress T(h)17 and iTreg development, transcriptional regulation of T(h)17 and iTreg differentiation by cytokines remains to be clarified. In this study, we found that expression of the growth factor independent 1 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Gfi1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) gene, which has been implicated in T(h)2 development, was repressed in <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(h)17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and iTreg cells compared with T(h)1 and T(h)2 lineages. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Gfi1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression was enhanced by the IFN-gamma/STAT1 and IL-4/STAT6 pathways, whereas it was repressed by the transforming growth factor-beta1 stimulation at the promoter level. Over-expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Gfi1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> strongly reduced IL-17A transcription in the EL4 T cell line, as well as in primary T cells. This was due to the blockade of recruitment of retinoid-related orphan receptor gammat to the IL-17A promoter. In contrast, IL-17A expression was significantly enhanced in Gfi1-deficient T cells under T(h)17-promoting differentiation conditions as compared with wild-type T cells. In contrast, the impacts of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Gfi1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in iTregs were not as strong as in T(h)17 cells. Taken together, these data strongly suggest that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Gfi1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is a negative regulator of T(h)17 differentiation, which represents a novel mechanism for the regulation of T(h)17 development by cytokines.</div></details></details></td>
    </tr>
    <tr>
      <th>46</th>
      <td>TET2</td>
      <td>2</td>
      <td>TFH:1, TH:1, TREG:1</td>
      <td>0.057324</td>
      <td>ENSG00000168769</td>
      <td><details><summary>Subtypes</summary><details><summary>TFH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/22760778">22760778</a><div class="entities" style="line-height: 2.5"><h3>Recurrent TET2 mutations in peripheral T cell lymphomas correlate with TFH-like features and adverse clinical parameters.</h3></br>Inactivating mutations of the Ten-Eleven Translocation 2 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TET2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) gene were first identified in myeloid malignancies and more recently in peripheral T cell lymphomas (PTCLs). In the present study, we investigated the presence of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TET2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> coding sequence mutations and their clinical relevance in a large cohort of 190 PTCL patients. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TET2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mutations were identified in 40 of 86 (47%) cases of angioimmunoblastic T cell lymphoma (AITL) and in 22 of 58 (38%) cases of peripheral T cell lymphoma, not otherwise specified (PTCL-NOS), but were absent in all other PTCL entities, with the exception of 2 of 10 cases of enteropathy-associated T cell lymphoma. Among PTCL-NOS, a heterogeneous group of lymphoma-comprising cases likely to derive from Th follicular (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(FH)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells similarly to AITL, TET2 mutations were more frequent when PTCL-NOS expressed T(FH) markers and/or had features reminiscent of AITL (58% vs 24%, P = .01). In the AITL and PTCL-NOS subgroups, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TET2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mutations were associated with advanced-stage disease, thrombocytopenia, high International Prognostic Index scores, and a shorter progression-free survival.</div></details><details><summary>TH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/22760778">22760778</a><div class="entities" style="line-height: 2.5"><h3>Recurrent TET2 mutations in peripheral T cell lymphomas correlate with TFH-like features and adverse clinical parameters.</h3></br>Inactivating mutations of the Ten-Eleven Translocation 2 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TET2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) gene were first identified in myeloid malignancies and more recently in peripheral T cell lymphomas (PTCLs). In the present study, we investigated the presence of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TET2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> coding sequence mutations and their clinical relevance in a large cohort of 190 PTCL patients. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TET2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mutations were identified in 40 of 86 (47%) cases of angioimmunoblastic T cell lymphoma (AITL) and in 22 of 58 (38%) cases of peripheral T cell lymphoma, not otherwise specified (PTCL-NOS), but were absent in all other PTCL entities, with the exception of 2 of 10 cases of enteropathy-associated T cell lymphoma. Among PTCL-NOS, a heterogeneous group of lymphoma-comprising cases likely to derive from <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> follicular (T(FH)) cells similarly to AITL, TET2 mutations were more frequent when PTCL-NOS expressed T(FH) markers and/or had features reminiscent of AITL (58% vs 24%, P = .01). In the AITL and PTCL-NOS subgroups, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TET2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mutations were associated with advanced-stage disease, thrombocytopenia, high International Prognostic Index scores, and a shorter progression-free survival.</div></details><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/26275994">26275994</a><div class="entities" style="line-height: 2.5"><h3>Hydrogen Sulfide Promotes Tet1- and Tet2-Mediated Foxp3 Demethylation to Drive Regulatory T Cell Differentiation and Maintain Immune Homeostasis.</h3></br>Regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are essential for maintenance of immune homeostasis. Here we found that hydrogen sulfide (H2S) was required for Foxp3(+) Treg cell differentiation and function and that H2S deficiency led to systemic autoimmune disease. H2S maintained expression of methylcytosine dioxygenases Tet1 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tet2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> by sulfhydrating nuclear transcription factor Y subunit beta (NFYB) to facilitate its binding to Tet1 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tet2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> promoters. Transforming growth factor-β (TGF-β)-activated Smad3 and interleukin-2 (IL-2)-activated Stat5 facilitated Tet1 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tet2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> binding to Foxp3. Tet1 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tet2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> catalyzed conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) in Foxp3 to establish a Treg-cell-specific hypomethylation pattern and stable Foxp3 expression. Consequently, Tet1 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tet2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> deletion led to Foxp3 hypermethylation, impaired Treg cell differentiation and function, and autoimmune disease. Thus, H2S promotes Tet1 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tet2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression, which are recruited to Foxp3 by TGF-β and IL-2 signaling to maintain Foxp3 demethylation and Treg-cell-associated immune homeostasis. </div></details></details></td>
    </tr>
    <tr>
      <th>47</th>
      <td>BCL11B</td>
      <td>3</td>
      <td>TFH:1, TH:1, TH2:1, TREG:1</td>
      <td>0.056777</td>
      <td>ENSG00000127152</td>
      <td><details><summary>Subtypes</summary><details><summary>TFH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28943543">28943543</a><div class="entities" style="line-height: 2.5"><h3>Expression of Master Regulators of T cell, Helper T cell and Follicular Helper T cell Differentiation in Angioimmunoblastic T cell Lymphoma.</h3></br>Objective It has been postulated that the normal counterpart of angioimmunoblastic T cell lymphoma (AITL) is the follicular helper T cell (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TFH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>). Recent immunological studies have identified several transcription factors responsible for T cell differentiation. The master regulators associated with T cell, helper T cell (Th), and TFH differentiation are reportedly <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL11B    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, Th-POK, and BCL6, respectively. We explored the postulated normal counterpart of AITL with respect to the expression of the master regulators of T cell differentiation. Methods We performed an immunohistochemical analysis in 15 AITL patients to determine the expression of the master regulators and several surface markers associated with T cell differentiation. Results <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL11B    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> was detected in 10 patients (67%), and the surface marker of T cells (CD3) was detected in all patients. Only 2 patients (13%) expressed the marker of naïve T cells (CD45RA), but all patients expressed the marker of effector T cells (CD45RO). Nine patients expressed Th-POK (60%), and 7 (47%) expressed a set of surface antigens of Th (CD4-positive and CD8-negative). In addition, BCL6 and the surface markers of TFH (CXCL13, PD-1, and SAP) were detected in 11 (73%), 8 (53%), 14 (93%), and all patients, respectively. Th-POK-positive/BCL6-negative patients showed a significantly shorter overall survival (OS) than the other patients (median OS: 33.0 months vs. 74.0 months, p=0.020; log-rank test). Conclusion Many of the AITL patients analyzed in this study expressed the master regulators of T cell differentiation. The clarification of the diagnostic significance and pathophysiology based on the expression of these master regulators in AITL is expected in the future.</div></details><details><summary>TH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28943543">28943543</a><div class="entities" style="line-height: 2.5"><h3>Expression of Master Regulators of T cell, Helper T cell and Follicular Helper T cell Differentiation in Angioimmunoblastic T cell Lymphoma.</h3></br>Objective It has been postulated that the normal counterpart of angioimmunoblastic T cell lymphoma (AITL) is the follicular helper T cell (TFH). Recent immunological studies have identified several transcription factors responsible for T cell differentiation. The master regulators associated with T cell, helper T cell (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>), and TFH differentiation are reportedly <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL11B    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, Th-POK, and BCL6, respectively. We explored the postulated normal counterpart of AITL with respect to the expression of the master regulators of T cell differentiation. Methods We performed an immunohistochemical analysis in 15 AITL patients to determine the expression of the master regulators and several surface markers associated with T cell differentiation. Results <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BCL11B    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> was detected in 10 patients (67%), and the surface marker of T cells (CD3) was detected in all patients. Only 2 patients (13%) expressed the marker of naïve T cells (CD45RA), but all patients expressed the marker of effector T cells (CD45RO). Nine patients expressed Th-POK (60%), and 7 (47%) expressed a set of surface antigens of Th (CD4-positive and CD8-negative). In addition, BCL6 and the surface markers of TFH (CXCL13, PD-1, and SAP) were detected in 11 (73%), 8 (53%), 14 (93%), and all patients, respectively. Th-POK-positive/BCL6-negative patients showed a significantly shorter overall survival (OS) than the other patients (median OS: 33.0 months vs. 74.0 months, p=0.020; log-rank test). Conclusion Many of the AITL patients analyzed in this study expressed the master regulators of T cell differentiation. The clarification of the diagnostic significance and pathophysiology based on the expression of these master regulators in AITL is expected in the future.</div></details><details><summary>TH2</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/29700302">29700302</a><div class="entities" style="line-height: 2.5"><h3><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Bcl11b    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is essential for licensing Th2 differentiation during helminth infection and allergic asthma.</h3></br>During helminth infection and allergic asthma, naive CD4+  T cells differentiate into cytokine-producing Type-2 helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells that resolve the infection or induce asthma-associated pathology. Mechanisms regulating the Th2 differentiation in vivo remain poorly understood. Here we report that mice lacking <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Bcl11b    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in mature T cells have a diminished capacity to mount Th2 responses during helminth infection and allergic asthma, showing reduced Th2 cytokines and Gata3, and elevated Runx3. We provide evidence that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Bcl11b    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is required to maintain chromatin accessibility at Th2-cytokine promoters and locus-control regions, and binds the Il4 HS IV silencer, reducing its accessibility. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Bcl11b    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> also binds Gata3-intronic and downstream-noncoding sites, sustaining the Gata3 expression. In addition, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Bcl11b    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> binds and deactivates upstream enhancers at Runx3 locus, restricting the Runx3 expression and its availability to act at the Il4 HS IV silencer. Thus, our results establish novel roles for <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Bcl11b    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in the regulatory loop that licenses Th2 program in vivo.</div></details><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/21875956">21875956</a><div class="entities" style="line-height: 2.5"><h3>Critical role of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Bcl11b    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in suppressor function of T regulatory cells and prevention of inflammatory bowel disease.</h3></br>Dysregulated CD4(+) T cell responses and alterations in T regulatory cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells) play a critical role in autoimmune diseases, including inflammatory bowel disease (IBD). The current study demonstrates that removal of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Bcl11b    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> at the double-positive stage of T cell development or only in <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells causes IBD because of proinflammatory cytokine-producing CD4(+) T cells infiltrating the colon. Provision of WT T(reg) cells prevented IBD, demonstrating that alterations in <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells are responsible for the disease. Furthermore, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Bcl11b    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>-deficient T(reg) cells had reduced suppressor activity with altered gene expression profiles, including reduced expression of the genes encoding Foxp3 and IL-10, and up-regulation of genes encoding proinflammatory cytokines. Additionally, the absence of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Bcl11b    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> altered the induction of Foxp3 expression and reduced the generation of induced <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells (iT(reg) cells) after Tgf-β treatment of conventional CD4(+) T cells. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Bcl11b    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> bound to Foxp3 and IL-10 promoters, as well as to critical conserved noncoding sequences within the Foxp3 and IL-10 loci, and mutating the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Bcl11b    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> binding site in the Foxp3 promoter reduced expression of a luciferase reporter gene. These experiments demonstrate that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Bcl11b    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is indispensable for T(reg) suppressor function and for maintenance of optimal Foxp3 and IL-10 gene expression, as well as for the induction of Foxp3 expression in conventional CD4(+) T cells in response to Tgf-β and generation of iT(reg) cells.</div></details></details></td>
    </tr>
    <tr>
      <th>48</th>
      <td>CIC</td>
      <td>1</td>
      <td>TH:1</td>
      <td>0.054383</td>
      <td>ENSG00000079432</td>
      <td><details><summary>Subtypes</summary><details><summary>TH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/6242007">6242007</a><div class="entities" style="line-height: 2.5"><h3>Immune derangements in asymptomatic male homosexuals in Israel: a pre-AIDS condition?</h3></br>We have described several immune derangements found in a clinically asymptomatic group of 117 male homosexuals (MHS) in Israel. These consisted of a marked decrease in <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and TS cells, decreased NK and allogeneic response, and increased levels of acid labile alpha-interferon and circulating immune complexes (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    CIC    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>). Most of these alterations were found in approximately 40% of the subjects, with no simple correlation between them. Since Israel is a low incidence area for AIDS and related syndromes, it is suggested that this situation reflects a common situation among asymptomatic MHS in general, although the reasons for these impairments are not clear. This situation may therefore explain susceptibility of the male homosexual for developing AIDS, given the appropriate circumstances, environment, and genetic background.</div></details></details></td>
    </tr>
    <tr>
      <th>49</th>
      <td>ONECUT2</td>
      <td>1</td>
      <td>TH:1</td>
      <td>0.054383</td>
      <td>ENSG00000119547</td>
      <td><details><summary>Subtypes</summary><details><summary>TH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/18418398">18418398</a><div class="entities" style="line-height: 2.5"><h3>Onecut transcription factor OC2 is a direct target of T-bet in type-1 T-helper cells.</h3></br>T-box transcription factor, T-bet, has a central role in the differentiation of T-helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) progenitor cells to Th1 or Th2 effector cells, partly by regulating the expression of genes such as interferon-gamma (IFN-gamma). However, the direct target genes, especially those mediating the transcriptional network initiated by T-bet, are not yet fully understood. By combining chromatin immunoprecipitation from Th1 cells with human cytosine-phosphate-guanine-island array analysis, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Onecut 2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (OC2), which encodes a member of the ONECUT class of transcriptional activators, was identified as a direct target gene of T-bet. OC2 is expressed in Th1 but not Th2 cells and reporter assays showed that T-bet transactivates OC2 transcription through putative T-bet half-sites locating -451 to -347 of OC2 promoter region. Moreover, we found that OC2 binds and transactivates human T-bet promoter. These results suggest that not only cell-extrinsic regulation via the IFN-gamma/STAT1 pathway, but also cell-intrinsic transcriptional positive feedback loop between T-bet and OC2 could be involved in Th1 development.</div></details></details></td>
    </tr>
    <tr>
      <th>50</th>
      <td>FOXP1</td>
      <td>2</td>
      <td>TH:1, TREG:1</td>
      <td>0.054383</td>
      <td>ENSG00000114861</td>
      <td><details><summary>Subtypes</summary><details><summary>TH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/29018172">29018172</a><div class="entities" style="line-height: 2.5"><h3>Foxo1 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> play opposing roles in regulating the differentiation and antitumor activity of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> 9 cells programmed by IL-7.</h3></br>Tumor-specif<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    ic CD    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>4+  T helper 9 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> 9) cells, so-called becaus<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    e of     <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>their production of the cytokine interleukin-9 (IL-9), are a powerful effector T cell subset for cancer immunotherapy. We found that pretreatment of naïve CD4+  T cells with IL-7 further enhanced their differentiation into <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> 9 cells and augmented their antitumor activity. IL-7 markedly increased the abundance of the histone acetyltransferase p300 by activating the STAT5 and PI3K-AKT-mTOR signaling pathways and promoting the acetylation of histones at the <i>Il9</i> promoter. As a result, the transcriptional regulator Foxo1 was dephosphorylated and translocated to the nucleus, bound to the <i>Il9</i> promoter, and induced the production of IL-9 protein. In contrast, Foxp1, which bound to the <i>Il9</i> promoter in naïve CD4+  T cells and inhibited <i>Il9</i> expression, was outcompeted for binding to the <i>Il9</i> promoter by Foxo1 and translocated to the cytoplasm. Furthermore, forced expression of Foxo1 or a deficiency in <i>Foxp1</i> in CD4+  T cells markedly increased the production of IL-9, whereas a deficiency in <i>Foxo1</i> inhibited the ability of IL-7 to enhance the differentiation and antitumor activity of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> 9 cells. Thus, we identified the roles of Foxo1 as a positive regulator and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> as a negative regulator of TH 9 cell differentiation and antitumor activity, which may provide potential targets for cancer immunotherapy.</div></details><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/25701076">25701076</a><div class="entities" style="line-height: 2.5"><h3>Systems biologic analysis of T regulatory cells genetic pathways in murine primary biliary cirrhosis.</h3></br>CD4(+)Foxp3(+) regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) play a non-redundant role in control of excessive immune responses, and defects in Tregs have been shown both in patients and murine models of primary biliary cirrhosis (PBC), a progressive autoimmune biliary disease. Herein, we took advantage of a murine model of PBC, the dominant negative transforming growth factor β receptor II (dnTGFβRII) mice, to assess Treg genetic defects and their functional effects in PBC. By using high-resolution microarrays with verification by PCR and protein expression, we found profound and wide-ranging differences between dnTGFβRII and normal, wild type Tregs. Critical transcription factors were down-regulated including Eos, Ahr, Klf2, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxp1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in dnTGFβRII Tregs. Functionally, dnTGFβRII Tregs expressed an activated, pro-inflammatory phenotype with upregulation of Ccl5, Granzyme B and IFN-γ. Genetic pathway analysis suggested that the primary effect of loss of TGFβ pathway signaling was to down regulate immune regulatory processes, with a secondary upregulation of inflammatory processes. These findings provide new insights into T regulatory genetic defects; aberrations of the identified genes or genetic pathways should be investigated in human PBC Tregs. This approach which takes advantage of biologic pathway analysis illustrates the ability to identify genes/pathways that are affected both independently and dependent on abnormalities in TGFβ signaling. Such approaches will become increasingly useful in human autoimmunity. </div></details></details></td>
    </tr>
    <tr>
      <th>51</th>
      <td>FOS</td>
      <td>1</td>
      <td>TH:1</td>
      <td>0.054383</td>
      <td>ENSG00000170345</td>
      <td><details><summary>Subtypes</summary><details><summary>TH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/22474330">22474330</a><div class="entities" style="line-height: 2.5"><h3>Stable IL-2 decision making by endogenous c-Fos amounts in peripheral memory T-helper cells.</h3></br>The cytokine IL-2 performs opposite functions supporting efficient immune responses and playing a key role in peripheral tolerance. Therefore, precise fine-tuning of IL-2 expression is crucial for adjusting the immune response. Combining transcription factor analysis at the single cell and the single nucleus level using flow cytometry with statistical analysis, we showed that physiological differences in the expression levels of c-Fos and NFATc2, but not of c-Jun and NF-κBp65, are limiting for the decision whether IL-2 is expressed in a strongly activated human memory T-helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cell. Variation in the expression of c-Fos leads to substantial diversity of IL-2 expression in ∼40% of the memory Th cells. The remaining cells exhibit an equally high c-<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Fos    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression level, thereby ensuring robustness in IL-2 response within the population. These findings reveal how memory Th cells benefit from regulated variation in transcription factor expression to achieve a certain stability and variability of cytokine expression in a controlled manner.</div></details></details></td>
    </tr>
    <tr>
      <th>52</th>
      <td>BACH2</td>
      <td>2</td>
      <td>TREG:2</td>
      <td>0.053729</td>
      <td>ENSG00000112182</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/30089837">30089837</a><div class="entities" style="line-height: 2.5"><h3>SENP3 maintains the stability and function of regulatory T cells via <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BACH2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> deSUMOylation.</h3></br>Regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are essential for maintaining immune homeostasis and tolerance, but the mechanisms regulating the stability and function of Treg cells have not been fully elucidated. Here we show SUMO-specific protease 3 (SENP3) is a pivotal regulator of Treg cells that functions by controlling the SUMOylation and nuclear localization of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BACH2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. Treg cell-specific deletion of Senp3 results in T cell activation, autoimmune symptoms and enhanced antitumor T cell responses. SENP3-mediated <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BACH2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> deSUMOylation prevents the nuclear export of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BACH2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, thereby repressing the genes associated with CD4+  T effector cell differentiation and stabilizing Treg cell-specific gene signatures. Notably, SENP3 accumulation triggered by reactive oxygen species (ROS) is involved in Treg cell-mediated tumor immunosuppression. Our results not only establish the role of SENP3 in the maintenance of Treg cell stability and function via <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BACH2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> deSUMOylation but also clarify the function of SENP3 in the regulation of ROS-induced immune tolerance.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/23728300">23728300</a><div class="entities" style="line-height: 2.5"><h3><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BACH2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> represses effector programs to stabilize T(reg)-mediated immune homeostasis.</h3></br>Through their functional diversification, distinct lineages of CD4(+) T cells can act to either drive or constrain immune-mediated pathology. Transcription factors are critical in the generation of cellular diversity, and negative regulators antagonistic to alternate fates often act in conjunction with positive regulators to stabilize lineage commitment. Genetic polymorphisms within a single locus encoding the transcription factor <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BACH2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> are associated with numerous autoimmune and allergic diseases including asthma, Crohn's disease, coeliac disease, vitiligo, multiple sclerosis and type 1 diabetes. Although these associations point to a shared mechanism underlying susceptibility to diverse immune-mediated diseases, a function for <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BACH2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in the maintenance of immune homeostasis has not been established. Here, by studying mice in which the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Bach2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> gene is disrupted, we define <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BACH2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> as a broad regulator of immune activation that stabilizes immunoregulatory capacity while repressing the differentiation programs of multiple effector lineages in CD4(+) T cells. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BACH2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> was required for efficient formation of regulatory (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells and consequently for suppression of lethal inflammation in a manner that was Treg-cell-dependent. Assessment of the genome-wide function of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BACH2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, however, revealed that it represses genes associated with effector cell differentiation. Consequently, its absence during Treg polarization resulted in inappropriate diversion to effector lineages. In addition, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BACH2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> constrained full effector differentiation within TH1, TH2 and TH17 cell lineages. These findings identify <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    BACH2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> as a key regulator of CD4(+) T cell differentiation that prevents inflammatory disease by controlling the balance between tolerance and immunity. </div></details></details></td>
    </tr>
    <tr>
      <th>53</th>
      <td>FOXA1</td>
      <td>2</td>
      <td>TREG:2</td>
      <td>0.053729</td>
      <td>ENSG00000129514</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/25466634">25466634</a><div class="entities" style="line-height: 2.5"><h3>Divergent effects of type-I interferons on regulatory T cells.</h3></br>Regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) exert a dominant role in the protection of unwanted immune responses and in the resolution of inflammation. To ensure the proper mounting of protective immune responses, Treg should be finely modulated by microenvironmental signals, mostly conveyed by cytokines. Type-I interferons are pleiotropic cytokines, best known for their anti-viral activities but also playing relevant immunostimulatory as well as immunomodulatory functions. The impact of type-I interferons on Treg homeostasis and functions is quite controversial, as some studies indicate that interferons sustain Treg stability and suppression, while other reports describe a null or even negative role for interferons in Treg activities. Interferons may also establish alternative routes of suppression, through the induction of other suppressive populations, such as Tr1 and the recently discovered <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxA1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>+ Treg. Discrepant results about Treg behavior in vivo emerge also from data collected in patients with multiple sclerosis, chronic hepatitis C or cancer undergoing interferon therapy. Concurrent events, such as Treg-extrinsic interferon activities, desensitization to chronic interferon exposure, and changes in microenvironmental signals during the evolution of diseases, may contribute to depict such a complex scenario, in which short-term and long-term effects of interferon exposure may give rise to apparently opposite conclusions. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/24531377">24531377</a><div class="entities" style="line-height: 2.5"><h3><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxA1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS.</h3></br>The defective generation or function of regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells in autoimmune disease contributes to chronic inflammation and tissue injury. We report the identification of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxA1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> as a transcription factor in T cells that, after ectopic expression, confers suppressive properties in a newly identified Treg cell population, herein called <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxA1(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> Treg cells. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxA1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> bound to the Pdl1 promoter, inducing programmed cell death ligand 1 (Pd-l1) expression, which was essential for the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxA1(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> Treg cells to kill activated T cells. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxA1(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> Treg cells develop primarily in the central nervous system in response to autoimmune inflammation, have a distinct transcriptional profile and are <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    CD4(+)FoxA1(+)CD47(+)CD69(+)PD-    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>L1(hi)FoxP3(-). Adoptive transfer of stable <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxA1(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> Treg cells inhibited experimental autoimmune encephalomyelitis in a FoxA1-and Pd-l1-dependent manner. The development of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxA1(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> Treg cells is induced by interferon-β (IFN-β) and requires T cell-intrinsic IFN-α/β receptor (Ifnar) signaling, as the frequency of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxA1(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> Treg cells was reduced in Ifnb(-/-) and Ifnar(-/-) mice. In individuals with relapsing-remitting multiple sclerosis, clinical response to treatment with IFN-β was associated with an increased frequency of suppressive <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxA1(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> Treg cells in the blood. These findings suggest that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxA1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is a lineage-specification factor that is induced by IFN-β and supports the differentiation and suppressive function of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FoxA1(+)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> Treg cells. </div></details></details></td>
    </tr>
    <tr>
      <th>54</th>
      <td>DR1</td>
      <td>2</td>
      <td>TH1:1, TH2:1, TREG:1</td>
      <td>0.053530</td>
      <td>ENSG00000117505</td>
      <td><details><summary>Subtypes</summary><details><summary>TH1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/12165515">12165515</a><div class="entities" style="line-height: 2.5"><h3>Early events of TCR signaling are distinct in human <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells.</h3></br>To study the requirements for activation of human <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells, soluble peptide/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    DR1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> complexes were prepared from naturally expressed <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    DR1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> protein. When immobilized, this material induced T cell activation, as revealed by CD25 up-regulation. Unexpectedly, Th2 cells required a higher density of peptide/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    DR1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> complexes than Th1 cells to initiate CD25 up-regulation. Similar findings were obtained with immobilized or soluble and cross-linked anti-CD3 mAb. In contrast, peptide/DR1 complexes displayed on the surface of nonprofessional APC similarly induced CD25 up-regulation in <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells. Signaling events distinguishing human <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells following TCR engagement by anti-CD3 mAb were then studied. It was observed that upon TCR triggering, the overall tyrosine phosphorylation profiles were fainter in Th2 than in Th1 clones. Similar results were obtained with Th1- and Th2-polarized polyclonal lines. Varying the dose of anti-CD3 mAb, the kinetics of activation, and coengagement of CD3 and CD28 failed to increase tyrosine phosphorylation in Th2 cells to levels reached in Th1 cells. In contrast, treatment with the tyrosine phosphatase inhibitor phenylarsine oxide resulted in similar tyrosine phosphorylation levels in Th2 and Th1 cells. These findings indicated that Th2 cells had an intrinsically lower TCR-induced tyrosine phosphorylation capacity than Th1 cells, which might be controlled by Th1- and Th2-specific phosphatase profiles. Finally, a weaker association was found between ZAP-70 and CD3zeta in Th2 than in Th1 cells after TCR engagement. Taken together, these results constituted evidence that early events in the TCR signaling cascades are distinct in human <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells.</div></details><details><summary>TH2</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/12165515">12165515</a><div class="entities" style="line-height: 2.5"><h3>Early events of TCR signaling are distinct in human Th1 and Th2 cells.</h3></br>To study the requirements for activation of human Th1 and Th2 cells, soluble peptide/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    DR1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> complexes were prepared from naturally expressed <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    DR1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> protein. When immobilized, this material induced T cell activation, as revealed by CD25 up-regulation. Unexpectedly, Th2 cells required a higher density of peptide/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    DR1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> complexes than Th1 cells to initiate CD25 up-regulation. Similar findings were obtained with immobilized or soluble and cross-linked anti-CD3 mAb. In contrast, peptide/DR1 complexes displayed on the surface of nonprofessional APC similarly induced CD25 up-regulation in Th1 and Th2 cells. Signaling events distinguishing human Th1 and Th2 cells following TCR engagement by anti-CD3 mAb were then studied. It was observed that upon TCR triggering, the overall tyrosine phosphorylation profiles were fainter in Th2 than in Th1 clones. Similar results were obtained with Th1- and Th2-polarized polyclonal lines. Varying the dose of anti-CD3 mAb, the kinetics of activation, and coengagement of CD3 and CD28 failed to increase tyrosine phosphorylation in Th2 cells to levels reached in Th1 cells. In contrast, treatment with the tyrosine phosphatase inhibitor phenylarsine oxide resulted in similar tyrosine phosphorylation levels in <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th1 cells. These findings indicated that Th2 cells had an intrinsically lower TCR-induced tyrosine phosphorylation capacity than Th1 cells, which might be controlled by Th1- and Th2-specific phosphatase profiles. Finally, a weaker association was found between ZAP-70 and CD3zeta in Th2 than in Th1 cells after TCR engagement. Taken together, these results constituted evidence that early events in the TCR signaling cascades are distinct in human Th1 and Th2 cells.</div></details><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28467828">28467828</a><div class="entities" style="line-height: 2.5"><h3>Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells.</h3></br>Susceptibility and<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">     pr    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>otection against human autoimmune diseases, including type I diabetes, multiple sclerosis, and Goodpasture disease, is associated with particular human leukocyte antigen (HLA) alleles. However, the mechanisms underpinning such HLA-mediated effects on self-tolerance remain unclear. Here we investigate the molecular mechanism of Goodpasture disease, an HLA-linked autoimmune renal disorder characterized by an immunodominant CD4+  T cell self-epitope derived from the α3 chain of type IV collagen (α3135-145 ). While HLA-DR15 confers a markedly increased disease risk, the protective HLA-DR1 allele is dominantly protective in trans with HLA-DR15 (ref. 2). We show that autoreactive α3135-145 -specific T cells expand in patients with Goodpasture disease and, in α3135-145 -immunized HLA-DR15 transgenic mice, α3135-145 -specific T cells infiltrate the kidney and mice develop Goodpasture disease. HLA-DR15 and HLA-DR1 exhibit distinct peptide repertoires and binding preferences and present the α3135-145  epitope in different binding registers. HLA-DR15-α3135-145  tetramer+  T cells in HLA-DR15 transgenic mice exhibit a conventional T cell phenotype (Tconv ) that secretes pro-inflammatory cytokines. In contrast, HLA-DR1-α3135-145  tetramer+  T cells in HLA-DR1 and HLA-DR15/DR1 transgenic mice are predominantly CD4+ Foxp3+  re<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    gul    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>atory T cells <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    (Tr    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark><mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>  cells) expressing tolerogenic cytokines. HLA-DR1-induced <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>  cells confer resistance to disease in HLA-DR15/DR1 transgenic mice. HLA-DR15+  and HLA-DR1+  healthy human donors dis<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    pla    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>y altered α3135-145 -specific T cell antigen receptor usage, HLA-DR15-α3135-145  tetramer+  Foxp3-  Tconv  and HLA-DR1-α3135-145  tetramer+  Foxp3+ CD25hi CD127lo  Treg  dominant phenotypes. Moreover, patients with Goodpasture disease display a clonally expanded α3135-145 -specific CD4+  T cell repertoire. Accordingly, we provide a mechanistic basis for the dominantly protective effect of HLA in autoimmune disease, whereby HLA polymorphism shapes the relative abundance of self-epitope specific <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>  cells that leads to protection or causation of autoimmunity.</div></details></details></td>
    </tr>
    <tr>
      <th>55</th>
      <td>HES1</td>
      <td>2</td>
      <td>TH17:2, TH1:1, TH2:1, TREG:1</td>
      <td>0.051830</td>
      <td>ENSG00000114315</td>
      <td><details><summary>Subtypes</summary><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/25485537">25485537</a><div class="entities" style="line-height: 2.5"><h3>Inactivation of Notch signaling reverses the Th17/Treg imbalance in cells from patients with immune thrombocytopenia.</h3></br>T helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells and regulatory T (Treg) cells, along with Th1 and Th2 cells, may contribute to the development of immune thrombocytopenia (ITP). The imbalance of Th17/Treg toward Th17 cells has been shown to play a pivotal role in the peripheral immune response. Notch signaling has been implicated in peripheral T cell activation and effector cell differentiation. However, the role of Th17/Treg in the pathogenesis of ITP and the effect of Notch signaling on Th17/Treg imbalances remain largely elusive in ITP. In vitro, we treated peripheral blood mononuclear cells (PBMCs) from ITP and healthy controls with γ-secretase inhibitor (DAPT). Th17 cells and Treg cells were measured by flow cytometry and IL-17, IL-21, and IL-10 secretion by enzyme immunoassay technique. The mRNA expression of Ntoch1, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Hes1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, Hey1, RORγt, and Foxp3 was investigated by RT-PCR. Cell proliferation and apoptosis were determined by the Cell Counting Kit-8 and apoptosis detection kit. We demonstrated that DAPT was effective in inhibiting mRNA expression of Notch signaling molecules. In untreated cultured PBMCs from ITP patients, we observed elevated Th17 cell and IL-21 levels and RORγt mRNA expression, decreased Treg cells and Foxp3 mRNA expression, and an increased ratio of Th17/Treg and RORγt/Foxp3. After inactivating Notch signal by DAPT, Th17 cells and Th17/Treg ratio were dose dependently decreased and accompanied by the reduction of IL-17 in culture supernatants and RORγt mRNA expression in ITP patients. However, no significant difference was found for Treg cells and Foxp3 mRNA expression, RORγt/Foxp3 ratio, and IL-21 and IL-10 levels after DAPT treatment in ITP patients. We also present evidence that the effect of DAPT inhibition on the Th17 cell response was associated with downregulation of RORγt and IL-17 transcription using human in vitro polarization. In conclusion, our findings highlight the importance of Notch signaling in Th17/Treg imbalances in ITP. Inactivation of Notch signaling might be a potential immunoregulatory strategy in ITP patients. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27852366">27852366</a><div class="entities" style="line-height: 2.5"><h3>[Effects and mechanisms of Notch signaling pathway on immune imbalance in chronic obstructive pulmonary disease].</h3></br><b>Objecti<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    ve:<    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>/b> To explore the r<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    ole     <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>of Notch signaling pathway on immune imbalance in chronic obstructive pulmonary disease (COPD). <b>Methods:</b> Thirty BA<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    LB/c    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mice were randomly assigned into the healthy control group, COPD group, and COPD Gamma secretase inhibitors (GSI) group. Cigarette smoke exposure was used to establish the COPD model. T cells were enriched by filtering through nylon wool columns. The proportion of spleen-derived T lymphocyte subsets was detected by flow cytometry. Real-time quantitative polymerase chain reaction (RT-PCR) and Western blot (WB) were used to detect the expression of splenic T cells' Notch1 and its downstream <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Hes1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mRNA and protein respectively. <b>Results:</b> The percentage of Th1, <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Treg cells in CD4 <sup>＋</sup>T cells of COPD mice (13.20±0.95, 10.22±0.45, 0.41±0.09)% were significantly increased compared with the healthy control group (8.07±0.44, 5.98±0.26, 0.26±0.05)%(all <i>P</i><0.01). The proportion of Th1 and Th17 cells in COPD GSI group mice (9.48 ± 0.66, 7.70 ±0.39)% were significantly reduced compared with COPD group (all <i>P</i><0.01). Ratio of Th1/Th2 in COPD group (18.70±4.12) was significantly increased compared with the healthy control group (12.63±1.91) (<i>P</i><0.01), the percentage of Th17 and Treg in CD4 <sup>＋</sup> T cell increased 71% and 58% respectively. GSI decreased the ratios of Th1/Th2 and Th17/Treg (all <i>P</i><0.01). Notch1 receptor and its downstream Hes1 mRNA expression (5.15±0.77, 1.92±0.32) and protein expression (0.85±0.04, 0.16±0.02) of COPD mice were significantly increased compared with the healthy group respectively [(1.00 ± 0.00, 1.00 ± 0.00) and (0.17±0.01, 0.09±0.01)] (all <i>P</i><0.01). GSI significantly inhibited the expression of mRNA and protein in Notch1 and its downstream Hes1 (all <i>P</i><0.01). Notch1 and Hes1 mRNA and protein expressions were correlated positively with Th1 and Th17 cells and negatively correlated with Th2 and Treg cells in COPD group(all <i>P</i><0.05). <b>Conclusion:</b> In COPD mice, there was T lymphocyte subsets imbalance, such as the increased of Th1, Th17 proinflammatory cells, Notch1 and its downstream Hes1 mRNA and protein levels were increased, and was associated with T lymphocyte subsets imbalance. GSI could partially inhibit Notch1, Hes1 expression and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1     <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>and Th17 cells, and thus Notch signaling pathway was involved in the immune disorder of COPD mice.</div></details><details><summary>TH1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/25485537">25485537</a><div class="entities" style="line-height: 2.5"><h3>Inactivation of Notch signaling reverses the Th17/Treg imbalance in cells from patients with immune thrombocytopenia.</h3></br>T helper 17 (Th17) cells and regulatory T (Treg) cells, along with <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells, may contribute to the development of immune thrombocytopenia (ITP). The imbalance of Th17/Treg toward Th17 cells has been shown to play a pivotal role in the peripheral immune response. Notch signaling has been implicated in peripheral T cell activation and effector cell differentiation. However, the role of Th17/Treg in the pathogenesis of ITP and the effect of Notch signaling on Th17/Treg imbalances remain largely elusive in ITP. In vitro, we treated peripheral blood mononuclear cells (PBMCs) from ITP and healthy controls with γ-secretase inhibitor (DAPT). Th17 cells and Treg cells were measured by flow cytometry and IL-17, IL-21, and IL-10 secretion by enzyme immunoassay technique. The mRNA expression of Ntoch1, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Hes1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, Hey1, RORγt, and Foxp3 was investigated by RT-PCR. Cell proliferation and apoptosis were determined by the Cell Counting Kit-8 and apoptosis detection kit. We demonstrated that DAPT was effective in inhibiting mRNA expression of Notch signaling molecules. In untreated cultured PBMCs from ITP patients, we observed elevated Th17 cell and IL-21 levels and RORγt mRNA expression, decreased Treg cells and Foxp3 mRNA expression, and an increased ratio of Th17/Treg and RORγt/Foxp3. After inactivating Notch signal by DAPT, Th17 cells and Th17/Treg ratio were dose dependently decreased and accompanied by the reduction of IL-17 in culture supernatants and RORγt mRNA expression in ITP patients. However, no significant difference was found for Treg cells and Foxp3 mRNA expression, RORγt/Foxp3 ratio, and IL-21 and IL-10 levels after DAPT treatment in ITP patients. We also present evidence that the effect of DAPT inhibition on the Th17 cell response was associated with downregulation of RORγt and IL-17 transcription using human in vitro polarization. In conclusion, our findings highlight the importance of Notch signaling in Th17/Treg imbalances in ITP. Inactivation of Notch signaling might be a potential immunoregulatory strategy in ITP patients. </div></details><details><summary>TH2</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27852366">27852366</a><div class="entities" style="line-height: 2.5"><h3>[Effects and mechanisms of Notch signaling pathway on immune imbalance in chronic obstructive pulmonary disease].</h3></br><b>Objecti<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    ve:<    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>/b> To explore the r<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    ole     <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>of Notch signaling pathway on immune imbalance in chronic obstructive pulmonary disease (COPD). <b>Methods:</b> Thirty BA<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    LB/c    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mice were randomly assigned into the healthy control group, COPD group, and COPD Gamma secretase inhibitors (GSI) group. Cigarette smoke exposure was used to establish the COPD model. T cells were enriched by filtering through nylon wool columns. The proportion of spleen-derived T lymphocyte subsets was detected by flow cytometry. Real-time quantitative polymerase chain reaction (RT-PCR) and Western blot (WB) were used to detect the expression of splenic T cells' Notch1 and its downstream <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Hes1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mRNA and protein respectively. <b>Results:</b> The percentage of Th1, Th17 and Treg cells in CD4 <sup>＋</sup>T cells of COPD mice (13.20±0.95, 10.22±0.45, 0.41±0.09)% were significantly increased compared with the healthy control group (8.07±0.44, 5.98±0.26, 0.26±0.05)%(all <i>P</i><0.01). The proportion of Th1 and Th17 cells in COPD GSI group mice (9.48 ± 0.66, 7.70 ±0.39)% were significantly reduced compared with COPD group (all <i>P</i><0.01). Ratio of Th1/Th2 in COPD group (18.70±4.12) was significantly increased compared with the healthy control group (12.63±1.91) (<i>P</i><0.01), the percentage of Th17 and Treg in CD4 <sup>＋</sup> T cell increased 71% and 58% respectively. GSI decreased the ratios of Th1/Th2 and Th17/Treg (all <i>P</i><0.01). Notch1 receptor and its downstream Hes1 mRNA expression (5.15±0.77, 1.92±0.32) and protein expression (0.85±0.04, 0.16±0.02) of COPD mice were significantly increased compared with the healthy group respectively [(1.00 ± 0.00, 1.00 ± 0.00) and (0.17±0.01, 0.09±0.01)] (all <i>P</i><0.01). GSI significantly inhibited the expression of mRNA and protein in Notch1 and its downstream Hes1 (all <i>P</i><0.01). Notch1 and Hes1 mRNA and protein expressions were correlated positively with Th1 and Th17 cells and negatively correlated with <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Treg cells in COPD group(all <i>P</i><0.05). <b>Conclusion:</b> In COPD mice, there was T lymphocyte subsets imbalance, such as the increased of Th1, Th17 proinflammatory cells, Notch1 and its downstream Hes1 mRNA and protein levels were increased, and was associated with T lymphocyte subsets imbalance. GSI could partially inhibit Notch1, Hes1 expression and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1     <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>and Th17 cells, and thus Notch signaling pathway was involved in the immune disorder of COPD mice.</div></details><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/25485537">25485537</a><div class="entities" style="line-height: 2.5"><h3>Inactivation of Notch signaling reverses the Th17/Treg imbalance in cells from patients with immune thrombocytopenia.</h3></br>T helper 17 (Th17) cells and regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, along with Th1 and Th2 cells, may contribute to the development of immune thrombocytopenia (ITP). The imbalance of Th17/Treg toward Th17 cells has been shown to play a pivotal role in the peripheral immune response. Notch signaling has been implicated in peripheral T cell activation and effector cell differentiation. However, the role of Th17/Treg in the pathogenesis of ITP and the effect of Notch signaling on Th17/Treg imbalances remain largely elusive in ITP. In vitro, we treated peripheral blood mononuclear cells (PBMCs) from ITP and healthy controls with γ-secretase inhibitor (DAPT). Th17 cells and Treg cells were measured by flow cytometry and IL-17, IL-21, and IL-10 secretion by enzyme immunoassay technique. The mRNA expression of Ntoch1, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Hes1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, Hey1, RORγt, and Foxp3 was investigated by RT-PCR. Cell proliferation and apoptosis were determined by the Cell Counting Kit-8 and apoptosis detection kit. We demonstrated that DAPT was effective in inhibiting mRNA expression of Notch signaling molecules. In untreated cultured PBMCs from ITP patients, we observed elevated Th17 cell and IL-21 levels and RORγt mRNA expression, decreased Treg cells and Foxp3 mRNA expression, and an increased ratio of Th17/Treg and RORγt/Foxp3. After inactivating Notch signal by DAPT, Th17 cells and Th17/Treg ratio were dose dependently decreased and accompanied by the reduction of IL-17 in culture supernatants and RORγt mRNA expression in ITP patients. However, no significant difference was found for Treg cells and Foxp3 mRNA expression, RORγt/Foxp3 ratio, and IL-21 and IL-10 levels after DAPT treatment in ITP patients. We also present evidence that the effect of DAPT inhibition on the Th17 cell response was associated with downregulation of RORγt and IL-17 transcription using human in vitro polarization. In conclusion, our findings highlight the importance of Notch signaling in Th17/Treg imbalances in ITP. Inactivation of Notch signaling might be a potential immunoregulatory strategy in ITP patients. </div></details></details></td>
    </tr>
    <tr>
      <th>56</th>
      <td>ETS1</td>
      <td>2</td>
      <td>TH17:1, TREG:1</td>
      <td>0.048243</td>
      <td>ENSG00000134954</td>
      <td><details><summary>Subtypes</summary><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/21296190">21296190</a><div class="entities" style="line-height: 2.5"><h3>The dual nature of Ets-1: focus to the pathogenesis of systemic lupus erythematosus.</h3></br>E26 transformation-specific-1 (Ets-1) belongs to the Ets family of transcription factors which share a common 85-amino-acid DNA-binding domain. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ets-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is essential to regulation of the immune system including immune cell proliferation and differentiation. Past data demonstrated <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ets-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> play a role in negative regulation of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells and B cells differentiation. Recently, association of genetic variation in <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ets-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> with susceptibility to systemic lupus erythematosus (SLE) have been independently identified by two Genome-wide association studies (GWAS), and decreased Ets-1mRNA level in peripheral blood mononuclear cells (PBMCs) of SLE patients has been reported. All these findings suggest that the transcription factor is broadly linked to the pathogenesis of this disease. However, aberrant control of other immune cells and effector molecules illuminated the complexities of Ets-1 biology. In this review article, we will focus on the dual nature of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ets-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and discuss its regulatory capability. Hopefully the information obtained will lead to a better understanding of the pathogenesis and development of novel therapeutic strategies for SLE.</div></details><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/20427269">20427269</a><div class="entities" style="line-height: 2.5"><h3>Valproate treatment of human cord blood CD4-positive effector T cells confers on them the molecular profile (microRNA signature and FOXP3 expression) of natural regulatory CD4-positive cells through inhibition of histone deacetylase.</h3></br>Regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) play a key role in immune system homeostasis and tolerance to antigens, thereby preventing autoimmunity, and may be partly responsible for the lack of an appropriate immune response against tumor cells. Although not sufficient, a high expression of forkhead box P3 (FOXP3) is necessary for their suppressive function. Recent reports have shown that histones deacetylase inhibitors increased FOXP3 expression in T cells. We therefore decided to investigate in non-Tregs CD4-positive cells, the mechanisms by which an aspecific opening of the chromatin could lead to an increased FOXP3 expression. We focused on binding of potentially activating transcription factors to the promoter region of FOXP3 and on modifications in the five miRs constituting the Tregs signature. Valproate treatment induced binding of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ets-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and Ets-2 to the FOXP3 promoter and acted positively on its expression, by increasing the acetylation of histone H4 lysines. Valproate treatment also induced the acquisition of the miRs Tregs signature. To elucidate whether the changes in the miRs expression could be due to the increased FOXP3 expression, we transduced these non-Tregs with a FOXP3 lentiviral expression vector, and found no changes in miRs expression. Therefore, the modification in their miRs expression profile is not due to an increased expression of FOXP3 but directly results from histones deacetylase inhibition. Rather, the increased FOXP3 expression results from the additive effects of Ets factors binding and the change in expression level of miR-21 and miR-31. We conclude that valproate treatment of human non-Tregs confers on them a molecular profile similar to that of their regulatory counterpart.</div></details></details></td>
    </tr>
    <tr>
      <th>57</th>
      <td>IRF5</td>
      <td>1</td>
      <td>TH17:1</td>
      <td>0.048243</td>
      <td>ENSG00000128604</td>
      <td><details><summary>Subtypes</summary></details></td>
    </tr>
    <tr>
      <th>58</th>
      <td>SETDB1</td>
      <td>1</td>
      <td>TH17:1</td>
      <td>0.048243</td>
      <td>ENSG00000143379</td>
      <td><details><summary>Subtypes</summary><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27317259">27317259</a><div class="entities" style="line-height: 2.5"><h3>The Costimulatory Receptor OX40 Inhibits Interleukin-17 Expression through Activation of Repressive Chromatin Remodeling Pathways.</h3></br>T helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are prominently featured in multiple autoimmune diseases, but the regulatory mechanisms that control Th17 cell responses are poorly defined. Here we found that stimulation of OX40 triggered a robust chromatin remodeling response and produced a "closed" chromatin structure at interleukin-17 (IL-17) locus to inhibit Th17 cell function. OX40 activated the NF-κB family member RelB, and RelB recruited the histone methyltransferases G9a and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    SETDB1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> to the Il17 locus to deposit "repressive" chromatin marks at H3K9 sites, and consequently repressing IL-17 expression. Unlike its transcriptional activities, RelB acted independently of both p52 and p50 in the suppression of IL-17. In an experimental autoimmune encephalomyelitis (EAE) disease model, we found that OX40 stimulation inhibited IL-17 and reduced EAE. Conversely, RelB-deficient CD4(+) T cells showed enhanced IL-17 induction and exacerbated the disease. Our data uncover a mechanism in the control of Th17 cells that might have important clinic implications.</div></details></details></td>
    </tr>
    <tr>
      <th>59</th>
      <td>STAT2</td>
      <td>1</td>
      <td>TH1:1</td>
      <td>0.048205</td>
      <td>ENSG00000170581</td>
      <td><details><summary>Subtypes</summary><details><summary>TH1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/17361203">17361203</a><div class="entities" style="line-height: 2.5"><h3>Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response.</h3></br>Interferon lambda-1 (IFN-lambda1/IL-29) is a member of the Type-III interferon family, which contains three ligands: IFN-lambda1, 2 and 3. These three ligands use the same unique heterodimeric receptor composed of CRF2-12 (IFN-lambda-R1/IL-28Ralpha) and CRF2-4 (IL10-R-beta) chains. Like their close relatives, the Type-I interferons, IFN-lambda1, 2 and 3, promote the phosphorylation of STAT1 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, induce the ISRE3 complex, elevate OAS and MxA expression and exhibit antiviral activity in vitro. Their use of the IL10-R-beta chain and their ability to phosphorylate STAT3, STAT4 and STAT5 suggested that they may also exhibit immunomodulatory activity; their antiviral action led us to hypothesize that this activity might be directed toward the Th1/Th2 system. Here, we have demonstrated that IFN-lambda1 altered the activity of Th cells in three separate experimental systems: (i) mitogen stimulation, (ii) mixed-lymphocyte reaction (MLR) and (iii) stimulation of naive T cells by monocyte-derived dendritic cells (mDC). In Con-A stimulation assays, the inclusion of IFN-lambda1 consistently led to markedly diminished levels of secreted interleukin (IL-13) with occasional coincident, modest elevation of secreted IFN-gamma. IL-13 secretion was 100-fold more sensitive to IFN-lambda1 than was IFN-gamma secretion. These observations were also made in the allogeneic two-way MLR. IFN-lambda1 was able to alter cytokine-mediated Th biasing and when naive T cells were exposed to allogeneic mDC that had been matured in the presence of IFN-lambda1, secreted IL-13 was again markedly and consistently reduced, whereas secreted IFN-gamma was largely unaltered. These functions were independent of IL-10. Our data support a hitherto unsuspected role for IFN-lambda1 in modulating the development of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells, with an apparent emphasis on the diminution of IL-13 secretion.</div></details></details></td>
    </tr>
    <tr>
      <th>60</th>
      <td>FOXO3</td>
      <td>3</td>
      <td>TREG:2, TH1:1</td>
      <td>0.048205</td>
      <td>ENSG00000118689</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/29309928">29309928</a><div class="entities" style="line-height: 2.5"><h3>FOXOs in cancer immunity: Knowns and unknowns.</h3></br>In the tumor microenvironment (TME), cancer cells, stromal cells, and immune cells, along with their extracellular factors, have profound effects on either promoting or repressing anti-cancer immunity. Accumulating evidence has shown the paradoxical intrinsic role of the Forkhead box O (FOXO) family of transcription factors in cancer, which can act as a tumor repressor while also maintaining cancer stem cells. FOXOs also regulate cancer immunity. FOXOs promote antitumor activity through negatively regulating the expression of immunosuppressive proteins, such as programmed death 1 ligand 1 (PD-L1), and vascular endothelial growth factor (VEGF) in tumor cells or stromal cells, which can shape an immunotolerant state in the TME. FOXOs also intrinsically control the anti-tumor immune response as well as the homeostasis and development of immune cells, including T cells, B cells, natural killer (NK) cells, macrophages, and dendritic cells. As a cancer repressor, reviving the activity of Foxo1 forces tumor-infiltrating activated regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> ) cells to egress from tumor tissues. As a promoter of cancer development, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxo3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and Foxo1 negatively regulate cytotoxicity of both CD8+  T cells and NK cells against tumor cells. In this review, we focus on the complex role of FOXOs in regulating cancer immunity due to the various roles that they play in cancer cells, stromal cells, and immune cells. We also speculate on some possible additional roles of FOXOs in cancer immunity based on findings regarding FOXOs in non-cancer settings, such as infectious disease.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/24737144">24737144</a><div class="entities" style="line-height: 2.5"><h3>Highly heterogeneous, activated, and short-lived regulatory T cells during chronic filarial infection.</h3></br>The mechanisms underlying the increase in the numbers of regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells in chronic infection settings remain unclear. Here we have delineated the phenotype and transcriptional profiles of Treg cells from 18 filarial-infected (Fil(+) ) and 19 filarial-uninfected (Fil(-) ) subjects. We found that the frequencies of Foxp3(+) Treg cells expressing CTLA-4, GITR, LAG-3, and IL-10 were significantly higher in Fil(+) subjects compared with that in Fil(-) subjects. Foxp3-expressing Treg-cell populations in Fil(+) subjects were also more heterogeneous and had higher expression of IL-10, CCL-4, IL-29, CTLA-4, and TGF-β than Fil(-) subjects, each of these cytokines having been implicated in immune suppression. Moreover, Foxp3-expressing Treg cells from Fil(+) subjects had markedly upregulated expression of activation-induced apoptotic genes with concomitant downregulation of those involved in cell survival. To determine whether the expression of apoptotic genes was due to Treg-cell activation, we found that the expression of CTLA-4, CDk8, RAD50, TNFRSF1A, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    FOXO3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, and RHOA were significantly upregulated in stimulated cells compared with unstimulated cells. Taken together, our results suggest that in patent filarial infection, the expanded Treg-cell populations are heterogeneous, short-lived, activated, and express higher levels of molecules known to modulate immune responsiveness, suggesting that filarial infection is associated with high Treg-cell turnover. </div></details><details><summary>TH1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27742544">27742544</a><div class="entities" style="line-height: 2.5"><h3><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxo3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> Transcription Factor Drives Pathogenic T Helper 1 Differentiation by Inducing the Expression of Eomes.</h3></br>The transcription factor <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxo3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> plays a crucial role in myeloid cell fun<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    ction    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> but its role in lymphoid cells remains poorly defined. Here, we have shown that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Foxo3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression was increased after T cell receptor engagement and played a specific role in the polarization of CD4+  T cells toward pathogenic T helper 1 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells producing interferon-γ (IFN-γ) and granulocyte monocyte colony stimulating factor (GM-CSF). Consequently, Foxo3-deficient mice exhibited reduced susceptibility to experimental autoimmune encephalomyelitis. At the molecular level, we identified Eomes as a direct target gene for Foxo3 in CD4+  T cells and we have shown that lentiviral-based overexpression of Eomes in Foxo3-deficient CD4+  T cells restored both IFN-γ and GM-CSF production. Thus, the Foxo3-Eomes pathway is central to achieve the complete specialized gene program required for pathogenic Th1 cell differentiation and development of neuroinflammation.</div></details></details></td>
    </tr>
    <tr>
      <th>61</th>
      <td>HLX</td>
      <td>1</td>
      <td>TH1:1</td>
      <td>0.048205</td>
      <td>ENSG00000136630</td>
      <td><details><summary>Subtypes</summary><details><summary>TH1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/12055627">12055627</a><div class="entities" style="line-height: 2.5"><h3>Hlx is induced by and genetically interacts with T-bet to promote heritable T(H)1 gene induction.</h3></br>Type 1 helper T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(H)1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are essential for cellular immunity, but their ontogeny, maturation and durability remain poorly understood. By constructing a dominant-negative form of T-bet, we were able to determine the role played by this lineage-inducing trans-activator in the establishment and maintenance of heritable T(H)1 gene expression. Optimal induction of interferon-gamma (IFN-gamma) expression required genetic interaction between T-bet and its target, the homeoprotein <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Hlx    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. In fully mature T(H)1 cells, reiteration of IFN-gamma expression and stable chromatin remodeling became relatively independent of T-bet activity and coincided with demethylation of DNA. In contrast, some lineage attributes, such as expression of IL-12R beta 2 (interleukin 12 receptor beta 2), required ongoing T-bet activity in mature T(H)1 cells and their progeny. These findings suggest that heritable states of gene expression might be maintained by continued expression of the inducing factor or by a mechanism that confers a stable imprint of the induced state.</div></details></details></td>
    </tr>
    <tr>
      <th>62</th>
      <td>NFIL3</td>
      <td>1</td>
      <td>TH1:1</td>
      <td>0.048205</td>
      <td>ENSG00000165030</td>
      <td><details><summary>Subtypes</summary><details><summary>TH1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/25627813">25627813</a><div class="entities" style="line-height: 2.5"><h3>Glycogen synthase kinase-3 controls IL-10 expression in CD4(+) effector T cell subsets through epigenetic modification of the IL-10 promoter.</h3></br>The serine/threonine kinase glycogen synthase kinase-3 (GSK3) plays an important role in balancing pro- and anti-inflammatory cytokines. We have examined the role of GSK3 in production of IL-10 by subsets of CD4(+) T helper cells. Treatment of naive murine CD4(+) T cells with GSK3 inhibitors did not affect their production of IL-10. However, treatment of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells with GSK3 inhibitors dramatically increased production of IL-10. GSK3 inhibition also led to upregulation of IL-10 among Th1, Th2, and Th17 subsets isolated from human blood. The encephalitogenic potential of GSK3 inhibitor treated murine Th1 cells was significantly reduced in adoptive transfer experiments by an IL-10-dependent mechanism. Analysis of the murine IL-10 promoter in response to inhibition of GSK3 in Th1 cells showed modification to a transcriptionally active state indicated by changes in histone H3 acetylation and methylation. Additionally, GSK3 inhibition increased expression of the transcription factors c-Maf, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Nfil3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, and GATA3, correlating with the increase in IL-10. These findings are important in the context of autoimmune disease since they show that it is possible to reprogram disease-causing cells through GSK3 inhibition. </div></details></details></td>
    </tr>
    <tr>
      <th>63</th>
      <td>STAT5B</td>
      <td>3</td>
      <td>TREG:2, TH:1</td>
      <td>0.047097</td>
      <td>ENSG00000173757</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/19410687">19410687</a><div class="entities" style="line-height: 2.5"><h3>TH17 cells and regulatory T cells in primary immunodeficiency diseases.</h3></br>After activation by unique cytokines, CD4(+) naive T cells differentiate into lineages of helper/effector (T(H)) and regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells that are characterized by distinct developmental pathways and unique biologic functions. The trusted binary system of T(H)1 and T(H)2 has been expanded to include the IL-17-producing T(H)17 cell lineage, which plays a role in immune responses to infectious agents and maintenance of autoimmune diseases. Acting as counterbalance, Treg cells maintain peripheral tolerance and protect the host from autoaggressive lymphocytes. T(H)1 cells produce IFN-gamma and are involved in cell-mediated immunity, T(H)2 cells produce IL-4 and contribute to humoral immunity, T(H)17 cells generate IL-17 and play an important role in immune responses to fungi and extracellular pathogens, and forkhead box protein 3-positive (FOXP3(+)) Treg cells secrete TGF-beta and IL-10 and downregulate effector T cells. Autosomal dominant hyper-IgE syndrome, a rare primary immunodeficiency disorder, is caused by hypomorphic heterozygous mutations of signal transducer and activator of transcription 3 (STAT3), preventing T(H)17 lineage differentiation and increasing susceptibility to Staphylococcus and Candida species infections. Mutations in the FOXP3 gene interfere with Treg cell development and cause immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. Other single-gene defects resulting in reduced Treg cell function include CD25, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    signal transducer and activator of transcription 5b    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, autoimmune regulator, and Wiskott-Aldrich syndrome protein. These observations emphasize the importance of functionally distinct T cell lineages in maintaining a balanced innate and cognate immune system.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/17130555">17130555</a><div class="entities" style="line-height: 2.5"><h3>Upregulation of Foxp3 expression in mouse and human Treg is IL-2/STAT5 dependent: implications for the NOD <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT5B    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mutation in diabetes pathogenesis.</h3></br>Regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>), characterized as CD4(+)/CD25(+hi) T cells, are critical for sustaining and promoting immune tolerance. Treg are highly dependent on IL-2 and IL-2 signaling to maintain their numbers and function and interruption of this pathway promotes autoimmunity. The transcription factor, Foxp3, is also required for Treg function as defective Foxp3 promotes autoimmunity in both mice and humans. We previously reported a point mutation in the DNA-binding domain of the NOD <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT5B    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> gene that limits DNA binding when compared to wild-type STAT5 mice. Based on the presence of five <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT5B    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> consensus sequences in the Foxp3 promotor, we hypothesized a critical linkage between IL-2 signaling/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT5B    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and Foxp3 expression in Treg. Our data show IL-2 activates long-form (LF) STAT5 and sustains Foxp3 expression in Treg. In contrast, CD4(+)/CD25(-) T cells do not active LF STAT5 and do not express Foxp3 under the same conditions. In addition, blocking LF STAT5 activation with a Jak inhibitor (AG-490) significantly reduced Foxp3 expression in Treg. Examination of human Treg using flow cytometry and intracellular staining for Foxp3 expression likewise demonstrates that IL-2 maintains Foxp3 expression through LF STAT5 signaling. These studies reveal a critical link between IL-2 mediated JAK-STAT5 signaling and the maintenance of Foxp3 expression in Treg of mice and humans.</div></details><details><summary>TH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28612433">28612433</a><div class="entities" style="line-height: 2.5"><h3>Musculin inhibits human T-helper 17 cell response to interleukin 2 by controlling <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT5B    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> activity.</h3></br>We recently demonstrated that human T-helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) 17 cells, unlike Th1 cells, do not proliferate in response to T cell receptor stimulation, mainly because of their reduced capacity to produce and respond to IL-2. In this study, we show that their lower responsiveness to IL-2 is due to the selective expression of Musculin (MSC), a member of the basic helix-loop-helix transcription factors. We show that MSC expression in human Th17 cells is retinoic acid orphan receptor (ROR)γt-dependent, and allows the upregulation of PPP2R2B, a regulatory member of the protein phosphatase 2A (PP2A) enzyme. High PPP2R2B levels in human Th17 cells were responsible for the reduced <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT5B    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> Ser-193 phosphorylation upon IL-2 signalling and, therefore, impaired <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    STAT5B    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> DNA binding and transcriptional activity on IL-2 target genes. PP2A, observed in Th17 cells, controls also STAT3, dephosphorylating Ser727, thus increasing its activity that plays a crucial role in Th17 development and/or maintenance. Thus, our findings identify an additional mechanism responsible for the limited expansion of human Th17 cells, and could provide a further explanation for the rarity of these cells in inflamed tissues.</div></details></details></td>
    </tr>
    <tr>
      <th>64</th>
      <td>IRF8</td>
      <td>3</td>
      <td>TH17:1, TH2:1, TREG:1</td>
      <td>0.043707</td>
      <td>ENSG00000140968</td>
      <td><details><summary>Subtypes</summary><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/22983707">22983707</a><div class="entities" style="line-height: 2.5"><h3>A genomic regulatory element that directs assembly and function of immune-specific AP-1-IRF complexes.</h3></br>Interferon regulatory factor 4 (IRF4) and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF8    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> regulate B, T, macrophage, and dendritic cell differentiation. They are recruited to cis-regulatory Ets-IRF composite elements by PU.1 or Spi-B. How these IRFs target genes in most T cells is enigmatic given the absence of specific Ets partners. Chromatin immunoprecipitation sequencing in T helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(H)17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells reveals that IRF4 targets sequences enriched for activating protein 1 (AP-1)-IRF composite elements (AICEs) that are co-bound by BATF, an AP-1 factor required for T(H)17, B, and dendritic cell differentiation. IRF4 and BATF bind cooperatively to structurally divergent AICEs to promote gene activation and T(H)17 differentiation. The AICE motif directs assembly of IRF4 or <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF8    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> with BATF heterodimers and is also used in T(H)2, B, and dendritic cells. This genomic regulatory element and cognate factors appear to have evolved to integrate diverse immunomodulatory signals.</div></details><details><summary>TH2</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/20086239">20086239</a><div class="entities" style="line-height: 2.5"><h3>Distinct signal codes generate dendritic cell functional plasticity.</h3></br>Our adaptive immune system induces distinct responses to different pathogens because of the functional plasticity of dendritic cells (DCs); however, how DCs program unique responses remains unclear. Here, we found that the cytokine thymic stromal lymphopoietin (TSLP) potently transduced a unique T helper type 2 (T(H)2)-inducing compound signal in DCs. Whereas activation of nuclear factor kappaB (predominantly p50) drove DCs to produce OX40L to induce T(H)2 differentiation, the activation of signal transducer and activator of transcription 6 (STAT6) triggered DCs to secrete chemokines necessary for the recruitment of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(H)2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells. In addition, TSLP signaling limited the activation of STAT4 and interferon regulatory factor 8 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF-8    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>), which are essential factors for the production of the T(H)1-polarizing cytokine interleukin-12 (IL-12). By contrast, Toll-like receptor ligands and CD40 ligand did not activate STAT6 in myeloid DCs, but instead increased the abundance of STAT4 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF-8    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> to induce T(H)1 responses through the production of IL-12. Therefore, we propose that the functional plasticity of DCs relies on elaborate signal codes that are generated by different stimuli.</div></details><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28477415">28477415</a><div class="entities" style="line-height: 2.5"><h3>USP4 interacts and positively regulates <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF8    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> function via K48-linked deubiquitination in regulatory T cells.</h3></br>CD4+  CD25+  regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells comprise a unique subset of T cells required for maintaining immune homeostasis. However, the molecular mechanisms associated with the functional variety of Treg cells are not fully delineated. In the present study, we demonstrate that ubiquitin-specific protease (USP)4 physically interacted with interferon regulatory factor 8 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF8    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) function via a K48-linked deubiquitinase, which stabilized <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF8    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> protein levels in Treg cells. Depletion of USP4 promoted the polyubiquitination of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF8    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and the upregulation of type 2 inflammatory cytokine gene expression in Treg cells. Consistently, treatment of Treg cells with USP4 inhibitor facilitated the polyubiquitination of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF8    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. In addition, the deficiency of USP4 alleviated the suppressive function of Treg cells. Taken together, our results suggest that USP4 interacts with and stabilizes <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRF8    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> to promote the suppressive function of Treg cells.</div></details></details></td>
    </tr>
    <tr>
      <th>65</th>
      <td>SMAD3</td>
      <td>7</td>
      <td>TREG:5, TH17:2</td>
      <td>0.041779</td>
      <td>ENSG00000166949</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28598443">28598443</a><div class="entities" style="line-height: 2.5"><h3>Ash1l and lnc-<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Smad3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> coordinate <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Smad3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> locus accessibility to modulate iTreg polarization and T cell autoimmunity.</h3></br>Regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are important for the maintenance of immune homoeostasis and prevention of autoimmune diseases. Epigenetic modifications have been reported to modulate autoimmunity by altering Treg cell fate. Here we show that the H3K4 methyltransferase Ash1l facilitates TGF-β-induced Treg cell polarization in vitro and protects mice from T cell-mediated colitis in vivo. Ash1l upregulates <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Smad3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression by directly targeting <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Smad3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> promoter to increase local H3K4 trimethylation. Furthermore, we identify an lncRNA, namely lnc-<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Smad3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, which interacts with the histone deacetylase HDAC1 and silences <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Smad3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> transcription. After TGF-β stimulation, activated <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Smad3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> suppresses lnc-<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Smad3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> transcription, thereby recovering the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Smad3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> promoter accessibility to Ash1l. By revealing the opposite regulatory functions of Ash1l and lnc-<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Smad3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Smad3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression, our data provide insights for the epigenetic control of Treg cell fate to potentially aid in the development of therapeutic intervention for autoimmune diseases.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27793996">27793996</a><div class="entities" style="line-height: 2.5"><h3>Lin28b Regulates Fetal Regulatory T Cell Differentiation through Modulation of TGF-β Signaling.</h3></br>Immune tolerance between the fetus and mother represents an active process by which the developing fetus must not mount immune responses to noninherited Ags on chimeric maternal cells that reside in fetal tissue. This is, in part, mediated by the suppressive influence of CD4+ FOXP3+ CD25+  regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>). Fetal secondary lymphoid organs have an increased frequency of Tregs and, as compared with adult T cells, fetal naive CD4+  T cells exhibit a strong predisposition to differentiate into Tregs when stimulated. This effect is mediated by the TCR and TGF-β pathways, and fetal T cells show significantly increased Treg differentiation in response to anti-CD3 and TGF-β stimulation. Naive fetal T cells also exhibit increased signaling through the TGF-β pathway, with these cells demonstrating increased expression of the signaling mediators TGF-βRI, TGF-βRIII, and SMAD2, and higher levels of SMAD2/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    SMAD3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> phosphorylation. Increased fetal Treg differentiation is mediated by the RNA-binding protein Lin28b, which is overexpressed in fetal T cells as compared with adult cells. When Lin28b expression is decreased in naive fetal T cells, they exhibit decreased Treg differentiation that is associated with decreased TGF-β signaling and lowered expression of TGF-βRI, TGF-βRIII, and SMAD2. Lin28b regulates the maturation of let-7 microRNAs, and these TGF-β signaling mediators are let-7 targets. We hypothesize that loss of Lin28b expression in fetal T cells leads to increased mature let-7, which causes decreased expression of TGF-βRI, TGF-βRIII, and SMAD2 proteins. A reduction in TGF-β signaling leads to reduced Treg numbers.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27778276">27778276</a><div class="entities" style="line-height: 2.5"><h3>Transcriptional modulation of regulatory T cell development by novel regulators NR4As.</h3></br>Regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells with high expression of both CD25 and Foxp3 are developed in the thymus and also peripheral tissues. Treg cells suppress the activation and functions of effector T cells raised against specific antigens and are crucial for maintaining immune homeostasis. Treg cell development is associated with the induction of and epigenetic alterations of forkhead transcription factor Foxp3. Foxp3 expression is increased by the activation of several transcription factors including nuclear factor-kappa B (NF-κB), nuclear factor of activated T cells (NFAT), and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Smad3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in response to various signals such as TGFβ, retinoic acid, and rapamycin. Recently, the orphan nuclear receptor 4A proteins (NR4As) including NR4A1 (Nur77), NR4A2 (Nurr1), and NR4A3 (Nor1) are reported to regulate Treg cell development through activation of Foxp3 and have therapeutic potentials in treating immune disorders. This review summarizes the function and regulatory mechanisms of Treg cells and also implicates current advances in immunomodulatory functions of NR4As and their therapeutic potentials in inflammation and cancer.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/26275994">26275994</a><div class="entities" style="line-height: 2.5"><h3>Hydrogen Sulfide Promotes Tet1- and Tet2-Mediated Foxp3 Demethylation to Drive Regulatory T Cell Differentiation and Maintain Immune Homeostasis.</h3></br>Regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are essential for maintenance of immune homeostasis. Here we found that hydrogen sulfide (H2S) was required for Foxp3(+) Treg cell differentiation and function and that H2S deficiency led to systemic autoimmune disease. H2S maintained expression of methylcytosine dioxygenases Tet1 and Tet2 by sulfhydrating nuclear transcription factor Y subunit beta (NFYB) to facilitate its binding to Tet1 and Tet2 promoters. Transforming growth factor-β (TGF-β)-activated <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Smad3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and interleukin-2 (IL-2)-activated Stat5 facilitated Tet1 and Tet2 binding to Foxp3. Tet1 and Tet2 catalyzed conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) in Foxp3 to establish a Treg-cell-specific hypomethylation pattern and stable Foxp3 expression. Consequently, Tet1 and Tet2 deletion led to Foxp3 hypermethylation, impaired Treg cell differentiation and function, and autoimmune disease. Thus, H2S promotes Tet1 and Tet2 expression, which are recruited to Foxp3 by TGF-β and IL-2 signaling to maintain Foxp3 demethylation and Treg-cell-associated immune homeostasis. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/22585622">22585622</a><div class="entities" style="line-height: 2.5"><h3>Notch activation on effector T cells increases their sensitivity to Treg cell-mediated suppression through upregulation of TGF-βRII expression.</h3></br>Notch proteins play an important role in embryonic development and cell-fate decisions. Notch influences also the activation and differentiation of peripheral T cells. Here, we investigated whether Notch signaling modulates the response of effector T cells to regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. Pre-exposure of CD4(+) CD25(-)  effector T cells to the Notch ligands Delta-4 and Jagged-1, but not Delta-1, increases significantly effector T cell sensitivity to Treg cell-mediated suppression through upregulation of TGF-βRII expression and increased levels of the phosphorylated form of the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Smad 3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> protein. This effect is relieved by anti-TGF-β Abs. We demonstrate that HES (hairy and enhancer of split), the main transcription factor downstream of Notch, induces strong transactivation of TGF-ßRII by binding the TGF-βRII promoter through its DNA-binding domain. Thus, the crosstalk between Notch and the TGF-β pathway leads to potentiation of the suppressive effect of Treg cells.</div></details><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/29682722">29682722</a><div class="entities" style="line-height: 2.5"><h3>The role of transforming growth factor β in T helper 17 differentiation.</h3></br>T helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells play critical roles in inflammatory and autoimmune diseases. The lineage-specific transcription factor RORγt is the key regulator for Th17 cell fate commitment. A substantial number of studies have established the importance of transforming growth factor β (TGF-β) -dependent pathways in inducing RORγt expression and Th17 differentiation. TGF-β superfamily members TGF-β1  , TGF-β3  or activin A, in concert with interleukin-6 or interleukin-21, differentiate naive T cells into Th17 cells. Alternatively, Th17 differentiation can occur through TGF-β-independent pathways. However, the mechanism of how TGF-β-dependent and TGF-β-independent pathways control Th17 differentiation remains controversial. This review focuses on the perplexing role of TGF-β in Th17 differentiation, depicts the requirement of TGF-β for Th17 development, and underscores the multiple mechanisms underlying TGF-β-promoted Th17 generation, pathogenicity and plasticity. With new insights and comprehension from recent findings, this review specifically tackles the involvement of the canonical TGF-β signalling components, SMAD2, SMAD3 and SMAD4, sum<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    mariz    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>es diverse SMAD-independent mechanisms, and highlights the importance of TGF-β signalling in balancing the reciprocal conversion of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and regulatory T cells. Finally, this review includes discussions and perspectives and raises important mechanistic questions about the role of TGF-β in Th17 generation and function.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/23741351">23741351</a><div class="entities" style="line-height: 2.5"><h3>TGF-β enhanced IL-21-induced differentiation of human IL-21-producing CD4+ T cells via <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Smad3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>.</h3></br>IL-21 has pleiotropic effects on innate and adaptive immune response, and plays an important role in the development of autoimmune disease and antitumor activity. It has been reported that IL-21 is produced by CD4(+) T cells and NKT cells. However, the differentiation of IL-21-producing CD4(+) T cells in humans remains largely unclear. In the present study, we showed that cytokines of IL-1β, IL-6 or IL-21 induced differentiation of human IL-21-producing CD4(+) T cells, and TGF-β enhanced the effect of inflammatory cytokines on the development of IL-21-producing CD4(+) T cells. Furthermore, we found that the majority of IL-21-producing cells were distinct from Th17 cells and Th1 cells since they did not co-express IL-17 and IFN-γ. TGF-β significantly inhibited the production of IFN-γ and enhanced the effect of IL-21 on the development of IL-21-producing CD4(+) T cells. In addition, we found that IL-21 inhibited the differentiation of CD4(+) Foxp3(+) T cells induced by TGF-β. Further study indicated that IL-21 induced phosphorylation of transcriptional factors of STAT1, STAT3 and STAT5, and TGF-β induced phosphorylation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Smad3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in CD4(+) T cells. Taken together, our data indicated that TGF-β enhanced IL-21-induced differentiation of IL-21-producing CD4(+) T cells, and the majority of IL-21-producing cells were different from <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th1 cells. Our results provide a new sight regarding the differentiation of human CD4(+) T cells.</div></details></details></td>
    </tr>
    <tr>
      <th>66</th>
      <td>PRDM1</td>
      <td>3</td>
      <td>TFH:2, TREG:2, TH17:1</td>
      <td>0.040534</td>
      <td>ENSG00000057657</td>
      <td><details><summary>Subtypes</summary><details><summary>TFH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27436361">27436361</a><div class="entities" style="line-height: 2.5"><h3>ROCK2 signaling is required to induce a subset of T follicular helper cells through opposing effects on STATs in autoimmune settings.</h3></br>Rho-associated kinase 2 (ROCK2) determines the balance between human T helper 17 (TH17) cells and regulatory T (Treg) cells. We investigated its role in the generation of T follicular helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TFH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, which help to generate antibody-producing B cells under normal and autoimmune conditions. Inhibiting ROCK2 in normal human T cells or peripheral blood mononuclear cells from patients with active systemic lupus erythematosus (SLE) decreased the number and function of TFH cells induced by activation ex vivo. Moreover, inhibition of ROCK2 activity decreased the abundance of the transcriptional regulator Bcl6 (B cell lymphoma 6) and increased that of Blimp1 by reducing the binding of signal transducer and activator of transcription 3 (STAT3) and increasing that of STAT5 to the promoters of the genes Bcl6 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    PRDM1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, respectively. In the MRL/lpr murine model of SLE, oral administration of the selective ROCK2 inhibitor KD025 resulted in a twofold reduction in the numbers of TFH cells and antibody-producing plasma cells in the spleen, as well as a decrease in the size of splenic germinal centers, which are the sites of interaction between TFH cells and B cells. KD025-treated mice showed a substantial improvement in both histological and clinical scores compared to those of untreated mice and had reduced amounts of Bcl6 and phosphorylated STAT3, as well as increased STAT5 phosphorylation. Together, these data suggest that ROCK2 signaling plays a critical role in controlling the development of TFH cells induced by autoimmune conditions through reciprocal regulation of STAT3 and STAT5 activation.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21314428">21314428</a><div class="entities" style="line-height: 2.5"><h3>Follicular helper CD4 T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TFH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>).</h3></br>T cell help to B cells is a fundamental aspect of adaptive immunity and the generation of immunological memory. Follicular helper CD4 T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(FH)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are the specialized providers of B cell help. T(FH) cells depend on expression of the master regulator transcription factor Bcl6. Distinguishing features of T(FH) cells are the expression of CXCR5, PD-1, SAP (SH2D1A), IL-21, and ICOS, among other molecules, and the absence of Blimp-1 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    prdm1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>). T(FH) cells are important for the formation of germinal centers. Once germinal centers are formed, T(FH) cells are needed to maintain them and to regulate germinal center B cell differentiation into plasma cells and memory B cells. This review covers T(FH) differentiation, T(FH) functions, and human T(FH) cells, discussing recent progress and areas of uncertainty or disagreement in the literature, and it debates the developmental relationship between T(FH) cells and other CD4 T cell subsets (Th1, Th2, Th17, iTreg).</div></details><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27653378">27653378</a><div class="entities" style="line-height: 2.5"><h3>Identification of tonsillar CD4+ CD25- LAG3+  T cells as naturally occurring IL-10-producing regulatory T cells in human lymphoid tissue.</h3></br>IL-10-producing regulatory T cells (IL-10-producing <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) are one of the re<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    gulat    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>ory T cell subsets characterized by the production of high amounts of IL-10, the lack of FOXP3 expression and the strong immunosuppressive capabilities. IL-10-producing Tregs have been primarily reported as induced populations thus far, in part because identifying naturally occurring IL-10-producing Tregs was difficult due to the lack of definitive surface markers. Lymphocyte-activation gene 3 (LAG3) is a CD4 homologue that we have identified as being expressed on IL-10 producing Tregs. In human PBMC, LAG3 combined with CD49b efficiently identifies IL-10-producing Tregs. However, naturally occurring IL-10-producing Tregs in human secondary lymphoid tissue have not been described. In this report, we identified CD4+ CD25- LAG3+  T cells in human tonsil. This T cell subset produced high amounts of IL-10 and expressed low levels of FOXP3. Surface markers and microarray analysis revealed that this is a distinct tonsillar CD4+  T cell subset. CD4+ CD25- LAG3+  T cells expressed interleukin 10 (IL10), PR/SET domain 1 (PRDM1), and CD274 at high levels and chemokine receptor 5 (CXCR5) at low levels. CD4+ CD25- LAG3+  T cells suppressed antibody production more efficiently than CD4+ CD25+  T cells, and CD4+ CD25- LAG3+  T cells induced B cell apoptosis. Moreover, analysis of humanized mice revealed that this cell subset suppressed a graft-versus-host disease (GVHD) reaction in vivo. Our study reveals the existence of naturally occurring IL-10-producing Tregs in human secondary lymphoid tissue and their function in immune regulation.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/27436361">27436361</a><div class="entities" style="line-height: 2.5"><h3>ROCK2 signaling is required to induce a subset of T follicular helper cells through opposing effects on STATs in autoimmune settings.</h3></br>Rho-associated kinase 2 (ROCK2) determines the balance between human T helper 17 (TH17) cells and regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. We investigated its role in the generation of T follicular helper (TFH) cells, which help to generate antibody-producing B cells under normal and autoimmune conditions. Inhibiting ROCK2 in normal human T cells or peripheral blood mononuclear cells from patients with active systemic lupus erythematosus (SLE) decreased the number and function of TFH cells induced by activation ex vivo. Moreover, inhibition of ROCK2 activity decreased the abundance of the transcriptional regulator Bcl6 (B cell lymphoma 6) and increased that of Blimp1 by reducing the binding of signal transducer and activator of transcription 3 (STAT3) and increasing that of STAT5 to the promoters of the genes Bcl6 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    PRDM1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, respectively. In the MRL/lpr murine model of SLE, oral administration of the selective ROCK2 inhibitor KD025 resulted in a twofold reduction in the numbers of TFH cells and antibody-producing plasma cells in the spleen, as well as a decrease in the size of splenic germinal centers, which are the sites of interaction between TFH cells and B cells. KD025-treated mice showed a substantial improvement in both histological and clinical scores compared to those of untreated mice and had reduced amounts of Bcl6 and phosphorylated STAT3, as well as increased STAT5 phosphorylation. Together, these data suggest that ROCK2 signaling plays a critical role in controlling the development of TFH cells induced by autoimmune conditions through reciprocal regulation of STAT3 and STAT5 activation.</div></details><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27436361">27436361</a><div class="entities" style="line-height: 2.5"><h3>ROCK2 signaling is required to induce a subset of T follicular helper cells through opposing effects on STATs in autoimmune settings.</h3></br>Rho-associated kinase 2 (ROCK2) determines the balance between human T helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells and regulatory T (Treg) cells. We investigated its role in the generation of T follicular helper (TFH) cells, which help to generate antibody-producing B cells under normal and autoimmune conditions. Inhibiting ROCK2 in normal human T cells or peripheral blood mononuclear cells from patients with active systemic lupus erythematosus (SLE) decreased the number and function of TFH cells induced by activation ex vivo. Moreover, inhibition of ROCK2 activity decreased the abundance of the transcriptional regulator Bcl6 (B cell lymphoma 6) and increased that of Blimp1 by reducing the binding of signal transducer and activator of transcription 3 (STAT3) and increasing that of STAT5 to the promoters of the genes Bcl6 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    PRDM1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, respectively. In the MRL/lpr murine model of SLE, oral administration of the selective ROCK2 inhibitor KD025 resulted in a twofold reduction in the numbers of TFH cells and antibody-producing plasma cells in the spleen, as well as a decrease in the size of splenic germinal centers, which are the sites of interaction between TFH cells and B cells. KD025-treated mice showed a substantial improvement in both histological and clinical scores compared to those of untreated mice and had reduced amounts of Bcl6 and phosphorylated STAT3, as well as increased STAT5 phosphorylation. Together, these data suggest that ROCK2 signaling plays a critical role in controlling the development of TFH cells induced by autoimmune conditions through reciprocal regulation of STAT3 and STAT5 activation.</div></details></details></td>
    </tr>
    <tr>
      <th>67</th>
      <td>TEAD1</td>
      <td>1</td>
      <td>TH:1, TREG:1</td>
      <td>0.038455</td>
      <td>ENSG00000187079</td>
      <td><details><summary>Subtypes</summary><details><summary>TH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28504697">28504697</a><div class="entities" style="line-height: 2.5"><h3>The transcriptional coactivator TAZ regulates reciprocal differentiation of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> 17 cells and Treg  cells.</h3></br>An imbalance in the lineages of immunosuppressive regulatory T cells (Treg  cells) and the inflammatory TH 17 subset of helper T cells leads to the development of autoimmune and/or inflammatory disease. Here we found that TAZ, a coactivator of TEAD transcription factors of Hippo signaling, was expressed under TH 17 cell-inducing conditions and was required for TH 17 differentiation and TH 17 cell-mediated inflammatory diseases. TAZ was a critical co-activator of the TH 17-defining transcription factor RORγt. In addition, TAZ attenuated Treg  cell development by decreasing acetylation of the Treg  cell master regulator Foxp3 mediated by the histone acetyltransferase Tip60, which targeted Foxp3 for proteasomal degradation. In contrast, under Treg  cell-skewing conditions, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TEAD1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression and sequestration of TAZ from the transcription factors RORγt and Foxp3 promoted Treg  cell differentiation. Furthermore, deficiency in TAZ or overexpression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TEAD1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> induced Treg  cell differentiation, whereas expression of a transgene encoding TAZ or activation of TAZ directed TH 17 cell differentiation. Our results demonstrate a pivotal role for TAZ in regulating the differentiation of Treg  cells and <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> 17 cells.</div></details><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28504697">28504697</a><div class="entities" style="line-height: 2.5"><h3>The transcriptional coactivator TAZ regulates reciprocal differentiation of TH 17 cells and <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>  cells.</h3></br>An imbalance in the lineages of immunosuppressive regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>  cells) and the inflammatory TH 17 subset of helper T cells leads to the development of autoimmune and/or inflammatory disease. Here we found that TAZ, a coactivator of TEAD transcription factors of Hippo signaling, was expressed under TH 17 cell-inducing conditions and was required for TH 17 differentiation and TH 17 cell-mediated inflammatory diseases. TAZ was a critical co-activator of the TH 17-defining transcription factor RORγt. In addition, TAZ attenuated Treg  cell development by decreasing acetylation of the Treg  cell master regulator Foxp3 mediated by the histone acetyltransferase Tip60, which targeted Foxp3 for proteasomal degradation. In contrast, under Treg  cell-skewing conditions, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TEAD1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression and sequestration of TAZ from the transcription factors RORγt and Foxp3 promoted Treg  cell differentiation. Furthermore, deficiency in TAZ or overexpression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TEAD1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> induced Treg  cell differentiation, whereas expression of a transgene encoding TAZ or activation of TAZ directed TH 17 cell differentiation. Our results demonstrate a pivotal role for TAZ in regulating the differentiation of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>  cells and TH 17 cells.</div></details></details></td>
    </tr>
    <tr>
      <th>68</th>
      <td>IRX2</td>
      <td>1</td>
      <td>TREG:1</td>
      <td>0.037992</td>
      <td>ENSG00000170561</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/21915712">21915712</a><div class="entities" style="line-height: 2.5"><h3><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRX-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, a novel biologic, favors the expansion of T effector over T regulatory cells in a human tumor microenvironment model.</h3></br><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRX-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, a natural cytokine biological with multiple components, has been used in preclinical and clinical studies to promote antitumor activity of T lymphocytes. To define cellular mechanisms responsible for antitumor effects of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRX-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, its ability to induce effector T cells (Teff) was examined in a model simulating the tumor microenvironment. An in vitro model containing conventional CD4(+)CD25(-) cells co-cultured with autologous immature dendritic cells, irradiated tumor cells, and cytokines was used to study differentiation and expansion of regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) and Teff in the presence and absence of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRX-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. Phenotype, suppressor function, signaling, and cytokine production were serially measured using flow cytometry, Western blots, CFSE-based suppressor assays, and Luminex-based analyses. The presence of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRX-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in the co-cultures promoted the induction and expansion of IFN-γ(+)Tbet(+) Teff and significantly (p < 0.01) decreased the induction of inducible IL-10(+)TGF-β(+) Treg. The responsible mechanism involved IFN-γ-driven T cell polarization towards Teff and suppression of Treg differentiation. In an in vitro model simulating the human tumor microenvironment, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRX-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> promoted Teff expansion and antitumor activity without inducing Treg. Thus, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IRX-2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> could be considered as a promising component of future antitumor therapies.</div></details></details></td>
    </tr>
    <tr>
      <th>69</th>
      <td>TET1</td>
      <td>1</td>
      <td>TREG:1</td>
      <td>0.037992</td>
      <td>ENSG00000138336</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/26275994">26275994</a><div class="entities" style="line-height: 2.5"><h3>Hydrogen Sulfide Promotes <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tet1-    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and Tet2-Mediated Foxp3 Demethylation to Drive Regulatory T Cell Differentiation and Maintain Immune Homeostasis.</h3></br>Regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are essential for maintenance of immune homeostasis. Here we found that hydrogen sulfide (H2S) was required for Foxp3(+) Treg cell differentiation and function and that H2S deficiency led to systemic autoimmune disease. H2S maintained expression of methylcytosine dioxygenases <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tet1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and Tet2 by sulfhydrating nuclear transcription factor Y subunit beta (NFYB) to facilitate its binding to <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tet1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and Tet2 promoters. Transforming growth factor-β (TGF-β)-activated Smad3 and interleukin-2 (IL-2)-activated Stat5 facilitated <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tet1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and Tet2 binding to Foxp3. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tet1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and Tet2 catalyzed conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) in Foxp3 to establish a Treg-cell-specific hypomethylation pattern and stable Foxp3 expression. Consequently, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tet1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and Tet2 deletion led to Foxp3 hypermethylation, impaired Treg cell differentiation and function, and autoimmune disease. Thus, H2S promotes <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tet1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and Tet2 expression, which are recruited to Foxp3 by TGF-β and IL-2 signaling to maintain Foxp3 demethylation and Treg-cell-associated immune homeostasis. </div></details></details></td>
    </tr>
    <tr>
      <th>70</th>
      <td>RELB</td>
      <td>5</td>
      <td>TREG:3, TH:1, TH17:1</td>
      <td>0.032162</td>
      <td>ENSG00000104856</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27895173">27895173</a><div class="entities" style="line-height: 2.5"><h3>Human Regulatory T Cells Mediate Transcriptional Modulation of Dendritic Cell Function.</h3></br>Regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) attenuate dendritic cell (DC) maturation and stimulatory function. Current knowledge on the functional impact of semimature DC is limited to CD4+  T cell proliferation and cytokine production. Little is known about the molecular basis underpinning the functional effects of Treg-treated DC (Treg-DC). We present novel evidence that Treg-DC skewed CD4+  naive T cell polarization toward a regulatory phenotype and impaired CD8+  T cell allo-reactive responses, including their ability to induce target tissue damage in a unique in vitro human graft-versus-host disease skin explant model. Microarray analysis clustered Treg-DC as a discrete population from mature-DC and immature-DC, with 51 and 93 genes that were significantly over- or underexpressed, respectively, compared with mature-DC. Quantitative real-time PCR analysis revealed an intermediate expression level of CD38, CD83, CD80 and CD86 mRNA in Treg-DC, lower than mature-DC, higher than immature-DC. We also observed an attenuation of NF-κB pathway, an upstream regulator of the aforementioned genes, concomitant with reduced expression of two NF-κB-signaling related genes <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RELB    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and NFκBIZ, in the Treg-DC, together with an increased expression of Wnt5a, a negative regulator of DC differentiation. We further confirmed that the Treg-DC-mediated skewed CD4+  naive T cell polarization resulted from decreased IL-12 secretion by Treg-DC, which may be post-transcriptionally modulated by decreased expression of microRNA-155 in Treg-DC. To our knowledge, this is the first study demonstrating a transcriptional modulation of DC function by human Treg, partially via attenuation of the NF-κB signaling pathway and upregulation of Wnt5a, suggesting Treg may interfere with DC reprogramming during maturation, thereby modulating DC function.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/22879398">22879398</a><div class="entities" style="line-height: 2.5"><h3>Activation of the noncanonical NF-κB pathway by HIV controls a dendritic cell immunoregulatory phenotype.</h3></br>HIV modulates plasmacytoid dendritic cell (pDC) activation via Toll-like receptor 7, inducing type I IFN and inflammatory cytokines. Simultaneously, pDCs up-regulate the expression of indoleamine 2,3 dioxygenase (IDO), which is essential for the induction of regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>), which function to down-modulate immune activation. Here we demonstrate the crucial importance of the noncanonical NF-κB pathway in the establishment of this immunoregulatory phenotype in pDCs. In response to HIV, the noncanonical NF-κB pathway directly induces IDO and involves the recruitment of TNF receptor-associated factor-3 to the Toll-like receptor/MyD88 complex, NF-κB-inducing kinase-dependent IκB kinase-α activation, and p52/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RelB    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> nuclear translocation. We also show that pDC-induced Tregs can inhibit conventional DC (cDC) maturation partially through cytotoxic T lymphocyte antigen (CTLA)-4 engagement. Furthermore, CTLA-4 induces IDO in cDCs in a NF-κB-inducing kinase-dependent way. These CTLA-4-conditioned cDCs can in turn induce Treg differentiation in an IDO-dependent manner. Thus, the noncanonical NF-κB pathway is integral in controlling immunoregulatory phenotypes of both pDCs and cDCs.</div></details><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27317259">27317259</a><div class="entities" style="line-height: 2.5"><h3>The Costimulatory Receptor OX40 Inhibits Interleukin-17 Expression through Activation of Repressive Chromatin Remodeling Pathways.</h3></br>T helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are prominently featured in multiple autoimmune diseases, but the regulatory mechanisms that control Th17 cell responses are poorly defined. Here we found that stimulation of OX40 triggered a robust chromatin remodeling response and produced a "closed" chromatin structure at interleukin-17 (IL-17) locus to inhibit Th17 cell function. OX40 activated the NF-κB family member <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RelB    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RelB    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> recruited the histone methyltransferases G9a and SETDB1 to the Il17 locus to deposit "repressive" chromatin marks at H3K9 sites, and consequently repressing IL-17 expression. Unlike its transcriptional activities, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RelB    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> acted independently of both p52 and p50 in the suppression of IL-17. In an experimental autoimmune encephalomyelitis (EAE) disease model, we found that OX40 stimulation inhibited IL-17 and reduced EAE. Conversely, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    RelB    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>-deficient CD4(+) T cells showed enhanced IL-17 induction and exacerbated the disease. Our data uncover a mechanism in the control of Th17 cells that might have important clinic implications.</div></details></details></td>
    </tr>
    <tr>
      <th>71</th>
      <td>REL</td>
      <td>2</td>
      <td>TREG:2</td>
      <td>0.032109</td>
      <td>ENSG00000162924</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/21948370">21948370</a><div class="entities" style="line-height: 2.5"><h3>Nuclear factor-κB in immunity and inflammation: the Treg and Th17 connection.</h3></br>Although nuclear factor-kB (NF-kB) is generally considered to be a pro-inflammatory transcription factor, recent studies indicate that it also plays a critical role in the development of an anti-inflammatory T cell subset called regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. Two NF-kB proteins, c-<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Rel    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and p65, drive the development of Treg cells by promoting the formation of a Foxp3-specific enhanceosome. Consequently, c-<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Rel-    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>deficient mice have marked reductions in Treg cells, and c-<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Rel-    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>deficient T cells are compromised in Treg cell differentiation. However, with the exception of Foxp3, most NF-kB target genes in immune cells are pro-inflammatory. These include several Th17-related cytokine genes and the retinoid-related orphan receptor-g (Rorg or Rorc) that specifies Th17 differentiation and lineage-specific function. T cells deficient in c-<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Rel    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> or p65 are significantly compromised in Th17 differentiation, and c-Rel -deficient mice are defective in Th17 responses. Thus, NF-kB is required for the development of both anti-inflammatory Treg and pro-inflammatory Th17 cells.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/22118406">22118406</a><div class="entities" style="line-height: 2.5"><h3>Thymic and peripheral differentiation of regulatory T cells.</h3></br>The development of regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells is essential for the maintenance of immune tolerance and homeostasis. Here, we review recent studies that have advanced our understanding of Treg cell differentiation. In the thymus, TCR specificity to self-antigen appears to be a primary determinant for Treg cell lineage commitment, with c-<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Rel    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> being an important factor that links T cell receptor (TCR) engagement and Foxp3 expression, along with cytokines and costimulatory molecules. It is also clear that postthymic events shape the peripheral Treg cell population. This includes preferential maintenance of Treg cells specific to self-antigens presented in the periphery, as well as the de novo generation of Treg cells from conventional Foxp3(-) T cells. The process of peripheral Treg cell differentiation shares some features with thymic Treg cell development, but there are notable differences. Together, thymic and peripheral Treg cell differentiation appear to generate an "imprint" of both self- and foreign antigens in the peripheral Treg cell population to provide dominant tolerance.</div></details></details></td>
    </tr>
    <tr>
      <th>72</th>
      <td>TBX21</td>
      <td>6</td>
      <td>TH:2, TH1:2, TH17:2, TREG:1</td>
      <td>0.031909</td>
      <td>ENSG00000073861</td>
      <td><details><summary>Subtypes</summary><details><summary>TH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/24901011">24901011</a><div class="entities" style="line-height: 2.5"><h3>The role of protein modifications of T-bet in cytokine production and differentiation of T helper cells.</h3></br>T-Bet (T-box protein expressed in T cells, also called as <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TBX21    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) was originally cloned as a key transcription factor involved in the commitment of T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells to the Th1 lineage. T-Bet directly activates IFN-γ gene transcription and enhances development of Th1 cells. T-Bet simultaneously modulates IL-2 and Th2 cytokines in an IFN-γ-independent manner, resulting in an attenuation of Th2 cell development. Numerous studies have demonstrated that T-bet plays multiple roles in many subtypes of immune cells, including B cell, dendritic cells, natural killer (NK) cells, NK T cells, and innate lymphoid cells. Therefore, T-bet is crucial for the development and coordination of both innate and adaptive immune responses. To fulfill these multiple roles, T-bet undergoes several posttranslational protein modifications, such as phosphorylation at tyrosine, serine, and threonine residues, and ubiquitination at lysine residues, which affect lineage commitment during Th cell differentiation. This review presents a current overview of the progress made in understanding the roles of various types of T-bet protein modifications in the regulation of cytokine production during Th cell differentiation. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21367463">21367463</a><div class="entities" style="line-height: 2.5"><h3>RORC and Foxp3 axis in cerebrospinal fluid of patients with neuro-Behçet's disease.</h3></br>Neurological manifestations are present in 5% to 30% of patients with Behçet's disease (BD). Neuro-Behçet's Disease (NBD) is hypothetically caused by T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, which development is dependent on the expression of lineage-specific transcription factors. Cerebrospinal fluid (CSF) mRNA expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TBX21    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, GATA3, RORC, FOXP3 and EBI3 were assessed in 18 NBD patients and 26 controls disease [16 noninflammatory neurological disease (NIND) and 10 headache attributed to Behçet's disease (HaBD)]. Expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TBX21    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (Th1), RORC (Th17) and Foxp3 (Treg) were increased in NBD patients compared to HaBD and NIND patients. EBI3 and Th2-associated GATA3 expressions were found to be decreased (P<0.0001 and P<0.0001) in NBD patients. Analysis of transcription factor ratios, revealed an increase in the RORC/FOXP3 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TBX21    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>/GATA3 ratios in NBD patients (P<0.0001; P<0.0003). Our findings indicate that both Th1 and Th17 mRNA expressions involving a possible impairment of Treg cells. This might play a role in CSF-NBD inflammation, permitting activation of harmful T cell subpopulations. The <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TBX21    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>/GATA3 and RORC/FOXP3 ratios dysregulations in NBD are consistent with those reported in other inflammatory diseases and indicating the plasticity existing between Th1, Th17 and Treg cells during inflammation.</div></details><details><summary>TH1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/25972481">25972481</a><div class="entities" style="line-height: 2.5"><h3>CD155 (PVR/Necl5) mediates a costimulatory signal in CD4+ T cells and regulates allergic inflammation.</h3></br>Although <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells are known to be involved in allergic inflammatory diseases, the molecular mechanisms underlying their differentiation are incompletely understood. In this study, we identified CD155 as a costimulatory molecule on CD4(+) T cells. Importantly, CD155-mediated signaling induced Th1 development in both humans and mice, as evidenced by production of IFN-γ and upregulation of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tbx21    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> transcription; these effects were independent of IL-12 but dependent on NF-κB-induced autocrine IFN-γ that triggered positive feedback via STAT1 activation. Mice genetically deficient in CD155 or treated with anti-CD155 Ab exhibited attenuated Th1-type contact hypersensitivity. Thus, CD155 plays an important regulatory role in helper T cell differentiation and allergic diseases. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/24262372">24262372</a><div class="entities" style="line-height: 2.5"><h3>The polymorphisms of T cell-specific <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TBX21    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> gene may contribute to the susceptibility of chronic immune thrombocytopenia in Chinese population.</h3></br>Chronic primary immune thrombocytopenia (ITP) is an acquired autoimmune hemorrhagic disease characterized by both reduced platelet counts and suppression of megakaryocyte and platelet development. T cell-specific T-box transcription factor gene (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TBX21    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) plays a critical role in the development and maintenance of T helper 1 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. Recently, several studies have confirmed that the T-1554C and T-1993C polymorphisms of this gene can influence its expression level and are associated with autoimmune diseases. Therefore, we speculated that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TBX21    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> polymorphisms might be associated with the susceptibility of chronic ITP in Chinese population. We investigated the distributions of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TBX21    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (T-1514C and T-1993C) polymorphisms in 275 patients with chronic ITP and 261 healthy controls by polymerase chain reaction-restriction fragment length polymorphism. We observed significant overrepresentation of T allele and T/T genotype at T-1993C (but not T-1514C) in patients compared with controls. Stratified analysis by gender and age of disease onset revealed comparable observations in both female and childhood ITP cohorts. In conclusion, the T-1993C polymorphisms of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TBX21    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> gene may be associated with the susceptibility of chronic primary ITP in Chinese population. </div></details><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/22048764">22048764</a><div class="entities" style="line-height: 2.5"><h3>Human Th1 and Th17 cells exhibit epigenetic stability at signature cytokine and transcription factor loci.</h3></br>The linear model of Th cell lineage commitment is being revised due to reports that mature Th cells can trans-differentiate into alternate lineages. This ability of Th cells to reprogram is thought to be regulated by epigenetic mechanisms that control expression of transcription factors characteristic of opposing lineages. It is unclear, however, to what extent this new model of Th cell plasticity holds true in human Th cell subsets that develop under physiological conditions in vivo. We isolated in vivo-differentiated human Th1 and Th17 cells, as well as intermediate Th1/17 cells, and identified distinct epigenetic signatures at cytokine (IFNG and IL17A) and transcription factor (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TBX21    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, RORC, and RORA) loci. We also examined the phenotypic and epigenetic stability of human Th17 cells exposed to Th1-polarizing conditions and found that although they could upregulate <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TBX21    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and IFN-γ, this occurred without loss of IL-17 or RORC expression, and resulted in cells with a Th1/17 phenotype. Similarly, Th1 cells could upregulate IL-17 upon enforced expression of RORC2, but did not lose expression of IFN-γ or <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TBX21    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. Despite alterations in expression of these signature genes, epigenetic modifications were remarkably stable aside from the acquisition of active histone methylation marks at cytokine gene promoters. The limited capacity of human <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th1 cells to undergo complete lineage conversion suggests that the bipotent Th1/17 cells may arise from Th1 and/or Th17 cells. These data also question the broad applicability of the new model of Th cell lineage plasticity to in vivo-polarized human Th cell subsets.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21367463">21367463</a><div class="entities" style="line-height: 2.5"><h3>RORC and Foxp3 axis in cerebrospinal fluid of patients with neuro-Behçet's disease.</h3></br>Neurological manifestations are present in 5% to 30% of patients with Behçet's disease (BD). Neuro-Behçet's Disease (NBD) is hypothetically caused by T helper (Th) cells, which development is dependent on the expression of lineage-specific transcription factors. Cerebrospinal fluid (CSF) mRNA expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TBX21    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, GATA3, RORC, FOXP3 and EBI3 were assessed in 18 NBD patients and 26 controls disease [16 noninflammatory neurological disease (NIND) and 10 headache attributed to Behçet's disease (HaBD)]. Expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TBX21    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (Th1), RORC (Th17) and Foxp3 (Treg) were increased in NBD patients compared to HaBD and NIND patients. EBI3 and Th2-associated GATA3 expressions were found to be decreased (P<0.0001 and P<0.0001) in NBD patients. Analysis of transcription factor ratios, revealed an increase in the RORC/FOXP3 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TBX21    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>/GATA3 ratios in NBD patients (P<0.0001; P<0.0003). Our findings indicate that both Th1 and Th17 mRNA expressions involving a possible impairment of Treg cells. This might play a role in CSF-NBD inflammation, permitting activation of harmful T cell subpopulations. The <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TBX21    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>/GATA3 and RORC/FOXP3 ratios dysregulations in NBD are consistent with those reported in other inflammatory diseases and indicating the plasticity existing between Th1, <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Treg cells during inflammation.</div></details><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/23143995">23143995</a><div class="entities" style="line-height: 2.5"><h3>Regulatory T lymphocytes mediate amyotrophic lateral sclerosis progression and survival.</h3></br>In amyotrophic lateral sclerosis (ALS) mice, regulatory T lymphocytes (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) are neuroprotective, slowing disease progression. To address whether Tregs and FoxP3, a transcription factor required for Treg function, similarly influence progression rates of ALS patients, T lymphocytes from patients were assessed by flow cytometry. Both numbers of Tregs and their FoxP3 protein expressions were reduced in rapidly progressing ALS patients and inversely correlated with progression rates. The mRNA levels of FoxP3, TGF-β, IL4 and Gata3, a Th2 transcription factor, were reduced in rapidly progressing patients and inversely correlated with progression rates. Both FoxP3 and Gata3 were accurate indicators of progression rates. No differences in IL10, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tbx21    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, a Th1 transcription factor or IFN-γ expression were found between slow and rapidly progressing patients. A 3.5-year prospective study with a second larger cohort revealed that early reduced FoxP3 levels were indicative of progression rates at collection and predictive of future rapid progression and attenuated survival. Collectively, these data suggest that Tregs and Th2 lymphocytes influence disease progression rates. Importantly, early reduced FoxP3 levels could be used to identify rapidly progressing patients.</div></details></details></td>
    </tr>
    <tr>
      <th>73</th>
      <td>NFATC1</td>
      <td>2</td>
      <td>TH1:1, TH17:1, TH2:1</td>
      <td>0.030905</td>
      <td>ENSG00000131196</td>
      <td><details><summary>Subtypes</summary><details><summary>TH1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/18772129">18772129</a><div class="entities" style="line-height: 2.5"><h3>Cyclic AMP-induced chromatin changes support the NFATc-mediated recruitment of GATA-3 to the interleukin 5 promoter.</h3></br>Elevated intracellular cyclic AMP levels, which suppress the proliferation of naive T cells and type 1 T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are a property of T helper 2 (Th2) cells and regulatory T cells. While cyclic AMP signals interfere with the IL-2 promoter induction, they support the induction of Th2-type genes, in particular of il-5 gene. We show here that cyclic AMP signals support the generation of three inducible DNase I hypersensitive chromatin sites over the il-5 locus, including its promoter region. In addition, cyclic AMP signals enhance histone H3 acetylation at the IL-5 promoter and the concerted binding of GATA-3 and NFATc to the promoter. This is facilitated by direct protein-protein interactions involving the C-terminal Zn(2+)-finger of GATA-3 and the C-terminal region of the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NFATc1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> DNA binding domain. Because inhibition of NFATc binding to the IL-5 promoter in vivo also affects the binding of GATA-3, one may conclude that upon induction of Th2 effector cells NFATc recruits GATA-3 to Th2-type genes. These data demonstrate the functional importance of cyclic AMP signals for the interplay between GATA-3 and NFATc factors in the transcriptional control of lymphokine expression in Th2 effector cells.</div></details><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/25630465">25630465</a><div class="entities" style="line-height: 2.5"><h3>NFAT1 deficit and NFAT2 deficit attenuate EAE via different mechanisms.</h3></br>EAE serves as an animal model for multiple sclerosis and is initiated by autoreactive T cells that infiltrate the CNS. Recognition of myelin-associated Ags within the CNS leads to activation of the transcription factor family NFAT. Here, we demonstrate an essential role for NFAT in disease induction, as the combined lack of NFAT1 (NFATc2) and NFAT2 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NFATc1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) completely protected mice. Single deficiency of either NFAT1 or NFAT2 ameliorated the course of EAE, and NFAT2 ablation resulted in an obstructed proinflammatory reaction. However, NFAT1 deficit led to an anti-inflammatory response with nonpathogenic <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells concurrently secreting IL-17, IL-4, and IL-10. Both IL-4 and IL-10 contributed to disease protection. In Nfat1(-/-) CD4(+) T cells, the expression of anti-inflammatory lymphokines was mediated by NFAT2, thus directly enabling protective IL expression. Consequently, blocking NFAT in toto may be an option for immunosuppressive therapy. More importantly, selective NFAT1 blockade could represent a safe long-term immunomodulatory treatment approach for multiple sclerosis patients, potentially avoiding the adverse effects of global immunosuppression.</div></details><details><summary>TH2</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/18772129">18772129</a><div class="entities" style="line-height: 2.5"><h3>Cyclic AMP-induced chromatin changes support the NFATc-mediated recruitment of GATA-3 to the interleukin 5 promoter.</h3></br>Elevated intracellular cyclic AMP levels, which suppress the proliferation of naive T cells and type 1 T helper (Th1) cells are a property of T helper 2 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells and regulatory T cells. While cyclic AMP signals interfere with the IL-2 promoter induction, they support the induction of Th2-type genes, in particular of il-5 gene. We show here that cyclic AMP signals support the generation of three inducible DNase I hypersensitive chromatin sites over the il-5 locus, including its promoter region. In addition, cyclic AMP signals enhance histone H3 acetylation at the IL-5 promoter and the concerted binding of GATA-3 and NFATc to the promoter. This is facilitated by direct protein-protein interactions involving the C-terminal Zn(2+)-finger of GATA-3 and the C-terminal region of the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NFATc1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> DNA binding domain. Because inhibition of NFATc binding to the IL-5 promoter in vivo also affects the binding of GATA-3, one may conclude that upon induction of Th2 effector cells NFATc recruits GATA-3 to Th2-type genes. These data demonstrate the functional importance of cyclic AMP signals for the interplay between GATA-3 and NFATc factors in the transcriptional control of lymphokine expression in Th2 effector cells.</div></details></details></td>
    </tr>
    <tr>
      <th>74</th>
      <td>NFATC2</td>
      <td>5</td>
      <td>TH:2, TH17:1, TH2:1, TREG:1</td>
      <td>0.030401</td>
      <td>ENSG00000101096</td>
      <td><details><summary>Subtypes</summary><details><summary>TH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/22474330">22474330</a><div class="entities" style="line-height: 2.5"><h3>Stable IL-2 decision making by endogenous c-Fos amounts in peripheral memory T-helper cells.</h3></br>The cytokine IL-2 performs opposite functions supporting efficient immune responses and playing a key role in peripheral tolerance. Therefore, precise fine-tuning of IL-2 expression is crucial for adjusting the immune response. Combining transcription factor analysis at the single cell and the single nucleus level using flow cytometry with statistical analysis, we showed that physiological differences in the expression levels of c-Fos and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NFATc2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, but not of c-Jun and NF-κBp65, are limiting for the decision whether IL-2 is expressed in a strongly activated human memory T-helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cell. Variation in the expression of c-Fos leads to substantial diversity of IL-2 expression in ∼40% of the memory Th cells. The remaining cells exhibit an equally high c-Fos expression level, thereby ensuring robustness in IL-2 response within the population. These findings reveal how memory Th cells benefit from regulated variation in transcription factor expression to achieve a certain stability and variability of cytokine expression in a controlled manner.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/15684054">15684054</a><div class="entities" style="line-height: 2.5"><h3><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NFATc2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and T-bet contribute to T-helper-cell-subset-specific regulation of IL-21 expression.</h3></br>T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) 2 cells selectively express IL-21 in addition to the classic Th2 cytokines IL-4, IL-5, and IL-13. In contrast to these clustered Th2 cell cytokine genes, the IL-21 gene resides on a different chromosome and is not coordinately regulated by the same locus control region that directs the expression of other Th2 cytokines. We demonstrate that the proximal promoter of IL-21 controls its Th-cell-subset-specific expression through the action of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NFATc2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and T-bet. Whereas <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NFATc2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> directly binds to and activates transcription of the IL-21 promoter in Th2 cells, T-bet represses IL-21 transcription by inhibiting the binding of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NFATc2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> to the promoter in Th1 cells. These data suggest that there are multiple mechanisms by which Th-cell-subset-specific cytokine genes are regulated.</div></details><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/25630465">25630465</a><div class="entities" style="line-height: 2.5"><h3>NFAT1 deficit and NFAT2 deficit attenuate EAE via different mechanisms.</h3></br>EAE serves as an animal model for multiple sclerosis and is initiated by autoreactive T cells that infiltrate the CNS. Recognition of myelin-associated Ags within the CNS leads to activation of the transcription factor family NFAT. Here, we demonstrate an essential role for NFAT in disease induction, as the combined lack of NFAT1 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NFATc2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) and NFAT2 (NFATc1) completely protected mice. Single deficiency of either NFAT1 or NFAT2 ameliorated the course of EAE, and NFAT2 ablation resulted in an obstructed proinflammatory reaction. However, NFAT1 deficit led to an anti-inflammatory response with nonpathogenic <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells concurrently secreting IL-17, IL-4, and IL-10. Both IL-4 and IL-10 contributed to disease protection. In Nfat1(-/-) CD4(+) T cells, the expression of anti-inflammatory lymphokines was mediated by NFAT2, thus directly enabling protective IL expression. Consequently, blocking NFAT in toto may be an option for immunosuppressive therapy. More importantly, selective NFAT1 blockade could represent a safe long-term immunomodulatory treatment approach for multiple sclerosis patients, potentially avoiding the adverse effects of global immunosuppression.</div></details><details><summary>TH2</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/20227920">20227920</a><div class="entities" style="line-height: 2.5"><h3>Combined T regulatory cell and <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> expression profile identifies children with cow's milk allergy.</h3></br>The role of T regulatory cells in spontaneous recovery from cow's milk allergy (CMA) is unclear. We investigated the mRNA expression of 12 T cell markers and the protein expression of CD4, CD25, CD127, FoxP3 after in vitro beta-lactoglobulin stimulation of peripheral blood mononuclear cells from children with persisting CMA (n=16), early recovery (n=20) or no atopy (n=21). Artificial neural networks with exhaustive search for all marker combinations revealed that markers FoxP3, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Nfat-C2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, IL-16 and GATA-3 distinguished patients with persisting CMA most accurately from other study groups. FoxP3 mRNA expression following beta-lactoglobulin stimulation was highest in children with persisting CMA. Also the FoxP3 intensity in CD4(+) CD25(high)CD127(low) cells was higher in children with CMA compared with non-atopic children. The expression profile of both Th2- and T regulatory cell-related genes thus reflects the clinical activity of CMA. Tolerance, in contrast, is not characterized by activation of circulating T regulatory cells.</div></details><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/19344427">19344427</a><div class="entities" style="line-height: 2.5"><h3>Deficiency of regulatory T cells in children with autoimmune neutropenia.</h3></br>CD4+ 25+ regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) play a role in controlling the development and progression of autoimmunity. The transcription factors Foxp3 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NFATC2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (NFAT1) play key roles in regulating the development and function of Tregs. The present study examined the involvement of Tregs in the pathophysiology of autoimmune neutropenia in children. Tregs were analysed by flow cytometry, based on the expressions of CD4, CD25, and intracellular Foxp3. The expressions of FOXP3 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NFATC2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mRNA in the CD4+ 25+ cells were determined by quantitative real-time polymerase chain reaction. The percentage of CD4+ 25(high) Tregs in patients with autoimmune neutropenia was significantly lower than that in age-matched healthy subjects. The intracellular expression of Foxp3 of CD4+ 25+ cells in patients similarly decreased in comparison to that in healthy subjects. The expression of FOXP3 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NFATC2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> mRNA of CD4+ 25+ cells in patients also significantly decreased in comparison to that in healthy subjects. These results suggest that the deficiency of Tregs might thus play an important role in the immunopathophysiology of autoimmune neutropenia in children.</div></details></details></td>
    </tr>
    <tr>
      <th>75</th>
      <td>RUNX1</td>
      <td>3</td>
      <td>TREG:3, TH:1</td>
      <td>0.027192</td>
      <td>ENSG00000159216</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/24716598">24716598</a><div class="entities" style="line-height: 2.5"><h3>Decreased expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Runx1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and lowered proportion of Foxp3⁺ CD25⁺ CD4⁺ regulatory T cells in systemic sclerosis.</h3></br>To investigate the role of Foxp3(+) CD25(+) CD4(+) regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) and their transcription factor, Runt-related transcription factor 1 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Runx1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>), in the pathogenesis and development of systemic sclerosis (SSc).</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/24741640">24741640</a><div class="entities" style="line-height: 2.5"><h3>Rapamycin regulates iTreg function through CD39 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Runx1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> pathways.</h3></br>It has been shown that rapamycin is able to significantly increase the expression of FoxP3 and suppress activity in induced <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> (iTreg) cells in vivo and in vitro. CD39 is a newly determined Treg marker that relates to cell suppression. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Runx1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, a regulator of FoxP3, controls the expression of adenosine deaminase (ADA) gene, which is found recently in the downstream of CD39 pathway in trophoblast cells. Whether rapamycin would influence CD39 pathway and regulate the expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Runx1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> remains to be determined. The addition of rapamycin to human CD4(+) naïve cells in the presence of IL-2, TGF-β promotes the expression of FoxP3. In this paper, we found that CD39 positively correlated with the FoxP3 expression in iTreg cells. Rapamycin induced iTreg cells showed a stronger CD39/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Runx1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression with the enhanced suppressive function. These data suggested that CD39 expression was involved in iTreg generation and the enhanced suppressive ability of rapamycin induced Treg was partly due to <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Runx1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> pathway. We conclude that rapamycin favors CD39/<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Runx1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression in human iTreg and provides a novel insight into the mechanisms of iTreg generation enhanced by rapamycin.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/21462833">21462833</a><div class="entities" style="line-height: 2.5"><h3>Plasticity of regulatory T cells under cytokine pressure.</h3></br>CD4+ T helper (Th) cells have been divided into different subsets as defined by their cytokine products and functions after their activation. CD4+ T cell subsets are continuously discovered and until now Th1, Th2, Th9, Th17, and regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells have been almost unanimously recognized but yet not completely characterized. The selective production of cytokines by each of the subsets is probably the master key of the mechanisms of immune regulation. The cytokine milieu is extremely important on deciding the fate of T cells. Generally, more than one cytokine is needed for differentiating to a particular lineage and just recently it was shown that this status quo of commitment could be challenged. It is well known that cytokines bind to Type I/II cytokine receptors signaling via Janus kinases (JAKs) followed by activation of Signal Transducer and Activator of Transcription (STAT). STAT molecules work together with other transcription factors (Foxp3, RORgammat and RORalpha, T-bet, GATA3, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Runx 1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, NFAT, etc.) also controlled by cytokines, in modulating the Th phenotype and functions. In this review, we analyze the plasticity of Treg population focusing on the most recent discoveries on how microenvironmental cytokines refine/modify Treg phenotype and function, thus changing their fate.</div></details><details><summary>TH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/21462833">21462833</a><div class="entities" style="line-height: 2.5"><h3>Plasticity of regulatory T cells under cytokine pressure.</h3></br>CD4+ T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells have been divided into different subsets as defined by their cytokine products and functions after their activation. CD4+ T cell subsets are continuously discovered and until now Th1, Th2, Th9, Th17, and regulatory T (Treg) cells have been almost unanimously recognized but yet not completely characterized. The selective production of cytokines by each of the subsets is probably the master key of the mechanisms of immune regulation. The cytokine milieu is extremely important on deciding the fate of T cells. Generally, more than one cytokine is needed for differentiating to a particular lineage and just recently it was shown that this status quo of commitment could be challenged. It is well known that cytokines bind to Type I/II cytokine receptors signaling via Janus kinases (JAKs) followed by activation of Signal Transducer and Activator of Transcription (STAT). STAT molecules work together with other transcription factors (Foxp3, RORgammat and RORalpha, T-bet, GATA3, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Runx 1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, NFAT, etc.) also controlled by cytokines, in modulating the Th phenotype and functions. In this review, we analyze the plasticity of Treg population focusing on the most recent discoveries on how microenvironmental cytokines refine/modify Treg phenotype and function, thus changing their fate.</div></details></details></td>
    </tr>
    <tr>
      <th>76</th>
      <td>AIRE</td>
      <td>9</td>
      <td>TREG:7, TH:1, TH17:1</td>
      <td>0.025636</td>
      <td>ENSG00000160224</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/26903483">26903483</a><div class="entities" style="line-height: 2.5"><h3>Anticommensal Responses Are Associated with Regulatory T Cell Defect in Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy Patients.</h3></br>Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is a monogenic autoimmune disease caused by mutations in the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AIRE    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> gene. Although mainly an endocrine disease, a substantial fraction of patients have gastrointestinal manifestations. In this study, we have examined the role of anticommensal responses and their regulation. APECED patients had increased levels of Abs against Saccharomyces cerevisiae (p < 0.0001) and against several species of commensal gut bacteria, but not against species predominantly associated with other locations. The anticommensal Ab levels did not correlate with gastrointestinal autoantibodies, neutralizing anti-IL-17 or -IL-22 Abs, or gastrointestinal symptoms, although scarcity of the available clinical data suggests that further study is required. However, the anti-S. cerevisiae Ab levels showed a significant inverse correlation with FOXP3 expression levels in regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>), previously shown to be dysfunctional in APECED. The correlation was strongest in the activated CD45RO(+) population (ρ = -0.706; p < 0.01). APECED patients also had decreased numbers of FOXP3(+) cells in gut biopsies. These results show that APECED patients develop early and sustained responses to gut microbial Ags in a pattern reminiscent of Crohn's disease. This abnormal immune recognition of gut commensals is linked to a systemic Treg defect, which is also reflected as a local decrease of gut-associated Treg. To our knowledge, these data are the first to show dysregulated responses to non-self commensal Ags in APECED and indicate that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AIRE    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> contributes to the regulation of gut homeostasis, at least indirectly. The data also raise the possibility of persistent microbial stimulation as a contributing factor in the pathogenesis of APECED. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/26098878">26098878</a><div class="entities" style="line-height: 2.5"><h3>Thymosin α1: burying secrets in the thymus.</h3></br>Thymosin α1 (Tα1), an epithelial cell (EC)-derived cytokine, has the strong ability to modulate signals delivered through innate immune receptors on dendritic cells (DCs), thus instructing the initiation of appropriate immune responses to T cells. In its ability to activate indoleamine 2,3-dioxygenase 1-dependent tolerogenic programs in DCs, Tα1 pivotally contributes to the maintenance of self-tolerance by regulating the function of regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. How Tα1 may contribute to the Treg cell ontogeny is not known. The transcriptional regulator autoimmune regulator (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AIRE    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) is known to control central and peripheral tolerance. <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AIRE    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is highly expressed in thymic medullary ECs where it controls the ectopic expression of tissue restricted antigens for negative selection. The absence of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AIRE    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>-induced tissue-specific antigens in the thymus can lead to autoimmunity in the antigen-expressing target organ. Recently, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AIRE    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> protein has been detected in peripheral lymphoid organs, suggesting that peripheral <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AIRE    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> may play a complementary role. We have addressed the possible relationship between <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AIRE    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and Tα1 and discovered an intricate crosstalk, whereby <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AIRE    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> may promote prothymosin cleavage to Tα1, and Tα1 in turn transcriptionally regulates <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AIRE    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression. Thus, similar to other members of thymic stromal poietins, Tα1 expressed within the thymus and peripheral tissues regulates the EC/DC crosstalk required for salutary immune homeostasis. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/24768600">24768600</a><div class="entities" style="line-height: 2.5"><h3>Autoimmune regulator expression in thymomas with or without autoimmune disease.</h3></br>The autoimmune regulator (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AIRE    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) regulates autoimmunity and self-antigen expression, such as acetylcholine receptor (AchR), in the thymus. Regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) can down-regulate autoimmunity, but also promote tumor growth. The objective of this study was to examine the levels of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AIRE    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, AchR, and Foxp3 expression in thymomas.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/17590173">17590173</a><div class="entities" style="line-height: 2.5"><h3>Expression of autoimmune regulator gene (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AIRE    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) and T regulatory cells in human thymomas.</h3></br>Expression of the autoimmune regulator gene (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AIRE    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) and the presence of CD25(+)/forkhead box p3 (FoxP3)(+) T regulatory (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells were investigated in histologically normal adult thymi and in thymomas using immunohistochemistry and quantitative real-time polymerase chain reaction (PCR). In the normal thymus staining for <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AIRE    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> was detected in the nucleus of some epithelial-like cells located in the medulla; in thymomas AIRE-positive cells were extremely rare and could be detected only in the areas of medullary differentiation of two B1 type, organoid thymomas. RNA was extracted from 36 cases of thymoma and 21 non-neoplastic thymi obtained from 11 myasthenic (MG(+)) and 10 non-myasthenic (MG(-)) patients. It was found that <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AIRE    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> is 8.5-fold more expressed in non-neoplastic thymi than in thymomas (P = 0.01), and that the amount of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AIRE    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> transcripts present in the thymoma tissue are not influenced by the association with MG, nor by the histological type. A possible involvement of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AIRE    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in the development of MG was suggested by the observation that medullary thymic epithelial cells isolated from <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AIRE    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>-deficient mice contain low levels of RNA transcripts for CHRNA 1, a gene coding for acetylcholine receptor. Expression of human CHRNA 1 RNA was investigated in 34 human thymomas obtained from 20 MG(-) patients and 14 MG(+) patients. No significant difference was found in the two groups (thymoma MG(+), CHRNA1 = 0.013 +/- 0.03; thymoma MG-, CHRNA1 = 0.01 +/- 0.03). In normal and hyperplastic thymi CD25(+)/Foxp3(+) cells were located mainly in the medulla, and their number was not influenced by the presence of MG. Foxp3(+) and CD25(+) cells were significantly less numerous in thymomas. A quantitative estimate of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells revealed that the levels of Foxp3 RNA detected in non-neoplastic thymi were significantly higher (P = 0.02) than those observed in 31 cases of thymomas. Our findings indicate that the tissue microenvironment of thymomas is defective in the expression of relevant functions that exert a crucial role in the negative selection of autoreactive lymphocytes.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/20805020">20805020</a><div class="entities" style="line-height: 2.5"><h3>Regulatory T cell defect in APECED patients is associated with loss of naive FOXP3(+) precursors and impaired activated population.</h3></br>The pathogenetic mechanisms of organ-specific autoimmune diseases remain obscured by the complexity of the genetic and environmental factors participating in the breakdown of tolerance. A unique opportunity to study the pathogenesis of human autoimmunity is provided by autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), a rare inherited autoimmune disease caused by mutations in Autoimmune Regulator (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AIRE    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) gene. Loss of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AIRE    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> function disrupts the deletion of autoreactive T cells and impairs the suppressive function of regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. Here we show by multiparameter flow cytometry that in healthy controls the peripheral naive Treg cell subset forms a slowly dividing, persistent reservoir of recent thymic emigrants (RTEs). In APECED patients the RTE Treg cells show accelerated turnover and shift to the activated pool and the RTE reservoir is depleted. Moreover, the activated Treg cell population in the patients expresses significantly less Forkhead box protein P3 (FOXP3) than in the healthy controls, consistent with the impairment of peripheral activation. Our results indicate that in addition to their thymic effects, loss-of-function mutations in <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AIRE    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> disrupt the peripheral homeostasis and activation of Treg cells. This may synergize with failed negative selection to cause APECED.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/17876107">17876107</a><div class="entities" style="line-height: 2.5"><h3>Thymic involution: implications for self-tolerance.</h3></br>The thymus contributes to the regulation of tolerance and the prevention of autoimmunity at many levels. First, auto-reactive CD4+ and CD8+ T cells are clonally deleted during negative selection in the thymus, establishing central tolerance. The unique expression of the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AIRE    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (autoimmune regulator) gene in medullary thymic epithelial cells results in expression of a broad array of tissue-specific antigens. Thymocytes bearing T cell receptors that bind to these tissue-specific antigens are clonally deleted. This process removes self-reactive T cells from the repertoire before T cells are exported to the periphery. Second, CD4+CD25 bright regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) develop in parallel with CD4+ and CD8+ effector T cells in the thymus. Unlike T effector cells, Treg fail to be deleted by exposure to tissue antigens during thymic maturation. After export to the periphery, Treg cells play a critical role in the prevention of autoimmunity, suppression of inflammatory responses, and the modulation of T cell homeostasis. Finally, productive thymopoiesis, in and of itself, may be a factor deterring autoimmunity, The thymus continuously generates stable, resting populations of naive T cells that maintain the numbers and the diversity of the T cell repertoire. Under conditions of lymphopenia prolonged by inadequate thymopoiesis, compensatory peripheral expansion of T cells occurs to maintain stable T cell levels. Under circumstances in which the repertoire is limited, Homeostatic proliferation may increase the opportunity for T cells reactive with self antigens to expand, leading to autoimmune disorders. In all of these respects, the thymus maintains immunologic tolerance to self. Given the importance of the thymus in control of autoimmunity, the gradual age-dependent decline in thymic cytoarchitecture and thymopoietic productivity may, therefore, contribute to the development of auto-reactivity and loss of self-tolerance.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/15981475">15981475</a><div class="entities" style="line-height: 2.5"><h3>Thymic commitment of regulatory T cells is a pathway of TCR-dependent selection that isolates repertoires undergoing positive or negative selection.</h3></br>The seminal work of Le Douarin and colleagues (Ohki et al. 1987; Ohki et al. 1988; Salaun et al. 1990; Coutinho et al. 1993) first demonstrated that peripheral tissue-specific tolerance is centrally established in the thymus, by epithelial stromal cells (TEC). Subsequent experiments have shown that TEC-tolerance is dominant and mediated by CD4 regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) that are generated intrathymically by recognition of antigens expressed on TECs (Modigliani et al. 1995; Modigliani et al. 1996a). From these and other observations, in 1996 Modigliani and colleagues derived a general model for the establishment and maintenance of natural tolerance (MM96) (Modigliani et al. 1996b), with two central propositions: (1) T cell receptor (TCR)-dependent sorting of emergent repertoires generates TEC-specific Treg displaying the highest TCR self-affinities below deletion thresholds, thus isolating repertoires undergoing positive and negative selection; (2) Treg are intrathymically committed (and activated) for a unique differentiative pathway with regulatory effector functions. The model explained the embryonic/perinatal time window of natural tolerance acquisition, by developmental programs determining (1) TCR multireactivity, (2) the cellular composition in the thymic stroma (relative abundance of epithelial vs hemopoietic cells), and (3) the dynamics of peripheral lymphocyte pools, built by accumulation of recent thymic emigrants (RTE) that remain recruitable to regulatory functions. We discuss here the MM96 in the light of recent results demonstrating the promiscuous expression of tissue-specific antigens by medullary TECs (Derbinski et al. 2001; Anderson et al. 2002; Gotter et al. 2004) and indicating that Treg represent a unique differentiative pathway (Fontenot et al. 2003; Hori et al. 2003; Khattri et al. 2003), which is adopted by CD4 T cells with high avidity for TEC-antigens (Bensinger et al. 2001; Jordan et al. 2001; Apostolou et al. 2002). In the likelihood that autoimmune diseases (AID) result from Treg deficits, some of which might have a thymic origin, we also speculate on therapeutic strategies aiming at selectively stimulating their de novo production or peripheral function, within recent findings on Treg responses to inflammation (Caramalho et al. 2003; Lopes-Carvalho et al., submitted, Caramalho et al., submitted). In short, the MM96 argued that natural tolerance is dominant, established and maintained by the activity of Treg, which are selected upon high-affinity recognition of self-ligands on TECs, and committed intrathymically to a unique differentiative pathway geared to anti-inflammatory and antiproliferative effector functions. By postulating the intrathymic deletion of self-reactivities on hemopoietic stromal cells (THC), together with the inability of peripheral resident lymphocytes to engage in the regulatory pathway, the MM96 simultaneously explained the maintenance of responsiveness to non-self in a context of suppression mediating dominant self-tolerance. The major difficulty of the MM96 is related to the apparent tissue specificity of Treg repertoires generated intrathymically. This difficulty has now been principally solved by the work of Hanahan, Kyewski and others (Jolicoeur et al. 1994; Derbinski et al. 2001; Anderson et al. 2002; Gotter et al. 2004), demonstrating the selective expression of a variety of tissue-specific antigens by TECs, in topological patterns that are compatible with the MM96, but difficult to conciliate with recessive tolerance models (Kappler et al. 1987; Kisielow et al. 1988). While the developmentally regulated multireactivity of TCR repertoires (Gavin and Bevan 1995), as well as the peripheral recruitment of Treg among RTE (Modigliani et al. 1996a) might add to this process, it would seem that the establishment of tissue-specific tolerance essentially stems from the "promiscuous expression of tissue antigens" by TEC. The findings of AID resulting from natural mutations (reviewed in Pitkanen and Peterson 2003) or the targeted inactivation (Anderson et al. 2002; Ramsey et al. 2002) of the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AIRE    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> transcription factor that regulates promiscuous gene expression on TECs support this conclusion. The observations on the correlation of natural or forced expression of the Foxp3 transcription factor in CD4 T cells with Treg phenotype and function (Fontenot et al. 2003; Hori et al. 2003; Khattri et al. 2003) provided support for the MM96 contention that Treg represent a unique differentiative pathway that is naturally established inside the thymus. Furthermore, Caton and colleagues (Jordan et al. 2001), as well as several other groups (Bensinger et al. 2001; Apostolou et al. 2002), have provided direct evidence for our postulate that Treg are selected among differentiating CD4 T cells with high affinity for ligands expressed on TECs (Modigliani et al. 1996b). Finally, the demonstration by Caramalho et al. that Treg express innate immunity receptors (Caramalho et al. 2003) and respond to pro-inflammatory signals and products of inflammation (Caramalho et al., submitted) brought about a new understanding on the peripheral regulation of Treg function. Together with the observation that Treg also respond to ongoing activities of "naïve/effector" T cells--possibly through the IL-2 produced in these conditions--these findings explain the participation of Treg in all immune responses (Onizuka et al. 1999; Shimizu et al. 1999; Annacker et al. 2001; Curotto de Lafaille et al. 2001; Almeida et al. 2002; Shevach 2002; Bach and Francois Bach 2003; Wood and Sakaguchi 2003; Mittrucker and Kaufmann 2004; Sakaguchi 2004), beyond their fundamental role in ensuring self-tolerance (e.g., Modigliani et al. 1996a; Shevach 2000; Hori et al. 2003; Sakaguchi 2004; Thompson and Powrie 2004). Thus, anti-inflammatory and anti-proliferative Treg are amplified by signals that promote or mediate inflammation and proliferation, accounting for the quality control of responses (Coutinho et al. 2001). In turn, such natural regulation of Treg by immune responses to non-self may well explain the alarming epidemiology of allergic and AID in wealthy societies (Wills-Karp et al. 2001; Bach 2002; Yazdanbakhsh et al. 2002), where a variety of childhood infections have become rare or absent. Thus, it is plausible that Treg were evolutionarily set by a given density of infectious agents in the environment. With hindsight, it is not too surprising that natural Treg performance falls once hygiene, vaccination, and antibiotics suddenly (i.e., 100 years) plunged infectious density to below some critical physiological threshold. As the immune system is not adapted to modern clean conditions of postnatal development, clinical immunologists must now deal with frequent Treg deficiencies (allergies and AID) for which they have no curative or rational treatments. It is essential, therefore, that basic immunologists concentrate on strategies to selectively stimulate the production, survival, and activity of this set of lymphocytes that is instrumental in preventing immune pathology. We have argued that the culprit of this inability of basic research to solve major clinical problems has been the self-righteousness of recessive tolerance champions, from Ehrlich to some of our contemporaries. It is ironical, however, that none of us--including the heretic opponents of horror autotoxicus--had understood that self-tolerance, or its robustness at least, is in part determined by the frequency and intensity of the responses to non-self. In the evolution of ideas on immunological tolerance, the time might be ripe for some kinds of synthesis. First, conventional theory reduced self-tolerance to negative selection and microbial defense to positive selection, while the MM96 solution was the precise opposite: positive selection of autoreactivities for self-tolerance (Treg) and negative selection (of Treg) for ridding responses. In contrast, it would now appear that positive and negative selection of autoreactive T cells are both necessary to establish either self-tolerance or competence to eliminate microbes, two processes that actually reinforce each other in the maintenance of self-integrity. Second, V-region recognition has generally been held responsible for specific discrimination between what should be either tolerated or eliminated from the organism. In contrast again, it would now seem that both processes of self-tolerance and microbial defense (self/non-self discrimination) also operate on the basis of evolutionarily ancient, germ-line-encoded innate, nonspecific receptors (Medzhitov and Janeway 2000) capable of a coarse level of self/non-self discrimination (Coutinho 1975). It could thus be interesting to revisit notions of cooperativity between V-regions and such mitogen receptors, both in single cell functions (Coutinho et al. 1974) and in the system's evolution (Coutinho 1975, 1980) as well. After all, major transitions in evolution were cooperative (Maynard-Smith and Szathmary 1995).</div></details><details><summary>TH</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27262317">27262317</a><div class="entities" style="line-height: 2.5"><h3>Expanded CD4(+) Effector/Memory T Cell Subset in APECED Produces Predominantly Interferon Gamma.</h3></br>Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is a rare human autoimmune disorder caused by mutations in the <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AIRE    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (autoimmune regulator) gene. Loss of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AIRE    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> disrupts thymic negative selection and gives rise to impaired cytotoxic and regulatory T cell populations. To date, CD4(+) T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells remain little studied. This study aims to elucidate their role in APECED pathogenesis.</div></details><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/24934596">24934596</a><div class="entities" style="line-height: 2.5"><h3>Myasthenia Gravis: paradox versus paradigm in autoimmunity.</h3></br>Myasthenia Gravis (MG) is a paradigm of organ-specific autoimmune disease (AID). It is mediated by antibodies that target the neuromuscular junction. The purpose of this review is to place MG in the general context of autoimmunity, to summarize the common mechanisms between MG and other AIDs, and to describe the specific mechanisms of MG. We have chosen the most common organ-specific AIDs to compare with MG: type 1 diabetes mellitus (T1DM), autoimmune thyroid diseases (AITD), multiple sclerosis (MS), some systemic AIDs (systemic lupus erythematous (SLE), rheumatoid arthritis (RA), Sjogren's syndrome (SS)), as well as inflammatory diseases of the gut and liver (celiac disease (CeD), Crohn's disease (CD), and primary biliary cirrhosis (PBC)). Several features are similar between all AIDs, suggesting that common pathogenic mechanisms lead to their development. In this review, we address the predisposing factors (genetic, epigenetic, hormones, vitamin D, microbiota), the triggering components (infections, drugs) and their interactions with the immune system [1,2]. The dysregulation of the immune system is detailed and includes the role of B cells, Treg cells, <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and cytokines. We particularly focused on the role of TNF-α and interferon type I whose role in MG is very analogous to that in several other AIDS. The implication of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    AIRE    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, a key factor in central tolerance is also discussed. Finally, if MG is a prototype of AIDS, it has a clear specificity compared to the other AIDS, by the fact that the target organ, the muscle, is not the site of immune infiltration and B cell expansion, but exclusively that of antibody-mediated pathogenic mechanisms. By contrast, the thymus in the early onset subtype frequently undergoes tissue remodeling, resulting in the development of ectopic germinal centers surrounded by high endothelial venules (HEV), as observed in the target organs of many other AIDs. </div></details></details></td>
    </tr>
    <tr>
      <th>77</th>
      <td>ASH1L</td>
      <td>1</td>
      <td>TREG:1</td>
      <td>0.024871</td>
      <td>ENSG00000116539</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/28598443">28598443</a><div class="entities" style="line-height: 2.5"><h3><mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ash1l    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and lnc-Smad3 coordinate Smad3 locus accessibility to modulate iTreg polarization and T cell autoimmunity.</h3></br>Regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are important for the maintenance of immune homoeostasis and prevention of autoimmune diseases. Epigenetic modifications have been reported to modulate autoimmunity by altering Treg cell fate. Here we show that the H3K4 methyltransferase Ash1l facilitates TGF-β-induced Treg cell polarization in vitro and protects mice from T cell-mediated colitis in vivo. Ash1l upregulates Smad3 expression by directly targeting Smad3 promoter to increase local H3K4 trimethylation. Furthermore, we identify an lncRNA, namely lnc-Smad3, which interacts with the histone deacetylase HDAC1 and silences Smad3 transcription. After TGF-β stimulation, activated Smad3 suppresses lnc-Smad3 transcription, thereby recovering the Smad3 promoter accessibility to <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ash1l    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. By revealing the opposite regulatory functions of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Ash1l    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and lnc-Smad3 in Smad3 expression, our data provide insights for the epigenetic control of Treg cell fate to potentially aid in the development of therapeutic intervention for autoimmune diseases.</div></details></details></td>
    </tr>
    <tr>
      <th>78</th>
      <td>SMAD4</td>
      <td>2</td>
      <td>TH17:1, TREG:1</td>
      <td>0.024121</td>
      <td>ENSG00000141646</td>
      <td><details><summary>Subtypes</summary><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/29682722">29682722</a><div class="entities" style="line-height: 2.5"><h3>The role of transforming growth factor β in T helper 17 differentiation.</h3></br>T helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells play critical roles in inflammatory and autoimmune diseases. The lineage-specific transcription factor RORγt is the key regulator for Th17 cell fate commitment. A substantial number of studies have established the importance of transforming growth factor β (TGF-β) -dependent pathways in inducing RORγt expression and Th17 differentiation. TGF-β superfamily members TGF-β1  , TGF-β3  or activin A, in concert with interleukin-6 or interleukin-21, differentiate naive T cells into Th17 cells. Alternatively, Th17 differentiation can occur through TGF-β-independent pathways. However, the mechanism of how TGF-β-dependent and TGF-β-independent pathways control Th17 differentiation remains controversial. This review focuses on the perplexing role of TGF-β in Th17 differentiation, depicts the requirement of TGF-β for Th17 development, and underscores the multiple mechanisms underlying TGF-β-promoted Th17 generation, pathogenicity and plasticity. With new insights and comprehension from recent findings, this review specifically tackles the involvement of the canonical TGF-β signalling components, SMAD2, SMAD3 and SMAD4, summarizes di<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    verse    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> SMAD-independent mechanisms, and highlights the importance of TGF-β signalling in balancing the reciprocal conversion of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and regulatory T cells. Finally, this review includes discussions and perspectives and raises important mechanistic questions about the role of TGF-β in Th17 generation and function.</div></details><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/26501792">26501792</a><div class="entities" style="line-height: 2.5"><h3>Regulatory T Cells Are Critical for Clearing Influenza A Virus in Neonatal Mice.</h3></br>We previously reported that neonatal mice infected with influenza A virus (IAV) develop interstitial pneumonia characterized by reduced lung cytokine and chemokine responses. The failure of T cells to infiltrate the airways of neonates correlated with delayed clearance of sublethal IAV infections compared to adults. We hypothesized that negative regulators in the neonatal lungs such as cytokines or T regulatory (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are responsible for these differences. Neonates either deficient in interleukin-10 (IL-10) or with T cells unresponsive to transforming growth factor-β signaling due to absence of SMAD family member 4 (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Smad4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) had similar IAV clearance kinetics to wild-type pups and no difference in T cell responses. In contrast, functional depletion of Treg cells with anti-CD25 monoclonal antibody resulted in increased proportions of activated CD4(+) T cells in the lungs, but failure to clear IAV. Similarly, scurfy pups (mutation in forkhead box P3 [Foxp3] rendering them deficient in Treg cells) had increased proportions of activated T cells in the lungs compared to littermate controls. Scurfy pups also had increased proportions of IL-13-producing CD4(+) T cells. Interestingly, like anti-CD25-treated pups, scurfy pups had significantly elevated viral loads compared to controls. Based on these data, we conclude that Tregs are critical for clearance of IAV in neonatal mice. </div></details></details></td>
    </tr>
    <tr>
      <th>79</th>
      <td>SOX4</td>
      <td>1</td>
      <td>TH17:1, TREG:1</td>
      <td>0.024121</td>
      <td>ENSG00000124766</td>
      <td><details><summary>Subtypes</summary><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/24362934">24362934</a><div class="entities" style="line-height: 2.5"><h3>Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis.</h3></br>Autoimmune diseases often result from an imbalance between regulatory T (Treg) cells and interleukin-17 (IL-17)-producing T helper (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells; the origin of the latter cells remains largely unknown. Foxp3 is indispensable for the suppressive function of Treg cells, but the stability of Foxp3 has been under debate. Here we show that TH17 cells originating from Foxp3(+) T cells have a key role in the pathogenesis of autoimmune arthritis. Under arthritic conditions, CD25(lo)Foxp3(+)CD4(+) T cells lose Foxp3 expression (herein called exFoxp3 cells) and undergo transdifferentiation into TH17 cells. Fate mapping analysis showed that IL-17-expressing exFoxp3 T (exFoxp3 <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    TH17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells accumulated in inflamed joints. The conversion of Foxp3(+)CD4(+) T cells to TH17 cells was mediated by synovial fibroblast-derived IL-6. These exFoxp3 TH17 cells were more potent osteoclastogenic T cells than were naive CD4(+) T cell-derived TH17 cells. Notably, exFoxp3 TH17 cells were characterized by the expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Sox4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, chemokine (C-C motif) receptor 6 (CCR6), chemokine (C-C motif) ligand 20 (CCL20), IL-23 receptor (IL-23R) and receptor activator of NF-κB ligand (RANKL, also called TNFSF11). Adoptive transfer of autoreactive, antigen-experienced CD25(lo)Foxp3(+)CD4(+) T cells into mice followed by secondary immunization with collagen accelerated the onset and increased the severity of arthritis and was associated with the loss of Foxp3 expression in the majority of transferred T cells. We observed IL-17(+)Foxp3(+) T cells in the synovium of subjects with active rheumatoid arthritis (RA), which suggests that plastic Foxp3(+) T cells contribute to the pathogenesis of RA. These findings establish the pathological importance of Foxp3 instability in the generation of pathogenic TH17 cells in autoimmunity. </div></details><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/24362934">24362934</a><div class="entities" style="line-height: 2.5"><h3>Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis.</h3></br>Autoimmune diseases often result from an imbalance between regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells and interleukin-17 (IL-17)-producing T helper (TH17) cells; the origin of the latter cells remains largely unknown. Foxp3 is indispensable for the suppressive function of Treg cells, but the stability of Foxp3 has been under debate. Here we show that TH17 cells originating from Foxp3(+) T cells have a key role in the pathogenesis of autoimmune arthritis. Under arthritic conditions, CD25(lo)Foxp3(+)CD4(+) T cells lose Foxp3 expression (herein called exFoxp3 cells) and undergo transdifferentiation into TH17 cells. Fate mapping analysis showed that IL-17-expressing exFoxp3 T (exFoxp3 TH17) cells accumulated in inflamed joints. The conversion of Foxp3(+)CD4(+) T cells to TH17 cells was mediated by synovial fibroblast-derived IL-6. These exFoxp3 TH17 cells were more potent osteoclastogenic T cells than were naive CD4(+) T cell-derived TH17 cells. Notably, exFoxp3 TH17 cells were characterized by the expression of <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Sox4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, chemokine (C-C motif) receptor 6 (CCR6), chemokine (C-C motif) ligand 20 (CCL20), IL-23 receptor (IL-23R) and receptor activator of NF-κB ligand (RANKL, also called TNFSF11). Adoptive transfer of autoreactive, antigen-experienced CD25(lo)Foxp3(+)CD4(+) T cells into mice followed by secondary immunization with collagen accelerated the onset and increased the severity of arthritis and was associated with the loss of Foxp3 expression in the majority of transferred T cells. We observed IL-17(+)Foxp3(+) T cells in the synovium of subjects with active rheumatoid arthritis (RA), which suggests that plastic Foxp3(+) T cells contribute to the pathogenesis of RA. These findings establish the pathological importance of Foxp3 instability in the generation of pathogenic TH17 cells in autoimmunity. </div></details></details></td>
    </tr>
    <tr>
      <th>80</th>
      <td>FOXP2</td>
      <td>1</td>
      <td>TH17:1, TREG:1</td>
      <td>0.024121</td>
      <td>ENSG00000128573</td>
      <td><details><summary>Subtypes</summary><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/20646003">20646003</a><div class="entities" style="line-height: 2.5"><h3>Involvement of T helper type 17 and regulatory T cell activity in tumour immunology of bladder carcinoma.</h3></br>T helper type 17 (Th17) and regulatory T cells (T(reg) ) play an important role in the pathogenesis of inflammation and autoimmune disorders. Recent studies have suggested that they also had an impact on tumour immunology. However, the relationship between <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and T(reg) cells in the pathogenesis of bladder carcinoma is still unclear. Flow cytometry was used to analyse the numbers, phenotype and cytokine production of Th17 cells in peripheral blood and tumour tissue from bladder carcinoma patients, in parallel with analysis of T(reg) cells. The suppressor capacity of T(reg) and the potential effects of interleukin (IL)-2 on the differentiation of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and T(reg) cells in vitro were studied in a T cell stimulation and suppression assays. The results were as follows: Th17 cells were enriched in the tumours of patients with bladder carcinoma compared with the peripheral blood of patients and controls; patients with bladder carcinoma had a higher proportion of T(reg) cells in peripheral blood compared with healthy controls and nearly all patients examined showed a relative enrichment of tumour-infiltrating T(reg) with respect to peripheral blood; there appeared to be an inverse relationship between tumour-infiltrating <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and T(reg) cells; IL-2 could convert tumour-infiltrating T(reg) cells cultured in the presence of the autologous irradiated CD3(-) fraction into Th17 cells, down-regulate <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    forkhead box P2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression and suppressive capacity of T(reg) cells. This study is the first to define the frequency and characteristics of Th17 cells in bladder carcinoma. We suggest that the balance between <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and T(reg) cells may be involved in the development or progression of bladder carcinoma.</div></details><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/20646003">20646003</a><div class="entities" style="line-height: 2.5"><h3>Involvement of T helper type 17 and regulatory T cell activity in tumour immunology of bladder carcinoma.</h3></br>T helper type 17 (Th17) and regulatory T cells (T(reg) ) play an important role in the pathogenesis of inflammation and autoimmune disorders. Recent studies have suggested that they also had an impact on tumour immunology. However, the relationship between Th17 and T(reg) cells in the pathogenesis of bladder carcinoma is still unclear. Flow cytometry was used to analyse the numbers, phenotype and cytokine production of Th17 cells in peripheral blood and tumour tissue from bladder carcinoma patients, in parallel with analysis of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells. The suppressor capacity of T(reg) and the potential effects of interleukin (IL)-2 on the differentiation of Th17 and T(reg) cells in vitro were studied in a T cell stimulation and suppression assays. The results were as follows: Th17 cells were enriched in the tumours of patients with bladder carcinoma compared with the peripheral blood of patients and controls; patients with bladder carcinoma had a higher proportion of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells in peripheral blood compared with healthy controls and nearly all patients examined showed a relative enrichment of tumour-infiltrating T(reg) with respect to peripheral blood; there appeared to be an inverse relationship between tumour-infiltrating Th17 and T(reg) cells; IL-2 could convert tumour-infiltrating <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells cultured in the presence of the autologous irradiated CD3(-) fraction into Th17 cells, down-regulate <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    forkhead box P2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> expression and suppressive capacity of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells. This study is the first to define the frequency and characteristics of Th17 cells in bladder carcinoma. We suggest that the balance between Th17 and T(reg) cells may be involved in the development or progression of bladder carcinoma.</div></details></details></td>
    </tr>
    <tr>
      <th>81</th>
      <td>ESR1</td>
      <td>2</td>
      <td>TREG:2</td>
      <td>0.020307</td>
      <td>ENSG00000091831</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/17261780">17261780</a><div class="entities" style="line-height: 2.5"><h3>A potential role for estrogen in experimental autoimmune encephalomyelitis and multiple sclerosis.</h3></br>The extensive literature and the work from our laboratory illustrate the large number of complex processes affected by estrogen that might contribute to the striking ability of 17-beta estradiol (E2) and its derivatives to inhibit clinical and histological signs of experimental autoimmune encephalomyelitis (EAE) in mice. These effects require sustained exposure to relatively low doses of exogenous hormone and offer better protection when initiated prior to induction of EAE. The E2 mediates inhibition of encephalitogenic T cells, inhibition of cell migration into central nervous system tissue, and neuroprotective effects that promote axon and myelin survival. E2 effects on EAE are mediated through <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Esr-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (alpha receptor for E2) but not Esr-2 (beta receptor for E2), as are its anti-inflammatory and neuroprotective effects. A novel finding is that E2 upregulated the expression of FoxP3 that contributes to the activity of CD4 + CD25 + T regulatory cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>). The protective effects of E2 in EAE suggest its use as a therapy for multiple sclerosis (MS). Possible risks may be minimized by using sub-pregnancy levels of exogenous E2 that produced synergistic effects when used in combination with another immunoregulatory therapy. Alternatively, one might envision using E2 derivatives alone or in combination therapies in both male and female MS patients.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/16318990">16318990</a><div class="entities" style="line-height: 2.5"><h3>Congruent effects of estrogen and T cell receptor peptide therapy on regulatory T cells in EAE and MS.</h3></br>Both estrogen (E2) and T cell receptor (TCR) peptides have beneficial effects on the clinical course of experimental autoimmune encephalomyelitis (EAE) and possibly multiple sclerosis (MS) that involve distinct but congruent mechanisms. Of interest, these two approaches share an ability to enhance expression of the FoxP3 gene and associated activity of regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells. E2 increases the number and activity of FoxP3(+) T cells through <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Esr-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> signaling during TCR activation of CD4(+)CD25(-) T cells. In contrast, TCR peptide therapy appears to increase the frequency of regulatory FoxP3(+) T cells specific for self-TCR determinants expressed by targeted pathogenic T cells. The combined effects on Treg expansion and activation induced by these distinct immunoregulatory approaches may account for their potent effects on clinical EAE and argue for a similar combined therapeutic approach for MS.</div></details></details></td>
    </tr>
    <tr>
      <th>82</th>
      <td>IKZF4</td>
      <td>2</td>
      <td>TREG:2</td>
      <td>0.020307</td>
      <td>ENSG00000123411</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27075967">27075967</a><div class="entities" style="line-height: 2.5"><h3>Human macrophages induce CD4(+)Foxp3(+) regulatory T cells via binding and re-release of TGF-β.</h3></br>While pro-inflammatory immune responses are a requirement to combat microbes, uncontrolled self-directed inflammatory immune responses are the hallmark of autoimmune diseases. Restoration of immunological tolerance involves both suppression of ongoing tissue-destructive immune responses and re-education of the host immune system. Both functionally immunosuppressive macrophages (M2) and regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) are implicated in these processes. Their mutual interaction is synergistic in this context and adoptive transfer of each cell type has been functioning as immunotherapy in experimental models, being particularly effective when using M2 macrophages generated with an optimized interleukin-4 (IL-4)/interleukin-10 (IL-10)/transforming growth factor-β (TGF-β) combination. As a prerequisite for eventual translation of M2 therapy into clinical settings we herein studied the induction, stability and mechanism of generation of human induced Tregs (iTregs) by M2 macrophages generated with IL-4/IL-10/TGF-β. The supernatants of monocyte-derived human M2 macrophages robustly induced FOXP3 and other Treg signature molecules such as CTLA-4 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IKZF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> in human naïve CD4 T cells. M2-induced iTregs displayed enhanced FOXP3 stability and low expression of pro-inflammatory cytokines interferon-γ and IL-17, as well as functional immunosuppressive activity compared with control T cells. The FOXP3-inducing activity was dependent on TGF-β, which was both expressed and captured with re-release by M2 macrophages into the soluble supernatant fraction, in which the TGF-β was not confined to extracellular vesicles such as exosomes. We propose that adoptive transfer of human M2 macrophages may be exploited in the future to induce Tregs in situ by delivering TGF-β, which could be developed as a therapeutic strategy to target autoimmune and other inflammatory diseases.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/20596022">20596022</a><div class="entities" style="line-height: 2.5"><h3>Genome-wide association study in alopecia areata implicates both innate and adaptive immunity.</h3></br>Alopecia areata (AA) is among the most highly prevalent human autoimmune diseases, leading to disfiguring hair loss due to the collapse of immune privilege of the hair follicle and subsequent autoimmune attack. The genetic basis of AA is largely unknown. We undertook a genome-wide association study (GWAS) in a sample of 1,054 cases and 3,278 controls and identified 139 single nucleotide polymorphisms that are significantly associated with AA (P <or= 5 x 10(-7)). Here we show an association with genomic regions containing several genes controlling the activation and proliferation of regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells), cytotoxic T lymphocyte-associated antigen 4 (CTLA4), interleukin (IL)-2/IL-21, IL-2 receptor A (IL-2RA; CD25) and Eos (also known as Ikaros family zinc finger 4; <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IKZF4    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>), as well as the human leukocyte antigen (HLA) region. We also find association evidence for regions containing genes expressed in the hair follicle itself (PRDX5 and STX17). A region of strong association resides within the ULBP (cytomegalovirus UL16-binding protein) gene cluster on chromosome 6q25.1, encoding activating ligands of the natural killer cell receptor NKG2D that have not previously been implicated in an autoimmune disease. By probing the role of ULBP3 in disease pathogenesis, we also show that its expression in lesional scalp from patients with AA is markedly upregulated in the hair follicle dermal sheath during active disease. This study provides evidence for the involvement of both innate and acquired immunity in the pathogenesis of AA. We have defined the genetic underpinnings of AA, placing it within the context of shared pathways among autoimmune diseases, and implicating a novel disease mechanism, the upregulation of ULBP ligands, in triggering autoimmunity.</div></details></details></td>
    </tr>
    <tr>
      <th>83</th>
      <td>HEY1</td>
      <td>1</td>
      <td>TH1:1, TH17:1, TREG:1</td>
      <td>0.016081</td>
      <td>ENSG00000164683</td>
      <td><details><summary>Subtypes</summary><details><summary>TH1</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/25485537">25485537</a><div class="entities" style="line-height: 2.5"><h3>Inactivation of Notch signaling reverses the Th17/Treg imbalance in cells from patients with immune thrombocytopenia.</h3></br>T helper 17 (Th17) cells and regulatory T (Treg) cells, along with <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Th2 cells, may contribute to the development of immune thrombocytopenia (ITP). The imbalance of Th17/Treg toward Th17 cells has been shown to play a pivotal role in the peripheral immune response. Notch signaling has been implicated in peripheral T cell activation and effector cell differentiation. However, the role of Th17/Treg in the pathogenesis of ITP and the effect of Notch signaling on Th17/Treg imbalances remain largely elusive in ITP. In vitro, we treated peripheral blood mononuclear cells (PBMCs) from ITP and healthy controls with γ-secretase inhibitor (DAPT). Th17 cells and Treg cells were measured by flow cytometry and IL-17, IL-21, and IL-10 secretion by enzyme immunoassay technique. The mRNA expression of Ntoch1, Hes1, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Hey1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, RORγt, and Foxp3 was investigated by RT-PCR. Cell proliferation and apoptosis were determined by the Cell Counting Kit-8 and apoptosis detection kit. We demonstrated that DAPT was effective in inhibiting mRNA expression of Notch signaling molecules. In untreated cultured PBMCs from ITP patients, we observed elevated Th17 cell and IL-21 levels and RORγt mRNA expression, decreased Treg cells and Foxp3 mRNA expression, and an increased ratio of Th17/Treg and RORγt/Foxp3. After inactivating Notch signal by DAPT, Th17 cells and Th17/Treg ratio were dose dependently decreased and accompanied by the reduction of IL-17 in culture supernatants and RORγt mRNA expression in ITP patients. However, no significant difference was found for Treg cells and Foxp3 mRNA expression, RORγt/Foxp3 ratio, and IL-21 and IL-10 levels after DAPT treatment in ITP patients. We also present evidence that the effect of DAPT inhibition on the Th17 cell response was associated with downregulation of RORγt and IL-17 transcription using human in vitro polarization. In conclusion, our findings highlight the importance of Notch signaling in Th17/Treg imbalances in ITP. Inactivation of Notch signaling might be a potential immunoregulatory strategy in ITP patients. </div></details><details><summary>TH17</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/25485537">25485537</a><div class="entities" style="line-height: 2.5"><h3>Inactivation of Notch signaling reverses the Th17/Treg imbalance in cells from patients with immune thrombocytopenia.</h3></br>T helper 17 (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Th17    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells and regulatory T (Treg) cells, along with Th1 and Th2 cells, may contribute to the development of immune thrombocytopenia (ITP). The imbalance of Th17/Treg toward Th17 cells has been shown to play a pivotal role in the peripheral immune response. Notch signaling has been implicated in peripheral T cell activation and effector cell differentiation. However, the role of Th17/Treg in the pathogenesis of ITP and the effect of Notch signaling on Th17/Treg imbalances remain largely elusive in ITP. In vitro, we treated peripheral blood mononuclear cells (PBMCs) from ITP and healthy controls with γ-secretase inhibitor (DAPT). Th17 cells and Treg cells were measured by flow cytometry and IL-17, IL-21, and IL-10 secretion by enzyme immunoassay technique. The mRNA expression of Ntoch1, Hes1, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Hey1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, RORγt, and Foxp3 was investigated by RT-PCR. Cell proliferation and apoptosis were determined by the Cell Counting Kit-8 and apoptosis detection kit. We demonstrated that DAPT was effective in inhibiting mRNA expression of Notch signaling molecules. In untreated cultured PBMCs from ITP patients, we observed elevated Th17 cell and IL-21 levels and RORγt mRNA expression, decreased Treg cells and Foxp3 mRNA expression, and an increased ratio of Th17/Treg and RORγt/Foxp3. After inactivating Notch signal by DAPT, Th17 cells and Th17/Treg ratio were dose dependently decreased and accompanied by the reduction of IL-17 in culture supernatants and RORγt mRNA expression in ITP patients. However, no significant difference was found for Treg cells and Foxp3 mRNA expression, RORγt/Foxp3 ratio, and IL-21 and IL-10 levels after DAPT treatment in ITP patients. We also present evidence that the effect of DAPT inhibition on the Th17 cell response was associated with downregulation of RORγt and IL-17 transcription using human in vitro polarization. In conclusion, our findings highlight the importance of Notch signaling in Th17/Treg imbalances in ITP. Inactivation of Notch signaling might be a potential immunoregulatory strategy in ITP patients. </div></details><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/25485537">25485537</a><div class="entities" style="line-height: 2.5"><h3>Inactivation of Notch signaling reverses the Th17/Treg imbalance in cells from patients with immune thrombocytopenia.</h3></br>T helper 17 (Th17) cells and regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells, along with Th1 and Th2 cells, may contribute to the development of immune thrombocytopenia (ITP). The imbalance of Th17/Treg toward Th17 cells has been shown to play a pivotal role in the peripheral immune response. Notch signaling has been implicated in peripheral T cell activation and effector cell differentiation. However, the role of Th17/Treg in the pathogenesis of ITP and the effect of Notch signaling on Th17/Treg imbalances remain largely elusive in ITP. In vitro, we treated peripheral blood mononuclear cells (PBMCs) from ITP and healthy controls with γ-secretase inhibitor (DAPT). Th17 cells and Treg cells were measured by flow cytometry and IL-17, IL-21, and IL-10 secretion by enzyme immunoassay technique. The mRNA expression of Ntoch1, Hes1, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Hey1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, RORγt, and Foxp3 was investigated by RT-PCR. Cell proliferation and apoptosis were determined by the Cell Counting Kit-8 and apoptosis detection kit. We demonstrated that DAPT was effective in inhibiting mRNA expression of Notch signaling molecules. In untreated cultured PBMCs from ITP patients, we observed elevated Th17 cell and IL-21 levels and RORγt mRNA expression, decreased Treg cells and Foxp3 mRNA expression, and an increased ratio of Th17/Treg and RORγt/Foxp3. After inactivating Notch signal by DAPT, Th17 cells and Th17/Treg ratio were dose dependently decreased and accompanied by the reduction of IL-17 in culture supernatants and RORγt mRNA expression in ITP patients. However, no significant difference was found for Treg cells and Foxp3 mRNA expression, RORγt/Foxp3 ratio, and IL-21 and IL-10 levels after DAPT treatment in ITP patients. We also present evidence that the effect of DAPT inhibition on the Th17 cell response was associated with downregulation of RORγt and IL-17 transcription using human in vitro polarization. In conclusion, our findings highlight the importance of Notch signaling in Th17/Treg imbalances in ITP. Inactivation of Notch signaling might be a potential immunoregulatory strategy in ITP patients. </div></details></details></td>
    </tr>
    <tr>
      <th>84</th>
      <td>XBP1</td>
      <td>1</td>
      <td>TREG:1</td>
      <td>0.014360</td>
      <td>ENSG00000100219</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/22961053">22961053</a><div class="entities" style="line-height: 2.5"><h3>A multiply redundant genetic switch 'locks in' the transcriptional signature of regulatory T cells.</h3></br>The transcription factor Foxp3 participates dominantly in the specification and function of Foxp3(+)CD4(+) regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells) but is neither strictly necessary nor sufficient to determine the characteristic <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cell signature. Here we used computational network inference and experimental testing to assess the contribution of other transcription factors to this. Enforced expression of Helios or <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Xbp1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> elicited distinct signatures, but Eos, IRF4, Satb1, Lef1 and GATA-1 elicited exactly the same outcome, acting in synergy with Foxp3 to activate expression of most of the <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cell signature, including key transcription factors, and enhancing occupancy by Foxp3 at its genomic targets. Conversely, the T(reg) cell signature was robust after inactivation of any single cofactor. A redundant genetic switch thus 'locked in' the <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cell phenotype, a model that would account for several aspects of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cell physiology, differentiation and stability.</div></details></details></td>
    </tr>
    <tr>
      <th>85</th>
      <td>NR4A1</td>
      <td>1</td>
      <td>TREG:1</td>
      <td>0.014360</td>
      <td>ENSG00000123358</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27778276">27778276</a><div class="entities" style="line-height: 2.5"><h3>Transcriptional modulation of regulatory T cell development by novel regulators NR4As.</h3></br>Regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells with high expression of both CD25 and Foxp3 are developed in the thymus and also peripheral tissues. Treg cells suppress the activation and functions of effector T cells raised against specific antigens and are crucial for maintaining immune homeostasis. Treg cell development is associated with the induction of and epigenetic alterations of forkhead transcription factor Foxp3. Foxp3 expression is increased by the activation of several transcription factors including nuclear factor-kappa B (NF-κB), nuclear factor of activated T cells (NFAT), and Smad3 in response to various signals such as TGFβ, retinoic acid, and rapamycin. Recently, the orphan nuclear receptor 4A proteins (NR4As) including <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NR4A1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (Nur77), NR4A2 (Nurr1), and NR4A3 (Nor1) are reported to regulate Treg cell development through activation of Foxp3 and have therapeutic potentials in treating immune disorders. This review summarizes the function and regulatory mechanisms of Treg cells and also implicates current advances in immunomodulatory functions of NR4As and their therapeutic potentials in inflammation and cancer.</div></details></details></td>
    </tr>
    <tr>
      <th>86</th>
      <td>ATF3</td>
      <td>1</td>
      <td>TREG:1</td>
      <td>0.014360</td>
      <td>ENSG00000162772</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/24856900">24856900</a><div class="entities" style="line-height: 2.5"><h3>miR-155 activates cytokine gene expression in Th17 cells by regulating the DNA-binding protein Jarid2 to relieve polycomb-mediated repression.</h3></br>Specification of the T helper 17 (Th17) cell lineage requires a well-defined set of transcription factors, but how these integrate with posttranscriptional and epigenetic programs to regulate gene expression is poorly understood. Here we found defective Th17 cell cytokine expression in miR-155-deficient CD4+ T cells in vitro and in vivo. Mir155 was bound by Th17 cell transcription factors and was highly expressed during Th17 cell differentiation. miR-155-deficient Th17 and T regulatory (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells expressed increased amounts of Jarid2, a DNA-binding protein that recruits the Polycomb Repressive Complex 2 (PRC2) to chromatin. PRC2 binding to chromatin and H3K27 histone methylation was increased in miR-155-deficient cells, coinciding with failure to express Il22, Il10, Il9, and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Atf3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. Defects in Th17 cell cytokine expression and Treg cell homeostasis in the absence of Mir155 could be partially suppressed by Jarid2 deletion. Thus, miR-155 contributes to Th17 cell function by suppressing the inhibitory effects of Jarid2.</div></details></details></td>
    </tr>
    <tr>
      <th>87</th>
      <td>SMAD1</td>
      <td>1</td>
      <td>TREG:1</td>
      <td>0.014360</td>
      <td>ENSG00000170365</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/20676092">20676092</a><div class="entities" style="line-height: 2.5"><h3>Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells.</h3></br>The aryl hydrocarbon receptor (AhR) participates in the differentiation of mouse regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells) and interleukin 17 (IL-17)-producing helper T cells (T(H)17 cells), but its role in human T cell differentiation is unknown. We investigated the role of AhR in the differentiation of human induced <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells (iT(reg) cells). We found that AhR activation promoted the differentiation of CD4(+)Foxp3(-) T cells, which produce IL-10 and control responder T cells through granzyme B. However, activation of AhR in the presence of transforming growth factor-beta1 induced Foxp3(+) iT(reg) cells, which suppress responder T cells through the ectonucleoside triphosphate diphosphohydrolase CD39. The induction of functional Foxp3(+) iT(reg) cells required coordinated action of the transcriptional regulators <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Smad1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and Aiolos. Thus, AhR is a potential target through which functional iT(reg) cells could be induced in human autoimmune disorders.</div></details></details></td>
    </tr>
    <tr>
      <th>88</th>
      <td>DBP</td>
      <td>1</td>
      <td>TREG:1</td>
      <td>0.014360</td>
      <td>ENSG00000105516</td>
      <td><details><summary>Subtypes</summary></details></td>
    </tr>
    <tr>
      <th>89</th>
      <td>NR4A3</td>
      <td>1</td>
      <td>TREG:1</td>
      <td>0.014360</td>
      <td>ENSG00000119508</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27778276">27778276</a><div class="entities" style="line-height: 2.5"><h3>Transcriptional modulation of regulatory T cell development by novel regulators NR4As.</h3></br>Regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells with high expression of both CD25 and Foxp3 are developed in the thymus and also peripheral tissues. Treg cells suppress the activation and functions of effector T cells raised against specific antigens and are crucial for maintaining immune homeostasis. Treg cell development is associated with the induction of and epigenetic alterations of forkhead transcription factor Foxp3. Foxp3 expression is increased by the activation of several transcription factors including nuclear factor-kappa B (NF-κB), nuclear factor of activated T cells (NFAT), and Smad3 in response to various signals such as TGFβ, retinoic acid, and rapamycin. Recently, the orphan nuclear receptor 4A proteins (NR4As) including NR4A1 (Nur77), NR4A2 (Nurr1), and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NR4A3    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (Nor1) are reported to regulate Treg cell development through activation of Foxp3 and have therapeutic potentials in treating immune disorders. This review summarizes the function and regulatory mechanisms of Treg cells and also implicates current advances in immunomodulatory functions of NR4As and their therapeutic potentials in inflammation and cancer.</div></details></details></td>
    </tr>
    <tr>
      <th>90</th>
      <td>NFYB</td>
      <td>1</td>
      <td>TREG:1</td>
      <td>0.014360</td>
      <td>ENSG00000120837</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/26275994">26275994</a><div class="entities" style="line-height: 2.5"><h3>Hydrogen Sulfide Promotes Tet1- and Tet2-Mediated Foxp3 Demethylation to Drive Regulatory T Cell Differentiation and Maintain Immune Homeostasis.</h3></br>Regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells are essential for maintenance of immune homeostasis. Here we found that hydrogen sulfide (H2S) was required for Foxp3(+) Treg cell differentiation and function and that H2S deficiency led to systemic autoimmune disease. H2S maintained expression of methylcytosine dioxygenases Tet1 and Tet2 by sulfhydrating nuclear transcription factor Y subunit beta (<mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    NFYB    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>) to facilitate its binding to Tet1 and Tet2 promoters. Transforming growth factor-β (TGF-β)-activated Smad3 and interleukin-2 (IL-2)-activated Stat5 facilitated Tet1 and Tet2 binding to Foxp3. Tet1 and Tet2 catalyzed conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) in Foxp3 to establish a Treg-cell-specific hypomethylation pattern and stable Foxp3 expression. Consequently, Tet1 and Tet2 deletion led to Foxp3 hypermethylation, impaired Treg cell differentiation and function, and autoimmune disease. Thus, H2S promotes Tet1 and Tet2 expression, which are recruited to Foxp3 by TGF-β and IL-2 signaling to maintain Foxp3 demethylation and Treg-cell-associated immune homeostasis. </div></details></details></td>
    </tr>
    <tr>
      <th>91</th>
      <td>DNMT1</td>
      <td>1</td>
      <td>TREG:1</td>
      <td>0.014360</td>
      <td>ENSG00000130816</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/19641188">19641188</a><div class="entities" style="line-height: 2.5"><h3>Epigenetic mechanisms of regulation of Foxp3 expression.</h3></br>Regulatory T cells play important roles in the control of autoimmunity and maintenance of transplantation tolerance. Foxp3, a member of the forkhead/winged-helix family of transcription factors, acts as the master regulator for regulatory T cell (Treg) development and function. Mutation of the Foxp3 gene causes the scurfy phenotype in mouse and IPEX syndrome (immune dysfunction, polyendocrinopathy, enteropathy, X-linked syndrome) in humans. Epigenetics is defined by regulation of gene expression without altering nucleotide sequence in the genome. Several epigenetic markers, such as histone acetylation and methylation, and cytosine residue methylation in CpG dinucleotides, have been reported at the Foxp3 locus. In particular, CpG dinucleotides at the Foxp3 locus are methylated in naive CD4+CD25- T cells, activated CD4+ T cells, and TGF-beta-induced adaptive <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>, whereas they are completely demethylated in natural Tregs. The DNA methyltransferases <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    DNMT1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and DNMT3b are associated with the Foxp3 locus in CD4+ T cells. Methylation of CpG residues represses Foxp3 expression, whereas complete demethylation is required for stable Foxp3 expression. In this review, we discuss how different cis-regulatory elements at the Foxp3 locus are subjected to epigenetic modification in different subsets of CD4+ T cells and regulate Foxp3 expression, and how these mechanisms can be exploited to generate efficiently large numbers of suppressive Tregs for therapeutic purposes.</div></details></details></td>
    </tr>
    <tr>
      <th>92</th>
      <td>LEF1</td>
      <td>1</td>
      <td>TREG:1</td>
      <td>0.014360</td>
      <td>ENSG00000138795</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/22961053">22961053</a><div class="entities" style="line-height: 2.5"><h3>A multiply redundant genetic switch 'locks in' the transcriptional signature of regulatory T cells.</h3></br>The transcription factor Foxp3 participates dominantly in the specification and function of Foxp3(+)CD4(+) regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells) but is neither strictly necessary nor sufficient to determine the characteristic <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cell signature. Here we used computational network inference and experimental testing to assess the contribution of other transcription factors to this. Enforced expression of Helios or Xbp1 elicited distinct signatures, but Eos, IRF4, Satb1, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Lef1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and GATA-1 elicited exactly the same outcome, acting in synergy with Foxp3 to activate expression of most of the <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cell signature, including key transcription factors, and enhancing occupancy by Foxp3 at its genomic targets. Conversely, the T(reg) cell signature was robust after inactivation of any single cofactor. A redundant genetic switch thus 'locked in' the <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cell phenotype, a model that would account for several aspects of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cell physiology, differentiation and stability.</div></details></details></td>
    </tr>
    <tr>
      <th>93</th>
      <td>IKZF2</td>
      <td>4</td>
      <td>TREG:4</td>
      <td>0.014360</td>
      <td>ENSG00000030419</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/26686412">26686412</a><div class="entities" style="line-height: 2.5"><h3>Transcriptome profiling of human FoxP3+ regulatory T cells.</h3></br>The major goal of this study was to perform an in depth characterization of the "gene signature" of human FoxP3(+) T regulatory cells (Tregs). Highly purified <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and T conventional cells (Tconvs) from multiple healthy donors (HD), either freshly explanted or activated in vitro, were analyzed via RNA sequencing (RNA-seq) and gene expression changes validated using the nCounter system. Additionally, we analyzed microRNA (miRNA) expression using TaqMan low-density arrays. Our results confirm previous studies demonstrating selective gene expression of FoxP3, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IKZF2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>, and CTLA4 in Tregs. Notably, a number of yet uncharacterized genes (RTKN2, LAYN, UTS2, CSF2RB, TRIB1, F5, CECAM4, CD70, ENC1 and NKG7) were identified and validated as being differentially expressed in human Tregs. We further characterize the functional roles of RTKN2 and LAYN by analyzing their roles in vitro human Treg suppression assays by knocking them down in Tregs and overexpressing them in Tconvs. In order to facilitate a better understanding of the human Treg gene expression signature, we have generated from our results a hypothetical interactome of genes and miRNAs in Tregs and Tconvs.</div><a href="https://www.ncbi.nlm.nih.gov/pubmed/25252160">25252160</a><div class="entities" style="line-height: 2.5"><h3>In vitro TNF blockade enhances ex vivo expansion of regulatory T cells in patients with immune thrombocytopenia.</h3></br>Tumour necrosis factor-α (TNF) is an inflammatory cytokine that is elevated in a number of autoimmune diseases including immune thrombocytopenia (ITP), a bleeding disorder characterized by low platelet counts. In vitro TNF blockade increases expansion of the regulatory T cell (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IKZF2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> (also termed Helios) subset in T cell-monocyte cocultures from healthy donors, but its role on proliferative responses of Tregs in ITP patients, who have altered immunoregulatory compartment, remains unclear. TNF in CD4+ T cells from patients with chronic ITP were elevated and negatively correlated with peripheral Treg frequencies, suggesting a possible inhibitory effect of TNF on ITP Tregs. In vitro antibody neutralization with anti-TNF in T cell-monocyte cocultures resulted in a robust expansion of pre-existing ITP Tregs, higher than in healthy controls. Similar to the effects of anti-TNF antibodies, TNF blockade with antibodies against TNFRSF1B (anti-TNFRSF1B, previously termed anti-TNFRII) almost doubled ITP Treg expansion whereas neutralization with anti-TNFRSF1A (anti-TNFRI) antibodies had no effect on proliferative responses of Tregs. In addition, TNFRSF1B levels on ITP Tregs were significantly elevated, which may explain the increased susceptibility of patient Tregs to the actions of TNF blockade. Altogether, these data raise the possibility that TNF blockers, through their ability to increase Treg proliferation, may be efficacious in ITP patients. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/24610777">24610777</a><div class="entities" style="line-height: 2.5"><h3>Interindividual variation in human T regulatory cells.</h3></br>FOXP3(+) regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells enforce immune self-tolerance and homeostasis, and variation in some aspects of Treg function may contribute to human autoimmune diseases. Here, we analyzed population-level Treg variability by performing genome-wide expression profiling of CD4(+) Treg and conventional CD4(+) T (Tconv) cells from 168 donors, healthy or with established type-1 diabetes (T1D) or type-2 diabetes (T2D), in relation to genetic and immunologic screening. There was a range of variability in Treg signature transcripts, some almost invariant, others more variable, with more extensive variability for genes that control effector function (ENTPD1, FCRL1) than for lineage-specification factors like FOXP3 or <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IKZF2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark>. Network analysis of Treg signature genes identified coregulated clusters that respond similarly to genetic and environmental variation in <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> and Tconv cells, denoting qualitative differences in otherwise shared regulatory circuits whereas other clusters are coregulated in Treg, but not Tconv, cells, suggesting Treg-specific regulation of genes like CTLA4 or DUSP4. Dense genotyping identified 110 local genetic variants (cis-expression quantitative trait loci), some of which are specifically active in Treg, but not Tconv, cells. The Treg signature became sharper with age and with increasing body-mass index, suggesting a tuning of Treg function with repertoire selection and/or chronic inflammation. Some Treg signature transcripts correlated with FOXP3 mRNA and/or protein, suggesting transcriptional or posttranslational regulatory relationships. Although no single transcript showed significant association to diabetes, overall expression of the Treg signature was subtly perturbed in T1D, but not T2D, patients. </div><a href="https://www.ncbi.nlm.nih.gov/pubmed/24152290">24152290</a><div class="entities" style="line-height: 2.5"><h3>Histone methylation mediates plasticity of human FOXP3(+) regulatory T cells by modulating signature gene expressions.</h3></br>CD4(+) FOXP3(+) regulatory T (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Treg    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) cells constitute a heterogeneous and plastic T cell lineage that plays a pivotal role in maintaining immune homeostasis and immune tolerance. However, the fate of human Treg cells after loss of FOXP3 expression and the epigenetic mechanisms contributing to such a phenotype switch remain to be fully elucidated. In the current study, we demonstrate that human CD4(+) CD25(high) CD127(low/-) Treg cells convert to two subpopulations with distinctive FOXP3(+) and FOXP3(-) phenotypes following in vitro culture with anti-CD3/CD28 and interleukin-2. Digital gene expression analysis showed that upon in vitro expansion, human Treg cells down-regulated Treg cell signature genes, such as FOXP3, CTLA4, ICOS, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    IKZF2    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and LRRC32, but up-regulated a set of T helper lineage-associated genes, especially T helper type 2 (Th2)-associated, such as GATA3, GFI1 and IL13. Subsequent chromatin immunoprecipitation-sequencing of these subpopulations yielded genome-wide maps of their H3K4me3 and H3K27me3 profiles. Surprisingly, reprogramming of Treg cells was associated with differential histone modifications, as evidenced by decreased abundance of permissive H3K4me3 within the down-regulated Treg cell signature genes, such as FOXP3, CTLA4 and LRRC32 loci, and increased abundance of H3K4me3 within the Th2-associated genes, such as IL4 and IL5; however, the H3K27me3 modification profile was not significantly different between the two subpopulations. In conclusion, this study revealed that loss of FOXP3 expression from human Treg cells during in vitro expansion can induce reprogramming to a T helper cell phenotype with a gene expression signature dominated by Th2 lineage-associated genes, and that this cell type conversion may be mediated by histone methylation events.</div></details></details></td>
    </tr>
    <tr>
      <th>94</th>
      <td>GLI1</td>
      <td>1</td>
      <td>TREG:1</td>
      <td>0.014360</td>
      <td>ENSG00000111087</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/27080341">27080341</a><div class="entities" style="line-height: 2.5"><h3>Mycobacteria-responsive sonic hedgehog signaling mediates programmed death-ligand 1- and prostaglandin E2-induced regulatory T cell expansion.</h3></br>CD4(+)CD25(+)FoxP3(+) regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) are exploited by mycobacteria to subvert the protective host immune responses. The Treg expansion in the periphery requires signaling by professional antigen presenting cells and in particularly dendritic cells (DC). However, precise molecular mechanisms by which mycobacteria instruct Treg expansion via DCs are not established. Here we demonstrate that mycobacteria-responsive sonic hedgehog (SHH) signaling in human DCs leads to programmed death ligand-1 (PD-L1) expression and cyclooxygenase (COX)-2-catalyzed prostaglandin E2 (PGE2) that orchestrate mycobacterial infection-induced expansion of Tregs. While SHH-responsive transcription factor <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GLI1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> directly arbitrated COX-2 transcription, specific microRNAs, miR-324-5p and miR-338-5p, which target PD-L1 were downregulated by SHH signaling. Further, counter-regulatory roles of SHH and NOTCH1 signaling during mycobacterial-infection of human DCs was also evident. Together, our results establish that Mycobacterium directs a fine-balance of host signaling pathways and molecular regulators in human DCs to expand Tregs that favour immune evasion of the pathogen. </div></details></details></td>
    </tr>
    <tr>
      <th>95</th>
      <td>GATA1</td>
      <td>1</td>
      <td>TREG:1</td>
      <td>0.014360</td>
      <td>ENSG00000102145</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/22961053">22961053</a><div class="entities" style="line-height: 2.5"><h3>A multiply redundant genetic switch 'locks in' the transcriptional signature of regulatory T cells.</h3></br>The transcription factor Foxp3 participates dominantly in the specification and function of Foxp3(+)CD4(+) regulatory T cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cells) but is neither strictly necessary nor sufficient to determine the characteristic <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cell signature. Here we used computational network inference and experimental testing to assess the contribution of other transcription factors to this. Enforced expression of Helios or Xbp1 elicited distinct signatures, but Eos, IRF4, Satb1, Lef1 and <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    GATA-1    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> elicited exactly the same outcome, acting in synergy with Foxp3 to activate expression of most of the <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cell signature, including key transcription factors, and enhancing occupancy by Foxp3 at its genomic targets. Conversely, the T(reg) cell signature was robust after inactivation of any single cofactor. A redundant genetic switch thus 'locked in' the <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cell phenotype, a model that would account for several aspects of <mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    T(reg)    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark> cell physiology, differentiation and stability.</div></details></details></td>
    </tr>
    <tr>
      <th>96</th>
      <td>KLF10</td>
      <td>1</td>
      <td>TREG:1</td>
      <td>0.014360</td>
      <td>ENSG00000155090</td>
      <td><details><summary>Subtypes</summary><details><summary>TREG</summary><a href="https://www.ncbi.nlm.nih.gov/pubmed/23052042">23052042</a><div class="entities" style="line-height: 2.5"><h3>Generation of functional T-regulatory cells in children with metabolic syndrome.</h3></br>Recent research implies a role of decreased number and/or function of T-regulatory cells (<mark class="entity" style="background: #09a3d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    Tregs    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">TYPE</span></mark>) in low-grade inflammation associated with obesity and atherosclerosis. The enhancement of atheroprotective immunity by the expansion of Tregs could serve as a therapeutic strategy in obesity-related immunological disturbances. The aim of our study was an attempt to generate Treg cells in children with risk factors for the development of cardiovascular disease and to compare the results to those obtained in healthy subjects. The study group consisted of 30 children with metabolic syndrome (MS) and 30 controls. Conventional CD4(+)CD25(-) cells separated from the peripheral blood were converted into Treg cells with the use of CD3/CD28 antibodies and interleukin (IL)-2/transforming growth factor (TGF)-β stimulation. The expression of critical Treg molecules and cytokines was assessed at mRNA and protein levels. The percentages of Treg cells in the peripheral blood were significantly lower in the children with MS compared to the healthy subjects. After the culture with CD3/CD28 and IL-2/TGF-β we detected a significant increase in the expression of Tregs marker transcription factor FoxP3. The Tregs induced from the children with MS varied from the ones obtained in the controls in the expression of some molecules at mRNA level (e.g. IL-27, LGAL, <mark class="entity" style="background: #05b083; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">    KLF10    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PROTEIN</span></mark> and NRP1) yet not in proliferation studies. For the first time, we have demonstrated the possibility of generating functional Treg cells in children with MS. The results of our study could be used in the design of therapeutic interventions in obesity associated immunologic disturbances.</div></details></details></td>
    </tr>
  </tbody>
</table>
</body>
</html>
